

GP 35730

(11)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044990 A2

- (51) International Patent Classification⁷: C12N Avenue NE, Rochester, MN 55906 (US). LEWIS, Marcia [US/US]: 67 Wheelwright Farm, Cohasset, MA 02025 (US).
- (21) International Application Number: PCT/US2004/036404
- (22) International Filing Date: 1 November 2004 (01.11.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 10/700,439 4 November 2003 (04.11.2003) US
- (71) Applicants (for all designated States except US): BAYER HEALTHCARE LLC [US/US]; 511 Benedict Avenue, Tarrytown, NY 10591 (US). MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street SW, Rochester, MN 55905 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BURGESS, Christopher [US/US]; 97 Canton Terrace, Westwood, MA 02090 (US). MYEROW, Susan [US/US]; 5 Ellison Road, Lexington, MA 02421 (US). THIAGALINGAM, Arunthathi [US/US]; 26 Winchester Drive, Lexington, MA 02420 (US). MAIMONIS, Peter [US/US]; 83 Fensview Drive, Westwood, MA 02090 (US). MOLINO, Gary [US/US]; 3 Essex Street, Norfolk, MA 02056 (US). BURGART, Lawrence [US/US]; 5685 Chateau Road NW, Rochester, MN 55901 (US). BOARDMAN, Lisa, Allyn [US/US]; 3831 Halling Place SW, Rochester, MN 55902 (US). THIBODEAU, Stephen [US/US]; 1610 21st
- (74) Agent: CAMPBELL EVANS, Paula; Palmer & Dodge LLP, 111 Huntington Avenue, Boston, MA 02199-7613 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF DIFFERENTIALLY EXPRESSED NUCLEIC ACID SEQUENCES AS BIOMARKERS FOR CANCER

(57) Abstract: The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.

WO 2005/044990 A2

**USE OF DIFFERENTIALLY EXPRESSED NUCLEIC ACID SEQUENCES AS
BIOMARKERS FOR CANCER**

Field of the Invention

The present invention relates to methods for diagnosis, prognosis, characterization,
5 management, and therapy of cancer including colon cancer, based on the identification of certain
colon cancer-associated differentially expressed marker sequences.

Background of the Invention

Cancers are the second leading cause of death, next to cardiovascular disease, in the
United States. The pathological and molecular mechanisms for cancer initiation and promotion
10 have been revealed after decades of researches. Many genes are involved in the initiation and
progression of cancers, including oncogenic and tumor suppressive genes. Multiple factors
including genetic, endocrinologic, immunologic, and environmental factors, intertwine in the
process of transformation and progression of cancers. The control and cure of cancers remain to
be one of the most challenging health care tasks. Particularly, one of the most pressing health
15 issues today is diagnosing, monitoring, and treating cancer.

Colorectal carcinoma is a malignant neoplastic disease. There is a high incidence of
colorectal carcinoma in the Western world, particularly in the United States. Tumors of this type
often metastasize through lymphatic and vascular channels. Many patients with colorectal
carcinoma eventually die from this disease. In fact, it is estimated that 62,000 persons in the
20 United States alone die of colorectal carcinoma annually.

However, if diagnosed early, colon cancer may be treated effectively by surgical removal
of the cancerous tissue. Colorectal cancers originate in the colorectal epithelium and typically
are not extensively vascularized (and therefore not invasive) during the early stages of
development. Colorectal cancer is thought to result from the clonal expansion of a single mutant
25 cell in the epithelial lining of the colon or rectum. The transition to a highly vascularized,
invasive and ultimately metastatic cancer which spreads throughout the body commonly takes
ten years or longer. If the cancer is detected prior to invasion, surgical removal of the cancerous
tissue is an effective cure. However, colorectal cancer is often detected only upon manifestation
of clinical symptoms, such as pain and black tarry stool. Generally, such symptoms are present
30 only when the disease is well established, often after metastasis has occurred, and the prognosis

for the patient is poor, even after surgical resection of the cancerous tissue. Early detection of colorectal cancer therefore is important in that detection may significantly reduce its morbidity.

Invasive diagnostic methods such as endoscopic examination allow for direct visual identification, removal, and biopsy of potentially cancerous growths such as polyps. Endoscopy is expensive, uncomfortable, inherently risky, and therefore not a practical tool for screening populations to identify those with colorectal cancer. Non-invasive analysis of stool samples for characteristics indicative of the presence of colorectal cancer or precancer is a preferred alternative for early diagnosis, but no known diagnostic methods are available which reliably achieve this goal.

Summary of the Invention

The present invention relates to nucleic acid sequences that are differentially expressed in cancer tissue compared to normal tissue, and various methods, reagents and kits for diagnosis, staging, prognosis, monitoring and treatment of cancer, including colon cancer.

In one aspect, the present invention provides methods for determining the expression levels of individual and/or combinations of the differentially expressed marker sequences in a biological sample that are indicative of the presence, or stage of the disease, or the efficacy of therapy. The method comprises contacting said sample with a polynucleotide probe or a polypeptide ligand under conditions effective for said probe or ligand to hybridize specifically to a nucleic acid or a polypeptide in said sample, and detecting the presence or absence of marker sequences. In one embodiment, methods are provided to determine the amounts and/or the differentially expressed levels at which the marker sequences of the present invention are expressed in samples. Such methods can comprise contacting said sample with a polynucleotide probe or a polypeptide ligand under conditions effective for said probe to hybridize specifically to the nucleic acids in said sample, and detecting the amounts or differentially expressed level of the marker sequences. In one preferred embodiment, said polynucleotide probe is a polynucleotide designed to identify one of the marker sequences in Tables 1 and 2. In another preferred embodiment, said polypeptide ligand is an antibody.

In another aspect, the present invention provides probes and primers designed to detect transcripts or genomic sequences corresponding to one or more marker sequences of the present

invention. The probes and primers may comprise a portion or all of the sequences listed in SEQ ID NOs: 1-93, or sequences complementary thereto, or sequences which hybridize under stringent conditions to a portion or all of SEQ ID NOs: 1-93.

5 In another aspect, the present invention provides polypeptides encoded by the marker sequences, biologically active portions thereof, and polypeptide fragments suitable for use as immunogens to raise antibodies directed against polypeptides of the marker sequences of the present invention.

10 In another aspect, the present invention provides ligands directed to polypeptides and fragments thereof of the marker sequences of the present invention. Preferably, said polypeptide ligands are antibodies. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, or chimeric antibodies, single chain antibodies, Fab fragments, Fv fragments F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic antibodies, or other epitope binding polypeptide. Preferably, an antibody, useful in the present invention for the detection of the individual marker sequences (and optionally at
15 least one additional colon cancer-specific marker), is a human antibody or fragment thereof, including scFv, Fab, Fab', F(ab'), Fd, single chain antibody, or Fv. Antibodies, useful in the invention may include a complete heavy or light chain constant region, or a portion thereof, or an absence thereof.

20 Another aspect of the present invention provides a method of assessing whether a subject is suffering from or at risk of developing cancer including colon cancer by detecting the differential expression of the marker sequences of the present invention. In one embodiment, the diagnostic method comprises determining whether a subject has an abnormal mRNA or cDNA and/or protein level of the marker sequences. The method comprises detecting the expression level of the individual and/or the combinations of the marker sequences in a biological sample
25 obtained from a patient. Specifically, the method comprises:

(1). Providing a nucleic acid probe comprising a nucleotide sequence at least about 8 nucleotides in length, at least about 12 nucleotides in length, preferably at least about 15 nucleotides, more preferably about 25 nucleotides, and most preferably at least about 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a

portion of the coding sequence of a nucleic acid sequence represented by SEQ ID NOs:1-93, or a sequence complementary thereto;

(2). Obtaining a clinical sample from a patient potentially comprising one or more nucleic acid marker sequences;

5 (3). Providing a second clinical sample from an individual known to not have colon cancer, or a cancer-free tissue of the same patient;

(4). Contacting the nucleic acid probe under stringent conditions with RNA of each of said first and second clinical samples (e.g., in a Northern blot or in situ hybridization assay); and

10 (5). Comparing (a) the amount of hybridization of the probe with RNA of the first serum sample, with (b) the amount of hybridization of the probe with RNA of the second clinical sample; wherein a statistically change (e.g., either an increase or a decrease) in the amount of hybridization with the RNA of the first clinical sample as compared to the amount of hybridization with the RNA of the second clinical sample is indicative of the presence of one or more marker sequences in the first clinical sample.

15 In another embodiment, the diagnostic methods comprise detecting the polypeptides encoded by the marker sequences of the present invention. The assay would include contacting the polypeptides of the test cell or tissue with one or more polypeptide ligands specific for the polypeptides represented by SEQ ID NOs: 94-186, and determining the approximate amount of complex formation by the ligands and polypeptides of the test cell or tissue, wherein a
20 statistically significant difference (either an increase or a decrease) in the amount of the complex formed with the polypeptides of a test cell or tissue as compared to a normal cell or tissue is an indication that the test cell is cancerous or pre-cancerous. In particular, the assay evaluates the level of marker polypeptide in the test cells, and preferably, compares the measured level with marker polypeptide detected in at least one control cell, e.g., a normal cell and/or a transformed
25 cell of known phenotype.

In another aspect, the present invention provides DNA and protein microarrays for detecting the differential expression levels of the marker sequences. In some embodiments, the microarrays comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, or more nucleic acids that are complimentary to at least a portion of the coding sequences of the marker sequences

represented by SEQ ID NOs: 1-93. In some embodiments, the microarrays comprise antibodies or antigen-binding fragments thereof, that specifically bind to at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 different marker polypeptides encoded by nucleic acids comprising a nucleotide
5 sequence selected from the group consisting of SEQ ID NOs: 1-93. In one embodiment, the probe/primer can comprise a sequence that hybridizes under stringent conditions to at least about 7, preferably 12, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400, or more consecutive nucleotides of SEQ ID NOs: 1-93 of the present invention. In another embodiment, the probe/primer can comprise a sequence that hybridizes
10 under moderately stringent conditions to at least about 7, preferably 12, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400, or more consecutive nucleotides of SEQ ID NOs: 1-93 of the present invention.

In another aspect, the present invention provides methods for determining cancer prognosis and stage based on examining the expression levels of the nucleic acid marker
15 sequences and polypeptides using the methods described in the present invention.

In one embodiment, the methods comprise:

- (1). detecting in a biological sample of the subject at a first point in time, the expression of one or more nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93;
- 20 (2). repeating step (a) at a subsequent point in time; and
- (3). comparing the expression level detected in steps (a) and (b), wherein a change in the expression level is indicative of progression of cancer or a pre-malignant condition thereof in the subject.

In another embodiment, the methods comprise:

- 25 (1). detecting in a biological sample of the subject at a first point in time, the expression of one or more polypeptides comprising one or more polypeptide sequences selected from the group consisting of SEQ ID NOs: 94-186;
- (2). repeating step (a) at a subsequent point in time; and

(3). comparing the expression level detected in steps (a) and (b), wherein a change in the expression level is indicative of progression of cancer or a pre-malignant condition thereof in the subject.

5 In another aspect, the present invention also provides methods that permit the assessment and/or monitoring of patients who will be likely to benefit from both traditional and non-traditional treatments and therapies for cancers, particularly colon cancer. The methods include assessing the levels of one or more of the marker sequences in a biological sample for the purposes of determining the status of a patient's disease an/or the efficacy, reaction, and response to cancer or neoplastic disease treatments or therapies that the patient is undergoing.

10 The present invention also includes methods of assessing the efficacy of a test composition for inhibiting cancer including colon cancer. The methods comprise comparing expression levels of one or more marker sequences in a first biological sample maintained in the presence of a test composition with the expression levels of the same marker sequences in a second biological sample maintained in the absence of the test composition.

15 In another aspect, the present invention provides assays for determining compounds that modulate the biological activity of the nucleic acids or the polypeptides encoded by the marker sequences. Methods of identifying compounds generally comprise steps in which a compound is placed in contact with a marker sequence, its transcription product, its translation product, or other target, and determination of whether the compound modulates the marker sequence.

20 In another aspect, the present invention also provides methods for screening drugs that inhibit cancer including colon cancer. Drug screening is performed by adding a test compound to a sample of cells and monitoring the effect. The screening methods may include both *in vitro* and *in vivo* screening of a cell or tissue.

25 In another aspect, the present invention also provides kits for determining the differential expression levels of the marker sequences of the present invention in a biological sample. Such kits can be used to determine (1) presence or absence of cancer, (2) prognosis and stage of cancer, (3) drugs that inhibit cancer, and (4) treatment for cancer.

Detailed Description of the Invention

I General

The present invention is based, in part, on the identification of marker sequences that are differentially expressed (including both over- and under-expression of the sequences) in various types of humans cells (i.e., cells obtained from a human, cultured human cells, archived or preserved human cells, and *in vivo* cells) relative to normal (i.e., non-cancerous) human cells. It has been discovered that the level of expression of individual marker sequences and combinations of marker sequences described in the present invention correlates with the presence of cancer or pre-malignant condition in a patient. The expression of one or more marker sequences in human cells can be assessed by detecting the RNA transcripts and/or proteins encoded by the marker sequences. Accordingly, the present invention provides methods for identifying cancer, particularly colon cancer, in an individual by screening for sequences which are over- or under-expressed in cancerous cells relative to the level of expression in normal cells, such as cells from colon tissue. Particularly, the present invention provides a method for the identifying colon cancer in an individual by detecting individual marker sequences and/or combinations of marker sequences in the individual relative to a control expression level of the marker sequences in an individual without cancer. The present invention further provides methods for monitoring the onset, progression, or regression of cancer, particularly colon cancer, in an individual by monitoring the expression level of individual marker sequences and/or combinations of marker sequences in the individual at different points in time. The present invention further provides methods for assessing the efficacy of a therapy for inhibiting cancer, particularly colon cancer in a patient by comparing the expression level of individual marker sequences and/or combinations of marker sequences in the individual prior to and after the therapeutic treatment. The present invention further provides methods for selecting a composition for inhibiting cancer, particularly colon cancer, in a patient by comparing the expression level of individual marker sequences and/or combinations of marker sequences in the presence and absence of the composition. The present invention further provides methods for inhibiting cancer, particularly colon cancer, in a patient by administering to the patient a therapeutic composition, wherein the efficacy of the therapeutic composition is indicated by the change in the expression level of individual marker sequences and/or combinations of marker sequences.

In addition to the above methods, the present invention also provides compositions and various kits for the use in the above methods.

II Definitions

As used herein, the term "differentially expressed" refers to expression levels in a test
5 cell that differ significantly from levels in a reference cell, e.g., mRNA is found at levels at least about 25%, at least about 50% to about 75%, at least about 90% increased or decreased, generally at least about 1.2-fold, at least about 1.5-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, or at least about 50-fold or more increased or decreased in a cancerous cell when compared with a cell of the same type that is not cancerous. The
10 comparison can be made between two tissues, for example, if one is using in situ hybridization or another assay method that allows some degree of discrimination among cell types in the tissue. The comparison may also be made between cells removed from their tissue source. "Differential expression" refers to both quantitative, as well as qualitative, differences in the genes' temporal and/or cellular expression patterns among, for example, normal and neoplastic tumor cells,
15 and/or among tumor cells which have undergone different tumor progression events.

As used herein, the term "a biological sample" refers to a whole organism or a subset of its tissues, cells or component parts (e.g. body fluids, including but not limited to blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid and semen). "A biological sample" further refers to a homogenate, lysate or
20 extract prepared from a whole organism or a subset of its tissues, cells or component parts, or a fraction or portion thereof, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs. Most often, the sample has been removed from an animal, but the term "biological sample" can also refer to cells or tissue analyzed *in vivo*, i.e.,
25 without removal from animal. Typically, a "biological sample" will contain cells from the animal, but the term can also refer to non-cellular biological material, such as non-cellular fractions of blood, saliva, or urine, that can be used to measure the cancer-associated polynucleotide or polypeptides levels. "A biological sample" further refers to a medium, such as a nutrient broth or gel in which an organism has been propagated, which contains cellular
30 components, such as proteins or nucleic acid molecules.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides. ESTs, chromosomes, cDNAs, mRNAs, and rRNAs are representative examples of molecules that may be referred to as nucleic acids.

As used herein, the term "change in the expression level" refers to either an increase or a decrease of the expression level in a test sample from the control level by an amount greater than the standard error of the assay employed to assess expression. Preferably, the change is by at least about twice, and more preferably three, four, five or ten times that amount. For increase, the change is determined by comparing the expression level in the test sample to the control level. For decrease, the change is determined by comparing the control level to the expression level in the test sample. Alternatively, the decrease is determined by comparing the expression level in the test sample to the control level and the decrease in the expression level is by at least about 15%, 25%, 30%, 40%, 50%, 65%, 80%, or greater. The term "significant change in the specific binding" refers to either an increase or a decrease from the specific binding in the cancer-free sample by at least about 10%, 20%, 25%, 30%, preferably at least about 40%, 50%, more preferably at least about 60%, 70%, or 90%.

As used herein, the term "expression level of one or more nucleic acid sequences" refers to the amount of mRNA transcribed from the corresponding genes that are present in a biological sample. The expression level can be detected with or without comparison to a level from a control sample or a level expected of a control sample.

As used herein, the term "control expression level of one or more nucleic acid sequences" refers to the amount of mRNA transcribed from the corresponding genes that are present in a biological sample representative of healthy, cancer-free subjects. The term "control expression level" can also refer to an established level of mRNA representative of the cancer-free population, that has been previously established based on measurement from healthy, cancer-free subjects.

As used herein, the term "cancerous cell" or "cancer cell", used either in the singular or plural form, refers to cells that have undergone a malignant transformation that makes them

pathological to the host organism. Malignant transformation is a single- or multi-step process, which involves in part an alteration in the genetic makeup of the cell and/or the gene expression profile. Malignant transformation may occur either spontaneously, or via an event or combination of events such as drug or chemical treatment, radiation, fusion with other cells, viral infection, or activation or inactivation of particular genes. Malignant transformation may occur in vivo or in vitro, and can if necessary be experimentally induced. Malignant cells may be found within the well-defined tumor mass or may have metastasized to other physical locations. A feature of cancer cells is the tendency to grow in a manner that is uncontrollable by the host, but the pathology associated with a particular cancer cell may take any form. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can be readily distinguished from non-cancerous cells by well-established pathology techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells.

As used herein, the term "efficacy" refers to either inhibition to some extent, of cell growth causing or contributing to a cell proliferative disorder, or the inhibition, to some extent, of the production of factors (e.g., growth factors) causing or contributing to a cell proliferative disorder. "A therapeutic efficacy" refers to relief of one or more of the symptoms of a cell proliferative disorder. In reference to the treatment of a cancer, a therapeutic efficacy refers to one or more of the following: 1) reduction in the number of cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 3) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 4) inhibition, to some extent, of tumor growth; and/or 5) relieving to some extent one or more of the symptoms associated with the disorder. In reference to the treatment of a cell proliferative disorder other than a cancer, a therapeutic efficacy refers to 1) either inhibition to some extent, of the growth of cells causing the disorder; 2) the inhibition, to some extent, of the production of factors (e.g., growth factors) causing the disorder; and/or 3) relieving to some extent one or more of the symptoms associated with the disorder.

As used herein, the term "detectable label" refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.

As used herein, the term “a polynucleotide probe” refers to a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified on bases (7-deazaguanosine, inosine, etc.) or on sugar moiety. In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

As used herein, the term “hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

As used herein, the term “subject” refers to any human or non-human organism.

As used herein, “individual” refers to a mammal, preferably a human.

As used herein, “detecting” refers to the identification of the presence or absence of a molecule in a sample. Where the molecule to be detected is a polypeptide, the step of detecting can be performed by binding the polypeptide with an antibody that is detectably labeled. A detectable label is a molecule which is capable of generating, either independently, or in response to a stimulus, an observable signal. A detectable label can be, but is not limited to a fluorescent label, a chromogenic label, a luminescent label, or a radioactive label. Methods for “detecting” a label include quantitative and qualitative methods adapted for standard or confocal microscopy, FACS analysis, and those adapted for high throughput methods involving multi-well plates, arrays or microarrays. One of skill in the art can select appropriate filter sets and excitation energy sources for the detection of fluorescent emission from a given fluorescent polypeptide or dye. “Detecting” as used herein can also include the use of multiple antibodies to a polypeptide to be detected, wherein the multiple antibodies bind to different epitopes on the

polypeptide to be detected. Antibodies used in this manner can employ two or more detectable labels, and can include, for example a FRET pair. A polypeptide molecule is “detected” according to the present invention when the level of detectable signal is at all greater than the background level of the detectable label, or where the level of measured nucleic acid is at all greater than the level measured in a control sample.

As used herein, “detecting” also refers to detecting the presence of a target nucleic acid molecule (e.g., a nucleic acid molecule encoding the marker sequence) refers to a process wherein the signal generated by a directly or indirectly labeled probe nucleic acid molecule (capable of hybridizing to a target, e.g., a sequence encoding Reg1 α , in a serum sample) is measured or observed. Thus, detection of the probe nucleic acid is directly indicative of the presence, and thus the detection, of a target nucleic acid, such as a sequence encoding a marker sequence. For example, if the detectable label is a fluorescent label, the target nucleic acid is “detected” by observing or measuring the light emitted by the fluorescent label on the probe nucleic acid when it is excited by the appropriate wavelength, or if the detectable label is a fluorescence/quencher pair, the target nucleic acid is “detected” by observing or measuring the light emitted upon association or dissociation of the fluorescence/quencher pair present on the probe nucleic acid, wherein detection of the probe nucleic acid indicates detection of the target nucleic acid. If the detectable label is a radioactive label, the target nucleic acid, following hybridization with a radioactively labeled probe is “detected” by, for example, autoradiography. Methods and techniques for “detecting” fluorescent, radioactive, and other chemical labels may be found in Ausubel et al. (1995, *Short Protocols in Molecular Biology*, 3rd Ed. John Wiley and Sons, Inc.). Alternatively, a nucleic acid may be “indirectly detected” wherein a moiety is attached to a probe nucleic acid which will hybridize with the target, such as an enzyme activity, allowing detection in the presence of an appropriate substrate, or a specific antigen or other marker allowing detection by addition of an antibody or other specific indicator. Alternatively, a target nucleic acid molecule can be detected by amplifying a nucleic acid sample prepared from a patient clinical sample, using oligonucleotide primers which are specifically designed to hybridize with a portion of the target nucleic acid sequence. Quantitative amplification methods, such as, but not limited to TaqMan, may also be used to “detect” a target nucleic acid according to the invention. A nucleic acid molecule is “detected” as used herein where the level of nucleic acid measured (such as by quantitative PCR), or the level of detectable signal provided by the detectable label is at all above the background level.

As used herein, "detecting" refers further to the early detection of colorectal cancer in a patient, wherein "early" detection refers to the detection of colorectal cancer at Dukes stage A or preferably, prior to a time when the colorectal cancer is morphologically able to be classified in a particular Dukes stage. "Detecting" as used herein further refers to the detection of colorectal cancer recurrence in an individual, using the same detection criteria as indicated above.

"Detecting" as used herein still further refers to the measuring of a change in the degree of colorectal cancer before and/or after treatment with a therapeutic compound. In this case, a change in the degree of colorectal cancer in response to a therapeutic compound refers to an increase or decrease in the expression of the marker sequences including one or more colorectal cancer associated markers, or alternatively, in the amount of the marker polypeptide including one or more colorectal cancer associated markers presented in a clinical sample by at least 10% in response to the presence of a therapeutic compound relative to the expression level in the absence of the therapeutic compound.

As used herein, the term "polypeptide" refers to a polymer in which the monomers are amino acids and are joined together through peptide or disulfide bonds. It also refers to either a full-length naturally-occurring amino acid sequence or a fragment thereof between about 8 and about 500 amino acids in length. Additionally, unnatural amino acids, for example, β -alanine, phenyl glycine and homoarginine may be included. Commonly-encountered amino acids which are not gene-encoded may also be used in the present invention. All of the amino acids used in the present invention may be either the D- or L- optical isomer. The L-isomers are preferred.

As used herein, the term "ligand" refers to any compound that interacts with the ligand binding domain of a receptor and modulate its activity. The term "ligand" also refers to a molecule, such as a peptide or variable segment sequence, that is recognized by a particular receptor. As one of ordinary skill in the art will recognize, a molecule (or macromolecular complex) can be both a receptor and a ligand. In general, the binding partner having a smaller molecular weight is referred to as the ligand and the binding partner having a greater molecular weight is referred to as a receptor. Representative ligands include but are not limited to drugs, drug derivatives, isomers thereof, hormones, polypeptides, nucleotides, and the like.

The term "antibody" refers to the conventional immunoglobulin molecule, as well as fragments thereof which are also specifically reactive with one of the subject polypeptides. Antibodies can be fragmented using conventional techniques and the fragments screened for

utility in the same manner as described herein below for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and humanized molecules having affinity for a polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibodies, the antibody further comprises a label attached thereto and able to be detected, (e.g., the label can be a radioisotope, fluorescent compound, chemiluminescent compound, enzyme, or enzyme co-factor).

The term "monoclonal antibody" refers to an antibody that recognizes only one type of antigen. This type of antibodies is produced by the daughter cells of a single antibody-producing hybridoma.

As used herein, the terms specific "binding" or "specifically binding", refers to the interaction of an antibody and a protein or peptide. The interaction is dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope A, the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

III Identification of marker sequences

One aspect of the present invention pertains to identification of differentially expressed marker sequences (either over- or under-expressed) in a biological sample from a patient with cancerous or pre-malignant conditions. In general, the method of identifying the marker sequences involves providing a pool of target nucleic acids (derived from both tumor and normal cells and/or tissue) comprising RNA transcripts of one or more target genes, or nucleic acids derived from the RNA transcripts, hybridizing the nucleic acid sample to one or more probes, and detecting the hybridized nucleic acids and calculating a relative expression level relative to the control expression level of the same nucleic acids. A variety of methods have been employed to achieve this end. They include differential screening of cDNA libraries with selective probes, subtractive hybridization utilizing DNA/DNA hybrids or DNA/RNA hybrids, RNA fingerprinting and differential display (Mather, et al. (1981) *Cell* 23:369-378; Hedrick et al.

(1984) *Nature* 308:149-153; Davis et al. (1992) *Cell* 51:987-1000; Welsh et al. (1992) *Nucleic Acids Res.* 20:4965-4970; and Liang and Pardee (1992) *Science* 257:967-971). Recently, PCR-coupled subtractive processes have also been reported (Straus and Ausubel (1990) *Proc. Natl. Sci. USA* 87:1889-1893; Sive and John (1988) *Nucleic Acids Res.* 16:10937; Wieland et al. 5 (1990) *Proc. Natl. Acad. Sci. USA* 87:2720-2724; Wang and Brown (1991) *Proc. Natl. Acad. Sci. USA* 88:11505-11509; Lisitsyn et al. (1993) *Science* 259:946-951; Zeng et al. (1994) *Nucleic Acids Res.* 22:4381-4385; Hubank and Schatz (1994) *Nucleic Acids Res.* 22:5640-5648). Also recently, a microarray technology (DNA chips) developed by Affymetrix (Santa Clara, CA) has been used as a powerful tool to simultaneously identify a large number of differentially 10 expressed genes in a biological sample. Each of these methods can be employed in the present invention and is hereby incorporated by reference in entirety.

By using the Affymetrix chips (GeneChip Human Genome U133 Set), the inventors of the present invention identified two clusters of differentially expressed marker sequences that have shown at least a two-fold change (either increase or decrease) in expression level in 15 biological samples from tumor cells and/or tissue, e.g., colon cancer-derived cells and/or tissue, relative to the expression level in samples from normal cells and/or tissue, e.g., normal colon tissue and/or normal non-colon tissue. Table 1 describes 47 marker sequences that are over-expressed (up-regulated) in tumor cells and/or tissue, e.g., colon cancer-derived cells and/or tissue.

Table 1. Over-expressed Marker sequences

SEQ ID NO	Gene Symbol & Locus ID	Accession Number	Type	Corresponding Protein Accession Number	Protein SEQ ID NO
1	KRT23, 25984	NM_015515	RNA	NP_056330	94
2	REG1A, 5967	NM_002909	RNA	NP_002900	95
3	REG1B, 5968	NM_006507	RNA	NP_006498	96
4	DPEP1, 1800	NM_004413	RNA	NP_004404	97

5	IL8, 3576	NM_000584	RNA	NP_00575	98
6	MMP1, 4312	NM_002421	RNA	NP_002412	99
7	MMP7, 4316	NM_002423	RNA	NP_002414	100
8	SSP1, 6696	NM_000582	RNA	NP_000573	101
9	CXCL10, 3627	NM_001565	RNA	NP_001556	102
10	SULF1, 23213	NM_015170	RNA	NP_055985	103
11	COL5A2, 1290	NM_000393	RNA	NP_000384	104
12	CXCL1, 2919	NM_001511	RNA	NP_001502	105
13	CCL18, 6362	NM_002988	RNA	NP_002979	106
14	CDH11, 1009	NM_001797	RNA	NP_001788	107
15	BST2, 684	NM_004335	RNA	NP_004326	108
16	C20orf97, 57761	NM_021158	RNA	NP_066981	109
17	THBS2, 7058	NM_003247	RNA	NP_003238	110
18	G1P3, 2537	NM_022873	RNA	NP_075011	111
19	CKTSF1B1, 26585	NM_013372	RNA	NP_037504	112
20	MMP9, 4318	NM_004994	RNA	NP_004985	113
21	RAB31, 11031	NM_006868	RNA	NP_006859	114
22	DD96, 10158	NM_005764	RNA	NP_005755	115

23	SUPT4H1, 6827	NM_003168	RNA	NP_003159	116
24	FXVD5, 53827	NM_014164	RNA	NP_054883	117
25	CSPG2, 1462	NM_004385	RNA	NP_004376	118
26	LAPTM4B, 55353	NM_018407	RNA	NP_060877	119
27	SOX4, 6659	NM_003107	RNA	NP_003098	120
28	SORD, 6652	NM_003104	RNA	NP_003095	121
29	MMP12, 4321	NM_002426	RNA	NP_002417	122
30	UBD, 10537	NM_006398	RNA	NP_006389	123
31	DKFZp564I192 2, 25878	NM_015419	RNA	NP_056234	124
32	COL1A1, 1277	NM_000088	RNA	NP_000079	125
33	PLAB, 9518	NM_004864	RNA	NP_004855	126
34	SCD, 6319	NM_005063	RNA	NP_005054	127
35	CCL20, 6364	NM_004591	RNA	NP_004582	128
36	BACE2, 25825	NM_012105	RNA	NP_036237	129
37	GTF3A, 2971	NM_002097	RNA	NP_002088	130
38	C20orf42, 55612	NM_017671	RNA	NP_060141	131
39	OSF-2, 10631	NM_006475	RNA	NP_006466	132
40	SPARC, 6678	NM_003118	RNA	NP_003109	133

41	TGFBI, 7045	NM_000358	RNA	NP_000349	134
42	FN1, 2335	NM_002026	RNA	NP_002017	135
43	COL1A2, 1278	NM_000089	RNA	NP_000080	136
44	S100A11, 6282	NM_005620	RNA	NP_005611	137
45	IFITM1, 8519	NM_003641	RNA	NP_003632	138
46		AF130095	RNA	AAG35520	139
47	COL3A1, 1281	NM_000090	RNA	NP_000081	140

Accordingly, the present invention provides marker sequences in Table 1 that are over-expressed by at least about 2 fold, at least about 5 fold, at least about 10 fold, at least about 20 fold, or at least about 50 fold. In one embodiment, the present invention encompasses marker sequences that are over-expressed (up-regulated) in tumor cells and/or tissue, especially in colon cancer cells and/or tissue and/or colon cancer-derived cell lines. In a preferred embodiment, the marker sequences are over-expressed (up-regulated) by at least about 2 fold, at least about 5 fold, at least about 10 fold, at least about 20 fold, or at least about 50 fold.

Table 2 describes 46 marker sequences that are under-expressed (down-regulated) in tumor cells and/or tissue, e.g., colon cancer-derived cells and/or tissue.

Table 2 Under-expressed Marker sequences

SEQ ID NO	Gene Symbol & Locus ID	Accession Number	Type	Corresponding Protein Accession Number	Protein SEQ ID NO
48	GCG, 2641	NM_002054	RNA	NP_002045	141
49	SPINK5, 11005	NM_006846	RNA	NP_006837	142
50	ANPEP, 290	NM_001150	RNA	NP_001141	143

51	AQP8, 343	NM_001169	RNA	NP_001160	144
52	GUCA2B, 2981	NM_007102	RNA	NP_009033	145
53	CLCA4, 22802	NM_012128	RNA	NP_036260	146
54	PRV1, 57126	NM_020406	RNA	NP_065139	147
55	EKI1, 55500	NM_018638	RNA	NP_061108	148
56	FLJ22595, 80117	NM_025047	RNA	NP_079323	149
57	UGT2B15	NM_001076	RNA	NP_001067	150
58	CEACAM7, 1087	NM_006890	RNA	NP_008821	151
59	CHGA, 1113	NM_001275	RNA	NP_001266	152
60	HPGD, 3248	NM_000860	RNA	NP_000851	153
61	MGC4172, 79154	NM_024308	RNA	NP_077284	154
62	CA4, 762	NM_000717	RNA	NP_000708	155
63	IL1R2, 7850	NM_004633	RNA	NP_004624	156
64	FLJ20127, 54827	NM_017678	RNA	NP_060148	157
65	MS4A12, 54860	NM_017716	RNA	NP_060186	158
66	EMP1, 2012	NM_001423	RNA	NP_001414	159
67	SLC4A4, 8671	NM_003759	RNA	NP_003750	160

68	ADH1C, 126	NM_000669	RNA	NP_000660	161
69	CEACAM1, 634	NM_001712	RNA	NP_001703	162
70	MAWBP, 64081	NM_022129	RNA	NP_071412	163
71	PCK1, 5105	NM_002591	RNA	NP_002582	164
72	UGT2B17, 7367	NM_001077	RNA	NP_001068	165
73	HSD17B2	NM_002153	RNA	NP_002144	166
74	LOC63928, 63928	NM_022097	RNA	NP_071380	167
75	RDHL, 10170	NM_005771	RNA	NP_005762	168
76	GUCA1B, 2979	NM_002098	RNA	NP_002089	169
77	FHL1, 2273	NM_001449	RNA	NP_001440	170
78	ADAMDEC1, 27299	NM_014479	RNA	NP_055294	171
79	SPINK4, 27290	NM_014471	RNA	NP_055286	172
80	CA1, 759	NM_001738	RNA	NP_001729	173
81	SGK, 6446	NM_005627	RNA	NP_005618	174
82	CKB, 1152	NM_001823	RNA	NP_001814	175
83	SLC26A2, 1836	NM_000112	RNA	NP_000103	176
84	RNAHP, 11325	NM_007372	RNA	NP_031398	177
85	MUC2, 4583	NM_002457	RNA	NP_002448	178

86	HMGCS2, 3258	NM_005518	RNA	NP_005509	179
87	CLCA1, 1179	NM_001285	RNA	NP_001276	180
88	MT1F, 4494	NM_005949	RNA	NP_005940	181
89	CA2, 760	NM_000067	RNA	NP_000058	182
90	MT1H, 4496	NM_005951	RNA	NP_005942	183
91	MT1G, 4495	NM_005950	RNA	NP_005941	184
92	ZG16, 123887	NM_152338	RNA	NP_689551	185
93	MT1X, 4501	NM_005952	RNA	NP_005943	186

Accordingly, the present invention provides marker sequences in Table 2 that are under-expressed (down-regulated) by at least about 2 fold, at least about 5 fold, at least about 10 fold, at least about 20 fold, or at least about 50 fold. In one embodiment, the present invention encompasses marker sequences that are over-expressed (down-regulated) in tumor cells and/or tissue, especially in colon cancer cells and/or tissue and/or colon cancer-derived cell lines. In a preferred embodiment, the marker sequences are under-expressed (down-regulated) by at least about 2 fold, at least about 5 fold, at least about 10 fold, at least about 20 fold, or at least about 50 fold.

The present invention also encompasses sequences which differ from the marker sequences identified in Tables 1 and 2, but which produce the same phenotypic effect, for example, an allelic variant.

The present invention further encompasses polynucleotides which are at least about 85%, or at least about 90%, or more preferably equal to or greater than about 95% identical to the sequences of the RNA transcripts or cDNAs of the marker sequences. Sequence identity as used herein refers to the proportion of base matches between two nucleic acid sequences or the proportion amino acid matches between two amino acid sequences. When sequence homology is

expressed as a percentage, e.g., 50%, the percentage denotes the proportion of matches over the length of sequence from one sequence that is compared to some other sequence.

The identification of marker sequences that are differentially expressed in tumor cells and/or tissue as compared to normal cells and/or tissue, has applications in a number of ways.

5 For example, diagnosis may be done or confirmed by comparing patient samples with the known expression profiles. Similarly, a particular treatment may be evaluated, such evaluation including whether a therapeutic treatment improves the long-term prognosis in a particular patient. Furthermore, the gene expression profiles or individual genes allow screening drug candidates. These methods can also be done at protein level. That is, protein expression levels
10 of the marker sequences associated with the tumor or pre-malignant conditions can be evaluated for diagnostic and prognostic purposes or for screening candidate composition for inhibiting tumors or pre-malignant conditions.

IV Primers and probes

The nucleic acid sequences of the identified marker sequences that are differentially
15 expressed in tumor cells and/or tissue will further allow for the generation of probes and primers designed to detect transcripts or genomic sequences corresponding to one or more marker sequences of the present invention. The probe/primer is typically used as one or more substantially purified oligonucleotides. The primer/probe may comprise a portion or all of the sequences listed in SEQ ID NOs: 1-93, or sequences complementary thereto, or sequences which
20 hybridize under stringent conditions to a portion or all of SEQ ID NOs: 1-93. In one embodiment, the probe/primer can comprise a sequence that hybridizes under stringent conditions to at least about 7, preferably about 12, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400, or more consecutive nucleotides of SEQ ID NOs: 1-93 of the present invention. As used herein, the term "hybridizes under stringent
25 conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 75% (about 80%, 85%, preferably about 90%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in sections 6.3.1-6.3.6 of *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989). A preferred, non-limiting example of
30 stringent hybridization conditions for annealing two single-stranded DNA each of which is at least about 100 bases in length and/or for annealing a single-stranded DNA and a single-stranded

RNA each of which is at least about 100 bases in length, are hybridization in 6 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 x SSC, 0.1% SDS at 50-65°C. Further preferred hybridization conditions are taught in Lockhart, et al., *Nature Biotechnology*, 14:1675-1680 (1996); Breslauer, et al., *Proc. Natl. Acad. Sci. USA*, 83:3746-3750 (1986); Van Ness, et al., *Nucleic Acids Research*, 19: 5143-5151 (1991); McGraw, et al., *BioTechniques*, 8: 674-678 (1990); and Milner, et al., *Nature Biotechnology*, 15: 537-541 (1997), all expressly incorporated by reference.

In another embodiment, the probe/primer can comprise a sequence that hybridizes under moderately stringent conditions to at least about 7, preferably 12, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400, or more consecutive nucleotides of SEQ ID NOs: 1-93 of the present invention. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 x SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C to 60°C, 5 x SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2 x, 0.5 x, and 0.2 x SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed.

In particular, these probes are useful because they provide a method for detecting mutations in wild-type marker sequences of the present invention. Nucleic acid probes which are complementary to a wild-type marker sequence of the present invention and can form mismatches with mutant marker sequences are provided, allowing for detection by enzymatic or chemical cleavage or by shifts in electrophoretic mobility. Likewise, probes based on the subject sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins, for use, for example, in prognostic or diagnostic assays.

Nucleic acid probes may be generated using techniques which are well known to those of skill in the art (see, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989), or *Current Protocols in Molecular Biology*, F. Ausubel et al., ed. Greene Publishing and Wiley-Interscience, New York (1987).

In order to measure the hybridization of a nucleic acid probe to a target sequence in a biological sample, the probe is preferably labeled with a detectable label. In preferred embodiments, the probe further comprises a label group attached thereto and able to be detected. Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., DynabeadsTM), fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like), radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted light. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.

The labels may be incorporated into a nucleic acid probe by any of a number of means well known to those of skill in the art. However, in a preferred embodiment, the label is simultaneously incorporated into the probe during an amplification step in the preparation of the probe polynucleotides. Thus, for example, polymerase chain reaction (PCR), or other amplification reaction, with labeled primers or labeled nucleotides will provide a labeled amplification product, and thus a labeled probe.

Alternatively, a label may be added directly to the probe. Means of attaching labels to polynucleotides are well known to those of skill in the art and include, for example nick translation or end-labeling (e.g. with a labeled RNA) and subsequent attachment (ligation) of a polynucleotide linker joining the sample polynucleotide to a label (e.g., a fluorophore).

In a preferred embodiment, the fluorescent modifications are by cyanine dyes e.g. Cy-3/Cy-5 dUTP, Cy-3/Cy-5 dCTP (Amersham Pharmacia) or alexa dyes (Khan, J., Simon, R., Bittner, M., Chen, Y., Leighton, S. B., Pohida, T., Smith, P. D., Jiang, Y., Gooden, G. C., Trent, J. M. & Meltzer, P. S. (1998) *Cancer Res.* 58, 50095013.).

5 V Polynucleotide composition

Full-length cDNA molecules comprising the disclosed nucleic acids of the marker sequences, useful for the generation of probes, primers, or for transcription to produce the protein of the marker sequences, or antibodies thereto may be obtained as follows. The nucleic acid sequences of the marker sequences or a portion thereof comprising at least approximately 8,
10 preferably about 12, preferably about 15, preferably about 25, more preferably about 40 nucleotides up to the full length of the sequence of SEQ ID NOs: 1-93, or a sequence complementary thereto, may be used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection techniques as described in U.S. Patent No. 5,654,173, "Secreted Proteins and Polynucleotides Encoding
15 Them," incorporated herein by reference. Libraries of cDNA may be made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical compound. Preferably, the tissue is the same as that used to generate the nucleic acids, as both the nucleic acid and the cDNA represent expressed genes. Alternatively, many cDNA libraries are available commercially. (Sambrook et al., *Molecular Cloning: A Laboratory
20 Manual*, 2nd Ed. (Cold Spring Harbor Press, Cold Spring Harbor, NY 1989). The choice of cell type for library construction may be made after the identity of the protein encoded by the nucleic acid-related gene is known. This will indicate which tissue and cell types are likely to express the related gene, thereby containing the mRNA for generating the cDNA.

Members of the library that are larger than the nucleic acid, and preferably that contain
25 the whole sequence of the native message, may be obtained. To confirm that the entire cDNA has been obtained, RNA protection experiments may be performed as follows. Hybridization of a full-length cDNA to an mRNA may protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized may be subject to RNase degradation. This may be assayed, as is known in the art, by changes in electrophoretic mobility
30 on polyacrylamide gels, or by detection of released mononucleotides. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed. (Cold Spring Harbor Press, Cold Spring

Harbor, NY 1989). In order to obtain additional sequences 5' to the end of a partial cDNA, 5' RACE (*PCR Protocols: A Guide to Methods and Applications* (Academic Press, Inc. 1990)) may be performed.

5 Genomic DNAs of the marker sequences may be isolated using nucleic acids in a manner similar to the isolation of full-length cDNAs. Briefly, the nucleic acids, or portions thereof, may be used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the nucleic acids. Most preferably, the genomic DNA is obtained from the biological material described herein in the Example. Such libraries may be in vectors suitable for carrying large segments of a genome, such as P1 or YAC, as described in detail in 10 Sambrook et al., pages 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntsville, Alabama, USA, for example. In order to obtain additional 5' or 3' sequences, chromosome walking may be performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These may be mapped and pieced together, as is 15 known in the art, using restriction digestion enzymes and DNA ligase.

Using the nucleic acids of the invention, corresponding full length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using either method, Northern blots, preferably, may be performed on a number of cell types to determine which cell lines express the gene of interest at the highest rate.

20 Classical methods of constructing cDNA libraries in Sambrook et al., *supra*. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be produced using the instant marker sequences or portions thereof as primers.

25 PCR methods may be used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert may contain sequence from the full length cDNA that corresponds to the sequence encoding Reg1 α . Such PCR methods include gene trapping and RACE methods.

Gene trapping may entail inserting a member of a cDNA library into a vector. The vector then may be denatured to produce single stranded molecules. Next, a substrate-bound probe, such as biotinylated oligonucleotide, may be used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence may be based on the nucleic acid of SEQ ID NOs: 1-93, or a sequence complementary thereto. Random primers or primers specific to the library vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al., PCT WO 95/04745 and Gruber et al., U.S. Pat. No. 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.

“Rapid amplification of cDNA ends,” or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs may be ligated to an oligonucleotide linker and amplified by PCR using two primers. One primer may be based on sequence from the instant nucleic acids, for which full length sequence is desired, and a second primer may comprise a sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this method is reported in PCT Pub. No. WO 97/19110.

In preferred embodiments of RACE, a common primer may be designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, *Biotechniques* 15:890-893 (1993); Edwards et al., *Nuc. Acids Res.* 19:5227-5232 (1991)). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook 15.3-15.63. The choice of codon or nucleotide to be replaced can be based on the disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.

As an alternative method to obtaining DNA or RNA from a biological material, such as serum, nucleic acid comprising nucleotides having the sequence of one or more nucleic acids of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from about 8 nucleotides (corresponding to at least 12 contiguous nucleotides

which hybridize under stringent conditions to or are at least 80% identical to the nucleic acid sequence of SEQ ID NOs:1-93, or a sequence complementary thereto) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid comprising the size of the full marker genes, or a sequence complementary thereto; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b); and (e) a recombinant viral particle comprising (a) or (b).

The sequence of a nucleic acid of the present invention is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired.

In various embodiments described above, the polynucleotides of the present invention can be modified at the base moiety, sugar moiety, or phosphate backbone to improve the stability, hybridization, or solubility of the molecule. For example, detectable markers (avidin, biotin, radioactive elements, fluorescent tags and dyes, energy transfer labels, energy-emitting labels, binding partners, etc.) or moieties which improve hybridization, detection, and/or stability can be attached to the polynucleotides. The polynucleotides can also be attached to solid supports, e.g., nitrocellulose, magnetic or paramagnetic microspheres (e.g., as described in U.S. Pat. Nos. 5,411,863; 5,543,289; for instance, comprising ferromagnetic, super-magnetic, paramagnetic, superparamagnetic, iron oxide and polysaccharide), nylon, agarose, diazotized cellulose, latex solid microspheres, polyacrylamides, etc., according to a desired method. See, e.g., U.S. Pat. Nos. 5,470,967, 5,476,925, and 5,478,893.

Polynucleotide according to the present invention can be labeled according to any desired method. The polynucleotide can be labeled using radioactive tracers such as ^{32}P , ^{35}S , ^3H , or ^{14}C , to mention some commonly used tracers. The radioactive labeling can be carried out according to any method, such as, for example, terminal labeling at the 3' or 5' end using a radiolabeled nucleotide, polynucleotide kinase (with or without dephosphorylation with a phosphatase) or a ligase (depending on the end to be labeled). A non-radioactive labeling can also be used, combining a polynucleotide of the present invention with residues having immunological

properties (antigens, haptens), a specific affinity for certain recomounds (ligands), properties enabling detectable enzyme reactions to be completed (enzymes or coenzymes, enzyme substrates, or other substances involved in an enzymatic reaction), or characteristic physical properties, such as fluorescence or the emission or absorption of light at a desired wavelength, etc.

VI Vectors and host cells

The present invention further provides vectors and plasmids useful for directing the expression of marker sequences, and further provides host cells which express the vectors and plasmids provided herein. Nucleic acid sequences useful for the expression from a vector or plasmid as described below include, but are not limited to any nucleic acid or gene sequence identified as being differentially regulated by the methods described above, and further include therapeutic nucleic acid molecules, such as antisense molecules. The host cell may be any prokaryotic or eukaryotic cell. Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures well known in the art.

Vectors

There is a wide array of vectors known and available in the art that are useful for the expression of differentially expressed nucleic acid molecules according to the invention. The selection of a particular vector clearly depends upon the intended use the polypeptide encoded by the differentially expressed nucleic acid. For example, the selected vector must be capable of driving expression of the polypeptide in the desired cell type, whether that cell type be prokaryotic or eukaryotic. Many vectors comprise sequences allowing both prokaryotic vector replication and eukaryotic expression of operably linked gene sequences.

Vectors useful according to the invention may be autonomously replicating, that is, the vector, for example, a plasmid, exists extrachromosomally and its replication is not necessarily directly linked to the replication of the host cell's genome. Alternatively, the replication of the vector may be linked to the replication of the host's chromosomal DNA, for example, the vector may be integrated into the chromosome of the host cell as achieved by retroviral vectors.

Vectors useful according to the invention preferably comprise sequences operably linked to the sequence of interest (e.g., the marker sequences) that permit the transcription and translation of the sequence. Sequences that permit the transcription of the linked sequence of interest include a promoter and optionally also include an enhancer element or elements permitting the strong expression of the linked sequences. The term "transcriptional regulatory sequences" refers to the combination of a promoter and any additional sequences conferring desired expression characteristics (e.g., high level expression, inducible expression, tissue- or cell-type-specific expression) on an operably linked nucleic acid sequence.

The selected promoter may be any DNA sequence that exhibits transcriptional activity in the selected host cell, and may be derived from a gene normally expressed in the host cell or from a gene normally expressed in other cells or organisms. Examples of promoters include, but are not limited to the following: A) prokaryotic promoters - *E. coli* lac, tac, or trp promoters, lambda phage P_R or P_L promoters, bacteriophage T7, T3, Sp6 promoters, *B. subtilis* alkaline protease promoter, and the *B. stearothermophilus* maltogenic amylase promoter, etc.; B) eukaryotic promoters - yeast promoters, such as GAL1, GAL4 and other glycolytic gene promoters (see for example, Hitzeman et al., 1980, *J. Biol. Chem.* 255: 12073-12080; Alber & Kawasaki, 1982, *J. Mol. Appl. Gen.* 1: 419-434), LEU2 promoter (Martinez-Garcia et al., 1989, *Mol Gen Genet.* 217: 464-470), alcohol dehydrogenase gene promoters (Young et al., 1982, in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al., eds., Plenum Press, NY), or the TPI1 promoter (U.S. Pat. No. 4,599,311); insect promoters, such as the polyhedrin promoter (U.S. Pat. No. 4,745,051; Vasuvedan et al., 1992, *FEBS Lett.* 311: 7-11), the P10 promoter (Vlak et al., 1988, *J. Gen. Virol.* 69: 765-776), the *Autographa californica* polyhedrosis virus basic protein promoter (EP 397485), the baculovirus immediate-early gene promoter gene 1 promoter (U.S. Pat. Nos. 5,155,037 and 5,162,222), the baculovirus 39K delayed-early gene promoter (also U.S. Pat. Nos. 5,155,037 and 5,162,222) and the OpMNPV immediate early promoter 2; mammalian promoters - the SV40 promoter (Subramani et al., 1981, *Mol. Cell. Biol.* 1: 854-864), metallothionein promoter (MT-1; Palmiter et al., 1983, *Science* 222: 809-814), adenovirus 2 major late promoter (Yu et al., 1984, *Nucl. Acids Res.* 12: 9309-21), cytomegalovirus (CMV) or other viral promoter (Tong et al., 1998, *Anticancer Res.* 18: 719-725), or even the endogenous promoter of a gene of interest in a particular cell type.

A selected promoter may also be linked to sequences rendering it inducible or tissue-specific. For example, the addition of a tissue-specific enhancer element upstream of a selected promoter may render the promoter more active in a given tissue or cell type. Alternatively, or in addition, inducible expression may be achieved by linking the promoter to any of a number of sequence elements permitting induction by, for example, thermal changes (temperature sensitive), chemical treatment (for example, metal ion- or IPTG-inducible), or the addition of an antibiotic inducing compound (for example, tetracycline).

Regulatable expression is achieved using, for example, expression systems that are drug inducible (e.g., tetracycline, rapamycin or hormone-inducible). Drug-regulatable promoters that are particularly well suited for use in mammalian cells include the tetracycline regulatable promoters, and glucocorticoid steroid-, sex hormone steroid-, ecdysone-, lipopolysaccharide (LPS)- and isopropylthiogalactoside (IPTG)-regulatable promoters. A regulatable expression system for use in mammalian cells should ideally, but not necessarily, involve a transcriptional regulator that binds (or fails to bind) nonmammalian DNA motifs in response to a regulatory agent, and a regulatory sequence that is responsive only to this transcriptional regulator.

Tissue-specific promoters may also be used to advantage in differentially expressed sequence-encoding constructs of the invention. A wide variety of tissue-specific promoters is known. As used herein, the term "tissue-specific" means that a given promoter is transcriptionally active (i.e., directs the expression of linked sequences sufficient to permit detection of the polypeptide product of the promoter) in less than all cells or tissues of an organism. A tissue specific promoter is preferably active in only one cell type, but may, for example, be active in a particular class or lineage of cell types (e.g., hematopoietic cells). A tissue specific promoter useful according to the invention comprises those sequences necessary and sufficient for the expression of an operably linked nucleic acid sequence in a manner or pattern that is essentially the same as the manner or pattern of expression of the gene linked to that promoter in nature. The following is a non-exclusive list of tissue specific promoters and literature references containing the necessary sequences to achieve expression characteristic of those promoters in their respective tissues; the entire content of each of these literature references is incorporated herein by reference. Examples of tissue specific promoters useful in the present invention are as follows:

Bowman et al., 1995 *Proc. Natl. Acad. Sci. USA* 92,12115-12119 describe a brain-specific transferrin promoter; the synapsin I promoter is neuron specific (Schoch et al., 1996 *J. Biol. Chem.* 271, 3317-3323); the nestin promoter is post-mitotic neuron specific (Uetsuki et al., 1996 *J. Biol. Chem.* 271, 918-924); the neurofilament light promoter is neuron specific (Charron et al., 1995 *J. Biol. Chem.* 270, 30604-30610); the acetylcholine receptor promoter is neuron specific (Wood et al., 1995 *J. Biol. Chem.* 270, 30933-30940); and the potassium channel promoter is high-frequency firing neuron specific (Gan et al., 1996 *J. Biol. Chem.* 271, 5859-5865). Any tissue specific transcriptional regulatory sequence known in the art may be used to advantage with a vector encoding a differentially expressed nucleic acid sequence obtained from an animal subjected to pain.

In addition to promoter/enhancer elements, vectors useful according to the invention may further comprise a suitable terminator. Such terminators include, for example, the human growth hormone terminator (Palmiter et al., 1983, *supra*), or, for yeast or fungal hosts, the TPII (Alber & Kawasaki, 1982, *supra*) or ADH3 terminator (McKnight et al., 1985, *EMBO J.* 4: 2093-2099).

Vectors useful according to the invention may also comprise polyadenylation sequences (e.g., the SV40 or Ad5E1b poly(A) sequence), and translational enhancer sequences (e.g., those from Adenovirus VA RNAs). Further, a vector useful according to the invention may encode a signal sequence directing the recombinant polypeptide to a particular cellular compartment or, alternatively, may encode a signal directing secretion of the recombinant polypeptide.

a. Plasmid vectors.

Any plasmid vector that allows expression of a coding sequence of interest (e.g., the coding sequence of Reg1 α) in a selected host cell type is acceptable for use according to the invention. A plasmid vector useful in the invention may have any or all of the above-noted characteristics of vectors useful according to the invention. Plasmid vectors useful according to the invention include, but are not limited to the following examples: Bacterial - pQE70, pQE60, pQE-9 (Qiagen) pBs, phagescript, psiX174, pBluescript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia); Eukaryotic - pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other plasmid or vector may be used as long as it is replicable and viable in the host.

b. Bacteriophage vectors.

There are a number of well known bacteriophage-derived vectors useful according to the invention. Foremost among these are the lambda-based vectors, such as Lambda Zap II or Lambda-Zap Express vectors (Stratagene) that allow inducible expression of the polypeptide encoded by the insert. Others include filamentous bacteriophage such as the M13-based family of vectors.

c. Viral vectors.

A number of different viral vectors are useful according to the invention, and any viral vector that permits the introduction and expression of one or more of the polynucleotides of the invention in cells is acceptable for use in the methods of the invention. Viral vectors that can be used to deliver foreign nucleic acid into cells include but are not limited to retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and Semliki forest viral (alphaviral) vectors. Defective retroviruses are well characterized for use in gene transfer (for a review see Miller, A.D. (1990) *Blood* 76:271). Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals.

In addition to retroviral vectors, Adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle (see for example Berkner et al., 1988, *BioTechniques* 6:616; Rosenfeld et al., 1991, *Science* 252:431-434; and Rosenfeld et al., 1992, *Cell* 68:143-155). Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Adeno-associated virus (AAV) is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al., 1992, *Curr. Topics in Micro. and Immunol.* 158:97-129). An AAV vector such as that described in Traschin et al. (1985, *Mol. Cell. Biol.* 5:3251-3260) can be used to introduce nucleic acid into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see, for example,

Hermonat et al., 1984, *Proc. Natl. Acad. Sci. USA* 81: 6466-6470; and Traschin et al., 1985, *Mol. Cell. Biol.* 4: 2072-2081).

Host cells

Any cell into which a recombinant vector carrying a gene of interest (e.g., a sequence
5 encoding the marker sequences) may be introduced and wherein the vector is permitted to drive
the expression of the peptide encoded by the differentially expressed sequence is useful
according to the invention. Any cell in which a differentially expressed molecule of the
invention may be expressed and preferably detected is a suitable host, wherein the host cell is
preferably a mammalian cell and more preferably a human cell. Vectors suitable for the
10 introduction of nucleic acid sequences to host cells from a variety of different organisms, both
prokaryotic and eukaryotic, are described herein above or known to those skilled in the art.

Host cells may be prokaryotic, such as any of a number of bacterial strains, or may be
eukaryotic, such as yeast or other fungal cells, insect or amphibian cells, or mammalian cells
including, for example, rodent, simian or human cells. Cells may be primary cultured cells, for
15 example, primary human fibroblasts or keratinocytes, or may be an established cell line, such as
NIH3T3, 293T or CHO cells. Further, mammalian cells useful in the present invention may be
phenotypically normal or oncogenically transformed. It is assumed that one skilled in the art can
readily establish and maintain a chosen host cell type in culture.

Introduction of vectors to host cells.

20 Vectors useful in the present invention may be introduced to selected host cells by any of
a number of suitable methods known to those skilled in the art. For example, vector constructs
may be introduced to appropriate bacterial cells by infection, in the case of *E. coli* bacteriophage
vector particles such as lambda or M13, or by any of a number of transformation methods for
plasmid vectors or for bacteriophage DNA. For example, standard calcium-chloride-mediated
25 bacterial transformation is still commonly used to introduce naked DNA to bacteria (Sambrook
et al., 1989, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY), but electroporation may also be used (Ausubel et al., 1988, *Current
Protocols in Molecular Biology*, (John Wiley & Sons, Inc., NY, NY)).

For the introduction of vector constructs to yeast or other fungal cells, chemical transformation methods are generally used (e.g. as described by Rose et al., 1990, *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). For transformation of *S. cerevisiae*, for example, the cells are treated with lithium acetate to achieve transformation efficiencies of approximately 10^4 colony-forming units (transformed cells)/ μ g of DNA. Transformed cells are then isolated on selective media appropriate to the selectable marker used. Alternatively, or in addition, plates or filters lifted from plates may be scanned for GFP fluorescence to identify transformed clones.

For the introduction of vectors comprising a sequence of interest to mammalian cells, the method used will depend upon the form of the vector. Plasmid vectors may be introduced by any of a number of transfection methods, including, for example, lipid-mediated transfection ("lipofection"), DEAE-dextran-mediated transfection, electroporation or calcium phosphate precipitation. These methods are detailed, for example, in *Current Protocols in Molecular Biology* (Ausubel et al., 1988, John Wiley & Sons, Inc., NY, NY).

Lipofection reagents and methods suitable for transient transfection of a wide variety of transformed and non-transformed or primary cells are widely available, making lipofection an attractive method of introducing constructs to eukaryotic, and particularly mammalian cells in culture. For example, LipofectAMINETM (Life Technologies) or LipoTaxiTM (Stratagene) kits are available. Other companies offering reagents and methods for lipofection include Bio-Rad Laboratories, CLONTECH, Glen Research, InVitrogen, JBL Scientific, MBI Fermentas, PanVera, Promega, Quantum Biotechnologies, Sigma-Aldrich, and Wako Chemicals USA.

Following transfection with a vector of the invention, eukaryotic (e.g., human) cells successfully incorporating the construct (intra- or extrachromosomally) may be selected, as noted above, by either treatment of the transfected population with a selection agent, such as an antibiotic whose resistance gene is encoded by the vector, or by direct screening using, for example, FACS of the cell population or fluorescence scanning of adherent cultures. Frequently, both types of screening may be used, wherein a negative selection is used to enrich for cells taking up the construct and FACS or fluorescence scanning is used to further enrich for cells expressing differentially expressed polynucleotides or to identify specific clones of cells, respectively. For example, a negative selection with the neomycin analog G418 (Life Technologies, Inc.) may be used to identify cells that have received the vector, and fluorescence

scanning may be used to identify those cells or clones of cells that express the vector construct to the greatest extent.

VII Polypeptides

One aspect of the present invention pertains to isolated polypeptides which correspond to individual marker sequences of the present invention, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide encoded by a nucleic acid marker sequence of the present invention. In one embodiment, the native polypeptide encoded by a marker sequence can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides encoded by a nucleic acid marker sequence of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide encoded by a nucleic acid marker sequence of the invention can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a polypeptide encoded by a nucleic acid marker sequence of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein encoded by the nucleic acid marker sequence (e.g., the amino acid sequence listed in the GenBank and IMAGE Consortium database records described herein), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

The polypeptides may contain amino acid substitutions, deletions or insertions made on the basis of similarity in polarity, charge, solubility, hydrophobicity, and/or the amphipathic nature of the residues involved. Such substitutions may be conservative in nature when the substituted residue has structural or chemical properties similar to the original residue (e.g., replacement of leucine with isoleucine or valine) or they may be nonconservative when the replacement residue is radically different (e.g., a glycine replaced by a tryptophan). Computer programs included in LASERGENE software (DNASTAR, Madison, Wis.) and algorithms included in RasMol software (University of Massachusetts, Amherst, Mass.) may be used to help determine which and how many amino acid residues in a particular portion of the protein may be substituted, inserted, or deleted without abolishing biological or immunological activity.

The present invention also provides chimeric or fusion proteins corresponding to a marker sequence of the invention. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably a biologically active part) of a polypeptide encoded by a nucleic acid marker sequence of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the polypeptide encoded by the nucleic acid marker sequence). Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.

One useful fusion protein is a GST fusion protein in which a polypeptide encoded by a nucleic acid marker sequence of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

5 In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a polypeptide encoded by a nucleic acid marker sequence of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence the baculovirus envelope protein can be used as a heterologous signal sequence (Ausubel et al., ed., *Current Protocols in Molecular*
10 *Biology*, John Wiley & Sons, NY, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, Calif.). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, N.J.). A signal sequence can be used to facilitate
15 secretion and isolation of the secreted protein or other proteins of interest.

In addition to recombinant production, proteins or portions thereof may be produced manually, using solid-phase techniques (Stewart et al. (1969) *Solid-Phase Peptide Synthesis*, WH Freeman, San Francisco, Calif.; Merrifield (1963) *J Am Chem Soc* 5:2149-2154), or using machines such as the 431A peptide synthesizer (Applied Biosystems (ABI), Foster City, Calif.).
20 Proteins produced by any of the above methods may be used as pharmaceutical compositions to treat disorders associated with null or inadequate expression of the genomic sequence.

VIII Antibodies

Another aspect of the present invention pertains to antibodies directed to polypeptides and fragments thereof of the marker sequences of the present invention. An isolated polypeptide
25 encoded by a nucleic acid marker sequence of the present invention, or fragment thereof, can be used as an immunogen to generate antibodies using standard techniques. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, or chimeric antibodies, single chain antibodies, Fab fragments, Fv fragments F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic antibodies, or other
30 epitope binding polypeptide. Preferably, an antibody, useful in the present invention for the

detection of the individual marker sequences (and optionally at least one additional colon cancer-specific marker), is a human antibody or fragment thereof, including scFv, Fab, Fab', F(ab'), Fd, single chain antibody, or Fv. Antibodies, useful in the invention may include a complete heavy or light chain constant region, or a portion thereof, or an absence thereof. An antibody, useful in the invention, may be obtained from an art recognized host, such as rabbit, mouse, rat, donkey, sheep, goat, guinea pig, camel, horse, or chicken. In one embodiment, an antibody, useful in the invention can be a humanized antibody, in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability. Methods for making humanized antibodies are described in Teng et al., 1983, *Proc. Natl. Acad. Sci. USA* 80: 7308-7312; Kozbor et al., 1983, *Immunology Today* 4: 7279; Olsson et al., 1982, *Meth. Enzymol.* 92: 3-16; WO 92/06193; EP 0239400.

Antibodies of the present invention may be monospecific, dispecific, trispecific, or of greater multispecificity. As such, the individual marker sequences useful for the detection of cancer maybe detected with separate antibodies, or may be detected with the same antibody. Alternatively, a multispecific antibody may exhibit different specificities for different epitopes on the same protein (e.g., different epitopes on a marker sequence). While specificity of an antibody useful in the present invention to one or more additional cancer-specific markers is preferred, antibodies that bind polypeptides with at least 95%, 90%, 85%, 75%, 65%, 55%, and at least 50% identity to a polypeptide useful in the present invention for the detection of cancer, particularly colon cancer are also included in the present invention. Also encompassed in the present invention are antibodies which bind to polypeptide molecules which are encoded by one or more nucleic acid sequences which are complementary to, or hybridize to the sequences of SEQ ID NOs: 1-93.

Antibodies of the present invention which are useful for the detection of colon cancer may further act as agonists or antagonists of the activity of the polypeptide molecules to which they bind, and may thus be useful as therapeutic molecules for the treatment or prevention of colon cancer.

An important, but not limiting, role of an antibody of the present invention is to provide for the purification, or detection of individual marker sequences in a patient sample, including both *in vitro* and *in vivo* detection methods. Antibodies useful for the detection of colon cancer as described herein do not have to be used alone, and can be fused to other polypeptides,

including a heterologous polypeptide at the N- or C-terminus of the antibody polypeptide sequence. For example, an antibody useful in the present invention may be fused with a detectable label to facilitate detection of the antibody when bound to a target polypeptide. Methods for detectably labeling an antibody polypeptide are known to those of skill in the art.

5 For the production of antibodies useful in the present invention, various hosts including goats, rabbits, rats, mice, etc., may be immunized by injection with the protein products (or any portion, fragment, or oligonucleotide thereof which retains immunogenic properties) of the candidate genes of the invention. Depending on the host species, various adjuvants may be used to increase the immunological response. Such adjuvants include but are not limited to Freund's, 10 mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are potentially useful human adjuvants.

Polyclonal antisera or monoclonal antibodies can be made using methods known in the 15 art. A mammal such as a mouse, hamster, or rabbit, can be immunized with an immunogenic form of a marker polypeptide, fragment, modified form thereof, or variant form thereof. Alternatively, an animal may be immunized with an immunogenic form of one or more additional colon cancer-specific marker polypeptides. Techniques for conferring 20 immunogenicity on such molecules include conjugation to carriers or other techniques well known in the art. For example, the immunogenic molecule can be administered in the presence of adjuvant as described above. Immunization can be monitored by detection of antibody titers in plasma or serum. Standard immunoassay procedures can be used with the immunogen as antigen to assess the levels and the specificity of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

25 To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art (see, e.g., Kohler and Milstein, 1975, *Nature* 256: 495-497; Kozbor et al., 1983, *Immunol. Today* 4: 72, Cole et al., 1985, In *Monoclonal Antibodies in Cancer Therapy*, 30 Allen R. Bliss, Inc., pages 77-96). Additionally, techniques described for the production of

single-chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce antibodies according to the invention.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Pat. No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Antibody fragments which can specifically bind to a marker polypeptide of the present invention, or fragments thereof, modified forms thereof, and variants thereof, also may be generated by known techniques. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. VH regions and FV regions can be expressed in bacteria using phage expression libraries (e.g., Ward et al., 1989, *Nature* 341: 544-546; Huse et al., 1989, *Science* 246: 1275-1281; McCafferty et al., 1990, *Nature* 348: 552-554).

Chimeric antibodies, i.e., antibody molecules that combine a non-human animal variable region and a human constant region also are within the scope of the invention. Chimeric antibody molecules include, for example, the antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. Standard methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes the gene product of individual marker antigens of the invention (see, e.g., Morrison et al., 1985,

Proc. Natl. Acad. Sci. USA 81: 6851; Takeda et al., 1985, *Nature* 314: 452; U.S. Patent No. 4,816,567; U.S. Patent No. 4,816,397).

Antibodies of the invention may be used as therapeutic agents in treating cancers. In a preferred embodiment, completely human antibodies of the invention are used for therapeutic
5 treatment of human cancer patients, particularly those having cervical cancer. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide encoded by a nucleic acid marker sequences of the
10 invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for
15 producing human antibodies, see Lonberg and Huszar (1995) *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Pat. No. 5,625,126; U.S. Pat. No. 5,633,425; U.S. Pat. No. 5,569,825; U.S. Pat. No. 5,661,016; and U.S. Pat. No. 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, Calif.), can be engaged to
20 provide human antibodies directed against a selected antigen using technology similar to that described above.

An antibody directed against a polypeptide encoded by a nucleic acid marker sequence of the invention (e.g., a monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an
25 antibody can be used to detect the marker sequence (e.g., in a cellular lysate or cell supernatant) in order to evaluate the level and pattern of expression of the marker sequence. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in an ovary-associated body fluid) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the
30 antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and

radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, .beta.-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Further, an antibody (or fragment thereof) can be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), .sup.bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine). Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described in U.S. Pat. No. 4,676,980.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84; Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in

Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.*, 62:119-58 (1982).

IX Detection of the marker sequences

5 In one aspect, the expression levels of the differentially expressed marker sequences are determined in normal and cancer cells and/or tissue, especially the colon cancer cells and/or tissue. In general, the present invention relates to methods of detecting a differentially-expressed nucleic acid sequence in a sample comprising nucleic acid. Such methods can comprise one or more of the following steps in any effective order, e.g., contacting said sample with
10 polynucleotide probes under conditions effective for said probe to hybridize specifically to the nucleic acids of the marker sequences in said sample, and detecting the presence or absence of the nucleic acid marker sequences in said sample. In one preferred embodiment, said probes are polynucleotides designed to identify the marker sequences either in Table 1 or Table 2. The detection method can be applied to any sample, e.g., cultured primary, secondary, or established
15 cell lines, tissue biopsy, blood, urine, stool, cerebral spinal fluid, and other bodily fluids, for any purpose.

In one embodiment, the probes of the individual and/or combinations of the marker sequences are applied to the samples obtained from both the normal and colon cancer cell lines, and the presence of the marker sequences are detected with the methods describes herein. In
20 another embodiment, the probes of the individual and/or combinations of the marker sequences are applied to the samples obtained from both the normal and colon cancer tissue, and the amount of the marker sequences are detected with the methods describes herein. For example, one determination assay can employ the over-expressed marker sequences in combination with an the over-expressed or an under-expressed marker sequences. Moreover, the determination
25 assay can employ a panel of at least two, or at least three, or at least four or more marker sequences, selected from both the over-expressed and the under-expressed marker sequences.

The methods of detecting the presence of the marker sequences can be carried out by any effective process, e.g., by Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, in situ hybridization, etc.. When PCR based techniques are
30 used, two or more probes are generally used. One probe can be specific for a defined sequence

which is characteristic of a selective polynucleotide, but the other probe can be specific for the selective polynucleotide, or specific for a more general sequence, e.g., a sequence such as polyA which is characteristic of mRNA, a sequence which is specific for a promoter, ribosome binding site, or other transcriptional features, a consensus sequence (e.g., representing a functional domain). For the former aspects, 5' and 3' probes (e.g., polyA, Kozak, etc.) are preferred which are capable of specifically hybridizing to the ends of transcripts. When PCR is utilized, the probes can also be referred to as "primers" in that they can prime a DNA polymerase reaction.

In addition to testing for the presence or absence of the marker polynucleotides, the present invention also relates to determining the amounts at which the marker sequences of the present invention are expressed in samples and determining the differential expression of such marker sequences in samples. Such methods can involve substantially the same steps as described above for presence/absence detection, e.g., contacting with probe, hybridizing, and detecting hybridized probe, but using more quantitative methods and/or comparisons to standards. The amount of hybridization between the probe and target can be determined by any suitable methods, e.g., PCR, RT-PCR, RACE PCR, Northern blot, polynucleotide microarrays, Rapid-Scan, etc., and includes both quantitative and qualitative measurements.

In one embodiment, reverse transcription PCR (RT-PCR) is performed using primers designed to specifically hybridize to a predetermined portion of the marker mRNA sequences isolated from a clinical sample. Generation of a PCR product by such a reaction is thus indicative of the presence of the marker sequences in the sample. The technique of designing primers for PCR amplification is well known in the art. Oligonucleotide primers and probes are about 5 to 100 nucleotides in length, ideally from about 17 to 40 nucleotides, although primers and probes of different length are of use. Primers for amplification are preferably about 17-25 nucleotides. Primers useful according to the invention are also designed to have a particular melting temperature (T_m) by the method of melting temperature estimation. Commercial programs, including Oligo™ (MBI, Cascade, CO), Primer Design and programs available on the internet, including Primer3 and Oligo Calculator can be used to calculate a T_m of a nucleic acid sequence useful according to the invention. Preferably, the T_m of an amplification primer useful according to the invention, as calculated for example by Oligo Calculator, is preferably between about 45 and 65° C and more preferably between about 50 and 60° C. Preferably, the T_m of a probe useful according to the invention is 7° C higher than the T_m of the corresponding

amplification primers. It is preferred that, following generation of cDNA by RT-PCR, the cDNA fragment is cloned into an appropriate sequencing vector, such as a PCRII vector (TA cloning kit; Invitrogen). The identity of each cloned fragment is then confirmed by sequencing in both directions. It is expected that the sequence obtained from sequencing would be the same as the known sequences of the marker sequences as described herein.

Alternatively, the presence of mRNA sequences encoding the marker sequences may be detected by Northern analysis. Sequence confirmed cDNAs, that is, cDNAs encoding the marker sequences are used to produce ^{32}P -labeled cDNA probes using techniques well known in the art (see, for example, Ausubel, *supra*). Labeled probes for Northern analysis may also be produced using commercially available kits (Prime-It Kit, Stratagene, La Jolla, CA). Northern analysis of total RNA obtained from a clinical sample may be performed using classically described techniques. For example, total RNA samples are denatured with formaldehyde / formamide and run for two hours in a 1% agarose, MOPS-acetate-EDTA gel. RNA is then transferred to nitrocellulose membrane by upward capillary action and fixed by UV cross-linkage. Membranes are pre-hybridized for at least 90 minutes and hybridized overnight at 42° C. Post hybridization washes are performed as known in the art (Ausubel, *supra*). The membrane is then exposed to x-ray film overnight with an intensifying screen at -80° C. Labeled membranes are then visualized after exposure to film. The signal produced on the x-ray film by the radiolabeled cDNA probes can then be quantified using any technique known in the art, such as scanning the film and quantifying the relative pixel intensity using a computer program such as NIH Image (National Institutes of Health, Bethesda, MD), wherein the detection of hybridization of a marker-specific probe to the clinical sample is indicative of the presence of the marker sequences and thus may be used to detect cancer such as colon cancer.

In an alternative embodiment, the presence and optionally the quantity of the marker sequences in a clinical sample may be determined using the Taqman™ (Perkin-Elmer, Foster City, CA) technique, which is performed with a transcript-specific antisense probe (i.e., a probe capable of specifically hybridizing to a marker sequence). This probe is specific for a marker sequence PCR product and is prepared with a quencher and fluorescent reporter probe complexed to the 5' end of the oligonucleotide. Different fluorescent markers can be attached to different reporters, allowing for measurement of two products in one reaction (e.g., measurement of the marker sequence). When Taq DNA polymerase is activated, it cleaves off the fluorescent

reporters by its 5'-to-3' nucleolytic activity. The reporters, now free of the quenchers, fluoresce. The color change is proportional to the amount of each specific product and is measured by fluorometer; therefore, the amount of each color can be measured and the RT-PCR product can be quantified. The PCR reactions can be performed in 96 well plates so that samples derived from many individuals can be processed and measured simultaneously. The Taqman™ system has the additional advantage of not requiring gel electrophoresis and allows for quantification when used with a standard curve.

The marker sequence-specific antibodies described above may be used to detect the presence of one or more marker sequences in a biological sample by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitation reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e. g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e. g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e. g., 1-4 hours) at 4 C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4 C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. In the case of immunonprecipitation of a serum sample, however the above protocol is carried out absent the cell lysis step. The ability of the antibody to immunoprecipitate Reg1 α or TIMP1 (or other colon cancer marker) antigen can be assessed by, e. g., western blot analysis. The parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e. g., preclearing the cell lysate with sepharose beads) are well known to those of skill in the art (Ausubel et al, *supra*).

The individual and/or the combinations of the marker sequences may be detected in a biological sample obtained from a patient using Western blot analysis. Briefly, Western blot analysis comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e. g., 8%-20% SDS-PAGE), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e. g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e. g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e. g., an antihuman antibody) conjugated to an enzymatic substrate (e. g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e. g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. Methods for the optimization of such an analysis are well known in the art (Ausubel, et al., *supra*).

Alternatively, the presence of one or more cancer specific marker sequences in a clinical sample may be detected by ELISA. ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate (or other suitable container) with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e. g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest, that is, the antibody which will bind to a cancer-specific marker) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. This method may be modified or optimized according techniques which are known to those of skill in the art.

The binding affinity of an antibody to an antigen and the off-rate of an antibody/antigen interaction can be determined by competitive binding assays. One example of such an assay is a radioimmunoassay comprising the incubation of labeled antigen (e. g., marker labeled with ^3H or ^{125}I) with an anti-marker antibody in the presence of increasing amounts of unlabeled antigen,

and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e. g., ^3H or ^{125}I) in the presence of increasing amounts of an unlabeled second antibody.

Preferably, the above detection assays may be carried out using antibodies to detect the protein product encoded by a nucleic acid having the sequence of SEQ ID NOs:1-93, or a sequence complementary thereto. In addition, the above detection assays may be conducted using one or more antibodies which specifically recognize and bind to at least one cancer-specific marker. Accordingly, in one embodiment, the assay would include contacting the proteins of the test cell with an antibody specific for the gene product of a nucleic acid represented by SEQ ID NO:1-93, or a sequence complementary thereto, and determining the approximate amount of immunocomplex formation by the antibody and the proteins of the test cell, wherein a detection of such an immunocomplex is indicative of the presence of the antigen, and thus, permits the detection of colon cancer.

Immunoassays, useful in the present invention include those described above, and can also include both homogeneous and heterogeneous procedures such as fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), and nephelometric inhibition immunoassay (NIA).

In another embodiment, the level of the encoded polypeptide product, i.e., the polypeptide product encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO:1-93, or a sequence complementary thereto, in a biological fluid (e.g., blood or urine) of a patient may be determined as a way of monitoring the level of expression of the marker nucleic acid sequence in cells of that patient. Such a method would include the steps of obtaining a sample of a biological sample from the patient, contacting the sample (or proteins from the sample) with an antibody specific for an encoded marker polypeptide, and determining the amount of immune complex formation by the antibody, with the amount of immune complex formation being indicative of the level of the marker encoded polypeptide product in the sample. This determination is particularly instructive when compared to the amount of immune complex

formation by the same antibody in a control sample taken from a normal individual or in one or more samples previously or subsequently obtained from the same person.

In another embodiment, the method can be used to determine the amount of marker polypeptide present in a cell, which in turn can be correlated with progression of a hyperproliferative disorder, e.g., colon cancer. The level of the marker polypeptide can be used predictably to evaluate whether a sample of cells contains cells which are, or are predisposed towards becoming, transformed cells. Moreover, the subject method can be used to assess the phenotype of cells which are known to be transformed, the phenotyping results being useful in planning a particular therapeutic regimen. For instance, very high levels of the marker polypeptide in sample cells is a powerful diagnostic and prognostic marker for a cancer, such as colon cancer. The observation of marker polypeptide level can be utilized in decisions regarding, e.g., the use of more aggressive therapies.

X Diagnostic assays

The determination of a detectable increase or decrease in the expression level of one or more marker sequences in a cancer patient compared to a normal patient provides a means of diagnosing or monitoring the patient's disease status, and/or patient response or benefit to cancer therapy. The present invention provides methods for detecting cancer, or alternatively, determining whether a subject is at risk for developing cancer by detecting the disclosed cancer-specific markers (i.e., the nucleic acid sequences of one or more nucleic acid sequences encoding the cancer specific marker and/or polypeptide sequences of one or more cancer specific markers) for the disease or condition encoded thereby. Examples of cancer include but not limited to, adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particularly, examples of cancer also include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer. Preferably, the cancers include breast, colon, and lung cancer. In a more preferred embodiment, the cancer is colon cancer, and

the marker sequences are the ones comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1-93.

5 In clinical applications, human tissue samples can be screened for the presence and/or absence of the biomarkers identified herein. Such samples may comprise tissue samples, whole cells, cell lysates, or isolated nucleic acids, including, for example, needle biopsy cores, surgical resection samples, lymph node tissue, plasma, or serum. For example, these methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. In certain embodiments, nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of selected
10 markers detected would be compared with statistically valid groups of metastatic, non-metastatic malignant, benign, or normal colon tissue samples.

In one embodiment, the diagnostic method comprises determining whether a subject has an abnormal mRNA or cDNA and/or protein level of the marker sequences. The method comprises using a nucleic acid probe to determine the expression level of the individual and/or
15 the combinations of the marker sequences in a biological sample obtained from a patient. Specifically, the method comprises:

1. Providing a nucleic acid probe comprising a nucleotide sequence at least about 8 nucleotides in length, at least about 12 nucleotides in length, preferably at least about 15 nucleotides, more preferably about 25 nucleotides, and most preferably
20 at least about 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence represented by SEQ ID NOs:1-93, or a sequence complementary thereto;
2. Obtaining a clinical sample from a patient potentially comprising one or more
25 nucleic acid marker sequences;
3. Providing a second clinical sample from an individual known to not have colon cancer;

4. Contacting the nucleic acid probe under stringent conditions with RNA of each of said first and second clinical samples (e.g., in a Northern blot or *in situ* hybridization assay); and
5. Comparing (a) the amount of hybridization of the probe with RNA of the first clinical sample, with (b) the amount of hybridization of the probe with RNA of the second clinical sample; wherein a statistically difference (e.g., by at least 0.5 fold, at least 2 fold, at least 5 fold, at least 20 fold, or at least 50 fold) in the amount of hybridization with the RNA of the first clinical sample as compared to the amount of hybridization with the RNA of the second clinical sample is indicative of the presence of one or more marker sequences in the first clinical sample.

In one embodiment, the method comprises *in situ* hybridization with a probe derived from a given marker nucleic acid sequence, which nucleic acid sequence is represented by SEQ ID NO:1-93, or a sequence complementary thereto. The method comprises contacting the labeled hybridization probe with a sample of a given type of tissue potentially containing cancerous or pre-cancerous cells as well as normal cells, and determining whether the probe labels some cells of the given tissue type to a degree significantly different (e.g., by at least 0.5 fold, at least 2 fold, at least 5 fold, at least 20 fold, or at least 50 fold) than the degree to which it labels other cells of the same tissue type.

Determining by hybridization whether the target is differentially expressed (e.g., up-regulated or down-regulated) in the sample can also be accomplished by any effective means. For instance, the target's expression pattern in the sample can be compared to its pattern in a known control, such as in a normal tissue, or it can be compared to another target in the same sample. When a second sample is utilized for the comparison, it can be a sample of normal tissue that is known not to contain diseased cells. The comparison can be performed on samples which contain the same amount of RNA (such as polyadenylated RNA or total RNA), or, on RNA extracted from the same amounts of starting tissue. Such a second sample can also be referred to as a control or standard. Hybridization can also be compared to a second target in the same tissue sample. Experiments can be performed that determine a ratio between the target nucleic acid and a second nucleic acid (a standard or control), e.g., in a normal tissue. When the ratio between the target and control are substantially the same in a normal sample, the sample is

determined or diagnosed not to contain cancer cells. However, if the ratio is at least 2 fold different between the normal and sample tissues, the sample is determined to contain cancer cells. The approaches can be combined, and one or more second samples, or second targets can be used. Any second target nucleic acid can be used as a comparison, including "housekeeping" genes, such as beta-actin, alcohol dehydrogenase, or any other gene whose expression does not vary depending upon the disease status of the cell.

Alternatively, the above diagnostic assays may be carried out using antibodies to detect the polypeptides encoded by the nucleic acid marker sequences, which nucleic acid sequences are represented by SEQ ID NOs:1-93, or a sequence complementary thereto. Preferably, the polypeptides have the sequence of one or more of SEQ ID NOs: 94-186. Accordingly, in one embodiment, the assay would include contacting the polypeptides of the test cell or tissue with one or more antibodies specific for the polypeptides represented by SEQ ID NOs: 94-186, and determining the approximate amount of immunocomplex formation by the antibodies and polypeptides of the test cell or tissue, wherein a statistically significant difference in the amount of the immunocomplex formed with the polypeptides of a test or tissue as compared to a normal cell or tissue is an indication that the test cell is cancerous or pre-cancerous. The term "significant difference" refers to a cell phenotype wherein the cell possesses a changed cellular amount of the marker polypeptide relative to a normal cell of similar tissue origin. For example, a cell may have either more or less than about 50%, 25%, 10%, or 5% of the marker polypeptide that a normal control cell. In particular, the assay evaluates the level of marker polypeptide in the test cells, and, preferably, compares the measured level with marker polypeptide detected in at least one control cell, e.g., a normal cell and/or a transformed cell of known phenotype.

In one embodiment, the assay is performed as a dot blot assay. The dot blot assay finds particular application where tissue samples are employed as it allows determination of the average amount of the marker polypeptide associated with a single cell by correlating the amount of marker polypeptide in a cell-free extract produced from a predetermined number of cells.

It is well established in the cancer literature that tumor cells of the same type (e.g., breast and/or colon tumor cells) may not show uniformly increased expression of individual oncogenes or uniformly decreased expression of individual tumor suppressor genes. There may also be varying levels of expression of a given marker sequence even between cells of a given type of cancer, further emphasizing the need for reliance on a battery of tests rather than a single test.

Accordingly, in one aspect, the invention provides for a battery of tests utilizing a number of probes of the invention, in order to improve the reliability and/or accuracy of the diagnostic test.

XI Arrays

In one aspect, the present invention also provides a method wherein nucleic acid probes
5 are immobilized on a DNA chip in an organized array. Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. These nucleic acid probes comprise a nucleotide sequence at least about 8 nucleotides in length, preferably at least about 12 preferably at least about 15 nucleotides, more preferably at least about 25 nucleotides, and most preferably at least about 40 nucleotides, and up to all or nearly all of a sequence which is complementary to
10 a portion of the coding sequence of a marker nucleic acid sequence represented by SEQ ID NO:1-93 and is differentially expressed in cancer cells, such as colon cancer cells. In some embodiments, the microarrays comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, or more nucleic acids that are complimentary to at least a portion of the coding sequences of the marker sequences comprising a nucleic acid sequence selected from the group consisting of SEQ
15 ID NOs: 1-93. The present invention provides significant advantages over the available tests for various cancers, such as colon cancer, because it increases the reliability of the test by providing an array of nucleic acid markers on a single chip.

The method includes obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. The DNA or RNA is
20 then extracted, amplified, and analyzed with a DNA chip to determine the presence or absence of the marker nucleic acid sequences.

In one embodiment, the nucleic acid probes are spotted onto a substrate in a two-dimensional matrix or array. Samples of nucleic acids can be labeled and then hybridized to the probes. Double-stranded nucleic acids, comprising the labeled sample nucleic acids bound to
25 probe nucleic acids, can be detected once the unbound portion of the sample is washed away.

The probe nucleic acids can be spotted on substrates including glass, nitrocellulose, etc. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. The sample nucleic acids can be labeled using radioactive labels, fluorophores, chromophores, etc.

Techniques for constructing arrays and methods of using these arrays are described in EP No. 0 799 897; PCT No. WO 97/292 12; PCT No. WO 97127317; EP No. 0 785 280; PCT No. WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP No. 0 728 520; U.S. Pat. No. 5,599,695; EP No. 0 721 016; U.S. Pat. No. 5,556,752; PCT No. WO 95/22058; and U.S. Pat. No. 5,631,734.

In another aspect, the present invention also provides a protein microarrays. Protein microarray technology, which is also known by other names including: protein chip technology and solid-phase protein array technology, is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified peptides or proteins on a fixed substrate, binding target molecules or biological constituents to the peptides, and evaluating such binding. See, e.g., G. MacBeath and S. L. Schreiber, "Printing Proteins as Microarrays for High-Throughput Function Determination," *Science* 289(5485):1760-1763, 2000. In general, the protein microarrays include antigen-binding ligands such as antibodies or fragments thereof, fixed to a solid substrate, wherein the ligands specifically bind to the polypeptides encoded by the marker sequences of the present invention. In one embodiment, the protein microarrays further include at least one control polypeptide molecule. In some embodiments, the microarray comprises antibodies or antigen-binding fragments thereof, that bind specifically to least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 different polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-93. In certain embodiment, the antibodies are monoclonal or polyclonal antibodies. In another certain embodiment, the antibodies are chimeric, human, or humanized antibodies. In yet another certain embodiment, the antibodies are single chain antibodies, and the antigen-binding fragments are F(ab')₂, Fab, Fd, or Fv fragments.

The solid microarray substrate may include, but not limited to, glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. The microarray substrates may be coated with a compound to enhance synthesis of a probe (peptide or nucleic acid) on the substrate. Coupling agents or groups on the substrate can be used to covalently link the first nucleotide or amino acid to the substrate. A variety of coupling agents or groups are known to those of skill in the art. Peptide or nucleic acid probes thus can be synthesized directly on the substrate in a predetermined grid.

Alternatively, peptide or nucleic acid probes can be spotted on the substrate, and in such cases the substrate may be coated with a compound to enhance binding of the probe to the substrate.

In these embodiments, presynthesized probes are applied to the substrate in a precise, predetermined volume and grid pattern, preferably utilizing a computer- controlled robot to

5 apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate.

XII Prognosis, staging, and monitoring of cancer

In one aspect, the present invention provides methods for determining cancer prognosis and stage based on examining the expression levels of the nucleic acid marker sequences and
10 polypeptides using the methods described in the present invention. If cancer is detected in a subject using a technique other than by determining the expression levels of the marker sequences, then the differential expression level of the marker sequences can be used to determine the prognosis and stage for the subject. As used herein, prognosis refers to the prediction of the probable course and outcome of a disease.

15 In general, methods used for prognosis or stage of cancer involve comparison of the amount of the marker sequences in a sample of interest with that of a control to detect relative differences in the expression of the marker sequences, wherein the difference can be measured qualitatively and/or quantitatively. For example, the expression levels of one or more marker RNAs or polypeptides can be compared with the expression levels of the same marker RNAs or
20 polypeptides in cancer free or normal samples. Alternatively, the expression levels of one or more marker RNAs or polypeptides can also be compared with the expression levels of the same marker RNAs or polypeptides observed in cancers that are known not to progress. In addition, the expression levels of one or more marker RNAs or polypeptides can also be compared with the expression levels of the same marker RNAs or polypeptides observed in cancers that are
25 known to progress and/or metastasize.

Also, as used herein, cancer stage refers to the sequence of the events, in which cancer develops and causes symptoms. In addition, staging is a process used to describe how advanced the cancerous state is in patient. Staging systems vary with the types of cancer, but generally involve the following "TNM" system: the type of tumor, indicated by T; whether the cancer has
30 metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to

more distant parts of the body, indicated by M. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or other site, are Stage IV, the most advanced stage. Methods of the present invention are useful in assaying the staging of cancer. The staging of cancer can be accomplished by determining the expression levels of one or more marker RNAs or polypeptides to a reference expression levels of the same marker RNAs or polypeptides. The reference expression levels of the marker RNAs or polypeptides can be that from cancer free or healthy or cancer samples, wherein the cancer can be at different stages in development.

The present invention further provides methods of monitoring cancer progression or recurrence by measuring the expression levels of the marker RNAs or polypeptides over the time. In one embodiment, the methods comprise:

- (1). detecting in a biological sample of the subject at a first point in time, the expression of one or more nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93;
- (2). repeating step (a) at a subsequent point in time; and
- (3). comparing the expression level detected in steps (a) and (b), wherein a change in the expression level is indicative of progression of cancer or a pre-malignant condition thereof in the subject.

In another embodiment, the methods comprise:

- (1). detecting in a biological sample of the subject at a first point in time, the expression of one or more polypeptides comprising one or more polypeptide sequences selected from the group consisting of SEQ ID NOs: 94-186;
- (2). repeating step (a) at a subsequent point in time; and

(3). comparing the expression level detected in steps (a) and (b), wherein a change in the expression level is indicative of progression of cancer or a pre-malignant condition thereof in the subject.

For example, elevated expression levels of one or more over-expressed marker RNAs or polypeptides, or reduced expression levels of one or more under-expressed marker RNAs or polypeptides in a subsequent point in time relative to an earlier point in time, indicate that the cancer is progressing to a more severe stage. On the other hand, reduced expression levels of one or more over-expressed marker RNAs or polypeptides, or elevated expression levels of one or more under-expressed marker RNAs or polypeptides in a subsequent point in time relative to an earlier point in time, indicate that the cancer is not progressing or is progressing slowly.

The methods used in prognosis, staging, and monitoring cancer can be applied to various types of cancer. Examples of cancer include but not limited to, adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particularly, examples of cancer also include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer. Preferably, the cancers include breast, colon, and lung cancer. More preferably, the cancer is colon cancer, and the marker sequences are the ones comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-93.

XIII Efficacy of therapy and therapeutic compositions

In one aspect, the present invention also provides methods that permit the assessment and/or monitoring of patients who will be likely to benefit from both traditional and non-traditional treatments and therapies for cancers, particularly colon cancer. The present invention thus embraces testing, screening and monitoring of patients undergoing anti-cancer treatments and therapies, used alone, in combination with each other, and/or in combination with anti-cancer drugs, anti-neoplastic agents, chemotherapeutics and/or radiation and/or surgery, to treat cancer patients.

An advantage of the present invention is the ability to monitor, or screen over time, those patients who can benefit from one, or several, of the available cancer therapies, and preferably, to monitor patients receiving a particular type of therapy, or a combination therapy, over time to determine how the patient is faring from the treatment(s), if a change, alteration, or cessation of treatment is warranted; if the patient's disease has been reduced, ameliorated, or lessened; or if the patient's disease state or stage has progressed, or become metastatic or invasive. The cancer treatments embraced herein also include surgeries to remove or reduce in size a tumor, or tumor burden, in a patient. Accordingly, the methods of the invention are useful to monitor patient progress and disease status post-surgery.

The identification of the correct patients for a cancer therapy according to this invention can provide an increase in the efficacy of the treatment and can avoid subjecting a patient to unwanted and life-threatening side effects of the therapy. By the same token, the ability to monitor a patient undergoing a course of therapy using the methods of the present invention can determine whether a patient is adequately responding to therapy over time, to determine if dosage or amount or mode of delivery should be altered or adjusted, and to ascertain if a patient is improving during therapy, or is regressing or is entering a more severe or advanced stage of disease, including invasion or metastasis, as discussed further herein.

A method of monitoring according to this invention reflects the serial, or sequential, testing or analysis of a cancer patient by testing or analyzing the patient's body fluid sample over a period of time, such as during the course of treatment or therapy, or during the course of the patient's disease. For instance, in serial testing, the same patient provides a body fluid sample, e.g., serum or plasma, or has sample taken, for the purpose of observing, checking, or examining the expression levels of one or more of the markers (RNA or polypeptide) of the invention in the patient by measuring the levels of one or more of these markers during the course of treatment, and/or during the course of the disease, according to the methods of the invention.

Similarly, a patient can be screened over time to assess the levels of one or more of the markers in a biological sample for the purposes of determining the status of his or her disease and/or the efficacy, reaction, and response to cancer or neoplastic disease treatments or therapies that he or she is undergoing. It will be appreciated that one or more pretreatment sample(s) is/are optimally taken from a patient prior to a course of treatment or therapy, or at the start of the treatment or therapy, to assist in the analysis and evaluation of patient progress and/or response

at one or more later points in time during the period that the patient is receiving treatment and undergoing clinical and medical evaluation.

In monitoring a patient's levels of one or more of the markers of the invention over a period of time, which may be days, weeks, months, and in some cases, years, or various intervals thereof, the patient's body fluid sample, e.g., a serum or plasma sample, is collected at intervals, as determined by the practitioner, such as a physician or clinician, to determine the levels of one or more of the markers in the cancer patient compared to the respective levels of one or more of these analytes in normal individuals over the course or treatment or disease. For example, patient samples can be taken and monitored every month, every two months, or combinations of one, two, or three month intervals according to the invention. Quarterly, or more frequent monitoring of patient samples, is advisable.

The levels of the one or more markers found in the patient are compared with the respective levels of the one or more of these markers in normal individuals, and with the patient's own marker levels, for example, obtained from prior testing periods, to determine treatment or disease progress or outcome. Accordingly, use of the patient's own marker levels monitored over time can provide, for comparison purposes, the patient's own values as an internal personal control for long-term monitoring of marker levels, and thus cancer presence and/or progression. As described herein, following a course of treatment or disease, the determination of an increase or a decrease in one or more of the marker levels in the cancer patient over time compared to the respective levels of one or more of these markers in normal individuals reflects the ability to determine the severity or stage of a patient's cancer, or the progress, or lack thereof, in the course or outcome of a patient's cancer therapy or treatment.

Increases or decreases in the levels of the markers in cancer patients are determined by comparing the values obtained from analyzing cancer patient samples compared to the normal control range expression levels. A biomarker is said to be over-expressed if expression of the marker is at least 2 fold greater in the cancer patient relative to a normal control, and a biomarker is said to be under expressed if the expression of the marker is at least 2 fold greater in the normal control relative to in the cancer patient.

In monitoring a patient over time, a reduction in the levels of one or more of a patient's marker levels from increased levels (i.e., at least 2 fold over-expressed) compared to normal

range values to levels at or near to the levels of the analytes found in normal individuals is indicative of treatment progress or efficacy, and/or disease improvement, remission, tumor reduction or elimination, and the like. Likewise, in all of the methods described in the embodiments of this invention, a determination of a reduction of one or more of a patient's marker levels from an elevated level (i.e., at least 2 fold over-expressed) to, or approximately to, the respective levels of one or more of these analytes found in normal individuals provides a further aspect of the methods of the invention, in which a patient's improvement, recovery or remission, and/or treatment progress or efficacy, is able to be ascertained over time following performance of the method.

Another embodiment of the present invention encompasses a method of monitoring a cancer patient's course of disease, or the efficacy of a cancer patient's treatment or therapy. The patient's treatment or therapy can involve traditional therapies, such as hormone therapy, chemotherapeutic drug therapy, radiation, or novel therapies, or a combination of any of the foregoing. The method involves measuring levels of one or more markers in a body fluid sample of the cancer patient and determining if the levels of one or more of the markers in the patient's sample are changed by at least 2 fold compared to the respective levels of one or more of these analytes in normal controls during the course of disease or cancer treatment. In accordance with the method, a change in the levels of the marker in the cancer patient compared to the respective levels of the marker in normal controls is indicative of a change in stage, grade, severity or progression of the patient's cancer and/or a lack of efficacy or benefit of the cancer treatment or therapy provided to the patient during a course of treatment, e.g., poor treatment or clinical outcome.

As will be understood by the skilled practitioner in the art, the monitoring method according to this invention is preferably, performed in a serial or sequential fashion, using samples taken from a patient during the course of disease, or a disease treatment regimen, (e.g., after a number of days, weeks, months, or occasionally, years, or various multiples of these intervals) to allow a determination of disease progression or outcome, and/or treatment efficacy or outcome. If the sample is amenable to freezing or cold storage, the samples may be taken from a patient (or normal individual) and stored for a period of time prior to analysis.

In another of its embodiments, the present invention encompasses the determination of the amounts or levels of one or more additional cancer markers in conjunction with the

determination of the levels of one or more of the markers of the invention in a sample to be analyzed.

The present invention also includes a method of assessing the efficacy of a test composition for inhibiting cancers, such as colon cancer. As described above, differential expression levels of the marker sequences of the invention correlate with the cancerous state of cancer cells, particularly colon cancer cells. It is recognized that changes in the expression levels of the marker sequences of the present invention result from the cancerous state of cells. Thus, composition which inhibit cancer in a patient will cause the expression levels of the marker sequences to change to a level near the normal level of expression for the marker sequences. The method thus comprises comparing expression levels of one or more marker sequences in a first biological sample maintained in the presence of a test composition with those of the same marker sequences in a second biological sample maintained in the absence of the test composition. A significant difference in the expression levels of one or more marker sequences is an indication that the test composition inhibits the cancer. In a preferred embodiment, the cancer is colon cancer, and the marker sequences are the ones listed in Tables 1 and 2. In another embodiment, the cell samples may be aliquots of a single sample obtained from either a healthy subject or a patient with cancerous conditions.

XIV Modulators of the marker sequences

It is recognized that changes in the expression levels of the marker sequences likely induce, maintain, and promote the cancerous state of cells. Thus, another aspect of the present invention is directed to the modulators of the marker sequences capable of modulating the differentiation and proliferation of cells. In this regard, the present invention provides assays for determining compounds that modulate the expression of the marker sequences. The compounds can be used to modulate the biological activity of the polypeptides encoded by the marker sequences or the marker sequences themselves. Compounds can also be useful in a variety of different environments, including as medicinal agents to treat or prevent disorders associated with cancer.

Methods of identifying compounds generally comprise steps in which a compound is placed in contact with a marker sequence, its transcription product, its translation product, or other target, and determination of whether the compound modulates the marker sequence. For

modulating the expression of a marker sequence, a method can comprise, in any effective order, one or more of the following steps, e.g., contacting the marker sequence (e.g., in a cell population) with a test compound under conditions effective for said test compound to modulate the expression of the marker sequence, and determining whether said test agent modulates said sequence. A compound can modulate expression of a sequence at any level, including
5 transcription (e.g., by modulating the promoter), translation, and/or perdurance of the nucleic acid (e.g., degradation, stability, etc.) in the cell.

For modulating the biological activity of polypeptides, a method can comprise, in any effective order, one or more of the following steps, e.g., contacting a polypeptide (e.g., in a cell,
10 lysate, or isolated) with a test compound under conditions effective for said test agent to modulate the biological activity of said polypeptide, and determining whether said test compound modulates said biological activity.

Contacting the polynucleotide or polypeptide with the test compound can be accomplished by any suitable method and/or means that places the compound in a position to
15 functionally control expression or biological activity of the gene or its product in the sample. Functional control indicates that the compound can exert its physiological effect through whatever mechanism it works. The choice of the method and/or means can depend upon the nature of the compound and the condition and type of environment in which the gene or its product is presented, e.g., lysate, isolated, or in a cell population (such as, in vivo, in vitro, organ
20 explants, etc.). For example, if the cell population is an *in vitro* cell culture, the compound can be contacted with the cells by adding it directly into the culture medium. If the compound cannot dissolve readily in an aqueous medium, it can be incorporated into liposomes, or another lipophilic carrier, and then administered to the cell culture. Contact can also be facilitated by incorporation of compound with carriers and delivery molecules and complexes, by injection, by
25 infusion, etc.

After the agent has been administered in such a way that it can gain access to the gene or gene product (including DNA, mRNA, and polypeptides), it can be determined whether the test compound modulates its expression or biological activity. Modulation can be of any type, quality, or quantity, e.g., increase, facilitate, enhance, up-regulate, stimulate, activate, amplify,
30 augment, induce, decrease, down-regulate, diminish, lessen, reduce, etc. The modulatory quantity can also encompass any value, e.g., 1%, 5%, 10%, 50%, 75%, 1-fold, 2-fold, 5-fold, 10-

fold, 100-fold, etc. To modulate gene expression means, e.g., that the test compound has an effect on its expression, e.g., to effect the amount of transcription, to effect RNA splicing, to effect translation of the RNA into polypeptide, to effect RNA or polypeptide stability, to effect polyadenylation or other processing of the RNA, to effect post-transcriptional or post-translational processing, etc. To modulate biological activity means, e.g., that a functional activity of the polypeptide is changed in comparison to its normal activity in the absence of the compound. This effect includes, increase, decrease, block, inhibit, enhance, etc.

A test compound can be of any molecular composition, e.g., chemical compounds, biomolecules, such as polypeptides, lipids, nucleic acids (e.g., antisense to a polynucleotide) carbohydrates, antibodies, ribozymes, double-stranded RNA, aptamers, etc. For example, if a polypeptide to be modulated is a cell-surface molecule, a test compound can be an antibody that specifically recognizes it and, e.g., causes the polypeptide to be internalized, leading to its down-regulation on the surface of the cell. Such effect does not have to be permanent, but can require the presence of the antibody to continue the down-regulatory effect. Antibodies can also be used to modulate the biological activity of a polypeptide in a lysate or other cell-free form.

XV Drug screening

In one aspect, the present invention is also directed to methods for screening drugs that inhibit cancer, particularly colon cancer. Drug screening is performed by adding a test compound to a sample of cells, and monitoring the effect. A parallel sample which does not receive the test compound is also monitored as a control. The treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, and the ability of the cells to interact with other cells or compounds. Differences between treated and untreated cells indicates effects attributable to the test compound.

Desirable effects of a test compound include an effect on any phenotype that was conferred by the cancer-associated marker nucleic acid sequence. Examples include a test compound that limits the overabundance of mRNA, limits production of the encoded protein, or limits the functional effect of the protein. The effect of the test compound would be apparent when comparing results between treated and untreated cells. For example, candidate compounds

may be identified that down-regulate expression of one specific gene. In one embodiment, candidate compounds may be identified that up-regulate expression of one specific gene. Generally a plurality of assay mixtures are run in parallel with different compound concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Screening assays can be based upon any of a variety of techniques readily available and known to one of ordinary skill in the art. In general, the screening assays involve contacting a cancerous cell (preferably a cancerous colon cell) with a candidate agent, and assessing the effect upon biological activity of a differentially expressed gene product. The effect upon a biological activity can be detected by, for example, detection of expression of a gene product of a differentially expressed gene (e.g., a decrease in mRNA or polypeptide levels, would in turn cause a decrease in biological activity of the gene product). Alternatively or in addition, the effect of the candidate agent can be assessed by examining the effect of the candidate agent in a functional assay. For example, where the differentially expressed gene product is an enzyme, then the effect upon biological activity can be assessed by detecting a level of enzymatic activity associated with the differentially expressed gene product. The functional assay will be selected according to the differentially expressed gene product.

The screening methods may include both *in vitro* and *in vivo* screening of a cell or tissue. One particular embodiment of *in vitro* method comprises a method of determining the efficacy of a test compound for inhibiting cancer in a subject, the method comprising comparing a) the expression level of one or more nucleic acid sequences in a first biological sample from the subject wherein the sample has been exposed to the test compound, with b) the expression level of said nucleic acid sequences in a second biological sample from the subject wherein the sample has not been exposed to the test compound, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93, wherein a change of at least two fold in the expression level of said nucleic acid sequences is an indication that the test compound is efficacious for inhibiting cancer in the subject.

In another embodiment, the *in vivo* methods of screening for compounds that alter the expression of the marker sequences comprise exposing a subject, preferably a mammal having cancer cells in which the marker sequences (either at mRNA or polypeptide level) are detectable,

to a compound, and determining the level of the marker sequences. Where the differentially expressed gene is increased in expression in a cancerous cell, the compound of interest is those that decrease activity of the differentially expressed gene product, and where the differentially expressed gene is decreased in expression in a cancerous cell, the compound of interest is those that increase activity of the differentially expressed gene product.

Assays for determining the differentially expressed marker sequences (described *supra*) can be readily adapted in the screening assay embodiments of the present invention. Exemplary assays useful in screening candidate compounds include, but are not limited to, hybridization-based assays (e.g. use of nucleic acid probes or primers to assess expression levels), antibody-based assays (e.g. to assess levels of polypeptide gene products), binding assays (e.g. to detect interaction of a candidate agent with a differentially expressed polypeptide, which assays may be competitive assays where a natural or synthetic ligand for the polypeptide is available), and the like. Additional exemplary assays include, but are not necessarily limited to, cell proliferation assays, antisense knockout assays, assays to detect inhibition of cell cycle, assays of induction of cell death/apoptosis, and the like.

In one embodiment, the candidate compound is naturally occurring or modified proteins. In another embodiment, candidate compounds are peptides. The peptides may be digests of naturally occurring proteins, or the one made by chemical synthesis. Furthermore, the synthetic process can be designed to generate randomized proteins, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate proteinaceous drugs.

In another embodiment, the candidate compounds are nucleic acids, either naturally occurring or modified. In a preferred embodiment, the nucleic acid compounds are antisense nucleic acids. Drug candidates that are antisense molecules include antisense or sense oligonucleotides comprising a single-strand nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA or DNA sequences for lung cancer molecules identified by the methods of the invention.

In yet another preferred embodiment, drug candidates are antibodies. An antibody used in methods for screening for a candidate drug may either bind a full length protein or a fragment thereof. In a preferred embodiment, the antibody binds a unique epitope on a target protein and

shows little or no cross-reactivity. The term "antibody" is understood to include antibody fragments, as are known in the art, including Fab, Fab₂, single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies known in the art. Antibodies as used
5 herein as drug candidates include both polyclonal and monoclonal antibodies. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an antigenic agent and, if desired, an adjuvant. It may be useful to conjugate the antigenic agent to a protein known to be immunogenic in the mammal being immunized.

In yet another embodiment, the candidate compounds are chemical compounds. In a
10 preferred embodiment, the candidate compounds are small organic compounds having a molecular weight of more than 100 and less than about 2500 daltons. Candidate compounds may also include functional groups necessary for structural interaction with proteins or nucleic acids.

XVI Kits

The present invention also provides for kits that contain the necessary reagents for
15 detection of the expression levels (either at RNA or polypeptide level) of the individual and/or combinations of marker sequences in a biological sample. Reagents can include marker sequence-specific probes/primers and antibodies as described *supra*. Kits can also contain a control/reference value or a set of control/reference values indicating normal and various clinical progression stages of cancer. In a preferred embodiment, the control/reference value or a set of
20 control/reference values are indicative of normal and various clinical progression stages of colon cancer. Moreover, kits can contain positive controls, and/or negative controls for comparison with the test sample. A negative control can contain a sample that does not have any marker RNA or polypeptide. A positive control can contain a sample that have various known levels of marker RNA or polypeptide. Kits can also contain any combinations of the marker sequence-
25 specific probes/primers and/or antibodies. Kits can also contain instructions for conducting the assays and for interpreting the results. For antibody-based kit, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label. For
30 oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a

polypeptide corresponding to a marker sequence of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

Such kits can be used to determine whether a subject is suffering from or at an increased risk of developing cancer, particularly colon cancer. Furthermore, such kits can be used to determine the prognosis, stage, or monitoring the progression of cancer, particularly colon cancer. Furthermore, such kits can be used for drug screening or for selection of treatment for cancer, particularly colon cancer.

Examples

The examples below are non-limiting and are merely representative of various aspects and features of the present invention.

Example 1. Identification of differentially expressed marker sequences

Twenty well characterized, microdissected samples of colorectal cancer tissue were obtained from consenting patients. A second set of twenty, microdissected samples of normal adjacent colon tissue were also obtained. Total RNA was extracted from these samples using RNeasy kits (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Expression profiling was performed using the GeneChip expression arrays from Affymetrix (Santa Clara, CA). Reverse transcription, second-strand synthesis, and probe generation was accomplished by standard Affymetrix protocols. The Human Genome U133A GeneChip, which contains more than 15,000 substantiated human genes, was hybridized, washed, and scanned according to Affymetrix protocols. Changes in cellular mRNA levels in the cancerous tissues were compared with mRNA levels in the normal colon tissues. GeneSpring v4.2 (Silicon Genetics, Redwood City, CA) was used to normalize and scale results and compare gene expression levels in the cancer tissue relative to that in the normal tissue.

Applying a set of filters to the normalized data identified the up- and down-regulated genes. First, a non-parametric test defined the genes that were statistically associated with either the cancer or the normal samples. Next, a pair of filters was used to remove the genes with low signals and to set a high threshold for a minimum expression levels. The final filter required a three-fold average expression difference between the two conditions (cancer and normal).

This analysis resulted in 47 genes that were up-regulated in the colorectal cancer tissue relative to the normal adjacent colon tissue. These genes are identified in Table 1. Likewise, 46 down-regulated genes were identified in the colorectal cancer tissue relative to the normal adjacent colon tissue. These genes are listed in Table 2.

Other embodiments

Other embodiments will be evident to those of skill in the art. It should be understood that the foregoing detailed description is provided for clarity only and is merely exemplary. The spirit and scope of the present invention are not limited to the above examples, but are encompassed by the following claims.

Claims

1. A method of detecting differential expression of one or more nucleic acid sequences in a biological sample, comprising:

(a) obtaining the sample from a subject; and

5 (b) detecting a change in the expression level of one or more nucleic acid sequences relative to a control expression level of the nucleic acid sequences, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93.

2. The method of claim 1, wherein said step of detecting comprises:

10 (a) contacting said sample with a polynucleotide probe comprising at least 12 consecutive nucleotides of a nucleic acid sequence, said probe is capable of hybridizing under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-93;

(b) detecting the hybridization of said polynucleotide probe to said nucleic acid
15 sequence selected from the group consisting of SEQ ID NOs: 1-93, wherein the signal intensity of hybridization is indicative of the expression level of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-93.

3. The method of claim 2, wherein said probe comprises a detectable label.

4. The method of claim 1, wherein said change in the expression level is either an increase
20 or an decrease in expression level.

5. The method of claim 1, wherein said change in the expression level is at least two fold.

6. A method of detecting cancer or a pre-malignant condition thereof in a subject comprising comparing a) the expression level of one or more nucleic acid sequences in a biological sample from the subject with b) a control expression level of said nucleic acid
25 sequences, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93, wherein a change of at least two-fold in the

expression level of said nucleic acid sequences is indicative of cancer or pre-malignant condition.

7. The method of claim 6, wherein said change in the expression level is either an increase or decrease in the expression level.

5 8. A method of monitoring the onset, progression, or regression of cancer or a pre-malignant condition thereof in a subject, the method comprising:

(a) detecting in a biological sample of the subject at a first point in time, the expression of one or more nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93;

10 (b) repeating step (a) at a subsequent point in time; and

(c) comparing the expression level detected in steps (a) and (b), wherein a change in the expression level is indicative of progression of cancer or a pre-malignant condition thereof in the subject.

15 9. The method of claim 8, wherein the change in the expression level is either an increase or decrease.

10. A method of determining prognosis for cancer or a pre-malignant condition thereof in a subject, comprising:

20 (a) detecting in a biological sample of the subject, the expression level of one or more nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93;

(b) comparing the expression level detected in steps (a) with a reference expression level of said nucleic acid sequences; and

(c) evaluating the prognosis of the subject based on the comparison in step (b).

25 11. The method of claim 10, wherein the reference expression level is the expression level of said nucleic acid sequences in cancer free or normal sample.

12. The method of claim 10, wherein the reference expression level is the expression level of said nucleic acid sequences cancer samples that are known not to progress to aggressive form.

13. A method of determining the efficacy of a test compound for inhibiting cancer in a subject, the method comprising comparing a) the expression level of one or more nucleic acid sequences in a first biological sample from the subject wherein the sample has been exposed to the test compound, with b) the expression level of said nucleic acid sequences in a second biological sample from the subject wherein the sample has not been exposed to the test compound, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93, wherein a change of at least two fold in the expression level of said nucleic acid sequences is an indication that the test compound is efficacious for inhibiting cancer in the subject.

14. The method of claim 13, wherein the change in the expression level is either an increase or decrease.

15. A method of determining the efficacy of a therapy for inhibiting cancer in a subject, the method comprising comparing a) the expression level of one or more nucleic acid sequences in a first biological sample from the subject prior to providing at least a portion of the therapy to the subject, with b) the expression level of said nucleic acid sequences in a second biological sample from the subject following the provision of the portion of the therapy, said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93, wherein a change of at least two fold in the expression level of said nucleic acid sequences is an indication that the therapy is efficacious for inhibiting cancer in the subject.

16. The method of claim 15, wherein the change in the expression level is either an increase or decrease.

17. A method of selecting a composition for inhibiting cancer in a subject, the method comprising:

- (a) obtaining a first biological sample comprising cancer cells from the subject;
- (b) separately exposing aliquots of the sample in the presence of a plurality of test compositions;

(c) comparing the expression level of one or more nucleic acid sequences in each of the aliquots from (b) with the expression level in the sample produced by (a), said nucleic acid sequences comprising one or more nucleic acid sequences selected from the group consisting of SEQ ID NOs: 1-93; and

5 (d) selecting one of the test compositions which induces a change of at least two fold in the expression level of said nucleic acid sequences in one aliquot containing the test composition.

18. The method of claim 17, wherein the change in the expression level is either an increase or decrease.

10 19. A method of inhibiting cancer in a subject, the method comprising:

(a) obtaining a first biological sample comprising cells from the subject;

(b) administering to the subject one or more test compositions;

(c) obtaining a second biological sample comprising cells from the subject of (b); and

15 (d) comparing the expression level of one or more nucleic acid sequences in the first sample with the expression level of said nucleic acid sequences in the second sample, wherein a change of at least two fold in the expression level is indicative of inhibition of cancer by said test compositions.

20. A polypeptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186.

20 21. An antibody that specifically binds to a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186.

22. The antibody of claim 21, wherein said antibody is polyclonal antibody.

23. The antibody of claim 21, wherein said antibody is monoclonal antibody.

24. A method of detecting in a biological sample the presence of a polypeptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, said method comprising:

(a) obtaining said biological sample from a subject;

5 (b) contacting said sample with a polypeptide ligand which is capable of binding to one or more of SEQ ID NOs: 94-186; and

(c) detecting the binding of said polypeptide ligand to said polypeptide, wherein detecting of binding is indicative of the presence of said polypeptide sequence comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186 in said
10 biological sample.

25. The method of claim 24, wherein the polypeptide ligand is an antibody.

26. The method of claim 24, wherein the polypeptide ligand comprises a detectable label.

27. The method of claim 25, wherein the antibody is a monoclonal antibody.

28. A method of detecting cancer or a pre-malignant condition thereof in a subject
15 comprising:

(a) obtaining a biological sample from a subject;

(b) contacting the sample with one or more polypeptide ligands that bind specifically to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186;

20 (c) determining specific binding; and

(d) comparing the specific binding between the polypeptide ligands and the polypeptides in the sample with the specific binding between the polypeptide ligands and the polypeptides in a cancer-free sample, wherein a significant change in the specific binding is diagnostic for cancer in the subject.

29. A method of monitoring the onset, progression, or regression of cancer in a subject, comprising:

(a) contacting at a first point in time a first biological sample with one or more polypeptide ligands that specifically bind to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, determining specific binding between the polypeptide ligands and the polypeptides;

(b) contacting at a subsequent point in time a second biological sample with said polypeptide ligands that specifically bind to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, determining specific binding between the polypeptide ligands and the polypeptides; and

(c) comparing the specific binding in the first biological sample to the specific binding in the second biological sample, wherein a significant change in the specific binding is an indication of the onset, progression, or regression of cancer.

30. A method of determining prognosis for cancer or a pre-malignant condition thereof in a subject, comprising:

(a) contacting a biological sample obtained from a subject having cancer with one or more polypeptide ligands that bind specifically to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186;

(b) determining specific binding;

(c) comparing the specific binding between the polypeptide ligands and the polypeptides in the sample with the specific binding between the polypeptide ligands and the polypeptides either in a cancer-free sample or in a cancer sample that is known not to progress to aggressive form; and

(d) evaluating the prognosis of the subject based on the comparison in step (c).

31. A method of determining the efficacy of a test compound for inhibiting cancer in a subject, the method comprising comparing a) in a first biological sample from the subject binding between one or more polypeptide ligands that specifically bind to one or more

polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186 and one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, wherein the sample has not been exposed to the test compound, with b) in a second biological sample from the subject, the specific binding of said polypeptide ligands and said polypeptides, wherein the sample has been exposed to the test compound, and wherein a significant change in the specific binding is an indication that the test compound is efficacious for inhibiting cancer in the subject.

32. A method of determining the efficacy of a therapy for inhibiting cancer in a subject, comprising comparing a) in a first biological sample from the subject prior to a treatment, binding between one or more polypeptide ligands that specifically bind to one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186 and one or more polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, with b) in a second biological sample from the subject following the treatment, the specific binding of said polypeptide ligands and said polypeptides, and wherein a significant change in the specific binding is an indication that the test compound is efficacious for inhibiting cancer in the subject.

33. A method of selecting a composition for inhibiting cancer in a subject, comprising

- (a) obtaining a first biological sample comprising cancer cells from the subject;
- (b) separately exposing aliquots of the sample in the presence of a plurality of test compositions;

(c) comparing the specific binding between one or more polypeptide ligands and one or more polypeptides in each of the aliquots from (b) with the specific binding between said polypeptide ligands and said polypeptides in each of the aliquots from (a), wherein said ligands comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, and wherein said polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186; and

(d) selecting one of the test compositions which induces a significant change in specific binding .

34. A method of inhibiting cancer in a subject with cancer, comprising:

- (a) obtaining a first biological sample comprising cells from the subject;
- (b) administering to the subject one or more test compositions;
- (c) obtaining a second biological sample comprising cells from the subject of (b); and

5 (d) comparing the specific binding between one or more polypeptide ligands and one or more polypeptides in the first sample with the specific binding between said polypeptide ligands and said polypeptides in the second sample, wherein said ligands comprising a polypeptide sequence selected from the group consisting of SEQ ID NOs: 94-186, and wherein said polypeptides comprising a polypeptide sequence selected from the group consisting of SEQ
10 ID NOs: 94-186, and wherein a significant change in the specific binding is an indication of inhibition cancer by said test compositions.

SEQUENCE LISTING 1657-2022.txt

SEQUENCE LISTING

<110> Mayo Foundation for Medical Education and Research
Bayer Healthcare LLC
Burgess, Christopher
Myerow, Susan
Thiagalingam, Arunthathi
Maimonis, Peter
Molino, Gary
Burgart, Lawrence
Boardman, Lisa A.
Thibodeau, Steven
Lewis, Marcia

<120> Use of Differentially Expressed Nucleic Acid Sequences as Biomarkers for Cancer

<130> 1657/2022

<140> US 10/700,439

<141> 2003-11-04

<160> 186

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2163

<212> DNA

<213> Homo sapiens

<400> 1

ggcagatgaa	atataagatt	catcaaccac	atttgacagc	ccatggcagg	tttcctgttt	60
tccatcgctc	ctctgcaggt	cacagacaca	cagagcccag	ccgtggcagg	ctcagccggg	120
gtccggggct	gctaacaacg	gctacattcc	tcccccagg	ccaagggaaa	tcctgagcgc	180
aggccagggt	tgtttgtgtt	tgaggtgtgc	tgggatgaaa	ggcaccctgg	aagtggagg	240
taaatagaaca	atggaaaaac	ttcacggcaa	gattagaaaag	atacctgagc	ccaatacccg	300
cctgatgtcg	tgggccacac	ctccgggtta	ccaggggaag	ggaggaagca	aactgtcata	360
ttgatgtggc	tctaaacaac	aacagtgtgc	gaaggcccag	gggcactttg	ggattgacca	420
agaggaaca	caagttgcac	aatgatacaa	tcttgttggg	acaattgtca	gagaagggaa	480
ctcccacagc	aaaggccata	aaaccatcca	gggcagtctg	gggcggtctc	gttctgcggg	540
gccaggaggt	ggagcagagc	tcagccccgt	cccaaacaca	gatgggacca	tgaactccgg	600
acacagcttc	agccagaccc	cctcggcctc	cttccatggc	gccggagggtg	gctggggccg	660
gcccaggagc	ttccccaggg	ctcccaccgt	ccatggcggt	gcggggggag	cccgcattct	720
cctgtccttc	accaagcgga	gctgcccacc	ccctggaggg	tcttgggggt	ctggaagaag	780
cagcccccta	ctaggcgga	atgggaaggc	caccatgcag	aatctcaacg	accgcctggc	840
ctcctacctg	gagaaggttc	gcgccctgga	ggaggccaac	atgaagctgg	aaagccgcag	900
cctgaaatgg	caccagcaga	gagatcctgg	cagtaagaaa	gattattccc	agtatgagga	960
aaacatcaca	cacctgcagg	agcagatagt	ggatggtaag	atgaccaatg	ctcagattat	1020
tctttctcatt	gacaatgcc	ggatggcagt	ggatgacttc	aacctcaagt	atgaaaatga	1080
acactccttt	aagaaagact	tggaaattga	agtcgagggc	ctccgaagga	ccttagacaa	1140
cctgaccttt	gtcacaacag	acctagaaca	ggaggtggaa	ggaatgagga	aagagctcat	1200
tctcatgaag	aagcaccatg	agcaggaat	ggagaagcat	catgtgccaa	gtgacttcaa	1260
tgtcaatgtg	aaggtggata	caggtcccag	ggaagatctg	attaaggtcc	tggaggatat	1320
gagacaagaa	tatgagctta	taataaagaa	gaagcatcga	gacttgga	cttggtataa	1380
agaacagctc	gcagccatgt	cccaggaggg	agccagctca	gccactgtgc	agagcagaca	1440
aggtgacatc	cacgaactga	agcgcacatt	ccaggccctg	gagattgacc	tgcagacaca	1500
gtacagcacg	aaatctgctt	tggaaaacat	gttatccgag	acccagtctc	ggtactcctg	1560
caagctccag	gacatgcaag	agatcatctc	ccactatgag	gaggaactga	cgcagctacg	1620
ccatgaactg	gagcggcaga	acaatgaata	ccaagtgtct	ctgggcatca	aaaccacct	1680
ggagaaggaa	atcaccacgt	accgacggct	cctggaggga	gagagtgaag	ggacacggga	1740
agaatcaaag	tcgagcatga	aagtgtctgc	aactccaaag	atcaaggcca	taaccaggga	1800
gaccatcaac	ggaagattag	ttctttgtca	agtgaatgaa	atccaaaagc	acgcatgaga	1860
ccaatgaaag	tttccgcctg	ttgtaaaatc	tattttcccc	caaggaaagt	ccttgcacag	1920
acaccagtga	gtgagttcta	aaagataccc	ttggaattat	cagactcaga	aactttttatt	1980
ttttttttct	gtaacagctc	caccagactt	ctcataatgc	tcttaatata	ttgcactttt	2040

SEQUENCE LISTING 1657-2022.txt

ctaatacaag tgcgagttta tgagggtaaa gctctacttt cctactgcag ccttcagatt 2100
 ctcacattt tgcattctatt ttgtagccaa taaaactccg cactagcaaa aaaaaaaaaa 2160
 aaa 2163

<210> 2
 <211> 808
 <212> DNA
 <213> Homo sapiens

<400> 2
 gatataaagc tcctacagct acctggcctg agaagccaac tcagactcag ccaacagaga 60
 ttgttgattt gcctcttaag caagagattc attgcagctc agcatggctc agaccagctc 120
 atacttcatg ctgatctcct gcctgatgtt tctgtctcag agccaaggcc aagaggccca 180
 gacagagttg cccagaggcc ggatcagctg cccagaaggc accaatgcct atcgctccta 240
 ctgctactac tttaatgaag accgtgagac ctgggttgat gcagatctct attgccagaa 300
 catgaattcg ggcaacctgg tgtctgtgct caccagggc gaggggtgct ttgtggcctc 360
 actgattaag gagagtggca ctgatgactt caatgtctgg attggcctcc atgaccccaa 420
 aaagaaccgc cgctggcact ggagcagtggt gtccctggct tcctacaagt cctggggcat 480
 tggagcccca agcagtgtta atcctggcta ctgtgtgagc ctgacctcaa gcacaggatt 540
 ccagaaatgg aaggatgtgc ctgtgtgaaga caagttctcc tttgtctgca agttcaaaaa 600
 ctgagggcaa ctggaaaaata catgtctaga actgatccag caattacaac ggagtcaaaa 660
 attaaaccgg accatctctc caactcaact caacctggac actctcttct ctgctgagtt 720
 tgccttggtt atcttcaata gttttaccta cccagctctt tggaaacccta aataataaaa 780
 ataaacatgt ttccactatt gtgctgtc 808

<210> 3
 <211> 773
 <212> DNA
 <213> Homo sapiens

<400> 3
 aagccacctc aagtggacaa ggcacttacc aacagagatt gctgatttgc tccttaagca 60
 agagattcac tgccgctaag catggctcag accaactcgt tcttcatgct gatctcctcc 120
 ctgatgttcc tgtctctgag ccaaggccag gagtcccaga cagagctgcc taatccccga 180
 atcagctgcc cagaaggcac caatgcctat cgctcctact gctactactt taatgaagac 240
 cctgagacct ggggttgatgc agatctctat tgccagaaca tgaattcagg caacctgggtg 300
 tctgtgtcta cccaggcgga ggggtgccttc gtggcctcac tgattaagga gtagtagact 360
 gatgacagca atgtctggat tggcctccat tgggacactg gacccaaaaa agaaccgccg ctggcactgg 420
 agtagtgggt ccctgggtct ctacaagtcc tgggacactg gatccccgag cagtgtctaat 480
 gctggctact gtgcaagcct gacttcatgc tcaggattca agaaatggaa ggatgaatct 540
 tgtgagaaga agttctcctt tgtttgcaag ttcaaaaact agaggaagct gaaaaatgga 600
 tgtctagaac tggctctgca attactatga agtcaaaaat taaactagac tatgtctcca 660
 actcagttca gaccatctcc tccctaatag tttgtcatcg ctgatcttca gtaccttcac 720
 ctgtctcagt ctctagagcc ctgaaaaata aaaacaaact tattttttatc cag 773

<210> 4
 <211> 1738
 <212> DNA
 <213> Homo sapiens

<400> 4
 cgggggggta ctgtgcgagc cctcaaggag gtggctgttc tgtagctgga gagctccgtg 60
 ggtggcagga ctgaacttga acaccagaaa caacccccaa gccttgtgac ctgggaggca 120
 ggaggcggtt ctgtctccct gggacttggg tggctgagcc gaggtactcg ggacctgtc 180
 ccgcgcattg cagagtggct cctcacagcc tgaagctcat ccttctgcac gggccagcca 240
 ggccagcaca gaggcaccag ggcagcagtc cacacaggtc cccggggacc ccacatgtg 300
 gagcggatgg tggctgtggc ccttgtgtgc cgtctgact gcagacttct ttcggggaga 360
 ggccagagag atcatgaggg actcccctgt cattgatggg cacaatgacc tcccctggca 420
 gctgtctggat atgttcaaca accggctgca ggacgagagg gccaacctga ccaccttggc 480
 cggcagacac accaacatcc ccaagctgag ggccggcttt gtgggaggcc agttctgtgc 540
 cgtgtacacg ccctgcgaca cccagaacaa agacgccgtg cggaggacgc tggagcagat 600
 ggacgtgggt caccgcatgt gccggatgta cccggagacc ttcctgtatg tcaccagcag 660
 tgcaggcatt cggcaggcct tccgggaagg gaaggtggcc agcctgatcg gcgtggaggg 720
 cggccactcc attgacagca gtttgggcgt cctgcgggca ctctatcagc tgggcatgca 780
 gtacctgacc ctcaccacac gctgcaacac gccctgggct gacaactggc tgggtggacac 840
 gggagacagc gagccccaga gccaaaggctt gtcacccttt gggcagcgtg tgggtgaagg 900
 gctgaaccgt ctgggggttc tcatcgactt ggctcacgtg tctgtggcca ccatgaaggc 960

SEQUENCE LISTING 1657-2022.txt

caccctgcag	ctgtccagag	ccccggtcat	cttcagccac	tcctcggcct	acagcgtgtg	1020
cgcaagccgg	cgcaacgtgc	ctgacgacgt	cctgaggctg	gtgaaacaga	cagacagcct	1080
ggtagtgggtg	aactttctaca	acaattacat	ttcctgcacc	aacaaggcca	acctgtccca	1140
agtggccgac	catctggatc	acatcaagga	ggtaggcagga	gccagagccg	tgggttttgg	1200
tggggacttt	gatggtgttc	caaggggtccc	tgaggggctg	gaggacgtct	ccaagtatcc	1260
agacctgac	gctgagctgc	tcaggaggaa	ctggacggag	gcggagggtca	agggcgcaact	1320
ggctgacaac	ctgctgaggg	tcttcgaggc	tgtggaacag	gccagcaacc	tcacacaggc	1380
tcccaggagg	gagcccatcc	cgctggacca	gctgggtggc	tcctgcagga	cccattacgg	1440
ctactcctct	ggggctttcca	gcctccatcg	ccactggggg	ctcctgctgg	cctccctcgc	1500
tcccctggtc	ctctgtctgt	ctctcctgtg	aaacctggga	gaccagagtc	cccttttaggg	1560
ttcccggagc	tccgggaaga	cccggccatc	ccaggactcc	agatgccagg	agccctgtctg	1620
cccacatgca	aggaccagca	tctcctgaga	ggacgcctgg	gcttacctgg	ggggcaggat	1680
gcctggggac	agttcaggac	acacacacag	tagggccgca	ataaaagcaa	caccctt	1738

<210> 5

<211> 1666

<212> DNA

<213> Homo sapiens

<400> 5

ctccataaag	cacaaacttt	cagagacagc	agagcacaca	agcttctagg	acaagagcca	60
ggaagaaacc	accggaagga	accatctcac	tgtgtgtaaa	catgacttcc	aagctggccg	120
tggctctctt	ggcagccttc	ctgatttctg	cagctctgtg	tgaagggtgca	gttttgccaa	180
ggagtgtctaa	agaacttaga	tgtcagtgca	taaagacata	ctccaaacct	ttccacccca	240
aatattatcaa	agaactgaga	gtgattgaga	gtggaccaca	ctgcgccaac	acagaaatta	300
ttgtaaagct	ttctgatgga	agagagctct	gtctggaccc	caaggaaaac	tgggtgcaga	360
gggttgtgga	gaagtttttg	aagagggctg	agaattcata	aaaaaattca	ttctctgtgg	420
tatccaagaa	tcagtgaaga	tgccagtgaa	acttcaagca	aatctacttc	aacacttcat	480
gtattgtgtg	ggtctgttgt	aggggttgca	gatgcaatac	aagattcctg	gttaaatttg	540
aattttcagta	aacaatgaat	agtttttcat	tgtaccatga	aatatccaga	acatacttat	600
atgtaaagta	ttattttatt	gaatctacaa	aaaacaacaa	ataattttta	aatataagga	660
ttttcctaga	tattgcacgg	gagaatatac	aaatagcaaa	attgaggcca	agggccaaga	720
gaatatccga	actttaattt	caggaattga	atgggtttgc	tagaatgtga	tatttgaagc	780
atcacataaa	aatgatggga	caataaaatt	tgccataaag	tcaaatttag	ctggaaattc	840
tggatttttt	tctgttaaat	ctggcaaccc	tagcttgcta	gccaggatcc	acaagtcctt	900
gttccactgt	gccttggttt	ctcctttatt	tctaagtggg	aaaagtatta	gccaccatct	960
tacctcacag	tgatgttggtg	aggacatgtg	gaagcacttt	aagttttttc	atcataacat	1020
aaattatttt	caagtgtaac	ttattaacct	atttattatt	tatgtattta	tttaagcatc	1080
aaattattgt	gcaagaattt	ggaaaaatag	aagatgaatc	attgattgaa	tagttataaa	1140
gatgttatag	ttaaatttatt	ttatttttaga	tattaaatga	tgttttatta	gataaatttc	1200
aatcagggtt	tttagattaa	acaaacaac	aattgggtac	ccagttaaatt	tttcatttca	1260
gataaacaac	aaataatttt	ttagtataag	tacattattg	tttatctgaa	attttaattg	1320
aactaacaat	cctagtttga	tactcccagt	cttgcatttg	ccagctgtgt	tggtagtgct	1380
gtgttggaatt	acggaataat	gagtttagaag	tattaaaaca	gccaaaactc	cacagtcaat	1440
attagtaatt	tcttgctggt	tgaaacttgt	ttattatgta	caaataagatt	cttataatat	1500
tatttaaatg	actgcatttt	taaatacaag	gctttatatt	tttaacttta	agatgttttt	1560
atgtgctctc	caaatttttt	ttactgtttc	tgattgtatg	gaaatataaa	agtaaatatg	1620
aaacatttta	aataataattt	gttggtcaag	taaaaaaaaa	aaaaaa		1666

<210> 6

<211> 1973

<212> DNA

<213> Homo sapiens

<400> 6

gggatatttg	agtagcaaga	ggctgggaag	ccatcactta	ccttgcactg	agaaagaaga	60
caaaggccag	tatgcacagc	tttcctccac	tgctgctgct	gctgttctgg	gggtgtggtg	120
ctcacagctt	cccagcgact	ctagaaacac	aagagcaaga	tgtggactta	gtccagaaat	180
acctggaaaa	atactacaac	ctgaagaatg	atgggaggca	agttgaaaag	cggagaaata	240
gtggcccagt	ggttgaaaaa	ttgaagcaaa	tgcaggaatt	ctttgggctg	aaagtgactg	300
ggaaaccaga	tgtgaaacc	ctgaagggtg	tgaagcagcc	cagatgtgga	gtgcctgatg	360
tggctcagtt	tgtcctcact	gaggggaacc	ctcgttggga	gcaaacacat	ctgacctaca	420
ggattgaaaa	ttacacgcc	gatttgccaa	gagcagatgt	ggaccatgcc	attgagaaag	480
ccttccaact	ctggagtaat	gtcacacctc	tgacattcac	caaggctctc	gaggggtcaag	540
cagacatcat	gatattcttt	gtcaggggag	atcatcgggg	caactctcct	tttgatggac	600
ctggaggaaa	tcttgctcat	gcttttcaac	caggcccagg	tattggaggg	gatgctcatt	660
ttgatgaaga	tgaaggtg	accaacaatt	tcagagagta	caacttacat	cgtgttgccg	720

SEQUENCE LISTING 1657-2022.txt

```

ctcatgaact cggccattct cttggactct cccattctac tgataticgg gctttgatgt 780
accctagcta caccttcagt ggtgatgttc agctagctca ggatgacatt gatggcatcc 840
aagccatata tggacgttcc caaaatcctg tccagcccat cggcccacaa accccaaaag 900
cgtgtgacag taagctaacc tttgatgcta taactacgat tcggggagaa gtgatgttct 960
ttaaagacag attctacatg cgcacaaatc ccttctaccc ggaagttgag ctcaatttca 1020
tttctgtttt ctggccacaa ctgccaatg ggcttgaagc tgcttacgaa tttgcccaga 1080
gagatgaagt ccggtttttc aaaggggaata agtactgggc tgttcaggga cagaatgtgc 1140
tacacggata ccccaaggac atctacagct cctttggctt ccctagaact gtgaagcata 1200
tcgatgctgc tctttctgag gaaaacactg gaaaaaccta cttctttgtt gctaacaaat 1260
actggaggtg tgatgaatat aaacgatcta tggatccagg ttatcccaaa atgatagcac 1320
atgactttcc tgggaattggc cacaagttg atgcagtttt catgaaagat ggatttttct 1380
atttctttca tgggaacaaga caatacaaat ttgatcctaa aacgaagaga attttgactc 1440
tccagaaaagc taatagctgg ttcaactgca ggaaaaattg aacattacta atttgaaatg 1500
aaaacacatg gtgtgagctc aaagaagggtg ttttcctgaa gaactgtcta ttttctcagt 1560
catttttaac ctctagagtc actgatacac agaataaat cttatttata cctcagtttg 1620
catatttttt tactatttag aatgtagccc tttttgtact gatataattt agttccacaa 1680
atggtgggta caaaaagtca agtttgtggc ttatggattc atataggcca gagttgcaaa 1740
gatcttttcc agagtatgca actctgacgt tgatcccaga gacgagcttc agtgacaaac 1800
atatcctttc aagacagaaa gagacaggag acatgagctt ttgccggagg aaaagcagct 1860
caagaacaca tgtgctgtca ctgggatagg caagggataa ctcttctaac 1920
acaaaataag tgttttatgt ttggaataaa gtcaaccttg tttctactgt ttt 1973

```

<210> 7

<211> 1127

<212> DNA

<213> Homo sapiens

<400> 7

```

accaaataca ccataggtcc aagaacaatt gtctctggac ggcagctatg cgactcaccg 60
tgctgtgtgc tgtgtgcctg ctgcctggca gcctggccct gccgctgcct caggaggcgg 120
gaggcatgag tgagctacag tgggaacagg ctccaggacta tctcaagaga ttttatctct 180
atgactcaga aacaaaaaat gccaacagtt tagaagccaa actcaaggag atgcaaaaat 240
tctttggcct acctataact ggaatgttaa actcccgcgt catagaaata atgcagaagc 300
ccagatgtgg agtgcagatg ttgacagatt actcactatt tccaaatagc ccaaaatgga 360
cttccaaagt ggtcacctac aggatcgtat catatactcg agacttaccg catattacag 420
tggatcgatt agtgtcaaaag gctttaaaca tgtggggcaa agagatcccc ctgcatttca 480
ggaaagtgtg atggggaaact gctgacatca tgattggctt tgcgcgagga gctcatgggg 540
actcctaccc atttgatggg ccaggaaaca cgctggctca tgcctttgcg cctgggacag 600
gtctcggagg agatgctcac ttcgatgagg atgaacgctg gacggatggg agcagtcctg 660
ggattaactt cctgtatgct gcaactcatg aacttgcca tcttttgggt atgggacatt 720
cctctgatcc taatgcagtg atgtatccaa cctatggaaa tggagatccc caaaatttta 780
aactttccca ggatgataat aaaggcattc agaaactata tggaaagaga agtaattcaa 840
gaaagaaata gaaacttcag gcagaacatc cattcattca ttcattggat tgtatatcat 900
tgttgacaca tcagaattga taagcactgt tcctccactc catttagcaa ttatgtcacc 960
cttttttatt gcagttgggt tttgaatgtc tttcactcct tttattgggt aaactccttt 1020
atggtgtgac tgtgtcttat tccatctatg agctttgtca gtgcgcgtag atgtcaataa 1080
atgttacata cacaataaaa taaaatgttt attccatggg aaatttta 1127

```

<210> 8

<211> 1524

<212> DNA

<213> Homo sapiens

<400> 8

```

gcagagcaca gcatcgctcg gaccagactc gtctcaggcc agttgcagcc ttctcagcca 60
aacgccgacc aagggaaaact cactaccatg agaattgcag tgatttgctt ttgcctccta 120
ggcatcacct gtgccatacc agttaaacag gctgattctg gaagttctga ggaaaagcag 180
ctttacaaca aataccacaga tgcctgtggc acatggctaa accctgacct atctcagaag 240
cagaatcttc tagccccaca gacccticca agtaagtcca acgaaagcca tgaccacatg 300
gatgatgtgg atgatgaaga tgactgtgac catgtggaca gccaggactc cattgactcg 360
aacgactctg atgatgtaga tgacactgac gattctcacc agtctgatga gtctcaccat 420
tctgatgaat ctgatgaact ggtcactgat tttcccacgg acctgccagc aaccgaagtt 480
ttcactccag ttgtccccac agtagacaca tatgatggcc gaggtgatag tgtggtttat 540
ggactgaggt caaaatctaa gaagtttcgc agacctgaca tccagtacct tgatgtcata 600
gacgaggaca tcacctcaca catggaaaagc gaggagttga atggtgcata caaggccatc 660
cccgttgccc aggacctgaa cgcgccttct gattggggaca gccgtgggaa ggacagttat 720
gaaacgagtc agctggatga ccagagtgtc gaaaccacaa gccacaagca gtccagatta 780

```

SEQUENCE LISTING 1657-2022.txt

tataagcggg	aagccaatga	tgagagcaat	gagcattccg	atgtgattga	tagtcaggaa	840
ctttccaaag	tcagccgtga	attccacagc	catgaatttc	acagccatga	agatatgctg	900
gttgtagacc	cctaaagtaa	ggaagaagat	aaacacctga	aatttcgtat	ttctcatgaa	960
ttagatagtg	catcttctga	ggccaattaa	aaggagaaaa	aatacaattt	ctcactttgc	1020
atttagtcaa	aagaaaaaat	gctttatagc	aaaatgaaag	agaacatgaa	atgcttcttt	1080
ctcagtttat	tgggtgaatg	tgtatctatt	tgagtctgga	aataactaat	gtgtttgata	1140
attagtttag	tttgtggctt	catggaaact	ccctgtaaac	taaaagcttc	aggggttatgt	1200
ctatgttcac	tctatagaag	aaatgcaaac	tatcactgta	ttttaatatt	tgttattctc	1260
tcataaatag	aaatttatgt	agaagcaaac	aaaatacttt	taccacttta	aaaagagaat	1320
ataacatttt	atgtcactat	aatcttttgt	tttttaagtt	agtgtatatt	ttgtttgat	1380
tatctttttg	tgggtgtgaat	aaatctttta	tcttgaatgt	aataagaatt	tgggtggtgtc	1440
aattgcttat	ttgttttccc	acggtgtgcc	agcaattaat	aaaacataac	cttttttact	1500
gcctaaaaaa	aaaaaaaaaa	aaaa				1524

<210> 9

<211> 1172

<212> DNA

<213> Homo sapiens

<400> 9

gagacattcc	tcaattgctt	agacatattc	tgagcctaca	gcagaggaac	ctccagtctc	60
agcaccatga	atcaaactgc	gattctgatt	tgctgcctta	tctttctgac	tctaagtggc	120
attcaaggag	tacctctctc	tagaaccgta	cgctgtacct	gcatcagcat	tagtaatcaa	180
cctgttaatc	caagggtctt	agaaaaactt	gaaattattc	ctgcaagcca	attttgtcca	240
cgtgttgaga	tcattgtctac	aatgaaaaag	aagggtgaga	agagatgtct	gaatccagaa	300
tcgaaggcca	tcaagaattt	actgaaagca	gttagcaagg	aaatgtctaa	aagatctcct	360
taaaaccaga	ggggagcaaa	atcgatgcag	tgcttccaag	gatggaccac	acagaggctg	420
cctctcccat	cacttcccta	catggagtat	atgtcaagcc	ataattgttc	ttagtttgca	480
gttacaactaa	aagggtgacca	atgatgggtca	ccaaatcagc	tgctactact	cctgtaggaa	540
gggttaatggt	catcatccta	agctattcag	taataactct	accctggcac	tataatgtaa	600
gctctactga	gggtgctatgt	tcttagtgga	tggtctgacc	ctgcttcaaa	tatttccctc	660
acctttccca	tcttccaagg	gtactaagga	atctttctgc	tttgggggtt	atcagaattc	720
tcagaatctc	aaataactaa	aagggtatgca	atcaaactctg	ctttttaaag	aatgctcttt	780
acttcatgga	cttccactgc	catctctcca	agggggccaa	attctttcag	tggctacctc	840
catacaattc	caaacacata	caggaaggta	gaaatatctg	aaaatgtatg	tgtaagtatt	900
cttatttaaat	gaaagactgt	acaaagtata	agtcttagat	gtatatattt	cctatatatt	960
tttcagtgta	catggaataa	catgtaatta	agtactatgt	atcaatgagt	aacaggaaaa	1020
ttttaaaaat	acagatagat	atatgctctg	catgtttacat	aagataaatg	tgctgaatgg	1080
ttttcaaaata	aaaatgaggt	actctctcgg	aaatattaag	aaagactatc	taaatgttga	1140
aagatcaaaa	gggttaataaa	gtaattataa	ct			1172

<210> 10

<211> 5699

<212> DNA

<213> Homo sapiens

<400> 10

ggagtttctca	gacctccagt	ttcagccctg	ccctcagcct	ccaatccgta	agagacaccc	60
agccccagca	attggattgg	gcagcccgtc	ttgacacacc	actgtgctga	gtgcttgagg	120
acgtgtttca	acagatgggt	gggggttagtg	tgtgtcatca	cattcgagtg	gggattaaga	180
gaagggaaggc	tgccctgctg	gagctgtgtg	gtcttctcca	agtgaagatc	gcaggcaata	240
gaactacttt	gcttttgag	gaaaaggagg	aattcatttt	cagcagacac	aagaaaagca	300
gttttttttt	cagggtattct	tcacttctct	tgaacaagga	actcactcag	agactaacac	360
aaaggaagta	atttcttacc	tggtcattat	ttagtctaca	ataagttcat	ccttcttcag	420
tgtgaccagt	aaattcttcc	catactcttg	aagagagcat	aattggaatg	gagagggtgg	480
gctagcggcc	atccaccatc	atctaaagaa	gataaacttg	gcaaatgaca	tgtaggttct	540
tcaaggcaga	ataattgcag	aaaatcttca	aaggacccta	tctgcagatg	ttctgaatac	600
ctctgagaat	agagattgat	tattcaacca	ggatacctaa	ttcaagaact	ccagaaatca	660
ggagacggag	acattttgtc	agttttgcaa	cattggacca	aatacaatga	agtattcttg	720
ctgtgctctg	gttttggtcg	tcctgggcac	agaattgctg	ggaagcctct	gttcgactgt	780
cagatgcccg	aggttcagag	gacggataca	gaggaacaga	aaaaacatcc	gacccaacat	840
tattcttgtg	cctaccgatg	atcaagatgt	ggagctgggg	tccctgcaag	tcatagaaca	900
aacgagaaag	attatggaac	atgggggggc	caccttcac	aatgcctttg	tgactacacc	960
catgtgctgc	ccgtcacggt	cctccatgct	caccgggaag	tatgtgcaca	atcacaatgt	1020
ctacaccaac	aacgagaact	gctcttcccc	ctcgtggcag	gccatgcatg	agcctcggag	1080
ttttgctgta	tatcttaaac	acactggcta	cagaacagcc	ttttttggaa	aataacctca	1140
tgaatataat	ggcagctaca	ttccccctgg	gtggcgagaa	tggcttggat	taatcaagaa	1200

SEQUENCE LISTING 1657-2022.txt

ttctcgccttc	tataattaca	ctgtttgtcg	caatggcatc	aaagaaaagc	atgggatttga	1260
ttatgcaaaag	gactacttca	cagactttaat	cactaacgag	agcattaatt	acttcaaaat	1320
gtctaagaga	atgtatcccc	ataggcccg	tatgtgggtg	atcagccacg	ctgcgcccc	1380
cggcccccag	gactcagccc	cacagttttc	taaactgtac	cccaatgctt	cccaacacat	1440
aactcctagt	tataactatg	caccaaatat	ggataaacac	tggattatgc	agtacacagg	1500
accaatgctg	cccattccaca	tggaaatttac	aaacatttcta	cagcgcaaaa	ggctccagac	1560
tttgatgtca	gtggatgatt	ctgtggagag	gctgtataac	atgctcgtgg	agacggggga	1620
gctggagaat	acttacatca	tttacaccgc	cgaccatggt	taccatattg	ggcagtttgg	1680
actgggtcaag	gggaaatcca	tgccatatga	ctttgatatt	cgtgtgcctt	tttttattcg	1740
tgggtccaagt	gtagaaccag	gatcaatagt	cccacagatc	gttctcaaca	ttgacttggc	1800
ccccacgatc	ctggatattg	ctgggctcga	cacacctcct	gatgtggacg	gcaagtctgt	1860
cctcaaactt	ctggaccag	aaaagccagg	taaacagttt	cgaacaaaca	agaaggccaa	1920
aatttggcgt	gatacattcc	tagtggaaag	aggcaaat	ctacgtaaga	aggaagaatc	1980
cagcaagaat	atccaacagt	caaatacact	gccccaaat	gaacgggtca	aagaactatg	2040
ccagcaggcc	aggtaccaga	cagcctgtga	acaaccgggg	cagaagtggc	aatgcattga	2100
ggatacatct	ggcaagcttc	ggcaagcttc	gggttccat	cccagtgacc	tgctcacagt	2160
ccggcagagc	acgcggaacc	tctacgctcg	cggcttccat	gacaaagaca	aagagtgcag	2220
ttgtagggag	tctggttacc	gtgccagcag	aagccaaaga	aagagtcaac	ggcaattctt	2280
gagaaaaccag	gggactccaa	agtacaagcc	cagatttgtc	catactcggc	agacacgttc	2340
cttgtccgct	gaatttgaag	gtgaaatata	tgacataaat	ctggaagaag	aagaagaatt	2400
gcaagtgttg	caaccaagaa	acattgctaa	gcgtcatgat	gaaggccaca	aggggccaa	2460
agatctccag	gcttccagtg	gtggcaacag	gggcaggatg	ctggcagata	gcagcaacgc	2520
cgtgggccc	cctaccactg	tccgagtgac	acacaagtgt	tttattcttc	ccaatgactc	2580
tatccattgt	gagagagaac	tgtaccaatc	ggccagagcg	tggaaggacc	ataaggcata	2640
cattgacaa	gagattgaag	ctctgcaaga	taaaattag	aatttaagag	aagtgaagag	2700
acatctgaag	agaaggaagc	ctgaggaatg	tagctgcagt	aaacaaagct	attacaataa	2760
agagaaaggt	gtaaaaaagc	aagagaaatt	aaagagccat	cttcacccat	tcaaggaggc	2820
tgctcaggaa	gtagatagca	aactgcaact	tttcaaggag	aacaaccgta	ggaggaagaa	2880
ggagaggaag	gagaagagac	ggcagaggaa	gggggaagag	tgacgctgc	ctggcctcac	2940
ttgtcttcag	catgacaaca	accactggca	gacagcccg	ttctggaacc	tggtatcttt	3000
ctgtgcttgc	acgagttcta	acaataacac	ctactggtgt	ttgcgtacag	ttaatgagac	3060
gcataatatt	cttttctgtg	agtttgcctc	tggctttttg	gagtattttg	atatgaatac	3120
agatccttat	cagctcaca	atacagtga	cacggtagaa	cgaggcattt	tgaatcagct	3180
acacgtacaa	ctaattggagc	tcagaagctg	aggaagctat	aagcagtga	acccaagacc	3240
taagaatctt	gatgttggaa	ataaagatgg	gtctcactgc	agacatcaac	tggaaggacc	3300
atgggatgga	tggaaggggt	aatcagcccc	tctatgagta	cagacaaaac	tacagactta	3360
tagaggagct	acacagtgtg	aatgaaaaca	atttagatag	agtattttga	ctgctgaaga	3420
gtctgggtgga	ctggactaag	tacttgaagg	ctcaaaactgc	tc aaagtgc	gggttcttgg	3480
gtcactatga	gcaaaataaa	acaaataaga	agatggcctc	tgctgactca	gatgaagacc	3540
ttgtctctgc	tgagcacgct	gtgtcaatgg	tgaccttgcc	agctgacctt	caaaccctgc	3600
caaggcataa	gggttgggaaa	acacctcatt	gtaaacttga	atggaataac	gacattccag	3660
atttgaaccg	accaacatta	agtccagaga	gaaaaaccga	aaaatggacg	gggcatgaag	3720
aagttaatca	tttgaattct	gatttcagtg	gcgatggcat	gacagagcta	gagctcgggc	3780
agactaatca	tctggaaacc	gatttcagtg	acccgaaaga	acttccccag	tatggtgggtc	3840
ccagccccag	gctgcagccc	attcgcaggc	atcttcctgt	gcattccgat	ggaatttcag	3900
ctggaaagga	catttttgaa	gatcaactat	aacaccgaag	taattccagc	atagcgggga	3960
ttcatcagat	gttcaccatg	gccaccgcag	aaaaggagaa	gtcacagcac	ctagaaggca	4020
agatgttgac	caagggtggag	aagaatcacg	tctgattaga	tgaaactgtt	accttaccct	4080
gcgcctcttc	ttcactctcc	tctgattaga	ataaaggtaa	tcacagccac	caacattcca	4140
tttcttttta	acttttttat	ttgtaaacta	gctagtggag	atgtgagcaa	gcggtgtgca	4200
agctaccctg	ggtacctttg	tgcagttaga	tgccaagagt	agaaagaaag	gctggggata	4260
cacggagact	catcggtata	atttactatc	tgtttgtttg	ttttgtacta	aaacagtatt	4320
tttgggttgg	cttgggtttg	attttttgct	atacatgtta	tccaatcaag	atggctagaa	4380
atcttttgaa	tatcgtaggg	acataagtat	acccttggtg	aatctttcaa	cacacttcca	4440
tgggtgcctt	ctgagtgtct	aaaacttgac	ttaaccactg	gaatttttca	atgccgtcat	4500
ctgcctgcgt	aatgaagtgt	tgattcaattt	taaaatgcca	tgctctattg	attagtctta	4560
tttcagttag	atgattttgc	actttgagat	actgttggct	gtcattgtga	caaagtcaaa	4620
tttttttatt	tttacaggct	tatcagtctc	tcacatatgt	tttgacatta	agcttttgcc	4680
taaaacccca	aggacgacac	acagtatgga	tgctaaaatc	gattagcaga	aaggcatggc	4740
agaaaatggt	gcattgtgtt	tacctcgact	aagtaaaaca	aatgaagatt	gcctgctctc	4800
taataatggt	gggtgtgaaa	ataaataaat	catcatacct	ttaagattgc	tatatatttg	4860
tctgtgccta	gcctcaaagc	gttcatacata	aagatctttt	attttcatct	tttttggttt	4920
gttattttct	tgacaggaga	aaaagatcta	ataaaatatg	actagttttg	aattttacacc	4980
tcttggcatg	actaagaagc	ttaaattgttg	tgctccacaa	tttcaacata	ccacaagaga	5040
aagaacttct	caataaaaga	aaatcatgat	tattttgtaa	accttcacca	agttctgata	5100
agttaatctt	ttaacattgt	gttctatgat	tgaaaatctg	tattcttgaa	aatatccttg	5160
tcttttaaa	acatagttca	aaattgcttt				5220

SEQUENCE LISTING 1657-2022.txt

```

ttgtgtatta ggttttttaa taccagctaa aggattacct cactgagtc tcaagtaccct 5280
cctatttcagc tccccaagat gatgtgtttt tgctttacct aagagagggt ttctttcttat 5340
ttttagataa ttcaagtgtc tagataaatt atgtttttct taagtgttta tggtaaaactc 5400
ttttaaagaa aatttaatat gttatagctg aatctttttg gtaactttta atcttttatca 5460
tagactctgt acatatgttc aaatttagctg cttgcctgat gtgtgtatca tcggtgggat 5520
gacagaacaa acatatattat gatcatgaat aatgtgcttt gtaaaaagat ttcaagttat 5580
taggaagcat actctgtttt ttaatcatgt ataattattc atgatacttt tatagaacaa 5640
ttctggcttc aggaaagtct agaagcaata tttcttcaaa taaaagggtg ttaaacttt 5699

```

<210> 11
 <211> 6217
 <212> DNA
 <213> Homo sapiens

<400> 11

```

cgcagactgt gctggagctg gtgctgaaaa aggggggtttg cagaggctgc cctggggctg 60
gtgctgaaag aagagccac agctgacttc atggtgctac aataacctca gaatctactt 120
ttcactctca ggagaaccca cagtctaata ttagacatg atggcaaact gggcggaagc 180
aagacctctc ctattcttta ttgtttttat agggcaattt gtctcaataa aagcccagga 240
agaagacgag gatgaaggat atggtgaaga aatagcctgc actcagaatg gccagatgta 300
cttaaacagg gacatttggg aacctgcccc ttgtcagatc tgtgtctgtg acaatggagc 360
cattctctgt gacaagatag aatgccagga tgtgctggac tgtgccgacc ctgtaacgcc 420
ccctggggaa tgctgtcctg tctgttcaca aacacctgga ggtggcaata caaatttttg 480
tagaggaaga aagggacaaa agggagaacc aggattagt cctgttgtaa caggcatacg 540
tggctcgcca ggaccggcag gacctccagg atcacaggga ccaagaggag agcgagggcc 600
aaaaggaaga cctggccctc gtggacctca gggaattgat ggagaaccag gtgttccttg 660
tcaacctggt gctccaggac ctcttggaac tccgtccac ccaggaccg atggcttgag 720
caggccgttt tcagctcaaa tggctgggtt ggatgaaaaa tctggacttg ggagtcaagt 780
aggactaatg cctggctctg tgggtcctgt tggcccaagg ggaccacagg gtttacaagg 840
acagcaagggt ggtgcaggac ctacaggacc tcttggtgaa cctggtgatc ctggaccaat 900
gggtccgatt ggttcacgtg gaccagaggg ccctcctggt aaacctgggg aagatggtga 960
acctggcaga aatggaaatc ctggtgaagt gggatttgca ggatctccg gagctcgtg 1020
atttcctggg gctcctggtc ttccaggtct gaagggtcac cgaggacaca aaggtcttga 1080
aggccctaaa ggtgaagtgt gacacactgt ttccaagggt gaagtggcc cactggtcc 1140
aatgggtgcc atgggtcctc tgggtccgag gggaaatgcca ggagagagag ggagacttgg 1200
gccacagggg gctcctggac aacgaggtgc acatggtatg cctggaaaac ctggaccaat 1260
gggtcctctt gggataccag gctcttctg ttttccagga aatcctggaa tgaagggaga 1320
agcaggtcct acagggcgcg gaggccctga aggtcctcag gggcagagag gtgaaactgg 1380
gccccaggtt ccagttggct ctccaggtct tcttggtgca ataggaactc atggtactcc 1440
tgggtccaaa ggccaacggt gctctccggg tacctctggt cctcctggct cagcagggcc 1500
tcctggatct ccaggacctc agggtagcac tggctcctcag ggggaattcgg gccttccggg 1560
tgcattcagg ttcaaaggag aagctggccc aaaaggggaa ccaggggccac atggtattca 1620
gggtccgata gggccacccg gtgaagaagg caaaagaggt cccagaggtg acccaggaac 1680
acttggctct ccaggggcag tgggagaaag ggggtgctct ggcaatcgtg gttttccagg 1740
ctctgatggt ttacctgggc caaagggtgc tcaaggagaa cggggtcctg taggttcttc 1800
aggacccaaa ggaagccagg gggatccagg acgtccaggg gaacctgggc ttccaggtgc 1860
tcgggggttt acaggaatc ctggtgttca aggtcctgaa ggaacttg gacctttggg 1920
tgcgccaggg gaagatggcc gtccaggtcc tccaggtccc ataggaatca aaggcgagcc 1980
cgggaccatg ggccttccag gccccaaagg tagcaatggt gacctggga aacctggaga 2040
agcaggaaat cctggagttc ctgggcaaaag gggagctcct ggaaaagatg gtaaaagtgg 2100
tccttatggt cctcctgggc cgccgggtct acgtgggtga agaggagaac aaggacctcc 2160
agggcccaca ggttttcagg ggcattcctg tctccaggt cctcctggag aaggtggaaa 2220
accaggtgat caaggtgttc ctggaggtcc cggagcagtt ggcccgttag gacctagagg 2280
agaacgagga aatcctgggg aaagaggaga acctgggata actggactcc ctggtgagaa 2340
gggaatggct ggaggacatg gtcctgatgg cccaaaaggc agtccaggtc catctgggac 2400
ccctggagat acagggccc caggtcttca caggtcttga catatggcc ggagaaagag gaattgcagg 2460
aactcctggc cccaagggtg acagaggtgg cataggagaa aaagggtgct aaggcacagc 2520
tggaaaatga ggtgcaggag gtcttccagg tcctttgggc cctccagggt cggcaggcct 2580
actgggagaa aagggtgaac ctggtcctcg aggtttagtt ggtcctcctg gctcccgggg 2640
caatcctggt tctcagaggt aaaatgggccc aactggagct gttggttttg ccggacccca 2700
gggtctgac ggacagctg gtagtaaaag tgaaacttga gagccaggac agaagggaga 2760
tgctggttct cctggaccac aaggttttag aggatccctt ggccctcatg gtcctaattg 2820
tggtccttga ctaaaagggt gtcgaggaac ccaaggtccg cctggtgcta caggatttcc 2880
tgggtcttgc ggcagagttg gacctccagg ccctgcttga gctccaggac ctgcccggac 2940
cctaggggaa cccgggaagg agggacctcc aggtcctcgt ggggacctg gctctcatgg 3000
gcgtgtggga gtccgaggac cagctggccc ccctggtggc ccaggagaca aaggggacc 3060
aggagaagat gggcaacctg gtccagatgg cccccctggt ccagctggaa cgaccgggca 3120

```

SEQUENCE LISTING 1657-2022.txt

```

gagaggaatt gttggcatgc ctgggcaacg tggagagaga ggcattgccc gcctaccagg 3180
cccagcggga acaccaggaa aagtaggacc aactggtgca acaggagata aaggtccacc 3240
tggacctgtg gggcccccag gctccaatgg tcctgtaggg gaacctggac cagaagggtcc 3300
agctggcaat gatggtaccc caggacggga tgggtgctgt ggagaacgtg gtgatcgtgg 3360
agaccctggg cctgcagggtc tgccagggtc tcagggtgcc cctggaactc ctggccctgt 3420
gggtgctcca ggagatgcag gacaaagagg agatccgggt tctcgggggtc ctataggaca 3480
cctgggtcga gctggaaaac gtggattacc tggaccccaa ggacctcgtg gtgacaaagg 3540
tgatcatgga gaccgaggcg acagagggtca gaagggttca ctgggtctta 3600
gggtcttcct ggccctcctg gtccaaatgg tgaacaagga agtgctggaa tccctggacc 3660
atttggccca agaggtcctc caggcccagt tgggtccttca ggtaaagaag gaaaccctgg 3720
gccacttggg ccattgggac ctccagggtg acgaggcagt gtaggagaag caggacctga 3780
gggcccctct ggtgagcctg gcccaactgt cccctcgggt ccccttgacc accctacagc 3840
tgctcttggg gatcatcatg ggcactatga tgaagcatg ccagatccac ttcctgagtt 3900
tactgaagat caggcggctc ctgatgacaa aaacaaaacg gaccagggg ttcattgctac 3960
cctgaagtca ctcatgagtc agattgaaac catgctgagc cccgatggct cgaaaaagca 4020
cccagccgcg acgtgtgatg acgttaaagt ttgccattcc gcaaagcaga gtggtgaata 4080
ctggattgat cctaaccag gatctgttga agatgccatc aaagtcttact gcaacatgga 4140
aacaggagaa acatgtatct cagcaaacc atccagtgtg ccacgtaaaa cctggtgggc 4200
cagtaaatct cctgacaata aacctgtttg gtatgggtctt gatatgaaca gaggggtctc 4260
gcttcgcttat ggagaccacc aatcacctaa tacagccatt actcagatga cttttttgcg 4320
ctttcttatc aaagaagcct cccagaacat cacttaccatc tgtaaaaaa gtgtaggata 4380
catggacgat caagctaaga acctcaaaaa agctgtgggt ctcaaagggg gttcttcaag 4440
agatatcaaa gcagagggaa atattagatt ccggtatatt gttcttcaag acacttgctc 4500
taagcggaa ggaaatgtgg gcaagactgt ctttgaatat agaacacaga atgtggcagc 4560
cttgcccctc atagatcctg tcctgtgga tgggtggcgc acagaccagg aattcggcgt 4620
tgaaattggg ccagtttgtt ttgtgtaaag taagccaaga cacatcgaca atgagcaca 4680
ccatcaatga ccaccgcat tcacaagaac ttgactgtt tgaagtgtat cctgagactc 4740
ttgaagtaat ggctgatcct gcatcagcat tgtatatatg gtcttaagtg cctggcctcc 4800
ttatcttcca gaattttat ttacttaca atcctcaagt ttaattgat ttaaatatt 4860
tttcaatata acagtttagg ttaagatga ccaatgacaa tgaccacct tgcagaaagt 4920
aaactgattg aataaataaa tctccgtttt cttcaattta tttcagtgt atgaaaagt 4980
tgcttagtat ttatgaggaa attcttcttc ctggcaggta gcttaaagag tggggtatat 5040
agagccacaa cacatgttta ttttgcttgg ctgcagttga aaaatagaaa ttagtgcctc 5100
tttgtgacct ctcatctcaa gattgtcaat ttaaaatgag ttaaaatgt ttaacttgt 5160
atcgagacct acatgcatgt ctgatattg tgaactata atagagactc ttaaggaga 5220
atcttaaaaa aaaaaaacgt ttctcactgt cttaaataga atttttaaat agtatatat 5280
cagtggcatt ttggagaaca aagtgaattt acttcgactt cttaaatttt tgtaaaagac 5340
tataagttaa gatattttc tcattcaaat ttaaagatat ctttctctc ttgatcaatc 5400
tatcaatatt gatagaagtc aactagtat ataccattta atacatttat actttcttat 5460
ttaagaagat attgaatgca aaataattga catatagaac tttacaaaca tatgtccaag 5520
gactctaaat tgagactctt ccacatgtac aatctcatca tcctgaagcc tataatgaag 5580
aaaaagatct agaaactgag ttgtggagct gactctaatac aaatgtgatg attggaatta 5640
gaccatttgg cctttgaact ttcataggaa aatgtgacca acatttctta gcatgagcta 5700
cctcatctct agaagctggg atggacttac tattcttgtt tatatttttag atactgaaag 5760
gtgctatgct tctgttatta ttccaagact ggagataggc agggctaaaa aggtattatt 5820
atttttctct taatgatggg gctaaaattc ttctataaaa attccttaaa aataaagatg 5880
gtttaatcac taccattgtg aaacataaac tgttagactt cccgtttctg aaagaaagag 5940
catcgtttcca atgcttgggt actgttcctc agaacatgta tctctggaat gctttgtaat 6000
acttgcattg ttcttagacc ctattttaat tttttcttt taaaataaac agctgggacc 6060
cttaattgca tttgttggct ctattttaac tgggtcatgta tctctgcaaa gcatcaaatt 6120
atcccaaaag acaagccatg catacaactt tcaaaaaaaa aaaaaaa 6180
aatgacacgc ttttgtcatg tcaaaaaaaa aaaaaaa 6217

```

<210> 12
 <211> 1103
 <212> DNA
 <213> Homo sapiens

```

<400> 12
cacagagccc gggccgcagg cacctcctcg ccagctcttc cgctcctctc acagccgcca 60
gaccgcctg ctgagcccca tggcccgcgc tgcctcttcc gccgccccca gcaatccccg 120
gctcctgcga gtggcactgc tgctcctgct cctggtagcc gctggccggc gcgcagcagg 180
agcgtccgtg gccactgaac tgcgtgcca gtgcttgagc accctgcagg gaattcacc 240
caagaacatc caaagtgtga acgtgaagtc ccccggaacc cactgcgcc aaaccgaagt 300
catagccaca ctcaagaatg ggcggaagc ttgctcaat cctgcatccc ccatagttaa 360
gaaaatcatc gaaaagatg tgaacagtga caaatccaac tgaccagaag ggaggaggaa 420
gctcactggg ggctgttcct gaaggaggcc ctgcccctat aggaacagaa gaggaaagag 480

```

SEQUENCE LISTING 1657-2022.txt

agacacagct	gcagaggcca	cctggattgt	gcctaattgt	tttgagcatc	gcttaggaga	540
agtcttctat	ttattttatt	attcattagt	tttgaagatt	ctatgttaat	attttaggtg	600
taaaataatt	aagggtatga	ttaactctac	ctgcacactg	tcctattata	ttcattcttt	660
ttgaaatgtc	aacccaagt	tagttcaatc	tggattcata	tttaatttga	aggtagaatg	720
ttttcaaagt	ttctccagtc	attatgttaa	tatttctgag	gagcctgcaa	catgccagcc	780
actgtgatag	aggctggcgg	atccaagcaa	atggccaatg	agatcattgt	gaaggcaggg	840
gaatgtatgt	gcacatctgt	tttgaactg	tttagatgaa	tgtcagttgt	tattttattga	900
aatgatttca	cagtgtgtgg	tcaacatttc	tcattgtgaa	actttaagaa	ctaaaatgtt	960
ctaaatatcc	cttggacatt	ttatgtcttt	cttghtaaggc	atactgcctt	gtttaatggt	1020
agttttacag	tgtttctggc	ttagaacaaa	ggggcttaat	tattgatgtt	ttcatagaga	1080
atataaaaaa	aaagcactta	tag				1103

<210> 13

<211> 793

<212> DNA

<213> Homo sapiens

<400> 13

aggagttgtg	agtttccaag	ccccagctca	ctctgaccac	ttctctgcct	gcccagcatc	60
atgaagggcc	ttgcagctgc	cctccttgtc	ctcgtctgca	ccatggccct	ctgctcctgt	120
gcacaagtgt	gtaccaacaa	agagctctgc	tgcctcgtct	atacctcctg	gcagattcca	180
caaaagtcca	tagttgacta	ttctgaaacc	agccccagct	gccccaaagc	aggtgtcatc	240
ctcctaacca	agagaggccg	gcagatctgt	gctgacccca	ataagaagtg	ggtccagaaa	300
tacatcagcg	acctgaagct	gaatgcctga	ggggcctgga	agctgcgagg	gcccagtgaa	360
cttggtgggc	ccaggaggga	acaggagcct	gagccagggc	aatggccctg	ccaccctgga	420
ggccacctct	tctaagagtc	ccatctgcta	tgcccagcca	cattaactaa	ctttaatctt	480
agtttatgca	tcataatttc	ttttgaaatt	gatttctatt	gttgagctgc	attatgaaat	540
tagtattttc	tctgacatct	catgacattg	tctttatcat	cctttcccct	ttcccttcaa	600
ctcttcgtac	attcaatgca	tggatcaatc	agtgtgatta	gctttctcag	cagacattgt	660
gccatatgta	tcaaatgaca	aatctttatt	gaatggtttt	gctcagcacc	accttttaat	720
atattggcag	tacttattat	ataaaaggta	aaccagcatt	ctcactgtga	aaaaaaaaaa	780
aaaaaaaaaa	aaa					793

<210> 14

<211> 3654

<212> DNA

<213> Homo sapiens

<400> 14

agatgccgcg	ggggccgctc	gcagccgccc	ctgacttgtg	aatgggaccg	ggactggggc	60
cgggactgac	accgcagcgc	ttgccctgcg	ccagggactg	gcggctcgga	ggttgcgtcc	120
accctcaagg	gccccagaaa	tcactgtgtt	ttcagctcag	cggccctgtg	acattccttc	180
gtgttgtcat	ttggtgagt	accaatcaga	tgggtggagt	gtgttacaga	aattggcagc	240
aggtatccaa	tgggtgaaga	agaagctaac	tggggacgtg	ggcagccctg	acgtgatgag	300
ctcaaccagc	agagacattc	catcccaaga	gaggtctgcg	tgacgcgtcc	gggaggccac	360
cctcagcaag	accaccgtac	agttggtgga	aggggtgaca	gctgcattct	cctgtgccta	420
ccacgtaacc	aaaaatgaag	gagaactact	gtttacaagc	cgccctggtg	tgccctggga	480
tgctgtgcca	cagccatgcc	tttgccccag	agcggcgggg	gcacctgcgg	ccctccttcc	540
atgggcacca	tgagaagggc	aaggaggggc	aggtgctaca	gcgctccaag	cgtggctggg	600
tctggaacca	gttcttcgtg	atagaggagt	acaccgggcc	tgaccccggt	cttgtgggca	660
ggcttcattc	agatattgac	tctggtgatg	ggaacattaa	atacattctc	tcagggggag	720
gagctggaac	catttttgtg	attgatgaca	aatcagggaa	cattcatgcc	accaagacgt	780
tggatcgaga	agagagagcc	cagtacacgt	tgatggctca	ggcgggtggac	agggacacca	840
atcggccact	ggagccaccg	tcggaattca	ttgtcaaggc	ccaggacatt	aatgacaacc	900
ctccggaggt	cctgcacgag	acctatcatg	ccaacgtgcc	tgagagggtc	aatgtgggaa	960
cgctcagtaat	ccaggtgaca	gcttcagatg	cagatgaccc	cacttatgga	aatagcgcca	1020
agtttagtga	cagtatcctc	gaaggacaac	cctatttttc	ggtggaagca	cagacaggtg	1080
tcatacagaac	agccctaccc	aacatggaca	gggaggccaa	ggaggagtac	cacgtgggtg	1140
tccaggccaa	ggacatgggt	ggacatatgg	gcggactctc	agggacaacc	aaagtgcaga	1200
tcacactgac	cgatgtcaat	gacaacccac	caaagtcttc	gcagagcgta	taccagatgt	1260
ctgtgtcaga	agcagccgtc	cctggggagg	aagtgaagag	agtgaagct	aaagatccag	1320
acattggaga	aaatggctta	gtcacatata	atatgtttga	tggagatggt	atggaaatcg	1380
ttgaaatcac	aacggactat	gaaacacagg	agggggtgat	aaagctgaaa	aagcctgtag	1440
attttgaaac	caaaagagcc	tatagcttga	aggtagaggc	agccaacgtg	cacatcgacc	1500
cgaagtattat	cagcaattggc	cctttcaagg	acactgtgac	cgtcaagatc	tcagtagaag	1560
atgctgtatga	gccccttatg	ttcttgggcc	caagttacat	ccacgaagtc	caagaaaatg	1620
cagctgctgg	caccgtggtt	gggagagtgc	atgccaaaga	ccctgatgct	gccaacagcc	1680

SEQUENCE LISTING 1657-2022.txt

```

cgataaggta ttccatcgat cgtcacactg acctcgacag attttttact attaatccag 1740
aggatgggtt tattaataact acaaaacctc tggatagaga ggaaacagcc tggctcaaca 1800
tactgtcttt tgcagcagaa atccacaatc ggcatcagga agccaaagtc ccagtggcca 1860
ttagggtcct tgatgtcaac gataatgtct ccaagtttgc tgccccttat gaaggtttca 1920
tctgtgagag tgatcagacc aagccacttt ccaaccagcc aattgtttaca attagtgcag 1980
atgacaaggga tgacacggcc aatggaccaaa gattttatctt cagcctaccc cctgaaatca 2040
ttcacaatcc aaatttcaca gtcagagaca accgagataa cacagcaggc gtgtacgccc 2100
ggcgtggagg gttcagtcgg cagaagcagg acttgtacct tctgcccata gtgatcagcg 2160
atggcggcat cccgcccctg agtagcacca acaccctcac catcaaagtc tgcgggtgcg 2220
acgtgaacgg ggcactgtct tcctgcaacg cagaggccta cattctgaac gccggcctga 2280
gcacaggcgc cctgatcgcc atcctcgctt gcactgtcat tctcctgggtc attgtagtat 2340
tgttttgtgac cctgagaagg caaaagaaag aaccactcat tgtctttgag gaagaagatg 2400
tccgtgagaa catcattact tatgatgatg aaggggttgg ggaagaagac acagaagcct 2460
ttgatattgc caccctccag aatcctgatg gtatcaatgg atttatcccc cgcaaagaca 2520
tcaaacctga gtatcagtac atgcctagac ctgggctccg gccagcgcgc aacagcgtgg 2580
atgtcgtatga cttcatcaac acgagaatac aggaggcaga caatgacccc acggctcctc 2640
cttatgactc cattcaaatc tacggttatg aaggcagggg ctcatgtggc ggtcccctga 2700
gctccctaga gtcggccacc acagattcag acttgacta tgattatcta cagaactggg 2760
gacctcggtt taagaaacta gcagatttgt atggttccaa agacactttt gatgacgatt 2820
cttaacaata acgatacaaa tttggcctta agaacttgtt ctggcggttct caagaatcta 2880
gaagatgtgt aaacagggtat ttttttaaat caaagaaagg ctcatttaaa acaggcaaa 2940
ttttacagag aggatacatt taataaaact gcgaggacat caaagtggta aatactgtga 3000
aatacctttt ctcaaaaaaa ggcaaatatt gaagtgttt atcaacttcg ctagaaaaaa 3060
aaaacacttg gcatacaaaa tatttaagtg aaggagaagt ctaacgctga actgacaatg 3120
aagggaatgt gtttatgtgt tatgaacatc caagtccttc ttctttttta agttgtcaaa 3180
gaagcttcca caaaattaga aaggacaaca gttctgagct gtaatttcgc cttaaaactc 3240
ggacactcta tatgtagtgc attttttaac ttgaaatata taatattcag ccagcttaaa 3300
cccatacaat gtatgtacaa tacaatgtac aattatgtct cttgagcatc aatcttgta 3360
ctgctgattc ttgtaaatct ttttgcttct actttcatct taaactaata cgtgccagat 3420
ataactgtct tgtttcagtg agagacgccc tcttctatg tcatttttaa tgtatctatt 3480
tgtacaattt taaagttctt attttagtat acgtataaat atcagtattc tgacatgtaa 3540
gaaaatgtta cggcatcaca cttataatct atgaacattg tactgttgct ttaatatgag 3600
cttcaatata agaagcaatc tttgaaataa aaaaagattt ttttttaaaa aaaa 3654

```

<210> 15
 <211> 983
 <212> DNA
 <213> Homo sapiens

```

<400> 15
gtggaattca tggcatctac ttcgtatgac tattgcagag tgcccatgga agacggggat 60
aagcgtgta agcttctgct ggggatagga attctgggtc tcctgatcat cgtgattctg 120
ggggtgccct tgattatctt caccatcaag gccaacagcg aggcctgccc ggacggcctt 180
cgggcagtga tggagtgtcg caatgtcacc catctcctgc aacaagagct gaccgagccc 240
cagaagggtt ttcaggatgt ggaggccag gccgccacct gcaaccacac tgtgatggcc 300
ctaattggctt ccctggatgc agagaaggcc caaggacaac agaaagtgga ggagcttgag 360
ggagagatca ctacattaaa ccataagctt caggacgcgt ctgcagaggt ggagcgactg 420
agaagagaaa accaggtctt aagcgtgaga atcgcggaac agaagtacta cccagctcc 480
caggactcca gctccgctgc ggcgccccag ctgctgattg tgctgctggg cctcagcgtc 540
ctgctgagtg gagatcccag gaagctggca catcttgga ggtccgtcct gctcggcttt 600
tcgcttgaac attcccttga tctcatcagt tctgagcggg tcatggggca acacggttag 660
cgggggagagc acggggtagc cggagaaggg cctctggagc aggtctggag gggccatggg 720
gcagtcctgg gtgtggggac acagtcgggt tgacccaggg ctgtctccct ccagagcctc 780
cctccggaca atgagtcccc cctctgtctt cccaccctga gattgggcat ggggtgcggt 840
gtggggggca tgtgtgcct gttgttatgg gttttttttg cggggggggg tgcttttttc 900
tgggggtctt gagctccaaa aaataaacac ttcctttgag ggagagcaaa aaaaaaaaaa 960
aaaaaaaaaa aaa 983

```

<210> 16
 <211> 2257
 <212> DNA
 <213> Homo sapiens

```

<400> 16
gtgcgatccc gggcccagg gcatcagac gcggttgatt agctccggtt tgcatacccc 60
ggaccggggg attagctccg gtttgcata cccggaccgg gggccgggag cgcacgagac 120
tcgcagcggg agtgaggcgc gctccgcgc cgtccgctgc taggacccgg gcagggctgg 180

```

SEQUENCE LISTING 1657-2022.txt

```

agctgggctg ggatccccgag ctccggcagca gcgcagcggg ccggcccacc tgctggtgcc 240
ctggaggctc tgagccccgg cgccgccccg gccacgcgg aacgacgggg cgagatgcga 300
gccacccctc tagctgctcc tgcgggttcc ctgtccagga agaagcggtt ggagttggat 360
gacaacttag ataccgagcg tcccgtccag aaacgagctc gaagtggggc ccagcccaga 420
ctgccccctt gcctgttgcc cctgagccca cctactgtct cagatcgtgc aactgctgtg 480
gccactgcct cccgtcttgg gccctatgtc ctcttgagc ccgaggaggg cgggcggggc 540
taccaggccc tgcactgccc tacaggcact gagtatacct gcaagggtga ccccgctcag 600
gaagccccgg ccgtgctgga gccctatgcg cggtgcccc ctctacgcct ttttactcg gacctatggg 720
cccactgagg tcctggctgg taccagctc ctctacgcct ttttactcg gacctatggg 720
gacatgcaca gcctgggtgc aagccggcac cgtatccctg agcctgaggc tgcctgtgtc 780
ttccgccaga tggccaccgc cctggcgcac tgtcaccagc acggtctggt cctgctgtat 840
ctcaagctgt tgcgtttgt ctccgtgac gctgagagga agaagctggt gctggagaac 900
ctggaggact cctgctgtct gactgggcca gatgattccc tgtgggacaa gcacgcgtgc 960
ccagcctacg tgggacctga gatactcagc tcacgggcct catactcggg caaggcagcc 1020
gatgtctgga gcctgggctg ggcgtctctt accatgctgg ccggccacta ccccttccag 1080
gactcggagc ctgtctgtct ctccggcaag atccgcccgc gggcctacgc cttgctgca 1140
ggcctctcgg cccctgcccc ctgtctgggt cgctgcctcc ttcgtcggga gccagctgaa 1200
cggctcacag ccacaggcat cctcctgcac ccctggctgc gacaggaccc gatgccctta 1260
gcccccaacc gatcccatct ctgggaggct gcccagggtg tccctgatgg tctggggctg 1320
gacgaagcca gggaagagga gggagacaga gaagtgggtc tgtatggcta ggaccaccct 1380
actacagcct cagctgccaa cagtggattg agtttggggg tagctccaag cttctctctg 1440
cctctgaact gagccaaacc ttcagtgctt tccagaaggg agaaaggcag aagcctgtgt 1500
ggagtgtgct gtgtacacat ctgctttgtt ccacacacat gcagttcctg cttgggtgct 1560
tatcagggtg caagccctgt tctcgggtgt gggagtacag cagtgaagca aggagacaat 1620
attccctgct cacagagatg acaaactggc atccttgagc tgacaacact tttccatgac 1680
cataggtcac tgtctactct ggttactact tgtaccagtg tcggcctcca ctgatgctgg 1740
tgctcaggca cctctgtcca aggacaatcc ctttcacaaa caaaccagct gcctttgtat 1800
cttgtagctt ttcagagaaa gggagggtatc cctgtgccaa aggtccagg cctctcccct 1860
gcaactcagg acccaagccc agctcactct gggaaactgtg tttccagcat ctctgtcctc 1920
ttgattaaga gattctcctt ccaggcctaa gcctgggatt tgggccagag ataagaatcc 1980
aaactatgag gctagtctct gtctaactca agactgttct ggaatgaggg tccaggcctg 2040
tcaaccatgg ggcttctgac ctgagcacca aggttgaggg acaggattag gcagggtctg 2100
tccctgtggc acctggaaag tcccagggtg gactcttctg gggacacttg ggtccacaa 2160
tcccagggtc atacttagg ttttggtatc catgagtatg tatgtttacc tgtgcctaatt 2220
aaaggagaat tatgaaataa aaaaaaaaaa aaaaaaa 2257

```

<210> 17
 <211> 5784
 <212> DNA
 <213> Homo sapiens

```

<400> 17
acggcatcca gtacagaggg gctggacttg gacccctgca gcagccctgc acaggagaag 60
cggcatataa agccgcgctg cccgggagcc gctcggccac gtccaccgga gcatcctgca 120
ctgcaggggc ggtctctcgc tccagcagag cctgcgcctt tctgactcgg tccggaacac 180
tgaaaccagt catcactgca tctttttggc aaaccaggag ctcagctgca ggaggcagga 240
tggctctggg gctggctcctg ctggctctgt ggggtgtggc cagcacgcaa gctggtcacc 300
aggacaaaaga cagcacttcc gaccttttca gtatcagcaa catcaaccgc aagaccattg 360
gcgccaagca gttccgcggg cccgaccccc gcgtgcccgc ttaccgcttc gtgcgcttgg 420
actacatccc accggtgaac gcagatgacc tcagcaagat caccaagatc atgcggcaga 480
aggagggtct cttcctcacg gcccagctca agcaggacgg caagtccagg ggcacgctgt 540
tggctctgga gggccccggg ctctcccaga ggcagttcga gatcgtctcc aacggccccg 600
cggacacgct ggatctcacc tactggattg acggcaccgg gcatgtgggtc tccctggagg 660
acgtcggcct ggctgactcg cagtggaaaga acgtcaccgt gcagggtggc ggcgagacct 720
acagcttgca cgtgggctgc gacctcatag gaccagttgc tctggacgag ccttctacg 780
agcacctgca ggcggaaaag agccggattg acgtggccaa aggtcttgcc agagagagtc 840
acttcagggg tttgcttcag aacgtccacc tagtgtttga aaactctgtg gaagatattc 900
taagcaagaa ggggttgccag caaggccagg gagctgagat caacgccatc agtgagaaca 960
cagagacgct gcgcctgggt ccgcatgtca ccaccgagta cgtgggcccc agctcggaga 1020
ggaggccccg ggtgtgcgaa cgctcgtgca aggagctggg aaacatggtc caggagctct 1080
cggggtccca cgtcctcgtg aaccagctca ctcctaagac aaggaaacatg tcgaatgata 1140
accagtttct ctgggagctc attggtggcc ctcttaagac ggtggacagc tgcaccacgt 1260
ggcaggatgg ccggttcttt gcggaatg accatttgc accaaatcac cgtcccgcct gcaacctgcg 1320
gtacctgcaa gaaatttaaa ggcgaatgct gcccttctg cctccactcg gtggacgggtg 1380
ccagtccatc ctttgtggaa ggcgaatgct gcccttctg cgtgacgtgt ggctctggga 1440
aggagggtct gtctccgtgg gcagagtgga cccagtcctc cgtgacgtgt ggctctggga 1440
cccagcagag aggcgggtcc tgtgacgtca ccagcaacac ctgcttgggg ccctcgatcc 1500

```

SEQUENCE LISTING 1657-2022.txt

agacacgggc	ttgcagctctg	agcaagtgtg	acaccccgcat	ccggcaggac	ggcggctgga	1560
gccactgggtc	accttgggtct	tcattgctctg	tgacctgtgg	agtttgcaat	atcacacgca	1620
tccgtctctg	caactcccca	gtgccccaga	tggggggcaa	gaattgcaa	gggagtggcc	1680
gggagaccaa	agcctgccag	ggcgccccat	gcccgaatcga	tggccgctgg	agcccctggg	1740
ccccgtgggtc	ggcctgcaact	gtcacctgtg	ccggtgggat	ccgggagcgc	acccgggtct	1800
gcaacagccc	tgagcctcag	tacggaggga	aggcctgcgt	gggggatgtg	caggagcgtc	1860
agatgtgcaa	caagaggagc	tgccccgtgg	atggctgttt	atccaacccc	tgcttcccgg	1920
gagccagtg	cagcagcttc	cccgatgggt	cctggtcattg	cggcttctgc	cctgtgggct	1980
tcttgggcaa	tggcaccac	tgtgaggacc	tggacgagtg	tgccctggtc	cccgacatct	2040
gcttctccac	cagcaagggtg	cctcgcgtgtg	tcaacactca	gcctggcttc	cactgcctgc	2100
cctgcccggc	ccgatacaga	gggaaccagc	ccgtcggggt	cggcctggaa	gcagccaaga	2160
cggaaaagca	agtgtgtgag	cccgaatacc	ccactgacga	caagacacac	aactgccaca	2220
agcacgcgga	gtgcatctac	ctgggtcact	tcagcgaccc	catgtacaag	tgcgagtggc	2280
agacaggcta	cgcgggagac	gggctcatct	gcggggagga	ctcggacctg	gacggctggc	2340
ccaacctcaa	tctgggtctgc	gcaccaacg	ccacctacca	ctgcatcaag	gataactgcc	2400
cccattctgc	aaattctggg	caggaagact	ttgacaagga	cgggattggc	gatgcctgtg	2460
atgatgacga	tgacaatgac	gggtgtgaccg	atgagaagga	caactgccag	ctcctcttca	2520
atccccgcca	ggctgactat	gacaaggatg	agggttggga	ccgctgtgac	aactgccctt	2580
acgtgcacaa	ccctgcccag	atcgacacag	acaacaatgg	agagggtgac	gcctgctccg	2640
tggacattga	tggggacgat	gtcttcaatg	aacgagacaa	ttgtccctac	gtctacaaca	2700
ctgaccagag	ggacacggat	ggtagcgggt	tgggggatca	ctgtgacaa	tgccccctgg	2760
tgacaaaccc	tgaccagacc	gacgtggaca	atgacctgtg	tggggaccag	tgtgacaaca	2820
acgaggacat	agatgacgac	ggccaccaga	acaaccagga	caactgcccc	tacatctcca	2880
acgccaacca	ggctgaccat	gacagagacg	gccagggcga	cgcctgtgac	cctgatgatg	2940
acaacgatgg	cgtccccgat	gacagggaca	actgccggct	tgtgttcaac	ccagaccagg	3000
aggacttggg	cgggtgatgga	cggggtgata	ttgttaaaga	tgattttgac	aatgacaaca	3060
tcccagatat	tgatgatgtg	tgctctgaaa	acaatgccat	cagttagaca	gacttcagga	3120
acttccagat	gggtccccttg	gatcccaaa	ggaccaccca	aattgatccc	aactgggtca	3180
ttcccatca	aggcaaggag	ctggttcaga	cagccaactc	ggaccccggc	atcgctgtag	3240
gttttgacga	gtttgggtct	gtggacttca	gtggacatt	ctacgtaaac	actgaccggg	3300
acgacgacta	tgctggcttc	gtctttgggt	accagtcaag	cagccgcttc	tatgtgggta	3360
tgtggaagca	ggtagcgcag	acctaactgg	aggaccagcc	cacgcgggcc	tatggctact	3420
ccggcgtgtc	cctcaagggtg	gtgaactcca	ccacggggac	gggcgagcac	ctgaggaacg	3480
cgtgtgggca	cacggggaac	acgcgggggc	agggtcgcaac	cttatggcac	gacccagga	3540
acattggctg	gaaggactac	acggcctata	ggtagcactt	gactcacagg	ccaagaccg	3600
gctacatcag	agtcttagtg	catgaaggaa	aacagggtcat	ggcagactca	ggacctatct	3660
atgaccaaac	ctacgctggc	gggcggctgg	gtctatttgt	cttctctcaa	gaaatggtct	3720
atttctcaga	cctcaagtag	gaatgcagag	atatttaaac	aagatttgct	gcatttcccg	3780
caatgccttg	gggtccctaga	ggctccagtt	cacttcagtt	cattgtgggt	cttgcggctt	3840
ctctctctag	cagcacctcc	tgctccctga	ccttaactct	gatgggtctt	cacctctctg	3900
cagcaacccc	aaacccaagt	gccttcagag	gataaatatc	aatggaactc	agagatgaac	3960
atctaaccac	ctagaggaaa	ccagtttggg	gataatagag	actttatgtg	gagtgaataa	4020
tgggcatggc	attacattgc	tttttcttgt	ttggttaaaa	agaatgacgt	ttacatatata	4080
aatgttaatta	cttattgtat	ttatgtgtat	atgggaatact	aggggaatac	gtgcataaag	4140
cattatgata	aattaagcat	gaaaaatatt	gctgaactac	ttttgggtgct	taaagtgtgtc	4200
actattcttg	aattagagtt	gctctacaat	gacacacaaa	tcccgcataa	taaattataa	4260
acaagggtca	attcaaattt	gaagtaatgt	tttagtaagg	agagattaga	agacaacagg	4320
catagcaaat	gacataagct	accgattaac	taactcggaa	atgtaaaaca	gttacaaaaa	4380
taaacgaact	ctcctcttgt	cctacaatga	aagccctcat	gtgcagtaga	gatgcagttt	4440
catcaaagaa	caaacatcct	tgcaaatggg	tgtgacgcgg	ttccagatgt	ggatttggca	4500
aaacctcatt	taagtaaaa	gttagcagag	caaagtgcgg	tgctttagct	gctgcttgtg	4560
ccgttgtggc	gtcggggagg	ctcctgcctg	agcttccttc	cccagctttg	ctgcctgaga	4620
ggaaccagag	cagacgcaca	ggccggaaaa	ggcgcatcta	acgcgtatct	aggctttggg	4680
aactgcggac	aagttgcttt	tacctgattt	gatgatacat	ttcattaagg	ttccagttat	4740
aaatatattt	ttaatattta	tttaagtact	atagaatgca	actccattta	ccagtaactt	4800
attttaaata	tgccatgtaa	cacatatgta	gtataatttc	tagaaacaaa	catctaataa	4860
gtatataatc	ctgtgaaatt	atgaggcttg	ataaatattt	gttgtcacga	tgaagcatgc	4920
tagaagctgt	aacagaatac	atagagaata	atgaggagtt	tatgatggaa	ccttaataata	4980
taatgttgcc	agcgatttta	gttcaatatt	tgttactgtt	atctatctgc	tgtatatgga	5040
attcttttta	ttcaaacgct	gaaaacgaat	cagcatttag	tcttgccagg	cacacccaat	5100
aatcagtcac	gtgtaaatgt	cacaagtttg	tttttgggtt	tggttttttt	gttgggttgg	5160
ttttttgctt	taagtgtgat	gatctttctg	caggaaatag	tcactcatcc	cactccacat	5220
aaggggttta	gtaagagaag	tctgtctgtc	tgatgatgga	tagggggcaa	atcttttttc	5280
cctttctgtt	aatagtcatt	acatttctat	gccaacacag	aacgatccat	aacttttagtc	5340
tttaatgtaca	cattgcattt	tgataaaatt	aattttgggt	tttcctttga	ggttgatcgt	5400
tgtgttgttt	tgctgcactt	tttacttttt	tgcgttggga	gctgtatttc	cgagacaacg	5460
aagcgtttgg	atacttcatt	aaatgtagcg	actgtcaaca	gcgtgcaggt	tttctgtttc	5520

SEQUENCE LISTING 1657-2022.txt

```

tgtgtgtgtg ggtcaaccgt acaatggtgt gggaatgacg atgatgtgaa tatttagaat 5580
gtaccatatt ttttgtaaat ttttatgtt tttctaaaca aatttatcgt ataggttgat 5640
gaaacgtcat gtgttttgcc aaagactgta aatattttatt tatgtgttca catggtcaaa 5700
atttcaccac tgaaccctg cacttagcta gaacctcatt tttaaagatt aacaacagga 5760
aataaattgt aaaaaaggtt ttct

```

<210> 18
 <211> 841
 <212> DNA
 <213> Homo sapiens

```

<400> 18
gaaccgttta ctcgctgctg tgcccatcta tcagcaggct ccgggctgaa gattgcttct 60
cttctctcct ccaaggtcta gtgacggagc ccgcgcgcgg cgccaccatg cggcagaagg 120
cggtatcgct tttcttgtgc tacctgctgc tcttcacttg cagtggggtg gaggcagggt 180
agaatgcggg taaggatgca ggtaagaaaa agtgtcggga gagctcggac agcggctccg 240
ggttctggaa ggcctgacc ttcattggccg tcggaggagg actcgcagtc gccgggctgc 300
ccgcgctggg cttaccggc gccggcatcg cggccaactc ggtggctgcc tcgctgatga 360
gctggtctgc gatcctgaat gggggcggcg tgcccgcggg ggggctagt ggcacgctgc 420
agagcctcgg ggctgggtggc agcagcgtcg tcataggtaa tattggtgcc ctgatgggct 480
acgccaccca caagtatctc gatagtgagg aggatgagga gtaggcagca gctcccagaa 540
cctctctctc cttcttggcc taactcttcc agttaggatc tagaactttg cctttttttt 600
tttttttttt tttttttgag atgggttctc actatattgt ccaggctaga gtgcagtggc 660
tattcacaga tgcaacata gtacactgca gcctccaact cctagcctca agtgatcctc 720
ctgtctcaac ctccaagta ggattacaag catgcgccga cgatgccag aatccagaa 780
ttgtctatc actctcccca acaacctaga tgtgaaaaca gaataaactt caccagaaa 840
a

```

<210> 19
 <211> 555
 <212> DNA
 <213> Homo sapiens

```

<400> 19
atgagccgca cagcctacac ggtgggagcc ctgcttctcc tcttggggac cctgctgccg 60
gctgctgaag ggaaaaagaa aggggtccaa ggtgccatcc ccccgccaga caaggcccag 120
cacaatgact cagagcagac tcagtcgccc cagcagcctg gctccaggaa ccgggggcgg 180
ggccaaggcg ggggactgac catgcccggg gaggaggtgc tggagtccag ccaagaggcc 240
ctgcatgtga cggagcgcaa atacctgaag cgagactggt gcaaaaccca gccgcttaag 300
cagaccatcc acgaggaagg ctgcaacagt cgcacatca tcaaccgctt ctgttacggc 360
cagtgcactc ctttctacat cccagggcac atccggaagg aggaagggtc ctttcagtcc 420
tgctccttct gcaagcccaa gaaattcact accatgatgg tcacactcaa ctgccctgaa 480
ctacagccac ctaccaagaa gaagagagtc acacgtgtga agcagtgtcg ttgcataatc 540
atcgatttgg attaa

```

<210> 20
 <211> 2334
 <212> DNA
 <213> Homo sapiens

```

<400> 20
agacacctct gccctcacca tgagcctctg gcagcccctg gtcctgggtgc tcctgggtgct 60
gggctgctgc tttgtgccc ccagacagcg ccagtcacc cttgtgctct tccctggaga 120
cctgagaacc aatctcaccg acaggcagct ggagaggaa tacctgtacc gctatggta 180
cactcgggtg gcagagatgc gtggagagtc gaaatctctg gggcctgcgc tgctgcttct 240
ccagaagcaa ctgtccctgc ccgagaccgg tgagctggat agcgccacgc tgaaggccat 300
gcgaacccca cggtgcgggg tcccagacct gggcagattc caaacctttg agggcgacct 360
caagtggcac caccacaaca tcacctattg gatccaaaac tactcggaag acttgccgcg 420
ggcggtgatt gacgagcctt ttgcccgcgc cttcgactg tggagcgcgg tgacgccgct 480
caccttctac cgcgtgtaca gccgggacgc agacatcgct atccagtttg gtgtcgcgga 540
gcacggagac gggatatcct tcgacgggaa ggacgggctc ctggcacacg cctttctctc 600
tggccccggc attcagggag acgcccattt cgacgatgac gagttgtggt ccctgggcaa 660
gggcgtcgtg gttccaactc ggtttgaaa cgcagatggc gcggcctgcc acttcccctt 720
catcttcgag ggccgctcct actctgcctg caccaccgac ggtcgtcccg acggcttgcc 780
ctggtgcagt accacggcca actacgacac cgacgaccgg tttggcttct gccccagcga 840
gagactctac acccgggacg gcaatgctga tgggaaaccc tgccagtttc cattcatctt 900
ccaaggccaa tcctactccg cctgcaccac ggacggctgc tccgacggct accgctgggt 960

```

SEQUENCE LISTING 1657-2022.txt

```

cgccaccacc gccaaactacg accgggacaa gctcttcggc ttctgcccga cccgagctga 1020
ctcgacgggtg atgggggggca actcggcggg ggagctgtgc gtcttccccct tcactttcct 1080
gggtaaggag tactcgacct gtaccagcga gggccgcgga gatgggcgcc tctggtgcgc 1140
taccacctcg aactttgaca gcgacaagaa gtggggcttc tgcccggacc aaggatacag 1200
tttgttcctc gtggcggcgc atgagttcgg ccacgcgctg ggcttagatc attcctcagt 1260
gccggaggcg ctcatgtacc ctatgtaccg cttactgag gggccccctc tgcataagga 1320
cgacgtgaat ggcattcggc acctctatgg tcctcgccct gaacctgagc cacggcctcc 1380
aaccaccacc acaccgcagc ccacggctcc cccgacggtc tgccccaccg gacccccac 1440
tgtccacccc tcagagcgcc ccacagctgg cccacagggt cccccctcag ctggccccac 1500
aggtccccc actgctggcc cttctacggc cactactgtg cttttgagtc cgggtggacga 1560
tgctgcaac gtgaacatct tcgacgccat cgcgagatt gggaaaccagc tgtatttgtt 1620
caagatggg aagtctggc gattctctga gggcaggggg agccggccgc agggccctt 1680
ccttatcgcc gacaagtggc ccgcgctgcc ccgcaagctg gactcggctc ttgaggagc 1740
gctctccaag aagcttttct tcttctctgg gcgccaggtg tgggtgtaca caggcgctc 1800
gggtgctggc ccgagcgctc tggacaagct gggcctggga gccgacgtgg cccaggtgac 1860
cggggccctc cggagtggc gggggaagat gctgctgttc agcgggcggc gcctctggag 1920
gttcgacgtg aaggcgagc tgggtgatcc ccggaagcgc agcgagggtg accgatgtt 1980
ccccggggtg ctttggaca cgcacgacgt cttccagtac cgagagaaag cctatttctg 2040
ccaggaccgc ttctactggc gcgtgagttc ccgagtgag ttgaaccagg tggaccaagt 2100
gggctacgtg acctatgaca tcctgcagtg ccttgaggac tagggctccc gtcctgcttt 2160
gcagtgccat gtaaattccc actgggacca aggagccagt ttgccggata 2220
caaactggta ttctgttctg gaggaagggt aggagtgagg gtgggctggg cctctcttct 2280
tcacctttgt ttttgttgg agtgtttcta ataaacttgg attctctaac cttt 2334

```

<210> 21
<211> 921
<212> DNA
<213> Homo sapiens

```

<400> 21
ccctcgagcg gccccggagg atgctgctga gccccggcac tgcttggctg cgagcacatg 60
atggcgatac gggagctcaa agtgtgcctt ctcgggggaca ctgggggttg gaaatcaagc 120
atcgtgtgtc gatttgtcca ggatcacttt gaccacaaca tcagccctac tattggggca 180
tcttttatga ccaaaactgt gccttgtgga aatgaacttc acaagttcct catctgggac 240
actgctggtc aggaacggtt tcattcattg gctcccattg actatcgagg ctgagctgca 300
gctgttatcg tgtatgatat taccaagcag gattcatttt ataccttgaa gaaatgggtc 360
aaggagctga aagaacatgg tccagaaaac attgtaattg ccatacgttg aaacaagtgc 420
gacctctcag atattaggga gggtccccctg aaggatgcta aggaatacgc tgaatccata 480
ggtgccatcg tggttgagac aagtgcacaaa aatgctatta atatcgaaga gctctttcaa 540
ggaatcagcc gccagatccc acccttggac ccccatgaaa atggaaacaa tggaaacaatc 600
aaagttagga agccaacat gcaagccagc cgccgggtgt gttgacccaa gggcgtggtc 660
cacggtactt gaagaagcca gagccacat cctgtgcact gctgaaggac cctacgctcg 720
gtggcctggc acctcacttt gagaagagtg agcacactgg ctttgcattc tggaaaggcct 780
gcagggggcg gggcaggaaa tgtacctgaa aaggatttta gaaaaccctg ggaaccacac 840
cacaccacca caaaatggcc tttagtgtat gaaatgcaca tggaggggat gtagtgcac 900
ttttgctaaa aaaaaaaaaa a

```

<210> 22
<211> 345
<212> DNA
<213> Homo sapiens

```

<400> 22
atgtcggccc tcagcctcct cattctgggc ctgctcacgg cagtgccacc tgccagctgt 60
cagcaaggcc tggggaacct tcagccctgg atgcagggcc ttatcgcggt ggccgtgttc 120
ctggctcctc ttgcaatcgc ctttgcagtc aaccacttct ggtgcccagg ggagccggag 180
cctgcacaca tgatcctgac cgctcgaaac aaggcagatg gagtcttggt gggaaacagat 240
ggaagggtact cttcgtatggc ggccagtttc aggtccagtg agcatgagaa tgcctatgag 300
aatgtgcccc aggaggaagg caaggtccgc agcaccccga tgtaa 345

```

<210> 23
<211> 1499
<212> DNA
<213> Homo sapiens

```

<400> 23
tatttacttc ctgcggtgac acaggctgtg gtcgtctatc tccctgttgt tcttcccatc 60

```


SEQUENCE LISTING 1657-2022.txt

```
ggcgaagatg gccctggaga cgggtgccga ggacctgagg catctgcggg cctgtttgct 120
gtgttcgctg gtcaagacta tagaccagtt tgaatatgat ggttgtgaca attgtgatgc 180
atatctacaa atgaagggtg accgagagat ggtatatgac tgcactagct ctctctttga 240
tggaatcatt gcgatgatga gtccagagga cagctgggtc tccaagtggc agcgagtcag 300
taactttaag ccagggtgat atgcgggtgc agtcactggg cgcttgcccc aaggaatcgt 360
gcgggagctg aaaagtcgag gagtggccta caaatccaga gacacagcta taaagacctg 420
gcaagatgca aggctgccag catctttgct ctccacctcc tgcctctgct tatttcttgt 480
tctggaacta aatgaacaga acttcaaata cttctacccc tccaattcag actcagctga 540
ctgttgagag agcagcacat cattttatca ttttatcttc ttggactac aggtgggggtg 600
ggagggattt gggttgggtg attaacagat ggaattgagg agagagtagg atgctgattt 660
tcctacccgt ggcccagggtc tgtgccttcc ccattgccaag gactctaggt caaatgtcaa 720
taaataatgaa cctcgagaaa gttctgaagg ccatgacacc tgccttgctt ccctcttcca 780
ttctcttagg cacagtaata gcttatttgc gactataagg ccttcccaga gcagcagagg 840
cccttctact ccctcttgac tgtctcagcc tctgggattg cagcctttgt agtgtgcttc 900
cttgcttctc atcagagggt gctgatccag aggtcagta accccatcaa cttggtggcc 960
ctgggtgctc acacttgatc ccttctgccc tcgagacctg gcacagcagt atcccttgaa 1020
gaaatcctga ggctttgtag agtgcctctt gacctgtttt aataattctt cctcccctg 1080
cttgcttatt ttcttctctt cacggctctt cctatacctt aggccagtct caagcactca 1140
ctggagaccc ttgggccttg ggcgaccatt gagtccatgt ctcccttggt tgtgcccctg 1200
taggaggtag gtccttttct cctccggcct agtaggggac cttgggtaac atcccatatt 1260
tcggccaagg tgagttgttt taggataaaa aaatttacca caaattctca tttaaatttc 1320
cacagaaatc ctgttcgtat ccccattttg atttccctaa gttccttggt ctccctctaa 1380
aaagagaatg attgcaccct gcctgtttac ctacaggattg ttgtgattgt agaaacgaag 1440
ctatgtgaaa attatataag tattataaag gtgaaatact tttgtcttca aaaaaaaaaa 1499
```

<210> 24
<211> 946
<212> DNA
<213> Homo sapiens

```
<400> 24
ggaaacccaa gaggaatga ctgagcccggt ctgggtcccc gcccgtctgc gctccccctgg 60
ccacaccctc cgcttgagc cagcagccac cgccgcgtcc ctctctccac gaggtgccc 120
gcttaggacc ccagctccg acatgtcgcc ctctggctgc ctgtgtcttc tcaccatcgt 180
tgccctgatt ctccccacca gaggacagac gttgaaagat accacgtcca gttcttcagc 240
agactcaact atcatggaca ttcaggtccc gacacgagcc ccagatgcag tctacacaga 300
actccagccc acctctccaa cccaacctg gcctgtgat gaaacaccac aacccagac 360
ccagacccag caactggaag gaacggatgg gcctctagt acagatccag agacacacaa 420
gagcaccaaa gcagctcatc cactgatga caccacgacg ctctctgaga gaccatcccc 480
aagcacagac gtccagacag acccccagac cctcaagcca tctggttttc atgaggatga 540
ccccttcttc tatgatgaac acaccctcg gaaacggggg ctgttggtcg cagctgtgct 600
gttcatcaca ggcattatca tcctcaccag tggcaagtgc aggcagctgt cccggttatg 660
ccggaatcgt tgcaggtgag tccatcagaa acaggagctg acaacctgct gggcaccgga 720
agaccaagcc ccctgcccag tcaccgtgcc cagcctcctg catcccctg aagagcctgg 780
ccagagaggg aagacacaga tgatgaagtc ggagccaggg ctgcccgtcc gagtctccta 840
cctcccccaa ccctgcccgc ccctgaaggc tacctggcgc cttgggggct gtccctcaag 900
ttatctcctc tgctaagaca aaaagtaaag cactgtggtc tttgcc 946
```

<210> 25
<211> 11185
<212> DNA
<213> Homo sapiens

```
<400> 25
gctgccccga gcctttctgg ggaagaactc caggcgtgag gacgcaacag ccgagaacat 60
taggtgttgt ggacaggagc tgggaccaag atcttcggcc agccccgcat cctcccgcat 120
cttccagcac cgtcccgcac cctccgcacg ctctcccggg ccaccacgct tcctatgtga 180
cccgctggg caacgccgaa cccagtcgag cagcgtgca gtgaattttc cccccaact 240
gcaataagcc gccttccaag gccaagatgt tcataaatat aaagagcatc ttatggatgt 300
gttcaacctt aatagtaacc catgctgac ataaagtcaa agtgggaaaa agccccaccg 360
tgaggggctc cctctctgga aaagttagcc tacctgttca ttttcaacg atgcctactt 420
tgccacccag ttacaacacc agtgaatttc tccgcatcaa atgggtctaag attgaagtgg 480
acaaaaatgg aaaagatttg aaagagacta ctgtccttgt ggcccaaaat ggaaatatca 540
agattgggtc ggactacaaa gggagagtggt ctgtgcccac acatcccag gctgtgggag 600
atgcttccct cactgtggtc aagctgctgg caagtgtgc gggctcttac cgctgtgagc 660
tcactgtacg cattgaagac acacaagaca cgggtctact gactgtggat ggggttgtgt 720
ttactacag ggcggcaacc agcaggtaca cactgaattt tgaggctgct cagaaggctt 780
```

SEQUENCE LISTING 1657-2022.txt

gtttggacgt	tggggcagtc	atagcaactc	cagagcagct	ctttgctgcc	tatgaagatg	840
gatttgagca	gtgtgacgca	ggctggctgg	ctgatcagac	tgatcagatat	cccatccggg	900
ctcccagagt	aggctgttat	ggagataaga	tgggaaaggc	aggagtcagg	acttatggat	960
tccgttctcc	ccaggaaact	tacgatgtgt	attgttatgt	ggatcatctg	gatgggtgatg	1020
tgttccacct	cactgtcccc	agtaaaattca	ccttcgagga	ggctgcaaaa	gagtgtagaa	1080
accaggatgc	caggctggca	acagtggggg	aactccaggc	ggcatggagg	aacggctttg	1140
accagtgcga	ttacgggtgg	ctgtcggatg	ccagcgtgcg	ccaccctgtg	actgtggcca	1200
gggcccagtg	tggaggtggg	ctacttgggg	tgagaaccct	gtatcgtttt	gagaaccaga	1260
caggcttccc	tccccctgat	agcagatttg	atgcctactg	ctttaaacct	aaagaggcta	1320
caaccatcga	tttgagtatc	ctcgcagaaa	ctgcatcacc	cagtttatcc	aaagaaccac	1380
aaatggtttc	tgatagaact	acaccaatca	tccctttagt	tgatgaatta	cctgtcattc	1440
caacagagtt	ccctcccgtg	ggaaatattg	tcagttttga	acagaaagcc	acagtccaac	1500
ctcaggctat	cacagatagt	ttagccacca	acttactggc	acctactggc	agtaccaaga	1560
agccctggga	tatggatgac	tactcacctt	ctgcttcagg	acctcttggg	aagctagaca	1620
tatcagaaat	taagggaagaa	gtgctccaga	gtacaactgg	cgtctctcat	tatgctacgg	1680
attcatggga	tgggtgctgt	gaagataaac	aaacacaaga	atcggttaca	cagattgaac	1740
aaatagaagt	gggtcctttg	gtaacattct	tggaacattc	aaagcacatt	ccttccaagg	1800
aattccctgt	aactgaaaca	ccattggtaa	ctgcaagaat	gatcctggaa	tccaaaactg	1860
aaaagaaaat	ggtaagcact	gtttctgaat	tggtaaccac	aggctactat	ggattcacct	1920
tgggagaaga	ggatgatgaa	gacagaacac	ttacagttgg	atctgatgag	agcaccttga	1980
tccttgacca	aattctacga	gtcattacgg	tgtcagaagc	ttcagaagac	accatccaca	2040
ctcatttaga	agacttggag	tcagtctcag	ctccacaac	tgtttcccc	tttaattatgc	2100
ctgataataa	tggatcatcc	atggatgact	gggaagagag	acaaactagt	ggtaggataa	2160
cggaaagagt	tccttggcaaa	tatctgtcta	ctacaccttt	tccatcacag	catcgtagag	2220
aaatagaatt	gtttccttat	tctggtgata	aaatattagt	agaggggaatt	tccacagtta	2280
tttatccttc	ttcacaacaa	gaaatgacac	atagaagaga	aagaacagaa	acactaatat	2340
cagagatgag	aacagatact	tatacagatg	aaatacaaga	agagatcact	aaaagtccat	2400
ttatgggaaa	aacagaagaa	gaagtcttct	ctgggatgaa	actctctaca	tctctctcag	2460
agccaattca	tgttacagag	tcttctgtgg	aaatgaccaa	gtcttttgat	ttcccaacat	2520
tgataacaaa	gttaagtgcg	gagccaacag	aagtaagaga	tatggaggaa	gactttacag	2580
caactccagg	tactacaaaa	tatgatgaaa	atattacaac	agtgttttg	gccccatggt	2640
ctttaagtgt	tgaagcagcc	actgtatcaa	aatggctatg	ggatgaagat	aatacaacat	2700
ccaagccttt	agagtctaca	gaaccttcag	cctcttcaaa	attgccccct	gccttactca	2760
caactgtggg	gatgtattga	aaggataaag	actcccaag	tttactgaa	gatggagcag	2820
atgaatttac	tcttattcca	gatagtactc	aaaagcagtt	agaggagggt	actgatgaag	2880
acatagcagc	ccatggaaaa	ttcacaatta	gatttcagcc	aactacatca	actggtattg	2940
cagaaaagtc	aactttgaga	gattctacaa	ctgaagaaaa	agttccacct	atcacaagca	3000
ctgaaggcca	agtttatgca	accatggaa	agatgcttt	gggtgaagta	gaagatgtgg	3060
acctctctaa	gccagtatct	actgttcccc	aatttgcaca	cacttcagag	gtggaaggat	3120
tagcatttgt	tagtttatagt	agcaccaca	agcctactac	ttatgtagac	tcttcccata	3180
ccattcctct	ttctgtaatt	cccaagacag	actggggagt	gttagtagct	tctgttccat	3240
cagaagatga	agttctatgt	gaacctcttc	aaagcctatc	tgctattgat	cagactcgcc	3300
ttgaagcgac	tattttctcca	gaaactatga	gaacaacaaa	aatcacagag	ggaacaactc	3360
aggaagaatt	cccttggaaa	gaacagactg	cagagaaacc	agttcctgct	ctcagttcta	3420
cagcttggac	tcccgaaggag	gcagtaaac	cactggatga	acaagagggc	gatggatcag	3480
catatacagt	ctctaagatg	gaattgttga	caggttctga	gagggtccca	gttttagaaa	3540
caactccagt	tggaaaaaatt	gatcacagtg	tgtcttatcc	accaggtgct	gtaactgagc	3600
acaaagtga	aacagatgaa	gtggtaaac	taacaccacg	cattgggcca	aaagtatctt	3660
taagtccagg	gcctgaacaa	aaatatgaaa	cagaaggtag	tagtacaaca	ggattttacat	3720
catctttgag	tccttttagt	acccacatta	ccagcttat	ggaagaaacc	actactgaga	3780
aaacatccct	agaggatatt	gatttaggct	caggattatt	tgaaaagccc	aaagccacag	3840
aactcataga	attttcaaca	atcaaagtca	cagttccaag	tgatattacc	actgccttca	3900
gttcagtaga	cagacttcac	acaacttcag	cattcaagcc	atcttccgag	atcactaaga	3960
aaccacctct	catcgacagg	gaacctgggt	aagaaacaac	cagtgcacatg	gtaatcattg	4020
gagaatcaac	atctcatgtt	cctcccactg	cccttgaaga	tattgtagcc	aaggaaacag	4080
aaaccgatat	tgatagagag	tatttcacga	cttcaagtcc	tcctgctaca	cagccaacaa	4140
gaccacccac	tgtggaagac	aaagaggcct	ttggacctca	ggcgctttct	acgccacagc	4200
ccccagcaag	cacaaaattt	caccctgaca	taaattgtta	tattattgag	gtcagagaaa	4260
ataagacagg	tcgaatgagt	gatttggagt	taattgggtca	tccaatagat	tcagaattcta	4320
aagaagatga	accttgtagt	gaagaaacag	atccagtgca	tgatctaagt	gctgaaattt	4380
tacctgaatt	ccctgacata	attgaaatag	acctatacca	cagtgaagaa	aatgaagaag	4440
aagaagaaga	gtgtgcaaat	gctactgatg	tgacaaccac	cccatctgtg	cagtacataa	4500
atgggaagca	tctcgttacc	actgtgcccc	aggaccagga	agctgcagaa	gctaggcgtg	4560
gccagtttga	aagtgttgca	ccttctcaga	atttctcgga	cagctctgaa	agtgatactc	4620
atccatttgt	aatagccaaa	acggaattgt	ctactgctgt	gcaacctaat	gaatctacag	4680
aaacaactga	gtctcttgaa	gttacatgga	agcctgagac	ttaccctgaa	acatcagaac	4740
atttttcagg	tggtagcctt	gatgttttcc	ccacagtccc	attccatgag	gaatttgaaa	4800

SEQUENCE LISTING 1657-2022.txt

gtggaacagc caaaaaaggg gcagaatcag tcacagagag agatactgaa gttgggtcatc 4860
aggcacatga acatactgaa cctgtatctc tgtttcctga agagtcttca ggagagattg 4920
ccattgacca agaactctcag aaaatagcct ttgcaagggc tacagaagta acatttggtg 4980
aagaggtaga aaaaagtact tctgtcacat acactcccac tatagttcca agttctgcat 5040
cagcatatgt ttcagaggaa gaagcagtta ccctaattag aaatccttgg ccagatgacc 5100
tgttgtctac caaagaaagc tgggtagaag caactcctag acaagttgta gagctctcag 5160
ggagttcttc gattccaatt acagaaggct ctggagaagc agaagaagat gaagatacaa 5220
tgttcaccat ggtaaactgat ttatcacaga gaaatactac tgatacactc attactttag 5280
acactagcag gataatcaca gaaagctttt ttgaggttcc tgcaaccacc atttatccag 5340
tttctgaaca accttctgca aaagtgggtg ctaccaagtt tghtaagtga acagacactt 5400
ctgagtggtt ttccagtacc actgttgagg aaaagaaaag gaaggaggag gaggggaacta 5460
caggtacggc ttctacattt gaggtatatt catctacaca gagatcggat caattaattt 5520
taccctttga attagaaaagt ccaaagttag ctacatctag tgattcaggt accaggaaaa 5580
gttttatgtc cttgacaaca ccaacacagt ctgaaagggg aatgacagat tctactcctg 5640
tctttacaga aacaaatata tttagaaaatt tggggggcaca gaccactgag cacagcagta 5700
tccatcaacc tgggggttcag gaagggtctga ccactctccc acgtagtctt gcctctgtct 5760
ttatggagca gggctctgga gaagctgtct cggaccacaga aaccaccact gtttcttcat 5820
tttcattaaa cgtagagtat gcaattcaag ccgaaaagga agtagctggc actttgtctc 5880
cgcagtgtga aactacattt tccactgagc caacaggact ggttttgagt acagtaattg 5940
acagagtatg tgctgaaaat ataaccacaa catccaggga aatagtgatt tcagagcgat 6000
taggagaacc aaattctggg gcagaaataa ggggttttcc cacaggtttt cctttggagg 6060
aagatttcag tgggtacttt agagaatact caacagtgtc tcatccata gcaaaagaag 6120
aaacggtaat gatggaaggc tctggagatg cagcatttag ggacaccag acttcaccat 6180
ctacagtacc tacttcagtt cacatcagtc acatatctga ctcagaagga cccagtagca 6240
ccatggtcag cacttcagcc tttccctggg aagagtttac atcctcagct gagggctcag 6300
gtgagcaact ggtcacagtc agcagctctg ttgttccagt gcttccagct gctgtgcaa 6360
agttttctgg tacagcttcc tccattatcg acgaaggatt gggagaagtg ggtactgtca 6420
atgaaattga tagaagatcc accattttat caacagcaga agtggaaagt acgaaagctc 6480
cagtagaaga ggaggaagta aaggtcagtg ccacagtttc aacaaacttt ccccaacta 6540
tagagccagc caaattatgg tctaggcaag aggtcaaccc tgtaagacaa gaaattgaaa 6600
gtgaaacaac atcagaggaa caaattcaag aagaaaagtc atttgaatcc cctcaaaact 6660
ctctgcaac agaacaaca atctttgatt cacagacatt tactgaaact gaactcaaaa 6720
ccacagatta ttctgtacta acaacaaga aaactttacag tgatgataaa gaaatgaag 6780
aggaagacac ttcttttagt aacatgtcta ctccagatcc agatgcaaat ggcttggaat 6840
cttacacaac tctccctgaa gctactgaaa agtcacattt tttcttagct actgcattag 6900
taactgaatc tataccagct gaacatgtag tcacagattc accaatcaaa aaggaagaaa 6960
gtacaaaaca ttttccgaaa ggcattgagc caacaattca agagtcagat actgagctct 7020
tattctctgg actgggatca ggagaagaag ttttacctac tctaccaaca gagtcagtga 7080
attttactga agtggaacaa atcaataaca cattatatcc ccacacttct caagtggaaa 7140
gtacctcaag tgacaaaaat gaagacttta acagaatgga aaatgtggca aaagaagttg 7200
gaccactcgt atctcaataa gatctctttg aaggttagtg gtcagtaacc agcacaact 7260
taatagaaat tttaagtga actggagcag aaggaccac ggtggcacct ctccctttct 7320
ccacggacat cggacatcct caaatcaga ctgtcaggtg ggcagaagaa atccagacta 7380
gtagaccaca aaccataact gaacaagact ctaacaagaa ttcttcaaca gcagaaatta 7440
acgaaacaac aacctactct actgattttc tggctagagc ttatggtttt gaaatggcca 7500
aagaatttgt tacatcagca ccaaaaccat ctgacttgta ttatgaacct tctggagaag 7560
gatctggaga agtggaatatt gttgattcat ttcacacttc tgcaactact caggcaacca 7620
gacaagaaag cagcaccaca tttgtttctg atgggtccct ggaaaaacat cctgaggtgc 7680
caagcgctaa agctgttact gctgatggat tcccaacagt ttcagtgatg ctgcctcttc 7740
attcagagca gaacaaaagc tcccctgac caactagcac actgtcaaat acagtgtcat 7800
atgagagggtc cacagacggt agtttccaag accgtttcag ggaattcgag gattccacct 7860
taaaacctaa cagaaaaaaa cccactgaaa atattatcat agacctggac aaagaggaca 7920
aggatttaatt attgacaatt acagagagta catccttgga aattctacct gagctgacat 7980
cggataaaaa tactatcata gatattgatc atactaaacc tgtgtatgaa gacattcttg 8040
gaatgcaaac agatatagat acagaggtac catcagaacc acatgacagt aatgatgaaa 8100
gtaatgatga cagcactcaa gttcaagaga tctatgaggc agctgtcaac ctttctttaa 8160
ctgaggaaac atttgagggc tctgtgatg aactggctag ctacactcag gcaacacatg 8220
atgaatcaat gacttatgaa gatagaagcc catgggcttt cacttcacaa 8280
ctgggatccc tgctcctagc acagaaacag aattagacgt tttacttccc acggcaacat 8340
ccctgccaat tcctcgttag tctgccacag ttattccaga gattgaagga ataaaagctg 8400
aagcaaaaag ctggatgac atgtttgaa caagcacttt gtctgatggg caagctattg 8460
cagacaaaag tgaaataata ccaacatttg gccaatgtga agggactcag gaggagtatg 8520
aagacaaaaa acatgctggt ccttcttttc agccagaatt ctcttcagga gctgaggagg 8580
cattagtaga cctactccc tatctaagta ttgctactac ccaccttatg gatcagagtg 8640
taacagaggt gcctgatgtg atggaaggat ccaatcccc atattacact gatacaact 8700
tagcagtttc aacatttgcg aagttgtctt ctacagacc atcatctcc ctactatct 8760
actcaggcag tgaagcctct ggacacacag agatcccca gccagtgct ctgccaggaa 8820

SEQUENCE LISTING 1657-2022.txt

tagacgtcgg ctcattctgta atgtcccccaggattcttt taaggaaatt catgtaaata 8880
ttgaagcaac tttcaaacca tcaagtggagg aataccttca cataactgag cctccctctt 8940
tatctcctga cacaaaatta gaaccttcag aagatgatgg taaacctgag ttattagaag 9000
aaatggaagc ttctcccaca gaacttattg ctgtggaagg aactgagatt ctccaagatt 9060
tccaaaacaa aaccgatggg caagtttctg gagaagcaat caagatgttt cccaccatta 9120
aaacacctga ggctggaact gttattacaa ctgccgatga aattgaatta gaagggtgcta 9180
cacagtggcc acactctact tctgcttctg ccacctatgg ggtcgaggca ggtgtggtgc 9240
cttggttaag tccacagact tctgagaggc ccacgctttc ttcttctcca gaaataaacc 9300
ctgaaactca agcagcttta atcagagggc aggattccac gatagcagca tcagaacagc 9360
aagtggcagc gagaattctt gattccaatg atcaggcaac agtaaacctt gtggaattta 9420
atactgaggt tgcaaacacca ccattttccc ttctggagac ttctaataga acagatttcc 9480
tgattggcat taatgaagag tcagtggagg gcacggcaat ctatttaccg ggacctgatc 9540
gctgcaaat gaaccggtgc cttaacggag accagtgtga tctactgaa acttccctacg 9600
tatgcacctg tgtgccaggga tacagcggag accagtgtga acttgatttt gatgaatgac 9660
actctaattc ctgtcgtaat ggagccactt gtgttgatgg tttaacaca ttcagggtgcc 9720
tctgcttccc aagttatggt ggtgcacttt gtgagcaaga taccgagaca tgtgactatg 9780
gctggcctca attccaaggg cagtgtaca aactcttgc ccatcgacgc acatgggatg 9840
cagctgaacg ggaatgccgt ctgcagggtg cccatctcac aagcatcctg tctcacgaag 9900
aacaatggt tgtaaatcgt gtgggcatatg attatcagtg gataggcctc aatgacaaga 9960
tgattgagca tgacttccgt tggactgatg gcagcacact gcaatacagag aattggagac 10020
ccaaccagcc agacagcttc ttttctgctg gagaagactg tgttgtaatc atttggcatg 10080
agaatggcca gtggaatgat gttccctgca attaccatct cacctatacg tgcaagaaag 10140
gaacagttgc ttgcggccag cccctgtgtg tagaaaatgc caagaccttt ggaaagatga 10200
aacctcgtta tgaaatcaac tccctgatta gataccactg caaagatggt ttcattcaac 10260
gtcaccttcc aactatccgg tgcttaggaa atggaagatg ggctatacct aaaattacat 10320
gcatgaaccc atctgcatac caaaggactt attctatgaa atactttaaa aattcctcat 10380
cagcaaaagga caattcaata aatacatcca aacatgatca tctgtggagc cggagggtggc 10440
aggagtcgag gcgctgatcc ctaaaatggc gaacatgtgt ttcatcatt tcagccaaag 10500
tcctaacttc ctgtgccttt cctatcacct cgagaagtaa ttatcagttg gtttggattt 10560
ttggaccacc gttcagtcatt tttgggttgc cgtgctcca aaacatttta aatgaaagta 10620
ttggcattca aaaagacagc agacaaaatg aaagaaaatg agagcagaaa gtaagcattt 10680
ccagcctatc taatttcttt agttttctat ttgctccag tgcagtcctat ttcctaattg 10740
ataccagcct actgtactat ttaaaatgct caatttaccg accgatggcc atgtaaataa 10800
gatgatttaa tgttgatttt aatcctgtat ataaaaataa aagtcacaat gagtttgggc 10860
atatttaatg atgattatgg agccttagag gtctttaatc attggttcgg ctgcttttat 10920
gtagtttagg ctggaaatgg tttcacttgc tctttgactg tcagcaagac tgaagatggc 10980
ttttcctgga cagctagaaa acacaaaatg tgtgaggtca ttgcacctat ctcagccata 11040
ggtgcagttt gcttctacat gatgctaaag gctgcgaatg ggaactaagg 11100
actccaatgt cgaactcttc tttgtgcat tctttttct tcaattacaa gaaaggcctg 11160
aatggaggac ttttctgtaa ccagg 11185

<210> 26
<211> 2245
<212> DNA
<213> Homo sapiens

<400> 26
gaatctcgac ccttgaatgg agttacacga acggccagat gaaagaagga aggcccgagc 60
ctccactcag ggcgactag gggactggcg gaggtgacac gctgatggat ttactcaccg 120
ggtgcttggg gctccagcag ctggctggag cccgcgatga cgtcacggac tcgggtcaca 180
tggccgagtc cgccccgcc cctccccgtc cccgcgctg cagccgtcgc ctccggagcg 240
aagggatccg acccggcaga agctcggagc tctcggggta tcgaggaggc aggcccgcg 300
gcgcacggcg gagcgggcg ggagccggag cggcgaggca gccggcagca gcggcgcg 360
gggctccagg cgaggcggtg gacgctcctg aaaacttgcg cgcgcgctcg cgccactg 420
cccggagcga tgaagatggg cgcgcccctg acgcggttct actccaacag ctgctgcttg 480
tgctgcatg tccgcaccgg caccatcctg ctccggcgtct ggtatctgat catcaatgct 540
gtggtactgt tgatttctgt gagtgcctg gctgattcgg atcagtataa cttttcaagt 600
tctgaactgg gaggtgactt tgagttcatg gatgatgcca acatgtgcat tgccattg 660
atttctcttc tcatgatcct gatatgtgt atggctactt acggagcgta caagcaacgc 720
gcagcctgga tcatcccat ctctgtttac cagatctttg actttgacct gaacatgttg 780
gttgcaatca ctgtgcttat ttaaccaaac tctattcagg aatacatagc gcaactgcct 840
cctaattttc cctacagaga tgatgtcatg tcagtgaatc ctacctgtt ggtccttatt 900
attcttctgt ttattagcat tatcttgact ttttaagggtt acttgattag ctgtgtttgg 960
aactgctacc gatacatcaa tggtaggaac tctctgtatg tcctggttta tgttaccagc 1020
aatgcacta cgggtgtgct accccggtat gctgatgcca ctgtgaatgg tgctgccaag 1080
gagccaccgc caccttacgt gtctgcctaa gccttcaagt gggcgagct gagggcagca 1140
gcttgacttt gcagacatct gagcaatagt tctgttattt cacttttgcc atgagcctct 1200

SEQUENCE LISTING 1657-2022.txt

```

ctgagcttgt ttgttgctga aatgctactt tttaaaattt agatgttaga ttgaaaactg 1260
tagttttcaa catatgcttt gctggaacac tgtgatagat taactgtaga attcttcctg 1320
tacgattggg gatataatgg gcttcactaa ccttccctag gcattgaaac tcccccaaaa 1380
tctgatggac ctagaagtct gcttttgtac ctgctgggcc ccaaagttgg gcatttttct 1440
ctctgtttcc tctcttttga aaatgtaaaa taaaaacaaa aatagacaae tttttcttca 1500
gccattccag catagagaac aaaaccttat ggaaacagga atgtcaattg tgtaatcatt 1560
gttctaatta ggtaaataga agtccttatg tatgtgttac aagaatttcc cccacaacat 1620
cctttatgac tgaagttcaa tgacagtttg tgtttggtgg taaaggattt tctccatggc 1680
ctgaattaag accattagaa agcaccaggc cgtgggagca gtgaccatct gctgactgtt 1740
cttgtggatc ttgtgtccag ggacatgggg tgacatgcct cgtatgtgtt agaggggtga 1800
atggatgtgt ttggcgctgc atgggatctg gtgcccctct tctcctggat tcacatcccc 1860
accaggggcc cgcttttact aagtgttctg ccctagattg gttcaaggag gtcattccaa 1920
tgactttatc gagtggaaatt gggatatatt tgaataactt ctgcctaaca acatggaggt 1980
gggttttctt ttccctgcaa gctacatcct actgctttga acttccaagt atgtctagtc 2040
accttttaaa atgtaaacat ttccagaaaa atgaggattg ccttccctgt atgcgctttt 2100
taccttgact acctgaattg caagggattt ttatatattc atatgttaca aagtcagcaa 2160
ctctcctgtt gtttcattat tgaatgtgct gtaaattaag ttgtttgcaa ttaaaaacag 2220
gtttgcccac aaaaaaaaaa aaaaaa

```

<210> 27
 <211> 4912
 <212> DNA
 <213> Homo sapiens

```

<400> 27
attggggtct gctctaagct gcagcaagag aaactgtgtg tgaggggaag aggcctgttt 60
cgctgtcggg tctctagttc ttgcacgctc tttaaagagtc tgcactggag gaactcctgc 120
cattaccagc tcccttcttg cagaagggag ggggaaacat acatttattc atgccagtct 180
gtttatgca ggctttttgg cticctacct tgcaacaaaa taattgcacc aactccttag 240
tgccgattcc gccacagag agtcctggag ccacagtctt ttttgctttg cattgttaga 300
gagggactaa gtgctagaga ctatgtcgct ttcttgagct accgagagcg ctctgaact 360
ggaatcaact gcttcaggga aaaagaaaaa aaaaaaaaaa agacttgctt gggaggccgc 420
gagaaacttg cattggaagc ttcagcaacc agcattcgag aaactcctct ctactttagc 480
acggtctcca gactcagccg agagacagca aactgcagcg cggtagagaga gcgagagaga 540
gggagagaga gactctccag cctgggaact ataactcctc tgcgagaggc ggagaactcc 600
ttccccaat cttttgggga ctttctctc tttaccacc tccgcccctg cgaggagtgt 660
aggggcaagt tcggcgccg cgcgctctt cccgttcggc gtgtgcttgg cccggggaac 720
cgggagggcc cggcgatcgc gcggcgccg ccgaggggt gtgagcgcgc gtggcgccc 780
gccgagccga ggccatgggt cagcaaacca acaatgccga gaacacggaa gcgctgctgg 840
ccggcgagag ctccgactcg ggcgccggc tcgagctggg aatcgctctc tccccacgc 900
ccgctccac cgctccacg cgctccagc ccgagacc tgaatgcct tcatggtgtg gtcgcagatc gagcggcgca 1020
gtgggcacat caagcgacc atgaacgcct gacatgcaca acgcccagat ctccaagcgg ctgggcaaac 1080
agatcatgga gcagtcgccc gacatgcaca agcgagagat tccttttcat tcgagaggcg gagcggctgc 1140
gctggaagct gctcaaagac agcgacaaga tccctttcat gcccaggaag aaggtgaagt 1200
gcctcaagca catggctgac taccgcgact acaagtaccg ccgctcctc ccgctcctc cggcggcgcc 1260
ccggcaacgc caactccagc tccctcgccg atggggcgcc atggggcgcc gggagcagca 1320
acaaggctcg agggagcgcc ggtgagagtg gcggcgccg tggggttagc aaaccgcag 1440
acgcgggggg agggagcgcc gtggcgggcg gcggcgccg agcggctgcc gccgcccct 1500
aaaagagctg cggctccaaa ggcggcgccg cctgctgcc cctggcgcc gccgcccagc 1560
ccaagctcat cctggcaggc cgaacaggcg cggactccca gcgctcggc ctccgctcc tccgagcct 1620
ccttcgccc accactcgct gtacaaggcg gcccgggca agcacctggc ggagaagaag gtgaagcgcg 1680
cggcctccg agcgctcgc gcccgggca agcacctggc gggcgggcgt ggcgcgggag 1740
tctacctgtt cggcgccctg ggcacgtcgt cgtcgcccgt agggagagg cgcgggctgc tcgcccagc 1800
ccgaccccag cgaccccctg ggcctgtacg agcagcgccg cctcgtccc cgccgcccgc cgctcgccc 1860
cgccaccagc cggctacgcc agcctgccc cgcctcggc cgcctcctc cctcctcctg ggtcctcct 1920
cgcacgcgtc ctctcggcc tcgtccact ctcacttctc cccagctca aactttgaga 2040
cctccgacga cgagttcgaa gacgacctgc cggcgctcga ccgggacctg gattttaact 2100
gcatgtccc gggcagcttc cacttcgagt tcccggacta ctgcacgccc gaggtgagcg 2160
tcgagcccc ctccggctgc cacttcgagt gcatctccaa cctgggtttt acctactgaa 2220
agatgatctc gggagacttg gggccggggg gggtaggaga ggagaaaaaa aaagtgaaaa 2280
gggcgcgag gcagggagaa cgaagagttt aaagagaaaa gggaaaaaag aaagaaaaag 2340
aaagaaacga aaaggacaga cgcgttctgc tcgtcgatc aaggagcgcg gcggcgttt 2400
taagcagggc tggcttcgcc caccttcccc ggccggggac ccactctgcc cagccggagg 2460
ggacccgcgc tccatcccc tagacagggg cgacctgtga ttgttgttat tgatgttgtt 2520

```

SEQUENCE LISTING 1657-2022.txt

```

gttgatggca aaaaaaaaaa agcgacttcg agtttgctcc cctttgcttg aagagacccc 2580
ctcccccttc caacgagctt ccggacttgt ctgcaccccc agcaagaagg cgagttagtt 2640
ttctagagac ttgaaggagt ctcccccttc ctgcatcacc accttggttt tgttttattt 2700
tgcttcttgg tcaagaaagg aggggagaac ccagcgacc cctccccccc tttttttaa 2760
cgcgtgatga agacagaagg ctccggggtg acgaatttgg ccgatggcag atgttttggg 2820
ggaacgccgg gactgagaga ctccacgcag gcgaattccc gtttggggct ttttttctt 2880
ccctcttttc cccttgcccc ctctgcagcc ggaggaggag atgttgaggg gaggaggcca 2940
gccagtgtga ccggcgctag gaaatgacct gagaacccc ttggaagcgc agcagcggga 3000
gctagggggc ggggcggagg aggacacgaa ctggaagggg gttcacggtc aaactgaaat 3060
ggatttgcac gttggggagc tggcggcggc ggctgctggg cctccgcctt cttttctacg 3120
tgaaatcagt gaggtgagac ttcccagacc ccggaggcgt ggaggagagg agactgtttg 3180
atgtggtaca ggggcagtcg agtgaggggc agtggtttcg gaaaaaaaaa aagaaaaaaa 3240
gaaaaaaaaa gaaaaaaaaa agattttttt ctctcttaa tcggaatcgt gatggtgttg 3300
gattatttca atggtggggt taatatagca tgttatcttg tctatctttt aaagatttct 3360
gtataagact gttgagcagt ttttaaaata gtgtaggata atataaaaag cagatagatg 3420
gcgctatgtt tgattcctac aacgaaatta tcaccagctt tttttcattc ttaactcttt 3480
aaaggattca aacgcaactc aaatctgtgc ttggaattaa aaaaacaatt caggaccaaa 3540
ttttttctca gtgtgtgtgt ttattcctta taggtgtaaa tgagaagacg tgttttttct 3600
cttcaccgat gctccatcct cgtatttctt tttccttgta aatgtaatca gatgccattt 3660
tatatgtgga cgtatttata ctggccaaac atattttttt ttttgcctt ttttttcttt 3720
cctttctttt tacttctttt atttctttat tccttctttt cttttttttt 3780
tctttttttt tttttttttt tggtagttgt tgttaccac gccattttac gtctccttca 3840
ctgaagggct agagttttaa cttttaattt tttatattta aatgtagact tttgacactt 3900
ttaaaaaaca aaaaaagaca agagagatga aaacgtttga ttattttctc agtgtatttt 3960
tgtaaaaaat atataaagg gggtgtaaat ggtgtaaatc gctgtttgga tttcctgatt 4020
ttataacagg gcggtgtgtt aatatctcac acagttaaaa aaatcagccc ctaatttctc 4080
catgtttaca cttcaatctg caggcttctt aaagtgcag tatcccttaa cctgccacca 4140
gtgtccacc tccggccccc gtcttgtaaa agggggagga gaattagcca aacactgtaa 4200
gcttttaaga aaaaacaagt tttaaacgaa atactgtct gtccagaggc tttaaaactg 4260
gtgcaattac agcaaaaagg gattctgtag ctttaacttg taaaccacat cttttttgca 4320
ctttttttat aagcaaaaac gtgccgttta aaccactgga tctatctaaa tgccgatttg 4380
agttcgcgac actatgtact gcgtttttta ttctgtatt tgactattta atcctttcta 4440
cttgtcgcta aatataattg ttttagtctt atcctgatg gatagcatat gtgttcagg 4500
ttatagctgt tgtgtttaaa aattgaaaaa agtggaaaac atctttgtac atttaagtct 4560
gtattataat aagcaaaaag attgtgtgta tgtatgttta atataacatg acaggcacta 4620
ggacgtctgc ctttttaagg cagttccggt aaggggtttt gtttttaaac ttttttttgc 4680
gtcctatcct gtgcaatag cctgtgataa ttttgtctt aaaattcaag gccacaaaaa 4740
caatgtttgg gggaaaaaaa agaaaaaatc atgccagcta atcatgtcaa gttcactgcc 4800
tgtcagattg ttgatataa ccttctgtaa ataactttt ttgagaagga aataaaatca 4860
gctggaactg aaccctaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 4912

```

<210> 28
 <211> 2637
 <212> DNA
 <213> Homo sapiens

```

<400> 28
ggcacgaggc ccctgcgtgc ggcgcttctc ccaggcccca ccttccatcc agtgccctgg 60
accctcggct gggtagcgcc accagagcga ccaaactgcc cgcgcttcc aggccgcact 120
ccagagccaa aagagctcca tggcggcggc ggccaagccc aacaaccttt ccctgggtgg 180
gcacggaccg ggggacttgc gcctggagaa ctatcctatc cctgaaccag gcccaaatga 240
ggtcttgctg aggatgcatt ctgttggaat ctgtggctca gatgtccact actgggagta 300
tggtcgaatt gggaatttta ttgtgaaaaa gccatgggtg ctgggacatg aagcttcggg 360
aacagtcgaa aaagtgggat catcggtaaa gcacctaaaa ccaggtgatc gtgttgccat 420
cgagcctggg gctccccgag aaaatgatga attctgcaag atgggccgat acaatctgtc 480
accttccatc ttcttctgtg ccacgcccc ccatgacggg aacctctgcc ggttctataa 540
gcacaatgca gccttttgtt caaagcttcc tgacaatgtc acctttgagg aaggcgccct 600
gatcgagcca ctttctgtgg ggtccatg cgcaggaga ggcgagtta ccctgggaca 660
caaggctcct gtgtgtggag ctgggccaat cgggatgggt actttgctcg tggccaaagc 720
aatgggagca gctcaagtag tggtagtga tctgtctgct acccgattgt ccaaagccaa 780
ggagattggg gctgatttag tcctccagat ctccaaggag agccctcagg aaatcgccag 840
gaaagtagaa ggtcagctgg ggtgcaagg ccaggtcacc atcgagtgc cgggggcaga 900
ggcctccatc caggcgggca tctacgccac tcgctctggg gggaccctcg tgcctgtggg 960
ctggggctct gagatgacca ccgtaccctt actgcatgca gccatccggg aggtggatat 1020
caaggcgctg tttcgatact gcaacacgtg gccagtggcg atttcgatgc ttgcgtccaa 1080
gtctgtgaat gtaaaacccc tcgtcaccca taggttttct ctggagaaag ctctggaggc 1140
ctttgaaaca tttaaaaagg gattgggggt gaaaatcatg ctcaagtgtg accccagtg 1200

```


SEQUENCE LISTING 1657-2022.txt

```

ccagaatccc  tgatgttaat  gggctctgcc  ctcatcccca  cagtcttggg  atctcagggc  1260
acaatggctg  gacatgggtg  ggctctgatg  cagaaactttc  tcttttgaat  gttaagaata  1320
actaatacaa  ttcattgtga  acagaagtcc  ttaagcagag  gaattggtgt  gccttaaaga  1380
tacaatctgg  gatagtttgg  gggaaacttg  agccagaatg  ccctgttcac  gctgagcaaa  1440
gttcagcaag  tagagcagag  tttggcaggc  aggtgccagg  aactccccct  cttcctggag  1500
tgccttcatt  gaggaaggaa  atctggccct  tgggtttcct  ggttccactg  ctactgacct  1560
agaggggaat  gagggctgag  ttatgaaaag  ataacttcat  gaagacttaa  ctggcccaga  1620
agctgatttt  catgaaaatc  tgccactcag  ggtctgggat  gaaggcttgt  cagcacttcc  1680
agtttagaac  gcaatgtttc  tagagacata  ttggctgttt  gttttgatga  taaaaggaga  1740
ataagaaaaa  gctctacatt  cctggatcca  ggataatttt  taaaccaatc  aaatgaaaaa  1800
aacaacaaaa  caaaaaagga  aatgtcatgt  gaggttaaac  cagtttgcat  tcccctaagt  1860
tggaataaag  aagaggacta  ctcagcactg  ttgaaagatt  gcctcttcta  cagcttctga  1920
gaattgtgtt  atttcacttg  ccaagtgaag  gacccccctc  ccaacatgcc  ccagcccacc  1980
cctaagcatg  gtcccttggt  accaggcaac  caggaaaactg  ctacttggtg  acctcaccag  2040
agaccaggag  ggtttgggta  gctcacagga  cttcccccc  cccagaagat  tagcatccca  2100
tactagactc  atactcaact  caactaggct  catactcaat  tgatggttat  tagacaattc  2160
cattttcttc  tggttattat  aaacagaaaa  tctttcctct  tctcattacc  agtaaaggct  2220
cttggatctc  ttctgttggg  atgatttcta  tgatttctgt  ttattttaat  ggtgggtttt  2280
ttttctggta  agatttagac  ctaaactcga  tcatgccaac  ttgtgacttt  gagactattc  2340
atcaagaatg  aggatatagt  agccatgaca  tagcttgagc  tatagccttt  aattccttac  2400
tttggctatg  ggtggagggt  gagtttgaag  aggttctgat  tttcttgtaa  cctgggaaag  2460
ccatgacctt  gtgcccgttt  ctttcagatt  gctttgggta  ataaatattg  gtggtggtat  2520
ctgaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  2580
aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaa    2637

```

<210> 29
 <211> 1778
 <212> DNA
 <213> Homo sapiens

```

<400> 29
tagaagttta  caatgaagtt  tcttctaata  ctgctcctgc  aggccactgc  ttctggagct  60
cttccccctg  acagctctac  aagcctggaa  aaaaataatg  tgctatttgg  tgagagatac  120
ttagaaaaat  tttatggcct  tgagataaac  aaactttccg  tgacaaaaat  gaaatatagt  180
ggaaacttaa  tgaaggaaaa  aatccaagaa  atgcagcact  tcttgggtct  gaaagtgacc  240
gggcaactgg  acacatctac  cctggagatg  atgcacgcac  ctcgatgtgg  agtccccgat  300
ctccatcatt  tcagggaaat  gccagggggg  cccgatgga  ggaaacatta  tatcacctac  360
agaatcaata  ttacacacac  tgacatgaac  cgtgaggatg  ttgactacgc  aatccggaaa  420
gctttccaag  tatggagtaa  tgttaccccc  ttgaaattca  gcaagattaa  cacaggcatg  480
gctgacattt  tgggtggttt  tgcccgtgga  gctcatggag  acttccatgc  ttttgatggc  540
aaaggtggaa  tcctagecca  tgcttttgga  cctggatctg  gcattggagg  ggatgcacat  600
ttcgatggag  acgaattctg  gactacacat  tcaggaggca  caaacttggt  cctcactgct  660
gttcacgaga  ttggccattc  cttaggtctt  ggccattcta  gtgatccaaa  ggctgtaatg  720
ttccccacct  acaaatatgt  cgacatcaac  acatttcgcc  tctctgctga  tgacatacgt  780
ggcattcagt  cctctgatgg  agacccaaaa  gagaaccaac  gcttgccaaa  tcctgacaat  840
tcagaaccag  ctctctgtga  cccaatttg  agttttgatg  ctgtcactac  cgtgggaaat  900
aagatctttt  tcttcaaaga  caggttcttc  tggctgaagg  tttctgagag  accaaagacc  960
agtgttaatt  taatttcttc  cttatggcca  accttgccat  ctggcattga  agctgcttat  1020
gaaattgaag  ccagaaatca  agtttttctt  tttaaagatg  acaaatactg  gtttaattagc  1080
aatttaagac  cagagccaaa  ttatcccaag  agcatacatt  cttttgggtt  tcctaacttt  1140
gtgaaaaaaa  ttgatgcagc  tgtttttaac  ccacgttttt  ataggaccta  cttctttgta  1200
gataaccagt  attggaggta  tgatgaaagg  agacagatga  tggaccctgg  ttatcccaaa  1260
ctgattacca  agaacttcca  aggaatcggg  cctaaaaattg  atgcagtctt  ctattctaaa  1320
aacaataact  actatttctt  ccaaggatct  aaccaatttg  aatatgactt  cctactccaa  1380
cgtatcacca  aaacactgaa  aagcaatagc  tggtttgggt  gttagaaatg  gtgtaattaa  1440
tggtttttgt  tagttcactt  cagcttaata  agtatttatt  gcatatttgc  tatgtcctca  1500
gtgtaccact  acttagagat  atgtatcata  aaaaaaaat  ctgtaaacca  taggtaatga  1560
ttatataaaa  tacataatat  ttttcaattt  tgaaaactct  aattgtccat  tcttgcttga  1620
ctctactatt  aagtttgaag  atagttacct  tcaaagcaag  ataattctat  ttgaagcatg  1680
ctctgtaagt  tgcttcctaa  catccttgga  ctgagaaatt  atacttactt  ctggcataac  1740
taaaattaag  tatatatatt  ttggctcaaa  taaaattg    1778

```

<210> 30
 <211> 777
 <212> DNA
 <213> Homo sapiens

SEQUENCE LISTING 1657-2022.txt

<400> 30

ggccccctgt	ctgcagagat	ggctcccaat	gcttcctgcc	tctgtgtgca	tgtccgttcc	60
gaggaatggg	atttaatgac	ctttgatgcc	aacccatattg	acagcgtgaa	aaaaatcaaa	120
gaacatgtcc	ggtctaagac	caagggttctt	gtgcaggacc	aggttctttt	gctgggctcc	180
aagatcttaa	agccacggag	aagcctctca	tcttatggca	ttgacaaaga	gaagaccatc	240
caccttacc	tgaagtggt	gaagcccagt	gatgaggagc	tgcccttgtt	tcttgtggag	300
tcaggtgatg	aggcaaaagag	gcacctctc	caggtgcgaa	ggtccagctc	agtggcacia	360
gtgaaagcaa	tgatcgagac	taagacgggt	ataatccctg	agaccagat	tgtgacttgc	420
aatggaaaga	tggggaagat	tgggaagatg	atggcagatt	acggcatcag	aaagggcaac	480
ttactcttcc	tggcatctta	ttgtattgga	gggtgaccac	cctggggatg	gggtgttggc	540
aggggtcaaa	aagcttattt	cttttaattct	cttactcaac	gaacacatct	tctgatgatt	600
tcccaaaatt	aatgagaattg	agatgagtag	agtaagattt	gggtgggatg	ggtaggatga	660
agtattattgc	ccaactctat	gtttctttga	ttctaacaca	attaattaag	tgacatgatt	720
tttactaatg	tattactgag	actagtaaat	aaatttttaa	ggcaaaatag	agcattc	777

<210> 31

<211> 9645

<212> DNA

<213> Homo sapiens

<400> 31

atgcccaagc	gcgcgcactg	ggggggccctc	tccgtgggtgc	tgatcctgct	ttggggcccat	60
ccgcgagtg	cgctggcctg	cccgcacatcct	tgtgcctgct	acgtccccag	cgaggtccac	120
tgcacgttcc	gatccctggc	ttccgtgccc	gctggcattg	ctagacacgt	ggaaagaatc	180
aatttggggt	ttaatagcat	acaggccctg	tcagaaaacct	catttgcagg	actgaccaag	240
ttggagctac	ttatgattca	cggcaatgag	atcccaagca	tccccgatgg	agctttaaga	300
gacctcagct	ctcttcaggt	tttcaagttc	agctacaaca	agctgagagt	gatcacagga	360
cagaccctcc	agggctctctc	taacttaatg	aggtgcaca	ttgaccacaa	caagatcgag	420
tttatccacc	ctcaagcttt	caacggctta	acgtctctga	ggctactcca	tttggaaagg	480
aatctcctcc	accagctgca	ccccagcacc	ttctccacgt	tcacattttt	ggattatttc	540
agactctcca	ccataaggca	cctctactta	gcagagaaca	tggttagaac	tcttcttgcc	600
agcatgcttc	ggaacatgcc	gcttctggag	aatctttact	tgcaaggaaa	tccgtggacc	660
tgcgatttgg	agatgagatg	gtttttggaa	tgggatgcaa	aatccagagg	aattctgaag	720
tgtaaaaagg	acaaagctta	tgaaggcggg	cagttgtgtg	caatgtgctt	cagtcctaaag	780
aagttgtaca	aacatgagat	acacaagctg	aaggacatga	cttgtctgaa	gccttcaata	840
gagtcctcct	tgagacagaa	caggagcagg	agtattgagg	aggagcaaga	acaggaagag	900
gatgggtggc	cctggagaaa	ttccaactgc	ccagtgagg	ccagtgagg	catctctttg	960
aatatgaccg	acgagcacgg	gaacatgggt	aacttgggtc	gtgacatcaa	gaaaccaatg	1020
gatgtgtaca	agattcactt	gaaccaaacg	gatcctccag	atattgacat	aatgcaaca	1080
gttgcttggg	actttgagtg	tccaatgacc	cgagaaaact	atgaaaagct	atggaaattg	1140
atagcatact	acagtgaagt	tcccgtgaag	tcacacagag	agctcatgct	cagcaaaagc	1200
cccagagtca	gctaccagta	caggcaggat	gctgatgagg	aagctcttta	ctacacaggt	1260
gtgagagccc	agattcttgc	agaaccagaa	tgggtcatgc	agccatccat	agatatccag	1320
ctgaaccgac	gtcagagtac	ggccaagaag	gtgtactttt	cctactacac	ccagtattct	1380
caaacaatat	ccaccaaga	tacaaggcag	gctcggggca	gaagctgggt	aatgattgag	1440
cctagtggag	ctgtgcaaag	agatcagact	gtcctggaag	gggttccatg	ccagttgagc	1500
tgcaacgtga	aagcttctga	gagtccatct	atcttctggg	tgcttccaga	tggctccatc	1560
ctgaaagcgc	ccatggatga	cccagacagc	aagttctcca	ttctcagcag	tggctggctg	1620
aggatcaagt	atctgactca	ggcttgtacc	agtgcattgc	tcaagtgagg	tcaagtgagg	1680
gatgaaatgg	accgcatggt	atatagggta	cttgtgcagt	ctccctccac	tcagccagcc	1740
gagaaagaca	cagtgaacaat	tggcaagaac	ccaggggagt	cgggtgacatt	gccttgcaat	1800
gcttttagcaa	taccgaagc	ccaccttagc	tggattcttc	caaacagaag	gataattaat	1860
gatttggcta	acacatcaca	tgtatacatg	ttgccaaaatg	gaactctttc	catcccaaag	1920
gtccaagtca	gtgatagtgg	ttactacaga	tgtgtggctg	tcaaccagca	aggggagagc	1980
cattttacgg	tgggaatcac	agtgaaccaag	aaaggggtctg	gcttgccatc	caaaagaggc	2040
agacgcccag	gtgcaaaggc	tctttccaga	gtcagagaag	acatcgtgga	ggatgaaggg	2100
ggctcgggca	tgggagatga	agagaacact	tcaaggagac	ttctgcatcc	aaaggaccac	2160
gaggtgttcc	tcaaaacaaa	ggatgatgcc	atcaatggag	acaagaaagc	caagaaaggg	2220
agaagaaagc	tgaactctg	gaagcattcg	gaaaaagaac	cagagaccaa	tggtgcagaa	2280
ggtcgcagag	tggttgaatc	tagacgaagg	ataaacatgg	caaacaacaa	gattaatccg	2340
gagcgtggg	ctgatatttt	agccaaagtc	cgtgggaaaa	atctccctaa	gggcacagaa	2400
gtacccccgt	tgattaaaac	cacaagtcct	ccatccttga	gcctagaagt	cacaccacct	2460
tttctgctg	tttctcccc	ctcagcatct	cctgtgcaga	cagtaaccag	tgctgaagaa	2520
tctcagcag	atgtacctct	acttgggtgaa	gaagagcacg	ttttgggtac	catttctcta	2580
gccagcatgg	ggctagaact	caaccacaat	ggaggttattc	ttgttgaacc	tgaagtaaca	2640
agcacacctc	tggagggaagt	tggtgatgac	ctttctgaga	agactgagga	gataacttcc	2700
actgaaggag	acctgaaggg	gacagcagcc	cctacactta	tatctgagcc	ttatgaacca	2760

SEQUENCE LISTING 1657-2022.txt

tctcctactc	tgcacacatt	agacacagtc	tatgaaaagc	ccacccatga	agagacggca	2820
acagaggggt	gggtctgcagc	agatgttggg	tcgtcaccag	agccccacatc	cagtgaagtat	2880
gagcctccat	tggatgctgt	ctccttggct	gagtcctgagc	ccatgcaata	ctttgaccca	2940
gatttggaga	ctaagtcaca	accagatgag	gataagatga	aagaagacac	ctttgcacac	3000
ettactccaa	cccccccat	ctgggttaat	gactccagta	catcacagtt	atttgaggat	3060
tctactatag	gggaaccagg	tgtcccaggc	caatcacatc	tacaaggact	gacagacaac	3120
atccaccttg	tgaaaagtag	tctaagcact	caagacacct	tactgattaa	aaagggtatg	3180
aaagagatgt	ctcagacact	acagggagga	aatatgctag	agggagaccc	cacacactcc	3240
agaagtcttg	agagttaggg	ccaagagagc	aaatccatca	ctttgcctga	ctccacactg	3300
ggtataatga	gcagtatgtc	tccagttaag	aagcgtgcgg	aaaccacagt	tggtagcctc	3360
ctagacaaag	acaccacaac	agtaacaaca	acaccaaggc	aaaaagttgc	tccgtcatcc	3420
accatgagca	ctcacccttc	tcgaaggaga	cccaacggga	gaaggagatt	acgccccaac	3480
aaattccgcc	accggcacaa	gcaaacccca	cccacaactt	ttgccccatc	agagactttt	3540
tctactcaac	caactcaagc	acctgacatt	agcatttcaa	gtcaagtggg	gagttctctg	3600
gttctctacag	cttgggttgg	taacacagtt	aataccccca	aacagttgga	aatggagaag	3660
aatgcagaac	ccacatccaa	gggaacacca	cggagaaaac	acgggaagag	gccaaacaaa	3720
catcgatata	ccccctctac	agtgaactca	agagcgtccg	gatccaagcc	cagcccttct	3780
ccagaaaata	aacattgaaa	cattgttact	cccagttcag	aaactatact	tttgcttaga	3840
actgtttctc	tgaaaactga	gggcccttat	gattccttag	attacatgac	aaccaccaga	3900
aaaatatatt	catcttacct	taaagtccaa	gagacacttc	cagtcacata	taaaccacaa	3960
tcagatggaa	aagaaattaa	ggatgatgtt	gccacaaatg	ttgacaaaca	taaaagtgc	4020
tttttagtca	ctgggtgaat	aattactaat	gccattacaa	cttctcgctc	cttggctctc	4080
actatgggag	aatttaagga	agaatcctct	cctgtaggct	ttccaggaac	tccaacctgg	4140
aatccctcaa	ggacggccca	gcctgggagg	ctacagacag	acatacctgt	taccacttct	4200
ggggaaaaac	ttacagaacc	tccccctctt	aaagagcttg	aggatgtgga	tttcaacttc	4260
gagtttttgt	cctctttgac	agtctccaca	ccatttcacc	aggaagaagc	tggttcttcc	4320
acaactctct	caagcataaa	agtggagggt	gcttcaagtc	aggcagaaac	caccaccttc	4380
gatcaagatc	atcttgaaac	cactgtggct	attctccttt	ctgaaactag	accacagaat	4440
cacaccctca	ctgctgcccc	gatgaaggag	ccagcatcct	cgccccatc	cacaattctc	4500
atgtcttttg	gacaaaccac	caccactaag	ccagcacttc	ccagtccaag	aatatctcaa	4560
gcatctagag	attccaagga	aaatgttttc	ttgaattatg	tggggaaatc	agaaacagaa	4620
gcaacccag	tcaacaatga	aggaacacag	catatgtcag	ggccaaatga	attatcaaca	4680
ccctcttccg	accgggatgc	atttaacttg	tctacaaagc	tggaaattgga	aaagcaagta	4740
tttggttagt	ggagtctacc	acgtggccca	gatagccaac	gccaggatgg	aagagttcat	4800
gcttctcatc	aactaaccag	agtccctgcc	aaacccatcc	taccaacagc	aacagtggag	4860
ctacctgaaa	tgtccacaca	aagcgtcttc	agatactttg	taacttccca	gtcacctcgt	4920
cactggacca	acaaaccgga	aataactaca	tatccttctg	gggctttgcc	agagaacaaa	4980
cagttttacaa	ctccaagatt	atcaagtaca	acaattcctc	tcccattgca	catgtccaaa	5040
cccagcattc	ctagtaagtt	tactgaccga	agaactgacc	aattcaatgg	ttactccaaa	5100
gtgtttggaa	ataacaacat	ccctgaggca	agaaacccag	ttggaaagcc	tcccagtcca	5160
agaattcctc	attattccaa	tggaaagact	cctttcttta	ccaacaagac	tctttctttt	5220
ccacagtgtg	gagtcacccg	gagacccag	ataccacttc	ctcctgcccc	agtaattgag	5280
gagagaaaag	ttattccagg	ttcttacaac	aggatacatt	cccatagcac	cttccatctg	5340
gactttggcc	ctccggcacc	tccgttggtg	caactcctgc	agaccacggg	atcaccttca	5400
actaacttac	agaatatccc	tatggctctc	tcacccacaga	gttctatctc	ctttataaca	5460
tcttctgtcc	agcttccag	aatgctccac	cagagcagct	caaagttctt	tgcaggagga	5520
cctcctgcat	ccaaattctg	gtctcttggg	gaaaagcccc	aaatcctcac	caagtcccca	5580
cagactgtgt	ccgtcaccgc	tgagacagac	actgtgttcc	cctgtgaggc	aacaggaaaa	5640
ccaaagcctt	tcgttacttg	gacaaagggt	tccacaggag	ctcttatgac	tccgaatacc	5700
aggatacaac	ggtttgaggt	tctcaagaac	ggtaccttag	tgatacggaa	ggttcaagta	5760
caagatcgag	gccagtatat	gtgcaccgcc	agcaacctgc	acggcctgga	caggatgggtg	5820
gtcttgcttt	cggtcaccgt	gcagcaacct	caaactcctag	cctccactta	ccaggacgtc	5880
actgtctacc	tgggagacac	cattgcaatg	gagtgcttgg	ccaaagggac	cccagcccc	5940
caaatctctt	ggatcttccc	tgacaggagg	gtgtggcaaa	ctgtgtcccc	cgtggagagc	6000
cgcatacccc	tgcacgaaaa	cgggaccctt	tccatcaagg	aggcgtcctt	ctcagacaga	6060
ggcgtctata	agtgcgtggc	cagcaatgca	gccggggcgg	acagcctggc	catccgcctg	6120
cacgtggcgg	cactgcccc	cggtatccac	caggagaagc	tggagaacat	ctcgtgccc	6180
ccggggctca	gcattcacat	tcactgcact	gccaaggctg	cgccccctgc	cagcgtgcgc	6240
tgggtgctcg	gggacggtac	ccagatccgc	ccctgcaggt	tcctccacgg	gaacttggtt	6300
gttttcccca	acgggacgct	ctacatccgc	aacctcgcgc	ccaaggacag	gggcgctat	6360
gagtgcgtgg	ccgccaacct	ggtaggctcc	gcgcgcagga	cggtgcagct	gaactgtcag	6420
cgtgcagcag	ccaacgcgcg	catcacgggc	acctccccgc	ggaggacgga	cgtcaggtac	6480
ggaggaaccc	tcaagctgga	ctgcagcgc	ctgggggacc	cctggccgcg	catcctctgt	6540
aggctgccgt	ccaagaggat	gatcgacgcg	ctcttcagtt	ttgatagcag	aatcaagggtg	6600
tttgccaatg	ggaccctggt	ggtgaaatca	gtgacggaca	aagatgccgg	agattacctg	6660
tgctgagctc	gaaataaggt	tgggtgatgac	tacgtgggtc	tcaaagtggg	tgtggtgatg	6720
aaaccggcca	agattgaaca	caaggaggag	aacgaccaca	aagtcctcta	cgggggtgac	6780

SEQUENCE LISTING 1657-2022.txt

```

ctgaaagtgg actgtgtggc caccgggctt cccaatcccg agatctcctg gagcctccca 6840
gacgggagtc tgggtgaactc cttcatgcag tcggatgaca gcggtggacg caccaagcgc 6900
tatgtcgtct tcaacaatgg gacactctac tttaacgaag tggggatgag ggaggaagga 6960
gactacacct gctttgctga aaatcaggtc gggaaggacg agatgagagt cagagtcaag 7020
gtggtgacag cgcccgccac catccggaac aagacttact tggcggttca ggtgccctat 7080
ggagacgtgg tcaactgtagc ctgtgaggcc aaaggagaac ccatgcccac ggtgacttgg 7140
ttgtcccca ccaacaaggt gatccccacc tcctctgaga agtatcagat ataccaagat 7200
ggcactctcc ttattcagaa agcccagcgt tctgacagcg gcaactacac ctgcctggct 7260
aggaacagcg cgggagagga taggaagacg gtgtggattc acgtcaacgt ccagccacc 7320
aagatcaacg gtaaccccaa ccccatcacc accgtgcggg agatagcagc cgggggcagt 7380
cggaaactga ttgactgcaa agctgaaggc atccccaccc cgagggtgtt atgggctttt 7440
cccagggtg tggttctgcc agctccatac tatggaaacc ggatcactgt ccatggcaac 7500
ggttccctgg acatcaggag tttaggaag agcgtactcc tccagctggt atgcatggca 7560
cgcaacgagg gaggggaggc gaggttgatc gtgcagctca ctgtcctgga gcccatggag 7620
aaacccatct tccacgaccc gatcagcgag aagatcacgg ccatggcggg ccacaccatc 7680
agcctcaact gctctgccg ggggacccc acacccagcc tgggtgtggg ccttcccaat 7740
ggcaccgatc tgcagagtgg acagcgttct cagcgttct acccaaggc tgacggcatg 7800
ctacacatta gcggtctctc ctcggtggac gctggggcct accgctgcgt ggcccgcaat 7860
gccgctggcc acacggagag gctggtctcc ctgaagggtg gactgaagcc agaagcaaac 7920
aagcagtatc ataacctggt cagcatcatc aatggtgaga ccctgaagct cccctgcacc 7980
cctcccgggg ctgggcaggg acgtttctcc tggcgcctcc ccaatggcat gcatctggag 8040
ggccccaaa ccctgggacg cgtttctctt ctggacaatg gcacctcac ggttcgtgag 8100
gcctcggtgt ttgacagggg tacctatgta tgcaggatgg agacggagta cggcccttcg 8160
gtcaccagca tccccgtgat tgtgatcgcc tatcctcccc ggatcaccag cgagcccacc 8220
ccggtcatct acacccggcc cgggaacacc gtaaaactga actgcatggc tatggggatt 8280
cccaaagctg acatcacgtg ggagttaccg gtaagtgcg atctgaaggc aggggttcag 8340
gctcgtctgt atggaaacag atttcttcac ccccgaggat cactgaccat ccagcatgcc 8400
acacagagag atgccggctt ctacaagtgc atggcaaaaa acattctcgg cagtgaactc 8460
aaaacaactt acatccacgt cttctgaaat gtggattcca gaattgattg ttaggaactg 8520
acaacaaagc ggggtttgta agggaaagca ggttggggaa taggagctct taaataatgt 8580
gtcacagtgc atgggtggct ctggtgggtt tcaagttgag gttgatcttg atctacaatt 8640
gttgggaaaa ggaagcaatg cagacacgag aaggagggtc cagccttgct gagacacttt 8700
ctttgtgttt tacatcatgc caggggcttc attcagggtg tctgtgctct gactgcaatt 8760
tttcttcttt tgcaaatgcc actcgactgc cttcataagc gtccatagga tatctgagga 8820
acattcatca aaaataagcc atagacatga acaacacctc actaccccat tgaagacgca 8880
tcacctagtt aacctgctgc agtttttaca tgatagactt tgttccagat tgacaagtca 8940
tctttcagtt atttctctg tcacttcaaa actccagctt gccaataaag gatttagaac 9000
cagagtgaat gatataata tatatatatt aattcagagt tacatacata cagctaccat 9060
tttatatgaa aaaagaaaaa catttcttcc tggaaactcac tttttatata atgttttata 9120
tatatatatt ttcttttcaa atcagacgat gagactagaa ggagaaatac ttctgtctt 9180
attaaaatta ataaattatt ggtctttaca agacttggat acattacagc agacatggaa 9240
atataatttt aaaaaatttc tctcaacct ccttcaaat cagtcaccac tgttatatta 9300
ccttctccag gaacctcca gtggggaagg ctgcgatatt agatttcctt gtatgcaaag 9360
tttttgttga aagctgtgct cagaggaggt gagaggagag gaaggagaaa actgcatcat 9420
aactttacag aattgaattc agagtcttcc cggaaaagcc cagaaaactc tctgcagtat 9480
ctggctgtgc catctggtct aaggtggctg ctcttcccc agccatgagt cagtttgtgc 9540
ccatgaataa tacacgacct gttatttcca tgactgcttt actgtatttt taaggccaat 9600
atactgtaca tttgataata aaataatatt ctcccaaaaa aaaaa 9645

```

<210> 32
 <211> 5921
 <212> DNA
 <213> Homo sapiens

```

<400> 32
agcagacggg agtttctcct cggggtcggg gcaggaggca cgcggagtgt gaggccacgc 60
atgagcggag gctaaccccc tccccagcca caaagagtct acatgtctag ggtctagaca 120
tggtcagctt tgtggacctc cggctcctgc tctcttagc ggccaccgcc ctctgacgc 180
acggccaaga ggaaggccaa gtcgagggcc aagacgaaga catcccacca atcacctgcg 240
tacagaacgg cctcaggtac catgaccgag acgtgtggaa acccgagccc tgccggatct 300
gcgtctgcga caacggcaag gtgtgtgtcg atgacgtgat ctgtgacgag accaagaact 360
gccccggcgc cgaagtcccc accggcgtcg aggtgacctg ctgccccgac ggctcagagt 420
caccacccga ccaagaaacc accggcgtcg aggtgacctg gggagacact ggcccccgag 480
gccaagggg acccgagggc cccctggcc gagatggcat ccctggacag cctggacttc 540
ccggaccccc cggacccccg ggacctccc gaacccctgg cctcgaggga aactttgctc 600
ccagctgtc ttatggctat gatgagaaat caaccggagg aatttccgtg cctggcccca 660
tgggtccctc tggctcctcg ggtctccctg gccccctgg tgacacctgt cccaaggct 720

```

SEQUENCE LISTING 1657-2022.txt

tccaaggtcc	ccctggtgag	cctggcgagc	ctggagcttc	aggtcccatg	ggtcccccag	780
gtcccccagg	tccccctgga	aagaatggag	atgatgggga	agctggaaaa	cctggtcgtc	840
ctggtgagcg	tgggcctcct	gggcctcagg	gtgctcgagg	attgcccgga	acagctggcc	900
tccctggaat	gaagggacac	agaggtttca	gtggtttgga	tggtgccaag	ggagatgctg	960
gtcctgctgg	tcctaagggt	gagcctggca	gccctgggtga	aaatggagct	cctggtcaga	1020
tgggcccccg	tggcctgcct	ggtgagagag	gtcgccctgg	agccccctggc	cctgctggtg	1080
ctcgtggaaa	tgatggtgct	actggtgctg	ccgggcccc	tggtcccacc	ggccccgctg	1140
gtcctcctgg	cttccttgg	gctgttgggt	ctaagggtga	agctggtccc	caagggcccc	1200
gaggctctga	aggtcccccag	ggtgtgcgtg	gtgagcctgg	ccccctggc	cctgctggtg	1260
ctgctggccc	tgctggaaac	cctggtgctg	atggacagcc	tggtgctaaa	ggtgccaatg	1320
gtgctcctgg	tattgctggt	gctcctggct	tccctgggtc	ccgaggcccc	tctggacccc	1380
agggccccgg	cggcctctct	ggtcccaagg	gtaacagcgg	tgaacctggt	gctcctggca	1440
gcaaaggaga	cactggtgct	aaaggagagc	tggtgttcaa	ggacccccctg	ggacccccctg	1500
gccctgctgg	agaggaagga	aagcgaggag	ctcgaggtga	acccggaccc	actggcctgc	1560
ccggaccccc	tggcgagcgt	ggtggacctg	gtagccctgg	tttccctggc	gcagatggtg	1620
ttgctggtcc	caagggtccc	gctggtgaac	gtggttctcc	tgccccctgct	ggccccaaag	1680
gatctcctgg	tgaagctggt	cgctccggtg	aagctggtct	gcctggtgac	aagggtgagc	1740
ctggaagccc	tggcagccct	ggtcctgatg	gcaaaactgg	ccccctggt	cccgccggtc	1800
aagatggtcg	ccccggaccc	ccaggccac	ctggtgccc	tggtcaggct	ggtgtgatgg	1860
gattccctgg	acctaaaggt	gctgctggag	agcccggcaa	ggctggagag	cgaggtgttc	1920
ccggaccccc	tggcctgctc	ggtcctgctg	gcaaaagtgg	agaggctgga	gctcagggac	1980
ccccctggccc	tgctggtccc	gctggcgaga	gaggtgaaca	aggccctgct	ggctcccccg	2040
gattccagggt	tctccctggt	cctgctggtc	ctccaggtga	agcaggcaaa	cctggtgaac	2100
aggggtgttc	tggagacctt	ggcgccccctg	gccccctctg	agcaagaggc	gagagaggtt	2160
tccctggcga	gcgtggtgtg	caagggtccc	ctggtctgct	tggacccccga	ggggccaacg	2220
gtgctcccg	caacgatggt	gctaagggtg	atgctggtgc	ccctggagct	cccggtagcc	2280
agggcgcccc	tggccttcag	ggaatgcctg	gtgaacgtgg	tgcaagctgg	cttccagggc	2340
ctaagggtga	cagaggtgat	gctggtccca	aaggtgctga	tggtctcct	ggcaaagatg	2400
gcgtccgtgg	tctgaccggc	cccattggtc	ctcctggccc	tgctggtgcc	cctggtgaca	2460
aggggtgaaag	tgggtccagc	ggccctgctg	gtcccaactgg	agctcggtgg	gcccccgag	2520
accgtggtga	gcctggtccc	ccgggcccctg	ctggctttgc	tgccccccct	ggtgctgacg	2580
gccaacctgg	tgctaaaggt	gaacctggtg	atgctggtgc	caaaggcgat	gctggtcccc	2640
ctgggcccctg	cggaccctgc	ggacccccctg	gccccattgg	taatgttgg	gctcctggag	2700
ccaaagggtgc	tcgcggcagc	gctggtcccc	ctggtgctac	tggtttccct	ggtgctgctg	2760
gccgagtcgg	tctcctggtc	ccctctggaa	atgctggacc	ccctggccct	cctggtcctg	2820
ctggcaaaga	aggcggaaca	ggtccccctg	gtgagactgg	ccctgctgga	cgctcctggtg	2880
aagttggtcc	ccctggtccc	cctggcccctg	ctggcgagaa	aggatcccc	ggtgctgatg	2940
gtcctgctgg	tgctcctggt	actccccggc	ctcaagggtat	tgctggacag	cggtggtggtg	3000
tcggcctgcc	tggctcagaga	ggagagagag	gcttccctgg	tcttccctggc	ccctctggtg	3060
aacctggcaa	acaagggtccc	tctggagcaa	gtggtgaacg	tgggtcccc	ggtcccatgg	3120
gccccctgg	attggtgga	ccccctggtg	aatctggacg	tgagggggct	cctgctgccc	3180
aaggttcccc	tggacgagac	ggttctcctg	gcgccaaggg	tgaccgtggt	gagaccggcc	3240
ccgctggacc	ccctggtgct	cctggtgctc	ctggtgcccc	tgccccctgt	ggccctgctg	3300
gcaagagtgg	tgatcgtggt	gagactggtc	ctgctggtcc	cgccggtccc	gtcgcccccg	3360
tcggcgccc	tggccccg	ggacccccag	gccccctggt	tgacaagggt	gagacaggcg	3420
aacagggcga	cagagggcata	aaagggtcacc	gtggcttctc	tggcctccag	ggtccccctg	3480
gccctcctgg	ctctcctggt	gaacaagggtc	cctctggagc	ctctggtcct	gctggtcccc	3540
gaggtcccc	tggctctgct	ggtgctcctg	gcaaagatgg	actcaacggt	ctccctggcc	3600
ccattgggccc	ccctggtcct	cgcggtcgca	ctggtgatgc	tggtcctggt	ggtccccccg	3660
gccctcctgg	acctcctggt	ccccctggtc	ctcccagcgc	tggtttcgac	ttcagcttcc	3720
tgccccagcc	acctcaagag	aaaggctcacg	atggtggccg	ctactaccgg	gctgatgatg	3780
ccaatgtggt	tcgtgaccgt	gacctcgagg	tggacaccac	cctcaagagc	ctgagccagc	3840
agatcgagaa	catccggagc	ccagagggaa	gccgcaagaa	ccccgcccgc	acctgcccgtg	3900
acctcaagat	gtgccactct	gactggaaga	gtggagagta	ctggattgac	cccaaccaag	3960
gctgcaacct	ggatgccatc	aaagtcttct	gcaacatgga	gactggtgag	acctgctggt	4020
acccactca	gcccagtgtg	gcccagaaga	actggtacat	cagcaagaac	cccaaggaca	4080
agaggcatgt	ctggttccgg	gagagcatga	ccgatggatt	ccagttcgag	tatggcggcc	4140
agggctccga	ccctgctcgg	gtggccatcc	agctgacctt	cctgcccctg	atgtccaccg	4200
aggcctccca	gaacatcacc	taccactgca	agaacagcgt	ggcctacatg	gaccagcaga	4260
ctggcaacct	caagaaggcc	ctgctcctca	agggctccaa	cgagatcgag	atccgcgccc	4320
agggcaacag	ccgcttcacc	tacagcgtca	ctgtcgatgg	ctgcacgagt	cacaccggag	4380
ctgggggcaa	gacagtgtat	gaatacaaaa	ccaccaagtc	ctcccgcctg	cccatcatcg	4440
atgtggcccc	cttggacgtt	ggtgccccag	accaggaatt	cggttctgac	gttggcccctg	4500
tctgcttctt	gtaaactccc	tccatcccaa	cctggtctcc	tcccacccaa	ccaaactttcc	4560
cccaaacctg	gaaacagaca	agcaacccaa	actgaacccc	cccaaaagcc	aaaaaatggg	4620
agacaatttc	acatggactt	tggaaaatat	tttttctctt	tgcatctatc	tctcaaacctt	4680
agtttttatc	tttgaccaac	cgaacatgac	caaaaaccaa	aagtgcattc	aaccttacc	4740

SEQUENCE LISTING 1657-2022.txt

```
aaaaaaaaa aaaaaaaaaa agaataaata aataagtttt taaaaaagga agcttggtcc 4800
acttgcttga agacccatgc gggggtaagt ccctttctgc ccgttggtt atgaaacccc 4860
aatgctgccc ttctgctcc ttctccaca cccctctgg cctccctcc actccttccc 4920
aaatctgtct cccagaaga cacaggaaac aatgtattgt ctgcccagca atcaaaggca 4980
atgctcaaac acccaagtgg ccccccacct cagcccgtc ctgcccgcc agcaccccca 5040
ggccctgggg acctgggggt ctcagactgc caaagaagcc ttgccatctg gcgctcccat 5100
ggctcttga acatctcccc ttctgttttg aggggggtcat gccgggggag ccaccagccc 5160
ctcactgggt tcggaggaga gtcaggaaag gccacgacaa agcagaaaca tcggatttgg 5220
ggaacgcgtg tcatcccttg tgccgcaggc tgggcgggag agactgttct gttctgttcc 5280
ttgtgtaact gtgttgctga aagactacct cgttcttgtc ttgatgtgtc accggggcaa 5340
ctgcctgggg gcgggggatgg gggcaggggtg gaagcggctc cccattttta taccaaaggt 5400
gctacatcta tgtgatgggt ggggtgggga gggactact ggtgctatag aaattgagat 5460
gccccccag gccagcaaat gttccttttt gttcaaatgc tatttttatt cttgatatt 5520
ttttctttct tttttttttt ttttgtggat ggggacttgt gaatttttct aaaggtgcta 5580
tttaacatgg gaggagagcg tgtgcgtccc agcccagccc gctgctcact ttccaccctc 5640
tctccacctg cctctggctt ctcaggcctc tctctccga cctctctcct ctgaaaccct 5700
cctccacagc tgcagcccat cctccggctt gcctctagt ctgtcctgct tctctgttcc 5760
ccgggtttca gagacaactt cccaaagcac aaagcagttt ttccctaggg gtggggaggaa 5820
gcaaaagact ctgtacctat tttgtatgtg tataataatt tgagatgttt ttaattattt 5880
tgattgctgg aataaagcat gtggaatga cccaaacata a 5921
```

<210> 33

<211> 1204

<212> DNA

<213> Homo sapiens

<400> 33

```
cggaacgagg gcaacctgca cagccatgcc cgggcaagaa ctcaggacgg tgaatggctc 60
tcagatgctc ctgggtgtgc tgggtgcttc gtggctgccc catgggggcg ccctgtctct 120
ggccgaggcg agccgcgcaa gtttcccggg accctcagag ttgactccg aagactccag 180
attccgagag ttgcggaaac gctacgagga cctgctaacc aggcgtcggg ccaaccagag 240
ctgggaagat tcgaacaccg acctcgtccc gggccctgca gtccggatag tcacgccaga 300
agtgcggctg ggaatccggc gccacctgca cctgcgtatc tctcggggcg cccttcccga 360
ggggctcccc gaggcctccc gccttcaccg ggctctgttc cggctgtccc cgacggcgctc 420
aaggctcgtg gacgtgacac gaccgctgcg gcgtcagctc agccttgcaa gaccccaagc 480
gccgcgctg cacctgcgac tgtcggcgcc gccgtcgag tcggaccaac tgetggcaga 540
atcttctgct gccagggccc agctggagtt gaccttgcgg ccgcaagccg ccagggggcg 600
ccgagagcg cgtgcgcgca acggggacga ctgtccgctc gggcccgggc gttgtgctcg 660
tctgcacacg gtccgcgcgt cgctggaaga cctgggctgg gccgattggg tgtgtctgcc 720
acgggaggtg caagtgaaca tgtgcatcgg cgcgtgcccg agccagttcc gggcggcaaa 780
catgcacgcg cagacctgca cgactgaag cccgacacgg agccagcgcc 840
ctgctgcgtg cccgccagct acaatcccat ggtgtctcatt caaaagaccg acaccgggg 900
gtcgtccag acctatgatg acttgtagc caaagactgc cactgcatac gagcagtcct 960
ggctcttcca ctgtgcacct gcgcggggga ggcgacctca gttgtcctgc cctgtggaat 1020
gggctcaagg ttctgagac acccgattcc tgcccacaac gctgtattta tataagctctg 1080
ttatttatta ttaattttat ggggtgacct tcttggggac tcgggggctg gtctgatgag 1140
actgtgtatt tatttaaaac tctggtgata aaaataaagc tgtctgaact gttaaaaaaa 1200
aaaa 1204
```

<210> 34

<211> 5221

<212> DNA

<213> Homo sapiens

<400> 34

```
ataaaagggg gctgaggaaa taccggacac ggtcacccgt tgccagctct agcctttaa 60
ttcccggctc ggggacctcc acgcaccgcg gctagcgccg acaaccagct agcgtgcaag 120
gcgccgcggc tcagcgcgta ccggcgggct tcgaaaccgc agtcctccgg cgaccccgaa 180
ctccgctccg gagcctcagc cccctggaaa gtgatcccgg catccgagag ccaagatgcc 240
ggccccattg ctgcaggacg atatctctag ctcctatacc accaccacca ccattacagc 300
gcctcccttc agggctctgc agaattggag agataagttg gagacgatgc ccctctactt 360
ggaagacgac atttcgccctg atataaaaga tgatatatat gaccccacct acaaggataa 420
ggaaggccca agcccaagg ttgaatatgt ctggagaaac atcatcctta tgtctctgct 480
acacttggga gccctgtatg ggatcacttt gattcctacc tgcaagttct acacctggct 540
ttgggggggt ttctactatt ttgtcagtc cctgggcata acagcaggag ctcatcgtct 600
gtggagccac cgctcttaca aagctcggct gccctacgg ctctttctga tcattgccaa 660
cacaatggca ttccagaatg atgtctatga atgggctcgt gaccaccgtg cccaccacaa 720
```

SEQUENCE LISTING 1657-2022.txt

gttttcagaa	acacatgctg	atcctcataa	ttccccgacgt	ggcttttttct	tctctcacgt	780
gggttggtg	cttgtgcgca	aacacccagc	tgtcaaaagag	aaggggagta	cgctagactt	840
gtctgacctg	gaagctgaga	aactgggtgat	gttccagagg	aggtactaca	aacctggctt	900
gctgctgatg	tgcttcatcc	tgcccacgct	tgtgccctgg	tatttctggg	gtgaaacttt	960
tcaaaacagt	gtgttcgttg	ccacttttct	gcgatatgct	gtggtgctta	atgccacctg	1020
gctggtgaac	agtgtgcgcc	acctcttcgg	atatcgctct	tatgacaaga	acatttagccc	1080
ccgggagaat	atcctggttt	cacttgaggc	tgtgggtgag	ggcttccaca	actaccacca	1140
ctcctttccc	tatgactact	ctgccagtga	gtaccgctgg	cacatcaact	tcaccacatt	1200
cttcattgat	tgcatggccg	ccctcggtct	ggcctatgac	cggaagaaag	tctccaaggc	1260
cgccattctg	gccaggatta	aaagaaccgg	agatggaaac	tacaagagtg	gctgagtttg	1320
gggtccctca	ggtttccctt	ttcaaaaacc	agccaggcag	aggttttaat	gtctgtttat	1380
taactactga	ataatgctac	caggatgcta	aagatgatga	tgtaaaccca	ttccagtaca	1440
gtattctttt	aaaattcaaa	agtattgaaa	gccaacaact	ctgcctttat	gatgctaagc	1500
tgatattatt	tctctcttta	tctctctctt	cttctaggcc	cattgtcctc	cttttcactt	1560
tattgctatc	gccctccctt	cccttattgc	ctcccaggca	agcagctggg	cagtctttgc	1620
tcagtgtcca	gcttccaaag	cctagacaac	ctttctgtag	cctaaaacga	atgggtctttg	1680
ctccagataa	ctctctttcc	ttgagctggt	gtgagctttg	aagtaggtgg	cttgagctag	1740
agataaaaca	gaatctcttg	ggtagtcccc	gttgatttat	cttcagcccc	ggcttttgct	1800
agatggaatg	gaaaagcaac	ttcatttgac	acaaagcttc	taaagcagg	aaattgtcgg	1860
gggagagagt	tagcatgtat	gaatgtaagg	atgaggggaag	cgaagcaaga	ggaacctctc	1920
gccatgatca	gacatacagc	tgccctaccta	atgaggactt	caagccccac	cacatagcat	1980
gcttcttttc	tctctgggct	cggggtaaaa	atgggtctcg	gtgtttggca	atgctaattc	2040
aatgccgcaa	catatagtgt	aggccgagga	ttaaagaaaag	acattttaag	ttttagtagta	2100
aagtgggtctc	tgctggggaa	gggttttctt	ttcttttttt	ctttaataac	aaggagattt	2160
cttagttcat	atatcaagaa	gtcttgaagt	tgggtgtttc	cagaattggt	aaaaacagca	2220
gctcatggaa	ttttgagtat	tccatgagct	gctcattaca	gttctttcct	ctttctgctc	2280
tgccatcttc	aggatattgg	ttcttcccc	catagtaata	agatggctgt	ggcattttcca	2340
aacatccaaa	aaaagggaag	gatttaaggga	gggtgaagtcg	gggtcaaaaat	aaaatatata	2400
tacatatata	cattgcttag	aacgttaaac	tattagagta	tttcccttcc	aaagagggat	2460
gtttggaata	aactctgaag	gagaggagga	attagttggg	atgccaattt	cctctccact	2520
gctggacatg	agatggagag	gctgagggac	aggatctata	ggcagcttct	aagagcgaa	2580
ttcacatagg	aagggatctg	agaacacggt	gccaggggct	tgagaagggt	actgagtgag	2640
ttattgggag	tcctaataaa	ataaactaga	tattaggtcc	attcattaat	tagttccagt	2700
ttctctttga	aatgagtaaa	aactagaagg	cttctctcca	cagtgtttgt	ccccttcat	2760
catttttttt	tgaggagaag	gggtctctct	ttaacatcta	gcctaaagta	tacaactgcc	2820
tggggggcag	ggttaggaat	ctcttccacta	ccctgattct	tgattcctgg	ctctaccctg	2880
tctgtccctt	ttctttgacc	agatctttct	cttccctgaa	cgttttcttc	tttccctgga	2940
caggcagcet	ttctttgtgt	tattcagagg	ttgtgtgac	ttgtgttcca	ggcagctccc	3000
tcctgcacac	agaatgctca	gggtcactga	accactgctt	ctcttttgaa	agtagagcta	3060
gctgccactt	tcacgtggcc	tccgcagtgt	ctccacctac	acccctgtgc	tcccctgcca	3120
cactgatggc	tcaagacaag	gctggcaaac	ctcccagaa	acatctctgg	cccagaaagc	3180
ctctctcttc	ctccctctct	catgaggcac	agccctcatg	agcgctcatg	ttgagccagt	3240
gggccagcca	cagagcaaaa	gagggtttat	tttcagtccc	ctctctctgg	gtcagaacca	3300
gagggcatgc	tgaatgcccc	ctgcttactt	gggtgagggtg	ccccgcctga	gtcagtgtct	3360
tcagctggca	gtgcaatgct	tgtagaagta	ggaggaaaca	gttctcactg	ggaagaagca	3420
agggcaagaa	cccaagtgcc	tcacctcgaa	aggaggccct	gttccctgga	gtcagggtga	3480
actgcaaagc	tttggtctgag	acctgggatt	tgagatacca	caaaccctgc	tgaacacagt	3540
gtctgttcag	caaactaacc	agcattccct	acagcctagg	gcagacaata	gtatagaagt	3600
ctggaaaaaa	acaaaaacag	aatttgagaa	ccttggaaca	ctcctgtccc	tgtagctcag	3660
tcatacaagc	agaagtcttg	ctttgtctta	ttaagattgg	aaatgtacac	taccaaacc	3720
tcagtccact	gttgagcccc	agtgtcggaa	gggaggaagg	cctttcttct	gtgttaattg	3780
cgtagaggct	acaggggtta	gcctggacta	aaggcatcct	tgtcttttga	gctattcacc	3840
tcagtagaaa	aggatctaag	ggaagatcac	tgtagttag	ttctgttgac	ctgtgcacct	3900
accccttggg	aatgtctgct	ggatatttcta	attccacagg	tcatcagatg	cctgcttgat	3960
aatatataaa	caataaaaa	aactttcact	tcttcttatt	gtaatcgtgt	gccatggatc	4020
tgatctgtac	catgacccta	cataaggctg	gatggcacct	caggctgagg	gccccaatgt	4080
atgtgtggct	gtgggtgtgg	gtgggagtgt	gtctgtctgag	taaggaaacac	gattttcaag	4140
attctaagc	tcaaatcaag	tgacaacatta	atgataaact	cagatctgat	caagagctcg	4200
gatttctaac	agtccctgct	ttgggggggtg	tgtgacaac	ttagctcagg	tgccctacat	4260
cttttcta	cacagtgttg	catatgagcc	tgccctcact	ccctctgcag	aatccctttg	4320
cacctgagac	cctactgaag	tggctggtag	aaaaaggggc	ctgagtggag	gattatcagt	4380
atcacgattt	gcaggatttc	cttctgggct	tctattcgga	aacttttgtt	agggctgctt	4440
ttcttaagt	cccacatttg	atggagggtg	gaaataattt	gaatgtattt	gatttataag	4500
ttttttttt	tttttgggtt	aaaagatggt	tgtatctctt	aaaatggaaa	attttctcct	4560
tggtttgcta	gtatcttggg	tgtattctct	gtaagtgtag	ctcaaataag	tcatactgaa	4620
aggttaaaaa	agcgaggtgg	ccatgtttatg	ctgtgtggtta	agggcagggc	ctctccaact	4680
actgtgccac	tgacttgctg	tgtgacctg	ggcaagtcac	ttaactataa	gggtgcctcag	4740

SEQUENCE LISTING 1657-2022.txt

ttttccttct gttaaaatgg ggataataat actgacctac ctcaaagggc agttttgagg 4800
catgactaat gcttttttaga aagcattttg ggatccttca gcacagggaat tctcaagacc 4860
tgagtatttt ttataatagg aatgtccacc atgaacttga tacgtccgtg tgtcccagat 4920
gctgtcatta gtctatatgg ttctccaaga aactgaatga atccattgga gaagcgggtg 4980
ataactagcc agacaaaatt tgagaataca taaacaacgc attgccacgg aaacatacag 5040
aggatgcctt ttctgtgatt ggggtgggatt ttttcccttt ttatgtggga tatagtagtt 5100
acttgtgaca aaaataattt tggataaatt tctattaata tcaactctga agctaattgt 5160
actaatctga gattgtgttt gttcataata aaagtgaagt gaattctaaaa aaaaaaaaaa 5220
a 5221

<210> 35
<211> 799
<212> DNA
<213> Homo sapiens

<400> 35
cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat 60
gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgctac tccacctctg 120
cggcgaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct 180
tcatcctaaa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa 240
tgctatcatt ttccacacaa agaaaaagtt gtctgtgtgc gcaaattcaa aacagacttg 300
ggtgaaatat attgtgcgtc tcctcagtaa aacagaaaga acctgtctgg ggttggagggt 420
tttctggaat ggaattggac atagcccaag aacagaaaga acctgtctgg ggttggagggt 480
ttcacttgca catcatggag ggttttagtg ttatctaatt tgtgcctcac tggacttgct 540
caattaatga agttgattca tattgcatga tagtttgctt tgtttaagca tcacattaaa 600
gttaaaactgt attttatgtt atttatagct gtaggttttc tgtgttttagc tatttaatac 660
taattttcca taagctattt tggtttagtg caaagtataa aatttatattt gggggggaat 720
aagattatat ggacttttct gcaagcaaca agctattttt taaaaaaact atttaacatt 780
ctttgtttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa 799
cattaataag acaaatatt

<210> 36
<211> 2993
<212> DNA
<213> Homo sapiens

<400> 36
cgctggggcg ctttccgagg aaattcgagg ctcgagtttc ccgggggaaga ggcgcggcct 60
gagcccggcg aggggtggga gggcaggcgc aggtggaccc cggcgcccc ctagccccgc 120
tgtgaccttg gccgcggggg aggggtctgg ccgctgcggg gcagtcgcgg ccgcccagag 180
gggcagcgga gaagaacttg cccaacttgg cggcgcgggc tggggcggtt ctgcccctcc 240
gcgcccgcct ccccggcctc gccttcttcc cctcccgcga ctcccgcgag 300
cctcctcccc tgggccccct tcccgtcttc cccgcccggg ccggtcccgg tgcgcgcccc 360
tccctgcccc cagccccgcg cgcggccga gtcgtgagc cgcggtgcc ggacgggacg 420
ggaccggcta ggctgggccc gccccccggg ccccgcctgt ggcattggcg cactggcccc 480
ggcgtgctgt ctgctcttgc tggcccagtg gctcctgcg gccgccccgg agctggcccc 540
cgcgcccctt acgctgcccc tccgggtggc cgcggccacg aaccgcgtag ttgcgcccac 600
cccgggaccc gggaccccct cccgagcgca cgcgacggc ttggcgctcg ccctggagcc 660
tgcccggcg tcccccgcg gcgcccga acctgagat gctgatcggg accccccgc agaagctaca 720
ggactctggc cgcggtact acctggagat gctgatcggg ggaacccccg actcctacat 780
gattctcggt gacactggaa gcagtaactt tgccgtggca ggaacccccg actcctacat 840
agacacgtac tttgacacag agaggtctag cacataccgc tccaagggtt ttgacgtcac 900
agtgaagtac acacaaggaa gctggacggg cttcgttggg gaagacctcg tcaccatccc 960
caaaggcttc aatacttctt ttcttgtcaa cattgccact atttttgaat cagagaattt 1020
ctttttgcct gggattaaat ggaatggaat acttggccta gcttatgcca cacttgccaa 1080
gccatcaagt tctctggaga cttcttctga ctccctgggt acacaagcaa acatcccaa 1140
cgttttctcc atgcagatgt gtggagccgg cttgcccgtt gctggatctg ggaccaacgg 1200
aggtagtctt gtcttgggtg gaattgaaac aagtttgtat aaaggagaca tctgggtatac 1260
ccctattaag gaagagtggg actaccagat agaaattctg aaattggaaa ttggaggcca 1320
aagccttaat ctggactgca gagagtataa cgcagacaag gccatcgtgg acagtggcac 1380
cacgtgctg cgctgcccc ctgagtgtt tcatggttt tccagctgg cgtgctggac 1440
atctctgatt ccagaattct ctgattgttt cttacttccc taaaatctcc atctacctga gagacgagaa 1500
gaattcggaa acaccttggg tcaaatcctt gttaccgatt cggcatttcc ccatccacaa atgcgctgg 1560
ctccagcagg aattatgaat agggcttcta cgtcatctt gacagagccc agaagaggg 1620
ggccggcctg gatcggtgcc ggcagagccc gcagtgctg aaatttccgg 1680
gggcttcgca ggcagcccc gtcagagaaat tgcaggtgct

SEQUENCE LISTING 1657-2022.txt

```

gccttttctca acagaggatg tagccagcaa ctgtgtcccc gctcagtctt tgagcgagcc 1860
catttttgtgg atttgtgtcct atgcgtctcat gagcgtctgt ggagccatcc tccttgtctt 1920
aatcgtcctg ctgctgtctgc cgttccggtg tcagcgtcgc ccccgtagacc ctgaggtcgt 1980
caatgatgag tccttctctgg tcagacatcg ctggaaatga atagccaggc ctgacctcaa 2040
gcaacctatga actcagctat taagaaaatc acatttccag ggagcagacc gggatcgatg 2100
gtggcgcttt ctctgtgtcc caccgtctt caatctctgt tctgtctcca gatgccttct 2160
agattcactg tcttttgatt cttgattttc aagctttcaa atcctcccta cttccaagaa 2220
aaataattaa aaaaaaaact tcatttctaaa ccaaaacaga gtggattggg ctgcaggctc 2280
tatgggggttc gttatgcca agtgtctaca tgtgccacca acataaaaca aaaccaagcc 2340
ttggctcggtt ctcttctctc ttcaatctct ggaaaaataa gtacatatag ttgataacc 2400
ctcttagctt acaggaagct ttttgtatta attgcctttg aggttatttt ccgccagacc 2460
tcaacctggg tcaaagtgg acaggaaggc ttgcagtatg atggcaggag aatcagcctg 2520
gggcctgggg atgtaaccaa gctgtacctt tgagacctgg aaccagagcc acaggcccc 2580
tttgtgggtt ctctgtgtct ctgaatggga ctgagaattc actaggagg catcaaccg 2640
tggctctcac aagcctcttc tgaagatgga aggccttttg cccgttgagg tagaggggaa 2700
ggaaatctcc tcttttgtac ccaatactta tgttgtattg ttggtgcgaa agtaaaaca 2760
ctacctctt tgagactttg cccagggtcc tgtgcttgg tgggggtgca ggcagcctt 2820
accacggctg tccccctcac ccaaaagaat tatcatcca acagccaaga ccaacagg 2880
gctgaactgt gcatcaacca ggaagagttc tatcccaag ctggccacta tcacatatgc 2940
ttactcttgc ttaaaattaa taaatcatgt tttgatgaga aaaaactatt cta 2993

```

<210> 37
 <211> 1381
 <212> DNA
 <213> Homo sapiens

```

<400> 37
atgcgcgatc tcccggagca tgcgcagcag cggcgccgac gcggggcggt gcctgggtgac 60
cgcgcgcgct cccggaagtg tgccggcgct gcgcgaaggt tcagcagggg gccgtgggac 120
gggcgcgcgg tcccggcac gtgtctcgcc acgtggcagc gcgcctggcc ctgggcttgg 180
aggcgccggc gccctggatc cgccggccgt ggtcgccgag tcggtgtcgt ccttgaccat 240
cgccgacgcy ttcattgcag ccggcgagag ctgagctccg accccgcgcg gccccgcgct 300
tcccaggagg ttcattgtgt agcacacggg ggagagacca tttgtttgtg actatgaagg 420
gcttgacgcy cacctgtgca agcacacggg tctgagccgc cacattctga ctcacacagg 480
gtgtggcaag gccttcatca gggactacca tctgagccgc cacattctga ctcacacagg 480
agaaaagccg tttgtttgtg cagccaatgg ctgtgatcaa aaattcaaca caaaatcaaa 540
cttgaagaaa cattttgaac gcaaactatg aaatcaacaa aaacaatata tatgcagttt 600
tgaagactgt aagaagacct ttaagaaaca tcagcagctg aaaatccatc agtgccagaa 660
taccaatgaa cctctattca agtgactcca ggaaggatgt gggaaacact ttgcatcacc 720
cagcaagctg aaacgacatg ccaaggccca cgagggttat gtatgtcaaa aaggatgttc 780
ctttgtggga aaaacttctt cggaacttct gaaactgtg agagaaaccc ataaagagga 840
aatactatgt gaagtatgcc ggaacacttt taacgcgaaa gattacctta agcaacacat 900
gaaaactcat gccccagaaa gggatgtatg tcgctgtcca agagaaggct gtggaagaac 960
ctatacaact gtgtttaatc tccaaagcca tatcctctcc ttccatgagg aaagccgccc 1020
ttttgtgtgt gaacatgtg gctgtggcaa aacatttgca atgaaacaaa gtctcactag 1080
gcatgctgtt gtacatgatc ctgacaagaa gaaaatgaag ctcaaagtca aaaaatctcg 1140
tgaaaaacgg gagtttgcc tctcatctca gtggatatat cctcccaaaa ggaaacaagg 1200
gcaaggctta tctttgtgtc aaaacggaga gtcacccaac tgtgtggaag acaagatgct 1260
ctcgacagtt gcagtactta cccttggcta agaactgcac tgctttgttt aaaggactgc 1320
agaccaagga gtcgagcttt ctctcagagc atgcttttct ttattaaaat tactgatgca 1380
g 1381

```

<210> 38
 <211> 4720
 <212> DNA
 <213> Homo sapiens

```

<400> 38
gcgagacctt gcaggccccg ggctgggctt gccctcgcct gccacgctgc gcgctgccct 60
cagccgggct gctggggccg tgcaagtgc cgggcacgcc gcgccaggct gggggcagcc 120
accgagcctc cgtgggaggt cccgagggag cttcgccctg tcgcccgtgc tccagccctc 180
acctgccgca gccttagctg agcagccgcc gccactgggc gccccccgct cccacttcg 240
ccagcggccg ctctcggct cggcccgggg tagttttag ggacgcagct ctccacgtgc 300
cgactgcga ggctggacgc tacgggctcc tggaaaggag acaccagcat ttgccacaat 360
gctgtcatcc actgacttta catttgcttc ctggagctt gtggtccgct ttgaccatcc 420
caatgaagag cagcagaaag acgtcacact gagagtatct ggagaccttc atgttgagg 480
agtgatgctc aagttagtag aacagatcaa tatatcccaa gactggtcag actttgctct 540

```

SEQUENCE LISTING 1657-2022.txt

ttggtgggaa	cagaagcatt	gctggcttct	gaaaacccac	tggaaccctgg	acaaatatgg	600
ggtccaggca	gatgcaaac	ttctcttcac	ccctcagcat	aaaatgctgc	gccttcgtct	660
gccgaatttg	aagatggtga	ggttgcgagt	cagcttctca	gctgtgggtt	ttaaagctgt	720
cagtgatatc	tgcaaaatcc	tgaatattag	aagatcagaa	gagctttcct	tgtaaagcc	780
gtctggtgac	tattttaaga	agaagaagaa	aaaagacaaa	aataataagg	aacccataat	840
tgaagatatt	ctaaacctgg	agagtctctc	aacagcttca	ggttcacag	taagtcctgg	900
tttatacagt	aaaaccatga	cccctatata	tgaccccatc	aatggaacac	cagcatcatc	960
caccatgact	tggttcagtg	acagcccttt	gacggaacaa	aactgcagca	tcctcgcatt	1020
cagccaaccc	ccccagttcc	cagaagcact	tgcggtatag	taccagcctc	ggtctctggg	1080
tgataaagcc	aagctcaatg	caggttggct	agactcctca	cgctccctta	tggaacaagg	1140
catccaagag	gatgagcagc	tgctcttag	atttaaata	tattctttct	tcgacttgaa	1200
tcctaaatat	gatgctgtcc	gaataaacca	actctatgag	caagccaggt	gggccattct	1260
cttagaagaa	attgattgca	cagaggaaga	aatgttgatc	tttgagctc	tacagtacca	1320
cctagcaaaa	ctgtcgctgt	ctgtgaaac	acaggatttt	gcaggcgagt	ccgaggttga	1380
tgaaatagaa	gcggcgcttt	ctaatttggg	agtaaaccta	gaaggtggaa	aagcggacag	1440
ccttttggag	gacattactg	atatccctaa	acttgcagat	aatctcaaat	tatttaggcc	1500
caagaagtta	ctaccaaaa	ctttcaaa	atattgggtt	atctttaaag	acacatccat	1560
agcatacttt	aaaaataagg	aacttgaaca	aggagaacca	ctagaaaaac	taaactctag	1620
aggctgcgaa	gttgtgcccc	atgtaaatgt	agcaggaaga	aaatttggaa	tcaagttact	1680
aatccctggt	gccgatggta	tgaatgaaat	gtatttgaga	tgtgaccatg	agaatcaata	1740
cgcccaatgg	atggctgcct	gcatgttggc	atcgaagggc	aaaaccatgg	cagacagctc	1800
ctaccagcca	gaggtcctca	actactacct	atttctgagg	atgaaaaaac	ggaactctgc	1860
atctcaggtg	gcttccagtc	tcgaaaacat	ggatatgaac	ccagaatggt	ttgtgtcacc	1920
acggtgtgca	aagaaacaca	aatccaaaca	gctggccgcc	cggtatcctg	aggcgacca	1980
gaacgtggcc	cagatgcccc	tggtcgaagc	caagctgcgg	ttcatccagg	cgtggcagtc	2040
actgcctgag	tttggcctca	ctactacct	tgtcagattt	aaaggaagca	aaaaagatga	2100
cattctggga	gtttcatata	acaggttgat	taaaattgat	gcagccaccg	ggattccagt	2160
gacaacatgg	agattcacaa	atatcaaaca	gtggaatgta	aactgggaaa	cccggcaggt	2220
ggtcatcgag	tttgaccaa	acgtctttac	tgctttcacc	tgcttgagtg	cagattgcaa	2280
gattgtgcac	gtgtacattg	gcggctacat	tttctgtgcc	acccgctcca	aggaccagaa	2340
tgaaacactc	gatgaggact	tgttccacaa	attgaccggc	ggtcaggatt	gaaacaagca	2400
cgcgtgctcg	gctcacacca	acaaggcaag	ccaaaggcgc	ccctcccag	agggatccct	2460
aacgtgcccc	gcatgtagat	tctggactaa	cagacaacat	acattcaccg	ctggtcaccc	2520
agatcctcat	tcaaaccac	tgctggcaca	tccctttcct	tactttgccc	tgtgtacca	2580
gccacggaag	gagcctctct	tgttttttct	ataaaatggg	taggcaggag	aaaagcaggt	2640
gccctaagat	tgctctaagg	cccagcatgt	ggttacagtt	ctctgacttg	cagaacctgc	2700
cagggtgatg	gctacaagtt	atcctcgtgc	tgatctgtct	cattactaag	tcaatggaga	2760
agacagaaag	gtataaatca	cgtgtagcaa	gaacaactct	tatttcacaa	actcaggtat	2820
gaaacgaaac	gcctgtcctt	catggaactg	cttttagctc	ctgtcttttc	aaaatggcag	2880
agggagttcc	tacacacact	ttttccctgg	aggccaaggt	ctaggggtag	aaaggggagg	2940
ggtggggcta	ccaggtagca	gttgacaacc	caaggtcaga	ggagtggccc	tcagtgtcat	3000
ctgtccacag	tgatagctgc	caagatgacc	actgagccac	atctggctct	agtcattggt	3060
ctcctcagat	ttctggggcc	acctgcaagc	cccattccat	tcctacagat	ctctcagcca	3120
cctgtaagtc	ctttgtgaag	atgtgggtga	cacaggggga	caggaaaacc	catttctcaa	3180
ccagatcca	tgctccact	gcttctactc	tggtttggga	ttcaggaaga	caggcacagt	3240
cctctctgtt	catagaaaca	cctggcagtg	tcaaggattc	cagtcagggt	tctatcccaa	3300
ctggtcaggg	agagaagggc	agacccattc	tcaaagacca	ccatgtccaa	ggtctgacag	3360
ctccccactg	gctgccccca	caggggcttt	aggctgggtc	gggtcatggg	gaagcgtccc	3420
tcttatcgct	ggtctgtggt	ctcctggatt	tggtatctat	ggttggtacga	ctcctggcct	3480
tttatctaaa	ggactttggc	ttttgtaaat	cacaagccaa	taatagactt	ttttctccc	3540
ctctgttttt	tgctgtgtca	tctctgcctt	gagactgcct	tgagacagtg	cttgccctga	3600
gagagtgagc	caattaacag	ctgcctgaat	tgctattttc	cattttgggt	tgtagagggt	3660
gggagggggtg	ggttttgaga	aggtaaaaag	caataccaga	agtaaaggga	aatatcagac	3720
aatattttat	tattttttca	tagatgttct	gccacacaaa	gaacttgggg	tgtaaggata	3780
aggcaaaagc	tccaatccca	tttttcagtt	ctcctaggat	gcacccctca	gggagcctgg	3840
ccagagttcc	gaggctcgtg	agcgtcagct	gttgctttat	tttccatcaa	agccctctga	3900
gaagtggagc	ctcagcaatt	ccgggagcca	catagagaca	gacttggcaa	gggacccctt	3960
ggttctgagc	cagtagctgc	catctggaaa	ttcctctttt	agcctctcct	tagaggtgaa	4020
tgtgaatgaa	gcctcccagg	caccgctga	atttctgagg	ccttgcttaa	agctcagaag	4080
tggttttaggc	atttggaaaa	tctggttcac	atcataaaga	acttgatttg	aaatgttttc	4140
tatagaaaca	agtgtcaagt	gtaccgtatt	atacttgatg	ttggtcattt	ctcagtccta	4200
tttctcagtt	ctattatttt	agaacctagt	cagttcttta	agattataac	tggtcctaca	4260
ttaaaataat	gcttctcgat	gtcagatttt	acctgtttgc	tgctgagaac	atctctgcct	4320
aattttacca	agccagacct	tcagttcaac	atgtttcctt	agcttttcat	agttgtctga	4380
catttccatg	aaaacaaagg	aaccaacttt	gttttaacca	aactttgttt	ggttacagtt	4440
ttcaggggag	cgtttctttc	atgacacaca	gcaacatccc	aaagaaataa	acaagtgtga	4500
caaaaaaaaa	aaaaaacaaa	cctaaatgct	actgtttcaa	agagcaactt	gatgggtttt	4560

SEQUENCE LISTING 1657-2022.txt

```

tttaatactg agtgcaaaag gtcacccaaa ttcctatgat gaaattttta attaatgggc 4620
acctttcaac atcatttgct tccttatcta cagttgattc agaaatctgc attttttatt 4680
cttttatatg acttttaagt aaaagattta tatggatttg 4720

```

```

<210> 39
<211> 3213
<212> DNA
<213> Homo sapiens

```

```

<400> 39
agagactcaa gatgattccc tttttaccca tgttttctct actattgctg cttattgtta 60
accctataaa cgccaacaat cattatgaca agatcttggc tcatagtcgt atcagggggtc 120
gggaccaagg cccaaatgtc tgtgcccttc aacagatttt gggcaccaaa aagaaatact 180
tcagcacttg taagaactgg tataaaaagt ccatctgtgg acagaaaacg actgttttat 240
atgaatgttg ccctggttat atgagaatgg aaggaaatgaa aggcgtgcca gcagttttgc 300
ccattgacca tgtttatggc actctgggca tcgtgggagc caccacaacg cagcgctatt 360
ctgacgcctc aaaactgagg gaggagatcg agggaaaagg atccttcact tactttgcac 420
cgagtaatga ggcttgggac aacttggatt ctgatatccg tagaggtttg gagagcaacg 480
tgaatgttga attactgaat gctttacata gtcacatgat taataagaga atgttgacca 540
aggacttaaa aaatggcatg attattcctt caatgtataa caatttgggg cttttcatta 600
accattatcc taatggggtt gatcctgta attgtgctcg aatcatccat gggaaccaga 660
ttgcaacaaa tgggtgtgtc catgtcattg accgtgtgct tacacaaaatt ggtacctcaa 720
ttcaagactt cattgaagca gaagatgacc ttctatcttt tagagcagct gccatcacat 780
cggacatatt ggaggccctt ggaagagacg gtcacttcac actctttgct cccaccaatg 840
aggcttttga gaaacttcca cgagggtgcc tagaaaaggt catgggagac aaagtggctt 900
ccgaagctct tatgaagtac cacatcttaa atactctcca gtgttctgag tctattatgg 960
gaggagcagt ctttgagacg ctggaaggaa atacaattga gataggatgt gacggtgaca 1020
gtataacagt aaatggaatc aaaatgggtga acaaaaagga tattgtgaca aataatgggtg 1080
tgatccattt gattgactcag gtcctaattc ctgattctgc caaacaagtt attgagctgg 1140
ctggaaaaca gcaaacacc ttcacggatc ttgtggccca attaggcttg gcatctgctc 1200
tgaggccaga tggagaatac actttgctgg cactgtgtaa taatgcattt tctgatgata 1260
ctctcagcat ggttcagcgc ctcccttaaat taattctgca gaatcacata ttgaaagtaa 1320
aagtggcctt taatgagctt tacaacgggc aaatactgga aaccatcggg ggcaaacagc 1380
tcagagtctt cgtatatcgt acagctgtct tagattgaaa ttcatgcatg gagaaaggga 1440
gtaagcaagg gagaaacggt gagaaacggt tattccgcga gatcatcaag ccagcagaga 1500
aatccctcca tgaaaagtta aaacaagata agcgtcttag caccttctct agcctacttg 1560
aagctgcaga cttgacagag ctctgacac aacctggaga ctggacatta tttgtgccaa 1620
ccaatgatgc ttttaaggga atgactagtg aagaaaaaga aattctgata cgggacaaaa 1680
atgctcttca aaacatcatt ctttatcacc tgacaccagg agttttcatt ggaaaaggat 1740
ttgaacctgg tgttactaac attttaagga ccacacaagg aagcaaaatc tttctgaaag 1800
aagtaaatga tacaatcttg gtgaatgaat tgaaatcaaa agaacttgac atcatgacaa 1860
caaatgggtg aattcatggt gtagataaac tcctctatcc agcagacaca cctgttggaa 1920
atgatcaact gctggaataa cttaataaat taatcaaata catccaaatt aagtttgttc 1980
gtggtagcac cttcaaagaa atccccgtga ctgtctatac aactaaaatt ataaccaag 2040
ttgtggaaac aaaaattaaa gtgattgaag gcagtcctca gcctattatc aaaactgaag 2100
gaccacact aacaaaagtc gtgacttga agtgaaactga attcagactg attaaagaag 2160
gtgaaacaat aactgaagt atccatggag agccaattat taaaaaatac accaaaatca 2220
ttgatggagt gcctgtggaa ataactgaaa aagagacacg agaagaacga atcattacag 2280
gtcctgaaat aaaatacact aggatttcta ctggagggtg agaaacagaa gaaactctga 2340
agaaattgtt acaagaagag gtcaccaagg tcaccaaatt cattgaagggt ggtgatgggt 2400
atttatttga agatgaagaa attaaaagac tgcttcaggg agacacaccc gtgaggaagt 2460
tgcaagccaa caaaaaagtt caaggttcta gaagacgatt aagggaagggt cgttctcagt 2520
gaaaaatcaa aaaccagaaa aaaatgttta tacaacccta agtcaataac ctgaccttag 2580
aaaattgtga gagccaagtt gacttcagga actgaaacat cagcacaag aagcaatcat 2640
caaataattc tgaacacaaa tttaatattt ttttttctga atgagaaaca tgagggaaat 2700
tgtggagtta gcctcctgtg gtaaaggaat tgaagaaaat ataacacctt acaccctttt 2760
tcactctgac attaaaagtt ctggctaact ttggaatcca ttagagaaaa atccttgtca 2820
ccagattcat tacaattcaa atcgaagagt tatcccattg aaaagaccga 2880
gccttgtagg tatgttatgg atacataaaa tgcacgcaag ccattatctc tccatgggaa 2940
gctaagttat aaaaataggt gcttgggtga caaaactttt tatatcaaaa ggctttgcac 3000
atttctatat gagtgggttt actggtaaat tatgttattt tttacaacta attttgtact 3060
ctcagaatgt ttgtcatatg cttcttgcaa tgcataattt ttaattctca acgtttcaat 3120
aaaaccattt ttcagatata aagagaatta cttcaaattg agtaattcag aaaaactcaa 3180
gatttaagtt aaaaagtggt ttggacttgg gaa 3213

```

```

<210> 40
<211> 2133

```

SEQUENCE LISTING 1657-2022.txt

<212> DNA

<213> Homo sapiens

<400> 40

```

cgggagagcg cgctctgcct gccgcctgcc tgccctgccac tgagggttcc cagcaccatg 60
agggcctgga tcttctttct cctttgcctg gccgggaggg ccttggcagc ccctcagcaa 120
gaagccctgc ctgatgagac agaggtgggt gaagaaactg tggcagaggt gactgaggta 180
tctgtgggag ctaatcctgt ccaggtggaa gtaggagaat ttgatgatgg tgcagaggaa 240
accgaagagg aggtgggtggc ggaaaaatccc tgccagaacc accactgcaa acacggcaag 300
gtgtgctgagc tggatgagaa caacaccccc atgtgctgtg gccaggaccc caccagctgc 360
ccagccccc a ttggcgagtt tgagaagggtg tgcagcaatg acaacaagac cttcgactct 420
tcctgccaat tctttgccac aaagtgcacc ctggagggca ccaagaaggg ccacaagctc 480
cacctggact acatcgggccc ttgcaaatac atccccctt gcctggactc tgagctgacc 540
gaattcccc tgcgcatgag ggactggctc aagaacgtcc tggtcaccct gtatgagagg 600
gatgaggaga acaacctttt gactgagaag cagaagctgc ggggtgaagaa gatccatgag 660
aatgagaagc gcctggagac aggagaccac cccgtggagc tgctggcccg ggacttcgag 720
aagaactata acatgtacat cttccctgta cctgtgcagt tcggccagct ggaccagcac 780
cccattgacg ggtacctctc ccacaccgag ctggctccac tgctgtctcc cctcatcccc 840
atggagcatt gcaccacccg ctttttcgag acctgtgacc tggacaatga caagtacatc 900
gccctggatg agtgggcccg ctgcttcggc atcaagcaga aggatatcga caaggatctt 960
gtgatctaaa tccactcctt ccacagtacc ggattctctc tttaaccttc ccttcgtgt 1020
ttcccccaat gtttaaaatg tttggatggg ttgttgttct gcctggagac aagggtgtaa 1080
catagattta agtgaatata ttaacgggtgc taaaaatgaa aattctaacc caagacatga 1140
cattcttagc tgtaacttaa ctattaaggc cttttccaca cgcattaata gtcccatttt 1200
tctcttgcca tttgtagctt tgcccattgt cttattggca catgggtgga cacggatctg 1260
ctgggctctg ccttaaacac acattgcagc ttcaactttt ctctttagtg ttctgtttga 1320
aactaatact taccgagtc a gactttgtgt tcatcttatt tcagggtctt ggctgcctgt 1380
gggcttcccc aggtggcctg gaggtgggca aagggaagta acagacacac gatgttgtca 1440
aggtatgggt tgggagtaga ggctcagtgg tgggagagat ccctgcagaa tccaccaaac 1500
agaacgtggg ttgcttgagg ctgtaactga gagaagatt ctggggctgt cttatgaaac 1560
tatagacatt ctcacataag cccagttcat caccatttcc tcctttacct ttcatgtcag 1620
tttcttttca cattaggtc ttggttcaaa cttttgggag cacggactgt cagtctctctg 1680
ggaagtgggt agcgactcct gcagggtctt tcctctctg tcttttgag aaccagggt 1740
cttctcaggg gctctaggg a ctgccaggct gtttcagcca ggaaggccaa aatcaagagt 1800
gagatgtaga aagttgtaaa atagaaaaag tggagtggg gaatcggtt ttctttctc 1860
acatttgatg gattgtcata aggtttttag catgttctc cttttcttca cctccccctt 1920
tgttcttcta ttaattcaaga gaaacttcaa agttaatggg atggctcgat ctacacaggc 1980
gagaactcgt tcacctcaa gcatttcatg aaaaagctgc ttcttattaa tcatacaaac 2040
tctcaccatg atgtgaagag tttcacaaat ctttcaaaat aaaaagtaat gacttagaaa 2100
ctgaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 2133

```

<210> 41

<211> 2691

<212> DNA

<213> Homo sapiens

<400> 41

```

gcttgcccgt cggtcgctag ctcgctcggt gcgctcgctc ccgctccatg gcgctcttcg 60
tgcggtgctt ggctctcgcc ctggctctgg ccctgggccc cgccgcgacc ctggcggggtc 120
ccgccaagtc gccctaccag ctggtgctgc agcacagcag gctccggggc cgccagcacg 180
gcccaacgt gtgtgctgtg cagaagggtt ttggcactaa taggaagtac ttaccaact 240
gcaagcagtg gtaccaaagg aaaatctgtg gcaaatcaac agtcatcagc tacgagtgtc 300
gtcctggata tgaaaagggt cctggggaga agggctgtcc agcagcccta ccactctcaa 360
acctttacga gaccctggga gtcgttggat ccaccaccac tcagctgtac acggaccgca 420
cggagaagct gaggcctgag atggaggggc ccggcagctt caccatcttc gcccctagca 480
acgaggcctg ggcctccttg ccagctgaag tgctggactc cctggtcagc aatgtcaaca 540
ttgagctgct caatgccctc cgctaccata tgggtggcag gcgagtcctg actgatgagc 600
tgaaacacgg catgaccctc acctctatgt accagaattc caacatccag atccaccat 660
atcctaattg gattgtaact gtgaactgtg cccggctcct gaaagccgac caccatgcaa 720
ccaacggggg ggtgcacctc atcgataagg tcatctccac catcaccaac aacatccagc 780
agatcattga gatcgaggac acctttgaga cctctcgggc tgctgtggct gcacagggc 840
tcaacacgat gcttgaagg aacggccagt acacgtttt ggccccgacc aatgaggcct 900
tcgagaagat ccctagttag actttgaacc gtatctctgg cgaccagaa gccctgagag 960
acctgttgaa caaccacatc ttgaagtcag ctatgtgtgc tgaagccatc gttgcggggc 1020
tgctgtaga gaccctggag ggcacgacac tggagggtgg ctgcagcggg gacatgtctc 1080
ctatcaacgg gaaggcgatc atctccaata agacatctc agccaccaac ggggtgatcc 1140
actacattga tgagctactc atcccagact cagccaagac actatttgaa ttggctgcag 1200

```

SEQUENCE LISTING 1657-2022.txt

```

agttctgatgt gtccacagcc attgaccttt tcagacaagc cggcctcggc aatcatctct 1260
ctggaagtga gcggttgacc ctcttggttc ccctgaattc tgtattcaaa gatggaaccc 1320
ctccaattga tgcctatata aggaatttgc ttcggaacca cataattaaa gaccagctgg 1380
cctctaagta tctgtaccat ggacagaccc tggaaactct gggcggaaca aaactgagag 1440
ttttgttta tcgtaatagc ctctgcattg agaacagctg catcgcgcc cagacaaga 1500
gggggaggta cgggaccctg ttacagatgg accgggtgct gaccccccca atggggactg 1560
tcatggatgt cctgaaggga gacaatcgct ttagcatgct ggtagctgcc atccagtctg 1620
caggactgac ggagaccctc aaccgggaag gagtctacac agtctttgct cccacaaatg 1680
aagccttcg agccttgcca ccaagagaac ggagcagact cttgggagat gccaaggaac 1740
ttgccaacat cctgaaatata cacattgggt atgaaatcct ggtagcgga ggcatcgggg 1800
ccctgggtgc gctaaagtct ctccaagggt acaagctgga agtcagcttg aaaaacaatg 1860
tggtgagtgt caacaaggag cctgttgccc agcctgacat catggccaca aatggcgtgg 1920
tccatgactt caccaatgtt ctgcagcctc cagccaacag acctcaggaa agaggggatg 1980
aacttgacga ctctgcgctt gagatcttca aacaagcatt agcgttttcc agggctttcc 2040
agaggctctg gcgactagcc cctgtctatc aaaagtattt agagaggatg aagcattagc 2100
ttgaagcact acaggaggaa tgcaccacgg cagctctccg ccaatttctc tcagatttcc 2160
acagagactg ttgtaatgtt ttcaaaacca agtatcacac tttaatgtac atgggccgca 2220
ccataatgag atgtgagcct tgtgcatgtg ggggaggagg gagagagatg tactttttaa 2280
atcatgttcc ccctaaacat ggctgttaac ccactgcatg cagaaacttg gatgtcactg 2340
cctgacattc acttccagag aggacctatc ccaaatgtgg aattgactgc ctatgccaag 2400
tccctggaaa aggcacttca gtattgtggg gctcataaaa catgaatcaa gcaatccagc 2460
ctcatgggaa gtcctggcac agtttttgta aagcccttgc acagctggag aaatggcacc 2520
attataagct atgagttgaa atgttctgtc aaatgtgtct cacatctaca cgtggcttgg 2580
aggcttttat ggggcccctg ccaggtagaa aagaaatggt atgtagagct tagatttccc 2640
tattgtgaca gagccatggt gtgtttgtaa taataaaacc aaagaaacat a 2691

```

<210> 42
 <211> 8027
 <212> DNA
 <213> Homo sapiens

```

<400> 42
acgcccgcgc cggctgtgct gcacaggggg aggagaggga accccaggcg cgagcgggaa 60
gaggggacct gcagccacaa cttctctggg cctctgcatc ccttctgtcc ctccaccggt 120
ccccttcccc accctctggc ccccaccttc ttggaggcga caacccccgg gaggcattag 180
aagggatatt tcccgcagtt gcgaaggga gcaaaacttg tggcaacttg cctcccgggt 240
cgggcgtctc tcccaccgg tctcaacatg ccttaggggtc cggggcccgg gctgctgtct 300
ctggccgtcc agtgccctggg gacagcgggt cctccacgg gagcctcgaa gagcaagag 360
caggctcagc aaatggttca gccccagtc ccggtggctg tcagtcaaag caagcccgg 420
tgttatgaca atggaaaaca ctatcagata aatcaacagt gggagcggac ctacctaggc 480
aatgcgttgg tttgtacttg ttatggagga agccgagggt ttaactgcga gagtaaacct 540
gaagctgaag agacttgctt tgacaagtac actgggaaca cttaccgagt gggtagacct 600
tatgagcgtc cttaaagactc catgatctgg gactgtacct gcatcggggc tgggcgaggg 660
agaataagct gtacctcgc aaaccgctgc catgaagggg gtcagtccta caagattgg 720
gacacctgga ggagaccaca ctgactgggt tagactgtgt gtgtcttgg 780
aatggaaaag agaatggag ctgcaagccc agactgaga agtgttttga tcatgtgct 840
gggacttcct atgtggctcg agaaacgtgg gagaagccct accaaggctg gatgatggta 900
gattgtactt gcctgggaga aggcagcggg cgcatacatt gcacttctag aatagatgc 960
aacgatcagg acacaaggac atcctataga attggagaca cctggagcaa gaaggataat 1020
cgaggaaacc tgctccagtg catctgcaca ggcaacggcc gaggagagtg gaagtgtgag 1080
aggcacacct ctgtgcagac cacatcgagc ggatctggcc ccttcaccga tgttcgtgca 1140
gctgtttacc aaccgcagcc tcacccccag cctcctccct atggccactg tgtcacagac 1200
agtgggtggt tctactctgt ggggatgcag tggctgaaga cacaaggaaa taagcaaatg 1260
ctttgcagtg gcctgggcaa cggagttagc tgccaagaga cagctgtaac ccagacttac 1320
ggtggcaact caaatggaga gccatgtgtc ttaccattca cctacaatgg caggacgttc 1380
tactcctgca ccacggaagg gcgacaggag ggacatcttt ggtgcagcac aacttcgaat 1440
tatgacagg ccaatgggtc cttgtgccac acagaccaca ctgttttggg tcagactcga 1500
ggaggaaatt ccaatgggtc cttgtgccac ttcccttccc tatacaacaa ccacaattac 1560
actgattgca cttctgaggg cagaagagac aacatgaagt ggtgtgggac cacacagaac 1620
tatgatgccg accagaagtt tgggttctgc cccatggctg cccacgagga aatctgcaca 1680
accaatgaag ggtcatgta ccgcatggga ggtcgtggg ataagcagca tgacatgggt 1740
cacatgatga ggtgcagctg tgttgggaat ggtcgtggg aatggacatg cattgcctac 1800
tcgacgcttc gagatcagtg cattgttgat gacatcactt acaatgtgaa cgacacattc 1860
cacaagcgtc atgaagaggg gcacatgctg aactgtacat gcttcgggtc gggctcgggg 1920
agggtggaag gtgatccggt cgaccaatgc caggattcag agactgggac gttttatcaa 1980
attggagatt catggggaga gtatgtgcat ggtgtcagat accagtgtca ctgctatggc 2040
cgtggcattg gggagtggca ttgccaacct ttacagacct atccaagctc aagtggctct 2100

```

SEQUENCE LISTING 1657-2022.txt

gtcgaagtat	ttatcactga	gactccgagt	cagcccaact	cccaccccat	ccagtgggaat	2160
gcaccacagc	catctcacat	ttccaagtac	atttctcagg	ggagacctaa	aaatttctgta	2220
ggccgttgga	aggaagctac	cataccaggc	cacttaaaact	cctacaccat	caaaggcctg	2280
aagcctgggtg	tggatatacga	gggccagctc	atcagcatcc	agcagtacgg	ccaccaagaa	2340
gtgactcgct	ttgacttcac	caccaccagc	accagcacac	ctgtgaccag	caacaccgtg	2400
acaggagaga	cgactccctt	ttctcctctt	gtggccactt	ctgaatctgt	gaccgaaatc	2460
acagccagta	gctttgtggt	ctcctgggtc	tcagcttccg	acaccgtgtc	gggattcccg	2520
gtggaatatg	agctgagtga	ggagggagat	gagccacagt	acctggatct	tccaagcaca	2580
gccacttctg	tgaacatccc	tgacctgtct	ctggccgaa	aatacattgt	aaatgtctat	2640
cagatatctg	aggatgggga	gcagagtttg	atcctgtcta	cttcacaaac	aacagcgcct	2700
gatgccccct	ctgacccgac	tgtaggacaa	gtagatgaca	cctcaattgt	tgttcgctgg	2760
agcagacccc	aggctcccat	cacagggtac	agaatatgtc	attcgccatc	agtagaagg	2820
agcagcacag	aactcaacct	tcctgaaact	gcaaacctcg	tcaccctcag	tgacttgcaa	2880
cctgggtgtc	agtataacat	cactatctat	gctgtggaag	aaaatcaaga	aagtacacct	2940
gttggtcattc	aacaagaaac	cactggcacc	ccacgctcag	atacagtgcc	ctctcccagg	3000
gacctgcagt	ttgtggaagt	gacagacgtg	aaggctacca	tcagtgtggc	accgcctgag	3060
agtgcagtgga	ccggctaccg	tgtagatgtg	atccccgtca	acctgcctgg	cgagcacggg	3120
cagaggctgc	ccatcagcag	gaacaccttt	gcagaagtca	ccgggctgtc	ccctgggggtc	3180
acctattact	tcaaagtctt	tgtagtgagc	catgggagg	agagcaagcc	tctgactgct	3240
caacagacaa	ccaaactgga	tgctcccat	aacctccagt	ttgtcaatga	aactgattct	3300
actgtcctgg	tgagctggag	tcacactcgg	gcccagataa	caggataaccg	actgaccgtg	3360
ggccttaccc	gaagaggcca	gcccaggcag	tacaatgtgg	gtccctctgt	ctccaagtac	3420
cccctgagga	atctgcagcc	tgcatctgag	tacaccgtat	ccctcgtggc	cataaagggc	3480
aaccaagaga	gccccaaagc	cactggagtc	tttaccacac	tgagcctgg	gagctctatt	3540
ccaccttaca	gacctgaggt	gactgagacc	accatcgta	tcacatggac	gcctgtctca	3600
agaattgggt	ttaagctggg	tgtacgacca	agccaggag	gagaggcacc	acgagaagt	3660
acttcagact	caggaagcat	cgttgtgtcc	ggcttgactc	caggagtaga	atacgtctac	3720
accatccaag	tcctgagaga	tggaacaggaa	agagatgcgc	caattgtaaa	caaagtgggt	3780
acaccattgt	ctccaccaac	aaacttgcat	ctggaggcaa	accctgacac	tggaagtgtc	3840
acagtctcct	gggagaggag	caccacccca	gacattactg	gttatagaat	taccacaacc	3900
cctacaaacg	gccagcaggg	aaattctttg	gaagaagtgg	tccatgctga	tcagagctcc	3960
tgcaactttg	ataacctgag	tcctggcctg	gagtacaatg	tcagtgttta	cactgtcaag	4020
gatgacaagg	aaagtgtccc	tatctctgat	accatcatcc	cagctgttcc	tcctcccat	4080
gacctgcat	tcaccaacat	tggtccagac	accatgcctg	tcacctgggc	tcacacccca	4140
tccattgatt	taaccaactt	cctgggtcgt	tactcacctg	tgaaaaatga	ggaagatgtt	4200
gcagagttgt	caatttctcc	ttcagacaat	gcagtggctt	taacaaatct	cctgcctgg	4260
acagaatatg	tagtgagtgc	ctccagtgtc	tacgaacaac	atgagagcac	acctcttaga	4320
ggaagacaga	aaacaggtct	tgattcccca	actggcattg	acttttctga	tattactgcc	4380
aactctttta	ctgtgcactg	gattgtctct	cgagccacca	tcactggcta	caggatccgc	4440
catcatcccc	agcacttcag	tgggagacct	cgagaagatc	gggtgcccca	ctctcggaat	4500
tccatcaccc	tcaccaacct	cactccaggc	acagagtatg	tggtcagcat	cggtgtctct	4560
aatggcagag	aggaaagtcc	cttattgatt	ggccaacaat	caacagtttc	tgatgttccg	4620
agggacctgg	aagttgttgc	tgcgaccccc	accagcctac	tgatcagctg	ggatgtctct	4680
gctgtcacag	tgagatatta	caggatcact	tacggagaaa	caggaggaaa	tagccctgtc	4740
caggagttca	ctgtgcctgg	gagcaagtct	acagctacca	tcagcggcct	taaacctgga	4800
gttgattata	ccatccctgt	gtatgctgtc	actggccgtg	gagacagccc	cgcaagcagc	4860
aagccaattt	ccattaatta	ccgaacagaa	attgacaaac	catcccagat	gcaagtgacc	4920
gatgttcagg	acaacagcat	tagtgtcaag	tggtgcctt	caagttcccc	tgttactgg	4980
tacagagtaa	ccaccactcc	caaaaatgga	ccaggacca	caaaaactaa	aactgcaggt	5040
ccagatcaaa	cagaaatgac	tattgaaggc	ttgcagccca	cagtggagta	tggtggttag	5100
gtctatgtct	agaatccaag	cggagagagt	cagcctctgg	ttcagactgc	agtaaccaac	5160
attgatcgcc	ctaaaggact	ggcattcact	gatgtggatg	tcgattccat	caaaattgct	5220
tggaagagcc	acagggggca	agtttccagg	tacagggtga	cctactcgag	ccctgaggat	5280
ggaaatccatg	agctattccc	tgacctgat	ggtgaagaag	acactgcaga	gctgcaaggc	5340
ctcagaccgg	gttctgagta	cacagtcagt	gtggttgctt	tgacgatga	tatggagagc	5400
cagcccctga	ttggaaccca	gtccacagct	attctgcac	caactgacct	gaagttcact	5460
caggtcacac	ccaagaacct	gagcgcccag	tggaacacc	ccaatgttca	gctcactgga	5520
tatcgagtgc	gggtgacccc	caaggagaa	ctggagacaa	tgaaagaaat	caacctgtgt	5580
cctgacagct	catccgtgg	tgtatcagga	cttatgggtg	ccaccaaaata	tgaagtga	5640
gtctatgtct	ttaaggacac	tttgacaagc	agaccagctc	aggggtgtgt	caccactctg	5700
gagaatgtca	gcccaccaag	aagggtcgt	gtgacagatg	ctactgagac	caccatcacc	5760
attagctgga	gaaccaagac	tgagacgatc	actggttcc	aagttgatgc	cgttccagcc	5820
aatggccaga	ctccaatcca	gagaaccatc	aagccagatg	tcagaagcta	caccatcaca	5880
ggtttacaac	caggcactga	ctacaagatc	tacctgtaca	ccttgaatga	caatgctcgg	5940
agctccccctg	tggtcatcga	cgctccact	gccattgatg	caccatccaa	cctgcgtttc	6000
ctggccacca	cacccaattc	cttgctggta	tcattggcag	cgccacgtgc	caggattacc	6060
ggctacatca	tcaagtatga	gaagcctggg	tctctccca	gagaagtgg	ccctcgccc	6120

SEQUENCE LISTING 1657-2022.txt

```

cgccctggtg  tcacagaggg  tactattact  ggcctggaac  cggaaccga  atatacaatt  6180
tatgtcattg  ccctgaagaa  taatcagaag  agcgagcccc  tgattggaag  gaaaaagaca  6240
gacgagcttc  cccaactggt  aacccttcca  caccccaatc  ttcattggacc  agagatcttg  6300
gatgttcctt  ccacagttca  aaagacccct  ttcgtcacc  accctgggta  tgacactgga  6360
aatggtattc  agcttcctgg  cacttctggt  cagcaaccca  gtgttgggca  acaaatgac  6420
tttgaggaac  atggttttag  gcggaccaca  ccgcccacaa  cggccacccc  cataaggcat  6480
aggccaagac  catacccgcc  gaatgtagga  caagaagctc  tctctcagac  aaccatctca  6540
tgggccccat  ttcaggacac  ttctgagtac  atcatttcat  gtcactctgt  tggcactgat  6600
gaagaacctt  tacagttcag  gggtcctgga  acttctacca  gtgccactct  gacaggcctc  6660
accagaggtg  ccacctacaa  catcatagt  gaggcactga  aagaccagca  gaggcataag  6720
gttcgggaag  aggttggtac  cgtgggcaac  tctgtcaacg  aaggcttgaa  ccaacctacg  6780
gatgactcgt  gctttgacct  ctacacagtt  tcccattatg  ccgttggaga  tgagtgggaa  6840
cgaatgtctg  aatcaggctt  taaactgttg  tgagcttgg  taggctttgg  aagtggctat  6900
ttcagatgtg  attcatctag  atggtgccat  gacaatgggt  tgaactacaa  gattggagag  6960
aagtgggacc  gtcagggaga  aaatggccag  atgatgagct  gcacatgtct  tgggaacgga  7020
aaaggagaat  tcaagtgtga  ccctcatgag  gcaacgtgtt  acgatgatgg  gaagacatac  7080
cacgtaggag  aacagtgtga  gaaggaatat  ctcggtgcca  tttgctcctg  cacatgcttt  7140
ggaggccagc  ggggctggcg  ctgtgacaac  tgccgcagac  ctgggggtga  acccagctcc  7200
gaaggcacta  ctggccagtc  ctacaaccag  tattctcaga  gataccatca  gagaacaaac  7260
actaagtgtt  attgccaat  tgagtgtctc  atgcttttag  atgtacaggc  tgacagagaa  7320
gattcccgag  agtaaatcat  ctttccaatc  cagaggaaca  agcatgtctc  tctgccaaga  7380
tccatctaaa  ctggagtgat  gttagcagac  ccagcttaga  gttcttcttt  ctttcttaag  7440
cccttgctc  tggaggaaat  tctccagctt  cagctcaact  cacagcttct  ccaagcatca  7500
ccctgggagt  ttcttgagg  ttttctcata  aatgagggtc  gcacattgcc  tgttctgctt  7560
cgaagtattc  aataccgctc  agtattttaa  atgaagtgat  tctaagattt  ggttggggt  7620
caataggaaa  gcatatgcag  ccaaccaaga  tgcaaatgtt  ttgaaatgat  atgacaaaaa  7680
ttttaagtag  gaaagtcacc  caaacacttc  tgctttcact  taagtgtctg  gcccgaata  7740
ctgtaggaac  aagcatgatc  ttgttactgt  gatattttaa  atatccacag  tactactttt  7800
ttccaaatga  tcttagtaat  tgcctagaaa  tatctttctc  ttacctgtta  tttatcaatt  7860
tttccagta  tttttatag  gaaaaaattg  tattgaaaac  acttagtatg  cagttgataa  7920
gaggaatttg  gtataattat  ggtgggtgat  tattttttat  actgtatgtg  ccaaagcttt  7980
actactgtgg  aaagacaact  gttttaataa  aagatttaca  ttccaca  8027

```

<210> 43
 <211> 5084
 <212> DNA
 <213> Homo sapiens

```

<400> 43
agcaccacgg  cagcaggagg  tttcggctaa  gttggaggta  ctggccacga  ctgcatgccc  60
gcgcccgcga  ggtgatacct  ccgcccgtga  cccaggggct  ctgcgacaca  aggagtctgc  120
atgtctaagt  gctagacatg  ctgagctttg  tggatacgcg  gactttgttg  ctgcttgctg  180
taaccttatg  cctagcaaca  tgccaatctt  tacaagagga  aactgtaaga  aagggcccg  240
ccggagatag  aggaccacgt  ggagaaagg  gtccaccagg  cccccaggc  agagatgggt  300
aagatgggtc  cacaggccct  cctggctcc  gatggaaaag  gagttggact  tggccctgga  360
ggaactttgc  tgctcagtat  gatggaaaag  cctgggtgag  ctggagcccc  aggccctcaa  420
taatgggacc  tagaggccca  gaacctgggt  ggtgaagatg  gtcaccctgg  aaaacccgga  480
gacctgctgg  tgagcctggt  tggcaaggct  ggtgagatg  ttggtttccc  tggaaactcct  540
ctggccctcc  tggcaaggct  cagggtgctc  cacaatggtc  tggatggatt  gaagggacag  600
agagaggagt  tggtggacca  cagggtgctc  ggtgcccctg  gtgaaaatgg  aactccagg  660
gcttcaagg  cattagggga  ggtgcccctg  agaggacgtg  ttggtgcccc  tggcccagct  720
ctgggtgtgaa  ggggtgaacct  tccgtgtgag  agaggacgtg  cctggtgccc  cattgggtct  780
cccgtgggtc  tccgtgtgag  cccgtgggtc  cccgtgggtc  ctgctgggtc  agctgttgg  840
gcagtgatgg  aagtgtgggt  ggccccagg  cgtgggtgag  ttactgtgct  caagggtgct  900
caggcttccc  aggtgcccct  cgcccggtcc  taatcctgga  tgggtcttcc  aggcctctcc  960
ctgctggtcc  cgccgggtcc  gcaaacggcc  ggcctcctg  gaccccggc  tattcctggc  1020
gacctcctgg  tggggctccc  agaggacttg  agaggacttg  ttggtgagcc  tgggtcctcc  1080
ccggcggtgc  tactgggtgc  gagcccggtc  ggggagcctg  gctctcatgg  aaggtcctgt  1140
ctgcccgtgc  taacaagggt  agggacttg  cctgggtctc  caagtggccc  tgctggagtc  1200
gagagagcgg  aggaagaga  gagaggtagt  agtcgtggtg  ggggagcctg  gctctcatgg  1260
gtggtgaaga  gagaggtagt  agtcgtggtg  ggggagcctg  ccaaggtcct  atctgccggc  1320
ctcctgggtc  gagaggtagt  agtcgtggtg  ggggagcctg  ggccttaatt  tggagctgat  1380
gcgtcatggg  cctcctggt  agtcgtggtg  ggggagcctg  gctggaagga  gcctggcaac  1440
atggagatgc  tgggtgccc  cagctggag  ggtgatcctg  gcaaaaacgg  tgataaagg  1500
ccctggaaa  tatcgcccc  ccaattggc  ggtgatcctg  gcaaaaacgg  tgataaagg  1560
gcaggcctgg  ccaattggc  ggtgatcctg  ggtgatcctg  gcaaaaacgg  tgataaagg  1620
ctggaccaa  agggccact  ggtgatcctg  ggtgatcctg  gcaaaaacgg  tgataaagg  1680

```

SEQUENCE LISTING 1657-2022.txt

```

ttgctggtgc tcgggggtgct ccaggtcctg atggaacaa tgggtgctcag ggacctcctg 1740
gaccacaggg tgttcaaggt ggaaaaggtg aacaggggtcc cgctggtcct ccaggcttcc 1800
agggtctgcc tggccccctca ggtcccgcctg gtgaagttgg caaaccagga gaaaggggtc 1860
tccatggtga gtttggcttc cctggtcctg ctggtccaag aggggaacgc ggtcccccag 1920
gtgagagtgg tgctgcegggt cctactgggtc ctattggaag ccgaggtcct tctggacccc 1980
cagggcctga tggaaacaag ggtgaacctg gtgtggttgg tgctgtgggc actgctggtc 2040
catctggtcc tagtggactc ccaggagaga ggggtgctgc tggcatacct ggaggcaagg 2100
gagaaaaggg tgaacctggt ctgagaggtg aaattggtaa ccctggcaga gatggtgctc 2160
gtggtgctca tgggtgctga ggtgcccctg gtcctgctgg agccacaggt gaccggggcg 2220
aagctggggc tgctggtcct gctggtcctg ctggtcctcg gggaaagccct ggtgaacgtg 2280
gcgaggtcgg tcctgctggc cccaacggat ttgctggtcc ggctggtgct gctggtcaac 2340
cgggtgctaa aggagaaaga ggagccaaag ggcctaaggg tgaaaacggt gttgttggtc 2400
ccacagggcc cggtggagct ctggtcccaa tgggtccccc ggtcctgctg 2460
gaagtcgtgg tgatggaggc cccctgggtg tgactggttt ccctgggtgct gctggacgtg 2520
ctggtccccc aggacctct ggtatttctg gccctcctgg tccccctggt cctgctggga 2580
aagaagggct tcgtggtcct cgtggtgacc aaggtccagt tggccgaact ggagaagtag 2640
gtgcatgtgg tccccctggt ttcgctgggt agaagggtcc ctctggagag gctggtactg 2700
ctggacctcc tggcactcca ggtcctcagg gctctcttgg tgctcctggt attcctgggt 2760
tccctggctc gagaggtgaa cgtggtctac ctggtgttgc tgggtgctgt ggtgaacctg 2820
gtcctcttgg cattgccggc cctcctgggg cccgtggtcc tcctggtgct gtgggtagtc 2880
ctggagtcaa cgtgctcct ggtgaagctg gtcgtgatgg caacctggg aacgatggtc 2940
ccccaggtcg cgatggtcaa cccggacaca agggagagcg cggttaccct ggcaatattg 3000
gtcccgttgg tgctgcaggt gcacctgggt ctcattggccc cgtgggtcct gctggcaaac 3060
atggaaaccg tgggtgaaact ggtccttctg gtcctgttgg tcctgctggt gctgttggcc 3120
caagaggtcc tagtgccca caagcattc tttaaaggac acaatggatt gggagagccc ggtgaaaagg 3180
ggcccagagg tcttctggc tttaaaggac gctccgtggg tccgtgctgt cctggtatcg 3240
ctggtcacca tgggtgatcaa ggtgctcctg gctggaaaag atggtcgcac tggacatcct ggtacggtt 3300
gacctgctgg cattcgagg cctcagggtc accaaggccc tgctggcccc cctggtcccc 3360
ctggccctcc tggacctcca ggtgtaagcg gctggtggta tgactttggt tacgatggag 3420
acttctacag ggctgaccag cctcgctcag caccttctct cagaccaag gactatgaag 3480
ttgatgtac tctgaagtct ctcaacaacc agattgagac ccttcttact cctgaaggct 3540
ctagaaagaa cccagctcgc acatgccgtg acttgagact cagccacca gactggagca 3600
gtggttacta ctggattgac cctaaccaag gatgcactat ggatgctatc aaagtatac 3660
gtgatttctc tactggcgaa acctgtatcc gggcccaacc tgaaaacatc ccagccaaga 3720
actggtatag gagctccaag gacaagaaac acgtctgggt aggagaaaact atcaatgctg 3780
gcagccagtt tgaatgagag aactatggag ctgagaacat ggaaatggct acccaacttg 3840
ccttcatgcg cctgctggcc gatgactggc acctgaaaaa ggctgtcatt ctacagggt 3900
gcattgcata ctaatgatgt tgaacttgtt gctgagggca acagcaggtt cacttacact gttctttag 4020
atggtgctc taataagaca aatgaatggg gaaagacaat cattgaatac gttctttag 4080
agccatcacg cctgcccctt cttgatattg gacatttggg caactcaatc aaaacaaata 4140
aattctttgt ggacattggc ccagtcgtgt tcaaataaat catcggtggt gctgacctag 4200
aagaaagaaa tttgaaaaaa ctttctcttt gccatttctt tcttctcttt ttaactgaa 4260
agctgaatcc ttccatttct tctgcacatc tacttgctta aattgtgggc aaaagagaaa 4320
aagaaggatt gatcagagca ttgtgcaata cagtttcatc aactccttcc cccgctcccc 4380
caaaaatttg aatttttttt tcaacactct tacacctgtt atggaaaatg tcaacctttg 4440
taagaaaacc aaaataaaaa ttgaaaaata aaaaccataa acatttgcac cacttgtggc 4500
ttttgaaat cttccacaga gggaaagtta aaacccaagc ttccaaagg ttaaactacc 4560
tcaaaacact ttcccatgag tggatccac attgttatgt gctgacctag acagagatga 4620
actgaggtcc ttgtttgtt ttgttcataa tacaaagggt ctaattaata gtatttcaga 4680
tacttgaaga atgttgatgg tgctagaaga atttgagaag aaatactcct gtattgagtt 4740
gtatcgtgtg gtgtattttt taaaaaattt gatttagcat tcataatttc catcttattc 4800
ccaattaaaa gtatgcagat tatttgccca aagttgtcct cttcttcaga ttcagcattt 4860
gttctttgcc agtctcattt tcatcttctt ccatggttcc acagaagctt tgtttcttgg 4920
gcaagcagaa aaattaaatt gtacctattt tgtatatgtg agatgtttta ataaattgtg 4980
aaaaaatga aataaagcat gtttggtttt ccaaaagaac atat 5040
5084

```

<210> 44
 <211> 595
 <212> DNA
 <213> Homo sapiens

<400> 44
 gggcaaggct gggccgggaa gggcgtgggt tgaggagagg ctccagacct gcacgccgcg 60
 cgcacagagc tctcagcgcc gctcccagcc acagcctccc gcgcctcget cagctccaac 120
 atggcaaaaa tctccagccc tacagagact gagcgggtgca tcgagtcctt gattgctgtc 180

SEQUENCE LISTING 1657-2022.txt

```

ttccagaagt atgctggaaa ggatgggttat aactacactc tctccaagac agagttccta 240
agcttcatga atacagaact agctgccttc acaaagaacc agaaggaccc tgggtgcctt 300
gaccgcatga tgaagaaact ggacaccaac agtgatggtc agctagattt ctcagaattt 360
cttaattctga ttggtggcct agctatggct tgccatgact ccttcctcaa ggctgtccct 420
tcccagaagc ggacctgagg accccttggc cctggccttc aaaccacccc cctttccttc 480
cagcctttct gtcacatctt ccacagccca cccatcccct gagcacacta accacctcat 540
gcaggcccca cctgccaata gtaataaagc aatgtcactt ttttaaaaca tgaaa 595

```

```

<210> 45
<211> 647
<212> DNA
<213> Homo sapiens

```

```

<400> 45
gctcactgag caccgtccca gcatccggac accacagcgg cccttcgctc caccgagaaa 60
accacacttc tcataccttc actcaacact tctttcccca aagccagaag atgcacaagg 120
aggaacatga ttggtctgtg ctggggggcac cccccagcac catccttcca aggtccaccg 180
tgattaacat ccacagcgag acctccgtgc ccgaccatgt cgtctggctc ctgttcaaca 240
ccctcttctt gaactgggtgc tgtctgggct tcatagcatt cgcctactcc gtaaaagtcta 300
gggacaggaa gatgggttggc gacgtgaccg gggcccaggc ctatgcctcc accgccaagt 360
gcctgaacat ctggggccctg attctgggca tcctcatgac cattggattc atcctgttac 420
tggtattcgg ctctgtaaca gtctaccata ttatgttaca gataatacag gaaaaacggg 480
gttactagta gccgcccata gcctgcaacc tttgcactcc actgtgcaat gctggccctg 540
cacgctgggg ctggtgcccc tgcccccttg gtcctgcccc tagatacagc agtttatacc 600
cacacacctg tctacagtgt cattcaataa agtgcacgtg cttgtga 647

```

```

<210> 46
<211> 2067
<212> DNA
<213> Homo sapiens

```

```

<400> 46
cgcttttttt tttttttttt atgaataaat tgtatgtgtt tctagctgaa actactcacc 60
aatatgcatg ttaaattcaa tcctctctta cctattcttt gatataactc cttgaagttt 120
tcccattctc ctacatcatc tccccacccc ccactgagtc atttctataa tacaaacata 180
ttatcttttt attaaattaa aaatctacct gtacaccttg aatgacaatg ctcggagctc 240
ccctgtgggtc atcgacgcct ccactgccat tgatgcacca tccaacctgc gtttcttggc 300
caccacacccc aattccttgc tggatcatg gcagccgcca cgtgccagga ttaccggcta 360
catcatcaag tatgagaagc ctgggtctcc tcccagagaa gtggtccctc ggccccgccc 420
tgggtgtcaca gaggtacta ttactggcct ggaaccggga accgaatata caatttatgt 480
cattggcctg aagaataatc agaagagcga gcccctgatt ggaaggaaaa agacaggaca 540
agaagctctc tctcagacaa ccattctcat gggccctatt caggacactt ctgagtacat 600
catttcatgt catcctgttg gcactgatga agaaccctta cagttcaggg ttcttggaac 660
ttctaccagt gccactctga caggcctcac cagaggtgcc acctacaaca tcatagtggg 720
ggcactgaaa gaccagcaga ggcataaggc ttgggaagag gttgttaccg tgggcaactc 780
tgtcaacgaa ggcttgaacc aacctacgga tgactcgtgc ttgacccctt acacagtctc 840
ccattatgcc gttggagatg agtgggaacg aatgtctgaa tcaggcttta aactgttgtg 900
ccagtgccta ggctttggaa gtggtcattt cagatgtgat tcatctagat ggtgccatga 960
caatgggtgtg aactacaaga ttggagagaa gtgggaccgt caggagagaa atggccagat 1020
gatgagctgc acatgtcttg ggaacggaaa aggagaattc aagtgtgacc ctcatgaggc 1080
aacgtgttat gatgatggga agacatacca cgtaggagaa cagtggcaga aggaatatct 1140
cgggtgccatt tgctcctgca catgcttttg aggccagcgg ggctggcgct gtgacaactg 1200
ccgagacact ggggggtgaac ccagtcccga aggcactact tgcccatttg agtgcttcat 1260
ttctcagaga taccatcaga gaacaaacac taatgttaat tgcccatttg agtgcttcat 1320
gccttttagat gtacaggctg acagagaaga ttcccgagag taaatcatct ttccaatcca 1380
gaggaacaag catgtctctc tgccaagatc catctaaact ggagtgatgt tagcagaccc 1440
agctttagat tcttctttct tcttctcttg ctttgccttg gaggaagttc tccagcttca 1500
gctcaactca cagcttctcc aagcatcacc ctgtggagtt cctgaggggt ttctcataaa 1560
tgagggctgc acattgcctg ttctgcttcg aagtattcaa taccgctcag tatttttaaa 1620
gaagtgatcc taagatttgg tttgggatca ataggaaagc atatgcagcc aaccaagatg 1680
caaatgtttt gaaatgatat gccaaaattt ttaagtagga aagtcaccca aacacttctg 1740
ctttcactta agtgtctggc ccgcaatact gtaggaaaca gcatgatctt gttactgtga 1800
tatttttaaa atccacagta ctacttttt ccaaatgatc ctagtaattg cctagaaata 1860
tctttctctt acctgttatt tatcaatttt tccagattat tttatacggg aaaaattgta 1920
ttgaaaacac ttgatatgca aaagctttac ggaatttggg ataattatgg tgggtgatta 1980
ttttttatag tgtatgtgcc aaagctttac tactgtggaa agacaactgt ttttaataaa 2040
gatttacatt ccaaaaaaaa aaaaaaa 2067

```

SEQUENCE LISTING 1657-2022.txt

<210> 47
<211> 5489
<212> DNA
<213> Homo sapiens

<400> 47

```
ggctgagttt tatgacgggc ccggtgctga agggcagggg acaacttgat ggtgctactt 60
tgaactgctt ttcttttctc ctttttgac aaagagtctc atgtctgata ttagacatg 120
atgagctttg tgcaaaaggg gagctggcta cttctcgctc tgcttcatcc cactattatt 180
ttggcacaac aggaagctgt tgaaggagga tgttcccatc ttggtcagtc ctatgcggat 240
agagatgtct ggaagccaga accatgccaa atatgtgtct gtgactcagg atccgttctc 300
tgcatgaca taatatgtga cgatcaagaa ttgactgcc ccaaccaga aattccattt 360
ggagaatgtt gtgcagtttg cccacagcct ccaactgctc ctactcgccc tcctaattggt 420
caaggacctc aaggcccaa gggagatcca ggccctcctg gtattcctgg gagaaatggt 480
gacctggta ttccaggaca accagggtcc cctggttctc ctggcccccc tggaaatctgt 540
gaatcatgcc ctactggtcc tcagaactat tctccccagt atgattcata tgatgtcaag 600
tctggagtag cagtaggagg actcgcaggc tatcctggac cagctggccc cccaggccct 660
cccggctccc ctggtacatc tggatcatct gggtccctcg gatctccagg ataccaagga 720
ccccctgggt aacctgggca agctggtcct tcaggccctc caggacctcc tgggtctata 780
ggtccatctg gtcctgctgg aatacaggta gaaccggacg acctggagag 840
cgaggattgc ctggacctcc aggtatcaaa ggtccagctg ggatacctgg attccctggt 900
atgaaaggac acagaggcct cgatggacga aatggagaaa agggtgaaac aggtgtcctt 960
ggattaaagg gtgaaaatgg tcttccaggc gaaaatggag ctcttgacc catgggtcca 1020
agaggggctc ctgggtgagc aggcggcca ggacttctcg gggctgcagg gctcgggggt 1080
aatgacggtg ctcgaggcag tgatggtcaa ccaggccctc ctggtcctcc tggaaactgcc 1140
ggattccctg gatccccctg tgctaagggt gaagtgggac ctgcagggtc tcctggttca 1200
aatggtgccc ctggacaaa gaggaaacct ggacctcagg gacacgtctg tgctcaaggt 1260
cctcctggcc ctctgggat taatggtagt cctggtggta aaggcgaaat gggctccgct 1320
ggcattcctg gagctcctgg actgatggga gcccggggtc ctccaggacc agccgggtgct 1380
aatggtgctc ctggactgca aggtggtgca ggtgagcctg gtaagaatgg tgccaaagga 1440
gagcccgagc cacgtggtga acgcggtgag gctggtattc caggtgttcc agggactaaa 1500
ggcgaagatg gcaaggatgg atcacctgga gaacctggtg caaatgggct tccaggagct 1560
gcaggagaaa ggggtgcccc tgggttccga ggacctgctg gaccaaatgg catcccagga 1620
gaaaagggtc ctgctggaga gcgtggtgct ccaggccctg caggggccag agggactgct 1680
ggagaacctg gcagagatgg cgtccctgga ggtccaggaa tgaggggcat gcccggaagt 1740
ccaggaggac tgggaagtga tgggaaacca gggcctcccg gaagtcaagg agaaagtgg 1800
cgaccaggtc ctctggggcc atctggtccc cgaggtcagc ctggtgtcat gggcttcccc 1860
ggtcctaaag gaaatgatgg tgctcctggt aagaatggag aacgaggtgg ccctggagga 1920
cctggccctc aggtcctcc tggaaagaat ggtgaaactg gacctcaagg acccccagg 1980
cctactgggc ctggtggtga caaaggagac acaggacccc ctggtccaca aggattacaa 2040
ggcttgccct gtacaggtgg tcctccagga gaaaatggaa aacctgggga accaggtcca 2100
aaggggtgat ccggtgcacc tggagctcca ggaggcaagg gtgatgctgg tgcccctggt 2160
gaacgtggac ctctggatt ggcaggggccc ccaggactta gaggtggagc tgggtccccct 2220
ggtcccgaag gaggaagggt tgctgctggt cctcctgggc cacctggtgc tgctggtact 2280
cctggtctgc aaggaatgcc tggagaaaga ggaggtcttg gagggtcctg tccaaagggt 2340
gacaagggtg aaccaggcgg cccaggtgct gatggtgtcc cagggaagaa tggcccaagg 2400
ggtcctactg gtccatttgg tcctcctggc ccagctggcc agcctggaga taagggtgaa 2460
ggtggtgccc ccggacttcc aggtatagtt ggacctcgtg gtagccctgg tgagagaggt 2520
gaaactggcc ctccaggacc tgctggtttc cctggtgctc ctggacagaa tgggtgaacct 2580
ggtggtaaa gagaagagg ggctccgggt gagaaagggt aaggaggccc tcctggagtt 2640
gcaggacccc ctggaggttc tggacctgct ggtcctcctg gtccccaagg tgtcaaaggt 2700
gaaactggca gtcctggtgg gtcctggtgc gctggttcc ctggtgctcg tggctcttct 2760
ggtcctcctg gtagtaatgg taacctgga ccccaggtc ccagcggttc tccaggcaag 2820
gatgggcccc caggtcctgc ggttaacact ggtgtcctcg gcagccctgg agtgtctgga 2880
caaaaagggt atgtcggcca accaggagag aagggatcgc ctggtgccc gggcccacca 2940
ggagctccag gccacttgg gattgctggg atcactggag cacggggtct tgcaggacea 3000
ccaggcatgc caggtcctag gggagccct ggccctcagg gtgtcaaggg tgaaaagggt 3060
aaaccaggag ctaacggtct cagtggagaa cgtggtcccc ctggacccca gggctcttct 3120
ggtctggctg gtacagctgg tgaacctgga agagatggaa accctggatc agatggtctt 3180
ccaggccgag atggacttcc tgggtggca ggtgatcgt gtgaaaatgg ctctcctggt 3240
gcccctggcg ctctggttca tccaggccca cctggtcctg tcggtccagc tggaaagagt 3300
ggtgacagag gagaaagtgg ccctgctggc cctgctggtg ctcccgggtc tgctggttcc 3360
cgaggtgctc ctggtcctca agggccacgt ggtgacaaa ggtgaaaagg tgaaactgga 3420
gctgctggca tcaaaggaca tcgaggattc cgtgtaatc caggtgcccc aggttctcca 3480
ggccctgctg gtcagcagg ggaatcggc agtccaggac ctgcaggccc cagaggacct 3540
gttggaacca gtggacctcc tggcaaatg ggaaccagt gacatccagg tcccattgga 3600
```


SEQUENCE LISTING 1657-2022.txt

```

ccaccagggc ctcgaggttaa cagaggtgaa agaggatctg agggctcccc agggcaccaca 3660
gggcaaccag gccctcctgg accctcctgg gcccctgggc cttgctgtgg tgggtgttga 3720
gccgctgcca ttgctgggat tggaggtgaa aaagctggcg gttttgcccc gtattatgga 3780
gatgaaccaa tggatttcaa aatcaacacc gatgagatta tgacttctact caagtctgtt 3840
aatggacaaa tagaaagcct cattagtcct gatggttctc gtaaaaaccc cgctagaaac 3900
tgcagagacc tgaaattctg ccatcctgaa ctcaagagtg gagaatactg ggttgaccct 3960
aaccaaggat gcaaatttga tgctatcaag gtattctgta atatggaaac tggggaaaca 4020
tgcataagtg ccaatccttt gaatgttcca cgaaacact ggtggacaga ttctagtgtt 4080
gagaagaaac acggttgggt tggagagtc atggatgggt gttttcagtt tagctacggc 4140
aatcctgaac ttcctgaaga tgtccttgat gtgcagctgg cattccttcg acttctctcc 4200
agccgagctt cccagaacat cacatatcac tgcaaaaata gcattgcata catggatcag 4260
gccagtggaa atgtaaagaa ggccctgaag ctgatggggg caaatgaagg tgaattcaag 4320
gctgaaggaa atagcaaatt cacctacaca gttctggagg atggttgac gaaacacact 4380
ggggaattgga gcaaaacagt ctttgaatat cgaacacgca aggctgtgag actacctatt 4440
gtagatatgt caccctatga cattggtggt cctgatcaag aatttgggtt ggacgttggc 4500
cctgtttgtt ttttataaac caaactctat ctgaaatccc aacaaaaaaa atttaactcc 4560
atatgtgttc ctcttgttct aatcttgtca accagtgcac gtgaccgaca aaattccagt 4620
tatttatttc caaaatgttt ggaaacagta taatttgaca aagaaaaatg atacttctct 4680
ttttttgctg ttccaccaa tacaattcaa atgctttttg ttttattttt ttaccaattc 4740
caatttcaaa atgtctcaat ggtgctataa taataaaact tcaacactct ttatgataac 4800
aacactgtgt tatattcttt gatccttagc caactcgac agcaatgact gtgctcacca 4860
gtaaaagata acctttcttt ctgaaatagt caaatacgaa attagaaaag cctcccttat 4920
tttaactacc tcaactggtc agaaacacag attgtattct atgagtccca gaagatgaaa 4980
aaaattttat acgttgataa aacttataaa tttcattgat taatctcctg gaagattggt 5040
ttaaaaagaa aagtgtaatg caagaattta aagaaatatt ttaaagcca caattatttt 5100
aatattggat atcaactgct tgtaaagggt ctcctctttt ttcttgtcat tgcctggtaa 5160
gattactaat atttgggaag gctttaaaga cgcattgtat ggtgctaatt tactttcact 5220
tttaaaactct agatcagaat tgttgacttg cattcagaac ataaatgcac aaaatctgta 5280
catgtctccc atcagaaaga ttcattggca tgccacagg attctcctcc ttcatcctgt 5340
aaagggtcaac aataaaaacc aaattatggg gctgcttttg tcacactagc atagagaattg 5400
tggtgaaatt taactttgta agcttgtatg tgggtgttga tctttttttt ccttacagac 5460
accataataa aaatatcata ttaaaattc

```

<210> 48
 <211> 1128
 <212> DNA
 <213> Homo sapiens

```

<400> 48
acagagctta ggacacagag cacatcaaaa gttcccaaag agggcttgct ctctcttcac 60
ctgctctgtt ctacagcaca ctaccagaag acagcagaaa tgaaaagcat ttactttgtg 120
gctggattat ttgtaatgct ggtacaaggc agctggcaac gttcccttca agacacagag 180
gagaaatcca gatcattctc agcttcccag gcagaccac tcagtgatcc tgatcagatg 240
aacgaggaca agcgccattc acagggcaca ttcaccagtg actacagcaa gtatctggac 300
tccaggcgtg cccaagattt tgtgcaagg tttgatgaata ccaagaggaa caggaataac 360
attgccaac gtcacgatga atttgagaga catgctgaag ggacctttac cagtgtatgta 420
agttcttatt tgggaaggcca agctgccaag gaattcattg cttggctggg gaaaggccga 480
ggaaggcgag atttcccaga agaggtcgcc attgttgaag aacttggccg cagacatgct 540
gatggttctt tctctgatga gatgaacacc attcttgata atcttgccgc cagggaactt 600
ataaactggt tgattcagac caaaatcact gacaggaaat aactatatca ctattcaaga 660
tcattctcac aacatcacct gctagccacg tgggatgttt gaaatgttaa gtcctgtaaa 720
tttaagagg gtattctgag gccacattgc tttgcatgcc aataaataaa ttttctttta 780
gtgttgtgta gccaaaattt acaaatggaa taaagtttta tcaaaatatt gctaaaatat 840
cagctttaaa atatgaaagt gctagattct gttattttct tcttattttg gatgaagtac 900
cccaacctgt ttacatttag cgataaaatt attttctat gatataattt gtaaatgtaa 960
attattccga tctgacatat ctgcattata ataataagg aatagaagaa ctggtagcca 1020
cagtgggtgaa attggaaaga gaactttctt cctgaaacct ttgtctttaa aatactcagc 1080
tttcaatgta tcaaagatac aattaaataa aattttcaag cttcttta 1128

```

<210> 49
 <211> 3528
 <212> DNA
 <213> Homo sapiens

```

<400> 49
tatgcatgga gtggacctgt aggcgacttg catcgtcttc aacatgaaga tagccacagt 60
gtcagtgcct ctgcccttgg ctctttgcct catacaagat gctgccagta agaataga 120

```

SEQUENCE LISTING 1657-2022.txt

```

tcaggaaatg tgccatgaat ttcaggcatt tatgaaaaat ggaaaaactgt tctgtcccca 180
ggataagaaa ttttttcaaa gtcttgatgg aataatgttc atcaataaat gtgccacgtg 240
caaaatgata ctggaaaaag aagcaaaatc acagaagagg gccaggcatt tagcaagagc 300
tccaaggct actgccccaa cagagctgaa ttgtgatgat tttaaaaaag gagaaaagaga 360
tggggatttt atctgtcctg attattatga agctgtttgt ggacacagatg ggaaaacata 420
tgacaacaga tgtgactgtg gtgctgagaa tgcgaaaacc ggggtcccaa ttgggtgtaaa 480
aagtgaaggg gaatgtaaga gcagtaatcc agagcaggat gtatgcagtg cttttcggcc 540
ctttgttaga gatggaagac ttggatgcac aagggaaaat gatcctgttc ttgggtcctga 600
tggaagagcg catgtgcaata agtgtgcaat gtgtgctgag ctgtttttaa aagaagctga 660
aaatgccaa cgagagggtg aaactagaat tgcacgaaat gctgaaaagg atttttgcaa 720
ggaatatgaa aaacaagtga gaaatggaag gctttttgt acacgggaga gtgatccagt 780
ccgtggccct gacggcagga tgcattggca caaatgtgcc ctgtgtgtctg aaattttcaa 840
cgggcatttt tcagaggaaa acagtaaaac agatcaaaat ttgggaaaag ctgaagaaaa 900
aactaaagt aaaagagaaa ttgtgaaact ctgcagtcaa tatcaaaatc aggcagaaga 960
tggaatactt ttctgtacca gagaaaatga ccctattcgt ggtccagatg ggaaaatgca 1020
tggaactgt tgttccatgt gtcaagtcta cttccaagca gaaaatgaag aaaagaaaaa 1080
ggctgaagca cgagctagaa acaaaagaga atctggaaaa gcaacctcat atgcagagct 1140
ttgcaatgaa tatcgaagc ttgtgaggaa cggaaaaact gcttgacca gagagaacga 1200
tcctatccag ggcccagatg ggaaagtga cggcaacacc tgctccatgt gtgaggtctt 1260
cttccaagca gaagaagaag aaaagaaaaa gaagggaaggc gaatcaagaa acaaaagaca 1320
atctaaggat acagcttcct ttgaggagt gtgtagtga ccccatccag gggccagatg ggaaaatgca 1440
cggacggctt ttttgcacca gagagaatga ctttcaacaa gaagaaagag caagagcaaa 1500
tggcaacacc tgctccatgt gtgaggcctt aggaaatctg cagtgaattt cgggaccaag tgaggaatgg 1560
ggctaaaaga gaagctgcaa tgcaccagg agcataatcc ccagtgtgtt caaacttgaa gaagaagaga agaaaaatga 1680
aacacttata tgcaccagg gccatgtgtg aaagggaaa ttgaggctga aaaagttaag agagaagcag ttcaggagct 1740
aaacaagtgt aaagggaaa tatcgtcatt atgtgaggaa tggacgactc ccctgtacca gagagaatga 1800
taaagaagaa atctatttag ggtctagat ggaaaatcca cggcaaacacc tgctccatgt gtgaagcctt 1860
gtgcagttaa ggtctagat ggaaaatcca agctgaaccc agagcaaaag tcaaaagaga 1920
cctccagcaa gaagcaaaag atgaatttcg gagacttttg caaaatggaa aacttttctg 1980
agctgaaaag gagacatgcg aatgatcctg tgcgtggccc agatggcaag acctatggca acaagtgtgc 2040
cacaagagaa catgtgtaag gcagtcttcc agaaaagaaa agagagaaaag aagaggaaga 2100
catgtgtaag gctgcaggac atggttccag tggtgggtga ggaggaaca ctcaggacga 2160
tcagagaaat tatcaggaac aaatgaaaaa tgggaagact caacaatcag tgtaccatgt gtaaaagcaaa 2280
atgtgctgag gatgctgat gcaaatcgta caaatctcgc tccagatcaa atgggactgg 2340
tcctgtacgt attgaaaaga gaaaatgaa catgtgatga gtttagaagc caaatgaaaa atggaaaact 2400
atcagaatca ggaagggata accctgtccg ggggtccagat ggcaagacac atggtaataa 2460
tatctgcact gtgtactatg tgaaggaaa aactggaaag ggaagcagct gaaaaaaaaa agaaagagga 2520
tgaagacagg agcaatacag caatacagga gagaaatgga aagccttatc atgacaaaga 2580
ggatctgtgt gttcgaggcc catatggcaa gatgcacatc aataaatgtg ctatgtgtca 2700
aaataaccct gagcatcttt gatcgagaag ctaatgaaag aaaaaagaaa gatgaagaga aatcaagtag 2760
cagccctca aataatgcaa aggatgagtg cagtgaattt gaaactata taaggaaaca 2820
tgaactcatc tgccctagag agaatgacct agtgcacggt gctgatggaa agttctatc 2880
aaacaagtgc tacatgtgca gagctgtctt tctaacagaa gctttggaaa gggcaaagct 2940
tcaagaaaag ccatcccatg ttagagcttc tcaagaggaa gacagcccag actctttcag 3000
ttctctggat tctgagatgt gcaaagacta ccgagtattg cccaggatag gctatctttg 3060
tccaaaggat ttaaagcctg tctgtggtga cgatggccaa acctaacaac atccttgcat 3120
gctctgtcat gaaaacctga tacgccaac aaatacacac atccgcagta cagggaagtg 3180
tgaggagagc agcaccacag gaaccaccgc agccagcatg cccccgtctg acgaatgaca 3240
ggaagattgt tgaaagccat gagggaaaaa ataaaccca gttctgaatc acctacctc 3300
accatctgta tatacaaaga attcttcgga gcttgtctta tttgctatag aaaacaatac 3360
agagcttttg ggaatggaat cactgatttt cagtcttttc cattctttc ctcctagaat 3420
ctgtgatctg agggatataa gacattttca ccaagtttga gccctcaaaa tgtcctgatt 3480
acaatgctgt ctgtccaact gcctgttcaa taaaagtaaa ctcagcag 3528

```

<210> 50
 <211> 3494
 <212> DNA
 <213> Homo sapiens

<400> 50
 taatttttgc ccagtctgcc tgttgtgggg ctccctccct ttggggatat aagcccggcc 60
 tggggctgct ccgttctctg cctggcctga ggctccctga gccgcctccc caccatcacc 120
 atggccaagg gcttctatat ttccaagtcc ctgggcattc tggggatcct cctgggcgtg 180

SEQUENCE LISTING 1657-2022.txt

```

gcagccgtgt  gcacaatcat  cgcactgtca  gtgggtgtact  cccaggagaa  gaacaagaac  240
gccaacagct  ccccggtggc  ctccaccacc  ccgtccgcct  cagccaccac  caaccccgcc  300
tcggccacca  ccttggaacca  aagtaaagcg  tggaatcggt  accgcctccc  caacacgctg  360
aaacccgatt  cctaccaggt  gacgctgaga  ccgtacctca  cccccaatga  cagggggcctg  420
tacgttttta  aggggtccag  caccgtccgt  ttcacctgca  aggaggccac  tgacgtcatc  480
atcatccaca  gcaagaagct  caactacacc  ctcagccagg  ggcaacagggt  ggtcctgctg  540
ggtgtgggag  gctcccagcc  ccccgacatt  gacaagactg  agctggtgga  gcccaccgag  600
tacctggtgg  tgcacctcaa  gggctccctg  gtgaaggaca  gccagtatga  gatggacagc  660
gagttcgagg  gggagttggc  agatgacctg  gcgggcttct  accgcagcga  gtacatggag  720
ggcaatgtca  gaaaggtggg  ggccactaca  cagatgcagg  ctgcagatgc  ccggaagtcc  780
ttcccatgct  tcgatgagcc  ggccatgaag  gccgagttca  acatcacgct  tatccacccc  840
aaggacctga  cagccctgtc  caacatgctt  cccaaaggct  ccagcaccac  acttccagaa  900
gaccccaact  ggaatgtcc  tgaattccac  agaatgtccac  gtacttgctg  960
gccttcattg  tgcagtgtgt  cgactacgtg  gagaagcagg  catccaatgg  tgtcctgac  1020
cggatctggg  cccggcccag  tgccattgct  gcggggccac  gcgattatgc  cctgaacgtg  1080
acggggccca  tccttaactt  ctttgcgtgt  cattatgaca  caccctaccc  actcccaaaa  1140
tcagaccaga  ttggcctgcc  agacttcaac  gccggcgcca  tggagaactg  gggactggtg  1200
acctaccggg  agaactccct  gctgttcgac  cctccagcag  cctccagcag  caacaaggag  1260
cgggtgggtca  ctgtgattgc  tcatgagctg  gccaccagt  gggtcgggaa  cctggtgacc  1320
atagagtggt  ggaatgacct  gtggctgaac  gagggcttcg  cctcctacgt  ggagtacctg  1380
ggtgctgact  atgcggagcc  caccctggaac  ttgaaagacc  tcatggtgct  gaatgatgtg  1440
taccgcgtga  tggcagtgga  tgcactggcc  tcctccacc  cgctgtccac  acccgctcgt  1500
gagatcaaca  cgccggccca  gatcagtgag  ctgtccgagg  ccattctcta  cagcaagggc  1560
gcctcagtc  tcaggatgct  ctccagcttc  ctgtccgagg  acgtattcaa  gcagggcctg  1620
gcgtccctac  tccacacctt  tgccatgac  aacaccatct  acctgaacct  gtgggaccac  1680
ctgcaggagg  ctgtgaacaa  ccggtccatc  caactcccca  ccaccgtgct  ggacatcatc  1740
aaccgctgga  ccctgcagat  gggcttccc  gtcacacagg  ttaccgcgcc  ctgagaattc  1800
ctttcccagg  agcacttctc  ccttgacccc  gatccaatg  gacagagatg  gcagacagca  1860
aactacgtgt  ggattgtgct  catcacatcc  atcagagatg  catcaggcaa  tgagtggatc  1920
tggtgatag  atgtaagagc  ccagaacgat  ctcttcagca  acgacgaaga  gaactggagg  1980
ctgctgaacc  tcaatgtgac  gggctattac  cgggtgaact  acgacgaaga  gaactggagg  2040
aagattcaga  ctgagctgca  gagagaccac  tcggccatcc  ctgtcatcaa  tcggggcacag  2100
atcattaatg  acgccttcaa  cctggccagt  gcccataagg  tccctgtcac  tctggcgctg  2160
aacaacaccc  tcttctgat  tgaagagaga  cagtacatgc  cctgggaggc  cgccctgagc  2220
agcctgagct  acttcaagct  catgtttgac  cgctccgagg  tctatggccc  catgaagaac  2280
tacctgaaga  agcaggtcac  acccctcttc  attcacttca  gaaataatac  caacaactgg  2340
agggagatcc  cagaaaacct  gatggaccag  tacagcgagg  ttaatgccat  cagcaccgcc  2400
tgctccaacg  gagttccaga  gtgtgaggag  atggtctctg  gccttttcaa  gcagtggatg  2460
gagaacccca  ataataacct  gatccacccc  aacctgcggt  ccaccgtcta  ctgcaacgct  2520
atcgcccagg  gcggggaggga  ggagtgggac  ttcgcctggg  agcagttccg  aaatgccaca  2580
ctggtcaatg  aggcgtgaca  gctccgggca  gccctggcct  gcagcaaaga  gttgtggatc  2640
ctgaacagggt  acctgagcta  caccctgaac  ccggacttaa  tccggaagca  ggacgccacc  2700
tctaccatca  tcagcattac  caacaacgtc  attgggcaag  gtctggtctg  ggactttgtc  2760
cagagcaact  ggaagaagct  ttttaacgat  tatggtgggt  gctcgttctc  cttctccaac  2820
ctcatccagg  cagtgcacg  acgattcttc  accgagtatg  agctgcagca  gctggagcag  2880
ttcaagaagg  acaacgagga  aacaggcttc  ggctcaggca  cccgggccct  ggagcaagcc  2940
ctggagaaga  cgaaagccaa  catcaagtgg  gtgaaggaga  acaaggagggt  ggtgctccag  3000
tggttcacag  aaaacagcaa  atagtcacca  gcccttgaag  tcacccggcc  ccgatgcaag  3060
gtgcccacat  gtgtccatcc  cagcggctgg  tgcagggcct  ccattcctgg  agcccagggc  3120
accagtgtcc  tcccctcaag  gacaaagtct  ccagcccacg  ttctctctgc  ctgtgagcca  3180
gtctagtctc  tgatgacca  ggctgcctga  gcacctccca  gccctgccc  ctcatgccaa  3240
ccccgcccta  ggcctggcat  ggcacctgtc  gccagtgcc  ctggggctga  tctcagggaa  3300
gcccagctcc  agggccagat  gagcagaagc  tctcgatgga  caatgaacgg  ccttgctggg  3360
ggccgcccctg  taccctcttt  cacctttccc  taaagaccct  aaatctgagg  aatcaacagg  3420
gcagcagatc  tgtatatttt  tttctaagag  aaaatgtaaa  taaaggattt  ctgatgaaa  3480
aaaaaaaaaa  aaaa  3494

```

<210> 51
 <211> 1309
 <212> DNA
 <213> Homo sapiens

<400> 51
 taggagataa gagtatcttg cacagcaggt gcaggtttcc cagcagctca ggcaagagtc 60
 cgatgtttgt gccatctgat cctgatgtct ggagagatag ccatgtgtga gcctgaattt 120
 ggcaatgaca agggcaggga gccgagcgtg ggtggcaggt ggcgagtgtc ctggtacgaa 180
 cggtttgtgc agccatgtct ggtcgaactg ctgggctctg ctctcttcat cttcatcggg 240

SEQUENCE LISTING 1657-2022.txt

tgctgtcg	tcattgagaa	tgggacggac	actgggctgc	tgcagccggc	cctggccac	300
gggctggctt	tggggctcgt	gattgccacg	ctggggaata	tcagtgggtg	acacttcaac	360
cctgcggtgt	ccctggcagc	catgctgatc	ggaggcctca	acctgggtgat	gctcctccc	420
tactgggtct	cacagctgct	cggggggatg	ctcggggctg	ccttggccaa	gggtggtgagt	480
cctgaggaga	ggttctggaa	tgcattctgg	gcggcctttg	tgacagtcca	ggagcagggg	540
cagggtggcag	gggcgttgg	ggcagagatc	atcctgacga	cgctgctggc	cctggctgta	600
tgcattgggtg	ccatcaatga	gaagacaaag	ggccctcttg	ccccgttctc	catcggtctt	660
gccgtcaccg	tggatatcct	ggctgggggc	cctgtgtctg	gaggctgcat	gaatcccgc	720
cgtgctttttg	gacctgagct	gggtggccaac	cactggaaact	tccactggat	ctactggctg	780
ggcccactcc	tggctggcct	gcttgttgg	ctgctcatta	gggtgcttcat	tggagatggg	840
aagaccgccc	tcattcctgaa	ggctcgggtga	gcagagctcg	tgggattcct	gctgctccag	900
gtgtcctcag	ctcacctgtc	ccagactgag	gacaggggag	ttcctgcatt	tcctgccagg	960
gcagagggccc	agaggagcga	ccccctgctt	ggcctgcttt	cctcagataga	tcagataga	1020
ctgactgctg	aggaggctct	aggttcttgg	aattcctttg	tgctcatcag	agacccaga	1080
ctgggggaaca	cgctgcccgc	actgcccaga	gagcagtgca	aacaccacaa	cacgagcgtg	1140
tttcttgaga	ggaatgtccc	cgagttggac	aaggaggctg	tttctgcaca	tcagctcatt	1200
ttccgcaccc	catttcttgc	ttgattgctt	tggttggggc	ctggccactt	ccttgcttct	1260
caagctgaca	attctcactt	tgcaataaat	agtccagtg	ttccttcat		1309

<210> 52
 <211> 596
 <212> DNA
 <213> Homo sapiens

<400> 52	gacagcgcag	ggggaaccca	gggagcgcga	tgggctgcag	ggctgcgtca	gggctcctgc	60
	caggagtggc	cggtggtcctc	ctgctgctgc	tgcagagcac	acagtcagtc	tacatccagt	120
	accaaggctt	ccgggtccag	ctggaatcca	tgaagaagct	gagtgacctg	gaggcacagt	180
	gggacccag	ccccgcctg	caggcccaga	gcctcctgcc	cgccgtgtgc	caccaccctg	240
	ctctgcctca	ggaccttcag	cctgtctgcg	cctcgcagga	ggcttccagc	atcttcaaga	300
	ccctgaggac	catcgctaac	gacgactgtg	agctgtgtgt	gaacgttgcg	tgtaccggct	360
	gcctctgaga	tagccctggg	taccctgagc	ccaccaggga	cacctcgccc	ttcagcccac	420
	caccctggca	ggcttccatc	cccgtccatg	ctcaagatgg	gtccctggcc	accatgggtc	480
	tcaccacctt	tccagggcct	gagcagctgg	atctggtaca	aagcaatcgg	acatagagtt	540
	ggagggggag	gcccctgagg	cagcccagct	cctgaataaa	gattctacaa	cacacg	596

<210> 53
 <211> 3218
 <212> DNA
 <213> Homo sapiens

<400> 53	gaacaaacca	acatttgagc	caggaataac	tagagaggaa	caatgggggtt	attcagaggt	60
	tttgttttcc	tcttagttct	gtgcctgctg	caccagtcac	atacttctct	cattaagctg	120
	aataataatg	gctttgaaga	tattgtcatt	gttatagatc	ctagtgtgcc	agaagatgaa	180
	aaaataattg	aacaaataga	ggatatgggtg	actacagctt	ctacgtacct	gtttgaagcc	240
	acagaaaaaa	gatttttttt	caaaaatgta	tctatatata	ttcctgagaa	ttggaaggaa	300
	aatcctcagt	acaaaaggcc	aaaacatgaa	aaccataaac	atgctgatgt	tatagttgca	360
	ccacctacac	tcccaggtag	agatgaacca	tacaccaagc	agttcacaga	atgtggagag	420
	aaaggcgaat	acattcactt	caccctgac	cttctacttg	gaaaaaaaca	aaatgaatat	480
	ggaccaccag	gcaaactggt	tgtccatgag	tgggctcacc	tccggtgggg	agtggttgat	540
	gagtacaatg	aagatcagcc	tttctaccgt	gctaagtcaa	aaaaaatcga	agcaacaagg	600
	tgttccgcag	gtatctctgg	tagaaataga	gtttataagt	gtcaaggagg	cagctgtctt	660
	agtagagcat	gcagaattga	ttctacaaca	aaactgtatg	gaaaagattg	tcaattcttt	720
	cctgataaag	tacaaacaga	aaaagcatcc	ataatgttta	tgcaaagtat	tgattctgtt	780
	gttgaatttt	gtaacgaaaa	aaccataat	caagaagctc	caagcctaca	aaacataaag	840
	tgcaatttta	gaagtacatg	ggagggtgatt	agcaattctg	aggattttta	aaacaccata	900
	cccatgggtg	caccacctcc	tccacctgtc	ttctcattgc	tgaagatccg	tcaaagaatt	960
	gtgtgcttag	ttcttgataa	gtctggaagc	atggggggta	aggaccgcct	aaatcgaatg	1020
	aatcaagcag	caaaacattt	cctgtgcag	actgttgaaa	atggatcctg	gggtggggatg	1080
	gttcactttg	atagtactgc	cactattgta	aataagctaa	tccaaataaa	aagcagtgat	1140
	gaaagaaaca	cactcatggc	aggattacct	acatacctc	tgggaggaa	ttccatctgc	1200
	tctggaatta	aatatgcatt	tcagggtgatt	ggagagctac	attcccaact	cgatggatcc	1260
	gaagtactgc	tgctgactga	tggggaggat	gactctgcaa	gttcttgat	tgatgaagtg	1320
	aaacaaagtg	gggccattgt	tcattttatt	gctttgggaa	gagctgctga	tgaagcagta	1380
	atagagatga	gcaagataac	aggaggaagt	catttttatg	tttcagatga	agctcagaac	1440
	aatggcctca	ttgatgcttt	tggggctctt	acatcaggaa	atactgatct	ctcccagaag	1500

SEQUENCE LISTING 1657-2022.txt

```

tcccttcagc tcgaaagtaa gggattaaca ctgaatagta atgcctggat gaacgacact 1560
gtcataattg atagtacagt gggaaaggac acgttctttc tcatcacatg gaacagtctg 1620
cctcccagta tttctctctg ggatcccagt ggaacaataa tggaaaattt cacagtggat 1680
gcaacttcca aaatggccta tctcagtatt ccaggaactg caaagggtgg cacttgggca 1740
tacaatcttc aagccaaagc gaacccagaa acattaacta ttacagtaac ttctcgagca 1800
gcaaattctt ctgtgcctcc aatcacagtg aatgctaaaa tgaataagga cgtaaacagt 1860
ttccccagcc caatgattgt ttacgcagaa attctacaag gatatgtacc tgttcttggg 1920
gccaatgtga ctgctttcat tgaatcacag aatggacata cagaagtttt ggaacttttg 1980
gataattgta caggcgctga ttctttcaag aatgatggag tctactccag gtattttaca 2040
gcatatacag aaaatggcag atatagctta aaagttcggg ctcatggagg agcaaacact 2100
gccaggctaa aattacggcc tccactgaat agagccgcgt acataccagg ctgggtagtg 2160
aacggggaaa ttgaagcaaa cccgccaaag cctgaaattg atgaggatac tcagaccacc 2220
ttggaggatt tctgcccgaac agcatccgga ggtgcatttg tggtatcaca agtcccaagc 2280
cttcccttgc ctgaccaata cccaccaagt caaatcacag acctgatgc cacagtccat 2340
gaggataaga ttattcttac atggacagca ccaggagata attttgatgt tggaaaagtt 2400
caacgttata tcataagaat aagtgcaggt attcttgatc taagagacag ttttgatgat 2460
gctcttctga taaactactc tgaatctgtc ccaaaggagg ccaactccaa ggaaagcttt 2520
gcatttaaac cagaaaatat ctgagaagaa aatgcaaccc acatatttat tgccattaaa 2580
agtatagata aaagcaattt gacatcaaaa gtatccaaca ttgcacaagt aactttgttt 2640
atccctcaag caaatctctg tgacattgat cctactccta ctctactcc tactcctgat 2700
aaaagtcata attctggagt taatatttct acgttgggtat tgtctgtgat tgggtctgtt 2760
gtaattgtta actttatttt aagtaccacc ttttaaaaaa aaaacaatgt aagtaaagga tatttctgaa 2880
aagtagacct catcccatgt gtgatcataa actcataaaa ataattttta gatgtcggaa 2940
aaggatactt tgattaaata aaaacactca tggatatgta aaaactgtca agattaaaa 3000
ttaatagttt cattttattg ttattttatt tgatgcaaca gttttctgaa atgatatttc 3120
tttcatactg atacctgggt aagaaattaa aatcatctat ctgagtagtc aaaatacaag taaaggagag 3180
caaataaaca acatttggaa aaaaaaaaaa aaaaaaaa 3218

```

<210> 54
 <211> 1630
 <212> DNA
 <213> Homo sapiens

```

<400> 54
aaaagcagaa agagattacc agccacagac gggtcatgag cgcggtatta ctgctggccc 60
tcctggggtt catctcccca ctgccaggag tgcaggcgct gctctgccag ttggggagca 120
ttcagcatgt gtggaagggtg tccgacctgc cccggcaatg gacccctaag aacaccagct 180
gcgacagcgg cttgggggtgc caggacacgt tgatgtctat tgagagcggg cccaagtga 240
gcctgggtgt ctccaagggc tgacggagg ccaaggacca ggagccccgc gtcactgagc 300
accggatggg ccccggcctc tccctgatct cccacacctt cgtgtgccgc caggaggact 360
tctgcaacaa cctcgtaaac tccctccgcg tttgggcccc acagccccca gcagaccag 420
gatccttgag gtgcccagtc tgcttgtcta tggaaaggctg tctggagggg acaacagaag 480
agatctgccc caaggggacc acacactgtt atgatggcct cctcaggctc aggggaggag 540
gcatcttctc caatctgaga gtccagggat gcatgcccc gccaaggtgc aacctgtca 600
atgggacaca ggaaattggg cccgtgggta tgactgagaa ctgcaatagg aaagattttc 660
tgacctgtca tcgggggacc accattatga cacacggaaa cttggctcaa gaaccactg 720
attggaccac atcgaatacc gagatgtgcg aggtggggca ggtgtgtcag gagacgctgc 780
tgctcataga tgtaggactc acatcaaccc ttggtgggac actcagcccc cctggggtg cttgtggcct 900
gggctcaaaa ttcccagaag accaccatcc tggacctgt gcaatagtgc cagcagcagc agcgttctgc 960
cctataccca cctcctcaa gctgcccctg tcccaggaga ccggcagtg cctacctgtg 1020
tgaactccct ccctcctcaa tggaaacctg tcaagtggct ccccgaatg gacctgcccc aggggcgcca 1080
tgacgcccct tggaaacctg tcaagtggct ccccgaatg gctgtccacc aaaatgagca 1140
ctcattgtta tgatgggtac attcatctct caggaggtgg gctgtccacc aaaatgagca 1200
ttcagggtgt cgtggcccaa ccttccagct tcttgttgaa ccacaccaga caaatcgga 1260
tcttctctgc gcgtgagaag cgtgatgtgc agcctcctgc ggtgtgggct ggactggcc ccagcgtgt 1320
gggtgggggt ggttggccct tctgtctaac tctattacc ccacgattct tcaccgctgc 1380
tgaccacca cactcaacct cctctgacc tcataacctt atggccttg acaccagatt 1440
ctttccatt ctgtccatga atcatcttcc ccacacacaa tcatcatat ctactacct 1500
aacagcaaca ctggggagag cctggagcat agacctgtgc cctatgggag aggggacgct 1560
ggaggartgg ctgcatgtat ctgataatac agacctgtgc ctttcaaaaa aaaaaaaaaa 1620
aaaaaaaaa 1630

```

<210> 55
 <211> 2221

SEQUENCE LISTING 1657-2022.txt

<212> DNA
<213> Homo sapiens

<400> 55

```

gtgaccggag gcgagaaacc ccgcctcggc accctgacgc agcgcaggac ccgccccgcg 60
cgtgacgcca gcgtcaggcc agccccggca tgcctctgcg ccgcccgcg tccagctccg 120
acaacaggaa ttttctccga gagcgggccc ggctcagttc agctgctgtc cagacccgga 180
tcggcaacag tgccgcctcc agacgttctc ctgccgctcg cccgcccgtc ccagcgcgcc 240
cagccctccc gcgagggcgc cccgggacgg aaggatccac cagtctgtcg gcgcccgcg 300
ttctcgtggt cgccgtcgcc gtcgtcgtgg tggtagtctc cgccgtcgcc tggggccatgg 360
ccaattacat ccacgtccct cccggctccc cggagggtgcc caagctgaac gtcaccgttc 420
aggatcagga ggagcatcgc tgccgggagg gggccctgag cctcctgcaa cacctgcggc 480
ctcactggga cccaccaggg gtgaccctgc agctcttcac agatggaatc acaaataaac 540
ttattggctg ttacgtggga aacaccatgg aggatgtagt cctggtgaga atttatggca 600
ataagactga gttattagtc gatcgagatg aggaagtaaa gagttttcga gtgttgacgg 660
ctcatgggtg tgcaccacaa ctctactgta ccttcaataa tggactatgc tatgaattta 720
tacaaggaga agcactggat ccaaagcatg tctgcaaccc agccattttc aggctaatag 780
ctcgtcagct tgctaaaatc catgctattc atgcacacaa tggctggatc cccaaatcta 840
atctttggct aaagatggga aagtatttct ctctcattcc cacaggattt gcagatgaag 900
acattaataa aaggttccta agtgatatcc caagctctca gattctccag gaagagatga 960
cttgatgaa ggagattctt tccaacctgg gctcacctgt tgtgctttgc cataatgacc 1020
tattgtgtaa gaatataatc tacaatgaga aacaagggtg tgtacagttc attgattatg 1080
aatattctgg atacaactac ctggcatatg atattggaaa tcattttcaat gaatttgacg 1140
gtgtgagtga tgtagactat agtctgtatc cagatagaga actacagagt cagtggctgc 1200
gtgcttacct tgaagccctac aaagaattta agggctttgg gactgaagtt actgaaaagg 1260
aggtagaaat actcttcatt caagtcaatc agtttgcatt ggcttctcat ttcttttggg 1320
gattgtgggc tttgattcaa gccaaatact ccactattga gtttgatttc cttgggtatg 1380
caattgttcg ttttaaccga tactttaaaa tgaagcctga ggttactgca ttaaaagtcg 1440
ctgagtaaa aagagattta attattctcc agtagctgag caatgcttgt gaatcttttc 1500
ttaagaaatc ccaaaaagcc aatatttagt ttttctctgt tgtttaattt ggttatcttg 1560
ctttataaat tatgcctcta aacaatcaa tctatttttg aaatagactg aatgatgtca 1620
agaaatatac ctactgctat ccgtatgtgg tggattagaa atgtgttaaa tctgcaaaag 1680
gtataaagat gtcagtttaa ttcttttgat aatttaacct atgtgttatg tgaattattt 1740
attataaact tagcacgatt ctgtgactgt tttctctgtg ttcacgttcg ttgagtgtaa 1800
gcaatgaaaa tgtcccaaat aagtttttta agttttactt taataagatt aatttcagta 1860
aacattctag ttgttcagtg taaccttttt atcttgatgc attgtaaagta aaatgaatca 1920
tttactcttg aaatgccagt atactgactg tgtagataat ttaggatttt catataaaaa 1980
tagctgttta ggaagggtgaa atacattcac tgtctctgtt ggtggtacat cttgttgta 2040
tcaatattag aaagtatttc tttttggggt aatataacct agaattaaat ccctgtttct 2100
ctatgtagtc tggcagtata aatataaata tttaccatat aatcttgtaa taagtattag 2160
ttaatgttac caaatctgt attaaataat gttttcaaat gctaaaaaaa aaaaaaaaaa 2220
a 2221

```

<210> 56
<211> 1306
<212> DNA
<213> Homo sapiens

<400> 56

```

tgataagcta caacataaac acatctaggt tcttgttctt agaatacagc atgaagaatt 60
tgctttcttc tttcttccta acattttcat gtgagatcca gaaaggacac attgtctctg 120
gccattcgaa gagagaaaga aagaaagaaa aaaaaggat ttagagacag agagagaaaa 180
aggctgaaat ggttctcgctg ggttctaaaa atccgcaaac caaacaagcc caagtcttc 240
ttttgggact tgactcagct ggggaagtcta ctctccttta taaattaaag cttgctaagg 300
atattaccac catccctaca ataggtttca atgtggaaat gatcgagttg gaaaggaatc 360
tttactcac agtctgggat gttggaggac aggaaaaaat gagaactgtt tggggctgtt 420
actgtgagaa caccgatggg ctggtgtatg ttgtggacag tacagacaaa cagcagctgg 480
aagagtctca gagacagttt gagcacattt tgaagaaatg acacattaaa aatgtgcctg 540
ttgttctatt agccaacaaa caagacatgc ctggagctct gactgctgag gacatacca 600
gaatgttcaa agtgaagaag ctttgcagtg accggaactg gtatgtgcaa ccctgctgtg 660
ccctcacagg ggaggggctg gccagggatt aactggattt gtgaagagcc 720
acatgaaatc aagaggagac actttggcgt tcttcaagca gaactgaggc tgcgaaaaat 780
ccaagtctct acagagacac tgatgaagtt gaaagggtaa ttgtttttcc atgccaaatg 840
aggaaatcaa attaatgagt tgacaaaact ttcctgagat gttatttcat ctacatttag 900
ttaaacaaat tagaagtata tctagaaaaa atttattttc agccaggaac tttagcaaac 960
tgtggcaatg atcactggga atgaaaacgt ataagtgtct acaatttttg ttatcacatt 1020
ggatgacttt gaatatagta gtgacacttg ggaccaaata aattatttta tatgactact 1080

```


SEQUENCE LISTING 1657-2022.txt

```

agaacaaagt tttagtaagc tgtctgctaa tagagtcaga attcttccag attgtttcca 1140
gctgtaacag gtattgaatt tccaccgtgc tcctatgtaa cagctgggtg gtgtaaaaaa 1200
tgaacttcaa attatggagt ggaagaagcg taatgttaat atcttgtaaa ttcgtattcc 1260
ctattaaata aagctttctt attccctaaa aaaaaaaaaa aaaaaa 1306

```

```

<210> 57
<211> 2090
<212> DNA
<213> Homo sapiens

```

```

<400> 57
ttcggcacga gtaagaccag gatgtctctg aaatggacgt cagtctttct gctgatacag 60
ctcagttggtt acttttagctc tggaaagctg gaaaagggtg tagtgtggcc cacagaatac 120
agccattgga taaatatgaa gacaatcctg gaagagcttg ttcagagggg tcatgagggtg 180
actgtgttga catcttcggc ttctactctt gtcaatgccg gtaaatacatc tgctattaaa 240
ttagaagttt atcctacatc tttactaaa aatgatttgg aagattctct tctgaaaatt 300
ctcgatagat ggatataatg tgtttcaaaa aatacatttt ggtcatattt ttcacaatta 360
caagaattgt gttgggaata ttatgactac agtaacaagc tctgtaaaga tgcagttttg 420
aataagaaac ttatgatgaa actacaagag tcaaagtttg atgtcattct ggcagatgcc 480
cttaatccct gtgggtgagct actggctgaa ctatttaaca taccctttct gtacagtctt 540
cgattctctg ttggctacac atttgagaag aatgggtggg gatttctgtt cctcctttcc 600
tatgtacctg ttgttatgtc agaattaagt gatcaaatga ttttcatgga gaggataaaa 660
aatatgatac atatgcttta ttttgacttt tggtttcaaa tttatgatct gaagaagtgg 720
gaccagtttt atagtgaagt tctaggaaga cccactacat tatttgagac aatggggaaa 780
gctgaaatgt ggctcattcg aacctattgg aattttgaat ttcctcgccc attcttacca 840
aatgttgatt ttgttggagg acttcactgt aaaccagcca aacccttgcc taaggaaatg 900
gaagagtttg tgcagagctc tggagaaaat ggtatttggt tgttttctct ggggtcgatg 960
atcagtaaca tgtcagaaga aagtgccaac atgattgcat cagcccttgc ccagatccca 1020
caaaagggtt tatggagatt tgatggcaag aagccaaata cattaggttc caatactcga 1080
ctgtacaagt ggttacccca gaatgacctt cttggtcatc ccaaaacca agcttttata 1140
actcatgggt gaaccaatgg catctatgag gcatctacc atgggatccc tatgggtggg 1200
attcccttgt ttgcggtatc acatgataac attgctcaca tgaaagccaa gggagcagcc 1260
ctcagtgtgg acatcaggac catgtcaagt agagatttgc tcaatgcatt gaagtcagtc 1320
attaatgacc ctgtctataa agagaattgt caagaattca tcatgacca 1380
ccaatgaagc ccttgatcgc agcagctctc tggattgagt ttgtcatgcg ccacaaagga 1440
gccaagcacc ttcgagtcgc agctcacaa ctcacctgga tccagtacca ctctttggat 1500
gtgatagcat tctgtctggc ctgctgtggc actgtgatat ttatcatcac aaaattttgc 1560
ctgttttgtt tccgaaagct tgccaaaaca ggaagaagaga agaaaagaga ttagtattat 1620
caaaagcctg aagtggaaatg actgaaagat gggactcctc ctttatttca gcatggaggg 1680
ttttaaatgg aggatttcct ttttctctgt acaaaacatc ttttcacaac ttaccttgtt 1740
aagacaaaaa ttattttcca gggattttaa acgtacttta gttggaatta ttctatgtca 1800
atgattttta agctatgaaa aatacaatgg ggggaaggat agcatttggg gatataccta 1860
atgttaaata acgagttact ggatgcagca cgcaacatgg cacatgtgta tacatatgta 1920
gctaaccctt cgttgtgcac atgtacccta aaacttaag tataatttaa aaaaagcaaa 1980
aaaaaaaata accaactctt ttttttaaac caggaaggaa aatgtgaaca tggaaacaac 2040
ttctagtatt ggatctgaaa ataaagtgtc atccaagcca taaaaaaaaa 2090

```

```

<210> 58
<211> 2292
<212> DNA
<213> Homo sapiens

```

```

<400> 58
ccatgggttc cccttcagcc tgtccataca gagtgtgcat tccctggcag gggctcctgc 60
tcacagcctc gcttttaacc ttctggaacc tgccaaacag tgcccagacc aatattgatg 120
tcgtgcccgt caatgtcgca gaaggggaag aggtccttct agtagtccat aatgagttcc 180
agaactttta tggctacaac tggtaaaaag gggaaagggt gcatgccaac tatcgaatta 240
taggatattg aaaaaatata agtcaagaaa atgcccagg gcccgcacac aacggtcgag 300
agacaatata cccaatgga accctgtctg tccagaacgt taccacaat gacgcaggat 360
tctataccct acacgttata aaagaaaatc ttgtgaatga agaagtaacc agacaattct 420
acgtattctc ggagccacc aagcctcca tcaccagcaa caacttcaat ccggtggaga 480
acaaagatat tgtgttttta acctgtcaac ctgagactca gaacacaacc tacctgtggt 540
gggtaaacaa tcagagcctc ctggtcagtc ccaggctgct gctctccact gacaacagga 600
ccttcgttct actcagcgcc acaaagaatg acataggacc ctatgaatgt gaaatacaga 660
accagtggtt tgccagccgc agtgaccag tcaccctgaa tgtccgctat gagtcagtag 720
aagcaagttc acctgacctc tcagctggga ccgctgtcag catcatgatt ggagtactgg 780
ctgggatggc tctgatatag cagccttggt gtagtttctg catttcggga agagtgtttt 840

```

SEQUENCE LISTING 1657-2022.txt

tattatccac	ctgcagactg	gactggattc	ttctagctcc	ttcaatccca	ttttctcctg	900
tggcatcact	aagtataaga	cctgctctct	tcctgaagac	ctataagctg	gagggtggaca	960
actcaatgta	aattttcaagg	aaaaaccctc	atgcctgaga	tgtggggccac	tcagagctaa	1020
ccaaaatggt	caacaccata	actagagaca	ctcaaattgc	caaccaggac	aagaagtga	1080
tgacttcatg	ctgtggacag	tttttcccaa	gatgtcccaa	gcctcatcgt	gacgaggctc	1140
ttatcccact	ccatttttcc	ctgctcatgc	ctgcctcttt	aatttggtaa	gataatgctg	1200
taactagaat	ttcacatca	gcgccttggt	caggcaattt	gacagagtgt	tggatgtgtc	1260
atgtcatcat	gtcaaaccca	aatttttgac	ctaagggatc	ctttattctg	cccagtggtc	1320
aactttaaca	acatccctaa	tacaactggt	tattcaaatg	cacgggtggc	cctgttagag	1380
ttagacctct	agactcacct	gttctcacgc	cctgttttaa	tttaacccag	ctatgggatg	1440
ccagataaca	gaattgctgc	ctacgagctg	aacagggagg	agtttgtgca	gttgctgaca	1500
ctctttgttg	cacataaata	aatacagtgg	gtactataga	gactcagtgg	caaaaaattaa	1560
caaataatgt	gcttgattaa	aatgggtagg	cttctcatgt	ggctcattct	ttaatctatt	1620
ctcttttatt	tggtttgggt	catgggtgct	ctgcctatgg	atcatacttc	aaactcttgg	1680
tgtgatcctc	ctgattgtca	caatattagt	taccctgggt	tgctgtattc	tctaaaacct	1740
ttaaatgttt	gcattgtcaa	attcgtcaaa	tgtcaaatat	tctctctttg	gctggaatga	1800
caaaaaatca	aataaatgta	tgattaggag	gacatcataa	cctatgaatg	atggaaagta	1860
aaaatgatgg	taactgacag	tagtgtaaat	gccttatgtt	tagtcaaaact	ctcatttagg	1920
tgacagcctg	gtgactccag	aatggagcca	gtcatgctaa	atgccatata	ctcacactga	1980
aacatgagga	agcaggtaga	tcccagaaca	gacaaaaact	tcctaaaaaac	atgagagtcc	2040
aggctgtctg	agtcagcaca	gtaagaaagt	cctttctgct	ttaactctta	gaaaaaagta	2100
atatgaagta	ttctgaaatt	aaccaatcag	tttattttaa	tcaatttatt	tatattcttc	2160
tgttcctgga	ttcccatttt	acaaaaccca	ctgttctact	gttggtattgc	ccagtaggag	2220
ctatcactat	attttgcaga	atggaaactg	ccctgactct	tgaatcacaa	ataaaaagcca	2280
attgtatctg	tt					2292

<210> 59

<211> 1994

<212> DNA

<213> Homo sapiens

<400> 59

gctgccaccg	ctcctgccac	tgcagtgtct	gagccccgtg	caggggagct	tgcgggagga	60
tcgaccgaca	gacggacgca	cgccgaggca	ctgcgcccc	agccccgcgc	cggtgccacc	120
gcagcccggc	cccggccgcc	agtccagccg	cccctcgccc	gggtgcctagg	tgcccggccc	180
cacaccgcca	gctgctcggc	gccgggtcc	gccatgcgct	ccgcccgtgt	cctggctctt	240
ctgctctgcg	ccgggcaagt	actgctgctc	cctgtgaaca	gccctatgaa	taaagggtat	300
accgaggtga	tgaatgcat	cgttgagggtc	atctccgaca	cactttccaa	gcccagcccc	360
atgcctgtca	gccaggaatg	ttttgagaca	ctccgaggag	atgaacggat	cctttccatt	420
ctgagacatc	agaatttact	gaaggagctc	caagacctcg	ctctccaagg	cgccaaggag	480
agggcacatc	agcagaagaa	acacagcggg	tttgaagatg	aactctcaga	ggttcttgag	540
aaccagagca	gccaggccga	gctgaaagag	gcgggtggaag	agccatcatc	caaggatgtt	600
atggagaaaa	gagaggattc	caaggaggga	gagaaaagtg	gtgaagccac	agacggagcc	660
aggccccagg	ccctcccggg	gcccattgcag	ctgaggggaa	ctgaggggaa	caatcaggcc	720
cctggggagg	aagaggagga	ggaggaggag	gccaccaaca	cccaccctcc	agccagcctc	780
cccagccaga	aatacccagg	cccacaggcc	gagggggaca	gtgagggcct	ctctcagggt	840
ctggtggaca	gagagaaggg	cctgagtgtca	gagccagggt	ggcaggcaaa	gagagaagag	900
gaggaggagg	aggaggagga	ggctgaggct	ggagaggagg	ctgtccccga	ggaagaaggc	960
cccactgtag	tgctgaaccc	ccaccggagc	cttggtctaca	aggagatccg	gaaaggcgag	1020
agtccgtcgg	aggctctggc	tgtggatgga	gctgggaagc	ctggggctga	ggaggctcag	1080
gaccccgaag	ggaagggaga	acaggagcac	tcccagcaga	aagaggagga	ggaggagatg	1140
gcagtgtgtc	cgcaaggcct	cttccggggg	gggaagagcg	gagagctgga	gcaggaggag	1200
gagcggctct	ccaaggagtg	ggaggactcc	aaacgctgga	gcaagatgga	ccagctggcc	1260
aaggagctga	cggctgagaa	gcggctggag	gggcaggagg	aggaggagga	caaccgggac	1320
agttccatga	agctctcctt	ccgggcccgg	gcctacggct	tcaggggccc	tgggcccagc	1380
ctgcgacgag	gctggaggcc	atcctcccgg	gaggacagcc	ttgaggcggg	cctgcccctc	1440
cagggtccgag	gctaccccga	ggagaagaaa	gaggaggagg	gcagcgcaaa	ccgcagacca	1500
gaggaccagg	agctggagag	cctgtcgggc	attgaagcag	agctggagaa	agtggcccac	1560
cagctgcagg	cactacggcg	gggctgagac	accggctggc	agggctggcc	ccagggcacc	1620
ctgtggccct	ggctctgtcg	tccccttggc	aggtcctggc	cagatggccc	ggacgtgtct	1680
tccggtaggg	aggcagcctc	cagcctgccc	aagcccaggc	caccctatcg	ccccctacgc	1740
gccttgtctc	ctactcctga	ctcttacctg	ccttggaaaca	tcctttgtag	ggcagcccca	1800
caactttaaa	catttcacgt	tccttctctg	aacacaggca	gctttctaga	agtttccctt	1860
cctccatcct	atccactggg	cacaacttga	ataacttctg	accttttggg	gaaagctgag	1920
aactcctgac	tgtaacatat	tctgtatgaa	ctttatctaa	agaaaaataa	atctgttctg	1980
ggctctttcc	tctg					1994

SEQUENCE LISTING 1657-2022.txt

<210> 60
<211> 2518
<212> DNA
<213> Homo sapiens

<400> 60
ccagcagtggt ctgcaccatg cacgtgaacg gcaaagtggc gctgggtgacc ggcgcggctc 60
agggcatagg cagagccttt gcagaggcgc tgctgcttaa gggcgccaag gtagcgctgg 120
tggattggaa tcttgaagca ggtgtacagt gtaaaagctgc cctgcatgag caatttgaac 180
ctcagaagac tctgttcac cagtgcgatg tggctgacca gcaacaactg agagacactt 240
ttagaaaagt tgtagaccac tttggaagac tggacatittt ggtcaataat gctggagtga 300
ataatgagaa aaactgggaa aaaactctgc aaattaattt ggtttctgtt atcagtgagg 360
cctatcttgg tttggattac atgagtaagc aaaaatggagg tgaaggcggc atcattatca 420
atatgtcatc tttagcagga ctcatgcccg ttgcacagca gccggtttat tgtgcttcaa 480
agcatggcat agttggattc acacgctcag cagcgttggc tgctaatctt atgaacagt 540
gtgtgagact gaatgccatt tgtccaggct ttgttaacac agccatcctt gaatcaattg 600
aaaaagaaga aaacatggga caatatatag aatataggga tcataatcaag gatattgata 660
aatactatgg aattttggac ccaccattga ttgccaatgg attgataaca ctcatgtgaag 720
atgatgcttt aaatgggtgt attatgaaga tcacaacttc taagggaatt cattttcaag 780
actatgatac aactccattt caagcaaaaa cccaatgaac agcttatgtg ttagccatag 840
ctgaaataaa gcacaaatag ctatatttca catctatct tcatgtgaat atagctttta 900
aatgaaatgt tacagtttga agttttcctt catgcacttg gtgataaacg ttttctaatt 960
ttttagttaa gtatatggat aaaaagttaa gaactattaa aaatgtgatg tggaccaaag 1020
gctaggttgt aatcttgata gtctaaaaaa tgatcaaaac aaatgatttt caaggaatat 1080
tcaatattct gcctttcaga aagtgtattt aatatctgtc ttcataaata ttaatgttct 1140
tcagaacatc attttaaagg agatacttga attgttattt aaatcaaacc agatgtaaaa 1200
cactcacata caagttcata cttaaaaaga ggaaagctac ttaacaatga caaatatttc 1260
acaataataa tttttactta tataccatct tccaactgaa catttcagtt cttccaagag 1320
cttcttagag tagtatattt tgggggagcag caaggaataa actacagtgt aaacatatcc 1380
cagatgaaaa ctgctgtatg gaaaaatgac agaaagtaac tgattgacac tgttgattca 1440
cagttcagcc tcctatctgg gaaagacatt tctttcctct gctcacttta agaactttta 1500
ccgactccaa aaatctcagg aattaaactt ttaacagtta cagcaataaa gaatagttag 1560
tactccaaaa atattatatt taagatgctc aacaagaaaa aaatgcaaat gtaatatattt 1620
tttcaaatta cttctttatt gacttgtcca aatttcaaaa gtgcctacc ttcaataaaa 1680
cttttttatt ctgatctcca taaattactt agtcttctat gtatagctat caaggaaata 1740
aaaccaattt tgccacagcc acaactgtaa atgtttttgt acccatgctg aaactcataa 1800
caacacagac ataaaaatag ctgtgaggtt ttgtcttttt tgtgtcagc tatcttaaga 1860
atcattaaat acacctgctt tgggtaaaaa tcttttgcaag cagtaattaa cactagtaac 1920
agtgaagaca caagatttcc aaatcagtcg ttttctcaaa aaaatatcgt ataagtgact 1980
catcctgtct gctaactcca gacctcccag cttgaagcca aatctttcca tgtgagattg 2040
atatggattt cctagaagta ctggaatggt gtcatatctt gccctatttt aattctgcta 2100
tagaaaacaa ttgccttcac ttttaaggag ttaattgaat attaataact ctggctaga 2160
ttttcatata atgtattaaa gacaaagtag tgaacatcaa tgaacatctg atagagataa 2220
actgtaatca ggcataagct tgtttgtatg ttctggcagt gactaatcag taaatgatgt 2280
cgttttgccc agtattcact atcttctgta ttttctctt gtcgtgtaaa tagtataacc 2340
ttttcattta tggacaattt tttggactag tagccttcaa tatacattct gctttgaaat 2400
aattttttca aatcaataaa ttatgtagac atttaaaatc aaatatcaag tagaattgaa 2460
aaatgtgagt tacataagtt aaaaacttac tttaaatctt accttctata ggtagctc 2518

<210> 61
<211> 1510
<212> DNA
<213> Homo sapiens

<400> 61
ggcagcaggc ccaagcaggt cggcggcggc ggcaggagag cggcgggcg tcagctcctc 60
gacccccgtg tcgggctagt ccagcgaggc ccagcgaggc cgtggggcca tggccaggcc 120
cggcatggag cgggtggcgcg accggctggc gctgggtgacg ggggctcgg ggggcatcgg 180
cgcggccgtg gcccgggccc tgggtccagca gggactgaag gtgggtgggt gcgcccgcac 240
tgtgggcaac atcgaggagc tggctgctga atgtaagagt gcaggctacc ccgggacttt 300
gatccccac agatgtgacc tatcaaatg agaggacatc ctctccatgt tctcagctat 360
ccgttctcag cacagcgggt tagacatctg catcaacaat gctggcttgg cccggcctga 420
caccctgctc tcaggcagca ccagtgggtg gaaggacatg ttcaatgtga acgtgctggc 480
cctcagcatc tgcacacggg aagcctacca gtccatgaag gagcggaaat tggacgatgg 540
gcacatcatt aacatcaata gcattgtcgg ccaccgagt ttaccctgt ctgtgaccca 600
cttctatagt gccaccaagt atgccgtcac tgcgtgaca gagggactga ggcaagagct 660
tcgggaggcc cagaccacac tccgagccac gtgcattctt ccagggtgtg tggagacaca 720

SEQUENCE LISTING 1657-2022.txt

```

attcgccttc aaactccacg acaaggaccc tgagaaggca gctgccacct atgagcaaat 780
gaagtgtctc aaacccgagg atgtggccga ggctgttatc tacgtcctca gcaccccgcc 840
acacatccag attggagaca tccagatgag gccacggag caggtagact agtgactgtg 900
ggagctcctc cttccctccc cacccttcac ggcttgctc ctgcctctgg attttagggt 960
ttgatttctg gatcacggga taccacttcc tgtccacacc ccgaccaggg gctagaaaaat 1020
ttgtttgaga tttttatata atcttgtcaa attgcttcag ttgtaaattg gaaaaatggg 1080
ctggggaaaag gaggtgggtg ccctaattgt tttacttgtt aacttgttct tgtgcccctg 1140
ggcacttggc ctttgtctgc tctcagtgct tcccttttga catgggaaaag gaggttgtggc 1200
caaaatcccc atcttcttgc acctcaacgt ctgtggctca gggctggggg ggcagaggga 1260
ggccttcacc ttatatctgt gttgttatcc agggctccag acttcctcct ctgcctgccc 1320
cactgcaccc tctccccctt atctatctcc ttctcggtc cccagccag tcttggcttc 1380
ttgtcccctc ctggggtcac ccctccactc tgactctgac tatggcagca gaacaccagg 1440
gcctggccca ctggatttca tggtgatcat taaaaaagaa aaatcgcaac caaaaaaaa 1500
aaaaaaaaa 1510

```

<210> 62
 <211> 1104
 <212> DNA
 <213> Homo sapiens

```

<400> 62
ctcgggtgcgc gaccccggtc cagaggactc tttgctgtcc cgcaagatgc ggatgctgct 60
ggcgctcctg gccctctccg cggcgcgggc atcgccaggt gcagagtcac actggtgcta 120
cgaggttcaa gccgagtcct ccaactaccc ctgcttggtg ccagtcaagt ggggtggaaa 180
ctgccagaag gaccgccaagt cccccatcaa catcgtcacc accaaggcaa aggtggacaa 240
aaaactggga cgcttcttct tctctggcta cgataagaag caaacgtgga ctgtccaaaa 300
taacgggcac tcagtgatga tgttgcgtga gaacaaggcc agcatttctg gaggaggact 360
gcctgcccc aaccaggcca aacagttgca cctgcactgg tccgacttgc catataaggg 420
ctcggagcac agcctcgatg gggagcactt tgccatggag atgcacatag tacatgagaa 480
agagaagggg acatcgagga atgtgaaaga ggccaggac cctgaagacg aaattgcggg 540
gctggccttt ctggtggagg ctggaaccca ggtgaacgag ggcttccagc cactggtgga 600
ggcactgtct aatatcccca aacctgagat gagcactacg atggcagaga gcagcctgtt 660
ggcactgtct ccaagggagg agaaactgag gcactacttc cgctacctgg gctcactcac 720
cacaccgacc tgcgatgaga aggtcgtctg gactgtgttc cgggagccca ttcagcttca 780
cagagaacag atcctggcat tctctcagaa gctgtactac gacaaggaa acagagtgag 840
catgaaggac aatgtcaggc ccctgcagca gctggggcag cgacgggtga taaagtccgg 900
ggccccgggt cggccgctgc cctggccctc ctgggcccc tgggtgacct ctgttgctc 1020
cctgctggcc ggcttctctg gatgatggct cacttctgca cgcagcctct ctgttgctc 1080
agctctccaa gttccaggct tccggctcct agccttccca ggtgggactt taggcatgat 1104
taaaatatgg acatatTTTT ggag

```

<210> 63
 <211> 1484
 <212> DNA
 <213> Homo sapiens

```

<400> 63
cccgtgagga ggaaaagggt tgtccgctgc caccagtggt gagcgggtga caccacccgg 60
ttaggaaatc ccagctccca agagggtata aatccctgct ttactgtctga gctcctgctg 120
gaggtgaaag tctggcctgg cagccttccc caggtagca gcaacaaggc cacgtgctgc 180
tgggtctcag tcctccactt cccgtgtcct ctggaagttg tcaggagcaa tgttgcgctt 240
gtacgtgttg gtaatgggag tttctgcctt cacccttcag cctgcggcac acacaggggc 300
tgccagaagc tggcggtttc gtgggaggca ttacaagcgg gagttcaggc tggaagggga 360
gcctgtagcc ctgaggtgcc cccaggtgcc ctactgggtg tgggcctctg tcagcccccg 420
catcaacctg acatggcata aaaatgactc tgctaggacg gtcccaggag aagaagagac 480
acggatgtgg gccaggagc gtgctctgtg gcttctgcca gccttgcagg aggactctgg 540
cacctacgtc tgcactacta gaaatgcttc ttactgtgac aaaatgtcca ttgagctcag 600
agtttttgag aatacagatg ctttctgtcc gttcatctca taccgcgaaa ttttaacctt 660
gtcaacctct ggggtattag tatgccctga cctgagtgaa ttcacccgtg acaaaaactga 720
cgtgaagatt caatggatca aggattctct tcttttggat aaagacaatg agaaatttct 780
aagtgtgagg gggaccactc acttactcgt acacgatgtg gccctggaag atgctggcta 840
ttaccgctgt gtcctgacat ttgcccatag aggcagcaa tacaacatca ctaggagat 900
tgagctacgc atcaagaaaa aaaaagaaga gaccattcct gtgatcattt cccccctcaa 960
gaccatatac gcttctctgg ggtcaagact gacaatcccc tgaagggtgt ttctgggaac 1020
cggcacaccc ttaaccacca tgcgtgtgtg gacggccaat gacaccaca tagagagcgc 1080
ctacccggga ggccgcgtga ccgaggggcc acgcccagaa tattcagaaa ataatgagaa 1140
ctacattgaa gtgccattga tttttgatcc tgtcacaaga gaggatttgc acatggattt 1200

```

SEQUENCE LISTING 1657-2022.txt

taaattgtgtt	gtccataata	ccctgagttt	tcagacacta	cgcaccacag	tcaaggaagc	1260
ctcctccacg	ttctcctggg	gcattgtgct	ggccccactt	tcactggcct	tcttggtttt	1320
gggggggaata	tggatgcaca	gacggtgcaa	acacagaact	ggaaaagcag	atgggtctgac	1380
tgtgctatgg	cctcatcatc	aagactttca	atcctatccc	aagtgaataa	aatggaatga	1440
aataattcaa	acacaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa		1484

<210> 64
 <211> 1704
 <212> DNA
 <213> Homo sapiens

<400> 64

atccatgcta	aaggtaaaca	aactgcaact	tatatctgca	atttatTTTTg	gtatagacaa	60
gaggtatgcc	agtagcacac	tgggtggcttc	agaagaaatt	ctcaacacct	agctcgccag	120
agagtctatg	tatgggattg	aacaatctgt	aaactaaagg	atcctaatac	tgaaaaaag	180
tatgataaat	tataagtcac	tattggcact	gttgtttata	ttagcctcct	ggatcatttt	240
tacagttttc	cagaactcca	caaagggtttg	gtctgctcta	aacttatcca	tctccctcca	300
ttactggaac	aactccacaa	agtccttatt	ccctaaaaca	ccactgatat	cattaaagcc	360
actaacagag	actgaactca	gaataaaggga	aatcatagag	aaactagatc	agcagatccc	420
acccagacct	ttcacccacg	tgaacaccac	caccagcgcc	acacatagca	cagccaccat	480
cctcaaccct	cgagatagct	actgcagggg	agaccagctg	cacatcctac	tggagggtcaa	540
atgtgggtgt	agagattatg	gaaaaattca	atacaattag	tgcttccaaa	tgcaacaaag	600
aaacagttgc	aatgaaagag	aaatgcaagt	ttggaatgac	atccacaatc	cccagtgggc	660
atgtctggag	aaacacatgg	aatcctgtct	cctgtagttt	ggctacagtc	aaaatgaagg	720
aatgcctgag	aggaaaaact	atatacctaa	tgggagattc	cacgatccgc	cagtggatgg	780
aatacttcaa	agccagtatc	aacacactga	agtcagtggg	tctgcatgaa	tctggaaaat	840
tgcaacacca	gcttgctgtg	gatttggtata	ggaacatcaa	catccagtgg	caaaaatatt	900
gttatccctt	gataggatca	atgacctatt	cagtcaaaga	gatggagtac	ctcaccgggg	960
ccattgcagag	aactggaggga	gaaaaaaaat	actgtcattg	ttatttccct	gggcccagcat	1020
ttcagaccct	ttcccatgga	tgttttttatc	cgaaggggccc	tcaatgtcca	caaagccatt	1080
cagcatcttc	ttctgagaag	cccagacact	atgggttatca	tcaaaacaga	aaacatcagg	1140
gagatgtaca	atgatgcaga	aagatttagt	gactttcatg	gttacattca	atatctcatc	1200
ataaaggaca	ttttccagga	tctcagtgtg	gaatttcattg	atgcctggga	tataacaatt	1260
gcatatggca	caaataatgt	acacccacct	caacatgtag	tcggaaatca	gattaatata	1320
ttattaaact	atatttggtta	aataacacaa	aagtctgaaa	ttcattcact	taagtaaaaa	1380
aatttattga	ctgtctacta	gcaggccaga	tgctgtgttt	ggctctgaat	tcccaactag	1440
caagagcaga	gaatctacat	tatggctgat	ccataaggca	ccaattcagc	taaatgagat	1500
gtttctaatac	tgggcttcca	cttaaaaaata	aaactaaaaa	tactcatgaa	aagagcctac	1560
ccttcttgat	cagagccata	cccctcttca	ccaatgggaa	gtcaagacac	ctatgggtaa	1620
aagttctctc	tgatgcatga	aaactcagag	tgataaagta	attttaaaat	aaaaatttgg	1680
agaaagcaaa	aaaaaaaaaa	aaaa				1704

<210> 65
 <211> 1182
 <212> DNA
 <213> Homo sapiens

<400> 65

acacaggttg	gagcagagaa	agaggaaaca	tagaggtgcc	aaaggaacaa	agacataatg	60
atgtcatcca	agccaacaag	ccatgtctgaa	gtaaatgaaa	ccatacccaa	cccttacccta	120
ccaggcagct	ttatggctcc	tggatttcaa	cagcctctgg	gttcaatcaa	cttagaaaaac	180
caagctcagg	gtgctcagcg	tgctcagccc	tacggcatca	catctccggg	aatctttgct	240
agcagtcaac	cgggtcaagg	aaatatacaa	atgataaatc	caagtgtggg	aacagcagta	300
atgaacttta	aagaagaagc	aaaggcacta	gggggtgatcc	agatcatggg	tggattgatg	360
cacattgggt	ttggaattgt	tttgtgttta	atatccttct	cttttagaga	agtattaggt	420
tttgcctcta	ctgctgttat	tgggtggatac	ccattctggg	gtggcctttc	ttttattatc	480
tctggctctc	tctctgtgtc	agcatccaag	gagctttccc	gttgtctggg	gaaaggcagc	540
ctgggaatga	acattgttag	ttctatcttg	gccttcattg	gagtgtattct	gctgctggg	600
gatattgtgca	tcaatggggg	agctggccaa	gactactggg	ccgtgctttc	tggaaaaggc	660
atttcagcca	cgctgatgat	cttctccctc	ttggagtctt	tcgtagcttg	tgccacagcc	720
cattttggcca	accaagcaaa	caccacaacc	aatatgtctg	tcctggttat	tccaaatatg	780
tatgaaagca	accctgtgac	accagcgtct	tcttcagctc	ctcccagatg	caacaactac	840
tcagctaata	cccctaaata	gtaaaagaaa	aaggggtatc	agtctaattc	catggagaaa	900
aactacttgc	aaaaacttct	taagaagatg	tcttttattg	tctacaatga	tttctagtct	960
ttaaaaactg	tgttttgagat	ttgtttttag	ttgggtcgct	aatgatggct	gtatctccct	1020
tcactgtctc	ttctacatt	accactacta	cattgctggca	aagggtgaagg	atcagaggac	1080
tgaaaaatga	ttctgcaact	ctcttaaagt	tagaaatggt	tctgttcata	ttactttttc	1140

SEQUENCE LISTING 1657-2022.txt

cttaataaaaa tgtcattaga aacaaaaaaa aaaaaaaaaa aa

1182

<210> 66
<211> 2786
<212> DNA
<213> Homo sapiens

<400> 66

agcactctcc	agcctctcac	cgcaaaatta	cacaccccag	tacaccagca	gaggaaactt	60
ataacctcgg	gaggcggttc	cttccccctca	gtgcgggtcac	atacttccag	aagagcggac	120
cagggctgct	gccagcacct	gccactcaga	gcgcctctgt	cgctgggacc	cttcagaact	180
ctctttgctt	acaagttacc	aaaaaaaaaa	gagccaacat	gttggtattg	ctggctggta	240
tctttgtggt	ccacatcgct	actgttatta	tgctatttgt	tagcaccatt	gccaatgtct	300
ggttgggttc	caatacggta	gatgcatcag	taggtctttg	gaaaaactgt	accaacatta	360
gctgcagtga	cagcctgtca	tatgcccagt	aagatgccct	caagacagt	caggccttca	420
tgattctctc	tatcatcttc	tgtgtcattg	ccctcttggt	cttcgtgttc	cagctcttca	480
ccatggagaa	gggaaccgg	ttcttctctc	caggggccac	cacactggtg	tgctggctgt	540
gcattcttgt	gggggtgtcc	atctacacta	gtcattatgc	gaatcgtgat	ggaacgcagt	600
atcaccacgg	ctatttctac	atcctgggct	ggatctgctt	ctgcttcagc	ttcatcatcg	660
gcgttctcta	tctggtcctg	agaaagaaat	aaggccggac	gagttcatgg	ggatctgggg	720
gggtggggagg	aggaagccgt	tgaatctggg	aggggaagtg	aggttgctgt	acaggaaaaa	780
ccgagatagg	ggagggggga	gggggaagca	aaggggggag	gtcaaatccc	aaaccattac	840
tgaggggatt	ctctactgcc	aagcccctgc	cctggggaga	aagtagttgg	ctagtacttt	900
gatgtccctt	tgatggggct	cagagagcct	ccctgcagcc	accagacttg	gcctccagct	960
gttcttagtg	acacacactg	tctggggccc	cactagctgc	cacaacacca	gccccacttc	1020
tgggtcatgc	actgaggtcc	acagacctac	tgcatgtagt	taaaaatagc	gtacaagttc	1080
tggcaagagc	agatactgtc	tttgtgctga	atacgctaag	cctggaagcc	atcctgccct	1140
tctgacccaa	agcaaaacat	cacattccag	tctgaagtgc	ctactggggg	gctttggcct	1200
gtgagccatt	gtccctcttt	ggaacagata	tttagctctg	tggaaattcag	tgacaaaaatg	1260
ggaggaggaa	agagagtttg	taagggtcatg	ctggtgggtt	agctaaaacca	agaaggagac	1320
cttttcacaa	tggaaaacct	gggggatggg	cagagcccag	tcgagacctc	acacacggct	1380
gtccctcatg	gagacctcat	gccatgggtc	ttgttaggcc	tcttgctgaa	agccaaggca	1440
gctctttctg	agtttctcta	aagtcaactg	tgaacaattc	gggtgtaaaa	gtaccacaca	1500
aactatggga	tccaaggggc	agtcttgcaa	cagtgccatg	ttagggttat	gttttttagga	1560
ttccccctca	tgcagtcagt	gtttctttta	agtatacaac	aggagagaga	tggaatgggc	1620
tcattgtagc	acaatcctat	tactcttcct	ctaacttttt	tgaggaaagt	ttgtctaatt	1680
atcaatattg	aggatcaggg	ctcctagggc	cagtggtagc	tctggcttag	acaccacctg	1740
gagtgatcac	ctcttggggg	ccctgcctat	cccacttcac	aggtgaggca	tggcaattct	1800
ggaagctgat	taaaacacac	ataaaacaaa	accaaacaac	aggcccttgg	gtgaaagggtg	1860
ctatataatt	gtgaagtatt	aagcctaccg	tatttcagcc	atgataagaa	cagagtgcct	1920
gcattcccag	gaaaatacga	aaatcccattg	agataaataa	aaatataggt	gatgggcaga	1980
tcttttcttt	aaaataaaaa	agcaaaaact	cttgtggtac	ctagtcagat	ggtagacgag	2040
ctgtctgctg	ccgcaggagc	acctctatac	aggacttaga	agtagtatgt	tattcctggg	2100
taagcaggca	ttgctttgcc	ctggagcagc	tattttaagc	catctcagat	tctgtctaaa	2160
gggggttttt	gggaagacgt	tttctttatc	gccctgagaa	gatctacccc	agggagaatc	2220
tgagacatct	tgccactatt	tctttattag	ctttctcttc	atccatttct	tttatacatt	2280
tccttttttg	ggagtgttta	tgccatgatt	tttgggtatt	atgtaaaagg	attattacta	2340
attctatttc	tctatgttta	ttctagttaa	ggaaatgttg	agggcaagcc	accaaattac	2400
ctaggctgag	gttagagaga	ttggccagca	aaaactgtgg	gaagatgaac	tttgtcatta	2460
tgatttcatt	atcacatgat	tatagaaggc	tgtcttagtg	caaaaaacat	acttacattt	2520
cagacatatc	caaaggggaat	actcacattt	tgtaagaag	ttgaactatg	actggagtaa	2580
accatgtatt	cccttatctt	ttactttttt	tctgtgacat	ttatgtctca	tgtaatttgc	2640
attactctgg	tggattgttc	tagtactgta	ttgggcttct	tcgttaatag	attatttcat	2700
atactataat	tgtaaatatt	ttgatacaaa	tgtttataac	tctagggata	taaaaacaga	2760
ttctgattcc	cttcaaaaaa	aaaaaa				2786

<210> 67
<211> 7586
<212> DNA
<213> Homo sapiens

<400> 67

gttctttgtg	acacatcaca	cagaatttga	gtgctgtcct	tctggagagt	gggtggagaac	60
caagatacag	ttcagaacca	aaggaataga	gaagggtctt	gatttctttt	tggcttttaga	120
ttgggggattt	gggaggctta	gcaggaaaaga	gttcactga	aaatgtggaa	gggaagccca	180
gtaaccttgg	ggagagagga	agagcccggg	gtccacttt	cctcagggtt	gtccagccaa	240
tgtttaacca	cagtattttc	acttctgcag	tctctcctgc	tgcaaacgc	atccgattca	300

SEQUENCE LISTING 1657-2022.txt

tcttggggaga	ggaggatgac	agcccagctc	cccctcagct	cttcacggaa	ctggatgagc	360
tgctggccgt	ggatgggcag	gagatggagt	ggaaggaaac	agccagggtg	atcaagtttg	420
aagaaaaagt	ggaacagggg	ggggaaagat	ggagcaagcc	ccatgtggcc	acattgtccc	480
ttcatagttt	atgtgagctg	aggacatgta	tggagaaagg	atccatcatg	cttgatcggg	540
aggcttcttc	tctccacacg	ttggtggaga	tgattgttga	ccatcagatt	gagacaggcc	600
tattgaaacc	tgaacttaag	gataagggtg	cctatacttt	gctccggaag	caccggcatc	660
aaaccaagaa	atccaacctt	cggtcccctg	ctgacattgg	gaagacagtc	tccagtgcga	720
gtaggatgtt	taccaaccct	gataatggta	gcccagccat	gacccatagg	aatctgactt	780
ctccagttct	gaatgcacatt	tctgataaac	cggagaagga	ccagctgaag	aataagtcca	840
tgaaaaaatt	gccacgtgat	gcagaagcct	ccaacgtgct	tggtggggag	gttgactttt	900
tggatactcc	tttcattgcc	tttgtttaggc	tacagcaggc	tgctatgctg	ggtgccctga	960
ctgaagttcc	tgtgcccaca	aggttcttgt	tcatttctct	aggctcctaag	gggaaagcca	1020
agtcctacca	cgaggttggc	agagccattg	ccaccctgat	gtctgatgag	gtgttccatg	1080
acattgctta	taaagcaaaa	gacaggcacg	acctgattgc	tggtattgat	gagttccatg	1140
atgaagtcac	cgctcttcca	cctggggaaat	gggatccagc	aattaggata	gagcctccta	1200
agagtcttcc	atcctctgac	aaaagaaaga	atatgtactc	agggtggagag	aattgttcaga	1260
tgaatgggga	tacgcccacat	gatggagggt	acggaggagg	aggacatggg	gattgtgaag	1320
aattgcagcg	aactggacgg	ttctgtgggt	gactaattaa	agacataaag	aggaaagcgc	1380
cattttttgc	cagtgatttt	tatgatgctt	taaataattca	agctctttcg	gcaattctct	1440
tcatttatct	ggcaactgta	actaatgcta	tcacttttgg	aggactgctt	ggggatgcca	1500
ctgacaacat	gcagggcgtg	ttggagagtt	tcctgggcac	tgctgtctct	ggagccatct	1560
tttgcccttt	tgctgggtcaa	ccactcacta	ttctgagcag	caccggacct	gtcctagttt	1620
ttgagaggct	tctatttaaat	ttcagcaagg	acaataattt	tgactatttg	gagtttcgcc	1680
tttggaattg	cctgtgggtcc	gccttcctat	gtctcatttt	ggtagccact	gatgccagct	1740
tcttgggttca	atacttcaca	cgtttcacgg	aggaggcctt	ttcctctctg	attagcttca	1800
tctttatcta	tgatgctttc	aagaagatga	tcaagcttgc	agattactac	cccatcaact	1860
ccaacttcaa	agtgggctac	aacactctct	tttctgttac	ctgtgtgcca	cctgaccacg	1920
ctaataatct	aatatctaata	gacaccacac	tggccccaga	gtatttgcca	actatgtctt	1980
ctactgacat	gtaccataat	actacccttg	actgggcatt	tttgtcgaag	aaggagtgtt	2040
caaaatacgg	aggaaacctt	gtcgggaaca	actgttaatt	tgcttctgat	atcacactca	2100
tgtcttttat	cctcttcttg	ggaacctaca	cctcttccat	ggctctgaaa	aaattcaaaa	2160
ctagtcttta	ttttccaacc	acagcaagaa	aactgatcag	tgattttgcc	attatcttgt	2220
ccattctcat	cttttgtgta	atagatgccc	tagtaggcgt	ggacacccca	aaactaattg	2280
tgccaagtga	gttcaagcca	acaagtccaa	accgaggttg	gttcgttcca	ccgtttggag	2340
aaaacccttg	gtgggtgtgc	cctgtctgtg	ctatcccggc	tttggtggtc	actatactga	2400
ttttcatgga	ccaacaaatt	acagctgtga	ttgtaaacag	gaaagaacat	aaactcaaga	2460
aaggagcagg	gtatctcttg	gatctctttt	gggtggccat	cctcatgggt	atatgtctcc	2520
tcatggctct	tccgtgggtat	gtagctgcta	cggctatctc	cattgtctac	atcgacagtt	2580
tgaagatgga	gacagagact	tctgcacctg	gagaacaacc	aaagtttcta	ggagtgaggg	2640
aacaaagagt	cactggaacc	cctgtgttta	ttctgactgg	tctgtcagtc	tttatggctc	2700
ccattcttga	gtttataccc	atgcctgtac	tgtatgggtg	gttctgtgat	atgggagtag	2760
catcccttaa	tggtgtgcag	ttcatggatc	gtctgaagct	gcttctgatg	cctctgaagc	2820
atcagcctga	cttcatctac	ctgcgtcatg	ttcctctgcg	cagagtccac	ctgttcactt	2880
tcttgccagt	gttgtgtctg	gccctgcttt	ggatcctcaa	gtcaacgggtg	gctgtctatca	2940
tttttccagt	aatgtcttg	gcacttgtag	ctgtcagaaa	aggcatggac	tacctctctt	3000
cccagcatga	cctcagcttc	ctggatgatg	tcattccaga	aaaggacaag	aaaaagaagg	3060
aggatgagaa	gaaaaagaaa	aagaagaagg	gaagtctgga	cagtgacaat	gatgattctg	3120
actgcccata	ctcagaaaaa	gttccaagta	ttaaaattcc	aatggacatc	atggaacagc	3180
aacctttcct	aagcgatagc	aaaccttctg	acagagaaaag	atcaccaaca	ttccttgaac	3240
gccacacatc	atgctgataa	aattcctttc	cttcagtcac	tcggtatgcc	aagtcctcct	3300
agaactccag	taaaagtgtc	ctcaaattag	actagaactt	gaacctgaag	acaatgatta	3360
tttctggagg	agcaagggaa	cagaaactac	attgtaacct	gtttgtcttt	cttaaaactg	3420
acatttgggt	ttaatgtcat	ttgtttttgt	ttggctgttt	gtttattttt	taacttttat	3480
ttcgtctcag	tttttgggtca	caggccaaat	aatacagcgc	tctctctgct	tctctcttgc	3540
atagatacaa	tcaagacaat	agtgcaccgt	tccttaaaaa	cagcatctga	ggaatcccc	3600
ttttgttctt	aaactttcag	atgtgtcctt	tgaataccaa	attctgtcac	tcaagacaca	3660
gacacccaca	gaccttctca	tttgcttcta	tttaagcagag	gatggaagta	tttaaggattt	3720
tgtaacacct	tttatgaaaa	tgttgaagga	acttaaaact	ttagcttttg	agctgtgctt	3780
actggcttgt	ctttgtcttg	tagaacaac	ccttgacctc	agacagagtc	ccttctcact	3840
tatagagctc	tccaggactg	gaaaaagtgc	tgctatttta	acttgcctct	gcttgtataa	3900
cctaattcta	gagttatcaa	aagaagaata	aactgaaggt	actttactcc	ctatagagaa	3960
accattgcc	tcattgtagc	aagtgtctga	atgtcccttt	tttcttatgc	aactttttta	4020
taacccttta	atgaacttat	ctgtggagta	cattgaagaa	tatttttctt	cctagatttt	4080
gttgtttaaa	ttatggggcc	taacctgcca	cctatttttt	gtcaattttt	aaaacttttt	4140
tttaattact	gtaaaagaaa	tgaatttttt	ctcgcagcag	gaaacatagt	tttcagtagt	4200
tctacctctt	attttagtct	gccaggcttt	ctgtaaaaaa	tgtattgtat	ataatgtgat	4260
ttttacacat	acatacacac	acaaatacac	aattcttagg	gtaagccaga	aggcaagatc	4320

SEQUENCE LISTING 1657-2022.txt

```

agattaaaaa caccatgttt ctaagcatcc atttttcctt ttctttaaaa gaaacttaac 4380
tggtctatga aggagattga gggagaagag acaaactcct atgtcatgag aataaccgat 4440
gttctgataa tagtagcatc taggtacaga tgctggttgt attaccacgt caatgtccta 4500
tgcagtattg ttagacattt tctcatattg aaatatttgt gtgtttgtgt atgtgtctctg 4560
tgccatggct ggtgtatata tgtgcaatgt tagaaggcaa aagagtgatg gtaggcagag 4620
ggcaaagtca ttgaatctct tatgccagtt ttcataaaac ccaaaccaca tatgaaaaaa 4680
tccattaagg gtccaagaag tctgtccata tgaaaatgag ggtaaatata gtttatttcc 4740
caggtatcag tcattataat tgatataata gctctaacat gcaatataaa attcatagga 4800
gtattaatag cccattttaca catctataaa atgtaattgg attgcagagc tgcagagtac 4860
agtgtaacag tactctcatg caattttttt caggatgcaa aggcaattat tctttgttaag 4920
cgggacattt agatatattt gtgtacatat tatatgtatg tatatttcaa agtaccacac 4980
tgaaaattag acattttatta accaaattta acgtggtatt taaaggtaat atttttaata 5040
tgatacattg catgtatgta atgtatacta aaaaaacatt ttaaagtgtt aaattataat 5100
ttcagattca tataaccaca actgtgatat atcctaacta taaccagtgt ttgaggggta 5160
tactagaagc agaatgaaac cacatttttt ggtttgataa tatgcactta ttgactccca 5220
ctcattgtta tgtaattaa gttattattc tgtctccttg taattttgat taaaaaaatt 5280
ttattatcct gagtttctg ttacttttac attcctatgt atcctaataa cttttaactt 5340
atacaaatga gtcaataatg accccaattt ttctattaaa ataatagttg tgaattatat 5400
gttatttgtt taaaacctca cttgccaaat tctggcttca catttgtatt tagggctatc 5460
cttaaaatga tgagttctata ttatctagct ttctattacc ctaatataaa ctggtataag 5520
aagactttcc ttttttctt atgcatggaa gcatgataaa attgtttaaa aaccatgtat 5580
agtaaattca gcttaaccgg tgatcttctt aagttaaagg tacttttgtt ttataaaagc 5640
tctagataaa actttctttt ctgatcatga atcaagtatc tgtggtttca tgcccctctc 5700
tatacctttc aaagaactcc tgaagcaact taactcatca tttcagcctc tgagtagagg 5760
taaaacctat gtgtactttc gtttatgatc catattgata tttatgacat gaacacagaa 5820
tagtacctta catttgctaa acagacagtt aatatcaaat cctttcaata ttctgggaac 5880
ccagggaagt ttttaaaaat gtcattactt tcaaaggaac agaagtagtt aaccaaacta 5940
acaagcaaaa cctgagggtt acctagtgcac cggattttgt ggtggttttg ttctatgca aactggcac 6060
cccattgact aagaatgaa acgagagagg tttataagtg ctctcctt ctccatgatg tgacttccgg 6120
aaattacaac agtaaatatt tttataagtg ctctcctt ctccatgatg tgacttccgg 6180
agataaagga ttcaaaagat aaagacaaag tacgctcaga gttgttaacc agaaagtcct 6240
ggctgtggtt gcagaaacac tgttggaaga aaagagatga ctaagtcaag tgtctgcctt 6300
atcaaaagag caaaaatgcc tctggttttg tcttgggag aaaaatatct tggacgcact 6360
gttttccttg ataaaagtca tcttctctac tgtgtgaaat gaatacttgg aattctaatt 6420
gttttgtgtg ccaggggcag taatgtccct gcctctctc ccaatcaagg ttgaggagt 6480
gggctgggga gaggacttaa ctgacttaag aagtaggaaa acaaaaacct ctctcctcag 6540
ccttccacct aggaagagg aggaaaaaca gttgtctgct gtctgtaatt cagtttgcgt 6600
gtattttatg ctcatgcacc aacccataca gagtaaatct tttatcaact atatactgg 6660
gtttaataga gaatgattgt cttccgagtt ttttggttcc tttttaact gtgttaaagt 6720
acttgaatg tattgactgc tgactatatt ttaaaaaaca aatgaaataa tttgagttgt 6780
attagagagg ttgacattgt tcagggatgg gacaaagcct tcttcaatcc ttttcatact 6840
acttaatgat tttggtgcag gaacctgaga ttttctgatt tatatttcat gatatttcac 6900
atttgcctct cacagcatga gcatgaagcc cagtggcacc aaatggctgg gtacaatcaa 6960
gtgatatttt gtagcacctc actatctgaa aggccatgag ttttcagatg atttcattga 7020
gcttcattgc agcctgaaat tttaaaaaag tttgttaata cgccaaccag tcaagttgtg 7080
ttttggccag agatttagat atgtccaatt tcttggctca tttcattgtg ctctatgggt 7140
acgtataaaa agcaagaatt ctgtttccta ggcaaacatt gcaactcagg gctaaagtca 7200
tccagtgaac ctttttagagc cagaagtaac tttgtcccag tcttacaatg tgaaaagagt 7260
gaatagttgc ccttttttag ccattttcat ggtggtgaca tattcgtagc cattactttt 7320
cagaatcaat acgcactttc agatattctt atttttattc tcttaagctt ttattaactt 7380
tgagagagaga aatgatgcat ctttttattt taaatgaagt agatcaacat ggtggaacaa 7440
aatgataaag aacagaaaac atttcaatat attactaata actttttcca atataaatcc 7500
taaaattcct ataacatagt attttacagt tttatgaagc tttctattgt gacttttatg 7560
gaattaagag atgaagaaga tgagatatat tagcatttat atttttcaa attatatgta 7586
tacttaaaaa taaagtaact ttatgc

```

<210> 68
 <211> 1470
 <212> DNA
 <213> Homo sapiens

```

<400> 68
atgcactcaa gcagagaaga aatccacaag tactcaccag cctcctggtc tgcagagaag 60
acagaatcaa tatgagcaca gcaggaaaag taatcaaatg caaagcagct gtgctatggg 120
agttaaagaa acccttttcc attgaggagg tagaggttgc acctcctaag gctcatgaa 180
ttcgcattaa gatggtggct gcaggaatct gtcgttcaga tgagcatgtg gttagtggca 240
acctggtgac ccccttctct gtgattttag gccatgaggc agccggcatc gtggaaagt 300

```


SEQUENCE LISTING 1657-2022.txt

```

ttggagaagg ggtgactaca gtcaaaccag gtgataaagt catcccgtc tttactcctc 360
agtgtggaaa atgcagaatt tgtaaaaacc cagaaagcaa ctactgcttg aaaaatgatc 420
taggcaatcc tcggggggacc ctgcaggatg gcaccaggag gttcacctgc agcgggaagc 480
ccatccacca cttcgtcggc gtcagcacct tctccagta cacagtggg gatgagaatg 540
cagtggccaa aattgatgca gcctcgcccc tggagaaagt ctgcctcatt ggctgtggat 600
tttcgactgg ttatgggtct gcagtcaaag ttgccaaggt caccaccagg tctacctgtg 660
ctgtgttttg cctggggagg gtcggcctat ctgtgtttat gggctgtaaa gcagctggag 720
cagccagaat cattgctgtg gacatcaaca aggacaaatt tgcaaaggct aaagagtgg 780
gggccactga atgcataac cctcaagact ttgaagtcat cggctcggctt gacaccatga 900
aaatgactga tggaggtgtg gatttttcgt ttgaagtcat cggctcggctt gacaccatga 900
tggcttccct gttatgttgt catgaggcat gtggcacaaag tgtcattgta ggggtacctc 960
ctgattccca gaacctcga ataaacccta tgctgtact gactggacgc acgtggaaag 1020
gagctatttt tggaggcttt aagagttaaag aatctgtccc gaaacttgtg ctgacttta 1080
tggctaagaa gttttcactg gatgcattaa taacaaatat tttacctttt gaaaaataa 1140
atgaaggatt tgacctgctt cgctctggaa agagtatccg taccgtcctg acgttttgaa 1200
acaatacaga tgccttccct ttagcagttt ttcagcctcc tctaccctac atgatctgga 1260
gcaacagctg ggaatatca ttaattctgc tcttcagaga tgtaaaaaa aaattacacg 1320
tgggagcttt ccaaagaaat ggaaattgat gggaaattat ttgtcaagca aatgtttaaa 1380
atccaaatga gaactaaata aagtgttgaa catcaactgg ggaattgaag ccaataaacc 1440
ttccttctta accattcaaa aaaaaaaaaa 1470

```

<210> 69
 <211> 3464
 <212> DNA
 <213> Homo sapiens

```

<400> 69
cagccgtgct cgaagcgttc ctggagccca agctctcctc cacaggtgaa gacagggcca 60
gcaggagaca ccatggggca cctctcagcc ccacttcaca gagtgcgtgt accctggcag 120
gggcttctgc tcacagcctc acttctaacc ttctggaacc cgcccaccac tgcccagctc 180
actactgaat ccatgccatt caatgttgca gagggggaagg aggttcttct cttgttccac 240
aatctgcccc agcaactttt tggctacagc tggtaaaaaa gggaaagagt ggatggcaac 300
cgtcaaattg taggaattgc aataggaact caacaagcta cccagggcc cgcaaacagc 360
ggtcgagaga caatataccc caatgcatcc ctgctgatcc agaactgcac ccagaatgac 420
acaggattct acaccctaca agtcataaag tcagatcttg tgaatgaaga agcaactgga 480
cagttccatg tatacccggg gctgcccagg ccctccatct ccagcaaca ctccaaccct 540
gtggaggaga aggatctgtg ggccttcagg tgtgaacctg agactcagga cacaacctac 600
ctgtggtgga taaacaatca gagcctcccc gtcagtccta ggctgcagct gtccaatggc 660
aacaggaccc tcaacttact cagtgtcaca aggaatgaca caggacccta tgagtgtgaa 720
atacagaacc cagtgtgtgc gaaccgcagt gacccagtc ccttgaatgt cacctatggc 780
ccggacaccc ccaccatttc ccttccagac acctattacc gtccaggggc aaacctcagc 840
ctctcctgct atgcagcttc taacccacct gcacagtact cctggcttat caatggaag 900
ttccagcaaa gcacacaaga gctctttatc cctaacaatca ctgtgaataa tagtggatcc 960
tatacttccc acgccaataa ctcaagtcact ggctgcaaca ggaccacagt caagacgatc 1020
atagtactag agtgaagtcc agtagtagca aagcccaaaa tcaaagccag caagaccaca 1080
gtcacaggag ataggaactc tgtgaacctg acctgttcca caaatgacac tggaatctcc 1140
atccgttggg tcttcaaaaa ccagagtctc ccgtcctcgg agaggatgaa gctgtcccag 1200
ggcaacacca ccctcagcat aaaccctgtc aagagggagg atgctgggac gtattggtgt 1260
gaggtcttca acccaatcag taagaaccac agcgacccca tcatgctgaa cgtaaaactat 1320
aatgctctac cacaagaaaa tggccttcca cctggggcca ttgctggcat tgtgattgga 1380
gtagtggccc tgggtgtctt gatagcagta gccctggcat gttttctgca tttcgggaag 1440
accggcaggg caagcgacca gcgtgatctc acagagcaca aaccctcagt ctccaaccac 1500
actcaggacc actccaatga cccacctaac aagatgaatg aagttactta ttctaccctg 1560
aactttgaag cccagcaacc caacaaacca acttcagcct ccccatccct aacagccaca 1620
gaaataattt attcagaagt aaaaaagcag taatgaaacc tgtcctgctc actgcagtgc 1680
tgatgtattt caagtctctc acctctatca ctaggagatt cctttcccct ctagggtaga 1740
ggggtgggga cagaaacaac tttctcttcc tcttcttccc taataggcat ctccaggctg 1800
cctgtctact gccctctctc cagtgtcta atagtaaagt acattgggag tctgtaggaa 1860
acccaacctt cttgtcattg aaatttggca aagctgactt tgggaaagag ggaccagaa 1920
ttccccctcc ttcccccttt cccaacctgg acttgtttta aactgcctg ttcagagcac 1980
tcattctctc ccacccccag tcctgtctta cactctaat tcggatttgc catagccttg 2040
aggttatgtc cttttctatt aagtacatgt gccaggaac agcgagagag agaaagttaa 2100
cggcagtaat gcttctccta tttctccaaa gccttgtgtg aactagcaaa gagaagaaaa 2160
ccaaatatat aaccaatagt gaaatgccac aggttgttcc actgtcaggg ttgtctacct 2220
gtaggatcag ggtctaagca ccttgggtgt tagctagaat accaccta at ccttctggca 2280
agcctgtctt cagagaaccc actagaagca actaggaaaa atcacttgcc aaaatccaag 2340
gcaattcctg atggaaaatg caaaagcaca tatatgtttt aatatcttta tgggctctgt 2400

```

SEQUENCE LISTING 1657-2022.txt

```
tcaaggcagt gctgagaggg aggggttata gcttcaggag ggaaccagct tctgataaac 2460
acaatctgct aggaacttgg gaaaggaatc agagagctgc ccttcagcga ttattttaat 2520
tattgttaaa gaatacacaa ttgggggtat tgggattttt ctctttttct ctgagacatt 2580
ccaccatttt aatttttgta actgcttatt tatgtgaaaa gggttatttt tacttagctt 2640
agctatgtca gccaatccga ttgccttagg tgaagaaaac caccgaaatc cctcaggtcc 2700
cttggtcagg agcctctcaa gatttttttt gtcagaggct ccaaatagaa aataagaaaa 2760
ggttttcttc attcatggct agagctagat ttaactcagt ttctaggcac ctcagaccaa 2820
tcatcaacta ccattcttgg ccatgtttgc acctgtgcat ttctgtttg cccccattca 2880
ctttgtcagg aaacctttgg ctctgctaag gtgtatttgg tccttgagaa gtgggagcac 2940
cctacaggga cactatcact catgctgggt gcatgtttta cagctagaaa gctgcactgg 3000
tgctaatagcc ctttgggaaa tggggctgtg aggaggagga ttataactta ggcctagcct 3060
cttttaacag cctctgaaat ttatcttttc ttctatgggg cttataaatg tatcttataa 3120
taaaaaggaa ggacaggagg aagacaggga aatgtacttc tcaccagtc ttctacacag 3180
atggaatctc tttggggcta agagaaaggt tttattctat attgtctacc tgatctcatg 3240
ttaggcctaa gaggctttct ccaggaggat tagcttggag ttctctatac tcaggtagct 3300
ctttcagggt tttctaaccg tgacacggac tgtgcatact ttccctcatc catgctgtgc 3360
tgtgtatttt aatttttctt ggctaagatc atgtctgaat tatgtatgaa aattattcta 3420
tgtttttata ataaaaataa tatatcagac atcgaaaaaa aaaa 3464
```

<210> 70

<211> 2578

<212> DNA

<213> Homo sapiens

<400> 70

```
aagtgccttg aattccttgg taattatttc cttttaagcg tgtaactctt attattgcta 60
aactgctttt taagttaatg gtagttgttg tccaaaggaa gtctgatctg tgtttttgaa 120
acctcaatga tcgtctgttt ctaattaagg aattggatga agacatgcat cagaaaattg 180
caaggagatg gaacctctct gaaactgctt ttatccgaaa actgcacccg acagacaact 240
ttgcacaaag ttctgtcttt ggactgagat ggtttacacc agcgagttag gtccactct 300
gtggccatgc caccctggct tctgcagctg tgctgtttca caaaataaaa aacatgaaca 360
gcacgctcac gtttgtcact ctgagtggag aactaagggc cagacgagca gaggacggca 420
tcgttcaagg cttgcctctt tatccagccc acccccagga cttccatgaa gtagaggact 480
tgataaagac tgccataggc aacacactgg tccaggacat ctgttattct ccagataccc 540
aaaagctcct cgtccgcctc agtgacgttt acaacagggt gtttctggag aacctgaaag 600
tgaacacgga gaatctgctg caagttagaa acacagggaa ggtgaaaggg cttattctta 660
cccttaagag agagctgggt gggcagaccc aagcatttga cttttactca agatattttg 720
caccgtgggt tgggtgtggc tgacacgggt tgacacggtc gttctcagca 780
gctactgggt ccagcatctg ggaagaaaag aaatgcatgc ttttcagtgt tcccaccgag 840
gaggagagct ggggaatttcc cttcgtccag acggaagggt tgacattaga ggaggtgcag 900
ctgttgtttt agagggcaca ctgacagcct agaggtgggt atgctgtgac gctgctgtct 960
ctaaccacca agtattttct gcttaaaaag aatgttaagg ggctgccttt agcaaatgtg 1020
cgtagtagtc tacttaatcc tcatgttaaa aatcgaaaaa tgggccaggc gcagtggctc 1080
atgcctgtaa tcgtagcact ttgagaggcc aaggtgggtg gatcacctga ggtcaggggt 1140
tcgacaccag cctggccaac atggtgaaac ctgctctcta ctacaaatac aaaaattagc 1200
tgggtgtggg gccacatgcc tgtaattcca gctacttggg aggctgaggc atggagaatc 1260
gcttgaaccc aggaggcaga agttgcagtg agcagagatc acaccactgc actccagcct 1320
gggcaacaga gtaagactcc atccacacac acacacacac acacaaaatt gaaaagtga 1380
gacattttta tggagattta atagtgtttt ccagactaat gaactaatgg agttttggct 1440
ccactcatga gtgtatttga aatgtaagta accagctaca agaataatg tcacttcatt 1500
tgattatgac taccaatcaa gagaaggagg aatacatttc tgaggagtga tactaaacca 1560
tttgagctta aatgagtacc tgattttgca gccattaaaa tgagtcaata actatgtgga 1620
aatatagaaa aatattttat aatataatac taagaaagag gacagtaggc cataaagtgt 1680
tagcagtgtt atgctatgtc tatataaata agcatgggac attaaaaata gcaactgaa 1740
aacagttcat gtgtgggggg caagttaga agtaatttta atgtatctaa gaagtgtatt 1800
cctttattgt tgtactcagg tacgaagact aaaaatcagg atgaatccag aaaattaaca 1860
caaaaaagta tgtattaggg tacttctgtt catagtgaat taaacactc aaagtaattg 1920
aatctcagct gggcgtggcg gctcgtgct gtaatcccag cactttggca ggacaaggca 1980
ggaggatcac ttgaacctag gagttcgaga ccagctggg caacacagcg agaacttgtc 2040
tctattaaaa aaaaaaaaaa aggaatgtaa tttcaatctt tttcttgata tatggcttga 2100
gaatgataat gtaaaaggga attcttctct tacttcaata aaatggggtt taacataact 2160
ttaaattcag ttaaataaac aatattgaat acctatagtt gactttggga tggggacttt 2220
ttcaagtcac taagagtgtt tgtttaaggt gatctcattg atggtagttc tcagccgtct 2280
caaaaactgc aagctaatac gtcagacatt ctttaatgac cccaattttt tcactttaat 2340
tgttaccatg ttttctattt ttactgattt ttgctaaagc atgtaagagt gaatttatta 2400
tagcagtaat cttgtgtttc tcctgatgtg caataaatca ataattcacc agcaaaaaaa 2460
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2520
```


SEQUENCE LISTING 1657-2022.txt

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2578

<210> 71
<211> 2657
<212> DNA
<213> Homo sapiens

<400> 71

```
tgggaacaca aacttgctgg cgggaagagc ccggaagaa acctgtggat ctcccttcga 60
gatcatccaa agagaagaaa ggtgacctca cattcgtgcc ccttagcagc actctgcaga 120
aatgcctcct cagctgcaaa acggcctgaa cctctcggcc aaagtgtgcc aggggaagcct 180
ggacagcctg cccacaggcag tgagggaggtt tctcgagaat aacgctgagc tgtgtcagcc 240
tgatcacatc cacatctgtg acggctctga ggaggagaat gggcggcttc tgggccagat 300
ggaggaagag ggcatcctca ggcggctgaa gaagtatgac aactgctggt tggctctcac 360
tgacccaggg gatgtggcca ggatcgaaag caagacgggt atcgtcacc aagagcaaaag 420
agacacagtg cccatcccca aaacaggcct cagccagctc ggtcgtgga tgtcagagga 480
ggattttgag aaagcttgat atgcccaggt cccagggtgc atgaaaggtc gcaccatgta 540
cgatcatccca ttccagcatg ggcgctggg ctacactctg tcgaagatcg gcatcgagct 600
gacggattcg ccctacgtgg tggccagcat gcggatcatg acgcggtgg gcacgcccgt 660
cctggaagca ctgggcgatg gggagtttgt caaatgcctc cattctgtgg ggtgccctct 720
gcctttacaa aagcctttgg tcaacaactg gccctgcaac ccggagctga cgctcatcgc 780
ccacctgcct gaccgcagag agatcatctc ctttggcagt gggtacggcg ggaactcgtc 840
gctcgggaag aagtgtttt ctctcaggat ggccagccgg ctggcagagg aggaaggggtg 900
gctggcagag cacatgctga ttctgggtat aaccaaccct gagggtgaga agaagtacct 960
ggcggccgca ttcccagcg cctgcgggaa gaccaacctg gccatgatga accccagcct 1020
ccccgggtgg aagggttgag gcgtcgggga tgacattgcc tggatgaagt ttgacgcaca 1080
aggtcattta agggccatca acccagaaaa tggctttttc ggtgtcgttc ctgggacttc 1140
agtgaagacc aaccccaatg ccatcaagac catccagaag aacacaatct ttaccaatgt 1200
ggccgagacc agcgacggg gcgtttactg ggaaggcatt gatgagccgc tagcttcagg 1260
cgtcaccatc acgtcctgga agaataagga gtggagctca gaggatgggg aaccttgcgc 1320
ccaccccaac tcgaggttct gcacccctgc cagccagtgc cccatcattg atgtgcctg 1380
ggagtcctcg gaaggtgttc ccattgaagg cattatctt ggaggccgta gacctgtcg 1440
tgtccctcta gtcctatgaag ctctcagctg gcaacatgga gtctttgtgg gggcggccat 1500
gagatcagag gtcacagcgg ctgcagaaca taaaggcaaa atcatcatgc atgacccctt 1560
tgccatgcgg cccttctttg gctacaactt cggcaataac ctggccact ggcttagcat 1620
ggcccagcac ccagcagcca aactgcccaa gatctccat gtcaactggg tccggaagga 1680
caaggaaggc aaattcctct ggccaggctt tggagagaac tccagggtgc tggagtggat 1740
gttcaaccgg atcgatggaa aagccagcac caacgtcacg cccataggct acatcccaa 1800
ggaggatgcc ctgaacctga aaggcctggg gcacatcaac atgatggagc ttttcagcat 1860
ctccaaggaa ttctgggaca aggaggtgga agacatcgag aagtatctgg tggatcaagt 1920
caatgccgac ctcccctgtg aaatcgagag agagatcctt gccttgaagc aaagaataag 1980
ccagatgtaa tcagggcctg agaataagcc aggtgttaatc agggcctgag tgctttacct 2040
ttaaatcat taaattaaaa tccataaggt gcagtaggag caagagaggg caagtgttcc 2100
caaattgacg ccacctaata atcatcacca caccgggagc agatctgaag gcacactttg 2160
atttttttaa ggataagaac cacagaacac tgggtagtag ctaatgaaat tgagaagggg 2220
aatcttagca tgcctccaaa aattcacatc tgggtatag tttgttcaaa ttttaagggt 2280
ctcaggcatt gatcttttca gtgttttttc acttagctat gtggattagc tagaatgcac 2340
acaaaaaaga tacttgagct gtatatatat atgtgtgtgt gtgtgtgtgt gtgtgtgtgt 2400
gtgcatgtat gtgcacatgt gtctgtgtga tatttggat gtgtatttgt atgtactgtt 2460
attcaaaata ttttaatac ctttggaaaa tcttgggcaa gatgacctac tagttttcct 2520
tgaaaaaaag ttgctttgtt attaatattg tgcttaaatt atttttatac accattgttc 2580
cttaccttta cataattgca atatttcccc cttactactt cttggaaaaa aattagaaaa 2640
tgaagtttat agaaaag 2657
```

<210> 72
<211> 2107
<212> DNA
<213> Homo sapiens

<400> 72

```
ggcacgagga aagaaacaac aactggaaaa gaagcattgc ataagaccag gatgtctctg 60
aaatggatgt cagtctttct gctgatgcag ctacgttgtt acttttagctc tgggagttgt 120
ggaaaggtgc tgggtgtggc cacagaatac agccattgga taaatatgaa gacaatcctg 180
gaagagcttg ttccagagggg tcatgaggtg attgtgttga catcttcggc ttctattctt 240
gtcaatgccca gtaaatcatc tgctattaaa ttagaagttt atcctacatc ttttaactaaa 300
aatgatttgg aagatttttt tatgaaaatg ttcgatagat ggacatatag tatttcacaaa 360
aatacatttt ggtcatattt ttcacaacta caagaattgt gttgggaata ttctgactat 420
```

SEQUENCE LISTING 1657-2022.txt

```

aatataaagc tctgtgaaga tgcagttttg aacaagaaac ttatgagaaa actacaagag 480
tcaaaatttg atgtccttct ggcagatgcc gttaatccct gtggtgagct gctggctgaa 540
ctacttaaca taccctttct gtacagtctc cgcttctctg ttggctacac agttgagaag 600
aatggtggag gatttctggt ccctccttcc tatgtacctg ttgttatgtc agaattaagt 660
gatcaaatga ttttcatgga gaggataaaa aatatgatat atatgcttta ttttgacttt 720
tggtttcaag catatgatct gaagaagtgg gaccagtttt atagtgaagt tctaggaaga 780
cccactacat tatttgagac aatggggaaa gctgaaatgt ggctcattcg aacctattgg 840
gattttgaat ttcttcgccc attcttacca aatggttgatt ttggtggagg acttcactgt 900
aaaccagcca aaccttggcc taaggaaatg gaagagtttg tgcagagctc tggagaaaaa 960
ggtattgtgg tgttttctct ggggtcgatg atcagtaaca tgtcagaaga aagtgccaac 1020
atgattgcat cagcccttgc ccagatccca caaaagggtt tatggagatt tgatggcaag 1080
aagccaaata ctttaggttc caatactcga ctgtataagt ggttacccca gaatgacctt 1140
cttggctatc ccaaaaccaa agcttttata actcatggtg gaaccaatgg catctatgag 1200
gcatcttacc atgggatccc tatggtgggc attcccttgt ttgcggatca acatgataac 1260
attgctcaca tgaaagccaa gggagcagcc ctcatgtgtg acatcaggac catgtcaagt 1320
agagatttgc tcaatgcatt gaagtcagtc ataatgacc ctatctataa agagaatatc 1380
atgaaattat caagaattca tcatgatcaa ccggtgaagc ccttggatcg agcagctctc 1440
tggattgagt ttgtcatgcg ccataaagga gccaaagcacc ttcgggtcgc agcccacac 1500
ctcacctgga tccagtacca ctctttggat gtgatagcat tcttctggtc ctgctgtggc 1560
actatgatat ttatgatcac aaaatgttgc ctgttttgtt tccgaaagct tgccaaaaca 1620
ggaaaagaaga agaaaaggga ttagttatata ttttaaatgg aagtggaaatg accaaaagat 1680
gggactcctc ctttatcca gcatggaggg ttttaaatgg aggatttcct ttttcttgcg 1740
acaaaacgtc ttttcaaac ttaccctgtt aagtcaaaat ttattttcca ggaatttaat 1800
atgtacttta gttggaatta ttctatgtca atgattttta agctatgaaa aataataata 1860
taaaacctta tgggcttata ttgaaattta ttattctaag ccaaaagtta cccacacaa 1920
aagttactga gcttcttatt gtttcacaca ttattttga acacaaaaca ttaacaactc 1980
cactcatagt atcaacattg ttttgcaaat actcagaata ttttggtctc attttgagca 2040
gaatttttgt ttttaatttt gccaatgaaa tcttcaataa ttaaaaaaaa aaaaaaaaaa 2100
aaaaaaa 2107

```

<210> 73

<211> 1427

<212> DNA

<213> Homo sapiens

<400> 73

```

ctgggaatat gattatgctt aatctatgct cagtcgaaag gggctggggc tgctttctcc 60
cctcccttct tgactctctg ttcacagaac tcaggctgcc tccagccagc ctttgcccgc 120
tagactcact ggccctgagc acttgaaggt gcagcaagtc actgagaatg agcactttct 180
tctcggacac agcatggatc tgcctggctg tccccacagt actatgtggg acagtatttt 240
gcaaatacaa gaagagctca ggcagctgt ggagctggat ggtctgcctg gcaggcctct 300
gtgcagtctg cctgtctatc ctgtcccctt tttggggctt gatcctcttc tcggtgtcat 360
gcttctctat gtatacttac ttatctggcc aagaattgtt acctgtggat cagaaggcag 420
tcttggtagc aggtggtagt tgcgggcttg gccatgcttt gtgcaagtat ctggatgagc 480
tgggcttcac ggtatttgc ggagttttga atgaaaatgg ccaggagct gaggaattgc 540
gaagaacctg ctctccgcgc ctctcggtg tccaaatgga catcacgaag ccagtgcaga 600
taaaagatgc ttacagcaag gttgcagcaa tgctgcagga cagaggactg tgggctgtga 660
tcaacaatgc tggggtgctt ggctttccaa ctgatgggga gcttcttctt atgactgact 720
acaaacaatg catggccgtg aacttcttgg gaactgtgga ggtcacaaag acgtttttgc 780
ctcttcttag aaaatccaaa gggaggctgg tgaatgtcag cagcatggga ggaggggccc 840
caatggaaaag gctggcatct tatggctcat caaaggcggc tgtgacctg ttctcatcag 900
ttatgagact ggagctttcc aagtggggaa ttaaagtgtc ttccatccaa cctggaggct 960
tcctaacaata tatcgaggc accagtgaca agtgggaaaa gctggagaag gacattctgg 1020
accacctccc cgctgaggta caggaagact acggccagga ctacatctta gcacagcga 1080
atttcctcct attgatcaac tcgttagcca gcaaggactt ctctccggtg ctgcgggaca 1140
tccagcatgc tatcttggcg aagagccctt ttgcctatta cacgccaggg aaaggcgctt 1200
acttggtggat ctgccttgc cactatttgc ctatttggcat atatgattac tttgctaaaa 1260
gacatttttg ccaagacaag cccatgcccc gagctctaag aatgcctaac tacaagaaaa 1320
aggccacctt ggcaatggaa gccctcaaa aagtcggaat gtcatagtct tgaaatgaaa 1380
gggaaactgg gaaactgggt ttctcattaa agttgtttcc cactctg 1427

```

<210> 74

<211> 2396

<212> DNA

<213> Homo sapiens

<400> 74

SEQUENCE LISTING 1657-2022.txt

```

ggcaccagggt ctcccagggt tcctcagcgt cgacgcgagg gagcgccctg ggggtgggag 60
cgccccggggc ccgcgaaggga ggagggtggct cagggtgtcag ggcgaccgt ggggaaccggc 120
cccggggggag gcgtggaagac gcgggggcctg ggactcgacc agcctctccc gtgcggatcg 180
caaaatctcg gagctgaagac agcccgttgt tcgcagcctc cctctgaccc gccaccctgc 240
acattgtttt ccattcggcc gggtcgcggg tgggaggaga ggacgcccgg ggttctggag 300
cttgcccgcg cgccaggctt gtggccttcg tccccctggg gccactgggg cggccacgcc 360
tctccggcgg gaggagagaa cgcgtgggtc cgggtggctg ctccggccct tccgcctcca 420
gctcggccat ggggtcgcgc agctcccacg ccgcggtcat tcccgacggg gacagtattc 480
ggcgagagac cggcttctcc caagccagcc tgctccgctt gcaccaccgg ttccgggac 540
tggacaggaa taagaagggc tacctgagcc gcattggatct ccagcagata ggggctgctcg 600
ccgtgaaccc cctgggagac cgaattatag aaagcttctt ccccgatggg agccagcgag 660
tggatttccc aggtcttctc agggctcttg ctcatcttcg ccctgtagaa gatgaggaca 720
cagaacccca agacccaag aaacctgaac ctctcaacag cagaaggaa aaacttctact 780
atgcatttca gctctatgac ctggatcgcg atgggaagat ctccaggcat gagatgctgc 840
aggttctccg tctgatgggt ggggtacagg tgacagaaga gcagctggag aacatcgctg 900
accgcacggg gcaggagggt gatgaagatg gggatggggc tgtgtccttc gtggagttca 960
ccaagtccct agagaaagtg gacgttgag gctcctgcaa ccagtattct cttggaattc atccaaagcc 1020
tccgtttgtg ccttgggctt gctcctgcaa aaactgtatt ttcgtttcta actctattta 1140
cccattggacg catggacgca gggcgacaat aaactgtatt ttcgtttcta actctattta 1140
gggccaagag aagaaagctg gaaggatgtg tactaaagtc tagctcagca gtccccaacc 1200
tttttggcat cagggacagt tttccacgg atgggtgaca ggggatgggt ttgggatgat 1260
tcaagtgcac tacatttatt gtgcacttta ttctatttat gattacattg taatatataa 1320
tgaaataatt atacaactca ccataatgta gaatcagcag gagccctgag cttgttttcc 1380
tgcaattaga cgggtccata tgggagtgat gggagacagt gacagatcat caggcattag 1440
attctcataa ggagtgaca atctagatcc ttgtgtgtgc agttcacagt aggatttggg 1500
ctcctatgat aatctaagc cactgctgat ctgacaggag gcagagctca ggcggtaag 1560
caagcaatgg ggagtggctg taaatataga tgaagcttca gctcgcctgc cgctcacctt 1620
gtgctgtgca gccgggttcc taacagacca cagaccccac accagggtcta tctcatttgg 1680
tctcagagct gtgaatcagc agcaatatt ttagttgcaa atcactgaaa acccaactca 1740
aagtgactta agtcagaag aaattttatg aattcaggta attaaaaagt ccagaaggt 1800
ctgcctttag gcacagctgg atccaagggc acaaatgatg tcatcaggct ccagttattc 1860
tccatctccc agctcagctt tttctgtctg taagcctgat tttcagggaag gctctttcct 1920
agtgatggag atgaccacca tcagctccag gcttctatcc tgctaacca gtaaccaggt 1980
gggaagagat ttacttattc caatatttcc aagtggagag tgtcattgac ccggttgggg 2040
tctcatctct acttctaggg gaatgaaaca ctttgagtgg ccaggcctgt gtcattgtgt 2100
aattcctaga gccagggaaa taaggtctga ggattcagga tgggggtgaaa ggtgggtgtg 2160
taaaggaaaa tgaaatacaa ttagcagaat aaggggaaa gagtggctcg ctctgtctcg 2220
gcaaaacaag agatgcccac tactgtgagg gacccttgaa gtctggactc ttaaatgggt 2280
ttttgctgat ttcctgggtg catgctagga tgatggggct tgatgcagta ggggaagagac 2340
gatgtaaaaa taataaaca tatatacctt caaaaaaaaaa aaaaaaaaaa aaaaaa 2396

```

<210> 75
 <211> 2863
 <212> DNA
 <213> Homo sapiens

```

<400> 75
atctgaaaaa ttaataattc cttaattatc aaatatccat tatttaaatt tataatttgt 60
tcataaatat tgcataaat agatttgctg ttttaaagct tgttccttca ttttctctgt 120
tttgtttttag ataaacattg tcataaatag atttgttgtt tttaaagctt ttccttcatt 180
ttctctgatt gttttgtttt agattcagag gttacttatg cttgtttgtt acatggatgt 240
tacatgtgta atggggggata ttggacttct agtgtactca tcacccatatt actgaacact 300
gtactcaaaa gggattgaaa gaaactagga aacttggcag gaagatcatt ctttaagccag 360
gaaaaaaatt tttaatgctc acatgtgaac atgtgatggt cataccagaa ggagcaccca 420
cctccctccc tctgtgacag acacattttc ttagccttca cctttccttc tttcaagttg 480
ctgaaaatcc acagtgtttc tgttcatttg ttactttcat tctcacctat cttctctctt 540
gtccactcta ccagaacaat aattccccat ataacttctc tcacttcaact tttcaacgca 600
ggacctctg ttgggtctgt ctgtttgtct gtccgcttta tcaatattat cagatgtaag 660
tttacatgaa tacacacaca tattactaa actgagggga aaaaatgcct tgtagggtcat 720
aaaaaagcag ggaaattccc aacaattcat atttgatccc tggatccagg ggtggcgagca 780
ataagcctgc tttagatatt tactccccat tttatgatcc ggtgggttgg tttttcaaat 840
gatgatgtg ctctcttctg aatgacttga ttgttaggag gtgtgcttca ataaatacat 900
tttaaatca acaatcaagt tagagtgtga caaatggctc tgaaatgtcc cactacactg 960
ttagaccaag ggcacagatt gtgcttctgt actatttatc ctagtatccc tcggcatata 1020
ttaactgtc taataaatctc cttggctaca cgctgcatca aatcaaagtt aaatgttata 1080
ccactttct attctatttt taattattca agagggtgct cagatttttag aacaaatttc 1140
aatgtttaag tacacacaaa aaaatcatta actcatatat ttcaagagta ggaaatggga 1200

```

SEQUENCE LISTING 1657-2022.txt

```

actggtgtta aaactcttat aacaaatgtc actgtcttaa gggacagtgt ttaaaaacgc 1260
atacctggcc gggcgcggtg gctcatgcct gtaatccag cactttggga ggccgaggcc 1320
ggcggtacac aaggaaaaca aactcaggaa gaaaaaggaa agcagaagtg atcaaggaga 1380
gcgctcgagt tgcaatatct tcctttggct gctgacaggc agttactata aagcattgtg 1440
catggacacc atcttcttgt attatacaag aaaggagtgt acctatcaca cacaggggga 1500
aaaatgtctt tttgggtgct aggcctccta atcctctgtg gttttctgtg gactcgtaaa 1560
ggaaaactaa agattgaaga catcactgat aagtacattt ttatcactgg atgtgactcg 1620
ggctttggaa acttggcagc cagaactttt gataaaaagg gatttcattg aatcgctgcc 1680
tgtctgaact aatcaggatc aacagcttta aaggcagaaa cctcagagag acttcgtact 1740
gtgcttctgg atgtgaccga cccagagaat gtcaagagga ctgcccagtg ggtgaagaac 1800
caagttgggg agaaagggtc ctgggggtctg atcaataatg ctggtgttcc cggcgtgctg 1860
gctcccactg actggctgac actagaggac tacagagaac ctattgaagt gaacctgttt 1920
ggactcagca gtgtgacact aaatatgctt cctttgttca agaaagctca agggagagt 1980
attaatgtct ccagtgttgg aggtcgcctt gcaatcggtg gagggggcta tactccatcc 2040
aaatatgcag tggagggttt caatgacagc ttaagacggg acatgaaagc ttttgggtg 2100
cacgtctcat gcattgaacc aggtattgtt aaaacaaact tggcagatcc agtaaaggta 2160
attgaaaaaa aactcgccat ttgggagcag ctgtctccag acatcaaaac acaatatgga 2220
gaaggttaca ttgaaaaaag tctagacaaa ctgaaaggca ataaatccta tgtgaacatg 2280
gacctctctc cgggtggtaga gtgcatggac cacgctctaa caagtctctt ccctaagact 2340
cattatgccc ctggaaaaga tgccaaaatt ttctggatac ctctgtctca catgccagca 2400
gcttttgaaa actttttatt acttgaaacag aaagcagagc tggctaattc caaggcagtg 2460
tgactcagct aaccacaaat gtctcctcca ggctatgaaa ttggccgatt tcaagaacac 2520
atctcctttt caaccccat ccttatctgc tccaacctgg actcatitag atcgtgctta 2580
tttggattgc aaaagggagt cccaccatcg ctggtggtat cccagggctc ctgctcaagt 2640
tttctttgaa aaggagggtc ggaatggtac atgcataagg caagtcctgc cctgtattta 2700
ggctttgcct gcttgggtgt atgtaaggga aattgaaaga cttgcccatt caaaatgatc 2760
tttaccgtgg cctgccccat gcttatggtc cccagcatit acagtaactt gtgaatgtta 2820
agtatcatct cttatctaaa tattaaaaga taagtcaaac att 2863

```

<210> 76
 <211> 603
 <212> DNA
 <213> Homo sapiens

<400> 76

```

atggggcagg agtttagctg ggaggaggcg gaggcagctg gcgagataga tgtggcggag 60
ctccaggagt ggtacaagaa gtttgtgatg gatgccccca gcggcacact ctttatgcat 120
gagtttaagc gcttcttcaa ggtcacagag gatgaggagg cctcccagta tgtagagggc 180
atgttccgag ccttcgacaa gaatggggac aacaccatcg acttcctgga gtacgtggca 240
gctctgaatc tcgtgctgag gggcacccctg gagcacaagc tgaagtggac attcaagatc 300
tatgataagg atggcaatgg ctgcatcgac cgcttggagc tactcaacat tgtggaggga 360
atttaccagc tgaagaaaagc ctgcccgcga gacgtacaga ctgagcaaga ccagctgctc 420
acaccgagg aggtcgtgga caggatcttc ctctggtgg atgagaatgg agatggccag 480
ctgtctctga acgagtttgt tgaagggtgcc cgctcgggaca agtgggtgat gaagatgctg 540
cagatggaca tgaatcccag cagctggctc gctcagcaga gacggaaaag tgccatgttc 600
tga
603

```

<210> 77
 <211> 2407
 <212> DNA
 <213> Homo sapiens

<400> 77

```

ggcacgaggc ggagggggct cagtccgcag ccgcccgcgc caccgcccgc cctcggcctc 60
ggtgcaggca gcggccgccc ccgcccagac agctgcgcgg gcgagcatcc ccacgcagca 120
ccttggaaat tgttttcaac catatccagc ctttgccgaa tacatcctat ctgccacaca 180
tccagcgtga ggtccctcca gctacaaggt gggcaccatg gcggagaagt ttgactgcca 240
ctactgcagg gatcccttgc aggggaagaa gtatgtgcaa aaggatggcc accactgctg 300
cctgaaatgc tttgacaagt tctgtgccaa cacctgtgtg gaatgccgca agcccatcgg 360
tgcggaactc aaggagggtc actataagaa ccgcttctgg catgacacct gcttccgctg 420
tgccaagtgc cttcacccct tggccaatga gacctttgtg gccaaggaca acaagatcct 480
gtgcaacaag tgcaccactc gggaggactc cccaagtgc aagggggtgct tcaaggccat 540
tgtggcagga gatcaaaacg tggagtacaa ggggaccgtc tggcaciaag actgcttcac 600
ctgtagtaac tgcaagcaag tcatcgggac tggaaagctt ttccctaaag gggaggactt 660
ctactgcgtg acttgccatg agaccaagtt tgccaagcat tgcgtgaagt gcaacaaggg 720
catcacatct ggagggaatc cttaccagga tcagccctgg catgcccatt gctttgtgtg 780
tgttacctgc tctaagaagc tggctgggca gcgtttcacc gctgtggagg accagtatta 840

```

SEQUENCE LISTING 1657-2022.txt

```

ctgctgggat  tgctacaaga  actttgtggc  caagaagtgt  gctggatgca  agaaccccat  900
cactggggtt  ggtaaaaggc  ccagtgtggg  ggcctatgaa  ggacaatcct  ggcacgacta  960
ctgcttccac  tgcaaaaaat  gctccgtgaa  tctggccaac  aagcgctttg  ttttccacca  1020
ggagcaagtg  tattgtcccg  actgtgccaa  aaagctgtaa  actgacaggg  gctcctgtcc  1080
tgtaaaatgg  catttgaatc  tcgttctttg  tgccttact  ttctgcccta  taccatcaat  1140
aggggaagag  tggctcttcc  cttctttaa  gttctccttc  cgtcttttct  cccattttac  1200
agtattactc  aaataagggc  acacagtgat  catattagca  tttagcaaaa  agcaaccctg  1260
cagcaaagtg  aatttctgtc  cggctgcaat  ttaaaaatga  aaacttaggt  agattgactc  1320
ttctgcatgt  ttctcataga  gcagaaaagt  gctaatacatt  tagccactta  gtgatgtaag  1380
caagaagcat  aggagataaa  acccccactg  agatgcctct  catgcctcag  ctgggaccca  1440
ccgtgtagac  acacgacatg  caagagttgc  agcggctgct  ccaactcact  gctcacccctc  1500
ttctgtgagc  aggaaaagaa  ccctactgac  atgcatgggt  taacttcctc  atcagaactc  1560
tgcccttctc  tctgttcttt  tgtgctttca  aataactaac  acgaacttcc  agaaaattaa  1620
catttgaact  tagctgtaat  tctaaactga  gtttctcttc  tactaacgtt  tggtttcccc  1680
gtgtggcatg  ttttctgagc  gttcctactt  taaagcatgg  aacatgcagg  tgatttggga  1740
agtgtagaaa  gacctgagaa  aacgagcctg  tttcagagga  acatcgtcac  aacgaatact  1800
tctggaagct  taacaaaact  aacctgctg  tcctttttat  tgtttttaat  taatattttt  1860
gttttaattg  atagcaaaat  agtttatggg  tttggaaact  tgcatgaaaa  tattttgacc  1920
ccctcagatg  ttctgtcagt  gctgaaattc  atcctacgga  agtaaccgca  aaactctaga  1980
gggggagttg  agcaggcgcc  agggctgtca  tcaacatgga  tatgacattt  cacaacagt  2040
actagtgtga  tccctgtgaa  cgtagttagt  gctgtctctt  tgtccatgtg  ttaatgagga  2100
ctgcaaagtc  ccttctgttg  tgattcctag  gacttttctt  caagaggaaa  tctggatttc  2160
cacctaccgc  ttacctgaaa  tgcaggatca  cctacttact  gtattctaca  ttattatatg  2220
acatagtata  atgagacaat  atcaaaagta  aacatgtaat  gacaatacat  actaacattc  2280
ttgtaggagt  ggtagagaa  gctgatgcct  catttctaca  ttctgtcatt  agctattatc  2340
atctaactgt  tcagtgtatc  cttacagaaa  taaagcagca  tatgaaaaaa  aaaaaaaaaa  2400
aaaaaaaaa  2407

```

<210> 78
 <211> 2175
 <212> DNA
 <213> Homo sapiens

```

<400> 78
gagaaattgg  agaagataaa  actggacact  ggggagacca  caacttcatt  ctgctgggga  60
tctcccagct  acctgcagtg  gccaccatgt  cttgggtcct  gctgcctgta  ctttggctca  120
ttgttcaaac  tcaagcaata  gccacaatga  aaacacctga  attaacgctc  catgaaatag  180
tttgtcctaa  aaaacttcac  attttacaca  aaagagagat  caagaacaac  cagacagaaa  240
agcatggcaa  agaggaaaag  tatgaacctg  aagttcaata  tcagatgatc  ttaaatggag  300
aagaaatcat  tcttctccct  caaaaaacca  agcacctcct  ggggccagac  tacttgaaa  360
cattgtactc  acccagagga  gaggaatata  ccacgaaacc  tgagaacatg  gaacactgtt  420
actataaagg  aaacatccta  aatgaaaaga  attctgttgc  cagcatcagt  acttgtgacg  480
ggttgagagg  atacttcaca  catcatcacc  aaagatacca  gataaaacct  ctgaaaagca  540
cagacgagaa  agaacatgcc  gtctttacat  ctaaccagga  ggaacaagac  ccagctaacc  600
acacatgtgg  tgtgaagagc  actgacggga  aacaaggccc  aattcgaatc  tctagatcac  660
tcaaaagccc  agagaaagaa  gactttcttc  gggcacagaa  atacattgat  tcttatttgg  720
tgctggataa  tgcccttttat  aagaactata  atgagaatct  aactctgata  agaagctttg  780
tgtttgatgt  gatgaaccta  ctcaatgtga  tatataacac  catagatgtt  caagtggcct  840
tggtagggtat  ggaaatctgg  tctgatgggg  ataagataaa  ggtggtgccc  agcgcaagca  900
ccacgtttga  caacttcctg  agatggcaca  gttctaacct  ggggaaaaag  atccacgacc  960
atgctcagct  tctcagcggg  attagcttca  acaatcgacg  tgtgggactg  gcagcttcaa  1020
attccttgtg  ttccccatct  tcggttgtg  ttattgaggc  taaaaaaaag  aataatgtgg  1080
ctcttgttag  agtgatgtca  catgagctgg  gccatgtcct  tggtatgcct  gatgttccat  1140
tcaacaccaa  gtgtccctct  ggcagttgtg  tgatgaatca  gtatctgagt  tcaaaattcc  1200
caaaggattt  cagtacatct  tgccgtgcac  attttgaaag  atacctttta  tctcagaaac  1260
caaagtgcct  gctgcaagca  cctatttcta  caaatataat  gacaacacca  gtgtgtggga  1320
accaccttct  agaagtggga  gaagactgtg  attgtggctc  tcctaaggag  tgtaccaatc  1380
tctgtgtgta  agccctaacg  tgtaaaactg  agcctggaa  tgattgcgga  ggagatgctc  1440
caaaccatac  cacagagtga  atccaaaagt  ctgcttctac  gagatgctac  cttgccagga  1500
caagaaccaa  gaactctaac  tgtcccagga  atcttgtgaa  ttttcacca  taatggctct  1560
tcaactgtca  ttctactttc  tatattgtta  tcagtccagg  aaacaggtaa  acagatgtaa  1620
ttagagacat  tggctctttg  tttaggccta  atctttcttt  ttactttttt  ttttcttttt  1680
tctttttttt  taaagatcat  gaatttgtga  cttagtcttg  ccctttggag  aacaaaagaa  1740
agcagtcttc  catcaaatca  ccttaaaagt  cagggttaa  ctattcagag  ttaacactcc  1800
agaattgtta  aattacaagt  actatgcttt  aatgcttctt  tcatcttact  agtatggcct  1860
ataaaaaaaaa  taataccact  tgatgggtga  aggctttggc  aatagaaaga  agaatagaat  1920
tcagggtttta  tgttatttct  ctgtgttcac  ttcgccttgc  tcttgaaagt  gcagtatttt  1980

```

SEQUENCE LISTING 1657-2022.txt

tctacatcat	gtcgagaatg	attcaatgta	aatatttttc	attttatcat	gtatatccta	2040
tacacacatc	tccttcacat	tcatatatga	agtttatttt	gagaagtcta	cattgcttac	2100
atttttaattg	agccagcaaa	gaaggcttaa	tgattttattg	aaccataatg	tcaataaaaa	2160
cacaactttt	gaggc					2175

<210> 79
 <211> 386
 <212> DNA
 <213> Homo sapiens

<400> 79						
ccaggatcag	catggccgct	cgccagtggt	taatcgccct	ggccttggt	gccctccttg	60
ttgtggacag	ggaagtgcc	gtggcagcag	gaaagctccc	tttctcaaga	atgcccatct	120
gtgaacacat	ggtagagtct	ccaacctgtt	cccagatgtc	caacctgggt	tgccggcactg	180
atgggctcac	atatacgaat	gaatgccagc	tctgcttggc	ccggataaaa	accaaacagg	240
acatccagat	catgaaagat	ggcaaatgct	gatcccaac	tggaataaac	agccatgaag	300
tgtagctgg	agaacagtgg	tgggcatgga	gaggatatga	catgaaataa	aagatccagc	360
ccaactgaaa	aaaaaaaaaa	aaaaaa				386

<210> 80
 <211> 1264
 <212> DNA
 <213> Homo sapiens

<400> 80						
gtggtaccca	gtcctcaggt	gcaaccccc	gcgtgggtcct	ctgtggcagc	cttctctcat	60
tcagagctgt	tttccacaga	ggtagtgaaa	agaactggat	tttcaagttc	actttgcaag	120
agaaaaagaa	aactcagtag	aagataatgg	caagtccaga	ctggggatat	gatgacaaaa	180
atggtcctga	acaatggagc	aagctgtatc	ccattgccaa	tggaataaac	caatccccctg	240
ttgatattaa	aaccagtga	accaaaccatg	acacctctct	gaaacctatt	agtgtctcct	300
acaacccagc	cacagccaaa	gaaattatca	atgtggggca	ttctttccat	gtaaattttg	360
aggacaacga	taaccgatca	gtgctgaaag	gtggtccttt	ctctgacagc	tacaggctct	420
ttcagtttca	ttttcactgg	ggcagtacaa	atgagcatgg	ttcagaacat	acagtggatg	480
gagtcacata	ttctgcccag	cttcacgtag	ctcactggaa	ttctgcaaag	tactccagcc	540
ttgctgaagc	tgccacaaag	gctgatgggt	tggcagttat	tggtgttttg	atgaagggtg	600
gtgaggccaa	cccaaagctg	cccaaagtaa	ttgatgccct	ccaagcaatt	aaaaccaagg	660
gcaaacgagc	cccattcaca	aattttgacc	ctctactctc	ccttccttca	tccctggatt	720
tctggacctt	ccctggctct	ctgactcatc	ctcctcttta	tgagagtgtg	acttggtatc	780
tctgtaagga	gagcatcagt	gtcagctcag	agcagctggc	acaattccgc	agccttctat	840
caaatgttga	agggtataac	gctgtcccca	tgcagcacaa	caaccgcccc	acccaacctc	900
tgaagggcag	aacagtggag	gcttcatttt	gatgtattctg	agaagaaact	tgctcttctc	960
caagaacaca	gccctgcttc	tgacataatc	cagttaaaat	aataattttt	aagaaataaa	1020
tttattttcaa	tattagcaag	acagcatgcc	ttcaaataca	tctgtaaaac	taagaaactt	1080
aaatttttagt	tcttactgct	taattcaaat	aataattagt	aagctagcaa	atagtaattct	1140
gtaagcataa	gcttatctta	aattcaagtt	tagtttgagg	aattctttta	aattacaact	1200
aagtgatttg	tatgtctatt	tttttcagtt	tatttgaacc	aataaaataa	ttttatctct	1260
ttct						1264

<210> 81
 <211> 2386
 <212> DNA
 <213> Homo sapiens

<400> 81						
agcatacgcc	gagccgggtct	ttgagcgcta	acgtctttct	gtctccccgc	ggtggtgatg	60
acggtgaaaa	ctgaggctgc	taagggcacc	ctcacttact	ccaggatgag	gggcatgggtg	120
gcaatttctca	tcgctttcat	gaagcagagg	aggatgggtc	tgaacgactt	tattcagaag	180
attgccaata	actcctatgc	atgcaaacc	cctgaagttc	agtccatctt	gaagatctcc	240
caacctcagg	agcctgagct	tatgaatgcc	aaccttctc	ctccaccaag	tccttctcag	300
caaatcaacc	ttggcccgtc	gtccaatcct	catgctaaac	catctgactt	tcacttcttg	360
aaagtgatcg	gaaaggcgag	ttttggaaag	gttcttctag	caagacacaa	ggcagaagaa	420
gtgttctatg	cagtcaaagt	tttacagaag	aaagcaatcc	tgaaaaagaa	agaggagaag	480
catattatgt	cggagcggaa	tgttctgttg	aagaatgtga	agcacccttt	cctgggtgggc	540
cttcacttct	ctttccagac	tgctgacaaa	ttgtactttg	tcctagacta	cattaatggt	600
ggagagtgtg	tctaccatct	ccagagggaa	cgctgcttcc	tggaaccacg	ggctcgtttc	660
tatgctgctg	aaatagccag	tgcttggggc	tacctgcatt	cactgaacat	cgtttataga	720
gacttaaaac	cagagaatat	tttgctagat	tcacagggac	acattgtcct	tactgacttc	780

SEQUENCE LISTING 1657-2022.txt

```

ggactctgca aggagaacat tgaacacaac agcacaacat ccaccttctg tggcacgccc 840
gagtatctcg cacctgaggt gcttcataag cagccttatg acaggactgt ggactgggtg 900
tgcctgggag ctgtcttgta tgagatgctg tatggcctgc cgccttttta tagccgaaac 960
acagctgaaa tgtacgacaa cattctgaac aagcctctcc agctgaaacc aaatattaca 1020
aattccgcaa gacacctcct ggagggcctc ctgcagaagg acaggacaaa gcggctcggg 1080
gccaaggatg acttcatgga gattaagagt catgtcttct tctccttaat taactgggat 1140
gatctcatta ataagaagat tactccccct ttttaaccaa atgtgagtgg gcccaacgac 1200
ctacggcact ttgacccccg gtttaccgaa gagcctgtcc ccaactccat tggcaagtcc 1260
cctgacagcg tcctcgtcac agccagcgtc aaggaagctg ccgaggcttt cctaggcttt 1320
tcctatgctc ctccacgga ctctttcctc tgaacctgtg tagggcttgg ttttaaagga 1380
ttttatgtgt gtttccgaat gttttagtta gccttttggg ggagccgcca gctgacagga 1440
catcttataa gagaatttgc acatctctgg aagcttagca atcttattgc acactgttcg 1500
ctggaagcct tttgaagagc acattctcct cagtgaagtc atgaggtttt catttttatt 1560
cttcttcca acgtggtgct atctctgaaa cgagcgttag agtgccgcct tagacggagg 1620
caggagtttc gttagaaagc ggacgctggt ctaaaaaagg tctcctgcag atctgtctgg 1680
gctgtgatga cgaatattat gaaatgtgcc ttttctgaag agattgtgtt agctccaaag 1740
cttttcctat cgcagtggtt agtttccctg tggatatgct gtgtgaaccg 1800
tcgtgtgagt gtggtatgcc tgatcacaga tggattttgt tataagcatc aatgtgacac 1860
ttgcaggaca ctacaacgtg ggacattggt tgtttcttcc atatttgga gataaattta 1920
tgtgtagact tttttgtaag atacggttaa taactaaaat ttattgaaat ggtcttgcaa 1980
tgactcgtat tcagatgctt aaagaaagca ttgtcgtac aaatatttct atttttagaa 2040
agggttttta tggaccaatg cccagttgt cagtcagagc cgttggtgtt tttcattggt 2100
taaaatgtca cctgtaaaat gggcattatt tatgtttttt tttttgcatt cctgataatt 2160
gtatgtattg tataaagaac gtctgtacat tgggttataa cactagtata tttaaactta 2220
caggcttatt tgtaatgtaa accaccattt taatgtactg taattaacat ggttataata 2280
cgtacaatcc ttccctcatc ccatacacaca actttttttg tgtgtgataa actgattttg 2340
gtttgcaata aaaccttgaa aaatattttac aaaaaaaaaa aaaaaa 2386

```

<210> 82
 <211> 1432
 <212> DNA
 <213> Homo sapiens

```

<400> 82
gctgttcggc ctgctgctgct ccgggagctg ccgacggagc gagcgccccc gccccgccc 60
ggccgcccgc ccgcccgcgc catgcccttc tccaacagcc acaacgcaact gaagctgctg 120
ttcccggccg aggcagagtt ccccgacctg agcgcccaca acaaccacat ggccaagggtg 180
ctgacccccg agctgtacgc ggagctgctg gccaagagca cgccgagcgg cttcacgctg 240
gacgacgtca tccagacagg cgtggacaac ccgggccacc cgtacatcat gaccgtgggc 300
tgctgtggcg gcgacgagga gtcttacgaa gtgttcaagg atctcttcca ccccatcatc 360
gaggaccggc acggcggcta caagcccagc gatgagcaca agaccgacct caaccccgac 420
aacctgcagg gcggcgacga cctggacccc aactacgtgc tgagctcgcg ggtgcgcacg 480
ggccgcagca tccgtggctt ctgctcccc ccgactgca gccgcgggga gcgcccgcgc 540
atcgagaagc tcgctggtga agcctgttcc agcctggagc gcgacctggc gggccgatac 600
tacgcgtcca agagcatgac ggagcgagc cagcagagc tcacgacga ccacttctc 660
ttcgacaagc ccgtgtcgcc cctgctgctg gcctcgggca tggcccgcga ctggcccgc 720
gcccgcggta tctggcaca tgacaataag accttctctg tgtgggtcaa cgaggaggac 780
cacctgcggg tcactctcat gcagaagggg ggcaacatga aggaggtgtt caccgcgttc 840
tgcaccggcc tcaccagat tgaaactctc ttcaagtcta aggactatga gttcatgtgg 900
aacctcacc tgggctacat cctcacctgc ccatccaacc tgggcaccgg gctgcgggca 960
ggtgtgcata tcaagctgcc caacctgggc aagcatgaga agttctcga ggtgcttaag 1020
cggctgcgac ttcagaagcg aggcacaggc ggtgtggaca cggctgcggg gggcggggtc 1080
ttcgacgtct ccaacgctga ccgctgggc ttctcagag tggagctggg gcagatgggt 1140
gtggacggag tgaagctgct catcgagatg gagcagcggc tggagcaggg ccaggccatc 1200
gacgacctca tgcctgcca gaaatgaagc ccggcccaca cccgacacca gccctgctgc 1260
ttcctaactt attgcctggg cagtgtccac catgcacccc tgatgttcgc cgtctggcga 1320
gccccttagc ttgctgtaga gacttctgta acccttggtg aggtttattt ttttgatggc 1380
taagatactg ctgatgctga aataaactag ggttttgccc tgccctgcgtc tg 1432

```

<210> 83
 <211> 2832
 <212> DNA
 <213> Homo sapiens

```

<400> 83
aggaagctga accatctatc tccagaaatg tcttcagaaa gtaaagagca acataacgtt 60
tcacccagag actcagctga aggaaatgac agttatccat ctgggatcca tctggaactt 120

```


SEQUENCE LISTING 1657-2022.txt

```

caaaggggaat caagtactga cttcaagcaa tttgagacca atgatcaatg cagaccttat 180
cataggatccc ttattgagcg tcaagagaaa tcagatacaa acttcaagga gtttgttatt 240
aaaaagctgc agaagaattg ccagtgacgt ccagccaaag ccaaaaatat gatttttaggt 300
ttccttcttg ttttgacgtg gctcccaaaa tacgacctaa agaaaaacat tttaggggat 360
gtgatgtcag gcttgattgt gggcatatta ttggtgcccc agtccattgc ttattccctg 420
ctggctggcc aagaacctgt ctatggtctg tacacatctt ttttgccag catcatttat 480
tttctcttgg gtacctcccg tcacatctct gtgggcattt ttggagtact gtgccttatg 540
attggtgaga cagttgaccg agaactacag aaagctggct atgacaatgc ccatagtgtc 600
ccttctcttag gaatggtttc aaatgggagc acattattaa atcatatc agacaggata 660
tgtgacaaaa gttgctatgc aattatggtt ggcagcactg taacctttat agctggagtt 720
tatcaggtag cgatgggctt ctttcaagtg ggttttgttt ctgtctacct ctcatgtgcc 780
ttgctgagtg gatttgtcac tgggtgcttc ttactattc ttacatctca ggccaagtat 840
cttcttgggc tcaacgtttc tcggactaat ggttgggct cactcatc tacctggata 900
catgtcttca gaaacatcca taagaccaat ctctgtgatc ttatcaccag ccttttgtgc 960
cctttggttc ttttgccaac caaagaactc aatgaacact tcaaatccaa gcttaaggca 1020
ccgattccta ttgaacttgt tgttgttgta gcagccacat tagcctctca ttttggaaaa 1080
ctacatgaaa attataattc tagtattgtc ggactattc ccactgggtt tatgccacc 1140
aaagtaccag aatggaacct aattcctagt gtggctgtag atgcaatagc tatttccatc 1200
attgggtttt ctatcactgt atcactttct gagatgtttg ccaagaaaca tggttacaca 1260
gtcaaagcaa accaggaaat gtatgccatt ggttttgtta atatcatccc ttccttcttc 1320
cactacttga ctactagtgc aagactttgc agctcttgga ttaaagaatc aacaggctgc 1380
catactcagc tttctggtgt ggtaacagcc ctggttcttt tgttggctct ctagtaata 1440
gctcctttgt tctattccct tcaaaaaagt gtcttgggtg tgatcacaat tgtaaatcta 1500
cggggagccc ttcgtaaatt tagggatctt cccaaaatgt ggagtattag tagaatggat 1560
acagtattct ggtttgttac tatgtgtctc tctgactgc taagtactga aataggccta 1620
cttgttgggg tttgtttttc tatattttgt gtcactctcc gcactcagaa gccaaagagt 1680
tactgtcttg gcttgggtgga agagtctgag gtctttgaaat ctgtgtctgc ttacaagaac 1740
cttcagacta agccaggcat caagattttc cgctttgtag cccctctcta ctacataaac 1800
aaagaatgct ttaaattctg tttatacaaa caaactgtca acccaatctt aataaagggt 1860
gcttgggaaga aggcagcaaa gagaaagatc aaagaaaaag tagtgactct tgggtggaatc 1920
caggatgaaa tgtcagtgc actttcccat gatcccttgg agctgcatac tatagtatt 1980
gactgcagtg caattcaatt tttagatata gcagggatcc acacactgaa agaagttcgc 2040
agagattatg aagccatttg aatccagggt ctgtggtc agtgcaatcc cactgtgagg 2100
gattccctaa ccaacggaga atattgcaaa aaggaagaag aaaaccttct cttctatagt 2160
gtgtatgaag cgatggcttt tgcagaagta tctaaaaatc agaaaggagt atgtgttccc 2220
aatggcttga gtcttagtag tgattaatgt agaaggtaga tagaagaatg tctagccaat 2280
aggttaaaat ttcaagtgtc caacatttcc cagtccaca gtgggaaatt ttgcacactt 2340
gaaattttaa ccaagtggct agatattatt cctcctttga agctaattggc atttgtatat 2400
acacactgca gcagagcttg tagctggaca gagtcaaaaa gaagaaaata cggtttcagg 2460
cttcttgca gatatgaagt attcttggaa tgcaataagt atgtattgaa ctgtactgta 2520
aagttagctc aaaacttaat tactctcctg ttttaggggt tatacatttg gactgtgcat 2580
tctccaagag atgaagcggg gaagttggga tttacattgg aagtgtgtga gacttcttta 2640
tgtggctcag tggagagagg gaaagaatgt tgcacctgtc ctagtaccat aggtcaagag 2700
gcttctggat cacaaagtca taactagaca ggtttgttct tgtagttttc tatccccagt 2760
cttgcctccc cagatggcag tagtttttag taggaaagtg ccattcctgt ccttaaggca 2820
cagtctcacc ag

```

<210> 84
 <211> 3347
 <212> DNA
 <213> Homo sapiens

```

<400> 84
atcccttggg ggcattcatg gctgaagtgg aggatcaggc agctagagac atgaagaggc 60
ttgaagaaaa ggacaaggaa agaaaaaacg taaagggtat tcgagatgac attgaagagg 120
aagatgacca agaagcttat tttegataca tggcagaaaa cccaactgct ggtgtgggtc 180
aggagggaaga ggaagacaat ctagaatatg atagtgcgg aaatccaatt gcacctacca 240
aaaaaatcat tgatcctctt cccccattg atcattcaga gattgactat ccaccatttg 300
aaaaaaactt ttacaatgag catgaagaga taaccaacct cactccacag cagttaatag 360
atctcggcca taagctcaat cttcgggtct ctggtgctgc acctcctaga ccaggaagta 420
gctttgtcca ttttgggttt gacgaacaac ttatgcacca gattcggaaa tctgaatata 480
cacagcccac tccaatacac tggcagggtg tgctgtggc attaagtggg agagacatga 540
ttggtattgc caaaacaggt agtgggaaaa ctgcagcctt catttgccc atgttgattc 600
atataatgga ccagaaggag ttggaaccag gtgatggacc aattgcagtg attgtgtgtc 660
ctaccaggga ctttggccag cagatccatg cagaatgtaa gcggtttgga aaagcatata 720
atcttcgac agtggccgta tatggaggag ggagtatgtg ggagcaggcc aaggcccttc 780
aggagggggc agagattggt gtgtgtaccc caggctcgact gatagatcat gtgaaaaaga 840

```


SEQUENCE LISTING 1657-2022.txt

```

aagctaccaaa tcttcaaaga gtctcttacc ttgtgtttga tgaagcagat cgaatgtttg 900
acatgggatt tgagtaccaa gttcgtacca tagcaagtca tgttcgtcct gacaggcaga 960
ctctcttatt tagtgcaact ttctcgaaga agattgaaaa gtggccaga gacatcctga 1020
tcgaccctat tcgagtgggt ggacctagta aatggaaact gcttaccggt cgctgtgtag 1140
ttgtggagat tctccattct gtctctctct ttgttactaa aaaagccaat gctgaagagc 1200
aattttacctc ttcagggagt gaggggtcata atcttgggct gctccatggg gatattggatc 1260
tagcgaataa ccttaaacag atttcagact ttaagaaaaa ggacatccca gtcctgggtg 1320
agagtggagag aaacaagggtc ggtctggaca ttccttcaat taagactgtc attaacattg 1380
ccacagatgt agacattgat acccacacgc ataggattgg ccgcacagga agagcgggtg 1440
atgtggcacg ggcctatacc ctactcactc ccaaggacag caattttgct ggtgacctgg 1500
agaaagggtgt tccggaactt ggaaggagcc aatcaacacg ttcttaagga actcctagat ctggcaatgc 1560
agaatggcctg gtttcggaag tctcgattca agggagggaa aggaaaaaag ctgaacattg 1620
gtggaggagg cctagggtac agggagcggc ctggcctggg ctctgagaac atggatcgag 1680
gaaataacaa tgtaatgagc aattatgagg cctacaagcc tccacagga gctatgggag 1740
atcgactaac ggcaatgaaa gcagctttcc agtcacagta caagagtcac tttgttgag 1800
ccagtttaag taatcagaag gctggaagtt ctgctctgg ggcaagtggg tggactagg 1860
cagggagctt gaattctgtt ccaactaact cagcacaaca gggccataac agtcctgaca 1920
gccccgtcac cagtgcggcc aagggcatcc caggctttgg caatactggc aacatcagtg 1980
gtgccccgtg gacctaccg tctgcccggg cccaaggagt caacaacaca gcttcaggga 2040
ataacagccg caaatgatgg gggggcagca actgggaaag agagagatat actgagaacc 2100
ggggcagcag cccgtcacag tcacggagag actggcaatc ggcatagcga tagtccactg 2160
cacggagatg gtggtcgcca tggagatgga taccgccatc cagaaagcag cagccgtcat 2220
actgatggcc atcggcacgg ggagaacaga catggaggaa gcgcaggccg gcatggggag 2280
aaccggggtg aacatgatgg tcggaatggg gaaagcagga aagaagcttt taatcgtgag 2340
agcaagatgg agcccaagat ggaacccaaa gtggacagca gcaagatgga caaggtggac 2400
agcaagacag ataagacagc tgacggcttt gctgtcccag agccgcctaa acgcaagaaa 2460
agtcgatggg acagttagag gggatgtgct aaagcgtgaa atcagttgtc cttaatTTTT 2520
agaaagattt tggttaactag gtgtctcagg gctgggtgg ggtccaaagt gtaaggaccc 2580
cctgccctta gtggagagct ggagcttgga gacattacc cttcatcaga aggaattttc 2640
ggatgttttc ttgggaagct gttttgggtc ttggaagcag tgagagctgg gaagcttctt 2700
ttggctctag gtgagttgtc atgtgggtaa gttgaggtta tcttgggata aagggtcttc 2760
tagggcacaa aactcactct aggtttatat tttatgtagc ttatatTTTT tactaaggtg 2820
tcaccttata agcatctata aattgacttc ttttcttag ttgtatggcc aggcagctcc 2880
catttttaga gttggcttct gcaaattcaa tccattgagc taactgttgg ggagcaattt 2940
ggtagtgtga gacatttgca ggggaaggag atgtctgatt ctaaattggga gttgatgtc 3000
aggtccccag ccaggtttgc atccagccct gagacatgta ggaaacacct ttcagacca 3060
ggctctgaag attcccagaa gccacaagga ttgaagggaa aagggtgatc ttgtaactgt 3120
tccaggattg ctccagggtt gagatgggtat tgctaaattt aaaattaaac aagaaacca 3180
acaacagctt ttaaagtgtc ttctatctca ttgtattttt ttaacttgc ccaatgata 3240
gaaaagtctt ttgttgaaat attttgttgc atcgtttata aaaagggaaa 3300
gaaatataca aactttgact tttgtgaaaa aaaaaaaa aaaaaa 3347

```

<210> 85
 <211> 15720
 <212> DNA
 <213> Homo sapiens

```

<400> 85
caaccacac cgccctgccc agccaccatg gggctgccac tagccgcct ggcggctgtg 60
tgcttgcccc tgtctttggc aggggggtcg gagctccaga cagagggcag aaccgatac 120
cacggccgca acgtctgcag cacctggggc aacttccact acaagacct cgacggggac 180
gtcttccgct tccccggcct ctgcgactac aacttcgect ccgactgccg aggtcctac 240
aagggaattt ctgtgcacct gaagcggggt ccgggcccag ctgaggcccc cgccgggggtg 300
gagtcacatc tgctgacct caaggatgac accatctacc tcaccgcca cctggctgtg 360
cttaacgggg ccgtggtcag caccgcgcac tacagccccg ggctgctcat tgagaagagc 420
gatgcctaca ccaaggtcta ctcccgcgc ggcctcacc tcagtggaa ccgggaggat 480
gcactcatgc tggagctgga cactaagttc cgggaaccaca cctgtggcct ctgaggggac 540
tacaacggcc tgcagagcta ttcagaattc ctctctgacg gcgtgctctt cagtcccctg 600
gagtttggga acatgcagaa gatcaaccag cccgatgtgg tgtgtgagga tcccaggagg 660
gaggtggccc ccgcatcctg ctccgagcac cgcgccgagt gtgagaggct gctgaccgcc 720
gaggccttcg cggactgtca ggacctgggt cctgtggagc cgtatctgcg cgcttgccc 780
caggaccgct gccgggtgcc gggcgggtgac acctgctgtc gcagaccgt ggccgagttc 840
tcccgcaggt gctcccacgc cggcgggccc cccgggaact ggaggaccgc cacgctctgc 900
cccaagacct cccccggaa cctgggtgac ctggagagcg gctcgccctg catggacacc 960
tgctcacacc tggaggtgag cagcctgtgc gaggagcacc gcatggacgg ctgtttctgc 1020
ccagaaggca ccgtatatga cgacatcggg gacagtggct gcgttctgt gagccagtgc 1080

```

SEQUENCE LISTING 1657-2022.txt

cactgcaggc tgcacggaca cctgtacaca ccggggccagg agatcaccaa tgactgagag 1140
cagtgtgtct gtaacgctgg ccgctgggtg tgcaaagacc tgccctgccc cggcacctgt 1200
gccctggaag gcggctccca catcaccacc ttcatgaggga agacgtacac cttccacggg 1260
gactgctact atgtcctggc caagggtgac cacaacgatt cctacgtctt cctgggagag 1320
ctggccccct gtggctccac agacaagcag acctgcctga agacgggtgt gctgctggct 1380
gacaagaaga agaatgcggt ggtcttcaag tccgatggca gtgtactgtt caaccagctg 1440
cagggtgaac tgccccacgt gaccgagagc ttctctgtct tccgcccgtc ttcctaccac 1500
atcatgttga gcatggccat tggcgtcccg ctgcagggtg agctggcccc agtcatgcaa 1560
ctctttgtga cactggacca ggcctcccag gggcagggtg agggcctctg cgggaacttc 1620
aacggcctgg aaggtgacga cttcaagacg gccagcgggc tgggtggaggc cacggggggc 1680
ggctttgcca acacctggaa ggcacagtca acctgccatg acaagctgga ctgggtggac 1740
gatccctgct ccctgaacat cgagagcgcc aactacgccc agcactgggt ctccctcctg 1800
aagaagacag agacccccct tggcagggtg cctacggctg tggaccctgc tgagtattac 1860
aagaggtgca aatatgacac gtgtaactgt cagaacaatg aggactgcct gtgcgcccgc 1920
ctgtctctct acgcgcgcgc ctgcaccgcc aagggcgctc tgctgtgggg ctggcgggag 1980
catgtctgca acaaggatgt gggctcctgc cccaactcgc aggtcttcct gtacaacctg 2040
accacctgcc agcagacctg ccgctccctc acagccactg tctcgagggc tctcgagggc 2100
tttgccctg tggacggctg cggctgccct gaccacacct tcttgagcga gaagggccgc 2160
tgctgacccc tggccaagtg ctctgtttac caccgcggtc tctacctgga ggcgggggat 2220
gtggtcgtga ggcaggaaga acgatgtgtg tgccgggatg ggcggctgca ctgtaggcag 2280
atccggctga tccggcagag ctgcacggcc ccaagatgcc acatggactg cagcaacctg 2340
actgcactgg ccacctcgaa gccccagacc ctacgtgcc agacgctggc cgccggctat 2400
taccacacag agtgtgtcag tggctgtgtg tgccccgacg ggctgatgga tgacggccgc 2460
gggtggctgc tgggtggaaa ggaatgccct tgcgtccata acaacgacct gtattcttcc 2520
ggcgccaaga tcaagggtga ctgaataacc tgcaactgca agagaggacg ctgggtgtgc 2580
acccaggctg tgtgccaatg cactgtctcc atttacggga gtggccacta catcacctt 2640
gatgggaagt actacgactt tgacggacac tgctctacg tggctgttca ggactactgc 2700
ggccagaact cctcactggg ctcatcagc atcatcaccg agaacgtccc ctgtggcact 2760
acgggcgtca cctgtccaa ggccatcaag atcttcattg ggaggacgga gctgaagtgc 2820
gaagacaagc accgtgtggt gatccagcgt gatgaggggt accacgtggc ctacaccacg 2880
cgggaggtgg gccagtacct ggtgtgtggg tccagcacgg gcatcatcgt catctgggac 2940
aagaggacca ccgtgttcat caagctgggt cctcctaca agggcaccgt gtgtggcctg 3000
tgtgggaact ttgaccacg ctccaacaac gacttcacca cgcgggacca catggtgtg 3060
agcagcgagc tggacttcgg gaacagctgg aaggaggccc ccacctgccc agatgtgagc 3120
accaaccccc agcctgcaag cctgaacccg caccgcccgt cctgggcccga gaagcagtgc 3180
agcatcctca aaagcagcgt gttcagcatc tgccacagca aggtggaccc caagcccttc 3240
tacgagccct gtgtgcacga ctgtgtcc cgtgacaggg gtggggactg tgagtgttc 3300
tgctctgccc tggcctccca cgcccaggag tgtaccaaa agggggcctg cgtgttctg 3360
aggacgcccg acctgtgccc catattctgc gactactaca accctccgca tgagtgtgag 3420
tggcactatg agccatgtgg gaaccggagc ttcgagacct gcaggacct caacggcatc 3480
cactccaaca tctcgtgtc ctacctggag ggtgtctacc cccggtgccc caaggacagg 3540
cccattctat agggaggtct gaagaagtgt gctactgcag acaagtgtgg ctgctatgtc 3600
gaggacaccc actaccaccc tggagcatcg gttcccaccg aggagacctg caagtccctg 3660
gtgtgtacca actcctccca agtcgtctgc agctgtggc atctgtggc ccaacgggac ggtggagaag 3720
acccaggatg gcgcttctg ctactggag taccagacgc ccgtccacc tgaccacct caccaccatc 3780
cacttcaaca tctgttccat tacgacacgc cctgcccacc actaccacca ccaccaccac cccgacctcc 3840
accctcccca ccacccccc ctcttccacc tccgaagctg tgctgcctt ggtctgactg gatcaatgag 3900
agcacagttt tatcaacaac tccgaagctg tgctgcctt ggtctgactg gatcaatgag 3960
gaccacccca gcagtggcag cgacgacggt gaccgagaac catttgatgg ggtctgcggg 4020
gcccctgagg acatcgagtg caggctgggtc aaggatcccc acctcagctt ggagcagctg 4080
ggccagaagg tgcagtgtga tgtctctgtt ggggttcattt gcaagaatga agaccagttt 4140
ggaaatggag catttgagct gtgttacgac tacaagatac gtgtcaattg ttgtggccc 4200
atggataagt gtatccacac tcccagccct ccaactacca ctcccagccc tccaccaacc 4260
acgacgacca ccttccacc aaccaccacc cccagccctc caaccaccac cacaaccacc 4320
cctccacca cccacacccc cagccctcca ataaccacca cgaccacccc tctaccaacc 4380
accactccca gccctccaat aagcaccaca accacccctc caccacccac cactcccagc 4440
cctccacca cctcccccag cctcccaacc accactccca gcccctccac aaccaccaca 4500
accacccctc caccacccac cactcccagc cctccaatga ctacgcccct cactccacca 4560
gccagcacta ccacccctcc accaaccacc actcccagcc ctcccaaac caccacaacc 4620
accctccac caaccaccac tcccagtcct ccaacgacta cgcccatcac tccaccaacc 4680
agcactacta ccttccacc aaccaccact ccagccctc caccaaccac cacaaccacc 4740
cctccacca caccactcc cagccctcca acaaccacca ctcccagtc tccaacaatc 4800
accacaacca cccctccacc aaccaccact cccagccctc caacaacgac cacaaccacc 4860
cctccacca cccactcc cagccctcca acgactacac ccatcactcc accaaccagc 4920
actaccaccc tccaccaaac caccactccc agcctccac caaccaccac aaccaccct 4980
ccaccaacca cctccacag cctccacca accaccactc ccagccctc aataaccacc 5040
acaaccaccc ctccaccaac caccactccc agctctccaa taaccaccac tcccagccct 5100

SEQUENCE LISTING 1657-2022.txt

ccaacaacca	ccatgaccac	cccttcacca	accaccaccc	ccagctctcc	aataaccacc	5160
acaaccaccc	cttcctcaac	taccactccc	agccctccac	caaccacccat	gaccaccctt	5220
tcaccaacca	ccactcccag	ccctccaaca	accaccatga	ccacccttcc	accaaccacc	5280
acttcagcc	ctctaacaac	tactcctcta	cctccatcaa	taactcctcc	tacattttca	5340
ccattctcaa	cgacaacccc	tactacccc	tgcgtgcctc	tctgcaattg	gactggctgg	5400
ctggattctg	gaaaacccaa	ctttcacaaa	ccaggtggag	acacagaatt	gattggagac	5460
gtctgtggac	caggctgggc	agctaacatc	tcttgagag	ccaccatgta	tcctgatgtt	5520
cccattggac	agcttggaac	aacagtgggt	tgtgatgtct	ctgtggggct	gatatgcaa	5580
aatgaagacc	aaaagccagg	tggggtcac	cctatggcct	tctgcctcaa	ctacagatc	5640
aacgttcagt	gctgtgagtg	tgtcacccaa	cccaccacca	tgacaaccac	caccacagag	5700
aacccaactc	cgccaaccac	gacacccatc	accaccacca	ctacggtgac	cccaacccca	5760
acacccaacc	gcacacagac	cccaaccacg	acacccatca	ccaccaccac	tacggtgacc	5820
ccaaccccaa	caccacccgg	cacacagacg	caacccatca	caccatcac	caccaccac	5880
acggtgaccc	caaccccaac	acccaccggc	acacagaccc	caaccacgac	acccatcacc	5940
accaccacta	cgggtgacccc	aaccccaaca	cccaccggca	cacagacccc	aaccacgaca	6000
cccatcacca	ccaccactac	ggtgacccca	accccaacac	ccaccggcac	acagacccca	6060
accacgacac	ccatcaccac	caccactacg	gtgaccacca	ccccaacacc	caccggcaca	6120
cagaccccaa	ccacgacacc	catcaccacc	accactacgg	tgaccccaac	cccaacaccc	6180
accggcacac	agaccccaac	cacgacaccc	atcaccacca	ccactacggt	gaccccaacc	6240
ccaacaccca	ccggcacaca	gaccccaacc	acgacaccca	tcaccaccac	cactacggtg	6300
accccaaccc	caacacccac	cggcacacag	accccaacca	cgacacccat	caccaccac	6360
actacggtga	ccccaacccc	aacacccacc	ggcacacaga	ccccaaccac	gacacccatc	6420
accaccacca	ctacggtgac	cccaacccca	acacccaccg	gcacacagac	cccaaccacg	6480
acacccatca	ccaccaccac	tacggtgacc	ccaaccccaa	cacccaccgg	cacacagacc	6540
ccaaccacga	caccatcac	caccaccact	acggtgaccc	caaccccaac	acccaccggc	6600
acacagaccc	caaccacgac	acccatcacc	accaccacta	cgggtgacccc	aaccccaaca	6660
cccaccggca	cacagacccc	aaccacgaca	cccatacca	ccaccactac	ggtgacccca	6720
accccaacac	ccaccggcac	acagacccca	accacgacac	ccatcaccac	caccactacg	6780
gtgaccccaa	ccccaacacc	caccggcaca	cagaccccaa	ccacgacacc	catcaccacc	6840
accactacgg	tgaccccaac	cccaacaccc	accggcacac	agaccccaac	cacgacaccc	6900
atcaccacca	ccactacggt	gaccccaacc	ccaacaccca	ccggcacaca	gaccccaacc	6960
acgacaccca	tcaccaccac	cactacggtg	accccaaccc	caacacccac	cggcacacag	7020
accccaacca	cgaacccat	caccaccac	actacggtga	cccaacccc	aacacccacc	7080
ggcacacaga	ccccaaccac	gacacccatc	accaccacca	ctacggtgac	cccaacccca	7140
acacccaccg	gcacacagac	cccaaccacg	acacccatca	ccaccaccac	tacggtgacc	7200
ccaaccccaa	cacccaccgg	cacacagacc	ccaaccacga	caccatcac	caccaccact	7260
acggtgaccc	caaccccaac	acccaccggc	acacagacc	caaccacgac	acccatcacc	7320
accaccacta	cgggtgacccc	aaccccaaca	cccaccggca	cacagacccc	aaccacgaca	7380
cccatcacca	ccaccactac	ggtgacccca	accccaacac	ccaccggcac	acagacccca	7440
accacgacac	ccatcaccac	caccactacg	gtgaccccaa	ccccaacacc	caccggcaca	7500
cagaccccaa	ccacgacacc	catcaccacc	actactacgg	tgaccccaac	cccaacaccc	7560
accggcacac	agaccccaac	cacgacaccc	atcaccacca	ccactacggt	gaccccaacc	7620
ccaacaccca	ccggcacaca	gaccccaacc	acgacaccca	tcaccaccac	cactacggtg	7680
accccaaccc	caacacccac	cggcacacag	accccaacca	cgacacccat	caccaccacc	7740
actacggtga	ccccaacccc	aacacccacc	ggcacacaga	cccaacccac	gacacccatc	7800
accaccacca	ctacggtgac	cccaacccca	acacccaccg	gcacacagac	cccaaccacg	7860
acacccatca	ccaccaccac	tacggtgacc	ccaaccccaa	cacccaccgg	cacacagacc	7920
ccaaccacga	caccatcac	caccaccact	acggtgaccc	caaccccaac	acccaccggc	7980
acacagaccc	caaccacgac	acccatcacc	acccacta	cgggtgacccc	aaccccaaca	8040
cccaccggca	cacagacccc	aaccacgaca	cccatcacca	ccaccactac	ggtgacccca	8100
accccaacac	ccaccggcac	acagacccca	accacgacac	ccatcaccac	caccactacg	8160
gtgaccccaa	cccaacaccc	caccggcaca	cagaccccaa	ccacgacacc	catcaccacc	8220
accactacgg	tgaccccaac	cccaacaccc	accggcacac	agaccccaac	cacgacaccc	8280
atcaccacca	ccactacggt	gaccccaacc	ccaacaccca	cgggcacaca	gaccccaacc	8340
acgacaccca	tcaccaccac	cactacggtg	accccaaccc	caacacccac	cggcacacag	8400
accccaacca	cgacacccat	caccaccacc	actacggtga	ccccaacccc	aacacccacc	8460
ggcacacaga	cccaacccac	gacacccatc	acacccacca	ctacggtgac	cccaacccca	8520
acacccaccg	gcacacagac	cccaaccacg	acacccatca	ccaccaccac	tacggtgacc	8580
ccaaccccaa	cacccaccgg	cacacagacc	ccaaccacga	cacccatcac	caccaccact	8640
acggtgaccc	caaccccaac	acccaccggc	acacagaccc	caaccacgac	acccatcacc	8700
accaccacta	cgggtgacccc	aaccccaaca	ccaccggca	cacagacccc	aaccacgaca	8760
cccatcacca	ccaccactac	ggtgacccca	accccaacac	ccaccggcac	acagacccca	8820
accacgacac	ccatcaccac	caccactacg	gtgaccccaa	cccaacaccc	caccggcaca	8880
cagaccccaa	ccacgacacc	catcaccacc	accactacgg	tgaccccaac	cccaacaccc	8940
accggcacac	agaccccaac	cacgacaccc	atcaccacca	ccactacggt	gaccccaacc	9000
ccaacaccca	ccggcacaca	gaccccaacc	acgacaccca	tcaccaccac	cactacggtg	9060
accccaaccc	caacacccac	cggcacacag	accccaacca	cgacacccat	caccaccacc	9120

SEQUENCE LISTING 1657-2022.txt

actacggtga	cccccaacccc	aacacccacc	ggcacacaga	cccccaaccac	gacacccatc	9180
accaccacca	ctacggtgac	cccaacccca	acacccaccg	gcacacagac	cccaaccacg	9240
acacccatca	ccaccaccac	tacggtgacc	ccaaccccaa	cacccaccgg	cacacagacc	9300
ccaaccagga	cacccatcac	caccaccact	acggtgaccc	caaccccaac	acccaccggc	9360
acacagaccc	caaccacgac	acccatcacc	accaccacta	cggtgacccc	aaccccaaca	9420
cccaccggca	cacagacccc	aaccacgaca	ccatcacca	ccaccactac	ggtgacccca	9480
accccaaacac	ccaccggcac	acagacccca	accacgacac	ccatcaccac	caccactacg	9540
gtgaccccaa	ccccaaacac	caccggcaca	cagaccccaa	ccacgacacc	catcaccacc	9600
accactacgg	tgaccccaac	cccaacaccc	accggcacac	agaccccaac	cacgacaccc	9660
atcaccacca	ccactacggt	gaccccaacc	ccaacaccca	ccggcacaca	gaccccaacc	9720
acgacaccca	tcaccaccac	cactacggtg	accccaaccc	caacacccac	cggcacacag	9780
accccaacca	cgacacccat	caccaccacc	actacggtga	cccccaacccc	aacacccacc	9840
ggcacacaga	cccaacccac	gacacccatc	acaccacca	ctacggtgac	cccaacccca	9900
acacccaccg	gcacacagac	cccaaccacg	acacccatca	ccaccaccac	tacggtgacc	9960
ccaaccccaa	cacccaccgg	cacacagacc	ccaaccacga	cacccatcac	caccaccact	10020
acggtgaccc	caaccccaac	acccaccggc	acacagaccc	caaccacgac	acccatcacc	10080
accaccacta	cgggtgacccc	aaccccaaca	cccaccggca	cacagacccc	aaccacgaca	10140
cccatcacca	ccaccactac	ggtgacccca	accccaacac	ccaccggcac	acagacccca	10200
accacgacac	ccatcaccac	caccactacg	gtgaccccaa	ccccaaacac	caccggcaca	10260
cagaccccaa	ccacgacacc	catcaccacc	accactacgg	tgaccccaac	cccaacaccc	10320
accggcacac	agaccccaac	cacgacaccc	atcaccacca	ccactacggt	gaccccaacc	10380
ccaacaccca	ccggcacaca	gaccccaacc	acgacaccca	tcaccaccac	cactacggtg	10440
accccaaccc	caacacccac	cggcacacag	accccaacca	cgacacccat	caccaccacc	10500
actacggtga	ccccaaacccc	aacacccacc	ggcacacaga	cccccaaccac	gacacccatc	10560
accaccacca	ctacggtgac	cccaacccca	acacccaccg	gcacacagac	cccaaccacg	10620
acacccatca	ccaccaccac	tacggtgacc	ccaaccccaa	cacccaccgg	cacacagacc	10680
ccaaccacga	cacccatcac	caccaccact	acggtgaccc	caaccccaac	acccaccggc	10740
acacagaccc	caaccacgac	acccatcacc	accaccacta	cgggtgacccc	aaccccaaca	10800
cccaccggca	cacagacccc	acacacgaca	cccatcacca	ccaccactac	ggtgacccca	10860
accccaaacac	ccaccggcac	acagacccca	accatgcacac	ccatcaccac	caccactacg	10920
gtgaccccaa	ccccaaacac	caccggcaca	cagaccccaa	ccacgacacc	catcaccacc	10980
accactacgg	tgaccccaac	cccaacaccc	accggcacac	agaccccaac	cacgacaccc	11040
atcaccacca	ccactacggt	gaccccaacc	ccaacaccca	ccggcacaca	gaccccaacc	11100
acgacaccca	tcaccaccac	cactacggtg	accccaaccc	caacacccac	cggcacacag	11160
accccaacca	cgacacccat	caccaccacc	actacggtga	cccccaacccc	aacacccacc	11220
ggcacacaga	ccccaaaccac	gacacccatc	accaccacca	ctacggtgac	cccaacccca	11280
acacccaccg	gcacacagac	cccaaccacg	acacccatca	ccaccaccac	tacggtgacc	11340
ccaaccccaa	caccacccgg	cacacagacc	ccaaccacga	cacccatcac	caccaccact	11400
acggtgaccc	caaccccaac	acccaccggc	acacagaccc	caaccacgac	acccatcacc	11460
accaccacta	cgggtgacccc	aaccccaaca	cccaccggca	cacagacccc	aaccacgaca	11520
cccatcacca	ccaccactac	ggtgacccca	accccaaacac	ccaccggcac	acagacccca	11580
accacgacac	ccatcaccac	caccactacg	gtgaccccaa	ccccaaacac	caccggcaca	11640
cagaccccaa	ccacgacacc	catcaccacc	accactacgg	tgaccccaac	cccaacaccc	11700
accggcacac	agaccccaac	cacgacaccc	atcaccacca	ccactacggt	gaccccaacc	11760
ccaacaccca	ccggcacaca	gaccccaacc	acgacaccca	tcaccaccac	cactacggtg	11820
accccaaccc	caaacaccac	cggcacacag	accccaacca	cgacacccat	caccaccacc	11880
actacggtga	ccccaaacccc	aacacccacc	ggcacacaga	cccccaaccac	gacacccatc	11940
accaccacca	ctacggtgac	cccaacccca	acacccaccg	gcacacagac	cccaaccacg	12000
acacccatca	ccaccaccac	tacggtgacc	ccaaccccaa	cacccaccgg	cacacagacc	12060
ccaaccacga	cacccatcac	caccaccact	acggtgaccc	caaccccaac	acccaccggc	12120
acacagaccc	caaccacgac	acccatcacc	accaccacta	cgggtgacccc	aaccccaaca	12180
cccaccggca	cacagacccc	aaccacgaca	cccatcacca	ccaccactac	ggtgacccca	12240
accccaaacac	ccaccggcac	acagacccca	accacgacac	ccatcaccac	caccactacg	12300
gtgaccccaa	ccccaaacac	caccggcaca	cagaccccaa	ccacgacacc	catcaccacc	12360
accactacgg	tgaccccaac	cccaacaccc	accggcacac	agaccccaac	cacgacaccc	12420
atcaccacca	ccactacggt	gaccccaacc	ccaacaccca	ccggcacaca	gaccccaacc	12480
acgacaccca	tcaccaccac	cactacggtg	accccaaccc	caacacccac	cggcacacag	12540
accccaacca	cgacacccat	caccaccacc	actacggtga	ccccaaacccc	aacacccacc	12600
ggcacacaga	ccgggcccccc	caccacacac	agcacagcac	cgattgctga	gttgaccaca	12660
tccaatcctc	cgcctgagtc	ctcaacccct	cagacctctc	ggtccacctc	ttccctctct	12720
acggagtcaa	ccacccttct	gagtacccta	ccacctgcca	ttgagatgac	cagcacggcc	12780
ccaccctcca	cacccacggc	acccacgacc	accagcgag	gccacacact	gtctccaccg	12840
cccagcacca	ccacgtcccc	tccaggcacc	cccactcgcg	gtaccacgac	cgggtcatct	12900
tcagccccca	ccccagcac	tgtgcagacg	accaccacca	gtgcctggac	cccaacgccg	12960
acccactctt	ccacacccag	catcatcagg	accacagccc	tgaggcccta	cccttctctt	13020
gtgcttatct	gctgtgtcct	gaacgacacc	tactacgcac	caggtgagga	ggtgtacaac	13080
ggcacatacg	gagacacctg	ttattttcgtc	aactgctcac	tgagctgtac	gttgaggttc	13140

SEQUENCE LISTING 1657-2022.txt

tataactggg	cctgcccac	cacgcccctcc	ccaacaccca	cgcccctccaa	gtcgcgcgccc	13200
acgccttcca	agccatcgtc	cacgcccctcc	aagccgacgc	ccggcaccaa	gccccccgag	13260
tgcccagact	ttgatcctcc	cagacaggag	aacgagactt	gggtggctgtg	cgactgcttc	13320
atggccacgt	gcaagtacaa	caacacgggtg	gagatcgtga	agggtggagt	tgagccgccc	13380
cccatgccc	cctgctccaa	cggcctccaa	cccgtgcgcg	tcgaggaccc	cgacggctgc	13440
tgctggcact	gggagtgcga	ctgctactgc	acgggtcggg	gcgacccgca	ctatgtcacc	13500
ttcgacggac	tctactacag	ctaccagggc	aactgcacct	acgtgctggg	ggaggagatc	13560
agccccctcg	tggaacaact	cggagtctac	atcgacaact	accactgcga	tcccaacgac	13620
aagggtgtcct	gtccccgcac	cctcatcgtg	cgccacgaga	cccaggagg	gctgatcaag	13680
accgtgcata	tgatgccc	gcagggtgcag	gtgcagggtga	acaggcaggc	gggtggcactg	13740
ccctacaaga	agtacgggct	ggagggtgtac	cagtctggca	tcaactacgt	gggtggacatc	13800
cccagctgg	gtgtcctcgt	ctcctacaat	ggcctgtcct	tctccgtcag	gctgcccctac	13860
caccgggttg	caaggggccac	caaggggccag	gtgtggcacct	gcaccaacac	cacctcctgc	13920
gactgcattc	tgcccagcgg	ggagatcgtc	tccaactgtg	aggctgcggc	tgaccagtgg	13980
ctgggtgaacg	acccctccaa	gccacactgc	ccccacagca	gctccacgac	caagcgccc	14040
gcccgtcctg	tgcccggggg	cggtaaaacg	acccacaca	aggactgcac	cccatctccc	14100
ctctgccagc	tcatacagg	cagcctgttt	cgccactggc	acgcactggg	gcccccgag	14160
cactactacg	atgcctgcgt	gttcgacagc	tgcttcatgc	cgggctcgag	cctggagtgc	14220
gccagtctgc	aggcctacgc	agccctctgt	gcccacgaga	acatctgcct	cgactggcgg	14280
aaccacacg	atggggcctg	cttgggtggag	tgcccatctc	acagggagta	ccaggcctgt	14340
ggccctgcag	aagagcccac	gtgcaaatcc	agctcctccc	agcagaacaa	cacagtctgt	14400
gtggaaggct	gcttctgtcc	tgagggcacc	atgaactacg	ctcctggcct	tgatgtctgc	14460
gtgaagacct	gcggctgtgt	gggacctgac	aatgtgcca	gagagtgttg	ggagcacttc	14520
gagttcgact	gcaagaactg	tgtctgcctg	gaggggtgaa	gtggcatcat	ctgccaaccc	14580
aagagggtgca	gccagaagcc	cggttaccac	tgctgtgaa	acggcaccta	cctcgccacg	14640
gaggtcaacc	ctgcccagac	ctgctgcaac	attaccgtct	gcaagtgcaa	caccagcctg	14700
tgcaaaagaga	agccctccgt	gtgcccgcgt	ggattcgaag	tgaagagcaa	gatgggtgcct	14760
ggaagggtgt	gtccccttcta	ctgggtgtgag	tccaaggggg	tgtgtgttca	cgggaatgct	14820
gagtaaccagc	ccgggttctcc	agttttattcc	tccaagtgcc	aggactgcgt	gtgcacggac	14880
aagggtggaca	acaacaccct	gctcaacgtc	atcgctgca	cccacgtgcc	ctgcaacacc	14940
tcttgagcc	ctggcttcga	actcatggag	gcccccgggg	agtgtgttaa	gaagtgtgaa	15000
cagacgcact	gtatcatcaa	acggcccgcac	aaccagcag	tcattcctgaa	gccccgggac	15060
ttcaagagcgc	acccgaagaa	caactgcaca	tcttctagct	gcgtgaagat	ccacaaccag	15120
ctcatctcgt	ccgtctccaa	catcacctgc	cccaactttg	atgccagcat	ttgcatcccc	15180
ggctccatca	cattcatgcc	caatggatgc	tgcaagacct	gcacccctcg	caatgagacc	15240
agggtgcccc	gctccaccgt	ccccgtcacc	acggagggtt	cgtacgccgg	ctgcaccaag	15300
accgtccctca	ctccgggtcc	ctccgggtcc	tgccggacat	ttgtcatgta	ctcggccagg	15360
gcccaggccc	tggaaccacag	ctgctcctgc	tgcaaaagg	agaaaaccag	ccagcgtgag	15420
gtggctcctga	gctgccccaa	tgccggctcg	ctgacacaca	cctacaccca	catcgagagc	15480
tgccagtgcc	aggacaccgt	ctgcccggctc	cccaccggca	cctcccgcg	ggcccggcgc	15540
tcccctaggc	atctggggag	cggtgtgagc	gggtgggac	agcccccttc	actgccctgc	15600
acagctttac	ctcccccgga	ccctctgagc	ctctcaagct	cggcttcttc	tcttcagata	15660
tttattgtct	gagtccttgt	tcagtccttg	ctttccaata	ataaactcag	ggggacatgc	15720

<210> 86
 <211> 2058
 <212> DNA
 <213> Homo sapiens

<400> 86						
cggtttctgc	tggtttctgc	aactgctggg	tttctgcttg	ctcctctgga	gatgcagcgt	60
ctgttgactc	cagtgaagcg	cattctgcaa	ctgacaagag	cggtgcagga	aacctccctc	120
acacctgctc	gcctgtctcc	agtagccac	caaagggttt	ctacagcctc	tgctgtcccc	180
ctggccaaaa	cagatacttg	gccaaaggac	gtgggcatcc	tgccctgga	ggtctacttc	240
ccagcccaat	atgtggacca	aactgacctg	gagaagtata	acaatgtgga	agcaggaaaag	300
tatacagtg	gcttgggcca	gacctgtgct	ggcttctgct	cagtccaaga	ggacatcaac	360
tccctgtgcc	tgacgggtgg	gcaacggctg	atggagcgca	tacagctccc	atgggactct	420
gtgggcaggc	tggaagttag	cactgagacc	atcattgaca	agtccaaagc	tgtcaaaaca	480
gtgctcatgg	aactcttcca	ggattcaggc	aatactgata	ttgagggcag	agataccacc	540
aatgcctgct	acgggtgtac	tgccctccct	ttcaatgctg	ccaactggat	ggagttccag	600
tccctgggatg	gtcgttatgc	catggtggct	tgtggagaca	ttgccgtcta	tcccagtggt	660
aatgctcgtc	ccacaggtgg	ggccggagct	gtggctatgc	tgattggccc	aaaggcccct	720
ctggcccttg	agcgaaggct	gaggggaacc	catatggaga	atgtgtatga	cttctacaaa	780
ccaaatttgg	cctcggagta	cccaatagtg	gatgggaagc	tttccatcca	gtgctacttg	840
cgggccttgg	atcgatgtta	cacatcatat	cgtaaaaaaa	tccagaatca	gtgggaagcaa	900
gctggcagcg	atcgaccctt	cacccttgac	gatttacagt	atatgatctt	tcatacacc	960

SEQUENCE LISTING 1657-2022.txt

ttttgcaaga	tgggtccagaa	gtctctggct	cgcctgatgt	tcaatgactt	cctgtcagcc	1020
agcagtga	cacaaaccag	cttatataag	gggctggagg	ctttcggggg	gctaaagctg	1080
gaagacacct	acaccaacaa	ggacctggat	aaagcacttc	taaaggcctc	tcaggacatg	1140
ttcgacaaga	aaaccaaggc	ttccctttac	ctctccactc	acaatgggaa	catgtacacc	1200
tcatccctgt	acgggtgcct	ggcctcgctt	ctgtcccacc	actctgcccc	agaactggct	1260
ggctccagga	ttgggtgcctt	ctcttatggc	tctggtttag	cagcaagttt	cttttcattt	1320
cgagtatccc	aggatgctgc	tccaggctct	cccctggaca	agttgggtgc	cagcacatca	1380
gacctgccaa	aacgcctagc	ctcccgaag	tgtgtgtctc	ctgaggagtt	cacagaaata	1440
atgaaccaa	gagagcaatt	ctaccataag	gtgaatttct	ccccacctgg	tgacacaaac	1500
agccttttcc	caggacttgc	gtacctggag	cgagtggacg	agcagcatcg	ccgaaagtat	1560
gcccggcgtc	ccgtctaaag	gtgttctgca	gatccatgga	aagcttcctg	ggaaacgtat	1620
gctagcagag	cttcttcccc	tgaatcatat	ttttaagatc	ccactcttag	ctggtaaatg	1680
aatttgaaatc	gacatagctg	cccataaagc	atcagccctg	tagagttagg	agccatctct	1740
agcgggccct	tcattctctt	ccatgctgca	atcactgtcc	tgggcttatg	gtgcctatgg	1800
actaggggtc	ctttgtgaaa	gagcaagatg	gagcaatgga	gagaagacct	cttcctgaat	1860
cactggactc	cagaaatgtg	catgcagatc	agctgttgcc	ttcaagatcc	agataaaatt	1920
tcctgtcatg	tgtagaact	ttattattgt	taatatgtgt	aaacttctgt	gctgttctgt	1980
tgaatctcca	aattttgtac	cttgttctaa	gctaatatat	agcaattaaa	aagagagaaa	2040
gagaaaaaaa	aaaaaaaa					2058

<210> 87

<211> 3311

<212> DNA

<213> Homo sapiens

<400> 87

tgctaagt	tttggtaaa	atggatgtgg	aatataattg	aatattttct	tgtttaaggg	60
gagcatgaag	agggtgtgag	gttatgtcaa	gcattctggca	cagctgaagg	cagatggaaa	120
tattttacaag	tacgcaattt	gagactaaga	tattgtttatc	attctcctat	tgaagacaag	180
agcaatagta	aaacacatca	ggtcaggggg	ttaaagacct	gtgataaacc	acttccgata	240
agttggaacc	gtgtgtctat	attttcatat	ctgtatataat	ataatggtaa	agaaagacac	300
cttcgtaacc	cgcattttcc	aaagagagga	atcacaggga	gatgtacagc	aatggggcca	360
tttaagagtt	ctgtgttcat	cttgattctt	caacttctag	aaggggccct	gagtaattca	420
ctcattcagc	tgaacaacaa	tggctatgaa	ggcattgtcg	ttgcaatcga	ccccaatgtg	480
ccagaagatg	aaacactcat	tcaacaaata	aaggacatgg	tgaccaggc	atctctgtat	540
ctgtttgaag	ctacaggaaa	gcgattttat	ttcaaaaatg	ttgccatttt	gattcctgaa	600
acatggaaga	caaaggctga	ctatgtgaga	ccaaaacttg	agacctacaa	aaatgctgat	660
gttctgggtg	ctgagtctac	tcctccaggt	aatgatgaac	cctacactga	gcagatgggc	720
aactgtggag	agaaggggtg	aaggatccac	ctcactcctg	atttcattgc	aggaaaaaag	780
ttagctgaat	atggaccaca	aggtaaggca	tttgtccatg	agtgggctca	tctacgatgg	840
ggagtatttg	acgagtaaaa	taatgatgag	aaatttctact	tatccaatgg	aagaatacaa	900
gcagtaagat	gttcagcagg	tattactggg	acaaatgtag	taaagaagtg	tcagggaggc	960
agctgtttaca	ccaaaagatg	cacattcaat	aaagttacag	gactctatga	aaaaggatgt	1020
gagtttgttc	ttcaattccc	ccagacggag	aaggcttcta	taatgtttgc	acaacatgtt	1080
gatttctatag	tgaattctg	tacagaacaa	aaccacaaca	aagaagctcc	aaacaagcaa	1140
aatcaaaaaat	gcaatctccg	aagcacatgg	gaagtgatcc	gtgattctga	ggacttttaag	1200
aaaaccactc	ctatgacaac	acagccacca	aatcccacct	tctcattgct	gcagatttga	1260
caaagaattg	tgtgtttagt	ccttgacaaa	tctggaagca	tggcgactgg	taaccgcctc	1320
aatcgactga	atcaagcagg	ccagcttttc	ctgtctgcaga	cagttgagct	ggggtcctgg	1380
gttgggatgg	tgacatttga	cagtgtgcc	catgtacaaa	gtgaactcat	acagataaac	1440
agtggcagtg	acagggacac	actcgccaaa	agattacctg	cagcagcttc	aggagggacg	1500
tccatctgca	gcgggcttcg	atcggcattt	actgtgatta	ggaagaaata	tccaactgat	1560
ggatctgaaa	ttgtgctgct	gacggatggg	gaagacaaca	ctataagtgg	gtgctttaac	1620
gaggtcaaac	aaagtgggtg	catcatccac	acagtcgctt	tggggccctc	tgagctcaa	1680
gaactagagg	agctgtccaa	aatgacagga	ggtttacaga	catatgcttc	agatcaagtt	1740
cagaacaatg	gcctcattga	tgcttttggg	gccctttcat	caggaaatgg	agctgtctct	1800
cagcgtccca	tccagcttga	gaagtaaggga	tttaacctcc	agaacagcca	gtggatgaat	1860
ggcacagtga	tcgtggacag	caccgtggga	aaggacactt	tgttttctat	cacctggaca	1920
acgcagcctc	cccaaactct	tctctgggat	cccagtgga	agaagcaagg	tggctttgta	1980
gtggacaaaa	acacaaaaat	ggcctacctc	caaatcccag	gcattgctaa	ggttggcact	2040
tggaaataca	agctcacaag	aagctcaca	accttgacc	tgactgtcac	gtcccgtgcg	2100
tccaatgcta	ccctgcctcc	aattacagtg	acttccaaaa	cgaacaagga	caccagcaaa	2160
ttccccagcc	ctctggtagt	ttatgcaaat	attcgccaag	gagcctcccc	aattctcagg	2220
gccagtgta	cagccctgat	tgaatcagtg	aatggaaaaa	cagttacctt	ggaactactg	2280
gataatggag	caggtgtctga	tgctactaag	gatgacggtg	tctactcaag	gtatttcaca	2340
acttatgaca	cgaatggtag	atacagtgta	aaagtgcggg	ctctggggagg	agttaacgca	2400
gccagacgga	gagtgatacc	ccagcagagt	ggagcactgt	acatacctgg	ctggattgag	2460

SEQUENCE LISTING 1657-2022.txt

```

aatgatgaaa tacaatggaa tccaccaaga cctgaaatta ataaggatga tgttcaacac 2520
aagcaagtgt gtttcagcag aacatcctcg ggaggctcat ttgtggcttc tgatgtccca 2580
aatgctccca tacctgatct cttcccacct ggccaaatca ccgacctgaa ggcggaaatt 2640
cacgggggca gtctcattaa tctgacttgg acagctcctg gggatgatta tgacctgga 2700
acagctcaca agtatatcat tcgaataagt acaagtattc ttgatctcag agacaagttc 2760
aatgaatctc ttcaagtga tactactgct ctcatcccaa aggaagccaa ctctgaggaa 2820
gtctttttgt ttaaaccaga aaacattact tttgaaaatg gcacagatct tttcattgct 2880
attcaggctg ttgataaggt cgatctgaaa tcagaaatat ccaacattgc acgagtatct 2940
ttgttttatt ctccacagac tccgccagag acacctagtc ctgatgaaac gtctgtctct 3000
tgtcctaata ttcatatcaa cagcaccatt cctggcattc acatttttaa aattatgtgg 3060
aagtggatag gagaactgca gctgtcaata gcctagggct gaatttttgt cagataaata 3120
aaataaatca ttcatccttt ttttgattat aaaattttct aaaatgtatt ttagacttcc 3180
tgtagggggc gatatactaa atgtatatag tacatttata ctaaatgtat tcctgtaggg 3240
ggcgaataac taaatgtatt ttagacttcc tgtagggggc gataaaataa aatgctaaac 3300
aactgggtaa a 3311

```

<210> 88
 <211> 468
 <212> DNA
 <213> Homo sapiens

```

<400> 88
gccccctccc ctgactatca aagcagcggc cggctgttgg ggtccaccac gccttccacc 60
tgccccactg ctcttcgctg tctctcttgg aaagtccagt ctctcctcgg cttgcaatgg 120
accccaactg ctcttcgccc gctgggtgct cctgcacctg cgctgggtcc tgcaagtga 180
aagagtgcaa atgcacctcc tgcaagaaga gctgtgtctc ctgctgcccc gtgggctgta 240
gcaagtgtgc ccagggtgtg gtttgcaaag gggcgtcaga gaagtgcagc tgctgcgact 300
gatgccagga caacctttct cccagatgta aacagagaga catgtacaaa cctggatttt 360
tttttatacc accttgaccc atttgctaca ttccttttcc tgtgaaatat gtgagtata 420
attaaacact ttagacccaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 468

```

<210> 89
 <211> 1551
 <212> DNA
 <213> Homo sapiens

```

<400> 89
ggcgcccaag ccgcccggc cagatcgggt ccgattcctg ccctgccccg accgccagcg 60
cgacctgtc ccactactgg ggggtacggc aacacaacgg acctgagcac tggcataagg 120
acttccccat tgccaaggga gagcgccagt cccctgttga catcgacact catacagcca 180
agtatgaccc ttccctgaag cccctgtctg tttcctatga tcaagcaact tccctgagga 240
tcctcaacaa tggatcatgt ttcaacgtgg agtttgatga ctctcaggac aaagcagtgc 300
tcaaggaggg acccctggat ggcacttaca gattgattca gtttcacttt cactgggggt 360
cacttgatgg acaaggttca gagcatactg tggataaaaa gaaatatgct gcagaacttc 420
acttgggtca ctggaacacc aaatatgggg attttgggaa agctgtgcag caacctgatg 480
gactggccgt tctaggtatt tttttgaagg ttggcagcgc taaaccgggc cttcagaaag 540
ttgttgatgt gctggattcc attaaaacaa agggcaagag tgctgacttc actaacttcg 600
atcctcgtgg cctccttctt tctggaatgt gtgacctgga ttgtgtcaa ggaaccatc agcgtcagca 720
cccctcctt gttgaaattc cgtaaacctt acttcaatgg ggagggtgaa cccgaagaac 780
gcgagcaggt caactggcgc ccagctcagc cactgaagaa caggcaaatac aaagcttctc 840
tgatggtgga tcaaataaga tgggtccata gtctgtatcc aaataatgaa tcttcgggtg tttcccttta 900
gctaagcaca gatctacctt ggtgatttgg accctgggtg ctttgtgtct agttttctag 960
acccttcac tcttacttga tagacttact aataaaatgt gaagactaga ccaattgtca 1020
tgcttgacac aactgctgtg gctgggttgg gctttgttta tggtagtagt ttttctgtaa 1080
cacagaatat aggataagaa ataagaataa agtaccttga cttgtgtcac agcatgtagg 1140
gtgatgagca ctcacaattg ttgactaaaa tgtgctttt aaaacatagg aaagtagaat 1200
ggttgagtgc aaatccatag cacaagataa attgagctag ttaaggcaaa tcagggtaaa 1260
tagtcatgat tctatgtaat gtaaacccaga aaaaataaat gttcatgatt tcaagatgtt 1320
atattaaaga aaaactttta aaattattat atatttatag caaagttatc ttaaatatga 1380
attctgttgt aatttgaatt cttttgaatt acagagatat aaatgaagta ttatctgtaa 1440
aaattgttat aattagagtt gtgatacaga gtatatattc attcagacaa tatatcataa 1500
cttaataaat attgtatatt agatatattc tctaataaaa ttcagaattc t 1551

```

<210> 90
 <211> 367
 <212> DNA

SEQUENCE LISTING 1657-2022.txt

<213> Homo sapiens

<400> 90

```

ctccagtctc acctcggcctt gcaatggacc ccaactgctc ctgcgaggct ggtggctcct 60
gcgcctgcgc cggctcctgc aagtgcacaaa agtgcaaatg caccctcctgc aagaagagct 120
gctgctcctg ttgccccctg ggctgtgcca agtgtgcca gggctgcatc tgcaaagggg 180
cgtcagagaa gtgcagctgc tgtgcctgat gtcgggacag ccctgctgtc agatgaaaac 240
agaatgacac gtaaaatccg aggttttttt tttctacaac tccgactcat ttgctacatt 300
cctttttttt tgtgaaatat gtgaataata attaaacact tagacttgaa aaaaaaaaaa 360
aaaaaaa 367

```

<210> 91

<211> 396

<212> DNA

<213> Homo sapiens

<400> 91

```

actccgcctt ccacgtgcac ccactgcctc ttcccttctc gcttgggaac tctagtctcg 60
cctcgggttg caatggaccc caactgctcc tgtgccgctg gtgtctcctg caccctgcgc 120
agctcctgca agtgcaaaaga gtgcaaatgc accctcctgca agaagagctg ctgctcctgc 180
tgccctgtgg gctgtgcca ggtgtgcca ggtgtcatct gcaaaggggc atcgagagaag 240
tgcagctgct gcgcctgatg tcgggacagc cctgctccca agtacaataa gagtgaccgc 300
taaaatctag gatTTTTTgt tttttgctac aatcttgacc cttttgctac attccctttt 360
ttctgtgaaa tatgtgaata ataattaaac acttag 396

```

<210> 92

<211> 632

<212> DNA

<213> Homo sapiens

<400> 92

```

cccagaatgt tgacagtcgc tctcctagcc cttctctgtg cctcagcctc tggcaatgcc 60
attcaggcca ggtcttcctc ctatagtggg agtatgtgaa gtggtggtgg aaagcgattc 120
tctcattctg gcaaccagtt ggacggcccc atcaccgccc tccgggtccg agtcaacaca 180
tactacatcg taggtcttca ggtgcgctat ggcaagggtg ggagcgacta tgtgggtggt 240
cgcaacggag acctggagga gatctttctg caccctgggg aatcagtgat ccaggtttct 300
gggaagtaca agtggtagct gaagaagctg gtatttgtga cagacaaggg ccgctatctg 360
tcttttggga aagacagtgg cacaagtttc aatgccgtcc cttgcaccc caacaccgtg 420
ctccgcttca tcagtggccg gtctggttct ctcctcgatg ccattggcct gcactgggat 480
gtttaaccca ctagtgcag cagatgctga gcctcctctc cttggcaggg gcactgtgat 540
gaggagtaag aactccctta tcactaacc ccatccaaat ggctcaataa aaaaatatgg 600
ttaaggctaa aaaaaaaaaa aaaaaaaaaa aa 632

```

<210> 93

<211> 257

<212> DNA

<213> Homo sapiens

<400> 93

```

accacgcttt tcatctgtcc cgctgcgtgt tttcctcttg atcgggaact cctgcttctc 60
cttgectcga aatggacccc aactgctcct gctgcctgt tggctcctgt gcctgtgccg 120
gctcctgcaa atgcaaagag tgcaaatgca cctcctgcaa gaagagctgc tgctcctgct 180
gccctgtcgg ctgtgccaag tgtgcccagg gctgcatctg caaagggacg tcagacaagt 240
gcagctgctg tgcctga 257

```

<210> 94

<211> 422

<212> PRT

<213> Homo sapiens

<400> 94

```

Met Asn Ser Gly His Ser Phe Ser Gln Thr Pro Ser Ala Ser Phe His
1      5      10      15
Gly Ala Gly Gly Trp Gly Arg Pro Arg Ser Phe Pro Arg Ala Pro
20      25      30
Thr Val His Gly Gly Ala Gly Gly Ala Arg Ile Ser Leu Ser Phe Thr
35      40      45

```


SEQUENCE LISTING 1657-2022.txt

Thr Arg Ser Cys Pro Pro Pro Gly Gly Ser Trp Gly Ser Gly Arg Ser
 50 55 60
 Ser Pro Leu Leu Gly Gly Asn Gly Lys Ala Thr Met Gln Asn Leu Asn
 65 70 75 80
 Asp Arg Leu Ala Ser Tyr Leu Glu Lys Val Arg Ala Leu Glu Glu Ala
 85 90 95
 Asn Met Lys Leu Glu Ser Arg Ile Leu Lys Trp His Gln Gln Arg Asp
 100 105 110
 Pro Gly Ser Lys Lys Asp Tyr Ser Gln Tyr Glu Glu Asn Ile Thr His
 115 120 125
 Leu Gln Glu Gln Ile Val Asp Gly Lys Met Thr Asn Ala Gln Ile Ile
 130 135 140
 Leu Leu Ile Asp Asn Ala Arg Met Ala Val Asp Asp Phe Asn Leu Lys
 145 150 155 160
 Tyr Glu Asn Glu His Ser Phe Lys Lys Asp Leu Glu Ile Glu Val Glu
 165 170 175
 Gly Leu Arg Arg Thr Leu Asp Asn Leu Thr Ile Val Thr Thr Asp Leu
 180 185 190
 Glu Gln Glu Val Glu Gly Met Arg Lys Glu Leu Ile Leu Met Lys Lys
 195 200 205
 His His Glu Gln Glu Met Glu Lys His His Val Pro Ser Asp Phe Asn
 210 215 220
 Val Asn Val Lys Val Asp Thr Gly Pro Arg Glu Asp Leu Ile Lys Val
 225 230 235 240
 Leu Glu Asp Met Arg Gln Glu Tyr Glu Leu Ile Ile Lys Lys Lys His
 245 250 255
 Arg Asp Leu Asp Thr Trp Tyr Lys Glu Gln Ser Ala Ala Met Ser Gln
 260 265 270
 Glu Ala Ala Ser Pro Ala Thr Val Gln Ser Arg Gln Gly Asp Ile His
 275 280 285
 Glu Leu Lys Arg Thr Phe Gln Ala Leu Glu Ile Asp Leu Gln Thr Gln
 290 295 300
 Tyr Ser Thr Lys Ser Ala Leu Glu Asn Met Leu Ser Glu Thr Gln Ser
 305 310 315 320
 Arg Tyr Ser Cys Lys Leu Gln Asp Met Gln Glu Ile Ile Ser His Tyr
 325 330 335
 Glu Glu Glu Leu Thr Gln Leu Arg His Glu Leu Glu Arg Gln Asn Asn
 340 345 350
 Glu Tyr Gln Val Leu Leu Gly Ile Lys Thr His Leu Glu Lys Glu Ile
 355 360 365
 Thr Thr Tyr Arg Arg Leu Leu Glu Gly Glu Ser Glu Gly Thr Arg Glu
 370 375 380
 Glu Ser Lys Ser Ser Met Lys Val Ser Ala Thr Pro Lys Ile Lys Ala
 385 390 395 400
 Ile Thr Gln Glu Thr Ile Asn Gly Arg Leu Val Leu Cys Gln Val Asn
 405 410 415
 Glu Ile Gln Lys His Ala
 420

<210> 95

<211> 166

<212> PRT

<213> Homo sapiens

<400> 95

Met Ala Gln Thr Ser Ser Tyr Phe Met Leu Ile Ser Cys Leu Met Phe
 1 5 10 15
 Leu Ser Gln Ser Gln Gly Gln Glu Ala Gln Thr Glu Leu Pro Gln Ala
 20 25 30
 Arg Ile Ser Cys Pro Glu Gly Thr Asn Ala Tyr Arg Ser Tyr Cys Tyr
 35 40 45
 Tyr Phe Asn Glu Asp Arg Glu Thr Trp Val Asp Ala Asp Leu Tyr Cys
 50 55 60
 Gln Asn Met Asn Ser Gly Asn Leu Val Ser Val Leu Thr Gln Ala Glu
 65 70 75 80
 Gly Ala Phe Val Ala Ser Leu Ile Lys Glu Ser Gly Thr Asp Asp Phe
 85

SEQUENCE LISTING 1657-2022.txt

```

      85      90      95
Asn Val Trp Ile Gly Leu His Asp Pro Lys Lys Asn Arg Arg Trp His
      100      105      110
Trp Ser Ser Gly Ser Leu Val Ser Tyr Lys Ser Trp Gly Ile Gly Ala
      115      120      125
Pro Ser Ser Val Asn Pro Gly Tyr Cys Val Ser Leu Thr Ser Ser Thr
      130      135      140
Gly Phe Gln Lys Trp Lys Asp Val Pro Cys Glu Asp Lys Phe Ser Phe
      145      150      155      160
Val Cys Lys Phe Lys Asn
      165

```

<210> 96
 <211> 166
 <212> PRT
 <213> Homo sapiens

```

<400> 96
Met Ala Gln Thr Asn Ser Phe Phe Met Leu Ile Ser Ser Leu Met Phe
  1      5      10      15
Leu Ser Leu Ser Gln Gly Gln Glu Ser Gln Thr Glu Leu Pro Asn Pro
      20      25      30
Arg Ile Ser Cys Pro Glu Gly Thr Asn Ala Tyr Arg Ser Tyr Cys Tyr
      35      40      45
Tyr Phe Asn Glu Asp Pro Glu Thr Trp Val Asp Ala Asp Leu Tyr Cys
      50      55      60
Gln Asn Met Asn Ser Gly Asn Leu Val Ser Val Leu Thr Gln Ala Glu
      65      70      75      80
Gly Ala Phe Val Ala Ser Leu Ile Lys Glu Ser Ser Thr Asp Asp Ser
      85      90      95
Asn Val Trp Ile Gly Leu His Asp Pro Lys Lys Asn Arg Arg Trp His
      100      105      110
Trp Ser Ser Gly Ser Leu Val Ser Tyr Lys Ser Trp Asp Thr Gly Ser
      115      120      125
Pro Ser Ser Ala Asn Ala Gly Tyr Cys Ala Ser Leu Thr Ser Cys Ser
      130      135      140
Gly Phe Lys Lys Trp Lys Asp Glu Ser Cys Glu Lys Lys Phe Ser Phe
      145      150      155      160
Val Cys Lys Phe Lys Asn
      165

```

<210> 97
 <211> 411
 <212> PRT
 <213> Homo sapiens

```

<400> 97
Met Trp Ser Gly Trp Trp Leu Trp Pro Leu Val Ala Val Cys Thr Ala
  1      5      10      15
Asp Phe Phe Arg Asp Glu Ala Glu Arg Ile Met Arg Asp Ser Pro Val
      20      25      30
Ile Asp Gly His Asn Asp Leu Pro Trp Gln Leu Leu Asp Met Phe Asn
      35      40      45
Asn Arg Leu Gln Asp Glu Arg Ala Asn Leu Thr Thr Leu Ala Gly Thr
      50      55      60
His Thr Asn Ile Pro Lys Leu Arg Ala Gly Phe Val Gly Gly Gln Phe
      65      70      75      80
Trp Ser Val Tyr Thr Pro Cys Asp Thr Gln Asn Lys Asp Ala Val Arg
      85      90      95
Arg Thr Leu Glu Gln Met Asp Val Val His Arg Met Cys Arg Met Tyr
      100      105      110
Pro Glu Thr Phe Leu Tyr Val Thr Ser Ser Ala Gly Ile Arg Gln Ala
      115      120      125
Phe Arg Glu Gly Lys Val Ala Ser Leu Ile Gly Val Glu Gly Gly His
      130      135      140

```

SEQUENCE LISTING 1657-2022.txt

```

Ser Ile Asp Ser Ser Leu Gly Val Leu Arg Ala Leu Tyr Gln Leu Gly
145      150      155      160
Met Arg Tyr Leu Thr Leu Thr His Ser Cys Asn Thr Pro Trp Ala Asp
      165      170      175
Asn Trp Leu Val Asp Thr Gly Asp Ser Glu Pro Gln Ser Gln Gly Leu
      180      185      190
Ser Pro Phe Gly Gln Arg Val Val Lys Glu Leu Asn Arg Leu Gly Val
      195      200      205
Leu Ile Asp Leu Ala His Val Ser Val Ala Thr Met Lys Ala Thr Leu
      210      215      220
Gln Leu Ser Arg Ala Pro Val Ile Phe Ser His Ser Ser Ala Tyr Ser
      225      230      235      240
Val Cys Ala Ser Arg Arg Asn Val Pro Asp Asp Val Leu Arg Leu Val
      245      250      255
Lys Gln Thr Asp Ser Leu Val Met Val Asn Phe Tyr Asn Asn Tyr Ile
      260      265      270
Ser Cys Thr Asn Lys Ala Asn Leu Ser Gln Val Ala Asp His Leu Asp
      275      280      285
His Ile Lys Glu Val Ala Gly Ala Arg Ala Val Gly Phe Gly Gly Asp
      290      295      300
Phe Asp Gly Val Pro Arg Val Pro Glu Gly Leu Glu Asp Val Ser Lys
      305      310      315      320
Tyr Pro Asp Leu Ile Ala Glu Leu Leu Arg Arg Asn Trp Thr Glu Ala
      325      330      335
Glu Val Lys Gly Ala Leu Ala Asp Asn Leu Leu Arg Val Phe Glu Ala
      340      345      350
Val Glu Gln Ala Ser Asn Leu Thr Gln Ala Pro Glu Glu Glu Pro Ile
      355      360      365
Pro Leu Asp Gln Leu Gly Gly Ser Cys Arg Thr His Tyr Gly Tyr Ser
      370      375      380
Ser Gly Ala Ser Ser Leu His Arg His Trp Gly Leu Leu Leu Ala Ser
      385      390      395      400
Leu Ala Pro Leu Val Leu Cys Leu Ser Leu Leu
      405      410

```

<210> 98
 <211> 99
 <212> PRT
 <213> Homo sapiens

```

<400> 98
Met Thr Ser Lys Leu Ala Val Ala Leu Leu Ala Ala Phe Leu Ile Ser
1      5      10      15
Ala Ala Leu Cys Glu Gly Ala Val Leu Pro Arg Ser Ala Lys Glu Leu
      20      25      30
Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe
      35      40      45
Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr
      50      55      60
Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro
      65      70      75      80
Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala
      85      90      95
Glu Asn Ser

```

<210> 99
 <211> 469
 <212> PRT
 <213> Homo sapiens

```

<400> 99
Met His Ser Phe Pro Pro Leu Leu Leu Leu Leu Phe Trp Gly Val Val
1      5      10      15
Ser His Ser Phe Pro Ala Thr Leu Glu Thr Gln Glu Gln Asp Val Asp

```

SEQUENCE LISTING 1657-2022.txt

```

20          25          30
Leu Val Gln Lys Tyr Leu Glu Lys Tyr Tyr Asn Leu Lys Asn Asp Gly
35          40          45
Arg Gln Val Glu Lys Arg Arg Asn Ser Gly Pro Val Val Glu Lys Leu
50          55          60
Lys Gln Met Gln Glu Phe Phe Gly Leu Lys Val Thr Gly Lys Pro Asp
65          70          75          80
Ala Glu Thr Leu Lys Val Met Lys Gln Pro Arg Cys Gly Val Pro Asp
85          90          95
Val Ala Gln Phe Val Leu Thr Glu Gly Asn Pro Arg Trp Glu Gln Thr
100         105         110
His Leu Thr Tyr Arg Ile Glu Asn Tyr Thr Pro Asp Leu Pro Arg Ala
115         120         125
Asp Val Asp His Ala Ile Glu Lys Ala Phe Gln Leu Trp Ser Asn Val
130         135         140
Thr Pro Leu Thr Phe Thr Lys Val Ser Glu Gly Gln Ala Asp Ile Met
145         150         155         160
Ile Ser Phe Val Arg Gly Asp His Arg Asp Asn Ser Pro Phe Asp Gly
165         170         175         180
Pro Gly Gly Asn Leu Ala His Ala Phe Gln Pro Gly Pro Gly Ile Gly
185         190         195
Gly Asp Ala His Phe Asp Glu Asp Glu Arg Trp Thr Asn Asn Phe Arg
200         205         210
Glu Tyr Asn Leu His Arg Val Ala Ala His Glu Leu Gly His Ser Leu
215         220         225
Gly Leu Ser His Ser Thr Asp Ile Gly Ala Leu Met Tyr Pro Ser Tyr
230         235         240
Thr Phe Ser Gly Asp Val Gln Leu Ala Gln Asp Asp Ile Asp Gly Ile
245         250         255
Gln Ala Ile Tyr Gly Arg Ser Gln Asn Pro Val Gln Pro Ile Gly Pro
260         265         270
Gln Thr Pro Lys Ala Cys Asp Ser Lys Leu Thr Phe Asp Ala Ile Thr
275         280         285
Thr Ile Arg Gly Glu Val Met Phe Phe Lys Asp Arg Phe Tyr Met Arg
290         295         300
Thr Asn Pro Phe Tyr Pro Glu Val Glu Leu Asn Phe Ile Ser Val Phe
305         310         315         320
Trp Pro Gln Leu Pro Asn Gly Leu Glu Ala Ala Tyr Glu Phe Ala Asp
325         330         335
Arg Asp Glu Val Arg Phe Phe Lys Gly Asn Lys Tyr Trp Ala Val Gln
340         345         350
Gly Gln Asn Val Leu His Gly Tyr Pro Lys Asp Ile Tyr Ser Ser Phe
355         360         365
Gly Phe Pro Arg Thr Val Lys His Ile Asp Ala Ala Leu Ser Glu Glu
370         375         380
Asn Thr Gly Lys Thr Tyr Phe Phe Val Ala Asn Lys Tyr Trp Arg Tyr
385         390         395         400
Asp Glu Tyr Lys Arg Ser Met Asp Pro Gly Tyr Pro Lys Met Ile Ala
405         410         415
His Asp Phe Pro Gly Ile Gly His Lys Val Asp Ala Val Phe Met Lys
420         425         430
Asp Gly Phe Phe Tyr Phe Phe His Gly Thr Arg Gln Tyr Lys Phe Asp
435         440         445
Pro Lys Thr Lys Arg Ile Leu Thr Leu Gln Lys Ala Asn Ser Trp Phe
450         455         460
Asn Cys Arg Lys Asn
465

```

<210> 100
 <211> 267
 <212> PRT
 <213> Homo sapiens

<400> 100
 Met Arg Leu Thr Val Leu Cys Ala Val Cys Leu Leu Pro Gly Ser Leu
 1 5 10 15

SEQUENCE LISTING 1657-2022.txt

Ala Leu Pro Leu Pro Gln Glu Ala Gly Gly Met Ser Glu Leu Gln Trp
 20 25 30
 Glu Gln Ala Gln Asp Tyr Leu Lys Arg Phe Tyr Leu Tyr Asp Ser Glu
 35 40 45
 Thr Lys Asn Ala Asn Ser Leu Glu Ala Lys Leu Lys Glu Met Gln Lys
 50 55 60
 Phe Phe Gly Leu Pro Ile Thr Gly Met Leu Asn Ser Arg Val Ile Glu
 65 70 75 80
 Ile Met Gln Lys Pro Arg Cys Gly Val Pro Asp Val Ala Glu Tyr Ser
 85 90 95
 Leu Phe Pro Asn Ser Pro Lys Trp Thr Ser Lys Val Val Thr Tyr Arg
 100 105 110
 Ile Val Ser Tyr Thr Arg Asp Leu Pro His Ile Thr Val Asp Arg Leu
 115 120 125
 Val Ser Lys Ala Leu Asn Met Trp Gly Lys Glu Ile Pro Leu His Phe
 130 135 140
 Arg Lys Val Val Trp Gly Thr Ala Asp Ile Met Ile Gly Phe Ala Arg
 145 150 155 160
 Gly Ala His Gly Asp Ser Tyr Pro Phe Asp Gly Pro Gly Asn Thr Leu
 165 170 175
 Ala His Ala Phe Ala Pro Gly Thr Gly Leu Gly Gly Asp Ala His Phe
 180 185 190
 Asp Glu Asp Glu Arg Trp Thr Asp Gly Ser Ser Leu Gly Ile Asn Phe
 195 200 205
 Leu Tyr Ala Ala Thr His Glu Leu Gly His Ser Leu Gly Met Gly His
 210 215 220
 Ser Ser Asp Pro Asn Ala Val Met Tyr Pro Thr Tyr Gly Asn Gly Asp
 225 230 235 240
 Pro Gln Asn Phe Lys Leu Ser Gln Asp Asp Ile Lys Gly Ile Gln Lys
 245 250 255
 Leu Tyr Gly Lys Arg Ser Asn Ser Arg Lys Lys
 260 265

<210> 101
 <211> 300
 <212> PRT
 <213> Homo sapiens

<400> 101
 Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala
 1 5 10 15
 Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu
 20 25 30
 Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro
 35 40 45
 Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Thr Leu Pro Ser Lys Ser
 50 55 60
 Asn Glu Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp
 65 70 75 80
 Asp His Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp
 85 90 95
 Val Asp Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser
 100 105 110
 Asp Glu Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala
 115 120 125
 Thr Glu Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly
 130 135 140
 Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe
 145 150 155 160
 Arg Arg Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr
 165 170 175
 Ser His Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro
 180 185 190
 Val Ala Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys
 195 200 205
 Asp Ser Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His

SEQUENCE LISTING 1657-2022.txt

210
 Ser His Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser
 225
 Asn Glu His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser
 230
 Arg Glu Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val
 245
 Val Asp Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile
 250
 Ser His Glu Leu Asp Ser Ala Ser Ser Glu Val Asn
 260
 270
 280
 290
 295
 300

<210> 102
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 102
 Met Asn Gln Thr Ala Ile Leu Ile Cys Cys Leu Ile Phe Leu Thr Leu
 1 5 10 15
 Ser Gly Ile Gln Gly Val Pro Leu Ser Arg Thr Val Arg Cys Thr Cys
 20 25 30
 Ile Ser Ile Ser Asn Gln Pro Val Asn Pro Arg Ser Leu Glu Lys Leu
 35 40 45
 Glu Ile Ile Pro Ala Ser Gln Phe Cys Pro Arg Val Glu Ile Ile Ala
 50 55 60
 Thr Met Lys Lys Lys Gly Glu Lys Arg Cys Leu Asn Pro Glu Ser Lys
 65 70 75 80
 Ala Ile Lys Asn Leu Leu Lys Ala Val Ser Lys Glu Met Ser Lys Arg
 85 90 95
 Ser Pro

<210> 103
 <211> 871
 <212> PRT
 <213> Homo sapiens

<400> 103
 Met Lys Tyr Ser Cys Cys Ala Leu Val Leu Ala Val Leu Gly Thr Glu
 1 5 10 15
 Leu Leu Gly Ser Leu Cys Ser Thr Val Arg Ser Pro Arg Phe Arg Gly
 20 25 30
 Arg Ile Gln Gln Glu Arg Lys Asn Ile Arg Pro Asn Ile Ile Leu Val
 35 40 45
 Pro Thr Asp Asp Gln Asp Val Glu Leu Gly Ser Leu Gln Val Met Asn
 50 55 60
 Lys Thr Arg Lys Ile Met Glu His Gly Gly Ala Thr Phe Ile Asn Ala
 65 70 75 80
 Phe Val Thr Thr Pro Met Cys Cys Pro Ser Arg Ser Ser Met Leu Thr
 85 90 95
 Gly Lys Tyr Val His Asn His Asn Val Tyr Thr Asn Asn Glu Asn Cys
 100 105 110
 Ser Ser Pro Ser Trp Gln Ala Met His Glu Pro Arg Thr Phe Ala Val
 115 120 125
 Tyr Leu Asn Asn Thr Gly Tyr Arg Thr Ala Phe Phe Gly Lys Tyr Leu
 130 135 140
 Asn Glu Tyr Asn Gly Ser Tyr Ile Pro Pro Gly Trp Arg Glu Trp Leu
 145 150 155 160
 Gly Leu Ile Lys Asn Ser Arg Phe Tyr Asn Tyr Thr Val Cys Arg Asn
 165 170 175
 Gly Ile Lys Glu Lys His Gly Phe Asp Tyr Ala Lys Asp Tyr Phe Thr
 180 185 190
 Asp Leu Ile Thr Asn Glu Ser Ile Asn Tyr Phe Lys Met Ser Lys Arg
 195 200 205

SEQUENCE LISTING 1657-2022.txt

```

Met Tyr Pro His Arg Pro Val Met Met Val Ile Ser His Ala Ala Pro
210 215 220
His Gly Pro Glu Asp Ser Ala Pro Gln Phe Ser Lys Leu Tyr Pro Asn
225 230 235 240
Ala Ser Gln His Ile Thr Pro Ser Tyr Asn Tyr Ala Pro Asn Met Asp
245 250 255
Lys His Trp Ile Met Gln Tyr Thr Gly Pro Met Leu Pro Ile His Met
260 265 270
Glu Phe Thr Asn Ile Leu Gln Arg Lys Arg Leu Gln Thr Leu Met Ser
275 280 285
Val Asp Asp Ser Val Glu Arg Leu Tyr Asn Met Leu Val Glu Thr Gly
290 295 300
Glu Leu Glu Asn Thr Tyr Ile Ile Tyr Thr Ala Asp His Gly Tyr His
305 310 315 320
Ile Gly Gln Phe Gly Leu Val Lys Gly Lys Ser Met Pro Tyr Asp Phe
325 330 335
Asp Ile Arg Val Pro Phe Phe Ile Arg Gly Pro Ser Val Glu Pro Gly
340 345 350
Ser Ile Val Pro Gln Ile Val Leu Asn Ile Asp Leu Ala Pro Thr Ile
355 360 365
Leu Asp Ile Ala Gly Leu Asp Thr Pro Pro Asp Val Asp Gly Lys Ser
370 375 380
Val Leu Lys Leu Leu Asp Pro Glu Lys Pro Gly Asn Arg Phe Arg Thr
385 390 395 400
Asn Lys Lys Ala Lys Ile Trp Arg Asp Thr Phe Leu Val Glu Arg Gly
405 410 415
Lys Phe Leu Arg Lys Lys Glu Glu Ser Ser Lys Asn Ile Gln Gln Ser
420 425 430
Asn His Leu Pro Lys Tyr Glu Arg Val Lys Glu Leu Cys Gln Gln Ala
435 440 445
Arg Tyr Gln Thr Ala Cys Glu Gln Pro Gly Gln Lys Trp Gln Cys Ile
450 455 460
Glu Asp Thr Ser Gly Lys Leu Arg Ile His Lys Cys Lys Gly Pro Ser
465 470 475 480
Asp Leu Leu Thr Val Arg Gln Ser Thr Arg Asn Leu Tyr Ala Arg Gly
485 490 495
Phe His Asp Lys Asp Lys Glu Cys Ser Cys Arg Glu Ser Gly Tyr Arg
500 505 510
Ala Ser Arg Ser Gln Arg Lys Ser Gln Arg Gln Phe Leu Arg Asn Gln
515 520 525
Gly Thr Pro Lys Tyr Lys Pro Arg Phe Val His Thr Arg Gln Thr Arg
530 535 540
Ser Leu Ser Val Glu Phe Glu Gly Glu Ile Tyr Asp Ile Asn Leu Glu
545 550 555 560
Glu Glu Glu Glu Leu Gln Val Leu Gln Pro Arg Asn Ile Ala Lys Arg
565 570 575
His Asp Glu Gly His Lys Gly Pro Arg Asp Leu Gln Ala Ser Ser Gly
580 585 590
Gly Asn Arg Gly Arg Met Leu Ala Asp Ser Ser Asn Ala Val Gly Pro
595 600 605
Pro Thr Thr Val Arg Val Thr His Lys Cys Phe Ile Leu Pro Asn Asp
610 615 620
Ser Ile His Cys Glu Arg Glu Leu Tyr Gln Ser Ala Arg Ala Trp Lys
625 630 635 640
Asp His Lys Ala Tyr Ile Asp Lys Glu Ile Glu Ala Leu Gln Asp Lys
645 650 655
Ile Lys Asn Leu Arg Glu Val Arg Gly His Leu Lys Arg Arg Lys Pro
660 665 670
Glu Glu Cys Ser Cys Ser Lys Gln Ser Tyr Tyr Asn Lys Glu Lys Gly
675 680 685
Val Lys Lys Gln Glu Lys Leu Lys Ser His Leu His Pro Phe Lys Glu
690 695 700
Ala Ala Gln Glu Val Asp Ser Lys Leu Gln Leu Phe Lys Glu Asn Asn
705 710 715 720
Arg Arg Arg Lys Lys Glu Arg Lys Glu Lys Arg Arg Gln Arg Lys Gly
725 730 735
Glu Glu Cys Ser Leu Pro Gly Leu Thr Cys Phe Thr His Asp Asn Asn

```

SEQUENCE LISTING 1657-2022.txt

740
 His Trp Gln Thr Ala Pro Phe Trp Asn Leu Gly Ser Phe Cys Ala Cys
 755
 Thr Ser Ser Asn Asn Asn Thr Tyr Trp Cys Leu Arg Thr Val Asn Glu
 770
 Thr His Asn Phe Leu Phe Cys Glu Phe Ala Thr Gly Phe Leu Glu Tyr
 785
 Phe Asp Met Asn Thr Asp Pro Tyr Gln Leu Thr Asn Thr Val His Thr
 800
 Val Glu Arg Gly Ile Leu Asn Gln Leu His Val Gln Leu Met Glu Leu
 815
 Arg Ser Cys Gln Gly Tyr Lys Gln Cys Asn Pro Arg Pro Lys Asn Leu
 830
 Asp Val Gly Asn Lys Asp Gly Gly Ser Tyr Asp Leu His Arg Gly Gln
 845
 Leu Trp Asp Gly Trp Glu Gly
 860
 865
 870

<210> 104
 <211> 1496
 <212> PRT
 <213> Homo sapiens

<400> 104
 Met Met Ala Asn Trp Ala Glu Ala Arg Pro Leu Leu Ile Leu Ile Val
 1 5 10 15
 Leu Leu Gly Gln Phe Val Ser Ile Lys Ala Gln Glu Glu Asp Glu Asp
 20 25 30
 Glu Gly Tyr Gly Glu Glu Ile Ala Cys Thr Gln Asn Gly Gln Met Tyr
 35 40 45
 Leu Asn Arg Asp Ile Trp Lys Pro Ala Pro Cys Gln Ile Cys Val Cys
 50 55 60
 Asp Asn Gly Ala Ile Leu Cys Asp Lys Ile Glu Cys Gln Asp Val Leu
 65 70 75 80
 Asp Cys Ala Asp Pro Val Thr Pro Pro Gly Glu Cys Cys Pro Val Cys
 85 90 95
 Ser Gln Thr Pro Gly Gly Gly Asn Thr Asn Phe Gly Arg Gly Arg Lys
 100 105 110
 Gly Gln Lys Gly Glu Pro Gly Leu Val Pro Val Val Thr Gly Ile Arg
 115 120 125
 Gly Arg Pro Gly Pro Ala Gly Pro Pro Gly Ser Gln Gly Pro Arg Gly
 130 135 140
 Glu Arg Gly Pro Lys Gly Arg Pro Gly Pro Arg Gly Pro Gln Gly Ile
 145 150 155 160
 Asp Gly Glu Pro Gly Val Pro Gly Gln Pro Gly Ala Pro Gly Pro Pro
 165 170 175
 Gly His Pro Ser His Pro Gly Pro Asp Gly Leu Ser Arg Pro Phe Ser
 180 185 190
 Ala Gln Met Ala Gly Leu Asp Glu Lys Ser Gly Leu Gly Ser Gln Val
 195 200 205
 Gly Leu Met Pro Gly Ser Val Gly Pro Val Gly Pro Arg Gly Pro Gln
 210 215 220
 Gly Leu Gln Gly Gln Gln Gly Gly Ala Gly Pro Thr Gly Pro Pro Gly
 225 230 235 240
 Glu Pro Gly Asp Pro Gly Pro Met Gly Pro Ile Gly Ser Arg Gly Pro
 245 250 255
 Glu Gly Pro Pro Gly Lys Pro Gly Glu Asp Gly Glu Pro Gly Arg Asn
 260 265 270
 Gly Asn Pro Gly Glu Val Gly Phe Ala Gly Ser Pro Gly Ala Arg Gly
 275 280 285
 Phe Pro Gly Ala Pro Gly Leu Pro Gly Leu Lys Gly His Arg Gly His
 290 295 300
 Lys Gly Leu Glu Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Ser Lys
 305 310 315 320
 Gly Glu Ala Gly Pro Thr Gly Pro Met Gly Ala Met Gly Pro Leu Gly
 325 330 335

SEQUENCE LISTING 1657-2022.txt

Pro Arg Gly Met Pro Gly Glu Arg Gly Arg Leu Gly Pro Gln Gly Ala
 340 345 350
 Pro Gly Gln Arg Gly Ala His Gly Met Pro Gly Lys Pro Gly Pro Met
 355 360 365
 Gly Pro Leu Gly Ile Pro Gly Ser Ser Gly Phe Pro Gly Asn Pro Gly
 370 375 380
 Met Lys Gly Glu Ala Gly Pro Thr Gly Ala Arg Gly Pro Glu Gly Pro
 385 390 395 400
 Gln Gly Gln Arg Gly Glu Thr Gly Pro Pro Gly Pro Val Gly Ser Pro
 405 410 415
 Gly Leu Pro Gly Ala Ile Gly Thr Asp Gly Thr Pro Gly Pro Lys Gly
 420 425 430
 Pro Thr Gly Ser Pro Gly Thr Ser Gly Pro Pro Gly Ser Ala Gly Pro
 435 440 445
 Pro Gly Ser Pro Gly Pro Gln Gly Ser Thr Gly Pro Gln Gly Asn Ser
 450 455 460
 Gly Leu Pro Gly Asp Pro Gly Phe Lys Gly Glu Ala Gly Pro Lys Gly
 465 470 475 480
 Glu Pro Gly Pro His Gly Ile Gln Gly Pro Ile Gly Pro Pro Gly Glu
 485 490 495
 Glu Gly Lys Arg Gly Pro Arg Gly Asp Pro Gly Thr Leu Gly Pro Pro
 500 505 510
 Gly Pro Val Gly Glu Arg Gly Ala Pro Gly Asn Arg Gly Phe Pro Gly
 515 520 525
 Ser Asp Gly Leu Pro Gly Pro Lys Gly Ala Gln Gly Asp Pro Gly Arg Pro
 530 535 540
 Val Gly Ser Ser Gly Pro Lys Gly Ser Gln Gly Asp Pro Gly Arg Pro
 545 550 555 560
 Gly Glu Pro Gly Leu Pro Gly Ala Arg Gly Leu Thr Gly Asn Pro Gly
 565 570 575
 Val Gln Gly Pro Glu Gly Lys Leu Gly Pro Leu Gly Ala Pro Gly Glu
 580 585 590
 Asp Gly Arg Pro Gly Pro Pro Gly Ser Ile Gly Ile Lys Gly Gln Pro
 595 600 605
 Gly Thr Met Gly Leu Pro Gly Pro Lys Gly Ser Asn Gly Asp Pro Gly
 610 615 620
 Lys Pro Gly Glu Ala Gly Asn Pro Gly Val Pro Gly Gln Arg Gly Ala
 625 630 635 640
 Pro Gly Lys Asp Gly Lys Val Gly Pro Tyr Gly Pro Pro Gly Pro Pro
 645 650 655
 Gly Leu Arg Gly Glu Arg Gly Glu Gln Gly Pro Pro Gly Pro Thr Gly
 660 665 670
 Phe Gln Gly His Pro Gly Pro Pro Gly Pro Pro Gly Glu Gly Gly Lys
 675 680 685
 Pro Gly Asp Gln Gly Val Pro Gly Gly Pro Gly Ala Val Gly Pro Leu
 690 695 700
 Gly Pro Arg Gly Glu Arg Gly Asn Pro Gly Glu Arg Gly Glu Pro Gly
 705 710 715 720
 Ile Thr Gly Leu Pro Gly Glu Lys Gly Met Ala Gly Gly His Gly Pro
 725 730 735
 Asp Gly Pro Lys Gly Ser Pro Gly Pro Ser Gly Thr Pro Gly Asp Thr
 740 745 750
 Gly Pro Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ile Ala Gly
 755 760 765
 Thr Pro Gly Pro Lys Gly Asp Arg Gly Gly Ile Gly Glu Lys Gly Ala
 770 775 780
 Glu Gly Thr Ala Gly Asn Asp Gly Ala Gly Gly Leu Pro Gly Pro Leu
 785 790 795 800
 Gly Pro Pro Gly Pro Ala Gly Leu Leu Gly Glu Lys Gly Glu Pro Gly
 805 810 815
 Pro Arg Gly Leu Val Gly Pro Pro Gly Ser Arg Gly Asn Pro Gly Ser
 820 825 830
 Arg Gly Glu Asn Gly Pro Thr Gly Ala Val Gly Phe Ala Gly Pro Gln
 835 840 845
 Gly Ser Asp Gly Gln Pro Gly Val Lys Gly Glu Pro Gly Glu Pro Gly
 850 855 860
 Gln Lys Gly Asp Ala Gly Ser Pro Gly Pro Gln Gly Leu Ala Gly Ser

SEQUENCE LISTING 1657-2022.txt

865 Pro Gly Pro His Gly 870 Pro Asn Gly Val 875 Pro Gly Leu Lys Gly Gly Arg 880
 Gly Thr Gln Gly 885 Pro Pro Gly Ala Thr 890 Gly Phe Pro Gly Ser Ala Gly 895
 Arg Val Gly 900 Pro Pro Gly Pro Ala Gly Ala Pro Gly Pro Ala Gly Pro 910
 Leu Gly 915 Glu Pro Gly Lys Glu Gly Pro Pro Gly Pro Arg Gly Asp Pro 925
 Gly Ser His Gly Arg Val Gly Val Arg Gly Pro Ala Gly Pro Pro Gly 930
 945 Gly Pro Gly Asp Lys 950 Gly Asp Pro Gly Glu Asp Gly Gln Pro Gly Pro 960
 Asp Gly Pro Pro Gly Pro Ala Gly Thr Thr Gly Gln Arg Gly Ile Val 975
 Gly Met Pro Gly Gln Arg Gly Glu Arg Gly Met Pro Gly Leu Pro Gly 985
 Pro Ala Gly Thr Pro Gly Lys Val Gly Pro Thr Gly Ala Thr Gly Asp 990
 1010 Lys Gly Pro Pro Gly Pro Val Gly Pro Pro Gly Ser Asn Gly Pro Val 1005
 1025 Gly Glu Pro Gly Pro Glu Gly Pro Ala Gly Asn Asp Gly Thr Pro Gly 1020
 Arg Asp Gly Ala Val Gly Glu Arg Gly Asp Arg Gly Asp Pro Gly Pro 1035
 Ala Gly Leu Pro Gly Ser Gln Gly Ala Pro Gly Thr Pro Gly Pro Val 1040
 Gly Ala Pro Gly Asp Ala Gly Gln Arg Gly Asp Pro Gly Ser Arg Gly 1050
 1075 Pro Ile Gly His Leu Gly Arg Ala Gly Lys Arg Gly Leu Pro Gly Pro 1070
 1105 Gln Gly Pro Arg Gly Asp Lys Gly Asp His Gly Asp Arg Gly Asp Arg 1085
 Gly Gln Lys Gly His Arg Gly Phe Thr Gly Leu Gln Gly Leu Pro Gly 1100
 Pro Pro Gly Pro Asn Gly Glu Gln Gly Ser Ala Gly Ile Pro Gly Pro 1115
 Phe Gly Pro Arg Gly Pro Pro Gly Pro Val Gly Pro Ser Gly Lys Glu 1130
 Gly Asn Pro Gly Pro Leu Gly Pro Leu Gly Pro Pro Gly Val Arg Gly 1145
 1185 Ser Val Gly Glu Ala Gly Pro Glu Gly Pro Pro Gly Glu Pro Gly Pro 1160
 Pro Gly Pro Pro Gly Pro Pro Gly His Leu Thr Ala Ala Leu Gly Asp 1175
 Ile Met Gly His Tyr Asp Glu Ser Met Pro Asp Pro Leu Pro Glu Phe 1180
 Thr Glu Asp Gln Ala Ala Pro Asp Asp Lys Asn Lys Thr Asp Pro Gly 1195
 Val His Ala Thr Leu Lys Ser Leu Ser Ser Gln Ile Glu Thr Met Arg 1200
 1265 Ser Pro Asp Gly Ser Lys Lys His Pro Ala Arg Thr Cys Asp Asp Leu 1215
 Lys Leu Cys His Ser Ala Lys Gln Ser Gly Glu Tyr Trp Ile Asp Pro 1230
 1300 Asn Gln Gly Ser Val Glu Asp Ala Ile Lys Val Tyr Cys Asn Met Glu 1245
 1315 Thr Gly Glu Thr Cys Ile Ser Ala Asn Pro Ser Ser Val Pro Arg Lys 1260
 1330 Thr Trp Trp Ala Ser Lys Ser Pro Asp Asn Lys Pro Val Trp Tyr Gly 1275
 1345 Leu Asp Met Asn Arg Gly Ser Gln Phe Ala Tyr Gly Asp His Gln Ser 1290
 Pro Asn Thr Ala Ile Thr Gln Met Thr Phe Leu Arg Leu Leu Ser Lys 1310
 1380 Glu Ala Ser Gln Asn Ile Thr Tyr Ile Cys Lys Asn Ser Val Gly Tyr 1325
 1395 1400 1405

SEQUENCE LISTING 1657-2022.txt

Met Asp Asp Gln Ala Lys Asn Leu Lys Lys Ala Val Val Leu Lys Gly
 1410 1415 1420
 Ala Asn Asp Leu Asp Ile Lys Ala Glu Gly Asn Ile Arg Phe Arg Tyr
 1425 1430 1435 1440
 Ile Val Leu Gln Asp Thr Cys Ser Lys Arg Asn Gly Asn Val Gly Lys
 1445 1450 1455
 Thr Val Phe Glu Tyr Arg Thr Gln Asn Val Ala Arg Leu Pro Ile Ile
 1460 1465 1470
 Asp Leu Ala Pro Val Asp Val Gly Gly Thr Asp Gln Glu Phe Gly Val
 1475 1480 1485
 Glu Ile Gly Pro Val Cys Phe Val
 1490 1495

<210> 105
 <211> 107
 <212> PRT
 <213> Homo sapiens

<400> 105
 Met Ala Arg Ala Ala Leu Ser Ala Ala Pro Ser Asn Pro Arg Leu Leu
 1 5 10 15
 Arg Val Ala Leu Leu Leu Leu Leu Val Ala Ala Gly Arg Arg Ala
 20 25 30
 Ala Gly Ala Ser Val Ala Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr
 35 40 45
 Leu Gln Gly Ile His Pro Lys Asn Ile Gln Ser Val Asn Val Lys Ser
 50 55 60
 Pro Gly Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn
 65 70 75 80
 Gly Arg Lys Ala Cys Leu Asn Pro Ala Ser Pro Ile Val Lys Lys Ile
 85 90 95
 Ile Glu Lys Met Leu Asn Ser Asp Lys Ser Asn
 100 105

<210> 106
 <211> 89
 <212> PRT
 <213> Homo sapiens

<400> 106
 Met Lys Gly Leu Ala Ala Ala Leu Leu Val Leu Val Cys Thr Met Ala
 1 5 10 15
 Leu Cys Ser Cys Ala Gln Val Gly Thr Asn Lys Glu Leu Cys Cys Leu
 20 25 30
 Val Tyr Thr Ser Trp Gln Ile Pro Gln Lys Phe Ile Val Asp Tyr Ser
 35 40 45
 Glu Thr Ser Pro Gln Cys Pro Lys Pro Gly Val Ile Leu Leu Thr Lys
 50 55 60
 Arg Gly Arg Gln Ile Cys Ala Asp Pro Asn Lys Lys Trp Val Gln Lys
 65 70 75 80
 Tyr Ile Ser Asp Leu Lys Leu Asn Ala
 85

<210> 107
 <211> 796
 <212> PRT
 <213> Homo sapiens

<400> 107
 Met Lys Glu Asn Tyr Cys Leu Gln Ala Ala Leu Val Cys Leu Gly Met
 1 5 10 15
 Leu Cys His Ser His Ala Phe Ala Pro Glu Arg Arg Gly His Leu Arg
 20 25 30
 Pro Ser Phe His Gly His His Glu Lys Gly Lys Glu Gly Gln Val Leu
 Page 81

SEQUENCE LISTING 1657-2022.txt

35 40 45
 Gln Arg Ser Lys Arg Gly Trp Val Trp Asn Gln Phe Phe Val Ile Glu
 50 55 60
 Glu Tyr Thr Gly Pro Asp Pro Val Leu Val Gly Arg Leu His Ser Asp
 65 70 75 80
 Ile Asp Ser Gly Asp Gly Asn Ile Lys Tyr Ile Leu Ser Gly Glu Gly
 85 90 95
 Ala Gly Thr Ile Phe Val Ile Asp Asp Lys Ser Gly Asn Ile His Ala
 100 105 110
 Thr Lys Thr Leu Asp Arg Glu Glu Arg Ala Gln Tyr Thr Leu Met Ala
 115 120 125
 Gln Ala Val Asp Arg Asp Thr Asn Arg Pro Leu Glu Pro Pro Ser Glu
 130 135 140
 Phe Ile Val Lys Val Gln Asp Ile Asn Asp Asn Pro Pro Glu Phe Leu
 145 150 155 160
 His Glu Thr Tyr His Ala Asn Val Pro Glu Arg Ser Asn Val Gly Thr
 165 170 175
 Ser Val Ile Gln Val Thr Ala Ser Asp Ala Asp Asp Pro Thr Tyr Gly
 180 185 190
 Asn Ser Ala Lys Leu Val Tyr Ser Ile Leu Glu Gly Gln Pro Tyr Phe
 195 200 205
 Ser Val Glu Ala Gln Thr Gly Ile Ile Arg Thr Ala Leu Pro Asn Met
 210 215 220
 Asp Arg Glu Ala Lys Glu Glu Tyr His Val Val Ile Gln Ala Lys Asp
 225 230 235 240
 Met Gly Gly His Met Gly Gly Leu Ser Gly Thr Thr Lys Val Thr Ile
 245 250 255
 Thr Leu Thr Asp Val Asn Asp Asn Pro Pro Lys Phe Pro Gln Ser Val
 260 265 270
 Tyr Gln Met Ser Val Ser Glu Ala Val Pro Gly Glu Glu Val Gly
 275 280 285
 Arg Val Lys Ala Lys Asp Pro Asp Ile Gly Glu Asn Gly Leu Val Thr
 290 295 300
 Tyr Asn Ile Val Asp Gly Asp Gly Met Glu Ser Phe Glu Ile Thr Thr
 305 310 315 320
 Asp Tyr Glu Thr Gln Glu Gly Val Ile Lys Leu Lys Lys Pro Val Asp
 325 330 335
 Phe Glu Thr Lys Arg Ala Tyr Ser Leu Lys Val Glu Ala Ala Asn Val
 340 345 350
 His Ile Asp Pro Lys Phe Ile Ser Asn Gly Pro Phe Lys Asp Thr Val
 355 360 365
 Thr Val Lys Ile Ser Val Glu Asp Ala Asp Glu Pro Pro Met Phe Leu
 370 375 380
 Ala Pro Ser Tyr Ile His Glu Val Gln Glu Asn Ala Ala Ala Gly Thr
 385 390 395 400
 Val Val Gly Arg Val His Ala Lys Asp Pro Asp Ala Ala Asn Ser Pro
 405 410 415
 Ile Arg Tyr Ser Ile Asp Arg His Thr Asp Leu Asp Arg Phe Phe Thr
 420 425 430
 Ile Asn Pro Glu Asp Gly Phe Ile Lys Thr Thr Lys Pro Leu Asp Arg
 435 440 445
 Glu Glu Thr Ala Trp Leu Asn Ile Thr Val Phe Ala Ala Glu Ile His
 450 455 460
 Asn Arg His Gln Glu Ala Lys Val Pro Val Ala Ile Arg Val Leu Asp
 465 470 475 480
 Val Asn Asp Asn Ala Pro Lys Phe Ala Ala Pro Tyr Glu Gly Phe Ile
 485 490 495
 Cys Glu Ser Asp Gln Thr Lys Pro Leu Ser Asn Gln Pro Ile Val Thr
 500 505 510
 Ile Ser Ala Asp Asp Lys Asp Asp Thr Ala Asn Gly Pro Arg Phe Ile
 515 520 525
 Phe Ser Leu Pro Pro Glu Ile Ile His Asn Pro Asn Phe Thr Val Arg
 530 535 540
 Asp Asn Arg Asp Asn Thr Ala Gly Val Tyr Ala Arg Arg Gly Gly Phe
 545 550 555 560
 Ser Arg Gln Lys Gln Asp Leu Tyr Leu Leu Pro Ile Val Ile Ser Asp
 565 570 575

SEQUENCE LISTING 1657-2022.txt

Gly Gly Ile Pro Pro Met Ser Ser Thr Asn Thr Leu Thr Ile Lys Val
 580 585 590
 Cys Gly Cys Asp Val Asn Gly Ala Leu Leu Ser Cys Asn Ala Glu Ala
 595 600 605
 Tyr Ile Leu Asn Ala Gly Leu Ser Thr Gly Ala Leu Ile Ala Ile Leu
 610 615 620
 Ala Cys Ile Val Ile Leu Leu Val Ile Val Val Leu Phe Val Thr Leu
 625 630 635 640
 Arg Arg Gln Lys Lys Glu Pro Leu Ile Val Phe Glu Glu Glu Asp Val
 645 650 655
 Arg Glu Asn Ile Ile Thr Tyr Asp Asp Glu Gly Gly Gly Glu Glu Asp
 660 665 670
 Thr Glu Ala Phe Asp Ile Ala Thr Leu Gln Asn Pro Asp Gly Ile Asn
 675 680 685
 Gly Phe Ile Pro Arg Lys Asp Ile Lys Pro Glu Tyr Gln Tyr Met Pro
 690 695 700
 Arg Pro Gly Leu Arg Pro Ala Pro Asn Ser Val Asp Val Asp Asp Phe
 705 710 715 720
 Ile Asn Thr Arg Ile Gln Glu Ala Asp Asn Asp Pro Thr Ala Pro Pro
 725 730 735
 Tyr Asp Ser Ile Gln Ile Tyr Gly Tyr Glu Gly Arg Gly Ser Val Ala
 740 745 750
 Gly Ser Leu Ser Ser Leu Glu Ser Ala Thr Thr Asp Ser Asp Leu Asp
 755 760 765
 Tyr Asp Tyr Leu Gln Asn Trp Gly Pro Arg Phe Lys Lys Leu Ala Asp
 770 775 780
 Leu Tyr Gly Ser Lys Asp Thr Phe Asp Asp Asp Ser
 785 790 795

<210> 108
 <211> 180
 <212> PRT
 <213> Homo sapiens

<400> 108
 Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
 1 5 10 15
 Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
 20 25 30
 Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
 35 40 45
 Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
 50 55 60
 Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly
 65 70 75 80
 Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
 85 90 95
 Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
 100 105 110
 Val Glu Glu Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu Gln
 115 120 125
 Asp Ala Ser Ala Glu Val Glu Arg Leu Arg Arg Glu Asn Gln Val Leu
 130 135 140
 Ser Val Arg Ile Ala Asp Lys Lys Tyr Tyr Pro Ser Ser Gln Asp Ser
 145 150 155 160
 Ser Ser Ala Ala Ala Pro Gln Leu Leu Ile Val Leu Leu Gly Leu Ser
 165 170 175
 Ala Leu Leu Gln
 180

<210> 109
 <211> 358
 <212> PRT
 <213> Homo sapiens

SEQUENCE LISTING 1657-2022.txt

<400> 109

```

Met Arg Ala Thr Pro Leu Ala Ala Pro Ala Gly Ser Leu Ser Arg Lys
 1      5      10      15
Lys Arg Leu Glu Leu Asp Asp Asn Leu Asp Thr Glu Arg Pro Val Gln
 20      25      30
Lys Arg Ala Arg Ser Gly Pro Gln Pro Arg Leu Pro Pro Cys Leu Leu
 35      40      45
Pro Leu Ser Pro Pro Thr Ala Pro Asp Arg Ala Thr Ala Val Ala Thr
 50      55      60
Ala Ser Arg Leu Gly Pro Tyr Val Leu Leu Glu Pro Glu Glu Gly Gly
 65      70      75      80
Arg Ala Tyr Gln Ala Leu His Cys Pro Thr Gly Thr Glu Tyr Thr Cys
 85      90      95
Lys Val Tyr Pro Val Gln Glu Ala Pro Ala Val Leu Glu Pro Tyr Ala
100      105      110
Arg Leu Pro Pro His Lys His Val Ala Arg Pro Thr Glu Val Leu Ala
115      120      125
Gly Thr Gln Leu Leu Tyr Ala Phe Phe Thr Arg Thr His Gly Asp Met
130      135      140
His Ser Leu Val Arg Ser Arg His Arg Ile Pro Glu Pro Glu Ala Ala
145      150      155      160
Val Leu Phe Arg Gln Met Ala Thr Ala Leu Ala His Cys His Gln His
165      170      175
Gly Leu Val Leu Arg Asp Leu Lys Leu Cys Arg Phe Val Phe Ala Asp
180      185      190
Arg Glu Arg Lys Lys Leu Val Leu Glu Asn Leu Glu Asp Ser Cys Val
195      200      205
Leu Thr Gly Pro Asp Asp Ser Leu Trp Asp Lys His Ala Cys Pro Ala
210      215      220
Tyr Val Gly Pro Glu Ile Leu Ser Ser Arg Ala Ser Tyr Ser Gly Lys
225      230      235      240
Ala Ala Asp Val Trp Ser Leu Gly Val Ala Leu Phe Thr Met Leu Ala
245      250      255
Gly His Tyr Pro Phe Gln Asp Ser Glu Pro Val Leu Leu Phe Gly Lys
260      265      270
Ile Arg Arg Gly Ala Tyr Ala Leu Pro Ala Gly Leu Ser Ala Pro Ala
275      280      285
Arg Cys Leu Val Arg Cys Leu Leu Arg Arg Glu Pro Ala Glu Arg Leu
290      295      300
Thr Ala Thr Gly Ile Leu Leu His Pro Trp Leu Arg Gln Asp Pro Met
305      310      315      320
Pro Leu Ala Pro Thr Arg Ser His Leu Trp Glu Ala Ala Gln Val Val
325      330      335
Pro Asp Gly Leu Gly Leu Asp Glu Ala Arg Glu Glu Glu Gly Asp Arg
340      345      350
Glu Val Val Leu Tyr Gly
355

```

<210> 110

<211> 1172

<212> PRT

<213> Homo sapiens

<400> 110

```

Met Val Trp Arg Leu Val Leu Leu Ala Leu Trp Val Trp Pro Ser Thr
 1      5      10      15
Gln Ala Gly His Gln Asp Lys Asp Thr Phe Asp Leu Phe Ser Ile
 20      25      30
Ser Asn Ile Asn Arg Lys Thr Ile Gly Ala Lys Gln Phe Arg Gly Pro
 35      40      45
Asp Pro Gly Val Pro Ala Tyr Arg Phe Val Arg Phe Asp Tyr Ile Pro
 50      55      60
Pro Val Asn Ala Asp Asp Leu Ser Lys Ile Thr Lys Ile Met Arg Gln
 65      70      75      80
Lys Glu Gly Phe Phe Leu Thr Ala Gln Leu Lys Gln Asp Gly Lys Ser
 85      90      95

```

SEQUENCE LISTING 1657-2022.txt

Arg Gly Thr Leu Leu Ala Leu Glu Gly Pro Gly Leu Ser Gln Arg Gln
 100 105 110
 Phe Glu Ile Val Ser Asn Gly Pro Ala Asp Thr Leu Asp Leu Thr Tyr
 115 120 125
 Trp Ile Asp Gly Thr Arg His Val Val Ser Leu Glu Asp Val Gly Leu
 130 135 140
 Ala Asp Ser Gln Trp Lys Asn Val Thr Val Gln Val Ala Gly Glu Thr
 145 150 155 160
 Tyr Ser Leu His Val Gly Cys Asp Leu Ile Gly Pro Val Ala Leu Asp
 165 170 175
 Glu Pro Phe Tyr Glu His Leu Gln Ala Glu Lys Ser Arg Met Tyr Val
 180 185 190
 Ala Lys Gly Ser Ala Arg Glu Ser His Phe Arg Gly Leu Gln Asn
 195 200 205
 Val His Leu Val Phe Glu Asn Ser Val Glu Asp Ile Leu Ser Lys Lys
 210 215 220
 Gly Cys Gln Gln Gly Gln Gly Ala Glu Ile Asn Ala Ile Ser Glu Asn
 225 230 235 240
 Thr Glu Thr Leu Arg Leu Gly Pro His Val Thr Thr Glu Tyr Val Gly
 245 250 255
 Pro Ser Ser Glu Arg Arg Pro Glu Val Cys Glu Arg Ser Cys Glu Glu
 260 265 270
 Leu Gly Asn Met Val Gln Glu Leu Ser Gly Leu His Val Leu Val Asn
 275 280 285
 Gln Leu Ser Glu Asn Leu Lys Arg Val Ser Asn Asp Asn Gln Phe Leu
 290 295 300
 Trp Glu Leu Ile Gly Gly Pro Pro Lys Thr Arg Asn Met Ser Ala Cys
 305 310 315 320
 Trp Gln Asp Gly Arg Phe Phe Ala Glu Asn Glu Thr Trp Val Val Asp
 325 330 335
 Ser Cys Thr Thr Cys Thr Cys Lys Lys Phe Lys Thr Ile Cys His Gln
 340 345 350
 Ile Thr Cys Pro Pro Ala Thr Cys Ala Ser Pro Ser Phe Val Glu Gly
 355 360 365
 Glu Cys Cys Pro Ser Cys Leu His Ser Val Asp Gly Glu Glu Gly Trp
 370 375 380
 Ser Pro Trp Ala Glu Trp Thr Gln Cys Ser Val Thr Cys Gly Ser Gly
 385 390 395 400
 Thr Gln Gln Arg Gly Arg Ser Cys Asp Val Thr Ser Asn Thr Cys Leu
 405 410 415
 Gly Pro Ser Ile Gln Thr Arg Ala Cys Ser Leu Ser Lys Cys Asp Thr
 420 425 430
 Arg Ile Arg Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser
 435 440 445
 Cys Ser Val Thr Cys Gly Val Gly Asn Ile Thr Arg Ile Arg Leu Cys
 450 455 460
 Asn Ser Pro Val Pro Gln Met Gly Gly Lys Asn Cys Lys Gly Ser Gly
 465 470 475 480
 Arg Glu Thr Lys Ala Cys Gln Gly Ala Pro Cys Pro Ile Asp Gly Arg
 485 490 495
 Trp Ser Pro Trp Ser Pro Trp Ser Ala Cys Thr Val Thr Cys Ala Gly
 500 505 510
 Gly Ile Arg Glu Arg Thr Arg Val Cys Asn Ser Pro Glu Pro Gln Tyr
 515 520 525
 Gly Gly Lys Ala Cys Val Gly Asp Val Gln Glu Arg Gln Met Cys Asn
 530 535 540
 Lys Arg Ser Cys Pro Val Asp Gly Cys Leu Ser Asn Pro Cys Phe Pro
 545 550 555 560
 Gly Ala Gln Cys Ser Ser Phe Pro Asp Gly Ser Trp Ser Cys Gly Phe
 565 570 575
 Cys Pro Val Gly Phe Leu Gly Asn Gly Thr His Cys Glu Asp Leu Asp
 580 585 590
 Glu Cys Ala Leu Val Pro Asp Ile Cys Phe Ser Thr Ser Lys Val Pro
 595 600 605
 Arg Cys Val Asn Thr Gln Pro Gly Phe His Cys Leu Pro Cys Pro Pro
 610 615 620
 Arg Tyr Arg Gly Asn Gln Pro Val Gly Val Gly Leu Glu Ala Ala Lys

SEQUENCE LISTING 1657-2022.txt

```

625      630      635      640
Thr Glu Lys Gln Val Cys Glu Pro Glu Asn Pro Cys Lys Asp Lys Thr
        645      650      655
His Asn Cys His Lys His Ala Glu Cys Ile Tyr Leu Gly His Phe Ser
        660      665      670
Asp Pro Met Tyr Lys Cys Glu Cys Gln Thr Gly Tyr Ala Gly Asp Gly
        675      680      685
Leu Ile Cys Gly Glu Asp Ser Asp Leu Asp Gly Trp Pro Asn Leu Asn
        690      695      700
Leu Val Cys Ala Thr Asn Ala Thr Tyr His Cys Ile Lys Asp Asn Cys
705      710      715      720
Pro His Leu Pro Asn Ser Gly Gln Glu Asp Phe Asp Lys Asp Gly Ile
        725      730      735
Gly Asp Ala Cys Asp Asp Asp Asp Asn Asp Gly Val Thr Asp Glu
        740      745      750
Lys Asp Asn Cys Gln Leu Leu Phe Asn Pro Arg Gln Ala Asp Tyr Asp
        755      760      765
Lys Asp Glu Val Gly Asp Arg Cys Asp Asn Cys Pro Tyr Val His Asn
770      775      780
Pro Ala Gln Ile Asp Thr Asp Asn Asn Gly Glu Gly Asp Ala Cys Ser
785      790      795      800
Val Asp Ile Asp Gly Asp Asp Val Phe Asn Glu Arg Asp Asn Cys
        805      810      815
Tyr Val Tyr Asn Thr Asp Gln Arg Asp Thr Asp Gly Asp Gly Val Gly
        820      825      830
Asp His Cys Asp Asn Cys Pro Leu Val His Asn Pro Asp Gln Thr Asp
        835      840      845
Val Asp Asn Asp Leu Val Gly Asp Gln Cys Asp Asn Asn Glu Asp Ile
        850      855      860
Asp Asp Asp Gly His Gln Asn Asn Gln Asp Asn Cys Pro Tyr Ile Ser
865      870      875      880
Asn Ala Asn Gln Ala Asp His Asp Arg Asp Gly Gln Gly Asp Ala Cys
        885      890      895
Asp Pro Asp Asp Asn Asp Gly Val Pro Asp Asp Arg Asp Asn Cys
        900      905      910
Arg Leu Val Phe Asn Pro Asp Gln Glu Asp Leu Asp Gly Asp Gly Arg
        915      920      925
Gly Asp Ile Cys Lys Asp Asp Phe Asp Asn Asp Asn Ile Pro Asp Ile
        930      935      940
Asp Asp Val Cys Pro Glu Asn Asn Ala Ile Ser Glu Thr Asp Phe Arg
945      950      955      960
Asn Phe Gln Met Val Pro Leu Asp Pro Lys Gly Thr Thr Gln Ile Asp
        965      970      975
Pro Asn Trp Val Ile Arg His Gln Gly Lys Glu Leu Val Gln Thr Ala
        980      985      990
Asn Ser Asp Pro Gly Ile Ala Val Gly Phe Asp Glu Phe Gly Ser Val
        995      1000      1005
Asp Phe Ser Gly Thr Phe Tyr Val Asn Thr Asp Arg Asp Asp Asp Tyr
1010      1015      1020
Ala Gly Phe Val Phe Gly Tyr Gln Ser Ser Ser Arg Phe Tyr Val Val
1025      1030      1035      1040
Met Trp Lys Gln Val Thr Gln Thr Tyr Trp Glu Asp Gln Pro Thr Arg
        1045      1050      1055
Ala Tyr Gly Tyr Ser Gly Val Ser Leu Lys Val Val Asn Ser Thr Thr
        1060      1065      1070
Gly Thr Gly Glu His Leu Arg Asn Ala Leu Trp His Thr Gly Asn Thr
        1075      1080      1085
Pro Gly Gln Val Arg Thr Leu Trp His Asp Pro Arg Asn Ile Gly Trp
1090      1095      1100
Lys Asp Tyr Thr Ala Tyr Arg Trp His Leu Thr His Arg Pro Lys Thr
1105      1110      1115      1120
Gly Tyr Ile Arg Val Leu Val His Glu Gly Lys Gln Val Met Ala Asp
        1125      1130      1135
Ser Gly Pro Ile Tyr Asp Gln Thr Tyr Ala Gly Gly Arg Leu Gly Leu
        1140      1145      1150
Phe Val Phe Ser Gln Glu Met Val Tyr Phe Ser Asp Leu Lys Tyr Glu
1155      1160      1165

```


SEQUENCE LISTING 1657-2022.txt

Cys Arg Asp Ile
1170

<210> 111
<211> 138
<212> PRT
<213> Homo sapiens

<400> 111
Met Arg Gln Lys Ala Val Ser Leu Phe Leu Cys Tyr Leu Leu Leu Phe
1 5 10 15
Thr Cys Ser Gly Val Glu Ala Gly Glu Asn Ala Gly Lys Asp Ala Gly
20 25 30
Lys Lys Lys Cys Ser Glu Ser Ser Asp Ser Gly Ser Gly Phe Trp Lys
35 40 45
Ala Leu Thr Phe Met Ala Val Gly Gly Leu Ala Val Ala Gly Leu
50 55 60
Pro Ala Leu Gly Phe Thr Gly Ala Gly Ile Ala Ala Asn Ser Val Ala
65 70 75 80
Ala Ser Leu Met Ser Trp Ser Ala Ile Leu Asn Gly Gly Gly Val Pro
85 90 95
Ala Gly Gly Leu Val Ala Thr Leu Gln Ser Leu Gly Ala Gly Gly Ser
100 105 110
Ser Val Val Ile Gly Asn Ile Gly Ala Leu Met Gly Tyr Ala Thr His
115 120 125
Lys Tyr Leu Asp Ser Glu Glu Asp Glu Glu
130 135

<210> 112
<211> 184
<212> PRT
<213> Homo sapiens

<400> 112
Met Ser Arg Thr Ala Tyr Thr Val Gly Ala Leu Leu Leu Leu Leu Gly
1 5 10 15
Thr Leu Leu Pro Ala Ala Glu Gly Lys Lys Lys Gly Ser Gln Gly Ala
20 25 30
Ile Pro Pro Pro Asp Lys Ala Gln His Asn Asp Ser Glu Gln Thr Gln
35 40 45
Ser Pro Gln Gln Pro Gly Ser Arg Asn Arg Gly Arg Gly Gln Gly Arg
50 55 60
Gly Thr Ala Met Pro Gly Glu Glu Val Leu Glu Ser Ser Gln Glu Ala
65 70 75 80
Leu His Val Thr Glu Arg Lys Tyr Leu Lys Arg Asp Trp Cys Lys Thr
85 90 95
Gln Pro Leu Lys Gln Thr Ile His Glu Gly Cys Asn Ser Arg Thr
100 105 110
Ile Ile Asn Arg Phe Cys Tyr Gly Gln Cys Asn Ser Phe Tyr Ile Pro
115 120 125
Arg His Ile Arg Lys Glu Glu Gly Ser Phe Gln Ser Cys Ser Phe Cys
130 135 140
Lys Pro Lys Lys Phe Thr Thr Met Met Val Thr Leu Asn Cys Pro Glu
145 150 155 160
Leu Gln Pro Pro Thr Lys Lys Lys Arg Val Thr Arg Val Lys Gln Cys
165 170 175
Arg Cys Ile Ser Ile Asp Leu Asp
180

<210> 113
<211> 707
<212> PRT
<213> Homo sapiens

SEQUENCE LISTING 1657-2022.txt

<400> 113

```

Met Ser Leu Trp Gln Pro Leu Val Leu Val Leu Leu Val Leu Gly Cys
1      5      10      15
Cys Phe Ala Ala Pro Arg Gln Arg Gln Ser Thr Leu Val Leu Phe Pro
20      25      30
Gly Asp Leu Arg Thr Asn Leu Thr Asp Arg Gln Leu Ala Glu Glu Tyr
35      40      45
Leu Tyr Arg Tyr Gly Tyr Thr Arg Val Ala Glu Met Arg Gly Glu Ser
50      55      60
Lys Ser Leu Gly Pro Ala Leu Leu Leu Leu Gln Lys Gln Leu Ser Leu
65      70      75      80
Pro Glu Thr Gly Glu Leu Asp Ser Ala Thr Leu Lys Ala Met Arg Thr
85      90      95
Pro Arg Cys Gly Val Pro Asp Leu Gly Arg Phe Gln Thr Phe Glu Gly
100     105     110
Asp Leu Lys Trp His His His Asn Ile Thr Tyr Trp Ile Gln Asn Tyr
115     120     125
Ser Glu Asp Leu Pro Arg Ala Val Ile Asp Asp Ala Phe Ala Arg Ala
130     135     140
Phe Ala Leu Trp Ser Ala Val Thr Pro Leu Thr Phe Thr Arg Val Tyr
145     150     155     160
Ser Arg Asp Ala Asp Ile Val Ile Gln Phe Gly Val Ala Glu His Gly
165     170     175
Asp Gly Tyr Pro Phe Asp Gly Lys Asp Gly Leu Leu Ala His Ala Phe
180     185     190
Pro Pro Gly Pro Gly Ile Gln Gly Asp Ala His Phe Asp Asp Glu
195     200     205
Leu Trp Ser Leu Gly Lys Gly Val Val Val Pro Thr Arg Phe Gly Asn
210     215     220
Ala Asp Gly Ala Ala Cys His Phe Pro Phe Ile Phe Glu Gly Arg Ser
225     230     235     240
Tyr Ser Ala Cys Thr Thr Asp Gly Arg Ser Asp Gly Leu Pro Trp Cys
245     250     255
Ser Thr Thr Ala Asn Tyr Asp Thr Asp Asp Arg Phe Gly Phe Cys Pro
260     265     270
Ser Glu Arg Leu Tyr Thr Arg Asp Gly Asn Ala Asp Gly Lys Pro Cys
275     280     285
Gln Phe Pro Phe Ile Phe Gln Gly Gln Ser Tyr Ser Ala Cys Thr Thr
290     295     300
Asp Gly Arg Ser Asp Gly Tyr Arg Trp Cys Ala Thr Thr Ala Asn Tyr
305     310     315     320
Asp Arg Asp Lys Leu Phe Gly Phe Cys Pro Thr Arg Ala Asp Ser Thr
325     330     335
Val Met Gly Gly Asn Ser Ala Gly Glu Leu Cys Val Phe Pro Phe Thr
340     345     350
Phe Leu Gly Lys Glu Tyr Ser Thr Cys Thr Ser Glu Gly Arg Gly Asp
355     360     365
Gly Arg Leu Trp Cys Ala Thr Thr Ser Asn Phe Asp Ser Asp Lys Lys
370     375     380
Trp Gly Phe Cys Pro Asp Gln Gly Tyr Ser Leu Phe Leu Val Ala Ala
385     390     395     400
His Glu Phe Gly His Ala Leu Gly Leu Asp His Ser Ser Val Pro Glu
405     410     415
Ala Leu Met Tyr Pro Met Tyr Arg Phe Thr Glu Gly Pro Pro Leu His
420     425     430
Lys Asp Asp Val Asn Gly Ile Arg His Leu Tyr Gly Pro Arg Pro Glu
435     440     445
Pro Glu Pro Arg Pro Thr Thr Thr Pro Gln Pro Thr Ala Pro
450     455     460
Pro Thr Val Cys Pro Thr Gly Pro Pro Thr Val His Pro Ser Glu Arg
465     470     475     480
Pro Thr Ala Gly Pro Gly Pro Pro Ser Ala Gly Pro Thr Gly Pro
485     490     495
Pro Thr Ala Gly Pro Ser Thr Ala Thr Thr Val Pro Leu Ser Pro Val
500     505     510
Asp Asp Ala Cys Asn Val Asn Ile Phe Asp Ala Ile Ala Glu Ile Gly
515     520     525

```

SEQUENCE LISTING 1657-2022.txt

Asn Gln Leu Tyr Leu Phe Lys Asp Gly Lys Tyr Trp Arg Phe Ser Glu
 530 535 540
 Gly Arg Gly Ser Arg Pro Gln Gly Pro Phe Leu Ile Ala Asp Lys Trp
 545 550 555 560
 Pro Ala Leu Pro Arg Lys Leu Asp Ser Val Phe Glu Glu Pro Leu Ser
 565 570 575
 Lys Lys Leu Phe Phe Phe Ser Gly Arg Gln Val Trp Val Tyr Thr Gly
 580 585 590
 Ala Ser Val Leu Gly Pro Arg Arg Leu Asp Lys Leu Gly Leu Gly Ala
 595 600 605
 Asp Val Ala Gln Val Thr Gly Ala Leu Arg Ser Gly Arg Gly Lys Met
 610 615 620
 Leu Leu Phe Ser Gly Arg Arg Leu Trp Arg Phe Asp Val Lys Ala Gln
 625 630 635 640
 Met Val Asp Pro Arg Ser Ala Ser Glu Val Asp Arg Met Phe Pro Gly
 645 650 655
 Val Pro Leu Asp Thr His Asp Val Phe Gln Tyr Arg Glu Lys Ala Tyr
 660 665 670
 Phe Cys Gln Asp Arg Phe Tyr Trp Arg Val Ser Ser Arg Ser Glu Leu
 675 680 685
 Asn Gln Val Asp Gln Val Gly Tyr Val Thr Tyr Asp Ile Leu Gln Cys
 690 695 700
 Pro Glu Asp
 705

<210> 114
 <211> 194
 <212> PRT
 <213> Homo sapiens

<400> 114
 Met Ala Ile Arg Glu Leu Lys Val Cys Leu Leu Gly Asp Thr Gly Val
 1 5 10 15
 Gly Lys Ser Ser Ile Val Cys Arg Phe Val Gln Asp His Phe Asp His
 20 25 30
 Asn Ile Ser Pro Thr Ile Gly Ala Ser Phe Met Thr Lys Thr Val Pro
 35 40 45
 Cys Gly Asn Glu Leu His Lys Phe Leu Ile Trp Asp Thr Ala Gly Gln
 50 55 60
 Glu Arg Phe His Ser Leu Ala Pro Met Tyr Tyr Arg Gly Ser Ala Ala
 65 70 75 80
 Ala Val Ile Val Tyr Asp Ile Thr Lys Gln Asp Ser Phe Tyr Thr Leu
 85 90 95
 Lys Lys Trp Val Lys Glu Leu Lys Glu His Gly Pro Glu Asn Ile Val
 100 105 110
 Met Ala Ile Ala Gly Asn Lys Cys Asp Leu Ser Asp Ile Arg Glu Val
 115 120 125
 Pro Leu Lys Asp Ala Lys Glu Tyr Ala Glu Ser Ile Gly Ala Ile Val
 130 135 140
 Val Glu Thr Ser Ala Lys Asn Ala Ile Asn Ile Glu Glu Leu Phe Gln
 145 150 155 160
 Gly Ile Ser Arg Gln Ile Pro Pro Leu Asp Pro His Glu Asn Gly Asn
 165 170 175
 Asn Gly Thr Ile Lys Val Glu Lys Pro Thr Met Gln Ala Ser Arg Arg
 180 185 190
 Cys Cys

<210> 115
 <211> 114
 <212> PRT
 <213> Homo sapiens

<400> 115
 Met Ser Ala Leu Ser Leu Leu Ile Leu Gly Leu Leu Thr Ala Val Pro
 Page 89

SEQUENCE LISTING 1657-2022.txt

```

1         5         10         15
Pro Ala Ser Cys Gln Gln Gly Leu Gly Asn Leu Gln Pro Trp Met Gln
20
Gly Leu Ile Ala Val Ala Val Phe Leu Val Leu Val Ala Ile Ala Phe
35
Ala Val Asn His Phe Trp Cys Gln Glu Glu Pro Glu Pro Ala His Met
50
Ile Leu Thr Val Gly Asn Lys Ala Asp Gly Val Leu Val Gly Thr Asp
65
Gly Arg Tyr Ser Ser Met Ala Ala Ser Phe Arg Ser Ser Glu His Glu
85
Asn Ala Tyr Glu Asn Val Pro Glu Glu Gly Lys Val Arg Ser Thr
100
Pro Met
105
110

```

<210> 116
 <211> 117
 <212> PRT
 <213> Homo sapiens

```

<400> 116
Met Ala Leu Glu Thr Val Pro Lys Asp Leu Arg His Leu Arg Ala Cys
1         5         10         15
Leu Leu Cys Ser Leu Val Lys Thr Ile Asp Gln Phe Glu Tyr Asp Gly
20
Cys Asp Asn Cys Asp Ala Tyr Leu Gln Met Lys Gly Asn Arg Glu Met
35
Val Tyr Asp Cys Thr Ser Ser Ser Phe Asp Gly Ile Ile Ala Met Met
50
Ser Pro Glu Asp Ser Trp Val Ser Lys Trp Gln Arg Val Ser Asn Phe
65
Lys Pro Gly Val Tyr Ala Val Ser Val Thr Gly Arg Leu Pro Gln Gly
85
Ile Val Arg Glu Leu Lys Ser Arg Gly Val Ala Tyr Lys Ser Arg Asp
100
Thr Ala Ile Lys Thr
115

```

<210> 117
 <211> 178
 <212> PRT
 <213> Homo sapiens

```

<400> 117
Met Ser Pro Ser Gly Arg Leu Cys Leu Leu Thr Ile Val Gly Leu Ile
1         5         10         15
Leu Pro Thr Arg Gly Gln Thr Leu Lys Asp Thr Thr Ser Ser Ser
20
Ala Asp Ser Thr Ile Met Asp Ile Gln Val Pro Thr Arg Ala Pro Asp
35
Ala Val Tyr Thr Glu Leu Gln Pro Thr Ser Pro Thr Pro Thr Trp Pro
50
Ala Asp Glu Thr Pro Gln Pro Gln Thr Gln Thr Gln Gln Leu Glu Gly
65
Thr Asp Gly Pro Leu Val Thr Asp Pro Glu Thr His Lys Ser Thr Lys
85
Ala Ala His Pro Thr Asp Asp Thr Thr Thr Leu Ser Glu Arg Pro Ser
100
Pro Ser Thr Asp Val Gln Thr Asp Pro Gln Thr Leu Lys Pro Ser Gly
115
Phe His Glu Asp Asp Pro Phe Phe Tyr Asp Glu His Thr Leu Arg Lys
130
Arg Gly Leu Leu Val Ala Ala Val Leu Phe Ile Thr Gly Ile Ile Ile
145
150
155
160

```

SEQUENCE LISTING 1657-2022.txt

Leu Thr Ser Gly Lys Cys Arg Gln Leu Ser Arg Leu Cys Arg Asn Arg
 165 170 175
 Cys Arg

<210> 118
 <211> 3396
 <212> PRT
 <213> Homo sapiens

<400> 118
 Met Phe Ile Asn Ile Lys Ser Ile Leu Trp Met Cys Ser Thr Leu Ile
 1 5 10 15
 Val Thr His Ala Leu His Lys Val Lys Val Gly Lys Ser Pro Pro Val
 20 25 30
 Arg Gly Ser Leu Ser Gly Lys Val Ser Leu Pro Cys His Phe Ser Thr
 35 40 45
 Met Pro Thr Leu Pro Pro Ser Tyr Asn Thr Ser Glu Phe Leu Arg Ile
 50 55 60
 Lys Trp Ser Lys Ile Glu Val Asp Lys Asn Gly Lys Asp Leu Lys Glu
 65 70 75 80
 Thr Thr Val Leu Val Ala Gln Asn Gly Asn Ile Lys Ile Gly Gln Asp
 85 90 95
 Tyr Lys Gly Arg Val Ser Val Pro Thr His Pro Glu Ala Val Gly Asp
 100 105 110
 Ala Ser Leu Thr Val Val Lys Leu Leu Ala Ser Asp Ala Gly Leu Tyr
 115 120 125
 Arg Cys Asp Val Met Tyr Gly Ile Glu Asp Thr Gln Asp Thr Val Ser
 130 135 140
 Leu Thr Val Asp Gly Val Val Phe His Tyr Arg Ala Ala Thr Ser Arg
 145 150 155 160
 Tyr Thr Leu Asn Phe Glu Ala Ala Gln Lys Ala Cys Leu Asp Val Gly
 165 170 175
 Ala Val Ile Ala Thr Pro Glu Gln Leu Phe Ala Ala Tyr Glu Asp Gly
 180 185 190
 Phe Glu Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr Val Arg Tyr
 195 200 205
 Pro Ile Arg Ala Pro Arg Val Gly Cys Tyr Gly Asp Lys Met Gly Lys
 210 215 220
 Ala Gly Val Arg Thr Tyr Gly Phe Arg Ser Pro Gln Glu Thr Tyr Asp
 225 230 235 240
 Val Tyr Cys Tyr Val Asp His Leu Asp Gly Asp Val Phe His Leu Thr
 245 250 255
 Val Pro Ser Lys Phe Thr Phe Glu Glu Ala Ala Lys Glu Cys Glu Asn
 260 265 270
 Gln Asp Ala Arg Leu Ala Thr Val Gly Glu Leu Gln Ala Ala Trp Arg
 275 280 285
 Asn Gly Phe Asp Gln Cys Asp Tyr Gly Trp Leu Ser Asp Ala Ser Val
 290 295 300
 Arg His Pro Val Thr Val Ala Arg Ala Gln Cys Gly Gly Gly Leu Leu
 305 310 315 320
 Gly Val Arg Thr Leu Tyr Arg Phe Glu Asn Gln Thr Gly Phe Pro Pro
 325 330 335
 Pro Asp Ser Arg Phe Asp Ala Tyr Cys Phe Lys Pro Lys Glu Ala Thr
 340 345 350
 Thr Ile Asp Leu Ser Ile Leu Ala Glu Thr Ala Ser Pro Ser Leu Ser
 355 360 365
 Lys Glu Pro Gln Met Val Ser Asp Arg Thr Thr Pro Ile Ile Pro Leu
 370 375 380
 Val Asp Glu Leu Pro Val Ile Pro Thr Glu Phe Pro Pro Val Gly Asn
 385 390 395 400
 Ile Val Ser Phe Glu Gln Lys Ala Thr Val Gln Pro Gln Ala Ile Thr
 405 410 415
 Asp Ser Leu Ala Thr Lys Leu Pro Thr Pro Thr Gly Ser Thr Lys Lys
 420 425 430
 Pro Trp Asp Met Asp Asp Tyr Ser Pro Ser Ala Ser Gly Pro Leu Gly

SEQUENCE LISTING 1657-2022.txt

435
 Lys Leu Asp Ile Ser Glu Ile Lys Glu Glu Val Leu Gln Ser Thr Thr
 450
 Gly Val Ser His Tyr Ala Thr Asp Ser Trp Asp Gly Val Val Glu Asp
 465
 Lys Gln Thr Gln Glu Ser Val Thr Gln Ile Glu Gln Ile Glu Val Gly
 485
 Pro Leu Val Thr Ser Met Glu Ile Leu Lys His Ile Pro Ser Lys Glu
 500
 Phe Pro Val Thr Glu Thr Pro Leu Val Thr Ala Arg Met Ile Leu Glu
 515
 Ser Lys Thr Glu Lys Lys Met Val Ser Thr Val Ser Glu Leu Val Thr
 530
 Thr Gly His Tyr Gly Phe Thr Leu Gly Glu Glu Asp Asp Glu Asp Arg
 545
 Thr Leu Thr Val Gly Ser Asp Glu Ser Thr Leu Ile Phe Asp Gln Ile
 565
 Pro Glu Val Ile Thr Val Ser Lys Thr Ser Glu Asp Thr Ile His Thr
 580
 His Leu Glu Asp Leu Glu Ser Val Ser Ala Ser Thr Thr Val Ser Pro
 595
 Leu Ile Met Pro Asp Asn Asn Gly Ser Ser Met Asp Asp Trp Glu Glu
 610
 Arg Gln Thr Ser Gly Arg Ile Thr Glu Glu Phe Leu Gly Lys Tyr Leu
 625
 Ser Thr Thr Pro Phe Pro Ser Gln His Arg Thr Glu Ile Glu Leu Phe
 645
 Pro Tyr Ser Gly Asp Lys Ile Leu Val Glu Gly Ile Ser Thr Val Ile
 660
 Tyr Pro Ser Leu Gln Thr Glu Met Thr His Arg Arg Glu Arg Thr Glu
 675
 Thr Leu Ile Pro Glu Met Arg Thr Asp Thr Tyr Thr Asp Glu Ile Gln
 690
 Glu Glu Ile Thr Lys Ser Pro Phe Met Gly Lys Thr Glu Glu Glu Val
 705
 Phe Ser Gly Met Lys Leu Ser Thr Ser Leu Ser Glu Pro Ile His Val
 725
 Thr Glu Ser Ser Val Glu Met Thr Lys Ser Phe Asp Phe Pro Thr Leu
 740
 Ile Thr Lys Leu Ser Ala Glu Pro Thr Glu Val Arg Asp Met Glu Glu
 755
 Asp Phe Thr Ala Thr Pro Gly Thr Thr Lys Tyr Asp Glu Asn Ile Thr
 770
 Thr Val Leu Leu Ala His Gly Thr Leu Ser Val Glu Ala Ala Thr Val
 785
 Ser Lys Trp Ser Trp Asp Glu Asp Asn Thr Thr Ser Lys Pro Leu Glu
 805
 Ser Thr Glu Pro Ser Ala Ser Ser Lys Leu Pro Pro Ala Leu Leu Thr
 820
 Thr Val Gly Met Asn Gly Lys Asp Lys Asp Ile Pro Ser Phe Thr Glu
 835
 Asp Gly Ala Asp Glu Phe Thr Leu Ile Pro Asp Ser Thr Gln Lys Gln
 850
 Leu Glu Glu Val Thr Asp Glu Asp Ile Ala Ala His Gly Lys Phe Thr
 865
 Ile Arg Phe Gln Pro Thr Thr Ser Thr Gly Ile Ala Glu Lys Ser Thr
 885
 Leu Arg Asp Ser Thr Thr Glu Glu Lys Val Pro Pro Ile Thr Ser Thr
 900
 Glu Gly Gln Val Tyr Ala Thr Met Glu Gly Ser Ala Leu Gly Glu Val
 915
 Glu Asp Val Asp Leu Ser Lys Pro Val Ser Thr Val Pro Gln Phe Ala
 930
 His Thr Ser Glu Val Glu Gly Leu Ala Phe Val Ser Tyr Ser Ser Thr
 945
 Gln Glu Pro Thr Thr Tyr Val Asp Ser Ser His Thr Ile Pro Leu Ser
 965
 970
 975

SEQUENCE LISTING 1657-2022.txt

val Ile Pro Lys Thr Asp Trp Gly Val Leu Val Pro Ser Val Pro Ser
 980 985 990
 Glu Asp Glu Val Leu Gly Glu Pro Ser Gln Asp Ile Leu Val Ile Asp
 995 1000 1005
 Gln Thr Arg Leu Glu Ala Thr Ile Ser Pro Glu Thr Met Arg Thr Thr
 1010 1015 1020
 Lys Ile Thr Glu Gly Thr Thr Gln Glu Glu Phe Pro Trp Lys Glu Gln
 1025 1030 1035 1040
 Thr Ala Glu Lys Pro Val Pro Ala Leu Ser Ser Thr Ala Trp Thr Pro
 1045 1050 1055
 Lys Glu Ala Val Thr Pro Leu Asp Glu Gln Glu Gly Asp Gly Ser Ala
 1060 1065 1070
 Tyr Thr Val Ser Glu Asp Glu Leu Thr Gly Ser Glu Arg Val Pro
 1075 1080 1085
 Val Leu Glu Thr Thr Pro Val Gly Lys Ile Asp His Ser Val Ser Tyr
 1090 1095 1100
 Pro Pro Gly Ala Val Thr Glu His Lys Val Lys Thr Asp Glu Val Val
 1105 1110 1115 1120
 Thr Leu Thr Pro Arg Ile Gly Pro Lys Val Ser Leu Ser Pro Gly Pro
 1125 1130 1135
 Glu Gln Lys Tyr Glu Thr Glu Gly Ser Ser Thr Thr Gly Phe Thr Ser
 1140 1145 1150
 Ser Leu Ser Pro Phe Ser Thr His Ile Thr Gln Leu Met Glu Glu Thr
 1155 1160 1165
 Thr Thr Glu Lys Thr Ser Leu Glu Asp Ile Asp Leu Gly Ser Gly Leu
 1170 1175 1180
 Phe Glu Lys Pro Lys Ala Thr Glu Leu Ile Glu Phe Ser Thr Ile Lys
 1185 1190 1195 1200
 Val Thr Val Pro Ser Asp Ile Thr Thr Ala Phe Ser Ser Val Asp Arg
 1205 1210 1215
 Leu His Thr Thr Ser Ala Phe Lys Pro Ser Ser Ala Ile Thr Lys Lys
 1220 1225 1230
 Pro Pro Leu Ile Asp Arg Glu Pro Gly Glu Glu Thr Thr Ser Asp Met
 1235 1240 1245
 Val Ile Ile Gly Glu Ser Thr Ser His Val Pro Pro Thr Thr Leu Glu
 1250 1255 1260
 Asp Ile Val Ala Lys Glu Thr Glu Thr Asp Ile Asp Arg Glu Tyr Phe
 1265 1270 1275 1280
 Thr Thr Ser Ser Pro Pro Ala Thr Gln Pro Thr Arg Pro Pro Thr Val
 1285 1290 1295
 Glu Asp Lys Glu Ala Phe Gly Pro Gln Ala Leu Ser Thr Pro Gln Pro
 1300 1305 1310
 Pro Ala Ser Thr Lys Phe His Pro Asp Ile Asn Val Tyr Ile Ile Glu
 1315 1320 1325
 Val Arg Glu Asn Lys Thr Gly Arg Met Ser Asp Leu Ser Val Ile Gly
 1330 1335 1340
 His Pro Ile Asp Ser Glu Ser Lys Glu Asp Glu Pro Cys Ser Glu Glu
 1345 1350 1355 1360
 Thr Asp Pro Val His Asp Leu Met Ala Glu Ile Leu Pro Glu Phe Pro
 1365 1370 1375
 Asp Ile Ile Glu Ile Asp Leu Tyr His Ser Glu Glu Asn Glu Glu Glu
 1380 1385 1390
 Glu Glu Glu Cys Ala Asn Ala Thr Asp Val Thr Thr Thr Pro Ser Val
 1395 1400 1405
 Gln Tyr Ile Asn Gly Lys His Leu Val Thr Thr Val Pro Lys Asp Pro
 1410 1415 1420
 Glu Ala Ala Glu Ala Arg Arg Gly Gln Phe Glu Ser Val Ala Pro Ser
 1425 1430 1435 1440
 Gln Asn Phe Ser Asp Ser Ser Glu Ser Asp Thr His Pro Phe Val Ile
 1445 1450 1455
 Ala Lys Thr Glu Leu Ser Thr Ala Val Gln Pro Asn Glu Ser Thr Glu
 1460 1465 1470
 Thr Thr Glu Ser Leu Glu Val Thr Trp Lys Pro Glu Thr Tyr Pro Glu
 1475 1480 1485
 Thr Ser Glu His Phe Ser Gly Gly Glu Pro Asp Val Phe Pro Thr Val
 1490 1495 1500
 Pro Phe His Glu Glu Phe Glu Ser Gly Thr Ala Lys Lys Gly Ala Glu

SEQUENCE LISTING 1657-2022.txt

```

1505          1510          1515          1520
Ser Val Thr Glu Arg Asp Thr Glu Val Gly His Gln Ala His Glu His
1525          1530          1535
Thr Glu Pro Val Ser Leu Phe Pro Glu Ser Ser Gly Glu Ile Ala
1540          1545          1550
Ile Asp Gln Glu Ser Gln Lys Ile Ala Phe Ala Arg Ala Thr Glu Val
1555          1560          1565
Thr Phe Gly Glu Glu Val Glu Lys Ser Thr Ser Val Thr Tyr Thr Pro
1570          1575          1580
Thr Ile Val Pro Ser Ser Ala Ser Ala Tyr Val Ser Glu Glu Glu Ala
1585          1590          1595          1600
Val Thr Leu Ile Gly Asn Pro Trp Pro Asp Leu Leu Ser Thr Lys
1605          1610          1615
Glu Ser Trp Val Glu Ala Thr Pro Arg Gln Val Val Glu Leu Ser Gly
1620          1625          1630
Ser Ser Ser Ile Pro Ile Thr Glu Gly Ser Gly Glu Ala Glu Glu Asp
1635          1640          1645
Glu Asp Thr Met Phe Thr Met Val Thr Asp Leu Ser Gln Arg Asn Thr
1650          1655          1660
Thr Asp Thr Leu Ile Thr Leu Asp Thr Ser Arg Ile Ile Thr Glu Ser
1665          1670          1675          1680
Phe Phe Glu Val Pro Ala Thr Thr Ile Tyr Pro Val Ser Glu Gln Pro
1685          1690          1695
Ser Ala Lys Val Val Pro Thr Lys Phe Val Ser Glu Thr Asp Thr Ser
1700          1705          1710
Glu Trp Ile Ser Ser Thr Thr Val Glu Glu Lys Lys Arg Lys Glu Glu
1715          1720          1725
Glu Gly Thr Thr Gly Thr Ala Ser Thr Phe Glu Val Tyr Ser Ser Thr
1730          1735          1740
Gln Arg Ser Asp Gln Leu Ile Leu Pro Phe Glu Leu Glu Ser Pro Asn
1745          1750          1755          1760
Val Ala Thr Ser Ser Asp Ser Gly Thr Arg Lys Ser Phe Met Ser Leu
1765          1770          1775
Thr Thr Pro Thr Gln Ser Glu Arg Glu Met Thr Asp Ser Thr Pro Val
1780          1785          1790
Phe Thr Glu Thr Asn Thr Leu Glu Asn Leu Gly Ala Gln Thr Thr Glu
1795          1800          1805
His Ser Ser Ile His Gln Pro Gly Val Gln Glu Gly Leu Thr Thr Leu
1810          1815          1820
Pro Arg Ser Pro Ala Ser Val Phe Met Glu Gln Gly Ser Gly Glu Ala
1825          1830          1835          1840
Ala Ala Asp Pro Glu Thr Thr Thr Val Ser Ser Phe Ser Leu Asn Val
1845          1850          1855
Glu Tyr Ala Ile Gln Ala Glu Lys Glu Val Ala Gly Thr Leu Ser Pro
1860          1865          1870
His Val Glu Thr Thr Phe Ser Thr Glu Pro Thr Gly Leu Val Leu Ser
1875          1880          1885
Thr Val Met Asp Arg Val Val Ala Glu Asn Ile Thr Gln Thr Ser Arg
1890          1895          1900
Glu Ile Val Ile Ser Glu Arg Leu Gly Glu Pro Asn Tyr Gly Ala Glu
1905          1910          1915          1920
Ile Arg Gly Phe Ser Thr Gly Phe Pro Leu Glu Glu Asp Phe Ser Gly
1925          1930          1935
Asp Phe Arg Glu Tyr Ser Thr Val Ser His Pro Ile Ala Lys Glu Glu
1940          1945          1950
Thr Val Met Met Glu Gly Ser Gly Asp Ala Ala Phe Arg Asp Thr Gln
1955          1960          1965
Thr Ser Pro Ser Thr Val Pro Thr Ser Val His Ile Ser His Ile Ser
1970          1975          1980
Asp Ser Glu Gly Pro Ser Thr Met Val Ser Thr Ser Ala Phe Pro
1985          1990          1995          2000
Trp Glu Glu Phe Thr Ser Ser Ala Glu Gly Ser Gly Glu Gln Leu Val
2005          2010          2015
Thr Val Ser Ser Val Val Pro Val Leu Pro Ser Ala Val Gln Lys
2020          2025          2030
Phe Ser Gly Thr Ala Ser Ser Ile Ile Asp Glu Gly Leu Gly Glu Val
2035          2040          2045

```


SEQUENCE LISTING 1657-2022.txt

Gly Thr Val Asn Glu Ile Asp Arg Arg Ser Thr Ile Leu Pro Thr Ala
 2050 2055 2060
 Glu Val Glu Gly Thr Lys Ala Pro Val Glu Lys Glu Glu Val Lys Val
 2065 2070 2075 2080
 Ser Gly Thr Val Ser Thr Asn Phe Pro Gln Thr Ile Glu Pro Ala Lys
 2085 2090 2095
 Leu Trp Ser Arg Gln Glu Val Asn Pro Val Arg Gln Glu Ile Glu Ser
 2100 2105 2110
 Glu Thr Thr Ser Glu Glu Gln Ile Gln Glu Glu Lys Ser Phe Glu Ser
 2115 2120 2125
 Pro Gln Asn Ser Pro Ala Thr Glu Gln Thr Ile Phe Asp Ser Gln Thr
 2130 2135 2140
 Phe Thr Glu Thr Glu Leu Lys Thr Thr Asp Tyr Ser Val Leu Thr Thr
 2145 2150 2155 2160
 Lys Lys Thr Tyr Ser Asp Asp Lys Glu Met Lys Glu Glu Asp Thr Ser
 2165 2170 2175
 Leu Val Asn Met Ser Thr Pro Asp Pro Asp Ala Asn Gly Leu Glu Ser
 2180 2185 2190
 Tyr Thr Thr Leu Pro Glu Ala Thr Glu Lys Ser His Phe Phe Leu Ala
 2195 2200 2205
 Thr Ala Leu Val Thr Glu Ser Ile Pro Ala Glu His Val Val Thr Asp
 2210 2215 2220
 Ser Pro Ile Lys Lys Glu Glu Ser Thr Lys His Phe Pro Lys Gly Met
 2225 2230 2235 2240
 Arg Pro Thr Ile Gln Glu Ser Asp Thr Glu Leu Leu Phe Ser Gly Leu
 2245 2250 2255
 Gly Ser Gly Glu Glu Val Leu Pro Thr Leu Pro Thr Glu Ser Val Asn
 2260 2265 2270
 Phe Thr Glu Val Glu Gln Ile Asn Asn Thr Leu Tyr Pro His Thr Ser
 2275 2280 2285
 Gln Val Glu Ser Thr Ser Ser Asp Lys Ile Glu Asp Phe Asn Arg Met
 2290 2295 2300
 Glu Asn Val Ala Lys Glu Val Gly Pro Leu Val Ser Gln Thr Asp Ile
 2305 2310 2315 2320
 Phe Glu Gly Ser Gly Ser Val Thr Ser Thr Thr Leu Ile Glu Ile Leu
 2325 2330 2335
 Ser Asp Thr Gly Ala Glu Gly Pro Thr Val Ala Pro Leu Pro Phe Ser
 2340 2345 2350
 Thr Asp Ile Gly His Pro Gln Asn Gln Thr Val Arg Trp Ala Glu Glu
 2355 2360 2365
 Ile Gln Thr Ser Arg Pro Gln Thr Ile Thr Glu Gln Asp Ser Asn Lys
 2370 2375 2380
 Asn Ser Ser Thr Ala Glu Ile Asn Glu Thr Thr Thr Ser Ser Thr Asp
 2385 2390 2395 2400
 Phe Leu Ala Arg Ala Tyr Gly Phe Glu Met Ala Lys Glu Phe Val Thr
 2405 2410 2415
 Ser Ala Pro Lys Pro Ser Asp Leu Tyr Tyr Glu Pro Ser Gly Glu Gly
 2420 2425 2430
 Ser Gly Glu Val Asp Ile Val Asp Ser Phe His Thr Ser Ala Thr Thr
 2435 2440 2445
 Gln Ala Thr Arg Gln Glu Ser Ser Thr Thr Phe Val Ser Asp Gly Ser
 2450 2455 2460
 Leu Glu Lys His Pro Glu Val Pro Ser Ala Lys Ala Val Thr Ala Asp
 2465 2470 2475 2480
 Gly Phe Pro Thr Val Ser Val Met Leu Pro Leu His Ser Glu Gln Asn
 2485 2490 2495
 Lys Ser Ser Pro Asp Pro Thr Ser Thr Leu Ser Asn Thr Val Ser Tyr
 2500 2505 2510
 Glu Arg Ser Thr Asp Gly Ser Phe Gln Asp Arg Phe Arg Glu Phe Glu
 2515 2520 2525
 Asp Ser Thr Leu Lys Pro Asn Arg Lys Lys Pro Thr Glu Asn Ile Ile
 2530 2535 2540
 Ile Asp Leu Asp Lys Glu Asp Lys Asp Leu Ile Leu Thr Ile Thr Glu
 2545 2550 2555 2560
 Ser Thr Ile Leu Glu Ile Leu Pro Glu Leu Thr Ser Asp Lys Asn Thr
 2565 2570 2575
 Ile Ile Asp Ile Asp His Thr Lys Pro Val Tyr Glu Asp Ile Leu Gly

SEQUENCE LISTING 1657-2022.txt

2580 2585 2590
Met Gln Thr Asp Ile Asp Thr Glu Val Pro Ser Glu Pro His Asp Ser
2595 2600 2605
Asn Asp Glu Ser Asn Asp Asp Ser Thr Gln Val Gln Glu Ile Tyr Glu
2610 2615 2620
Ala Ala Val Asn Leu Ser Leu Thr Glu Glu Thr Phe Glu Gly Ser Ala
2625 2630 2635 2640
Asp Val Leu Ala Ser Tyr Thr Gln Ala Thr His Asp Glu Ser Met Thr
2645 2650 2655
Tyr Glu Asp Arg Ser Gln Leu Asp His Met Gly Phe His Phe Thr Thr
2660 2665 2670
Gly Ile Pro Ala Pro Ser Thr Glu Thr Glu Leu Asp Val Leu Leu Pro
2675 2680 2685
Thr Ala Thr Ser Leu Pro Ile Pro Arg Lys Ser Ala Thr Val Ile Pro
2690 2695 2700
Glu Ile Glu Gly Ile Lys Ala Glu Ala Lys Ala Leu Asp Asp Met Phe
2705 2710 2715 2720
Glu Ser Ser Thr Leu Ser Asp Gly Gln Ala Ile Ala Asp Gln Ser Glu
2725 2730 2735
Ile Ile Pro Thr Leu Gly Gln Phe Glu Arg Thr Gln Glu Glu Tyr Glu
2740 2745 2750
Asp Lys Lys His Ala Gly Pro Ser Phe Gln Pro Glu Phe Ser Ser Gly
2755 2760 2765
Ala Glu Glu Ala Leu Val Asp His Thr Pro Tyr Leu Ser Ile Ala Thr
2770 2775 2780
Thr His Leu Met Asp Gln Ser Val Thr Glu Val Pro Asp Val Met Glu
2785 2790 2795 2800
Gly Ser Asn Pro Pro Tyr Tyr Thr Asp Thr Thr Leu Ala Val Ser Thr
2805 2810 2815
Phe Ala Lys Leu Ser Ser Gln Thr Pro Ser Ser Pro Leu Thr Ile Tyr
2820 2825 2830
Ser Gly Ser Glu Ala Ser Gly His Thr Glu Ile Pro Gln Pro Ser Ala
2835 2840 2845
Leu Pro Gly Ile Asp Val Gly Ser Ser Val Met Ser Pro Gln Asp Ser
2850 2855 2860
Phe Lys Glu Ile His Val Asn Ile Glu Ala Thr Phe Lys Pro Ser Ser
2865 2870 2875 2880
Glu Glu Tyr Leu His Ile Thr Glu Pro Pro Ser Leu Ser Pro Asp Thr
2885 2890 2895
Lys Leu Glu Pro Ser Glu Asp Asp Gly Lys Pro Glu Leu Leu Glu Glu
2900 2905 2910
Met Glu Ala Ser Pro Thr Glu Leu Ile Ala Val Glu Gly Thr Glu Ile
2915 2920 2925
Leu Gln Asp Phe Gln Asn Lys Thr Asp Gly Gln Val Ser Gly Glu Ala
2930 2935 2940
Ile Lys Met Phe Pro Thr Ile Lys Thr Pro Glu Ala Gly Thr Val Ile
2945 2950 2955 2960
Thr Thr Ala Asp Glu Ile Glu Leu Glu Gly Ala Thr Gln Trp Pro His
2965 2970 2975
Ser Thr Ser Ala Ser Ala Thr Tyr Gly Val Glu Ala Gly Val Val Pro
2980 2985 2990
Trp Leu Ser Pro Gln Thr Ser Glu Arg Pro Thr Leu Ser Ser Ser Pro
2995 3000 3005
Glu Ile Asn Pro Glu Thr Gln Ala Ala Leu Ile Arg Gly Gln Asp Ser
3010 3015 3020
Thr Ile Ala Ala Ser Glu Gln Gln Val Ala Ala Arg Ile Leu Asp Ser
3025 3030 3035 3040
Asn Asp Gln Ala Thr Val Asn Pro Val Glu Phe Asn Thr Glu Val Ala
3045 3050 3055
Thr Pro Pro Phe Ser Leu Leu Glu Thr Ser Asn Glu Thr Asp Phe Leu
3060 3065 3070
Ile Gly Ile Asn Glu Glu Ser Val Glu Gly Thr Ala Ile Tyr Leu Pro
3075 3080 3085
Gly Pro Asp Arg Cys Lys Met Asn Pro Cys Leu Asn Gly Gly Thr Cys
3090 3095 3100
Tyr Pro Thr Glu Thr Ser Tyr Val Cys Thr Cys Val Pro Gly Tyr Ser
3105 3110 3115 3120

SEQUENCE LISTING 1657-2022.txt

Gly Asp Gln Cys Glu Leu Asp Phe Asp Glu Cys His Ser Asn Pro Cys
 3125 3130 3135
 Arg Asn Gly Ala Thr Cys Val Asp Gly Phe Asn Thr Phe Arg Cys Leu
 3140 3145 3150
 Cys Leu Pro Ser Tyr Val Gly Ala Leu Cys Glu Gln Asp Thr Glu Thr
 3155 3160 3165
 Cys Asp Tyr Gly Trp His Lys Phe Gln Gly Gln Cys Tyr Lys Tyr Phe
 3170 3175 3180
 Ala His Arg Arg Thr Trp Asp Ala Ala Glu Arg Glu Cys Arg Leu Gln
 3185 3190 3195 3200
 Gly Ala His Leu Thr Ser Ile Leu Ser His Glu Glu Gln Met Phe Val
 3205 3210 3215
 Asn Arg Val Gly His Asp Tyr Gln Trp Ile Gly Leu Asn Asp Lys Met
 3220 3225 3230
 Phe Glu His Asp Phe Arg Trp Thr Asp Gly Ser Thr Leu Gln Tyr Glu
 3235 3240 3245
 Asn Trp Arg Pro Asn Gln Pro Asp Ser Phe Phe Ser Ala Gly Glu Asp
 3250 3255 3260
 Cys Val Val Ile Ile Trp His Glu Asn Gly Gln Trp Asn Asp Val Pro
 3265 3270 3275 3280
 Cys Asn Tyr His Leu Thr Tyr Thr Cys Lys Lys Gly Thr Val Ala Cys
 3285 3290 3295
 Gly Gln Pro Pro Val Val Glu Asn Ala Lys Thr Phe Gly Lys Met Lys
 3300 3305 3310
 Pro Arg Tyr Glu Ile Asn Ser Leu Ile Arg Tyr His Cys Lys Asp Gly
 3315 3320 3325
 Phe Ile Gln Arg His Leu Pro Thr Ile Arg Cys Leu Gly Asn Gly Arg
 3330 3335 3340
 Trp Ala Ile Pro Lys Ile Thr Cys Met Asn Pro Ser Ala Tyr Gln Arg
 3345 3350 3355 3360
 Thr Tyr Ser Met Lys Tyr Phe Lys Asn Ser Ser Ser Ala Lys Asp Asn
 3365 3370 3375
 Ser Ile Asn Thr Ser Lys His Asp His Arg Trp Ser Arg Arg Trp Gln
 3380 3385 3390
 Glu Ser Arg Arg
 3395

<210> 119
 <211> 317
 <212> PRT
 <213> Homo sapiens

<400> 119
 Met Thr Ser Arg Thr Arg Val Thr Trp Pro Ser Pro Pro Arg Pro Leu
 1 5 10 15
 Pro Val Pro Ala Ala Ala Ala Val Ala Phe Gly Ala Lys Gly Thr Asp
 20 25 30
 Pro Ala Glu Ala Arg Ser Ser Arg Gly Ile Glu Glu Ala Gly Pro Arg
 35 40 45
 Ala His Gly Arg Ala Gly Arg Glu Pro Glu Arg Arg Arg Ser Arg Gln
 50 55 60
 Gln Arg Arg Gly Gly Leu Gln Ala Arg Arg Ser Thr Leu Leu Lys Thr
 65 70 75 80
 Cys Ala Arg Ala Arg Ala Thr Ala Pro Gly Ala Met Lys Met Val Ala
 85 90 95
 Pro Trp Thr Arg Phe Tyr Ser Asn Ser Cys Cys Leu Cys Cys His Val
 100 105 110
 Arg Thr Gly Thr Ile Leu Leu Gly Val Trp Tyr Leu Ile Ile Asn Ala
 115 120 125
 Val Val Leu Leu Ile Leu Leu Ser Ala Leu Ala Asp Pro Asp Gln Tyr
 130 135 140
 Asn Phe Ser Ser Ser Glu Leu Gly Gly Asp Phe Glu Phe Met Asp Asp
 145 150 155 160
 Ala Asn Met Cys Ile Ala Ile Ala Ile Ser Leu Leu Met Ile Leu Ile
 165 170 175
 Cys Ala Met Ala Thr Tyr Gly Ala Tyr Lys Gln Arg Ala Ala Trp Ile

SEQUENCE LISTING 1657-2022.txt

```

180      185      190
Ile Pro Phe Phe Cys Tyr Gln Ile Phe Asp Phe Ala Leu Asn Met Leu
195      200      205
Val Ala Ile Thr Val Leu Ile Tyr Pro Asn Ser Ile Gln Glu Tyr Ile
210      215      220
Arg Gln Leu Pro Pro Asn Phe Pro Tyr Arg Asp Val Met Ser Val
225      230      235
Asn Pro Thr Cys Leu Val Leu Ile Ile Leu Leu Phe Ile Ser Ile Ile
245      250      255
Leu Thr Phe Lys Gly Tyr Leu Ile Ser Cys Val Trp Asn Cys Tyr Arg
260      265      270
Tyr Ile Asn Gly Arg Asn Ser Ser Asp Val Leu Val Tyr Val Thr Ser
275      280      285
Asn Asp Thr Thr Val Leu Leu Pro Pro Tyr Asp Ala Thr Val Asn
290      295      300
Gly Ala Ala Lys Glu Pro Pro Pro Pro Tyr Val Ser Ala
305      310      315

```

```

<210> 120
<211> 474
<212> PRT
<213> Homo sapiens

```

```

<400> 120
Met Val Gln Gln Thr Asn Asn Ala Glu Asn Thr Glu Ala Leu Leu Ala
1      5      10      15
Gly Glu Ser Ser Asp Ser Gly Ala Gly Leu Glu Leu Gly Ile Ala Ser
20      25      30
Ser Pro Thr Pro Gly Ser Thr Ala Ser Thr Gly Gly Lys Ala Asp Asp
35      40      45
Pro Ser Trp Cys Lys Thr Pro Ser Gly His Ile Lys Arg Pro Met Asn
50      55      60
Ala Phe Met Val Trp Ser Gln Ile Glu Arg Arg Lys Ile Met Glu Gln
65      70      75      80
Ser Pro Asp Met His Asn Ala Glu Ile Ser Lys Arg Leu Gly Lys Arg
85      90      95
Trp Lys Leu Leu Lys Asp Ser Asp Lys Ile Pro Phe Ile Arg Glu Ala
100      105      110
Glu Arg Leu Arg Leu Lys His Met Ala Asp Tyr Pro Asp Tyr Lys Tyr
115      120      125
Arg Pro Arg Lys Lys Val Lys Ser Gly Asn Ala Asn Ser Ser Ser Ser
130      135      140
Ala Ala Ala Ser Ser Lys Pro Gly Glu Lys Gly Asp Lys Val Gly Gly
145      150      155      160
Ser Gly Gly Gly Gly His Gly Gly Gly Gly Gly Gly Ser Ser Asn
165      170      175
Ala Gly Gly Gly Gly Gly Gly Ala Ser Gly Gly Gly Ala Asn Ser Lys
180      185      190
Pro Ala Gln Lys Lys Ser Cys Gly Ser Lys Val Ala Gly Gly Ala Gly
195      200      205
Gly Gly Val Ser Lys Pro His Ala Lys Leu Ile Leu Ala Gly Gly Gly
210      215      220
Gly Gly Gly Lys Ala Ala Ala Ala Ala Ser Phe Ala Ala Glu
225      230      235
Gln Ala Gly Ala Ala Ala Leu Leu Pro Leu Gly Ala Ala Ala Asp His
245      250      255
His Ser Leu Tyr Lys Ala Arg Thr Pro Ser Ala Ser Ala Ser
260      265      270
Ser Ala Ala Ser Ala Ser Ala Ala Leu Ala Ala Pro Gly Lys His Leu
275      280      285
Ala Glu Lys Lys Val Lys Arg Val Tyr Leu Phe Gly Gly Leu Gly Thr
290      295      300
Ser Ser Ser Pro Val Gly Gly Val Gly Ala Gly Ala Asp Pro Ser Asp
305      310      315
Pro Leu Gly Leu Tyr Glu Glu Glu Gly Ala Gly Cys Ser Pro Asp Ala
325      330      335

```

SEQUENCE LISTING 1657-2022.txt

Pro Ser Leu Ser Gly Arg Ser Ser Ala Ala Ser Ser Pro Ala Ala Gly
 340 345 350
 Arg Ser Pro Ala Asp His Arg Gly Tyr Ala Ser Leu Arg Ala Ala Ser
 355 360 365
 Pro Ala Pro Ser Ser Ala Pro Ser His Ala Ser Ser Ala Ser Ser
 370 375 380
 His Ser Ser Ser Ser Ser Ser Ser Gly Ser Ser Ser Ser Asp Asp Glu
 385 390 395 400
 Phe Glu Asp Asp Leu Asp Leu Asn Pro Ser Ser Asn Phe Glu Ser
 405 410 415
 Met Ser Leu Gly Ser Phe Ser Ser Ser Ser Ala Leu Asp Arg Asp Leu
 420 425 430
 Asp Phe Asn Phe Glu Pro Gly Ser Gly Ser His Phe Glu Phe Pro Asp
 435 440 445
 Tyr Cys Thr Pro Glu Val Ser Glu Met Ile Ser Gly Asp Trp Leu Glu
 450 455 460
 Ser Ser Ile Ser Asn Leu Val Phe Thr Tyr
 465 470

<210> 121
 <211> 357
 <212> PRT
 <213> Homo sapiens

<400> 121
 Met Ala Ala Ala Ala Lys Pro Asn Asn Leu Ser Leu Val Val His Gly
 1 5 10 15
 Pro Gly Asp Leu Arg Leu Glu Asn Tyr Pro Ile Pro Glu Pro Gly Pro
 20 25 30
 Asn Glu Val Leu Leu Arg Met His Ser Val Gly Ile Cys Gly Ser Asp
 35 40 45
 Val His Tyr Trp Glu Tyr Gly Arg Ile Gly Asn Phe Ile Val Lys Lys
 50 55 60
 Pro Met Val Leu Gly His Glu Ala Ser Gly Thr Val Glu Lys Val Gly
 65 70 75 80
 Ser Ser Val Lys His Leu Lys Pro Gly Asp Arg Val Ala Ile Glu Pro
 85 90 95
 Gly Ala Pro Arg Glu Asn Asp Glu Phe Cys Lys Met Gly Arg Tyr Asn
 100 105 110
 Leu Ser Pro Ser Ile Phe Phe Cys Ala Thr Pro Pro Asp Asp Gly Asn
 115 120 125
 Leu Cys Arg Phe Tyr Lys His Asn Ala Ala Phe Cys Tyr Lys Leu Pro
 130 135 140
 Asp Asn Val Thr Phe Glu Glu Gly Ala Leu Ile Glu Pro Leu Ser Val
 145 150 155 160
 Gly Ile His Ala Cys Arg Arg Gly Gly Val Thr Leu Gly His Lys Val
 165 170 175
 Leu Val Cys Gly Ala Gly Pro Ile Gly Met Val Thr Leu Leu Val Ala
 180 185 190
 Lys Ala Met Gly Ala Ala Gln Val Val Val Thr Asp Leu Ser Ala Thr
 195 200 205
 Arg Leu Ser Lys Ala Lys Glu Ile Gly Ala Asp Leu Val Leu Gln Ile
 210 215 220
 Ser Lys Glu Ser Pro Gln Glu Ile Ala Arg Lys Val Glu Gly Gln Leu
 225 230 235 240
 Gly Cys Lys Pro Glu Val Thr Ile Glu Cys Thr Gly Ala Glu Ala Ser
 245 250 255
 Ile Gln Ala Gly Ile Tyr Ala Thr Arg Ser Gly Gly Thr Leu Val Leu
 260 265 270
 Val Gly Leu Gly Ser Glu Met Thr Thr Val Pro Leu Leu His Ala Ala
 275 280 285
 Ile Arg Glu Val Asp Ile Lys Gly Val Phe Arg Tyr Cys Asn Thr Trp
 290 295 300
 Pro Val Ala Ile Ser Met Leu Ala Ser Lys Ser Val Asn Val Lys Pro
 305 310 315 320
 Leu Val Thr His Arg Phe Pro Leu Glu Lys Ala Leu Glu Ala Phe Glu

SEQUENCE LISTING 1657-2022.txt

Thr Phe Lys Lys Gly Leu Gly Leu Lys Ile Met Leu Lys Cys Asp Pro
 Ser Asp Gln Asn Pro
 325 330 335
 340 345 350
 355

<210> 122
 <211> 470
 <212> PRT
 <213> Homo sapiens

<400> 122
 Met Lys Phe Leu Leu Ile Leu Leu Leu Gln Ala Thr Ala Ser Gly Ala
 1 5 10 15
 Leu Pro Leu Asn Ser Ser Thr Ser Leu Glu Lys Asn Asn Val Leu Phe
 20 25 30
 Gly Glu Arg Tyr Leu Glu Lys Phe Tyr Gly Leu Glu Ile Asn Lys Leu
 35 40 45
 Pro Val Thr Lys Met Lys Tyr Ser Gly Asn Leu Met Lys Glu Lys Ile
 50 55 60
 Gln Glu Met Gln His Phe Leu Gly Leu Lys Val Thr Gly Gln Leu Asp
 65 70 75 80
 Thr Ser Thr Leu Glu Met Met His Ala Pro Arg Cys Gly Val Pro Asp
 85 90 95
 Leu His His Phe Arg Glu Met Pro Gly Gly Pro Val Trp Arg Lys His
 100 105 110
 Tyr Ile Thr Tyr Arg Ile Asn Asn Tyr Thr Pro Asp Met Asn Arg Glu
 115 120 125
 Asp Val Asp Tyr Ala Ile Arg Lys Ala Phe Gln Val Trp Ser Asn Val
 130 135 140
 Thr Pro Leu Lys Phe Ser Lys Ile Asn Thr Gly Met Ala Asp Ile Leu
 145 150 155 160
 Val Val Phe Ala Arg Gly Ala His Gly Asp Phe His Ala Phe Asp Gly
 165 170 175
 Lys Gly Gly Ile Leu Ala His Ala Phe Gly Pro Gly Ser Gly Ile Gly
 180 185 190
 Gly Asp Ala His Phe Asp Glu Asp Glu Phe Trp Thr Thr His Ser Gly
 195 200 205
 Gly Thr Asn Leu Phe Leu Thr Ala Val His Glu Ile Gly His Ser Leu
 210 215 220
 Gly Leu Gly His Ser Ser Asp Pro Lys Ala Val Met Phe Pro Thr Tyr
 225 230 235 240
 Lys Tyr Val Asp Ile Asn Thr Phe Arg Leu Ser Ala Asp Asp Ile Arg
 245 250 255
 Gly Ile Gln Ser Leu Tyr Gly Asp Pro Lys Glu Asn Gln Arg Leu Pro
 260 265 270
 Asn Pro Asp Asn Ser Glu Pro Ala Leu Cys Asp Pro Asn Leu Ser Phe
 275 280 285
 Asp Ala Val Thr Thr Val Gly Asn Lys Ile Phe Phe Phe Lys Asp Arg
 290 295 300
 Phe Phe Trp Leu Lys Val Ser Glu Arg Pro Lys Thr Ser Val Asn Leu
 305 310 315 320
 Ile Ser Ser Leu Trp Pro Thr Leu Pro Ser Gly Ile Glu Ala Ala Tyr
 325 330 335
 Glu Ile Glu Ala Arg Asn Gln Val Phe Leu Phe Lys Asp Asp Lys Tyr
 340 345 350
 Trp Leu Ile Ser Asn Leu Arg Pro Glu Pro Asn Tyr Pro Lys Ser Ile
 355 360 365
 His Ser Phe Gly Phe Pro Asn Phe Val Lys Lys Ile Asp Ala Ala Val
 370 375 380
 Phe Asn Pro Arg Phe Tyr Arg Thr Tyr Phe Phe Val Asp Asn Gln Tyr
 385 390 395 400
 Trp Arg Tyr Asp Glu Arg Arg Gln Met Met Asp Pro Gly Tyr Pro Lys
 405 410 415
 Leu Ile Thr Lys Asn Phe Gln Gly Ile Gly Pro Lys Ile Asp Ala Val
 420 425 430

SEQUENCE LISTING 1657-2022.txt

Phe Tyr Ser Lys Asn Lys Tyr Tyr Phe Phe Gln Gly Ser Asn Gln
 435 440 445
 Phe Glu Tyr Asp Phe Leu Leu Gln Arg Ile Thr Lys Thr Leu Lys Ser
 450 455 460
 Asn Ser Trp Phe Gly Cys
 465 470

<210> 123
 <211> 165
 <212> PRT
 <213> Homo sapiens

<400> 123
 Met Ala Pro Asn Ala Ser Cys Leu Cys Val His Val Arg Ser Glu Glu
 1 5 10 15
 Trp Asp Leu Met Thr Phe Asp Ala Asn Pro Tyr Asp Ser Val Lys Lys
 20 25 30
 Ile Lys Glu His Val Arg Ser Lys Thr Lys Val Pro Val Gln Asp Gln
 35 40 45
 Val Leu Leu Leu Gly Ser Lys Ile Leu Lys Pro Arg Arg Ser Leu Ser
 50 55 60
 Ser Tyr Gly Ile Asp Lys Glu Lys Thr Ile His Leu Thr Leu Lys Val
 65 70 75 80
 Val Lys Pro Ser Asp Glu Glu Leu Pro Leu Phe Leu Val Glu Ser Gly
 85 90 95
 Asp Glu Ala Lys Arg His Leu Leu Gln Val Arg Arg Ser Ser Ser Val
 100 105 110
 Ala Gln Val Lys Ala Met Ile Glu Thr Lys Thr Gly Ile Ile Pro Glu
 115 120 125
 Thr Gln Ile Val Thr Cys Asn Gly Lys Arg Leu Glu Asp Gly Lys Met
 130 135 140
 Met Ala Asp Tyr Gly Ile Arg Lys Gly Asn Leu Leu Phe Leu Ala Ser
 145 150 155 160
 Tyr Cys Ile Gly Gly
 165

<210> 124
 <211> 2828
 <212> PRT
 <213> Homo sapiens

<400> 124
 Met Pro Lys Arg Ala His Trp Gly Ala Leu Ser Val Val Leu Ile Leu
 1 5 10 15
 Leu Trp Gly His Pro Arg Val Ala Leu Ala Cys Pro His Pro Cys Ala
 20 25 30
 Cys Tyr Val Pro Ser Glu Val His Cys Thr Phe Arg Ser Leu Ala Ser
 35 40 45
 Val Pro Ala Gly Ile Ala Arg His Val Glu Arg Ile Asn Leu Gly Phe
 50 55 60
 Asn Ser Ile Gln Ala Leu Ser Glu Thr Ser Phe Ala Gly Leu Thr Lys
 65 70 75 80
 Leu Glu Leu Leu Met Ile His Gly Asn Glu Ile Pro Ser Ile Pro Asp
 85 90 95
 Gly Ala Leu Arg Asp Leu Ser Ser Leu Gln Val Phe Lys Phe Ser Tyr
 100 105 110
 Asn Lys Leu Arg Val Ile Thr Gly Gln Thr Leu Gln Gly Leu Ser Asn
 115 120 125
 Leu Met Arg Leu His Ile Asp His Asn Lys Ile Glu Phe Ile His Pro
 130 135 140
 Gln Ala Phe Asn Gly Leu Thr Ser Leu Arg Leu Leu His Leu Glu Gly
 145 150 155 160
 Asn Leu Leu His Gln Leu His Pro Ser Thr Phe Ser Thr Phe Thr Phe
 165 170 175
 Leu Asp Tyr Phe Arg Leu Ser Thr Ile Arg His Leu Tyr Leu Ala Glu

SEQUENCE LISTING 1657-2022.txt

```

180
Asn Met Val Arg Thr Leu Pro Ala Ser Met Leu Arg Asn Met Pro Leu
195
Leu Glu Asn Leu Tyr Leu Gln Gly Asn Pro Trp Thr Cys Asp Cys Glu
210
Met Arg Trp Phe Leu Glu Trp Asp Ala Lys Ser Arg Gly Ile Leu Lys
225
Cys Lys Lys Asp Lys Ala Tyr Glu Gly Gly Gln Leu Cys Ala Met Cys
245
Phe Ser Pro Lys Lys Leu Tyr Lys His Glu Ile His Lys Leu Lys Asp
260
Met Thr Cys Leu Lys Pro Ser Ile Glu Ser Pro Leu Arg Gln Asn Arg
275
Ser Arg Ser Ile Glu Glu Glu Gln Glu Gln Glu Glu Asp Gly Gly Ser
290
Gln Leu Ile Leu Glu Lys Phe Gln Leu Pro Gln Trp Ser Ile Ser Leu
305
Asn Met Thr Asp Glu His Gly Asn Met Val Asn Leu Val Cys Asp Ile
325
Lys Lys Pro Met Asp Val Tyr Lys Ile His Leu Asn Gln Thr Asp Pro
340
Pro Asp Ile Asp Ile Asn Ala Thr Val Ala Leu Asp Phe Glu Cys Pro
355
Met Thr Arg Glu Asn Tyr Glu Lys Leu Trp Lys Leu Ile Ala Tyr Tyr
370
Ser Glu Val Pro Val Lys Leu His Arg Glu Leu Met Leu Ser Lys Asp
385
Pro Arg Val Ser Tyr Gln Tyr Arg Gln Asp Ala Asp Glu Glu Ala Leu
405
Tyr Tyr Thr Gly Val Arg Ala Gln Ile Leu Ala Glu Pro Glu Trp Val
420
Met Gln Pro Ser Ile Asp Ile Gln Leu Asn Arg Arg Gln Ser Thr Ala
435
Lys Lys Val Leu Leu Ser Tyr Tyr Thr Gln Tyr Ser Gln Thr Ile Ser
450
Thr Lys Asp Thr Arg Gln Ala Arg Gly Arg Ser Trp Val Met Ile Glu
465
Pro Ser Gly Ala Val Gln Arg Asp Gln Thr Val Leu Glu Gly Gly Pro
485
Cys Gln Leu Ser Cys Asn Val Lys Ala Ser Glu Ser Pro Ser Ile Phe
500
Trp Val Leu Pro Asp Gly Ser Ile Leu Lys Ala Pro Met Asp Asp Pro
515
Asp Ser Lys Phe Ser Ile Leu Ser Ser Gly Trp Leu Arg Ile Lys Ser
530
Met Glu Pro Ser Asp Ser Gly Leu Tyr Gln Cys Ile Ala Gln Val Arg
545
Asp Glu Met Asp Arg Met Val Tyr Arg Val Leu Val Gln Ser Pro Ser
565
Thr Gln Pro Ala Glu Lys Asp Thr Val Thr Ile Gly Lys Asn Pro Gly
580
Glu Ser Val Thr Leu Pro Cys Asn Ala Leu Ala Ile Pro Glu Ala His
595
Leu Ser Trp Ile Leu Pro Asn Arg Arg Ile Ile Asn Asp Leu Ala Asn
610
Thr Ser His Val Tyr Met Leu Pro Asn Gly Thr Leu Ser Ile Pro Lys
625
Val Gln Val Ser Asp Ser Gly Tyr Tyr Arg Cys Val Ala Val Asn Gln
645
Gln Gly Ala Asp His Phe Thr Val Gly Ile Thr Val Thr Lys Lys Gly
660
Ser Gly Leu Pro Ser Lys Arg Gly Arg Arg Pro Gly Ala Lys Ala Leu
675
Ser Arg Val Arg Glu Asp Ile Val Glu Asp Glu Gly Ser Gly Met
690
Gly Asp Glu Glu Asn Thr Ser Arg Arg Leu Leu His Pro Lys Asp Gln
705
710
715
720

```


SEQUENCE LISTING 1657-2022.txt

Glu Val Phe Leu Lys Thr Lys Asp Asp Ala Ile Asn Gly Asp Lys Lys
 725 730 735
 Ala Lys Lys Gly Arg Arg Lys Leu Lys Leu Trp Lys His Ser Glu Lys
 740 745 750
 Glu Pro Glu Thr Asn Val Ala Glu Gly Arg Arg Val Phe Glu Ser Arg
 755 760 765
 Arg Arg Ile Asn Met Ala Asn Lys Gln Ile Asn Pro Glu Arg Trp Ala
 770 775 780
 Asp Ile Leu Ala Lys Val Arg Gly Lys Asn Leu Pro Lys Gly Thr Glu
 785 790 795 800
 Val Pro Pro Leu Ile Lys Thr Thr Ser Pro Pro Ser Leu Ser Leu Glu
 805 810 815
 Val Thr Pro Pro Phe Pro Ala Val Ser Pro Pro Ser Ala Ser Pro Val
 820 825 830
 Gln Thr Val Thr Ser Ala Glu Glu Ser Ser Ala Asp Val Pro Leu Leu
 835 840 845
 Gly Glu Glu Glu His Val Leu Gly Thr Ile Ser Ser Ala Ser Met Gly
 850 855 860
 Leu Glu His Asn His Asn Gly Val Ile Leu Val Glu Pro Glu Val Thr
 865 870 875 880
 Ser Thr Pro Leu Glu Val Val Asp Asp Leu Ser Glu Lys Thr Glu
 885 890 895
 Glu Ile Thr Ser Thr Glu Gly Asp Leu Lys Gly Thr Ala Ala Pro Thr
 900 905 910
 Leu Ile Ser Glu Pro Tyr Glu Pro Ser Pro Thr Leu His Thr Leu Asp
 915 920 925
 Thr Val Tyr Glu Lys Pro Thr His Glu Glu Thr Ala Thr Glu Gly Trp
 930 935 940
 Ser Ala Ala Asp Val Gly Ser Ser Pro Glu Pro Thr Ser Ser Glu Tyr
 945 950 955 960
 Glu Pro Pro Leu Asp Ala Val Ser Leu Ala Glu Ser Glu Pro Met Gln
 965 970 975
 Tyr Phe Asp Pro Asp Leu Glu Thr Lys Ser Gln Pro Asp Glu Asp Lys
 980 985 990
 Met Lys Glu Asp Thr Phe Ala His Leu Thr Pro Thr Pro Thr Ile Trp
 995 1000 1005
 Val Asn Asp Ser Ser Thr Ser Gln Leu Phe Glu Asp Ser Thr Ile Gly
 1010 1015 1020
 Glu Pro Gly Val Pro Gly Gln Ser His Leu Gln Gly Leu Thr Asp Asn
 1025 1030 1035 1040
 Ile His Leu Val Lys Ser Ser Leu Ser Thr Gln Asp Thr Leu Leu Ile
 1045 1050 1055
 Lys Lys Gly Met Lys Glu Met Ser Gln Thr Leu Gln Gly Gly Asn Met
 1060 1065 1070
 Leu Glu Gly Asp Pro Thr His Ser Arg Ser Ser Glu Ser Glu Gly Gln
 1075 1080 1085
 Glu Ser Lys Ser Ile Thr Leu Pro Asp Ser Thr Leu Gly Ile Met Ser
 1090 1095 1100
 Ser Met Ser Pro Val Lys Lys Pro Ala Glu Thr Thr Val Gly Thr Leu
 1105 1110 1115 1120
 Leu Asp Lys Asp Thr Thr Thr Val Thr Thr Thr Pro Arg Gln Lys Val
 1125 1130 1135
 Ala Pro Ser Ser Thr Met Ser Thr His Pro Ser Arg Arg Arg Pro Asn
 1140 1145 1150
 Gly Arg Arg Arg Leu Arg Pro Asn Lys Phe Arg His Arg His Lys Gln
 1155 1160 1165
 Thr Pro Pro Thr Thr Phe Ala Pro Ser Glu Thr Phe Ser Thr Gln Pro
 1170 1175 1180
 Thr Gln Ala Pro Asp Ile Lys Ile Ser Ser Gln Val Glu Ser Ser Leu
 1185 1190 1195 1200
 Val Pro Thr Ala Trp Val Asp Asn Thr Val Asn Thr Pro Lys Gln Leu
 1205 1210 1215
 Glu Met Glu Lys Asn Ala Glu Pro Thr Ser Lys Gly Thr Pro Arg Arg
 1220 1225 1230
 Lys His Gly Lys Arg Pro Asn Lys His Arg Tyr Thr Pro Ser Thr Val
 1235 1240 1245
 Ser Ser Arg Ala Ser Gly Ser Lys Pro Ser Pro Ser Pro Glu Asn Lys

SEQUENCE LISTING 1657-2022.txt

1250 1255 1260
His Arg Asn Ile Val Thr Pro Ser Ser Glu Thr Ile Leu Leu Pro Arg
1265 1270 1275 1280
Thr Val Ser Leu Lys Thr Glu Gly Pro Tyr Asp Ser Leu Asp Tyr Met
1285 1290 1295
Thr Thr Thr Arg Lys Ile Tyr Ser Ser Tyr Pro Lys Val Gln Glu Thr
1300 1305 1310
Leu Pro Val Thr Tyr Lys Pro Thr Ser Asp Gly Lys Glu Ile Lys Asp
1315 1320 1325
Asp Val Ala Thr Asn Val Asp Lys His Lys Ser Asp Ile Leu Val Thr
1330 1335 1340
Gly Glu Ser Ile Thr Asn Ala Ile Pro Thr Ser Arg Ser Leu Val Ser
1345 1350 1355 1360
Thr Met Gly Glu Phe Lys Glu Glu Ser Ser Pro Val Gly Phe Pro Gly
1365 1370 1375
Thr Pro Thr Trp Asn Pro Ser Arg Thr Ala Gln Pro Gly Arg Leu Gln
1380 1385 1390
Thr Asp Ile Pro Val Thr Thr Ser Gly Glu Asn Leu Thr Asp Pro Pro
1395 1400 1405
Leu Leu Lys Glu Leu Glu Asp Val Asp Phe Thr Ser Glu Phe Leu Ser
1410 1415 1420
Ser Leu Thr Val Ser Thr Pro Phe His Gln Glu Glu Ala Gly Ser Ser
1425 1430 1435 1440
Thr Thr Leu Ser Ser Ile Lys Val Glu Val Ala Ser Ser Gln Ala Glu
1445 1450 1455
Thr Thr Thr Leu Asp Gln Asp His Leu Glu Thr Thr Val Ala Ile Leu
1460 1465 1470
Leu Ser Glu Thr Arg Pro Gln Asn His Thr Pro Thr Ala Ala Arg Met
1475 1480 1485
Lys Glu Pro Ala Ser Ser Ser Pro Ser Thr Ile Leu Met Ser Leu Gly
1490 1495 1500
Gln Thr Thr Thr Thr Lys Pro Ala Leu Pro Ser Pro Arg Ile Ser Gln
1505 1510 1515 1520
Ala Ser Arg Asp Ser Lys Glu Asn Val Phe Leu Asn Tyr Val Gly Asn
1525 1530 1535
Pro Glu Thr Glu Ala Thr Pro Val Asn Asn Glu Gly Thr Gln His Met
1540 1545 1550
Ser Gly Pro Asn Glu Leu Ser Thr Pro Ser Ser Asp Arg Asp Ala Phe
1555 1560 1565
Asn Leu Ser Thr Lys Leu Glu Leu Glu Lys Gln Val Phe Gly Ser Arg
1570 1575 1580
Ser Leu Pro Arg Gly Pro Asp Ser Gln Arg Gln Asp Gly Arg Val His
1585 1590 1595 1600
Ala Ser His Gln Leu Thr Arg Val Pro Ala Lys Pro Ile Leu Pro Thr
1605 1610 1615
Ala Thr Val Arg Leu Pro Glu Met Ser Thr Gln Ser Ala Ser Arg Tyr
1620 1625 1630
Phe Val Thr Ser Gln Ser Pro Arg His Trp Thr Asn Lys Pro Glu Ile
1635 1640 1645
Thr Thr Tyr Pro Ser Gly Ala Leu Pro Glu Asn Lys Gln Phe Thr Thr
1650 1655 1660
Pro Arg Leu Ser Ser Thr Thr Ile Pro Leu Pro Leu His Met Ser Lys
1665 1670 1675 1680
Pro Ser Ile Pro Ser Lys Phe Thr Asp Arg Arg Thr Asp Gln Phe Asn
1685 1690 1695
Gly Tyr Ser Lys Val Phe Gly Asn Asn Ile Pro Glu Ala Arg Asn
1700 1705 1710
Pro Val Gly Lys Pro Pro Ser Pro Arg Ile Pro His Tyr Ser Asn Gly
1715 1720 1725
Arg Leu Pro Phe Phe Thr Asn Lys Thr Leu Ser Phe Pro Gln Leu Gly
1730 1735 1740
Val Thr Arg Arg Pro Gln Ile Pro Thr Ser Pro Ala Pro Val Met Arg
1745 1750 1755 1760
Glu Arg Lys Val Ile Pro Gly Ser Tyr Asn Arg Ile His Ser His Ser
1765 1770 1775
Thr Phe His Leu Asp Phe Gly Pro Pro Ala Pro Pro Leu Leu His Thr
1780 1785 1790

SEQUENCE LISTING 1657-2022.txt

Pro Gln Thr Thr Gly Ser Pro Ser Thr Asn Leu Gln Asn Ile Pro Met
 1795 1800 1805
 Val Ser Ser Thr Gln Ser Ser Ile Ser Phe Ile Thr Ser Ser Val Gln
 1810 1815 1820
 Ser Ser Gly Ser Phe His Gln Ser Ser Ser Lys Phe Phe Ala Gly Gly
 1825 1830 1835 1840
 Pro Pro Ala Ser Lys Phe Trp Ser Leu Gly Glu Lys Pro Gln Ile Leu
 1845 1850 1855
 Thr Lys Ser Pro Gln Thr Val Ser Val Thr Ala Glu Thr Asp Thr Val
 1860 1865 1870
 Phe Pro Cys Glu Ala Thr Gly Lys Pro Lys Pro Phe Val Thr Trp Thr
 1875 1880 1885
 Lys Val Ser Thr Gly Ala Leu Met Thr Pro Asn Thr Arg Ile Gln Arg
 1890 1895 1900
 Phe Glu Val Leu Lys Asn Gly Thr Leu Val Ile Arg Lys Val Gln Val
 1905 1910 1915 1920
 Gln Asp Arg Gly Gln Tyr Met Cys Thr Ala Ser Asn Leu His Gly Leu
 1925 1930 1935
 Asp Arg Met Val Val Leu Leu Ser Val Thr Val Gln Gln Pro Gln Ile
 1940 1945 1950
 Leu Ala Ser His Tyr Gln Asp Val Thr Val Tyr Leu Gly Asp Thr Ile
 1955 1960 1965
 Ala Met Glu Cys Leu Ala Lys Gly Thr Pro Ala Pro Gln Ile Ser Trp
 1970 1975 1980
 Ile Phe Pro Asp Arg Arg Val Trp Gln Thr Val Ser Pro Val Glu Ser
 1985 1990 1995 2000
 Arg Ile Thr Leu His Glu Asn Arg Thr Leu Ser Ile Lys Glu Ala Ser
 2005 2010 2015
 Phe Ser Asp Arg Gly Val Tyr Lys Cys Val Ala Ser Asn Ala Ala Gly
 2020 2025 2030
 Ala Asp Ser Leu Ala Ile Arg Leu His Val Ala Ala Leu Pro Pro Val
 2035 2040 2045
 Ile His Gln Glu Lys Leu Glu Asn Ile Ser Leu Pro Pro Gly Leu Ser
 2050 2055 2060
 Ile His Ile His Cys Thr Ala Lys Ala Ala Pro Leu Pro Ser Val Arg
 2065 2070 2075 2080
 Trp Val Leu Gly Asp Gly Thr Gln Ile Arg Pro Ser Gln Phe Leu His
 2085 2090 2095
 Gly Asn Leu Phe Val Phe Pro Asn Gly Thr Leu Tyr Ile Arg Asn Leu
 2100 2105 2110
 Ala Pro Lys Asp Ser Gly Arg Tyr Glu Cys Val Ala Ala Asn Leu Val
 2115 2120 2125
 Gly Ser Ala Arg Arg Thr Val Gln Leu Asn Val Gln Arg Ala Ala Ala
 2130 2135 2140
 Asn Ala Arg Ile Thr Gly Thr Ser Pro Arg Arg Thr Asp Val Arg Tyr
 2145 2150 2155 2160
 Gly Gly Thr Leu Lys Leu Asp Cys Ser Ala Ser Gly Asp Pro Trp Pro
 2165 2170 2175
 Arg Ile Leu Trp Arg Leu Pro Ser Lys Arg Met Ile Asp Ala Leu Phe
 2180 2185 2190
 Ser Phe Asp Ser Arg Ile Lys Val Phe Ala Asn Gly Thr Leu Val Val
 2195 2200 2205
 Lys Ser Val Thr Asp Lys Asp Ala Gly Asp Tyr Leu Cys Val Ala Arg
 2210 2215 2220
 Asn Lys Val Gly Asp Asp Tyr Val Val Leu Lys Val Asp Val Val Met
 2225 2230 2235 2240
 Lys Pro Ala Lys Ile Glu His Lys Glu Glu Asn Asp His Lys Val Phe
 2245 2250 2255
 Tyr Gly Gly Asp Leu Lys Val Asp Cys Val Ala Thr Gly Leu Pro Asn
 2260 2265 2270
 Pro Glu Ile Ser Trp Ser Leu Pro Asp Gly Ser Leu Val Asn Ser Phe
 2275 2280 2285
 Met Gln Ser Asp Asp Ser Gly Gly Arg Thr Lys Arg Tyr Val Val Phe
 2290 2295 2300
 Asn Asn Gly Thr Leu Tyr Phe Asn Glu Val Gly Met Arg Glu Glu Gly
 2305 2310 2315 2320
 Asp Tyr Thr Cys Phe Ala Glu Asn Gln Val Gly Lys Asp Glu Met Arg

SEQUENCE LISTING 1657-2022.txt

2325
 Val Arg Val Lys Val Val Thr Ala Pro Ala Thr Ile Arg Asn Lys Thr
 2330 2335
 Tyr Leu Ala Val Gln Val Pro Tyr Gly Asp Val Val Thr Val Ala Cys
 2340 2345 2350
 Glu Ala Lys Gly Glu Pro Met Pro Lys Val Thr Trp Leu Ser Pro Thr
 2355 2360 2365
 Asn Lys Val Ile Pro Thr Ser Ser Glu Lys Tyr Gln Ile Tyr Gln Asp
 2370 2375 2380
 Gly Thr Leu Leu Ile Gln Lys Ala Gln Arg Ser Asp Ser Gly Asn Tyr
 2385 2390 2400
 Thr Cys Leu Val Arg Asn Ser Ala Gly Glu Asp Arg Lys Thr Val Trp
 2405 2410 2415
 Ile His Val Asn Val Gln Pro Pro Lys Ile Asn Gly Asn Pro Asn Pro
 2420 2425 2430
 Ile Thr Thr Val Arg Glu Ile Ala Ala Gly Gly Ser Arg Lys Leu Ile
 2435 2440 2445
 Asp Cys Lys Ala Glu Gly Ile Pro Thr Pro Arg Val Leu Trp Ala Phe
 2450 2455 2460
 Pro Glu Gly Val Val Leu Pro Ala Pro Tyr Tyr Gly Asn Arg Ile Thr
 2465 2470 2475
 Val His Gly Asn Gly Ser Leu Asp Ile Arg Ser Leu Arg Lys Ser Asp
 2480 2485 2490
 Ser Val Gln Leu Val Cys Met Ala Arg Asn Glu Gly Gly Glu Ala Arg
 2495 2500
 Leu Ile Val Gln Leu Thr Val Leu Glu Pro Met Glu Lys Pro Ile Phe
 2505 2510
 His Asp Pro Ile Ser Glu Lys Ile Thr Ala Met Ala Gly His Thr Ile
 2515 2520
 Ser Leu Asn Cys Ser Ala Ala Gly Thr Pro Thr Pro Ser Leu Val Trp
 2525 2530
 Val Leu Pro Asn Gly Thr Asp Leu Gln Ser Gly Gln Gln Leu Gln Arg
 2535 2540
 Phe Tyr His Lys Ala Asp Gly Met Leu His Ile Ser Gly Leu Ser Ser
 2545 2550
 Val Asp Ala Gly Ala Tyr Arg Cys Val Ala Arg Asn Ala Ala Gly His
 2555 2560
 Thr Glu Arg Leu Val Ser Leu Lys Val Gly Leu Lys Pro Glu Ala Asn
 2565 2570
 Lys Gln Tyr His Asn Leu Val Ser Ile Ile Asn Gly Glu Thr Leu Lys
 2575 2580
 Leu Pro Cys Thr Pro Pro Gly Ala Gly Gln Gly Arg Phe Ser Trp Thr
 2585 2590
 Leu Pro Asn Gly Met His Leu Glu Gly Pro Gln Thr Leu Gly Arg Val
 2595 2600
 Ser Leu Leu Asp Asn Gly Thr Leu Thr Val Arg Glu Ala Ser Val Phe
 2605 2610
 Asp Arg Gly Thr Tyr Val Cys Arg Met Glu Thr Glu Tyr Gly Pro Ser
 2615 2620
 Val Thr Ser Ile Pro Val Ile Val Ile Ala Tyr Pro Pro Arg Ile Thr
 2625 2630
 Ser Glu Pro Thr Pro Val Ile Tyr Thr Arg Pro Gly Asn Thr Val Lys
 2635 2640
 Leu Asn Cys Met Ala Met Gly Ile Pro Lys Ala Asp Ile Thr Trp Glu
 2645 2650
 Leu Pro Asp Lys Ser His Leu Lys Ala Gly Val Gln Ala Arg Leu Tyr
 2655 2660
 Gly Asn Arg Phe Leu His Pro Gln Gly Ser Leu Thr Ile Gln His Ala
 2665 2670
 Thr Gln Arg Asp Ala Gly Phe Tyr Lys Cys Met Ala Lys Asn Ile Leu
 2675 2680
 Gly Ser Asp Ser Lys Thr Thr Tyr Ile His Val Phe
 2685 2690
 2700 2705
 2710 2715
 2720 2725
 2730 2735
 2740 2745
 2750 2755
 2760 2765
 2770 2775
 2780 2785
 2790 2795
 2800 2805
 2810 2815
 2820 2825

<210> 125
 <211> 1464

SEQUENCE LISTING 1657-2022.txt

<212> PRT

<213> Homo sapiens

<400> 125

```

Met Phe Ser Phe Val Asp Leu Arg Leu Leu Leu Leu Ala Ala Thr
1   5   10   15
Ala Leu Leu Thr His Gly Gln Glu Gly Gln Val Glu Gly Gln Asp
20  25  30  35  40  45
Glu Asp Ile Pro Pro Ile Thr Cys Val Gln Asn Gly Leu Arg Tyr His
50  55  60  65  70  75  80
Asp Arg Asp Val Trp Lys Pro Glu Pro Cys Arg Ile Cys Val Cys Asp
85  90  95
Asn Gly Lys Val Leu Cys Asp Asp Val Ile Cys Asp Glu Thr Lys Asn
100 105 110 115
Cys Pro Gly Ala Glu Val Pro Glu Gly Glu Cys Cys Pro Val Cys Pro
120 125 130 135 140 145
Asp Gly Ser Glu Ser Pro Thr Asp Gln Glu Thr Thr Gly Val Glu Gly
150 155 160 165 170 175
Pro Lys Gly Asp Thr Gly Pro Arg Gly Pro Arg Gly Pro Ala Gly Pro
180 185 190 195 200 205
Pro Gly Arg Asp Gly Ile Pro Gly Gln Pro Gly Leu Gly Gly Asn Phe Ala
210 215 220 225 230 235 240
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Ile Ser
245 250 255 260 265 270 275
Pro Gln Leu Ser Tyr Met Gly Pro Ser Gly Pro Arg Gly Leu Pro Gly Pro
180 185 190 195 200 205
Val Pro Gly Pro Gly Pro Gln Gly Phe Gln Gly Pro Pro Gly Glu Pro
210 215 220 225 230 235 240
Pro Gly Ala Pro Gly Ala Ser Gly Pro Met Gly Pro Arg Gly Pro Pro Gly
245 250 255 260 265 270 275
Pro Pro Gly Lys Asn Gly Asp Asp Gly Glu Ala Gly Lys Pro Gly Arg
280 285 290 295 300 305 310
Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro
315 320 325 330 335 340 345
Gly Thr Ala Gly Leu Pro Gly Met Lys Gly His Arg Gly Phe Ser Gly
350 355 360 365 370 375 380
Leu Asp Gly Ala Lys Gly Asp Ala Gly Pro Ala Gly Pro Lys Gly Glu
385 390 395 400 405 410 415
Pro Gly Ser Pro Gly Glu Asn Gly Ala Pro Gly Gln Pro Gly Ala Asn
420 425 430 435 440 445 450
Gly Leu Pro Gly Glu Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly
455 460 465 470 475 480 485
Ala Arg Gly Asn Asp Gly Ala Thr Gly Ala Gly Pro Pro Gly Pro Gly
490 495 500 505 510 515 520
Thr Gly Pro Ala Gly Pro Pro Gly Phe Pro Gly Ala Val Gly Ala Lys
525 530 535 540 545 550 555
Gly Glu Ala Gly Pro Gln Gly Pro Arg Gly Ser Glu Gly Pro Gln Gly
560 565 570 575 580 585 590
Val Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Ala Ala Gly Pro
595 600 605 610 615 620 625
Ala Gly Asn Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Ala Asn
630 635 640 645 650 655 660
Gly Ala Pro Gly Ile Ala Gly Ala Pro Gly Phe Pro Gly Ala Arg Gly
665 670 675 680 685 690 695
Pro Ser Gly Pro Gln Gly Pro Gly Gly Pro Pro Gly Pro Lys Gly Asn
700 705 710 715 720 725 730
Ser Gly Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys
735 740 745 750 755 760 765
Gly Glu Pro Gly Pro Val Gly Val Gln Gly Pro Pro Gly Pro Ala Gly
770 775 780 785 790 795 800
Glu Glu Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Leu
805 810 815 820 825 830 835
Pro Gly Pro Pro Gly Glu Arg Gly Gly Pro Gly Ser Arg Gly Phe Pro
840 845 850 855 860 865 870
Gly Ala Asp Gly Val Ala Gly Pro Lys Gly Pro Ala Gly Glu Arg Gly

```

SEQUENCE LISTING 1657-2022.txt

500
 Ser Pro Gly Pro Ala Gly Pro Lys Gly Ser Pro Gly Glu Ala Gly Arg
 515
 Pro Gly Glu Ala Gly Leu Pro Gly Ala Lys Gly Leu Thr Gly Ser Pro
 530
 Gly Ser Pro Gly Pro Asp Gly Lys Thr Gly Pro Pro Gly Pro Ala Gly
 545
 Gln Asp Gly Arg Pro Gly Pro Pro Gly Pro Pro Gly Ala Arg Gly Gln
 560
 Ala Gly Val Met Gly Phe Pro Gly Pro Lys Gly Ala Ala Gly Glu Pro
 575
 Gly Lys Ala Gly Glu Arg Gly Val Pro Gly Pro Pro Gly Ala Val Gly
 590
 Pro Ala Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Pro Gly Pro
 605
 Ala Gly Pro Ala Gly Glu Arg Gly Glu Gln Gly Pro Ala Gly Ser Pro
 620
 Gly Phe Gln Gly Leu Pro Gly Pro Ala Gly Pro Pro Gly Glu Ala Gly
 635
 Lys Pro Gly Glu Gln Gly Val Pro Gly Asp Leu Gly Ala Pro Gly Pro
 650
 Ser Gly Ala Arg Gly Glu Arg Gly Phe Pro Gly Glu Arg Gly Val Gln
 665
 Gly Pro Pro Gly Pro Ala Gly Pro Arg Gly Ala Asn Gly Ala Pro Gly
 680
 Asn Asp Gly Ala Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly Ser
 695
 Gln Gly Ala Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Ala Ala
 710
 Gly Leu Pro Gly Pro Lys Gly Asp Arg Gly Asp Ala Gly Pro Lys Gly
 725
 Ala Asp Gly Ser Pro Gly Lys Asp Gly Val Arg Gly Leu Thr Gly Pro
 740
 Ile Gly Pro Pro Gly Pro Ala Gly Pro Thr Gly Ala Arg Gly Ala Pro Gly
 755
 Gly Pro Ser Gly Pro Ala Gly Pro Thr Gly Ala Arg Gly Ala Pro Gly
 770
 Asp Arg Gly Glu Pro Gly Pro Pro Gly Pro Ala Gly Phe Ala Gly Pro
 785
 Pro Gly Ala Asp Gly Gln Pro Gly Ala Lys Gly Glu Pro Gly Asp Ala
 800
 Gly Ala Lys Gly Asp Ala Gly Pro Pro Gly Pro Ala Gly Pro Ala Gly
 815
 Pro Pro Gly Pro Ile Gly Asn Val Gly Ala Pro Gly Ala Lys Gly Ala
 830
 Arg Gly Ser Ala Gly Pro Pro Gly Ala Thr Gly Phe Pro Gly Ala Ala
 845
 Gly Arg Val Gly Pro Pro Gly Pro Ser Gly Asn Ala Gly Pro Pro Gly
 860
 Pro Pro Gly Pro Ala Gly Lys Glu Gly Gly Lys Gly Pro Arg Gly Glu
 875
 Thr Gly Pro Ala Gly Arg Pro Gly Glu Val Gly Pro Pro Gly Pro Pro
 890
 Gly Pro Ala Gly Glu Lys Gly Ser Pro Gly Ala Asp Gly Pro Ala Gly
 905
 Ala Pro Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly Gln Arg Gly Val
 920
 Val Gly Leu Pro Gly Gln Arg Gly Glu Arg Gly Phe Pro Gly Leu Pro
 935
 Gly Pro Ser Gly Glu Pro Gly Lys Gln Gly Pro Ser Gly Ala Ser Gly
 950
 Glu Arg Gly Pro Pro Gly Pro Met Gly Pro Pro Gly Leu Ala Gly Pro
 965
 Pro Gly Glu Ser Gly Arg Glu Gly Ala Pro Ala Ala Glu Gly Ser Pro
 980
 Gly Arg Asp Gly Ser Pro Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly
 995
 1000
 1010
 1015
 1020
 1025
 1030
 1035
 1040

SEQUENCE LISTING 1657-2022.txt

Pro Ala Gly Pro Pro Gly Ala Pro Gly Ala Pro Gly Pro
 1045 1050 1055
 Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Thr Gly Pro Ala
 1060 1065 1070
 Gly Pro Ala Gly Pro Val Gly Pro Val Gly Ala Arg Gly Pro Ala Gly
 1075 1080 1085
 Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Gln Gly Asp
 1090 1095 1100
 Arg Gly Ile Lys Gly His Arg Gly Phe Ser Gly Leu Gln Gly Pro Pro
 1105 1110 1115 1120
 Gly Pro Pro Gly Ser Pro Gly Glu Gln Gly Pro Ser Gly Ala Ser Gly
 1125 1130 1135
 Pro Ala Gly Pro Arg Gly Pro Pro Gly Ser Ala Gly Ala Pro Gly Lys
 1140 1145 1150
 Asp Gly Leu Asn Gly Leu Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg
 1155 1160 1165
 Gly Arg Thr Gly Asp Ala Gly Pro Val Gly Pro Pro Gly Pro Pro Gly
 1170 1175 1180
 Pro Pro Gly Pro Pro Gly Pro Pro Ser Ala Gly Phe Asp Phe Ser Phe
 1185 1190 1195 1200
 Leu Pro Gln Pro Pro Gln Glu Lys Ala His Asp Gly Gly Arg Tyr Tyr
 1205 1210 1215
 Arg Ala Asp Asp Ala Asn Val Val Arg Asp Arg Asp Leu Glu Val Asp
 1220 1225 1230
 Thr Thr Leu Lys Ser Leu Ser Gln Ile Glu Asn Ile Arg Ser Pro
 1235 1240 1245
 Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Lys Met
 1250 1255 1260
 Cys His Ser Asp Trp Lys Ser Gly Glu Tyr Trp Ile Asp Pro Asn Gln
 1265 1270 1275 1280
 Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys Asn Met Glu Thr Gly
 1285 1290 1295
 Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val Ala Gln Lys Asn Trp
 1300 1305 1310
 Tyr Ile Ser Lys Asn Pro Lys Asp Lys Arg His Val Trp Phe Gly Glu
 1315 1320 1325
 Ser Met Thr Asp Gly Phe Gln Phe Glu Tyr Gly Gly Gln Gly Ser Asp
 1330 1335 1340
 Pro Ala Asp Val Ala Ile Gln Leu Thr Phe Leu Arg Leu Met Ser Thr
 1345 1350 1355 1360
 Glu Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Val Ala Tyr
 1365 1370 1375
 Met Asp Gln Gln Thr Gly Asn Leu Lys Lys Ala Leu Leu Leu Lys Gly
 1380 1385 1390
 Ser Asn Glu Ile Glu Ile Arg Ala Glu Gly Asn Ser Arg Phe Thr Tyr
 1395 1400 1405
 Ser Val Thr Val Asp Gly Cys Thr Ser His Thr Gly Ala Trp Gly Lys
 1410 1415 1420
 Thr Val Ile Glu Tyr Lys Thr Thr Lys Ser Ser Arg Leu Pro Ile Ile
 1425 1430 1435 1440
 Asp Val Ala Pro Leu Asp Val Gly Ala Pro Asp Gln Glu Phe Gly Phe
 1445 1450 1455
 Asp Val Gly Pro Val Cys Phe Leu -
 1460

<210> 126
 <211> 308
 <212> PRT
 <213> Homo sapiens

<400> 126
 Met Pro Gly Gln Glu Leu Arg Thr Val Asn Gly Ser Gln Met Leu Leu
 1 5 10 15
 Val Leu Leu Val Leu Ser Trp Leu Pro His Gly Gly Ala Leu Ser Leu
 20 25 30
 Ala Glu Ala Ser Arg Ala Ser Phe Pro Gly Pro Ser Glu Leu His Ser

SEQUENCE LISTING 1657-2022.txt

```

      35      40      45
Glu Asp Ser Arg Phe Arg Glu Leu Arg Lys Arg Tyr Glu Asp Leu Leu
 50      55      60
Thr Arg Leu Arg Ala Asn Gln Ser Trp Glu Asp Ser Asn Thr Asp Leu
 65      70      75      80
Val Pro Ala Pro Ala Val Arg Ile Leu Thr Pro Glu Val Arg Leu Gly
      85      90      95
Ser Gly Gly His Leu His Leu Arg Ile Ser Arg Ala Ala Leu Pro Glu
 100      105      110
Gly Leu Pro Glu Ala Ser Arg Leu His Arg Ala Leu Phe Arg Leu Ser
 115      120      125
Pro Thr Ala Ser Arg Ser Trp Asp Val Thr Arg Pro Leu Arg Arg Gln
 130      135      140
Leu Ser Leu Ala Arg Pro Gln Ala Pro Ala Leu His Leu Arg Leu Ser
 145      150      155      160
Pro Pro Pro Ser Gln Ser Asp Gln Leu Leu Ala Glu Ser Ser Ser Ala
      165      170      175
Arg Pro Gln Leu Glu Leu His Leu Arg Pro Gln Ala Ala Arg Gly Arg
 180      185      190
Arg Arg Ala Arg Ala Arg Asn Gly Asp Asp Cys Pro Leu Gly Pro Gly
 195      200      205
Arg Cys Cys Arg Leu His Thr Val Arg Ala Ser Leu Glu Asp Leu Gly
 210      215      220
Trp Ala Asp Trp Val Leu Ser Pro Arg Glu Val Gln Val Thr Met Cys
 225      230      235      240
Ile Gly Ala Cys Pro Ser Gln Phe Arg Ala Ala Asn Met His Ala Gln
      245      250      255
Ile Lys Thr Ser Leu His Arg Leu Lys Pro Asp Thr Glu Pro Ala Pro
 260      265      270
Cys Cys Val Pro Ala Ser Tyr Asn Pro Met Val Leu Ile Gln Lys Thr
 275      280      285
Asp Thr Gly Val Ser Leu Gln Thr Tyr Asp Asp Leu Leu Ala Lys Asp
 290      295      300
Cys His Cys Ile
305

```

<210> 127
 <211> 359
 <212> PRT
 <213> Homo sapiens

```

<400> 127
Met Pro Ala His Leu Leu Gln Asp Asp Ile Ser Ser Ser Tyr Thr Thr
 1      5      10      15
Thr Thr Thr Ile Thr Ala Pro Pro Ser Arg Val Leu Gln Asn Gly Gly
 20      25      30
Asp Lys Leu Glu Thr Met Pro Leu Tyr Leu Glu Asp Asp Ile Arg Pro
 35      40      45
Asp Ile Lys Asp Asp Ile Tyr Asp Pro Thr Tyr Lys Asp Lys Glu Gly
 50      55      60
Pro Ser Pro Lys Val Glu Tyr Val Trp Arg Asn Ile Ile Leu Met Ser
 65      70      75      80
Leu Leu His Leu Gly Ala Leu Tyr Gly Ile Thr Leu Ile Pro Thr Cys
      85      90      95
Lys Phe Tyr Thr Trp Leu Trp Gly Val Phe Tyr Tyr Phe Val Ser Ala
 100      105      110
Leu Gly Ile Thr Ala Gly Ala His Arg Leu Trp Ser His Arg Ser Tyr
 115      120      125
Lys Ala Arg Leu Pro Leu Arg Leu Phe Leu Ile Ile Ala Asn Thr Met
 130      135      140
Ala Phe Gln Asn Asp Val Tyr Glu Trp Ala Arg Asp His Arg Ala His
 145      150      155      160
His Lys Phe Ser Glu Thr His Ala Asp Pro His Asn Ser Arg Arg Gly
      165      170      175
Phe Phe Phe Ser His Val Gly Trp Leu Leu Val Arg Lys His Pro Ala
 180      185      190

```


SEQUENCE LISTING 1657-2022.txt

Val Lys Glu Lys Gly Ser Thr Leu Asp Leu Ser Asp Leu Glu Ala Glu
 195 200 205
 Lys Leu Val Met Phe Gln Arg Arg Tyr Tyr Lys Pro Gly Leu Leu Leu
 210 215 220
 Met Cys Phe Ile Leu Pro Thr Leu Val Pro Trp Tyr Phe Trp Gly Glu
 225 230 235 240
 Thr Phe Gln Asn Ser Val Phe Val Ala Thr Phe Leu Arg Tyr Ala Val
 245 250 255
 Val Leu Asn Ala Thr Trp Leu Val Asn Ser Ala Ala His Leu Phe Gly
 260 265 270
 Tyr Arg Pro Tyr Asp Lys Asn Ile Ser Pro Arg Glu Asn Ile Leu Val
 275 280 285
 Ser Leu Gly Ala Val Gly Glu Gly Phe His Asn Tyr His His Ser Phe
 290 295 300
 Pro Tyr Asp Tyr Ser Ala Ser Glu Tyr Arg Trp His Ile Asn Phe Thr
 305 310 315 320
 Thr Phe Phe Ile Asp Cys Met Ala Ala Leu Gly Leu Ala Tyr Asp Arg
 325 330 335
 Lys Lys Val Ser Lys Ala Ala Ile Leu Ala Arg Ile Lys Arg Thr Gly
 340 345 350
 Asp Gly Asn Tyr Lys Ser Gly
 355

<210> 128
 <211> 96
 <212> PRT
 <213> Homo sapiens

<400> 128
 Met Cys Cys Thr Lys Ser Leu Leu Leu Ala Ala Leu Met Ser Val Leu
 1 5 10 15
 Leu Leu His Leu Cys Gly Glu Ser Glu Ala Ala Ser Asn Phe Asp Cys
 20 25 30
 Cys Leu Gly Tyr Thr Asp Arg Ile Leu His Pro Lys Phe Ile Val Gly
 35 40 45
 Phe Thr Arg Gln Leu Ala Asn Glu Gly Cys Asp Ile Asn Ala Ile Ile
 50 55 60
 Phe His Thr Lys Lys Lys Leu Ser Val Cys Ala Asn Pro Lys Gln Thr
 65 70 75 80
 Trp Val Lys Tyr Ile Val Arg Leu Leu Ser Lys Lys Val Lys Asn Met
 85 90 95

<210> 129
 <211> 518
 <212> PRT
 <213> Homo sapiens

<400> 129
 Met Gly Ala Leu Ala Arg Ala Leu Leu Leu Pro Leu Leu Ala Gln Trp
 1 5 10 15
 Leu Leu Arg Ala Ala Pro Glu Leu Ala Pro Ala Pro Phe Thr Leu Pro
 20 25 30
 Leu Arg Val Ala Ala Ala Thr Asn Arg Val Val Ala Pro Thr Pro Gly
 35 40 45
 Pro Gly Thr Pro Ala Glu Arg His Ala Asp Gly Leu Ala Leu
 50 55 60
 Glu Pro Ala Leu Ala Ser Pro Ala Gly Ala Ala Asn Phe Leu Ala Met
 65 70 75 80
 Val Asp Asn Leu Gln Gly Asp Ser Gly Arg Gly Tyr Tyr Leu Glu Met
 85 90 95
 Leu Ile Gly Thr Pro Pro Gln Lys Leu Gln Ile Leu Val Asp Thr Gly
 100 105 110
 Ser Ser Asn Phe Ala Val Ala Gly Thr Pro His Ser Tyr Ile Asp Thr
 115 120 125
 Tyr Phe Asp Thr Glu Arg Ser Ser Thr Tyr Arg Ser Lys Gly Phe Asp

SEQUENCE LISTING 1657-2022.txt

```

130      135      140
Val Thr Val Lys Tyr Thr Gln Gly Ser Trp Thr Gly Phe Val Gly Glu
145      150      155
Asp Leu Val Thr Ile Pro Lys Gly Phe Asn Thr Ser Phe Leu Val Asn
165
Ile Ala Thr Ile Phe Glu Ser Glu Asn Phe Phe Leu Pro Gly Ile Lys
180      185
Trp Asn Gly Ile Leu Gly Leu Ala Tyr Ala Thr Leu Ala Lys Pro Ser
195      200
Ser Ser Leu Glu Thr Phe Phe Asp Ser Leu Val Thr Gln Ala Asn Ile
210      215      220
Pro Asn Val Phe Ser Met Gln Met Cys Gly Ala Gly Leu Pro Val Ala
225      230      235
Gly Ser Gly Thr Asn Gly Gly Ser Leu Val Leu Gly Gly Ile Glu Pro
245      250      255
Ser Leu Tyr Lys Gly Asp Ile Trp Tyr Thr Pro Ile Lys Glu Glu Trp
260      265      270
Tyr Tyr Gln Ile Glu Ile Leu Lys Leu Glu Ile Gly Gly Gln Ser Leu
275      280      285
Asn Leu Asp Cys Arg Glu Tyr Asn Ala Asp Lys Ala Ile Val Asp Ser
290      295      300
Gly Thr Thr Leu Leu Arg Leu Pro Gln Lys Val Phe Asp Ala Val Val
305      310      315
Glu Ala Val Ala Arg Ala Ser Leu Ile Pro Glu Phe Ser Asp Gly Phe
325      330      335
Trp Thr Gly Ser Gln Leu Ala Cys Trp Thr Asn Ser Glu Thr Pro Trp
340      345      350
Ser Tyr Phe Pro Lys Ile Ser Ile Tyr Leu Arg Asp Glu Asn Ser Ser
355      360      365
Arg Ser Phe Arg Ile Thr Ile Leu Pro Gln Leu Tyr Ile Gln Pro Met
370      375      380
Met Gly Ala Gly Leu Asn Tyr Glu Cys Tyr Arg Phe Gly Ile Ser Pro
385      390      395
Ser Thr Asn Ala Leu Val Ile Gly Ala Thr Val Met Glu Gly Phe Tyr
405      410      415
Val Ile Phe Asp Arg Ala Gln Lys Arg Val Gly Phe Ala Ala Ser Pro
420      425      430
Cys Ala Glu Ile Ala Gly Ala Ala Val Ser Glu Ile Ser Gly Pro Phe
435      440      445
Ser Thr Glu Asp Val Ala Ser Asn Cys Val Pro Ala Gln Ser Leu Ser
450      455      460
Glu Pro Ile Leu Trp Ile Val Ser Tyr Ala Leu Met Ser Val Cys Gly
465      470      475
Ala Ile Leu Leu Val Leu Ile Val Leu Leu Leu Pro Phe Arg Cys
485      490      495
Gln Arg Arg Pro Arg Asp Pro Glu Val Val Asn Asp Glu Ser Ser Leu
500      505      510
Val Arg His Arg Trp Lys
515

```

```

<210> 130
<211> 423
<212> PRT
<213> Homo sapiens

```

```

<400> 130
Met Arg Ser Ser Gly Ala Asp Ala Gly Arg Cys Leu Val Thr Ala Arg
1      5      10      15
Ala Pro Gly Ser Val Pro Ala Ser Arg Glu Gly Ser Ala Gly Ser Arg
20      25      30
Gly Pro Gly Ala Arg Phe Pro Ala Arg Val Ser Ala Arg Gly Ser Ala
35      40      45
Pro Gly Pro Gly Leu Gly Gly Ala Gly Ala Leu Asp Pro Pro Ala Val
50      55      60
Val Ala Glu Ser Val Ser Ser Leu Thr Ile Ala Asp Ala Phe Ile Ala
65      70      75      80

```

SEQUENCE LISTING 1657-2022.txt

Ala Gly Glu Ser Ser Ala Pro Thr Pro Arg Pro Ala Leu Pro Arg
 85 90 95
 Arg Phe Ile Cys Ser Phe Pro Asp Cys Ser Ala Asn Tyr Ser Lys Ala
 100 105 110
 Trp Lys Leu Asp Ala His Leu Cys Lys His Thr Gly Glu Arg Pro Phe
 115 120 125
 Val Cys Asp Tyr Glu Gly Cys Gly Lys Ala Phe Ile Arg Asp Tyr His
 130 135 140
 Leu Ser Arg His Ile Leu Thr His Thr Gly Glu Lys Pro Phe Val Cys
 145 150 155 160
 Ala Ala Asn Gly Cys Asp Gln Lys Phe Asn Thr Lys Ser Asn Leu Lys
 165 170 175
 Lys His Phe Glu Arg Lys His Glu Asn Gln Gln Lys Gln Tyr Ile Cys
 180 185 190
 Ser Phe Glu Asp Cys Lys Lys Thr Phe Lys Lys His Gln Gln Leu Lys
 195 200 205
 Ile His Gln Cys Gln Asn Thr Asn Glu Pro Leu Phe Lys Cys Thr Gln
 210 215 220
 Glu Gly Cys Gly Lys His Phe Ala Ser Pro Ser Lys Leu Lys Arg His
 225 230 235 240
 Ala Lys Ala His Glu Gly Tyr Val Cys Gln Lys Gly Cys Ser Phe Val
 245 250 255
 Ala Lys Thr Trp Thr Glu Leu Leu Lys His Val Arg Glu Thr His Lys
 260 265 270
 Glu Glu Ile Leu Cys Glu Val Cys Arg Lys Thr Phe Lys Arg Lys Asp
 275 280 285
 Tyr Leu Lys Gln His Met Lys Thr His Ala Pro Glu Arg Asp Val Cys
 290 295 300
 Arg Cys Pro Arg Glu Gly Cys Gly Arg Thr Tyr Thr Thr Val Phe Asn
 305 310 315 320
 Leu Gln Ser His Ile Leu Ser Phe His Glu Glu Ser Arg Pro Phe Val
 325 330 335
 Cys Glu His Ala Gly Cys Gly Lys Thr Phe Ala Met Lys Gln Ser Leu
 340 345 350
 Thr Arg His Ala Val Val His Asp Pro Asp Lys Lys Lys Met Lys Leu
 355 360 365
 Lys Val Lys Lys Ser Arg Glu Lys Arg Glu Phe Gly Leu Ser Ser Gln
 370 375 380
 Trp Ile Tyr Pro Pro Lys Arg Lys Gln Gly Gln Gly Leu Ser Leu Cys
 385 390 395 400
 Gln Asn Gly Glu Ser Pro Asn Cys Val Glu Asp Lys Met Leu Ser Thr
 405 410 415
 Val Ala Val Leu Thr Leu Gly
 420

<210> 131
 <211> 677
 <212> PRT
 <213> Homo sapiens

<400> 131
 Met Leu Ser Ser Thr Asp Phe Thr Phe Ala Ser Trp Glu Leu Val Val
 1 5 10 15
 Arg Val Asp His Pro Asn Glu Glu Gln Gln Lys Asp Val Thr Leu Arg
 20 25 30
 Val Ser Gly Asp Leu His Val Gly Gly Val Met Leu Lys Leu Val Glu
 35 40 45
 Gln Ile Asn Ile Ser Gln Asp Trp Ser Asp Phe Ala Leu Trp Trp Glu
 50 55 60
 Gln Lys His Cys Trp Leu Lys Thr His Trp Thr Leu Asp Lys Tyr
 65 70 75 80
 Gly Val Gln Ala Asp Ala Lys Leu Leu Phe Thr Pro Gln His Lys Met
 85 90 95
 Leu Arg Leu Arg Leu Pro Asn Leu Lys Met Val Arg Leu Arg Val Ser
 100 105 110
 Phe Ser Ala Val Val Phe Lys Ala Val Ser Asp Ile Cys Lys Ile Leu

SEQUENCE LISTING 1657-2022.txt

```

115      120      125
Asn Ile Arg Arg Ser Glu Glu Leu Ser Leu Leu Lys Pro Ser Gly Asp
130      135      140
Tyr Phe Lys Lys Lys Lys Lys Asp Lys Asn Asn Lys Glu Pro Ile
145      150      155
Ile Glu Asp Ile Leu Asn Leu Glu Ser Ser Pro Thr Ala Ser Gly Ser
165      170      175
Ser Val Ser Pro Gly Leu Tyr Ser Lys Thr Met Thr Pro Ile Tyr Asp
180      185      190
Pro Ile Asn Gly Thr Pro Ala Ser Ser Thr Met Thr Trp Phe Ser Asp
195      200      205
Ser Pro Leu Thr Glu Gln Asn Cys Ser Ile Leu Ala Phe Ser Gln Pro
210      215      220
Pro Gln Ser Pro Glu Ala Leu Ala Asp Met Tyr Gln Pro Arg Ser Leu
225      230      235
Val Asp Lys Ala Lys Leu Asn Ala Gly Trp Leu Asp Ser Ser Arg Ser
245      250      255
Leu Met Glu Gln Gly Ile Gln Glu Asp Glu Gln Leu Leu Leu Arg Phe
260      265      270
Lys Tyr Tyr Ser Phe Phe Asp Leu Asn Pro Lys Tyr Asp Ala Val Arg
275      280      285
Ile Asn Gln Leu Tyr Glu Gln Ala Arg Trp Ala Ile Leu Leu Glu Glu
290      295      300
Ile Asp Cys Thr Glu Glu Glu Met Leu Ile Phe Ala Ala Leu Gln Tyr
305      310      315
His Ile Ser Lys Leu Ser Leu Ser Ala Glu Thr Gln Asp Phe Ala Gly
325      330      335
Glu Ser Glu Val Asp Glu Ile Glu Ala Leu Ser Asn Leu Glu Val
340      345      350
Thr Leu Glu Gly Gly Lys Ala Asp Ser Leu Leu Glu Asp Ile Thr Asp
355      360      365
Ile Pro Lys Leu Ala Asp Asn Leu Lys Leu Phe Arg Pro Lys Lys Leu
370      375      380
Leu Pro Lys Ala Phe Lys Gln Tyr Trp Phe Ile Phe Lys Asp Thr Ser
385      390      395
Ile Ala Tyr Phe Lys Asn Lys Glu Leu Glu Gln Gly Glu Pro Leu Glu
400      405      410
Lys Leu Asn Leu Arg Gly Cys Glu Val Val Pro Asp Val Asn Val Ala
415      420      425
Gly Arg Lys Phe Gly Ile Lys Leu Leu Ile Pro Val Ala Asp Gly Met
430      435      440
Asn Glu Met Tyr Leu Arg Cys Asp His Glu Asn Gln Tyr Ala Gln Trp
445      450      455
Met Ala Ala Cys Met Leu Ala Ser Lys Gly Lys Thr Met Ala Asp Ser
460      465      470
Ser Tyr Gln Pro Glu Val Leu Asn Ile Leu Ser Phe Leu Arg Met Lys
475      480      485
Asn Arg Asn Ser Ala Ser Gln Val Ala Ser Ser Leu Glu Asn Met Asp
490      495      500
Met Asn Pro Glu Cys Phe Val Ser Pro Arg Cys Ala Lys Lys His Lys
505      510      515
Ser Lys Gln Leu Ala Ala Arg Ile Leu Glu Ala His Gln Asn Val Ala
520      525      530
Gln Met Pro Leu Val Glu Ala Lys Leu Arg Phe Ile Gln Ala Trp Gln
535      540      545
Ser Leu Pro Glu Phe Gly Leu Thr Tyr Tyr Leu Val Arg Phe Lys Gly
550      555      560
Ser Lys Lys Asp Ile Leu Gly Val Ser Tyr Asn Arg Leu Ile Lys
565      570      575
Ile Asp Ala Ala Thr Gly Ile Pro Val Thr Thr Trp Arg Phe Thr Asn
580      585      590
Ile Lys Gln Trp Asn Val Asn Trp Glu Thr Arg Gln Val Val Ile Glu
595      600      605
Phe Asp Gln Asn Val Phe Thr Ala Phe Thr Cys Leu Ser Ala Asp Cys
610      615      620
Lys Ile Val His Glu Tyr Ile Gly Gly Tyr Ile Phe Leu Ser Thr Arg
625      630      635
645      650      655

```

SEQUENCE LISTING 1657-2022.txt

Ser Lys Asp Gln Asn Glu Thr Leu Asp Glu Asp Leu Phe His Lys Leu
 660 665 670
 Thr Gly Gly Gln Asp
 675

<210> 132
 <211> 836
 <212> PRT
 <213> Homo sapiens

<400> 132
 Met Ile Pro Phe Leu Pro Met Phe Ser Leu Leu Leu Leu Leu Ile Val
 1 5 10 15
 Asn Pro Ile Asn Ala Asn Asn His Tyr Asp Lys Ile Leu Ala His Ser
 20 25 30
 Arg Ile Arg Gly Arg Asp Gln Gly Pro Asn Val Cys Ala Leu Gln Gln
 35 40 45
 Ile Leu Gly Thr Lys Lys Lys Tyr Phe Ser Thr Cys Lys Asn Trp Tyr
 50 55 60
 Lys Lys Ser Ile Cys Gly Gln Lys Thr Thr Val Leu Tyr Glu Cys Cys
 65 70 75 80
 Pro Gly Tyr Met Arg Met Glu Gly Met Lys Gly Cys Pro Ala Val Leu
 85 90 95
 Pro Ile Asp His Val Tyr Gly Thr Leu Gly Ile Val Gly Ala Thr Thr
 100 105 110
 Thr Gln Arg Tyr Ser Asp Ala Ser Lys Leu Arg Glu Glu Ile Glu Gly
 115 120 125
 Lys Gly Ser Phe Thr Tyr Phe Ala Pro Ser Asn Glu Ala Trp Asp Asn
 130 135 140
 Leu Asp Ser Asp Ile Arg Arg Gly Leu Glu Ser Asn Val Asn Val Glu
 145 150 155 160
 Leu Leu Asn Ala Leu His Ser His Met Ile Asn Lys Arg Met Leu Thr
 165 170 175
 Lys Asp Leu Lys Asn Gly Met Ile Ile Pro Ser Met Tyr Asn Asn Leu
 180 185 190
 Gly Leu Phe Ile Asn His Tyr Pro Asn Gly Val Val Thr Val Asn Cys
 195 200 205
 Ala Arg Ile Ile His Gly Asn Gln Ile Ala Thr Asn Gly Val Val His
 210 215 220
 Val Ile Asp Arg Val Leu Thr Gln Ile Gly Thr Ser Ile Gln Asp Phe
 225 230 235 240
 Ile Glu Ala Glu Asp Asp Leu Ser Ser Phe Arg Ala Ala Ala Ile Thr
 245 250 255
 Ser Asp Ile Leu Glu Ala Leu Gly Arg Asp Gly His Phe Thr Leu Phe
 260 265 270
 Ala Pro Thr Asn Glu Ala Phe Glu Lys Leu Pro Arg Gly Val Leu Glu
 275 280 285
 Arg Phe Met Gly Asp Lys Val Ala Ser Glu Ala Leu Met Lys Tyr His
 290 295 300
 Ile Leu Asn Thr Leu Gln Cys Ser Glu Ser Ile Met Gly Gly Ala Val
 305 310 315 320
 Phe Glu Thr Leu Glu Gly Asn Thr Ile Glu Ile Gly Cys Asp Gly Asp
 325 330 335
 Ser Ile Thr Val Asn Gly Ile Lys Met Val Asn Lys Lys Asp Ile Val
 340 345 350
 Thr Asn Asn Gly Val Ile His Leu Ile Asp Gln Val Leu Ile Pro Asp
 355 360 365
 Ser Ala Lys Gln Val Ile Glu Leu Ala Gly Lys Gln Gln Thr Thr Phe
 370 375 380
 Thr Asp Leu Val Ala Gln Leu Gly Leu Ala Ser Ala Leu Arg Pro Asp
 385 390 395 400
 Gly Glu Tyr Thr Leu Leu Ala Pro Val Asn Asn Ala Phe Ser Asp Asp
 405 410 415
 Thr Leu Ser Met Val Gln Arg Leu Leu Lys Leu Ile Leu Gln Asn His
 420 425 430
 Ile Leu Lys Val Lys Val Gly Leu Asn Glu Leu Tyr Asn Gly Gln Ile

SEQUENCE LISTING 1657-2022.txt

435
 Leu Glu Thr Ile Gly Gly Lys Gln Leu Arg Val Phe Val Tyr Arg Thr
 450
 Ala Val Cys Ile Glu Asn Ser Cys Met Glu Lys Gly Ser Lys Gln Gly
 465
 Arg Asn Gly Ala Ile His Ile Phe Arg Glu Ile Ile Lys Pro Ala Glu
 485
 Lys Ser Leu His Glu Lys Leu Lys Gln Asp Lys Arg Phe Ser Thr Phe
 500
 Leu Ser Leu Leu Glu Ala Ala Asp Leu Lys Glu Leu Leu Thr Gln Pro
 515
 Gly Asp Trp Thr Leu Phe Val Pro Thr Asn Asp Ala Phe Lys Gly Met
 530
 Thr Ser Glu Glu Lys Glu Ile Leu Ile Arg Asp Lys Asn Ala Leu Gln
 545
 Asn Ile Ile Leu Tyr His Leu Thr Pro Gly Val Phe Ile Gly Lys Gly
 565
 Phe Glu Pro Gly Val Thr Asn Ile Leu Lys Thr Thr Gln Gly Ser Lys
 580
 Ile Phe Leu Lys Glu Val Asn Asp Thr Leu Leu Val Asn Glu Leu Lys
 595
 Ser Lys Glu Ser Asp Ile Met Thr Thr Asn Gly Val Ile His Val Val
 610
 Asp Lys Leu Leu Tyr Pro Ala Asp Thr Pro Val Gly Asn Asp Gln Leu
 625
 Leu Glu Ile Leu Asn Lys Leu Ile Lys Tyr Ile Gln Ile Lys Phe Val
 645
 Arg Gly Ser Thr Phe Lys Glu Ile Pro Val Thr Val Tyr Thr Thr Lys
 660
 Ile Ile Thr Lys Val Val Glu Pro Lys Ile Lys Val Ile Glu Gly Ser
 675
 Leu Gln Pro Ile Ile Lys Thr Glu Gly Pro Thr Leu Thr Lys Val Lys
 690
 Ile Glu Gly Glu Pro Glu Phe Arg Leu Ile Lys Glu Gly Glu Thr Ile
 705
 Thr Glu Val Ile His Gly Glu Pro Ile Ile Lys Lys Tyr Thr Lys Ile
 725
 Ile Asp Gly Val Pro Val Glu Ile Thr Glu Lys Glu Thr Arg Glu Glu
 740
 Arg Ile Ile Thr Gly Pro Glu Ile Lys Tyr Thr Arg Ile Ser Thr Gly
 755
 Gly Gly Glu Thr Glu Glu Thr Leu Lys Lys Leu Leu Gln Glu Glu Val
 770
 Thr Lys Val Thr Lys Phe Ile Glu Gly Gly Asp Gly His Leu Phe Glu
 785
 Asp Glu Glu Ile Lys Arg Leu Leu Gln Gly Asp Thr Pro Val Arg Lys
 805
 Leu Gln Ala Asn Lys Lys Val Gln Gly Ser Arg Arg Arg Leu Arg Glu
 820
 Gly Arg Ser Gln
 835

<210> 133
 <211> 303
 <212> PRT
 <213> Homo sapiens

<400> 133
 Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
 1 5 10 15
 Ala Ala Pro Gln Gln Glu Ala Leu Pro Asp Glu Thr Glu Val Val Glu
 20 25 30
 Glu Thr Val Ala Glu Val Thr Glu Val Ser Val Gly Ala Asn Pro Val
 35 40 45
 Gln Val Glu Val Gly Glu Phe Asp Asp Gly Ala Glu Thr Glu Glu
 50 55 60

SEQUENCE LISTING 1657-2022.txt

Glu Val Val Ala Glu Asn Pro Cys Gln Asn His His Cys Lys His Gly
 65 70 75 80
 Lys Val Cys Glu Leu Asp Glu Asn Asn Thr Pro Met Cys Val Cys Gln
 85 90 95
 Asp Pro Thr Ser Cys Pro Ala Pro Ile Gly Glu Phe Glu Lys Val Cys
 100 105 110
 Ser Asn Asp Asn Lys Thr Phe Asp Ser Ser Cys His Phe Phe Ala Thr
 115 120 125
 Lys Cys Thr Leu Glu Gly Thr Lys Lys Gly His Lys Leu His Leu Asp
 130 135 140
 Tyr Ile Gly Pro Cys Lys Tyr Ile Pro Pro Cys Leu Asp Ser Glu Leu
 145 150 155 160
 Thr Glu Phe Pro Leu Arg Met Arg Asp Trp Leu Lys Asn Val Leu Val
 165 170 175
 Thr Leu Tyr Glu Arg Asp Glu Asp Asn Asn Leu Leu Thr Glu Lys Gln
 180 185 190
 Lys Leu Arg Val Lys Lys Ile His Glu Asn Glu Lys Arg Leu Glu Ala
 195 200 205
 Gly Asp His Pro Val Glu Leu Leu Ala Arg Asp Phe Glu Lys Asn Tyr
 210 215 220
 Asn Met Tyr Ile Phe Pro Val His Trp Gln Phe Gly Gln Leu Asp Gln
 225 230 235 240
 His Pro Ile Asp Gly Tyr Leu Ser His Thr Glu Leu Ala Pro Leu Arg
 245 250 255
 Ala Pro Leu Ile Pro Met Glu His Cys Thr Thr Arg Phe Phe Glu Thr
 260 265 270
 Cys Asp Leu Asp Asn Asp Lys Tyr Ile Ala Leu Asp Glu Trp Ala Gly
 275 280 285
 Cys Phe Gly Ile Lys Gln Lys Asp Ile Asp Lys Asp Leu Val Ile
 290 295 300

<210> 134
 <211> 683
 <212> PRT
 <213> Homo sapiens

<400> .134

Met Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu Ala Leu
 1 5 10 15
 Gly Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu
 20 25 30
 Val Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val
 35 40 45
 Cys Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn
 50 55 60
 Cys Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile
 65 70 75 80
 Ser Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly
 85 90 95
 Cys Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val
 100 105 110
 Val Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu
 115 120 125
 Arg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser
 130 135 140
 Asn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val
 145 150 155 160
 Ser Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val
 165 170 175
 Gly Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Thr
 180 185 190
 Ser Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly
 195 200 205
 Ile Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala
 210 215 220
 Thr Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr

SEQUENCE LISTING 1657-2022.txt																		
225	Asn	Asn	Ile	Gln	Gln	Ile	Ile	Glu	Ile	Glu	235	Asp	Thr	Phe	Glu	Thr	240	Leu
Arg	Ala	Ala	Val	245	Ala	Ala	Ser	Gly	Leu	250	Asn	Thr	Met	Leu	Glu	255	Gly	Asn
Gly	Gln	Tyr	Thr	260	Leu	Leu	Ala	Pro	Thr	265	Asn	Glu	Ala	Phe	Glu	Lys	Ile	
Pro	Ser	Glu	Thr	275	Leu	Asn	Arg	Ile	Leu	280	Gly	Asp	Pro	285	Glu	Ala	Leu	Arg
Asp	Leu	Leu	Asn	Asn	His	Ile	Leu	Lys	Ser	310	Ala	Met	Cys	Ala	Glu	Ala	320	Glu
Ile	Val	Ala	Gly	Leu	Ser	Val	Glu	Thr	Leu	315	Glu	Gly	Thr	Thr	Leu	335	Ile	Ile
Val	Gly	Cys	Ser	Gly	Asp	Met	Leu	Thr	Ile	330	Asn	Gly	Lys	Ala	350	Ile	Ile	
Ser	Asn	Lys	Asp	Ile	Leu	Ala	Thr	Asn	Gly	345	Val	Ile	His	Tyr	Ile	Asp		
Glu	Leu	Leu	Ile	Pro	Asp	Ser	Ala	Lys	Thr	360	Leu	Phe	Glu	Leu	Ala	Ala		
Glu	Ser	Asp	Val	Ser	Thr	Ala	Ile	Asp	Leu	375	Phe	Arg	Gln	Ala	Gly	Leu	400	Leu
Gly	Asn	His	Leu	Ser	Gly	Ser	Glu	Arg	Leu	390	Thr	Leu	Leu	Ala	Pro	415	Thr	Arg
Asn	Ser	Val	Phe	Lys	Asp	Gly	Thr	Pro	410	Pro	Ile	Asp	Ala	His	430	Ser	Lys	Tyr
Asn	Leu	Leu	Arg	Asn	His	Ile	Ile	Lys	Asp	425	Gln	Leu	Ala	445	Lys	Lys	Leu	Arg
Leu	Tyr	His	Gly	Gln	Thr	Leu	Glu	Thr	Leu	440	Gly	Gly	Lys	Lys	Leu	Arg		
Val	Phe	Val	Tyr	Arg	Asn	Ser	Leu	Cys	Ile	455	Glu	Asn	Ser	Cys	Ile	Ala	480	Arg
Ala	His	Asp	Lys	Arg	Gly	Arg	Tyr	Gly	Thr	470	Leu	Phe	Thr	Met	Asp	495	Gly	Asp
Val	Leu	Thr	Pro	Pro	Met	Gly	Thr	Val	Met	485	Met	Asp	Val	Leu	Lys	510	Gly	Asp
Asn	Arg	Phe	Ser	Met	Leu	Val	Ala	Ile	Gln	500	Ala	Ser	Ala	525	Gly	Leu	Thr	
Glu	Thr	Leu	Asn	Arg	Glu	Gly	Val	Tyr	Thr	515	Val	Phe	Ala	Pro	Thr	Asn		
Glu	Ala	Phe	Arg	Ala	Leu	Pro	Pro	Arg	Glu	530	Arg	Ser	Arg	Leu	Leu	Gly	560	Glu
Asp	Ala	Lys	Glu	Leu	Ala	Asn	Ile	Leu	Lys	535	Tyr	His	Ile	Gly	Asp	575	Glu	
Ile	Leu	Val	Ser	Gly	Gly	Ile	Gly	Ala	Leu	550	Val	Arg	Leu	Lys	Ser	Leu		
Gln	Gly	Asp	Lys	Leu	Glu	Val	Ser	Leu	Lys	565	Asn	Asn	Val	Val	Ser	Val		
Asn	Lys	Glu	Pro	Val	Ala	Glu	Pro	Asp	Ile	580	Met	Ala	Thr	Asn	Gly	Val		
Val	His	Val	Ile	Thr	Asn	Val	Leu	Gln	Pro	600	Pro	Ala	Asn	Arg	Pro	Gln	640	Gln
Glu	Arg	Gly	Asp	Glu	Leu	Ala	Asp	Ser	Ala	615	Leu	Glu	Ile	Phe	Lys	655	Gln	
Ala	Ser	Ala	Phe	Ser	Arg	Ala	Ser	Gln	Arg	630	Ser	Val	Arg	Leu	Ala	Pro		
Val	Tyr	Gln	Lys	Leu	Leu	Glu	Arg	Met	Lys	645	His							
										660								
										675								
										680								

```
<210> 135
<211> 2355
<212> PRT
<213> Homo sapiens
```

<400> 135
Met Leu Arg Gly Pro Gly Pro Gly Leu Leu Leu Leu Ala Val Gln Cys
1 5 10 15

SEQUENCE LISTING 1657-2022.txt

Leu Gly Thr Ala Val Pro Ser Thr Gly Ala Ser Lys Ser Lys Arg Gln
 20 25 30
 Ala Gln Gln Met Val Gln Pro Gln Ser Pro Val Ala Val Ser Gln Ser
 35 40 45
 Lys Pro Gly Cys Tyr Asp Asn Gly Lys His Tyr Gln Ile Asn Gln Gln
 50 55 60
 Trp Glu Arg Thr Tyr Leu Gly Asn Ala Leu Val Cys Thr Cys Tyr Gly
 65 70 75 80
 Gly Ser Arg Gly Phe Asn Cys Glu Ser Lys Pro Glu Ala Glu Glu Thr
 85 90 95
 Cys Phe Asp Lys Tyr Thr Gly Asn Thr Tyr Arg Val Gly Asp Thr Tyr
 100 105 110
 Glu Arg Pro Lys Asp Ser Met Ile Trp Asp Cys Thr Cys Ile Gly Ala
 115 120 125
 Gly Arg Gly Arg Ile Ser Cys Thr Ile Ala Asn Arg Cys His Glu Gly
 130 135 140
 Gly Gln Ser Tyr Lys Ile Gly Asp Thr Trp Arg Arg Pro His Glu Thr
 145 150 155 160
 Gly Gly Tyr Met Leu Glu Cys Val Cys Leu Gly Asn Gly Lys Gly Glu
 165 170 175
 Trp Thr Cys Lys Pro Ile Ala Glu Lys Cys Phe Asp His Ala Ala Gly
 180 185 190
 Thr Ser Tyr Val Val Gly Glu Thr Trp Glu Lys Pro Tyr Gln Gly Trp
 195 200 205
 Met Met Val Asp Cys Thr Cys Leu Gly Glu Gly Ser Gly Arg Ile Thr
 210 215 220
 Cys Thr Ser Arg Asn Arg Cys Asn Asp Gln Asp Thr Arg Thr Ser Tyr
 225 230 235 240
 Arg Ile Gly Asp Thr Trp Ser Lys Lys Asp Asn Arg Gly Asn Leu Leu
 245 250 255
 Gln Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys Glu Arg
 260 265 270
 His Thr Ser Val Gln Thr Thr Ser Gly Ser Gly Pro Phe Thr Asp
 275 280 285
 Val Arg Ala Ala Val Tyr Gln Pro Gln Pro His Pro Gln Pro Pro Pro
 290 295 300
 Tyr Gly His Cys Val Thr Asp Ser Gly Val Val Tyr Ser Val Gly Met
 305 310 315 320
 Gln Trp Leu Lys Thr Gln Gly Asn Lys Gln Met Leu Cys Thr Cys Leu
 325 330 335
 Gly Asn Gly Val Ser Cys Gln Glu Thr Ala Val Thr Gln Thr Tyr Gly
 340 345 350
 Gly Asn Ser Asn Gly Glu Pro Cys Val Leu Pro Phe Thr Tyr Asn Gly
 355 360 365
 Arg Thr Phe Tyr Ser Cys Thr Thr Glu Gly Arg Gln Asp Gly His Leu
 370 375 380
 Trp Cys Ser Thr Thr Ser Asn Tyr Glu Gln Asp Gln Lys Tyr Ser Phe
 385 390 395 400
 Cys Thr Asp His Thr Val Leu Val Gln Thr Arg Gly Gly Asn Ser Asn
 405 410 415
 Gly Ala Leu Cys His Phe Pro Phe Leu Tyr Asn Asn His Asn Tyr Thr
 420 425 430
 Asp Cys Thr Ser Glu Gly Arg Arg Asp Asn Met Lys Trp Cys Gly Thr
 435 440 445
 Thr Gln Asn Tyr Asp Ala Asp Gln Lys Phe Gly Phe Cys Pro Met Ala
 450 455 460
 Ala His Glu Glu Ile Cys Thr Thr Asn Glu Gly Val Met Tyr Arg Ile
 465 470 475 480
 Gly Asp Gln Trp Asp Lys Gln His Asp Met Gly His Met Met Arg Cys
 485 490 495
 Thr Cys Val Gly Asn Gly Arg Gly Glu Trp Thr Cys Ile Ala Tyr Ser
 500 505 510
 Gln Leu Arg Asp Gln Cys Ile Val Asp Asp Ile Thr Tyr Asn Val Asn
 515 520 525
 Asp Thr Phe His Lys Arg His Glu Glu Gly His Met Leu Asn Cys Thr
 530 535 540
 Cys Phe Gly Gln Gly Arg Gly Arg Trp Lys Cys Asp Pro Val Asp Gln

SEQUENCE LISTING 1657-2022.txt

545 Cys Gln Asp Ser Glu 550 Thr Gly Thr Phe Tyr 555 Gln Ile Gly Asp Ser Trp 560
 Glu Lys Tyr Val 565 Gly Val Arg Tyr 570 Gln Cys Tyr Cys Tyr 575 Gly Arg
 Gly Ile Gly 580 Glu Trp His Cys Gln Pro Leu Gln Thr Tyr 590 Pro Ser Ser
 Ser Gly 595 Pro Val Glu Val Phe 600 Ile Thr Glu Thr Pro 605 Ser Gln Pro Asn
 Ser 610 His Pro Ile Gln Trp Asn Ala Pro Gln Pro Ser His Ile Ser Lys
 625 Tyr Ile Leu Arg Trp 630 Arg Pro Lys Asn Ser 635 Val Gly Arg Trp Lys Glu
 Ala Thr Ile Pro 645 Gly His Leu Asn Ser Tyr Thr Ile Lys Gly Leu Lys
 Pro Gly Val 660 Tyr Glu Gly Gln Leu Ile Ser Ile Gln Gln Tyr Gly
 His Gln Glu Val Thr Arg Phe 680 Asp Phe Thr Thr Thr Ser Thr Ser Thr
 Pro 690 Val Thr Ser Asn Thr 695 Val Thr Gly Glu Thr Thr Pro Phe Ser Pro
 705 Leu Val Ala Thr Ser 710 Glu Ser Val Thr Glu Ile Thr Ala Ser Ser Phe
 Val Val Ser Trp 725 Val Ser Ala Ser Asp Thr Val Ser Gly Phe Arg Val
 Glu Tyr Glu 740 Leu Ser Glu Glu Gly Asp Glu Pro Gln Tyr Leu Asp Leu
 Pro Ser 755 Thr Ala Thr Ser Val 760 Asn Ile Pro Asp Leu Leu Pro Gly Arg
 Lys 770 Tyr Ile Val Asn Val 775 Tyr Gln Ile Ser Glu Asp Gly Glu Gln Ser
 785 Leu Ile Leu Ser Thr 790 Ser Gln Thr Thr Ala Pro Asp Ala Pro Pro Asp
 Pro Thr Val Asp 805 Gln Val Asp Asp Thr Ser Ile Val Val Arg Trp Ser
 Arg Pro Gln 820 Ala Pro Ile Thr Gly Tyr Arg Ile Val Tyr Ser Pro Ser
 Val Glu Gly Ser Ser Thr 835 Glu Leu Asn Leu Pro Glu Thr Ala Asn Ser
 Val Thr Leu Ser Asp 850 Leu Gln Pro Gly Val Gln Tyr Asn Ile Thr Ile
 865 Tyr Ala Val Glu Glu 870 Asn Gln Glu Ser Thr Pro Val Val Ile Gln Gln
 Glu Thr Thr Gly 885 Thr Pro Arg Ser Asp Thr Val Pro Ser Pro Arg Asp
 Leu Gln Phe Val Glu Val Thr 900 Asp Val Lys Val Thr Ile Met Trp Thr
 Pro Pro 915 Glu Ser Ala Val Thr 920 Gly Tyr Arg Val Asp Val Ile Pro Val
 Asn 930 Leu Pro Gly Glu His 935 Gly Gln Arg Leu Pro Ile Ser Arg Asn Thr
 945 Phe Ala Glu Val Thr 950 Gly Leu Ser Pro Gly Val Thr Tyr Tyr Phe Lys
 Val Phe Ala Val Ser His Gly Arg Glu Ser Lys Pro Leu Thr Ala Gln
 Gln Thr Thr Lys 980 Leu Asp Ala Pro Thr Asn Leu Gln Phe Val Asn Glu
 Thr Asp Ser Thr Val Leu Val Arg Trp Thr Pro Pro Arg Ala Gln Ile
 1010 Thr Gly Tyr Arg Leu Thr Val Gly Leu Thr Arg Arg Gly Gln Pro Arg
 1025 Gln Tyr Asn Val Gly 1030 Pro Ser Val Ser Lys Tyr Pro Leu Arg Asn Leu
 Gln Pro Ala Ser Glu Tyr Thr Val Ser 1045 Leu Val Ala Ile Lys Gly Asn
 Gln Glu Ser Pro Lys Ala Thr Gly Val Phe Thr Thr Leu Gln Pro Gly
 1075 1080 1085

SEQUENCE LISTING 1657-2022.txt

Ser Ser Ile Pro Pro Tyr Asn Thr Glu Val Thr Glu Thr Thr Ile Val
 1090 1095 1100
 Ile Thr Trp Thr Pro Ala Pro Arg Ile Gly Phe Lys Leu Gly Val Arg
 1105 1110 1115 1120
 Pro Ser Gln Gly Gly Glu Ala Pro Arg Glu Val Thr Ser Asp Ser Gly
 1125 1130 1135
 Ser Ile Val Val Ser Gly Leu Thr Pro Gly Val Glu Tyr Val Tyr Thr
 1140 1145 1150
 Ile Gln Val Leu Arg Asp Gly Gln Glu Arg Asp Ala Pro Ile Val Asn
 1155 1160 1165
 Lys Val Val Thr Pro Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala
 1170 1175 1180
 Asn Pro Asp Thr Gly Val Leu Thr Val Ser Trp Glu Arg Ser Thr Thr
 1185 1190 1195 1200
 Pro Asp Ile Thr Gly Tyr Arg Ile Thr Thr Thr Pro Thr Asn Gly Gln
 1205 1210 1215
 Gln Gly Asn Ser Leu Glu Glu Val Val His Ala Asp Gln Ser Ser Cys
 1220 1225 1230
 Thr Phe Asp Asn Leu Ser Pro Gly Leu Glu Tyr Asn Val Ser Val Tyr
 1235 1240 1245
 Thr Val Lys Asp Asp Lys Glu Ser Val Pro Ile Ser Asp Thr Ile Ile
 1250 1255 1260
 Pro Ala Val Pro Pro Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro
 1265 1270 1275 1280
 Asp Thr Met Arg Val Thr Trp Ala Pro Pro Ser Ile Asp Leu Thr
 1285 1290 1295
 Asn Phe Leu Val Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala
 1300 1305 1310
 Glu Leu Ser Ile Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu
 1315 1320 1325
 Leu Pro Gly Thr Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln
 1330 1335 1340
 His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp Ser
 1345 1350 1355 1360
 Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe Thr Val
 1365 1370 1375
 His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly Tyr Arg Ile Arg His
 1380 1385 1390
 His Pro Glu His Phe Ser Gly Arg Pro Arg Glu Asp Arg Val Pro His
 1395 1400 1405
 Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr Pro Gly Thr Glu Tyr
 1410 1415 1420
 Val Val Ser Ile Val Ala Leu Asn Gly Arg Glu Glu Ser Pro Leu Leu
 1425 1430 1435 1440
 Ile Gly Gln Gln Ser Thr Val Ser Asp Val Pro Arg Asp Leu Glu Val
 1445 1450 1455
 Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala
 1460 1465 1470
 Val Thr Val Arg Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
 1475 1480 1485
 Ser Pro Val Gln Glu Phe Thr Val Pro Gly Ser Lys Ser Thr Ala Thr
 1490 1495 1500
 Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala
 1505 1510 1515 1520
 Val Thr Gly Arg Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile
 1525 1530 1535
 Asn Tyr Arg Thr Glu Ile Asp Lys Pro Ser Gln Met Gln Val Thr Asp
 1540 1545 1550
 Val Gln Asp Asn Ser Ile Ser Val Lys Trp Leu Pro Ser Ser Ser Pro
 1555 1560 1565
 Val Thr Gly Tyr Arg Val Thr Thr Pro Lys Asn Gly Pro Gly Pro
 1570 1575 1580
 Thr Lys Thr Lys Thr Ala Gly Pro Asp Gln Thr Glu Met Thr Ile Glu
 1585 1590 1595 1600
 Gly Leu Gln Pro Thr Val Glu Tyr Val Val Ser Val Tyr Ala Gln Asn
 1605 1610 1615
 Pro Ser Gly Glu Ser Gln Pro Leu Val Gln Thr Ala Val Thr Asn Ile

SEQUENCE LISTING 1657-2022.txt

1620 1625 1630
 Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val Asp Val Asp Ser Ile
 1635 1640 1645
 Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg Tyr Arg Val
 1650 1655 1660
 Thr Tyr Ser Ser Pro Glu Asp Gly Ile His Glu Leu Phe Pro Ala Pro
 1665 1670 1675 1680
 Asp Gly Glu Glu Asp Thr Ala Glu Leu Gln Gly Leu Arg Pro Gly Ser
 1685 1690 1695
 Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp Met Glu Ser Gln
 1700 1705 1710
 Pro Leu Ile Gly Thr Gln Ser Thr Ala Ile Pro Ala Pro Thr Asp Leu
 1715 1720 1725
 Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp Thr Pro
 1730 1735 1740
 Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr Pro Lys Glu
 1745 1750 1755 1760
 Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser
 1765 1770 1775
 Val Val Val Ser Gly Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val
 1780 1785 1790
 Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly Val Val
 1795 1800 1805
 Thr Thr Leu Glu Asn Val Ser Pro Pro Arg Arg Ala Arg Val Thr Asp
 1810 1815 1820
 Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu Thr
 1825 1830 1835 1840
 Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr Pro
 1845 1850 1855
 Ile Gln Arg Thr Ile Lys Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly
 1860 1865 1870
 Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp
 1875 1880 1885
 Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala Ser Thr Ala Ile Asp
 1890 1895 1900
 Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu
 1905 1910 1915 1920
 Val Ser Trp Gln Pro Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys
 1925 1930 1935
 Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg
 1940 1945 1950
 Pro Gly Val Thr Glu Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu
 1955 1960 1965
 Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn Gln Lys Ser Glu Pro
 1970 1975 1980
 Leu Ile Gly Arg Lys Lys Thr Asp Glu Leu Pro Gln Leu Val Thr Leu
 1985 1990 1995 2000
 Pro His Pro Asn Leu His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr
 2005 2010 2015
 Val Gln Lys Thr Pro Phe Val Thr His Pro Gly Tyr Asp Thr Gly Asn
 2020 2025 2030
 Gly Ile Gln Leu Pro Gly Thr Ser Gly Gln Gln Pro Ser Val Gly Gln
 2035 2040 2045
 Gln Met Ile Phe Glu Glu His Gly Phe Arg Arg Thr Thr Pro Pro Thr
 2050 2055 2060
 Thr Ala Thr Pro Ile Arg His Arg Pro Arg Pro Tyr Pro Pro Asn Val
 2065 2070 2075 2080
 Gly Gln Glu Ala Leu Ser Gln Thr Thr Ile Ser Trp Ala Pro Phe Gln
 2085 2090 2095
 Asp Thr Ser Glu Tyr Ile Ile Ser Cys His Pro Val Gly Thr Asp Glu
 2100 2105 2110
 Glu Pro Leu Gln Phe Arg Val Pro Gly Thr Ser Thr Ser Ala Thr Leu
 2115 2120 2125
 Thr Gly Leu Thr Arg Gly Ala Thr Tyr Asn Ile Ile Val Glu Ala Leu
 2130 2135 2140
 Lys Asp Gln Gln Arg His Lys Val Arg Glu Glu Val Val Thr Val Gly
 2145 2150 2155 2160

SEQUENCE LISTING 1657-2022.txt

Asn Ser Val Asn Glu Gly Leu Asn Gln Pro Thr Asp Asp Ser Cys Phe
 2165 2170 2175
 Asp Pro Tyr Thr Val Ser His Tyr Ala Val Gly Asp Glu Trp Glu Arg
 2180 2185 2190
 Met Ser Glu Ser Gly Phe Lys Leu Leu Cys Gln Cys Leu Gly Phe Gly
 2195 2200 2205
 Ser Gly His Phe Arg Cys Asp Ser Ser Arg Trp Cys His Asp Asn Gly
 2210 2215 2220
 Val Asn Tyr Lys Ile Gly Glu Lys Trp Asp Arg Gln Gly Glu Asn Gly
 2225 2230 2235 2240
 Gln Met Met Ser Cys Thr Cys Leu Gly Asn Gly Lys Gly Glu Phe Lys
 2245 2250 2255
 Cys Asp Pro His Glu Ala Thr Cys Tyr Asp Asp Gly Lys Thr Tyr His
 2260 2265 2270
 Val Gly Glu Gln Trp Gln Lys Glu Tyr Leu Gly Ala Ile Cys Ser Cys
 2275 2280 2285
 Thr Cys Phe Gly Gly Gln Arg Gly Trp Arg Cys Asp Asn Cys Arg Arg
 2290 2295 2300
 Pro Gly Gly Glu Pro Ser Pro Glu Gly Thr Thr Gly Gln Ser Tyr Asn
 2305 2310 2315 2320
 Gln Tyr Ser Gln Arg Tyr His Gln Arg Thr Asn Thr Asn Val Asn Cys
 2325 2330 2335
 Pro Ile Glu Cys Phe Met Pro Leu Asp Val Gln Ala Asp Arg Glu Asp
 2340 2345 2350
 Ser Arg Glu
 2355

<210> 136
 <211> 1366
 <212> PRT
 <213> Homo sapiens

<400> 136
 Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr
 1 5 10 15
 Leu Cys Leu Ala Thr Cys Gln Ser Leu Gln Glu Glu Thr Val Arg Lys
 20 25 30
 Gly Pro Ala Gly Asp Arg Gly Pro Arg Gly Glu Arg Gly Pro Pro Gly
 35 40 45
 Pro Pro Gly Arg Asp Gly Glu Asp Gly Pro Thr Gly Pro Pro Gly Pro
 50 55 60
 Pro Gly Pro Pro Gly Pro Pro Gly Leu Gly Gly Asn Phe Ala Ala Gln
 65 70 75 80
 Tyr Asp Gly Lys Gly Val Gly Leu Gly Pro Gly Pro Met Gly Leu Met
 85 90 95
 Gly Pro Arg Gly Pro Pro Gly Ala Ala Gly Ala Pro Gly Pro Gln Gly
 100 105 110
 Phe Gln Gly Pro Ala Gly Glu Pro Gly Glu Pro Gly Gln Thr Gly Pro
 115 120 125
 Ala Gly Ala Arg Gly Pro Ala Gly Pro Pro Gly Lys Ala Gly Glu Asp
 130 135 140
 Gly His Pro Gly Lys Pro Gly Arg Pro Gly Glu Arg Gly Val Val Gly
 145 150 155 160
 Pro Gln Gly Ala Arg Gly Phe Pro Gly Thr Pro Gly Leu Pro Gly Phe
 165 170 175
 Lys Gly Ile Arg Gly His Asn Gly Leu Asp Gly Leu Lys Gly Gln Pro
 180 185 190
 Gly Ala Pro Gly Val Lys Gly Glu Pro Gly Ala Pro Gly Glu Asn Gly
 195 200 205
 Thr Pro Gly Gln Thr Gly Ala Arg Gly Leu Pro Gly Glu Arg Gly Arg
 210 215 220
 Val Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Ser Asp Gly Ser Val
 225 230 235 240
 Gly Pro Val Gly Pro Ala Gly Pro Ile Gly Ser Ala Gly Pro Pro Gly
 245 250 255
 Phe Pro Gly Ala Pro Gly Pro Lys Gly Glu Ile Gly Ala Val Gly Asn

SEQUENCE LISTING 1657-2022.txt

260 265 270
 Ala Gly Pro Ala Gly Pro Ala Gly Pro Arg Gly Glu Val Gly Leu Pro
 275 280 285
 Gly Leu Ser Gly Pro Val Gly Pro Pro Gly Asn Pro Gly Ala Asn Gly
 290 295 300
 Leu Thr Gly Ala Lys Gly Ala Ala Gly Leu Pro Gly Val Ala Gly Ala
 305 310 315 320
 Pro Gly Leu Pro Gly Pro Arg Gly Ile Pro Gly Pro Val Gly Ala Ala
 325 330 335
 Gly Ala Thr Gly Ala Arg Gly Leu Val Gly Glu Pro Gly Pro Ala Gly
 340 345 350
 Ser Lys Gly Glu Ser Gly Asn Lys Gly Glu Pro Gly Ser Ala Gly Pro
 355 360 365
 Gln Gly Pro Pro Gly Pro Ser Gly Glu Glu Gly Lys Arg Gly Pro Asn
 370 375 380
 Gly Glu Ala Gly Ser Ala Gly Pro Pro Gly Pro Gly Leu Arg Gly
 385 390 395 400
 Ser Pro Gly Ser Arg Gly Leu Pro Gly Ala Asp Gly Arg Ala Gly Val
 405 410 415
 Met Gly Pro Pro Gly Ser Arg Gly Ala Ser Gly Pro Ala Gly Val Arg
 420 425 430
 Gly Pro Asn Gly Asp Ala Gly Arg Pro Gly Glu Pro Gly Leu Met Gly
 435 440 445
 Pro Arg Gly Leu Pro Gly Ser Pro Gly Asn Ile Gly Pro Ala Gly Lys
 450 455 460
 Glu Gly Pro Val Gly Leu Pro Gly Ile Asp Gly Arg Pro Gly Pro Ile
 465 470 475 480
 Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Asn Ile Gly Phe Pro Gly
 485 490 495
 Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His
 500 505 510
 Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn
 515 520 525
 Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly
 530 535 540
 Glu Gln Gly Pro Ala Gly Pro Pro Gly Phe Gln Gly Leu Pro Gly Pro
 545 550 555 560
 Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His
 565 570 575
 Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly
 580 585 590
 Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser
 595 600 605
 Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro
 610 615 620
 Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly
 625 630 635 640
 Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu
 645 650 655
 Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp
 660 665 670
 Gly Ala Arg Gly Ala His Gly Ala Val Gly Ala Pro Gly Pro Ala Gly
 675 680 685
 Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro
 690 695 700
 Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala
 705 710 715 720
 Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly
 725 730 735
 Ala Lys Gly Glu Arg Gly Ala Lys Gly Pro Lys Gly Glu Asn Gly Val
 740 745 750
 Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn
 755 760 765
 Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Pro Pro Gly
 770 775 780
 Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro
 785 790 795 800

SEQUENCE LISTING 1657-2022.txt

Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu
 805 810 815
 Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly
 820 825 830
 Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro
 835 840 845
 Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln
 850 855 860
 Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly
 865 870 875 880
 Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro
 885 890 895
 Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val
 900 905 910
 Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly
 915 920 925
 Asn Pro Gly Asn Asp Gly Pro Gly Arg Asp Gly Gln Pro Gly His
 930 935 940
 Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala
 945 950 955 960
 Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly
 965 970 975
 Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala
 980 985 990
 Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys
 995 1000 1005
 Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Leu Lys Gly
 1010 1015 1020
 His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His Gly Asp
 1025 1030 1035 1040
 Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala
 1045 1050 1055
 Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly
 1060 1065 1070
 Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro
 1075 1080 1085
 Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser
 1090 1095 1100
 Gly Gly Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp
 1105 1110 1115 1120
 Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp
 1125 1130 1135
 Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr Pro
 1140 1145 1150
 Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu
 1155 1160 1165
 Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln
 1170 1175 1180
 Gly Cys Thr Met Asp Ala Ile Lys Val Tyr Cys Asp Phe Ser Thr Gly
 1185 1190 1195 1200
 Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp
 1205 1210 1215
 Tyr Arg Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile
 1220 1225 1230
 Asn Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys
 1235 1240 1245
 Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr Ala
 1250 1255 1260
 Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr Met Asp
 1265 1270 1275 1280
 Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn
 1285 1290 1295
 Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val
 1300 1305 1310
 Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile
 1315 1320 1325
 Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile

SEQUENCE LISTING 1657-2022.txt

1330 1335 1340
 Ala Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile
 1345 1350 1355 1360
 Gly Pro Val Cys Phe Lys
 1365

<210> 137
 <211> 105
 <212> PRT
 <213> Homo sapiens

<400> 137
 Met Ala Lys Ile Ser Ser Pro Thr Glu Thr Glu Arg Cys Ile Glu Ser
 1 5 10 15
 Leu Ile Ala Val Phe Gln Lys Tyr Ala Gly Lys Asp Gly Tyr Asn Tyr
 20 25 30
 Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu Leu Ala
 35 40 45
 Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg Met Met
 50 55 60
 Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser Glu Phe
 65 70 75 80
 Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe Leu
 85 90 95
 Lys Ala Val Pro Ser Gln Lys Arg Thr
 100 105

<210> 138
 <211> 125
 <212> PRT
 <213> Homo sapiens

<400> 138
 Met His Lys Glu Glu His Glu Val Ala Val Leu Gly Ala Pro Pro Ser
 1 5 10 15
 Thr Ile Leu Pro Arg Ser Thr Val Ile Asn Ile His Ser Glu Thr Ser
 20 25 30
 Val Pro Asp His Val Val Trp Ser Phe Asn Thr Leu Phe Leu Asn
 35 40 45
 Trp Cys Cys Leu Gly Phe Ile Ala Phe Ala Tyr Ser Val Lys Ser Arg
 50 55 60
 Asp Arg Lys Met Val Gly Asp Val Thr Gly Ala Gln Ala Tyr Ala Ser
 65 70 75 80
 Thr Ala Lys Cys Leu Asn Ile Trp Ala Leu Ile Leu Gly Ile Leu Met
 85 90 95
 Thr Ile Gly Phe Ile Leu Leu Leu Val Phe Gly Ser Val Thr Val Tyr
 100 105 110
 His Ile Met Leu Gln Ile Ile Gln Glu Lys Arg Gly Tyr
 115 120 125

<210> 139
 <211> 163
 <212> PRT
 <213> Homo sapiens

<400> 139
 Met Ser Glu Ser Gly Phe Lys Leu Leu Cys Gln Cys Leu Gly Phe Gly
 1 5 10 15
 Ser Gly His Phe Arg Cys Asp Ser Ser Arg Trp Cys His Asp Asn Gly
 20 25 30
 Val Asn Tyr Lys Ile Gly Glu Lys Trp Asp Arg Gln Gly Glu Asn Gly
 35 40 45
 Gln Met Met Ser Cys Thr Cys Leu Gly Asn Gly Lys Gly Glu Phe Lys
 50 55 60

SEQUENCE LISTING 1657-2022.txt

Cys Asp Pro His Glu Ala Thr Cys Tyr Asp Asp Gly Lys Thr Tyr His
 65 70 75 80
 Val Gly Glu Gln Trp Gln Lys Glu Tyr Leu Gly Ala Ile Cys Ser Cys
 85 90 95
 Thr Cys Phe Gly Gly Gln Arg Gly Trp Arg Cys Asp Asn Cys Arg Arg
 100 105 110
 Pro Gly Gly Glu Pro Ser Pro Glu Gly Thr Thr Gly Gln Ser Tyr Asn
 115 120 125
 Gln Tyr Ser Gln Arg Tyr His Gln Arg Thr Asn Thr Asn Val Asn Cys
 130 135 140
 Pro Ile Glu Cys Phe Met Pro Leu Asp Val Gln Ala Asp Arg Glu Asp
 145 150 155 160
 Ser Arg Glu

<210> 140
 <211> 1466
 <212> PRT
 <213> Homo sapiens

<400> 140
 Met Met Ser Phe Val Gln Lys Gly Ser Trp Leu Leu Leu Ala Leu Leu
 1 5 10 15
 His Pro Thr Ile Leu Ala Gln Gln Glu Ala Val Glu Gly Cys
 20 25 30
 Ser His Leu Gly Gln Ser Tyr Ala Asp Arg Asp Val Trp Lys Pro Glu
 35 40 45
 Pro Cys Gln Ile Cys Val Cys Asp Ser Gly Ser Val Leu Cys Asp Asp
 50 55 60
 Ile Ile Cys Asp Asp Gln Glu Leu Asp Cys Pro Asn Pro Glu Ile Pro
 65 70 75 80
 Phe Gly Glu Cys Cys Ala Val Cys Pro Gln Pro Pro Thr Ala Pro Thr
 85 90 95
 Arg Pro Pro Asn Gly Gln Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly
 100 105 110
 Pro Pro Gly Ile Pro Gly Arg Asn Gly Asp Pro Gly Ile Pro Gly Gln
 115 120 125
 Pro Gly Ser Pro Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys
 130 135 140
 Pro Thr Gly Pro Gln Asn Tyr Ser Pro Gln Tyr Asp Ser Tyr Asp Val
 145 150 155 160
 Lys Ser Gly Val Ala Val Gly Gly Leu Ala Gly Tyr Pro Gly Pro Ala
 165 170 175
 Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Thr Ser Gly His Pro Gly
 180 185 190
 Ser Pro Gly Ser Pro Gly Tyr Gln Gly Pro Pro Gly Glu Pro Gly Gln
 195 200 205
 Ala Gly Pro Ser Gly Pro Pro Gly Pro Pro Gly Ala Ile Gly Pro Ser
 210 215 220
 Gly Pro Ala Gly Lys Asp Gly Glu Ser Gly Arg Pro Gly Arg Pro Gly
 225 230 235 240
 Glu Arg Gly Leu Pro Gly Pro Pro Gly Ile Lys Gly Pro Ala Gly Ile
 245 250 255
 Pro Gly Phe Pro Gly Met Lys Gly His Arg Gly Phe Asp Gly Arg Asn
 260 265 270
 Gly Glu Lys Gly Glu Thr Gly Ala Pro Gly Leu Lys Gly Glu Asn Gly
 275 280 285
 Leu Pro Gly Glu Asn Gly Ala Pro Gly Pro Met Gly Pro Arg Gly Ala
 290 295 300
 Pro Gly Glu Arg Gly Arg Pro Gly Leu Pro Gly Ala Ala Gly Ala Arg
 305 310 315 320
 Gly Asn Asp Gly Ala Arg Gly Ser Asp Gly Gln Pro Gly Pro Pro Gly
 325 330 335
 Pro Pro Gly Thr Ala Gly Phe Pro Gly Ser Pro Gly Ala Lys Gly Glu
 340 345 350
 Val Gly Pro Ala Gly Ser Pro Gly Ser Asn Gly Ala Pro Gly Gln Arg

SEQUENCE LISTING 1657-2022.txt

355
 Gly Glu Pro Gly Pro Gln Gly His Ala Gly Ala Gln Gly Pro Pro Gly
 370
 Pro Pro Gly Ile Asn Gly Ser Pro Gly Gly Lys Gly Glu Met Gly Pro
 385
 Ala Gly Ile Pro Gly Ala Pro Gly Leu Met Gly Ala Arg Gly Pro Pro
 405
 Gly Pro Ala Gly Ala Asn Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly
 420
 Glu Pro Gly Lys Asn Gly Ala Lys Gly Glu Pro Gly Pro Arg Gly Glu
 435
 Arg Gly Glu Ala Gly Ile Pro Gly Val Pro Gly Ala Lys Gly Glu Asp
 450
 Gly Lys Asp Gly Ser Pro Gly Glu Pro Gly Ala Asn Gly Leu Pro Gly
 465
 Ala Ala Gly Glu Arg Gly Ala Pro Gly Phe Arg Gly Pro Ala Gly Pro
 485
 Asn Gly Ile Pro Gly Glu Lys Gly Pro Ala Gly Glu Arg Gly Ala Pro
 500
 Gly Pro Ala Gly Pro Arg Gly Ala Gly Glu Pro Gly Arg Asp Gly
 515
 Val Pro Gly Gly Pro Gly Met Arg Gly Met Pro Gly Ser Pro Gly Gly
 530
 Pro Gly Ser Asp Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser
 545
 Gly Arg Pro Gly Pro Pro Gly Pro Ser Gly Pro Arg Gly Gln Pro Gly
 565
 Val Met Gly Phe Pro Gly Pro Lys Gly Asn Asp Gly Ala Pro Gly Lys
 580
 Asn Gly Glu Arg Gly Gly Pro Gly Gly Pro Gly Pro Gln Gly Pro Pro
 595
 Gly Lys Asn Gly Glu Thr Gly Pro Gln Gly Pro Pro Gly Pro Thr Gly
 610
 Pro Gly Gly Asp Lys Gly Asp Thr Gly Pro Pro Gly Pro Gln Gly Leu
 625
 Gln Gly Leu Pro Gly Thr Gly Gly Pro Pro Gly Glu Asn Gly Lys Pro
 645
 Gly Glu Pro Gly Pro Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly
 660
 Gly Lys Gly Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro Pro Gly Leu
 675
 Ala Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly Pro Pro Gly Pro Glu
 690
 Gly Gly Lys Gly Ala Ala Gly Pro Pro Gly Pro Gly Ala Ala Gly
 705
 Thr Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Gly Leu Gly Ser
 725
 Pro Gly Pro Lys Gly Asp Lys Gly Glu Pro Gly Gly Pro Gly Ala Asp
 740
 Gly Val Pro Gly Lys Asp Gly Pro Arg Gly Pro Thr Gly Pro Ile Gly
 755
 Pro Pro Gly Pro Ala Gly Gln Pro Gly Asp Lys Gly Glu Gly Gly Ala
 770
 Pro Gly Leu Pro Gly Ile Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg
 785
 Gly Glu Thr Gly Pro Gly Pro Ala Gly Phe Pro Gly Ala Pro Gly
 805
 Gln Asn Gly Glu Pro Gly Gly Lys Gly Glu Arg Gly Ala Pro Gly Glu
 820
 Lys Gly Glu Gly Pro Pro Gly Val Ala Gly Pro Pro Gly Gly Ser
 835
 Gly Pro Ala Gly Pro Pro Gly Pro Gln Gly Val Lys Gly Glu Arg Gly
 850
 Ser Pro Gly Gly Pro Gly Ala Ala Gly Phe Pro Gly Ala Arg Gly Leu
 865
 Pro Gly Pro Pro Gly Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser
 885

SEQUENCE LISTING 1657-2022.txt

Gly Ser Pro Gly Lys Asp Gly Pro Pro Gly Pro Ala Gly Asn Thr Gly
 900 905 910
 Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys Gly Asp Ala Gly Gln
 915 920 925
 Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly Pro Gly Ala Pro
 930 935 940
 Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly Leu Ala Gly
 945 950 955 960
 Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro Gly Pro Gln Gly Val
 965 970 975
 Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser Gly Glu Arg
 980 985 990
 Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly Thr Ala Gly
 995 1000 1005
 Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu Pro Gly Arg
 1010 1015 1020
 Asp Gly Ser Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn Gly Ser Pro
 1025 1030 1035 1040
 Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro Pro Gly Pro Val Gly
 1045 1050 1055
 Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro Ala Gly Pro
 1060 1065 1070
 Ala Gly Ala Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro Gly Pro Gln
 1075 1080 1085
 Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly Ala Ala Gly
 1090 1095 1100
 Ile Lys Gly His Arg Gly Phe Pro Gly Asn Pro Gly Ala Pro Gly Ser
 1105 1110 1115 1120
 Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala
 1125 1130 1135
 Gly Pro Arg Gly Pro Val Gly Pro Ser Gly Pro Pro Gly Lys Asp Gly
 1140 1145 1150
 Thr Ser Gly His Pro Gly Pro Ile Gly Pro Pro Gly Pro Arg Gly Asn
 1155 1160 1165
 Arg Gly Glu Arg Gly Ser Glu Gly Ser Pro Gly His Pro Gly Gln Pro
 1170 1175 1180
 Gly Pro Pro Gly Pro Pro Gly Ala Pro Gly Pro Cys Cys Gly Gly Val
 1185 1190 1195 1200
 Gly Ala Ala Ala Ile Ala Gly Ile Gly Gly Glu Lys Ala Gly Gly Phe
 1205 1210 1215
 Ala Pro Tyr Tyr Gly Asp Glu Pro Met Asp Phe Lys Ile Asn Thr Asp
 1220 1225 1230
 Glu Ile Met Thr Ser Leu Lys Ser Val Asn Gly Gln Ile Glu Ser Leu
 1235 1240 1245
 Ile Ser Pro Asp Gly Ser Arg Lys Asn Pro Ala Arg Asn Cys Arg Asp
 1250 1255 1260
 Leu Lys Phe Cys His Pro Glu Leu Lys Ser Gly Glu Tyr Trp Val Asp
 1265 1270 1275 1280
 Pro Asn Gln Gly Cys Lys Leu Asp Ala Ile Lys Val Phe Cys Asn Met
 1285 1290 1295
 Glu Thr Gly Glu Thr Cys Ile Ser Ala Asn Pro Leu Asn Val Pro Arg
 1300 1305 1310
 Lys His Trp Trp Thr Asp Ser Ser Ala Glu Lys Lys His Val Trp Phe
 1315 1320 1325
 Gly Glu Ser Met Asp Gly Gly Phe Gln Phe Ser Tyr Gly Asn Pro Glu
 1330 1335 1340
 Leu Pro Glu Asp Val Leu Asp Val Gln Leu Ala Phe Leu Arg Leu Leu
 1345 1350 1355 1360
 Ser Ser Arg Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile
 1365 1370 1375
 Ala Tyr Met Asp Gln Ala Ser Gly Asn Val Lys Lys Ala Leu Lys Leu
 1380 1385 1390
 Met Gly Ser Asn Glu Gly Glu Phe Lys Ala Glu Gly Asn Ser Lys Phe
 1395 1400 1405
 Thr Tyr Thr Val Leu Glu Asp Gly Cys Thr Lys His Thr Gly Glu Trp
 1410 1415 1420
 Ser Lys Thr Val Phe Glu Tyr Arg Thr Arg Lys Ala Val Arg Leu Pro

```

1425          1430          1435          1440
Ile Val Asp Ile Ala Pro Tyr Asp Ile Gly Gly Pro Asp Gln Glu Phe
          1445          1450          1455
Gly Val Asp Val Gly Pro Val Cys Phe Leu
          1460          1465

```

```
<210> 141
<211> 180
<212> PRT
<213> Homo sapiens
```

[illegible]

```
<210> 142
<211> 1064
<212> PRT
<213> Homo sapiens
```

<400>	142															
Met	Lys	Ile	Ala	Thr	Val	Ser	Val	Leu	Leu	Pro	Leu	Ala	Leu	Cys	Leu	
1				5					10					15		
Ile	Gln	Asp	Ala	Ala	Ser	Lys	Asn	Glu	Asp	Gln	Glu	Met	Cys	His	Glu	
			20					25					30			
Phe	Gln	Ala	Phe	Met	Lys	Asn	Gly	Lys	Leu	Phe	Cys	Pro	Gln	Asp	Lys	
		35					40					45				
Lys	Phe	Phe	Gln	Ser	Leu	Asp	Gly	Ile	Met	Phe	Ile	Asn	Lys	Cys	Ala	
	50					55					60					
Thr	Cys	Lys	Met	Ile	Leu	Glu	Lys	Glu	Ala	Lys	Ser	Gln	Lys	Arg	Ala	
65					70					75					80	
Arg	His	Leu	Ala	Arg	Ala	Pro	Lys	Ala	Thr	Ala	Pro	Thr	Glu	Leu	Asn	
				85					90					95		
Cys	Asp	Asp	Phe	Lys	Lys	Gly	Glu	Arg	Asp	Gly	Asp	Phe	Ile	Cys	Pro	
			100					105					110			
Asp	Tyr	Tyr	Glu	Ala	Val	Cys	Gly	Thr	Asp	Gly	Lys	Thr	Tyr	Asp	Asn	
		115					120					125				
Arg	Cys	Ala	Leu	Cys	Ala	Glu	Asn	Ala	Lys	Thr	Gly	Ser	Gln	Ile	Gly	
	130					135					140					
Val	Lys	Ser	Glu	Gly	Glu	Cys	Lys	Ser	Ser	Asn	Pro	Glu	Gln	Asp	Val	
145					150					155					160	
Cys	Ser	Ala	Phe	Arg	Pro	Phe	Val	Arg	Asp	Gly	Arg	Leu	Gly	Cys	Thr	
				165					170					175		

SEQUENCE LISTING 1657-2022.txt

Arg Glu Asn Asp Pro Val Leu Gly Pro Asp Gly Lys Thr His Gly Asn
 180 185 190
 Lys Cys Ala Met Cys Ala Glu Leu Phe Leu Lys Glu Ala Glu Asn Ala
 195 200 205
 Lys Arg Glu Gly Glu Thr Arg Ile Arg Arg Asn Ala Glu Lys Asp Phe
 210 215 220
 Cys Lys Glu Tyr Glu Lys Gln Val Arg Asn Gly Arg Leu Phe Cys Thr
 225 230 235 240
 Arg Glu Ser Asp Pro Val Arg Gly Pro Asp Gly Arg Met His Gly Asn
 245 250 255
 Lys Cys Ala Leu Cys Ala Glu Ile Phe Lys Arg Arg Phe Ser Glu Glu
 260 265 270
 Asn Ser Lys Thr Asp Gln Asn Leu Gly Lys Ala Glu Glu Lys Thr Lys
 275 280 285
 Val Lys Arg Glu Ile Val Lys Leu Cys Ser Gln Tyr Gln Asn Gln Ala
 290 295 300
 Lys Asn Gly Ile Leu Phe Cys Thr Arg Glu Asn Asp Pro Ile Arg Gly
 305 310 315 320
 Pro Asp Gly Lys Met His Gly Asn Leu Cys Ser Met Cys Gln Val Tyr
 325 330 335
 Phe Gln Ala Glu Asn Glu Glu Lys Lys Lys Ala Glu Ala Arg Ala Arg
 340 345 350
 Asn Lys Arg Glu Ser Gly Lys Ala Thr Ser Tyr Ala Glu Leu Cys Asn
 355 360 365
 Glu Tyr Arg Lys Leu Val Arg Asn Gly Lys Leu Ala Cys Thr Arg Glu
 370 375 380
 Asn Asp Pro Ile Gln Gly Pro Asp Gly Lys Val His Gly Asn Thr Cys
 385 390 395 400
 Ser Met Cys Glu Val Phe Phe Gln Ala Glu Glu Glu Lys Lys Lys
 405 410 415
 Lys Glu Gly Glu Ser Arg Asn Lys Arg Gln Ser Lys Ser Thr Ala Ser
 420 425 430
 Phe Glu Glu Leu Cys Ser Glu Tyr Arg Lys Ser Arg Lys Asn Gly Arg
 435 440 445
 Leu Phe Cys Thr Arg Glu Asn Asp Pro Ile Gln Gly Pro Asp Gly Lys
 450 455 460
 Met His Gly Asn Thr Cys Ser Met Cys Glu Ala Phe Phe Gln Gln Glu
 465 470 475 480
 Glu Arg Ala Arg Ala Lys Ala Lys Arg Glu Ala Ala Lys Glu Ile Cys
 485 490 495
 Ser Glu Phe Arg Asp Gln Val Arg Asn Gly Thr Leu Ile Cys Thr Arg
 500 505 510
 Glu His Asn Pro Val Arg Gly Pro Asp Gly Lys Met His Gly Asn Lys
 515 520 525
 Cys Ala Met Cys Ala Ser Val Phe Lys Leu Glu Glu Glu Lys Lys
 530 535 540
 Asn Asp Lys Glu Glu Lys Gly Lys Val Glu Ala Glu Lys Val Lys Arg
 545 550 555 560
 Glu Ala Val Gln Glu Leu Cys Ser Glu Tyr Arg His Tyr Val Arg Asn
 565 570 575
 Gly Arg Leu Pro Cys Thr Arg Glu Asn Asp Pro Ile Glu Gly Leu Asp
 580 585 590
 Gly Lys Ile His Gly Asn Thr Cys Ser Met Cys Glu Ala Phe Phe Gln
 595 600 605
 Gln Glu Ala Lys Glu Lys Glu Arg Ala Glu Pro Arg Ala Lys Val Lys
 610 615 620
 Arg Glu Ala Glu Lys Glu Thr Cys Asp Glu Phe Arg Arg Leu Leu Gln
 625 630 635 640
 Asn Gly Lys Leu Phe Cys Thr Arg Glu Asn Asp Pro Val Arg Gly Pro
 645 650 655
 Asp Gly Lys Thr His Gly Asn Lys Cys Ala Met Cys Lys Ala Val Phe
 660 665 670
 Gln Lys Glu Asn Glu Glu Arg Lys Arg Lys Glu Glu Glu Asp Gln Arg
 675 680 685
 Asn Ala Ala Gly His Gly Ser Ser Gly Gly Gly Gly Asn Thr Gln
 690 695 700
 Asp Glu Cys Ala Glu Tyr Gln Glu Gln Met Lys Asn Gly Arg Leu Ser

SEQUENCE LISTING 1657-2022.txt

705 Cys Thr Arg Glu Ser 710 Asp Pro Val Arg Asp Ala Asp Gly Lys Ser Tyr
 725 Met Cys Lys Ala Lys Leu Glu Arg Glu Ala Glu
 740 Thr Ser Arg Ser Arg Ser Asn Gly Thr Gly Ser Glu
 755 Lys Asp Thr Cys Asp Glu Phe Arg Ser Gln Met Lys Asn Gly
 770 Lys Leu Ile Cys Thr Arg Glu Ser Asp Pro Val Arg Gly Pro Asp Gly
 785 Lys Thr His Gly Asn Lys Cys Thr Met Cys Lys Glu Lys Leu Glu Arg
 805 Glu Ala Ala Glu Lys Lys Lys Lys Glu Asp Glu Asp Arg Ser Asn Thr
 820 Gly Glu Arg Ser Asn Thr Gly Glu Arg Ser Asn Asp Lys Glu Asp Leu
 835 Cys Arg Glu Phe Arg Ser Met Gln Arg Asn Gly Lys Leu Ile Cys Thr
 850 Arg Glu Asn Asn Pro Val Arg Gly Pro Tyr Gly Lys Met His Ile Asn
 865 Lys Cys Ala Met Cys Gln Ser Ile Phe Asp Arg Glu Ala Asn Glu Arg
 885 Lys Lys Lys Asp Glu Glu Lys Ser Ser Lys Pro Ser Asn Asn Ala
 900 Lys Asp Glu Cys Ser Glu Phe Arg Asn Tyr Ile Arg Asn Asn Glu Leu
 915 Ile Cys Pro Arg Glu Asn Asp Pro Val His Gly Ala Asp Gly Lys Phe
 930 Tyr Thr Asn Lys Cys Tyr Met Cys Arg Ala Val Phe Leu Thr Glu Ala
 945 Leu Glu Arg Ala Lys Leu Gln Glu Lys Pro Ser His Val Arg Ala Ser
 965 Gln Glu Glu Asp Ser Pro Asp Ser Phe Ser Ser Leu Asp Ser Glu Met
 980 Cys Lys Asp Tyr Arg Val Leu Pro Arg Ile Gly Tyr Leu Cys Pro Lys
 995 Asp Leu Lys Pro Val Cys Gly Asp Asp Gly Gln Thr Tyr Asn Asn Pro
 1010 Cys Met Leu Cys His Glu Asn Leu Ile Arg Gln Thr Asn Thr His Ile
 1025 Arg Ser Thr Gly Lys Cys Glu Glu Ser Ser Thr Pro Gly Thr Thr Ala
 1045 Ala Ser Met Pro Pro Ser Asp Glu 1050 1055
 1060

<210> 143
 <211> 967
 <212> PRT
 <213> Homo sapiens

<400> 143
 Met Ala Lys Gly Phe Tyr Ile Ser Lys Ser Leu Gly Ile Leu Gly Ile
 1 5 10 15
 Leu Leu Gly Val Ala Ala Val Cys Thr Ile Ile Ala Leu Ser Val Val
 20 25 30
 Tyr Ser Gln Glu Lys Asn Lys Asn Ala Asn Ser Ser Pro Val Ala Ser
 35 40 45
 Thr Thr Pro Ser Ala Ser Ala Thr Thr Asn Pro Ala Ser Ala Thr Thr
 50 55 60
 Leu Asp Gln Ser Lys Ala Trp Asn Arg Tyr Arg Leu Pro Asn Thr Leu
 65 70 75 80
 Lys Pro Asp Ser Tyr Gln Val Thr Leu Arg Pro Tyr Leu Thr Pro Asn
 85 90 95
 Asp Arg Gly Leu Tyr Val Phe Lys Gly Ser Ser Thr Val Arg Phe Thr
 100 105 110

SEQUENCE LISTING 1657-2022.txt

Cys Lys Glu Ala Thr Asp Val Ile Ile Ile His Ser Lys Lys Leu Asn
 Tyr Thr 115 Ser Gln Gly His Arg Val Val Leu Arg Gly Val Gly Gly
 Ser 130 Gln Pro Pro Asp Ile Asp Lys Thr Glu Leu Val Glu Pro Thr Glu
 145 Tyr Leu Val Val His Leu Lys Gly Ser Leu Val Lys Asp Ser Gln Tyr
 Glu Met Asp Ser 165 Phe Glu Gly Glu 170 Ala Asp Asp Leu Ala Gly
 Phe Tyr Arg Ser Glu Tyr Met Glu Gly Asn Val Arg Lys Val Val Ala
 Thr Thr 195 Met Gln Ala Ala Asp Ala Arg Lys Ser Phe Pro Cys Phe
 210 Asp Glu Pro Ala Met Lys Ala Glu Phe Asn Ile Thr Leu Ile His Pro
 225 Lys Asp Leu Thr Ala 230 Ser Asn Met Leu 235 Pro Lys Gly Pro Ser Thr
 Pro Leu Pro Glu Asp Pro Asn Trp Asn Val Thr Glu Phe His Thr Thr
 Pro Lys Met 260 Ser Thr Tyr Leu Leu 265 Phe Ile Val Ser Glu Phe Asp
 Tyr Val Glu Lys Gln Ala Ser Asn Gly Val Leu Ile Arg Ile Trp Ala
 Arg 290 Pro Ser Ala Ile Ala 310 Gly His Gly Asp Tyr Ala Leu Asn Val
 305 Thr Gly Pro Ile Leu Asn Phe Phe Ala Gly His Tyr Asp Thr Pro Tyr
 Pro Leu Pro Lys 325 Ser Asp Gln Ile Gly 330 Leu Pro Asp Phe Asn Ala Gly
 Ala Met Glu Asn Trp Gly Leu Val Thr Tyr Arg Glu Asn Ser Leu Leu
 Phe Asp 355 Pro Leu Ser Ser Ser 360 Ser Ser Asn Lys Glu Arg Val Val Thr
 Val 370 Ile Ala His Glu Leu Ala His Gln Trp Phe Gly Asn Leu Val Thr
 385 Ile Glu Trp Trp Asn 390 Asp Leu Trp Leu Asn 410 Glu Gly Phe Ala Ser Tyr
 Val Glu Tyr Leu Gly Ala Asp Tyr Ala Glu Pro Thr Trp Asn Leu Lys
 Asp Leu Met 420 Val Leu Asn Asp Val Tyr Arg Val Met Ala Val Asp Ala
 Leu Ala Ser Ser His Pro Leu Ser Thr Pro Ala Ser Glu Ile Asn Thr
 Pro 450 Ala Gln Ile Ser Glu 455 Leu Phe Asp Ala Ile Ser Tyr Ser Lys Gly
 465 Ala Ser Val Leu Arg Met Leu Ser Ser Phe Leu Ser Glu Asp Val Phe
 Lys Gln Gly Leu 485 Ala Ser Tyr Leu His 505 Thr Phe Ala Tyr Gln Asn Thr
 Ile Tyr Leu Asn Leu Trp Asp His 520 Leu Gln Glu Ala Val Asn Asn Arg
 Ser Ile 515 Gln Leu Pro Thr Thr 535 Val Arg Asp Ile Met Asn Arg Trp Thr
 Leu 530 Gln Met Gly Phe Pro Val Ile Thr Val Asp Thr Ser Thr Gly Thr
 545 Leu Ser Gln Glu His 550 Phe Leu Leu Asp Pro Asp Ser Asn Val Thr Arg
 Pro Ser Glu Phe Asn Tyr Val Trp Ile Val Pro Ile Thr Ser Ile Arg
 Asp Gly Arg 580 Gln Gln Asp Tyr 585 Leu Ile Asp Val Arg Ala Gln
 Asn Asp 595 Leu Phe Ser Thr Ser Gly Asn Glu Trp Val Leu Leu Asn Leu
 610 Asn Val Thr Gly Tyr Tyr 615 Arg Val Asn Tyr Asp Glu Glu Asn Trp Arg
 625 Lys Ile Gln Thr Gln Leu Gln Arg Asp His Ser Ala Ile Pro Val Ile

SEQUENCE LISTING 1657-2022.txt

```

        645          650          655
Asn Arg Ala Gln Ile Ile Asn Asp Ala Phe Asn Leu Ala Ser Ala His
Lys Val Pro 660 Thr Leu Ala Leu 665 Asn Asn Thr Leu Phe 670 Leu Ile Glu
Glu Arg Gln Tyr Met Pro Trp 680 Glu Ala Ala Leu Ser 685 Ser Leu Ser Tyr
Phe 690 Lys Leu Met Phe Asp 695 Arg Ser Glu Val Tyr 700 Gly Pro Met Lys Asn
705 Tyr Leu Lys Lys Gln Val Thr Pro Leu Phe Ile His Phe Arg Asn Asn
725 Thr Asn Asn Trp Arg Glu Ile Pro Glu 730 Asn Leu Met Asp Gln Tyr Ser
740 Glu Val Asn Ala Ile Ser Thr Ala Cys Ser Asn Gly Val 750 Pro Glu Cys
755 Glu Glu Met Val Ser Gly Leu 760 Phe Lys Gln Trp Met 765 Glu Asn Pro Asn
770 Asn Asn Pro Ile His Pro Asn Leu Arg Ser Thr Val Tyr Cys Asn Ala
785 Ile Ala Gln Gly Gly 790 Glu Glu Glu Trp Asp 795 Phe Ala Trp Glu Gln Phe
805 Arg Asn Ala Thr Leu Val Asn Glu Ala Asp Lys Leu Arg Ala Ala Leu
820 Ala Cys Ser Lys Glu Leu Trp Ile Leu Asn Arg Tyr Leu Ser Tyr Thr
835 Leu Asn Pro Asp Leu Ile Arg Lys Gln Asp Ala Thr Ser Thr Ile Ile
850 Ser Ile Thr Asn Asn Val Ile Gly Gln Gly Leu Val Trp Asp Phe Val
865 Gln Ser Asn Trp Lys Lys Leu Phe Asn Asp Tyr Gly Gly Gly Ser Phe
885 Ser Phe Ser Asn Leu Ile Gln Ala Val Thr Arg Arg Phe Ser Thr Glu
900 Tyr Glu Leu Gln Gln Leu Glu Gln Phe Lys Lys Asp Asn Glu Glu Thr
915 Gly Phe Gly Ser Gly Thr Arg Ala Leu Glu Gln Ala Leu Glu Lys Thr
930 Lys Ala Asn Ile Lys Trp Val Lys Glu Asn Lys Glu Val Val Leu Gln
945 Trp Phe Thr Glu Asn Ser Lys 955
        965

```

<210> 144
 <211> 261
 <212> PRT
 <213> Homo sapiens

```

<400> 144
Met Ser Gly Glu Ile Ala Met Cys Glu Pro Glu Phe Gly Asn Asp Lys
1 5 10 15
Ala Arg Glu Pro Ser Val Gly Gly Arg Trp Arg Val Ser Trp Tyr Glu
20 25 30
Arg Phe Val Gln Pro Cys Leu Val Glu Leu Leu Gly Ser Ala Leu Phe
35 40 45
Ile Phe Ile Gly Cys Leu Ser Val Ile Glu Asn Gly Thr Asp Thr Gly
50 55 60
Leu Leu Gln Pro Ala Leu Ala His Gly Leu Ala Leu Gly Leu Val Ile
65 70 75 80
Ala Thr Leu Gly Asn Ile Ser Gly Gly His Phe Asn Pro Ala Val Ser
85 90 95
Leu Ala Ala Met Leu Ile Gly Gly Leu Asn Leu Val Met Leu Leu Pro
100 105 110
Tyr Trp Val Ser Gln Leu Leu Gly Gly Met Leu Gly Ala Ala Leu Ala
115 120 125
Lys Val Val Ser Pro Glu Glu Arg Phe Trp Asn Ala Ser Gly Ala Ala
130 135 140

```


SEQUENCE LISTING 1657-2022.txt

```

Phe Val Thr Val Gln Glu Gln Gly Gln Val Ala Gly Ala Leu Val Ala
145      150      155      160
Glu Ile Ile Leu Thr Leu Leu Ala Leu Ala Val Cys Met Gly Ala
      165      170      175
Ile Asn Glu Lys Thr Lys Gly Pro Leu Ala Pro Phe Ser Ile Gly Phe
      180      185      190
Ala Val Thr Val Asp Ile Leu Ala Gly Gly Pro Val Ser Gly Gly Cys
      195      200      205
Met Asn Pro Ala Arg Ala Phe Gly Pro Ala Val Val Ala Asn His Trp
      210      215      220
Asn Phe His Trp Ile Tyr Trp Leu Gly Pro Leu Leu Ala Gly Leu Leu
225      230      235      240
Val Gly Leu Leu Ile Arg Cys Phe Ile Gly Asp Gly Lys Thr Arg Leu
      245      250      255
Ile Leu Lys Ala Arg
      260

```

<210> 145
 <211> 112
 <212> PRT
 <213> Homo sapiens

```

<400> 145
Met Gly Cys Arg Ala Ala Ser Gly Leu Leu Pro Gly Val Ala Val Val
1      5      10      15
Leu Leu Leu Leu Leu Gln Ser Thr Gln Ser Val Tyr Ile Gln Tyr Gln
      20      25      30
Gly Phe Arg Val Gln Leu Glu Ser Met Lys Lys Leu Ser Asp Leu Glu
      35      40      45
Ala Gln Trp Ala Pro Ser Pro Arg Leu Gln Ala Gln Ser Leu Leu Pro
      50      55      60
Ala Val Cys His His Pro Ala Leu Pro Gln Asp Leu Gln Pro Val Cys
65      70      75      80
Ala Ser Gln Glu Ala Ser Ser Ile Phe Lys Thr Leu Arg Thr Ile Ala
      85      90      95
Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
      100      105      110

```

<210> 146
 <211> 917
 <212> PRT
 <213> Homo sapiens

```

<400> 146
Met Gly Leu Phe Arg Gly Phe Val Phe Leu Leu Val Leu Cys Leu Leu
1      5      10      15
His Gln Ser Asn Thr Ser Phe Ile Lys Leu Asn Asn Asn Gly Phe Glu
      20      25      30
Asp Ile Val Ile Val Ile Asp Pro Ser Val Pro Glu Asp Glu Lys Ile
      35      40      45
Ile Glu Gln Ile Glu Asp Met Val Thr Thr Ala Ser Thr Tyr Leu Phe
      50      55      60
Glu Ala Thr Glu Lys Arg Phe Phe Phe Lys Asn Val Ser Ile Leu Ile
65      70      75      80
Pro Glu Asn Trp Lys Glu Asn Pro Gln Tyr Lys Arg Pro Lys His Glu
      85      90      95
Asn His Lys His Ala Asp Val Ile Val Ala Pro Pro Thr Leu Pro Gly
      100      105      110
Arg Asp Glu Pro Tyr Thr Lys Gln Phe Thr Glu Cys Gly Glu Lys Gly
      115      120      125
Glu Tyr Ile His Phe Thr Pro Asp Leu Leu Leu Gly Lys Lys Gln Asn
      130      135      140
Glu Tyr Gly Pro Pro Gly Lys Leu Phe Val His Glu Trp Ala His Leu
145      150      155      160
Arg Trp Gly Val Phe Asp Glu Tyr Asn Glu Asp Gln Pro Phe Tyr Arg

```

SEQUENCE LISTING 1657-2022.txt

165 170 175
 Ala Lys Ser Lys Lys Ile Glu Ala Thr Arg Cys Ser Ala Gly Ile Ser
 180 185 190
 Gly Arg Asn Arg Val Tyr Lys Cys Gln Gly Gly Ser Cys Leu Ser Arg
 195 200 205
 Ala Cys Arg Ile Asp Ser Thr Thr Lys Leu Tyr Gly Lys Asp Cys Gln
 210 215 220
 Phe Phe Pro Asp Lys Val Gln Thr Glu Lys Ala Ser Ile Met Phe Met
 225 230 235 240
 Gln Ser Ile Asp Ser Val Val Glu Phe Cys Asn Glu Lys Thr His Asn
 245 250 255
 Gln Glu Ala Pro Ser Leu Gln Asn Ile Lys Cys Asn Phe Arg Ser Thr
 260 265 270
 Trp Glu Val Ile Ser Asn Ser Glu Asp Phe Lys Asn Thr Ile Pro Met
 275 280 285
 Val Thr Pro Pro Pro Pro Val Phe Ser Leu Leu Lys Ile Arg Gln
 290 295 300
 Arg Ile Val Cys Leu Val Leu Asp Lys Ser Gly Ser Met Gly Gly Lys
 305 310 315 320
 Asp Arg Leu Asn Arg Met Asn Gln Ala Ala Lys His Phe Leu Leu Gln
 325 330 335
 Thr Val Glu Asn Gly Ser Trp Val Gly Met Val His Phe Asp Ser Thr
 340 345 350
 Ala Thr Ile Val Asn Lys Leu Ile Gln Ile Lys Ser Ser Asp Glu Arg
 355 360 365
 Asn Thr Leu Met Ala Gly Leu Pro Thr Tyr Pro Leu Gly Gly Thr Ser
 370 375 380
 Ile Cys Ser Gly Ile Lys Tyr Ala Phe Gln Val Ile Gly Glu Leu His
 385 390 395 400
 Ser Gln Leu Asp Gly Ser Glu Val Leu Leu Leu Thr Asp Gly Glu Asp
 405 410 415
 Asn Thr Ala Ser Ser Cys Ile Asp Glu Val Lys Gln Ser Gly Ala Ile
 420 425 430
 Val His Phe Ile Ala Leu Gly Arg Ala Ala Asp Glu Ala Val Ile Glu
 435 440 445
 Met Ser Lys Ile Thr Gly Gly Ser His Phe Tyr Val Ser Asp Glu Ala
 450 455 460
 Gln Asn Asn Gly Leu Ile Asp Ala Phe Gly Ala Leu Thr Ser Gly Asn
 465 470 475 480
 Thr Asp Leu Ser Gln Lys Ser Leu Gln Leu Glu Ser Lys Gly Leu Thr
 485 490 495
 Leu Asn Ser Asn Ala Trp Met Asn Asp Thr Val Ile Ile Asp Ser Thr
 500 505 510
 Val Gly Lys Asp Thr Phe Phe Leu Ile Thr Trp Asn Ser Leu Pro Pro
 515 520 525
 Ser Ile Ser Leu Trp Asp Pro Ser Gly Thr Ile Met Glu Asn Phe Thr
 530 535 540
 Val Asp Ala Thr Ser Lys Met Ala Tyr Leu Ser Ile Pro Gly Thr Ala
 545 550 555 560
 Lys Val Gly Thr Trp Ala Tyr Asn Leu Gln Ala Lys Ala Asn Pro Glu
 565 570 575
 Thr Leu Thr Ile Thr Val Thr Ser Arg Ala Ala Asn Ser Ser Val Pro
 580 585 590
 Pro Ile Thr Val Asn Ala Lys Met Asn Lys Asp Val Asn Ser Phe Pro
 595 600 605
 Ser Pro Met Ile Val Tyr Ala Glu Ile Leu Gln Gly Tyr Val Pro Val
 610 615 620
 Leu Gly Ala Asn Val Thr Ala Phe Ile Glu Ser Gln Asn Gly His Thr
 625 630 635 640
 Glu Val Leu Glu Leu Leu Asp Asn Gly Ala Gly Ala Asp Ser Phe Lys
 645 650 655
 Asn Asp Gly Val Tyr Ser Arg Tyr Phe Thr Ala Tyr Thr Glu Asn Gly
 660 665 670
 Arg Tyr Ser Leu Lys Val Arg Ala His Gly Gly Ala Asn Thr Ala Arg
 675 680 685
 Leu Lys Leu Arg Pro Pro Leu Asn Arg Ala Ala Tyr Ile Pro Gly Trp
 690 695 700

SEQUENCE LISTING 1657-2022.txt

```

val Val Asn Gly Glu Ile Glu Ala Asn Pro Pro Arg Pro Glu Ile Asp
705      710      715      720
Glu Asp Thr Gln Thr Leu Glu Asp Phe Ser Arg Thr Ala Ser Gly
725      730      735
Gly Ala Phe Val Val Ser Gln Val Pro Ser Leu Pro Leu Pro Asp Gln
740      745      750
Tyr Pro Pro Ser Gln Ile Thr Asp Leu Asp Ala Thr Val His Glu Asp
755      760      765
Lys Ile Ile Leu Thr Trp Thr Ala Pro Gly Asp Asn Phe Asp Val Gly
770      775      780
Lys Val Gln Arg Tyr Ile Ile Arg Ile Ser Ala Ser Ile Leu Asp Leu
785      790      795      800
Arg Asp Ser Phe Asp Asp Ala Leu Gln Val Asn Thr Thr Asp Leu Ser
805      810      815
Pro Lys Glu Ala Asn Ser Lys Glu Ser Phe Ala Phe Lys Pro Glu Asn
820      825      830
Ile Ser Glu Glu Asn Ala Thr His Ile Phe Ile Ala Ile Lys Ser Ile
835      840      845
Asp Lys Ser Asn Leu Thr Ser Lys Val Ser Asn Ile Ala Gln Val Thr
850      855      860
Leu Phe Ile Pro Gln Ala Asn Pro Asp Asp Ile Asp Pro Thr Pro Thr
865      870      875      880
Pro Thr Pro Thr Pro Asp Lys Ser His Asn Ser Gly Val Asn Ile Ser
885      890      895
Thr Leu Val Leu Ser Val Ile Gly Ser Val Val Ile Val Asn Phe Ile
900      905      910
Leu Ser Thr Thr Ile
915

```

<210> 147
 <211> 437
 <212> PRT
 <213> Homo sapiens

```

<400> 147
Met Ser Ala Val Leu Leu Leu Ala Leu Leu Gly Phe Ile Leu Pro Leu
1      5      10      15
Pro Gly Val Gln Ala Leu Leu Cys Gln Phe Gly Thr Val Gln His Val
20      25      30
Trp Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn Thr Ser
35      40      45
Cys Asp Ser Gly Leu Gly Cys Gln Asp Thr Leu Met Leu Ile Glu Ser
50      55      60
Gly Pro Gln Val Ser Leu Val Leu Ser Lys Gly Cys Thr Glu Ala Lys
65      70      75      80
Asp Gln Glu Pro Arg Val Thr Glu His Arg Met Gly Pro Gly Leu Ser
85      90      95
Leu Ile Ser Tyr Thr Phe Val Cys Arg Gln Glu Asp Phe Cys Asn Asn
100      105      110
Leu Val Asn Ser Leu Pro Leu Trp Ala Pro Gln Pro Pro Ala Asp Pro
115      120      125
Gly Ser Leu Arg Cys Pro Val Cys Leu Ser Met Glu Gly Cys Leu Glu
130      135      140
Gly Thr Thr Glu Glu Ile Cys Pro Lys Gly Thr Thr His Cys Tyr Asp
145      150      155      160
Gly Leu Leu Arg Leu Arg Gly Gly Gly Ile Phe Ser Asn Leu Arg Val
165      170      175
Gln Gly Cys Met Pro Gln Pro Gly Cys Asn Leu Leu Asn Gly Thr Gln
180      185      190
Glu Ile Gly Pro Val Gly Met Thr Glu Asn Cys Asn Arg Lys Asp Phe
195      200      205
Leu Thr Cys His Arg Gly Thr Thr Ile Met Thr His Gly Asn Leu Ala
210      215      220
Gln Glu Pro Thr Asp Trp Thr Thr Ser Asn Thr Glu Met Cys Glu Val
225      230      235      240
Gly Gln Val Cys Gln Glu Thr Leu Leu Leu Ile Asp Val Gly Leu Thr

```

SEQUENCE LISTING 1657-2022.txt

```

                245                250                255
Ser Thr Leu Val Gly Thr Lys Gly Cys Ser Thr Val Gly Ala Gln Asn
                260                265                270
Ser Gln Lys Thr Thr Ile His Ser Ala Pro Pro Gly Val Leu Val Ala
                275                280                285
Ser Tyr Thr His Phe Cys Ser Ser Asp Leu Cys Asn Ser Ala Ser Ser
                290                295                300
Ser Ser Val Leu Leu Asn Ser Leu Pro Pro Gln Ala Ala Pro Val Pro
305                310                315
Gly Asp Arg Gln Cys Pro Thr Cys Val Gln Pro Leu Gly Thr Cys Ser
                325                330                335
Ser Gly Ser Pro Arg Met Thr Cys Pro Arg Gly Ala Thr His Cys Tyr
                340                345                350
Asp Gly Tyr Ile His Leu Ser Gly Gly Gly Leu Ser Thr Lys Met Ser
355                360                365
Ile Gln Gly Cys Val Ala Gln Pro Ser Ser Phe Leu Leu Asn His Thr
370                375                380
Arg Gln Ile Gly Ile Phe Ser Ala Arg Glu Lys Arg Asp Val Gln Pro
385                390                395
Pro Ala Ser Gln His Glu Gly Gly Gly Ala Glu Gly Leu Glu Ser Leu
400                405                410                415
Thr Trp Gly Val Gly Leu Ala Leu Ala Pro Ala Leu Trp Trp Gly Val
420                425                430
Val Cys Pro Ser Cys
435

```

<210> 148
 <211> 452
 <212> PRT
 <213> Homo sapiens

```

<400> 148
Met Leu Cys Gly Arg Pro Arg Ser Ser Ser Asp Asn Arg Asn Phe Leu
1 5 10 15
Arg Glu Arg Ala Gly Leu Ser Ser Ala Val Gln Thr Arg Ile Gly
20 25 30
Asn Ser Ala Ala Ser Arg Arg Ser Pro Ala Ala Arg Pro Pro Val Pro
35 40 45
Ala Pro Pro Ala Leu Pro Arg Gly Arg Pro Gly Thr Glu Gly Ser Thr
50 55 60
Ser Leu Ser Ala Pro Ala Val Leu Val Val Ala Val Ala Val Val Val
65 70 75 80
Val Val Val Ser Ala Val Ala Trp Ala Met Ala Asn Tyr Ile His Val
85 90 95
Pro Pro Gly Ser Pro Glu Val Pro Lys Leu Asn Val Thr Val Gln Asp
100 105 110
Gln Glu Glu His Arg Cys Arg Glu Gly Ala Leu Ser Leu Leu Gln His
115 120 125
Leu Arg Pro His Trp Asp Pro Gln Glu Val Thr Leu Gln Leu Phe Thr
130 135 140
Asp Gly Ile Thr Asn Lys Leu Ile Gly Cys Tyr Val Gly Asn Thr Met
145 150 155 160
Glu Asp Val Val Leu Val Arg Ile Tyr Gly Asn Lys Thr Glu Leu Leu
165 170 175
Val Asp Arg Asp Glu Glu Val Lys Ser Phe Arg Val Leu Gln Ala His
180 185 190
Gly Cys Ala Pro Gln Leu Tyr Cys Thr Phe Asn Asn Gly Leu Cys Tyr
195 200 205
Glu Phe Ile Gln Gly Glu Ala Leu Asp Pro Lys His Val Cys Asn Pro
210 215 220
Ala Ile Phe Arg Leu Ile Ala Arg Gln Leu Ala Lys Ile His Ala Ile
225 230 235 240
His Ala His Asn Gly Trp Ile Pro Lys Ser Asn Leu Trp Leu Lys Met
245 250 255
Gly Lys Tyr Phe Ser Leu Ile Pro Thr Gly Phe Ala Asp Glu Asp Ile
260 265 270

```

SEQUENCE LISTING 1657-2022.txt

Asn Lys Arg Phe Leu Ser Asp Ile Pro Ser Ser Gln Ile Leu Gln Glu
 275 280 285
 Glu Met Thr Trp Met Lys Glu Ile Leu Ser Asn Leu Gly Ser Pro Val
 290 295 300
 Val Leu Cys His Asn Asp Leu Leu Cys Lys Asn Ile Ile Tyr Asn Glu
 305 310 315 320
 Lys Gln Gly Asp Val Gln Phe Ile Asp Tyr Glu Tyr Ser Gly Tyr Asn
 325 330 335
 Tyr Leu Ala Tyr Asp Ile Gly Asn His Phe Asn Glu Phe Ala Gly Val
 340 345 350
 Ser Asp Val Asp Tyr Ser Leu Tyr Pro Asp Arg Glu Leu Gln Ser Gln
 355 360 365
 Trp Leu Arg Ala Tyr Leu Glu Ala Tyr Lys Glu Phe Lys Gly Phe Gly
 370 375 380
 Thr Glu Val Thr Glu Lys Glu Val Glu Ile Leu Phe Ile Gln Val Asn
 385 390 395 400
 Gln Phe Ala Leu Ala Ser His Phe Phe Trp Gly Leu Trp Ala Leu Ile
 405 410 415
 Gln Ala Lys Tyr Ser Thr Ile Glu Phe Asp Phe Leu Gly Tyr Ala Ile
 420 425 430
 Val Arg Phe Asn Gln Tyr Phe Lys Met Lys Pro Glu Val Thr Ala Leu
 435 440 445
 Lys Val Pro Glu
 450

<210> 149
 <211> 192
 <212> PRT
 <213> Homo sapiens

<400> 149
 Met Gly Ser Leu Gly Ser Lys Asn Pro Gln Thr Lys Gln Ala Gln Val
 1 5 10 15
 Leu Leu Leu Gly Leu Asp Ser Ala Gly Lys Ser Thr Leu Leu Tyr Lys
 20 25 30
 Leu Lys Leu Ala Lys Asp Ile Thr Thr Ile Pro Thr Ile Gly Phe Asn
 35 40 45
 Val Glu Met Ile Glu Leu Glu Arg Asn Leu Ser Leu Thr Val Trp Asp
 50 55 60
 Val Gly Gly Gln Glu Lys Met Arg Thr Val Trp Gly Cys Tyr Cys Glu
 65 70 75 80
 Asn Thr Asp Gly Leu Val Tyr Val Val Asp Ser Thr Asp Lys Gln Arg
 85 90 95
 Leu Glu Glu Ser Gln Arg Gln Phe Glu His Ile Leu Lys Asn Glu His
 100 105 110
 Ile Lys Asn Val Pro Val Val Leu Leu Ala Asn Lys Gln Asp Met Pro
 115 120 125
 Gly Ala Leu Thr Ala Glu Asp Ile Thr Arg Met Phe Lys Val Lys Lys
 130 135 140
 Leu Cys Ser Asp Arg Asn Trp Tyr Val Gln Pro Cys Cys Ala Leu Thr
 145 150 155 160
 Gly Glu Gly Leu Ala Gln Gly Phe Arg Lys Leu Thr Gly Phe Val Lys
 165 170 175
 Ser His Met Lys Ser Arg Gly Asp Thr Leu Ala Phe Phe Lys Gln Asn
 180 185 190

<210> 150
 <211> 530
 <212> PRT
 <213> Homo sapiens

<400> 150
 Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln Leu Ser Cys
 1 5 10 15
 Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu

SEQUENCE LISTING 1657-2022.txt

```

      20      25      30
Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu Leu Val Gln
      35      40      45
Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser Thr Leu Val
      50      55      60
Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr Pro Thr Ser
      65      70      75      80
Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile Leu Asp Arg
      85      90      95
Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr Phe Ser Gln
      100      105      110
Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn Lys Leu Cys
      115      120      125
Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu Gln Glu Ser
      130      135      140
Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys Gly Glu Leu
      145      150      155      160
Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu Arg Phe Ser
      165      170      175
Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Phe Leu Phe Pro Pro
      180      185      190
Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Ile Phe
      195      200      205
Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe Asp Phe Trp
      210      215      220
Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val
      225      230      235      240
Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Glu Met
      245      250      255
Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg Pro Phe Leu
      260      265      270
Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro
      275      280      285
Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
      290      295      300
Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met Ser Glu Glu
      305      310      315      320
Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val
      325      330      335
Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly Ser Asn Thr
      340      345      350
Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro Lys
      355      360      365
Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile Tyr Glu Ala
      370      375      380
Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln
      385      390      395      400
His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Leu Ser Val
      405      410      415
Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala Leu Lys Ser
      420      425      430
Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys Leu Ser Arg
      435      440      445
Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala Val Phe Trp
      450      455      460
Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala
      465      470      475      480
Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp Val Ile Ala
      485      490      495
Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe
      500      505      510
Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys Lys Lys
      515      520      525
Arg Asp
      530

```

SEQUENCE LISTING 1657-2022.txt

<210> 151
 <211> 265
 <212> PRT
 <213> Homo sapiens

<400> 151
 Met Gly Ser Pro Ser Ala Cys Pro Tyr Arg Val Cys Ile Pro Trp Gln
 1 5 10 15
 Gly Leu Leu Thr Ala Ser Leu Thr Phe Trp Asn Leu Pro Asn
 20 25 30
 Ser Ala Gln Thr Asn Ile Asp Val Val Pro Phe Asn Val Ala Glu Gly
 35 40 45
 Lys Glu Val Leu Leu Val Val His Asn Glu Ser Gln Asn Leu Tyr Gly
 50 55 60
 Tyr Asn Trp Tyr Lys Gly Glu Arg Val His Ala Asn Tyr Arg Ile Ile
 65 70 75 80
 Gly Tyr Val Lys Asn Ile Ser Gln Glu Asn Ala Pro Gly Pro Ala His
 85 90 95
 Asn Gly Arg Glu Thr Ile Tyr Pro Asn Gly Thr Leu Leu Ile Gln Asn
 100 105 110
 Val Thr His Asn Asp Ala Gly Phe Tyr Thr Leu His Val Ile Lys Glu
 115 120 125
 Asn Leu Val Asn Glu Glu Val Thr Arg Gln Phe Tyr Val Phe Ser Glu
 130 135 140
 Pro Pro Lys Pro Ser Ile Thr Ser Asn Asn Phe Asn Pro Val Glu Asn
 145 150 155 160
 Lys Asp Ile Val Val Leu Thr Cys Gln Pro Glu Thr Gln Asn Thr Thr
 165 170 175
 Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Leu Val Ser Pro Arg Leu
 180 185 190
 Leu Leu Ser Thr Asp Asn Arg Thr Leu Val Leu Leu Ser Ala Thr Lys
 195 200 205
 Asn Asp Ile Gly Pro Tyr Glu Cys Glu Ile Gln Asn Pro Val Gly Ala
 210 215 220
 Ser Arg Ser Asp Pro Val Thr Leu Asn Val Arg Tyr Glu Ser Val Gln
 225 230 235 240
 Ala Ser Ser Pro Asp Leu Ser Ala Gly Thr Ala Val Ser Ile Met Ile
 245 250 255
 Gly Val Leu Ala Gly Met Ala Leu Ile
 260 265

<210> 152
 <211> 457
 <212> PRT
 <213> Homo sapiens

<400> 152
 Met Arg Ser Ala Ala Val Leu Ala Leu Leu Leu Cys Ala Gly Gln Val
 1 5 10 15
 Thr Ala Leu Pro Val Asn Ser Pro Met Asn Lys Gly Asp Thr Glu Val
 20 25 30
 Met Lys Cys Ile Val Glu Val Ile Ser Asp Thr Leu Ser Lys Pro Ser
 35 40 45
 Pro Met Pro Val Ser Gln Glu Cys Phe Glu Thr Leu Arg Gly Asp Glu
 50 55 60
 Arg Ile Leu Ser Ile Leu Arg His Gln Asn Leu Lys Glu Leu Gln
 65 70 75 80
 Asp Leu Ala Leu Gln Gly Ala Lys Glu Arg Ala His Gln Gln Lys Lys
 85 90 95
 His Ser Gly Phe Glu Asp Glu Leu Ser Glu Val Leu Glu Asn Gln Ser
 100 105 110
 Ser Gln Ala Glu Leu Lys Glu Ala Val Glu Glu Pro Ser Ser Lys Asp
 115 120 125
 Val Met Glu Lys Arg Glu Asp Ser Lys Glu Ala Glu Lys Ser Gly Glu
 130 135 140
 Ala Thr Asp Gly Ala Arg Pro Gln Ala Leu Pro Glu Pro Met Gln Glu
 Page 141

SEQUENCE LISTING 1657-2022.txt

```

145      150      155      160
Ser Lys Ala Glu Gly Asn Asn Gln Ala Pro Gly Glu Glu Glu Glu Glu
Glu Glu Glu Ala 165 Asn Thr His Pro 170 Pro Ala Ser Leu Pro Ser Gln
Lys Tyr Pro Gly 180 Thr 185 Pro 190
Gly Leu Val Asp Arg Glu Lys 200 Gly Leu Ser Ala Glu Gly Leu Ser Gln
Ala Lys Arg Glu Glu Glu Glu Glu Glu Glu Glu Glu Ala Glu Ala Gly
225 230 235 240
Glu Glu Ala Val Pro 245 Glu Glu Glu Gly Pro Thr Val Val Leu Asn Pro
His Pro Ser Leu Gly Tyr Lys Glu Ile Arg Lys Gly Glu Ser Arg Ser
Glu Ala Leu Ala Val Asp Gly Ala Gly Lys Pro Gly Ala Glu Glu Ala
Gln Asp Pro Glu Gly Lys Gly Glu Gln Glu His Ser Gln Gln Lys Glu
305 310 315 320
Lys Ser Gly Glu Leu Glu Gln Glu Glu Glu Arg Leu Ser Lys Glu Trp
Glu Asp Ser Lys Arg Trp Ser Lys Met Asp Gln Leu Ala Lys Glu Leu
Thr Ala Glu Lys Arg Leu Glu Gly Gln Glu Glu Glu Glu Asp Asn Arg
Asp Ser Ser Met Lys Leu Ser Phe Arg Ala Arg Ala Tyr Gly Phe Arg
Gly Pro Gly Pro Gln Leu Arg Arg Gly Trp Arg Pro Ser Ser Arg Glu
385 390 395 400
Asp Ser Leu Glu Ala Gly Leu Pro Leu Gln Val Arg Gly Tyr Pro Glu
Glu Lys Lys Glu Glu Glu Gly Ser Ala Asn Arg Arg Pro Glu Asp Gln
420 425 430 435
Glu Leu Glu Ser Leu Ser Ala Ile Glu Ala Glu Leu Glu Lys Val Ala
His Gln Leu Gln Ala Leu Arg Arg Gly
450 455

```

```

<210> 153
<211> 266
<212> PRT
<213> Homo sapiens

```

```

<400> 153
Met His Val Asn Gly Lys Val Ala Leu Val Thr Gly Ala Ala Gln Gly
1 5 10 15
Ile Gly Arg Ala Phe Ala Glu Ala Leu Leu Leu Lys Gly Ala Lys Val
20 25 30
Ala Leu Val Asp Trp Asn Leu Glu Ala Gly Val Gln Cys Lys Ala Ala
35 40 45
Leu His Glu Gln Phe Glu Pro Gln Lys Thr Leu Phe Ile Gln Cys Asp
50 55 60
Val Ala Asp Gln Gln Gln Leu Arg Asp Thr Phe Arg Lys Val Val Asp
65 70 75 80
His Phe Gly Arg Leu Asp Ile Leu Val Asn Asn Ala Gly Val Asn Asn
85 90 95
Glu Lys Asn Trp Glu Lys Thr Leu Gln Ile Asn Leu Val Ser Val Ile
100 105 110
Ser Gly Thr Tyr Leu Gly Leu Asp Tyr Met Ser Lys Gln Asn Gly Gly
115 120 125
Glu Gly Gly Ile Ile Ile Asn Met Ser Ser Leu Ala Gly Leu Met Pro
130 135 140
Val Ala Gln Gln Pro Val Tyr Cys Ala Ser Lys His Gly Ile Val Gly
145 150 155 160

```


SEQUENCE LISTING 1657-2022.txt

Phe Thr Arg Ser Ala Ala Leu Ala Ala Asn Leu Met Asn Ser Gly Val
 165 170 175
 Arg Leu Asn Ala Ile Cys Pro Gly Phe Val Asn Thr Ala Ile Leu Glu
 180 185 190
 Ser Ile Glu Lys Glu Glu Asn Met Gly Gln Tyr Ile Glu Tyr Lys Asp
 195 200 205
 His Ile Lys Asp Met Ile Lys Tyr Tyr Gly Ile Leu Asp Pro Pro Leu
 210 215 220
 Ile Ala Asn Gly Leu Ile Thr Leu Ile Glu Asp Asp Ala Leu Asn Gly
 225 230 235 240
 Ala Ile Met Lys Ile Thr Thr Ser Lys Gly Ile His Phe Gln Asp Tyr
 245 250 255
 Asp Thr Thr Pro Phe Gln Ala Lys Thr Gln
 260 265

<210> 154
 <211> 181
 <212> PRT
 <213> Homo sapiens

<400> 154
 Met Phe Ser Ala Ile Arg Ser Gln His Ser Gly Val Asp Ile Cys Ile
 1 5 10 15
 Asn Asn Ala Gly Leu Ala Arg Pro Asp Thr Leu Leu Ser Gly Ser Thr
 20 25 30
 Ser Gly Trp Lys Asp Met Phe Asn Val Asn Val Leu Ala Leu Ser Ile
 35 40 45
 Cys Thr Arg Glu Ala Tyr Gln Ser Met Lys Glu Arg Asn Val Asp Asp
 50 55 60
 Gly His Ile Ile Asn Ile Asn Ser Met Ser Gly His Arg Val Leu Pro
 65 70 75 80
 Leu Ser Val Thr His Phe Tyr Ser Ala Thr Lys Tyr Ala Val Thr Ala
 85 90 95
 Leu Thr Glu Gly Leu Arg Gln Glu Leu Arg Glu Ala Gln Thr His Ile
 100 105 110
 Arg Ala Thr Cys Ile Ser Pro Gly Val Val Glu Thr Gln Phe Ala Phe
 115 120 125
 Lys Leu His Asp Lys Asp Pro Glu Lys Ala Ala Thr Tyr Glu Gln
 130 135 140
 Met Lys Cys Leu Lys Pro Glu Asp Val Ala Glu Ala Val Ile Tyr Val
 145 150 155 160
 Leu Ser Thr Pro Ala His Ile Gln Ile Gly Asp Ile Gln Met Arg Pro
 165 170 175
 Thr Glu Gln Val Thr
 180

<210> 155
 <211> 312
 <212> PRT
 <213> Homo sapiens

<400> 155
 Met Arg Met Leu Leu Ala Leu Leu Ala Leu Ser Ala Ala Arg Pro Ser
 1 5 10 15
 Ala Ser Ala Glu Ser His Trp Cys Tyr Glu Val Gln Ala Glu Ser Ser
 20 25 30
 Asn Tyr Pro Cys Leu Val Pro Val Lys Trp Gly Gly Asn Cys Gln Lys
 35 40 45
 Asp Arg Gln Ser Pro Ile Asn Ile Val Thr Thr Lys Ala Lys Val Asp
 50 55 60
 Lys Lys Leu Gly Arg Phe Phe Phe Ser Gly Tyr Asp Lys Lys Gln Thr
 65 70 75 80
 Trp Thr Val Gln Asn Asn Gly His Ser Val Met Met Leu Leu Glu Asn
 85 90 95
 Lys Ala Ser Ile Ser Gly Gly Gly Leu Pro Ala Pro Tyr Gln Ala Lys

SEQUENCE LISTING 1657-2022.txt

100 105 110
 Gln Leu His Leu His Trp Ser Asp Leu Pro Tyr Lys Gly Ser Glu His
 115 120 125
 Ser Leu Asp Gly Glu His Phe Ala Met Glu Met His Ile Val His Glu
 130 135 140
 Lys Glu Lys Gly Thr Ser Arg Asn Val Lys Glu Ala Gln Asp Pro Glu
 145 150 155 160
 Asp Glu Ile Ala Val Leu Ala Phe Leu Val Glu Ala Gly Thr Gln Val
 165 170 175
 Asn Glu Gly Phe Gln Pro Leu Val Glu Ala Leu Ser Asn Ile Pro Lys
 180 185 190
 Pro Glu Met Ser Thr Thr Met Ala Glu Ser Ser Leu Leu Asp Leu Leu
 195 200 205
 Pro Lys Glu Glu Lys Leu Arg His Tyr Phe Arg Tyr Leu Gly Ser Leu
 210 215 220
 Thr Thr Pro Thr Cys Asp Glu Lys Val Val Trp Thr Val Phe Arg Glu
 225 230 235 240
 Pro Ile Gln Leu His Arg Glu Gln Ile Leu Ala Phe Ser Gln Lys Leu
 245 250 255
 Tyr Tyr Asp Lys Glu Gln Thr Val Ser Met Lys Asp Asn Val Arg Pro
 260 265 270
 Leu Gln Gln Leu Gly Gln Arg Thr Val Ile Lys Ser Gly Ala Pro Gly
 275 280 285
 Arg Pro Leu Pro Trp Ala Leu Pro Ala Leu Leu Gly Pro Met Leu Ala
 290 295 300
 Cys Leu Leu Ala Gly Phe Leu Arg
 305 310

<210> 156

<211> 398

<212> PRT

<213> Homo sapiens

<400> 156

Met Leu Arg Leu Tyr Val Leu Val Met Gly Val Ser Ala Phe Thr Leu
 1 5 10 15
 Gln Pro Ala Ala His Thr Gly Ala Ala Arg Ser Cys Arg Phe Arg Gly
 20 25 30
 Arg His Tyr Lys Arg Glu Phe Arg Leu Glu Gly Glu Pro Val Ala Leu
 35 40 45
 Arg Cys Pro Gln Val Pro Tyr Trp Leu Trp Ala Ser Val Ser Pro Arg
 50 55 60
 Ile Asn Leu Thr Trp His Lys Asn Asp Ser Ala Arg Thr Val Pro Gly
 65 70 75 80
 Glu Glu Glu Thr Arg Met Trp Ala Gln Asp Gly Ala Leu Trp Leu Leu
 85 90 95
 Pro Ala Leu Gln Glu Asp Ser Gly Thr Tyr Val Cys Thr Thr Arg Asn
 100 105 110
 Ala Ser Tyr Cys Asp Lys Met Ser Ile Glu Leu Arg Val Phe Glu Asn
 115 120 125
 Thr Asp Ala Phe Leu Pro Phe Ile Ser Tyr Pro Gln Ile Leu Thr Leu
 130 135 140
 Ser Thr Ser Gly Val Leu Val Cys Pro Asp Leu Ser Glu Phe Thr Arg
 145 150 155 160
 Asp Lys Thr Asp Val Lys Ile Gln Trp Tyr Lys Asp Ser Leu Leu Leu
 165 170 175
 Asp Lys Asp Asn Glu Lys Phe Leu Ser Val Arg Gly Thr Thr His Leu
 180 185 190
 Leu Val His Asp Val Ala Leu Glu Asp Ala Gly Tyr Tyr Arg Cys Val
 195 200 205
 Leu Thr Phe Ala His Glu Gly Gln Gln Tyr Asn Ile Thr Arg Ser Ile
 210 215 220
 Glu Leu Arg Ile Lys Lys Lys Glu Glu Thr Ile Pro Val Ile Ile
 225 230 235 240
 Ser Pro Leu Lys Thr Ile Ser Ala Ser Leu Gly Ser Arg Leu Thr Ile
 245 250 255

SEQUENCE LISTING 1657-2022.txt

Pro Cys Lys Val Phe Leu Gly Thr Gly Thr Pro Leu Thr Thr Met Leu
 260 265 270
 Trp Trp Thr Ala Asn Asp Thr His Ile Glu Ser Ala Tyr Pro Gly Gly
 275 280 285
 Arg Val Thr Glu Gly Pro Arg Gln Glu Tyr Ser Glu Asn Asn Glu Asn
 290 295 300
 Tyr Ile Glu Val Pro Leu Ile Phe Asp Pro Val Thr Arg Glu Asp Leu
 305 310 315 320
 His Met Asp Phe Lys Cys Val Val His Asn Thr Leu Ser Phe Gln Thr
 325 330 335
 Leu Arg Thr Thr Val Lys Glu Ala Ser Ser Thr Phe Ser Trp Gly Ile
 340 345 350
 Val Leu Ala Pro Leu Ser Leu Ala Phe Leu Val Leu Gly Ile Trp
 355 360 365
 Met His Arg Arg Cys Lys His Arg Thr Gly Lys Ala Asp Gly Leu Thr
 370 375 380
 Val Leu Trp Pro His His Gln Asp Phe Gln Ser Tyr Pro Lys
 385 390 395

<210> 157
 <211> 160
 <212> PRT
 <213> Homo sapiens

<400> 157
 Met Glu Lys Phe Asn Thr Ile Ser Ala Ser Lys Cys Asn Lys Glu Thr
 1 5 10 15
 Val Ala Met Lys Glu Lys Cys Lys Phe Gly Met Thr Ser Thr Ile Pro
 20 25 30
 Ser Gly His Val Trp Arg Asn Thr Trp Asn Pro Val Ser Cys Ser Leu
 35 40 45
 Ala Thr Val Lys Met Lys Glu Cys Leu Arg Gly Lys Leu Ile Tyr Leu
 50 55 60
 Met Gly Asp Ser Thr Ile Arg Gln Trp Met Glu Tyr Phe Lys Ala Ser
 65 70 75 80
 Ile Asn Thr Leu Lys Ser Val Asp Leu His Glu Ser Gly Lys Leu Gln
 85 90 95
 His Gln Leu Ala Val Asp Leu Asp Arg Asn Ile Asn Ile Gln Trp Gln
 100 105 110
 Lys Tyr Cys Tyr Pro Leu Ile Gly Ser Met Thr Tyr Ser Val Lys Glu
 115 120 125
 Met Glu Tyr Leu Thr Arg Ala Ile Asp Arg Thr Gly Gly Glu Lys Lys
 130 135 140
 Tyr Cys His Cys Tyr Phe Pro Gly Pro Ala Phe Gln Thr Leu Ser His
 145 150 155 160

<210> 158
 <211> 267
 <212> PRT
 <213> Homo sapiens

<400> 158
 Met Met Ser Ser Lys Pro Thr Ser His Ala Glu Val Asn Glu Thr Ile
 1 5 10 15
 Pro Asn Pro Tyr Pro Pro Gly Ser Phe Met Ala Pro Gly Phe Gln Gln
 20 25 30
 Pro Leu Gly Ser Ile Asn Leu Glu Asn Gln Ala Gln Gly Ala Gln Arg
 35 40 45
 Ala Gln Pro Tyr Gly Ile Thr Ser Pro Gly Ile Phe Ala Ser Ser Gln
 50 55 60
 Pro Gly Gln Gly Asn Ile Gln Met Ile Asn Pro Ser Val Gly Thr Ala
 65 70 75 80
 Val Met Asn Phe Lys Glu Glu Ala Lys Ala Leu Gly Val Ile Gln Ile
 85 90 95
 Met Val Gly Leu Met His Ile Gly Phe Gly Ile Val Leu Cys Leu Ile

SEQUENCE LISTING 1657-2022.txt

```

100      105      110
Ser Phe Ser Phe Arg Glu Val Leu Gly Phe Ala Ser Thr Ala Val Ile
115
Gly Gly Tyr Pro Phe Trp Gly Gly Leu Ser Phe Ile Ile Ser Gly Ser
130
Leu Ser Val Ser Ala Ser Lys Glu Leu Ser Arg Cys Leu Val Lys Gly
145
Ser Leu Gly Met Asn Ile Val Ser Ser Ile Leu Ala Phe Ile Gly Val
165
Ile Leu Leu Leu Val Asp Met Cys Ile Asn Gly Val Ala Gly Gln Asp
180
Tyr Trp Ala Val Leu Ser Gly Lys Gly Ile Ser Ala Thr Leu Met Ile
195
Phe Ser Leu Leu Glu Phe Phe Val Ala Cys Ala Thr Ala His Phe Ala
210
Asn Gln Ala Asn Thr Thr Thr Asn Met Ser Val Leu Val Ile Pro Asn
225
Met Tyr Glu Ser Asn Pro Val Thr Pro Ala Ser Ser Ser Ala Pro Pro
245
Arg Cys Asn Asn Tyr Ser Ala Asn Ala Pro Lys
260

```

<210> 159
 <211> 157
 <212> PRT
 <213> Homo sapiens

```

<400> 159
Met Leu Val Leu Leu Ala Gly Ile Phe Val Val His Ile Ala Thr Val
1      5      10
Ile Met Leu Phe Val Ser Thr Ile Ala Asn Val Trp Leu Val Ser Asn
20
Thr Val Asp Ala Ser Val Gly Leu Trp Lys Asn Cys Thr Asn Ile Ser
35
Cys Ser Asp Ser Leu Ser Tyr Ala Ser Glu Asp Ala Leu Lys Thr Val
50
Gln Ala Phe Met Ile Leu Ser Ile Ile Phe Cys Val Ile Ala Leu Leu
65
Val Phe Val Phe Gln Leu Phe Thr Met Glu Lys Gly Asn Arg Phe Phe
85
Leu Ser Gly Ala Thr Thr Leu Val Cys Trp Leu Cys Ile Leu Val Gly
100
Val Ser Ile Tyr Thr Ser His Tyr Ala Asn Arg Asp Gly Thr Gln Tyr
115
His His Gly Tyr Ser Tyr Ile Leu Gly Trp Ile Cys Phe Cys Phe Ser
130
Phe Ile Ile Gly Val Leu Tyr Leu Val Leu Arg Lys Lys
145
150
155

```

<210> 160
 <211> 1035
 <212> PRT
 <213> Homo sapiens

```

<400> 160
Met Ser Thr Glu Asn Val Glu Gly Lys Pro Ser Asn Leu Gly Glu Arg
1      5      10
Gly Arg Ala Arg Ser Ser Thr Phe Leu Arg Val Val Gln Pro Met Phe
20
Asn His Ser Ile Phe Thr Ser Ala Val Ser Pro Ala Ala Glu Arg Ile
35
Arg Phe Ile Leu Gly Glu Glu Asp Asp Ser Pro Ala Pro Pro Gln Leu
50
Phe Thr Glu Leu Asp Glu Leu Leu Ala Val Asp Gly Gln Glu Met Glu
65
70
75
80

```

SEQUENCE LISTING 1657-2022.txt

Trp Lys Glu Thr Ala Arg Trp Ile Lys Phe Glu Glu Lys Val Glu Gln
 85 90 95
 Gly Gly Glu Arg Trp Ser Lys Pro His Val Ala Thr Leu Ser Leu His
 100 105 110
 Ser Leu Phe Glu Leu Arg Thr Cys Met Glu Lys Gly Ser Ile Met Leu
 115 120 125
 Asp Arg Glu Ala Ser Ser Leu Pro Gln Leu Val Glu Met Ile Val Asp
 130 135 140
 His Gln Ile Glu Thr Gly Leu Leu Lys Pro Glu Leu Lys Asp Lys Val
 145 150 155 160
 Thr Tyr Thr Leu Leu Arg Lys His Arg His Gln Thr Lys Lys Ser Asn
 165 170 175
 Leu Arg Ser Leu Ala Asp Ile Gly Lys Thr Val Ser Ser Ala Ser Arg
 180 185 190
 Met Phe Thr Asn Pro Asp Asn Gly Ser Pro Ala Met Thr His Arg Asn
 195 200 205
 Leu Thr Ser Ser Ser Leu Asn Asp Ile Ser Asp Lys Pro Glu Lys Asp
 210 215 220
 Gln Leu Lys Asn Lys Phe Met Lys Lys Leu Pro Arg Asp Ala Glu Ala
 225 230 235 240
 Ser Asn Val Leu Val Gly Glu Val Asp Phe Leu Asp Thr Pro Phe Ile
 245 250 255
 Ala Phe Val Arg Leu Gln Gln Ala Val Met Leu Gly Ala Leu Thr Glu
 260 265 270
 Val Pro Val Pro Thr Arg Phe Leu Phe Ile Leu Leu Gly Pro Lys Gly
 275 280 285
 Lys Ala Lys Ser Tyr His Glu Ile Gly Arg Ala Ile Ala Thr Leu Met
 290 295 300
 Ser Asp Glu Val Phe His Asp Ile Ala Tyr Lys Ala Lys Asp Arg His
 305 310 315 320
 Asp Leu Ile Ala Gly Ile Asp Glu Phe Leu Asp Glu Val Ile Val Leu
 325 330 335
 Pro Pro Gly Glu Trp Asp Pro Ala Ile Arg Ile Glu Pro Pro Lys Ser
 340 345 350
 Leu Pro Ser Ser Asp Lys Arg Lys Asn Met Tyr Ser Gly Gly Glu Asn
 355 360 365
 Val Gln Met Asn Gly Asp Thr Pro His Asp Gly Gly His Gly Gly Gly
 370 375 380
 Gly His Gly Asp Cys Glu Glu Leu Gln Arg Thr Gly Arg Phe Cys Gly
 385 390 395 400
 Gly Leu Ile Lys Asp Ile Lys Arg Lys Ala Pro Phe Phe Ala Ser Asp
 405 410 415
 Phe Tyr Asp Ala Leu Asn Ile Gln Ala Leu Ser Ala Ile Leu Phe Ile
 420 425 430
 Tyr Leu Ala Thr Val Thr Asn Ala Ile Thr Phe Gly Gly Leu Leu Gly
 435 440 445
 Asp Ala Thr Asp Asn Met Gln Gly Val Leu Glu Ser Phe Leu Gly Thr
 450 455 460
 Ala Val Ser Gly Ala Ile Phe Cys Leu Phe Ala Gly Gln Pro Leu Thr
 465 470 475 480
 Ile Leu Ser Ser Thr Gly Pro Val Leu Val Phe Glu Arg Leu Leu Phe
 485 490 495
 Asn Phe Ser Lys Asp Asn Asn Phe Asp Tyr Leu Glu Phe Arg Leu Trp
 500 505 510
 Ile Gly Leu Trp Ser Ala Phe Leu Cys Leu Ile Leu Val Ala Thr Asp
 515 520 525
 Ala Ser Phe Leu Val Gln Tyr Phe Thr Arg Phe Thr Glu Glu Gly Phe
 530 535 540
 Ser Ser Leu Ile Ser Phe Ile Phe Ile Tyr Asp Ala Phe Lys Lys Met
 545 550 555 560
 Ile Lys Leu Ala Asp Tyr Tyr Pro Ile Asn Ser Asn Phe Lys Val Gly
 565 570 575
 Tyr Asn Thr Leu Phe Ser Cys Thr Cys Val Pro Pro Asp Pro Ala Asn
 580 585 590
 Ile Ser Ile Ser Asn Asp Thr Thr Leu Ala Pro Glu Tyr Leu Pro Thr
 595 600 605
 Met Ser Ser Thr Asp Met Tyr His Asn Thr Thr Phe Asp Trp Ala Phe

SEQUENCE LISTING 1657-2022.txt

610
 Leu Ser Lys Lys Glu Cys 615 Ser Lys Tyr Gly Gly 620 Asn Leu Val Gly Asn
 625 Asn Cys Asn Phe Val 630 Pro Asp Ile Thr Leu 635 Met Ser Phe Ile Leu 640 Phe
 Leu Gly Thr Tyr 645 Ser Ser Met Ala 650 Leu Lys Lys Phe Lys 655 Thr Ser
 Pro Tyr Phe 660 Pro Thr Thr Ala Arg 665 Lys Leu Ile Ser Asp 670 Phe Ala Ile
 Ile Leu Ser Ile Leu Ile Phe 680 Cys Val Ile Asp Ala 685 Leu Val Gly Val
 690 Asp Thr Pro Lys Leu Ile 695 Val Pro Ser Glu Phe 700 Lys Pro Thr Ser Pro
 705 Asn Arg Gly Trp Phe 710 Val Pro Pro Phe Gly 715 Glu Asn Pro Trp Trp Val
 Cys Leu Ala Ala 725 Ile Pro Ala Leu 730 Leu Val Thr Ile Leu 735 Ile Phe
 Met Asp Gln Gln Ile Thr Ala Val 745 Ile Val Asn Arg Lys Glu His Lys
 Leu Lys 755 Lys Gly Ala Gly Tyr 760 His Leu Asp Leu Phe Trp Val Ala Ile
 Leu Met Val Ile Cys Ser 770 Leu Met Ala Leu Pro Trp Tyr Val Ala Ala
 785 Thr Val Ile Ser Ile 790 Ala His Ile Asp Ser 795 Leu Lys Met Glu Thr Glu
 Thr Ser Ala Pro Gly Glu Gln Pro Lys Phe Leu Gly Val Arg 800 Glu Gln
 Arg Val Thr 810 Gly Thr Leu Val Phe 815 Ile Leu Thr Gly Leu Ser Val Phe
 Met Ala Pro Ile Leu Lys Phe 820 Ile Pro Met Pro Val Leu Tyr Gly Val
 Phe 835 Leu Tyr Met Gly Val 840 Ala Ser Leu Asn Gly Val Gln Phe Met Asp
 850 Arg Leu Lys Leu Leu 855 Leu Met Pro Leu Lys His Gln Pro Asp Phe Ile
 Tyr Leu Arg His 865 Val Pro Leu Arg Arg Val His Leu Phe Thr Phe Leu
 Gln Val Leu Cys Leu Ala Leu Leu Trp Ile Leu Lys Ser Thr Val Ala
 Ala Ile 870 Phe Pro Val Met Ile Leu Ala Leu Val Ala Val Arg Lys
 Gly Met Asp Tyr Leu Phe Ser Gln His Asp Leu Ser Phe Leu Asp Asp
 945 Val Ile Pro Glu Lys Asp Lys Lys Lys 950 Glu Asp Glu Lys Lys Lys
 Lys Lys Lys Lys Gly Ser Leu Asp Ser Asp Asn Asp Asp Ser Asp Cys
 Pro Tyr Ser Glu Lys Val Pro Ser Ile Lys Ile Pro Met Asp Ile Met
 Glu Gln Gln Pro Phe Leu Ser Asp Ser Lys Pro Ser Asp Arg Glu Arg
 Ser Pro Thr Phe Leu Glu Arg His Thr Ser Cys 1000 1005
 1010 1015 1020 1025 1030 1035

<210> 161
 <211> 375
 <212> PRT
 <213> Homo sapiens

<400> 161
 Met Ser Thr Ala Gly Lys Val Ile Lys Cys Lys Ala Ala Val Leu Trp
 1 5 10 15
 Glu Leu Lys Lys Pro Phe Ser Ile Glu Val Glu Val Ala Pro Pro
 20 25 30
 Lys Ala His Glu Val Arg Ile Lys Met Val Ala Ala Gly Ile Cys Arg
 35 40 45

SEQUENCE LISTING 1657-2022.txt

```

Ser Asp Glu His Val Val Ser Gly Asn Leu Val Thr Pro Leu Pro Val
50 55 60
Ile Leu Gly His Glu Ala Ala Gly Ile Val Glu Ser Val Gly Glu Gly
65 70 75 80
Val Thr Thr Val Lys Pro Gly Asp Lys Val Ile Pro Leu Phe Thr Pro
85 90 95
Gln Cys Gly Lys Cys Arg Ile Cys Lys Asn Pro Glu Ser Asn Tyr Cys
100 105 110
Leu Lys Asn Asp Leu Gly Asn Pro Arg Gly Thr Leu Gln Asp Gly Thr
115 120 125
Arg Arg Phe Thr Cys Ser Gly Lys Pro Ile His His Phe Val Gly Val
130 135 140
Ser Thr Phe Ser Gln Tyr Thr Val Val Asp Glu Asn Ala Val Ala Lys
145 150 155 160
Ile Asp Ala Ala Ser Pro Leu Glu Lys Val Cys Leu Ile Gly Cys Gly
165 170 175
Phe Ser Thr Gly Tyr Gly Ser Ala Val Lys Val Ala Lys Val Thr Pro
180 185 190
Gly Ser Thr Cys Ala Val Phe Gly Leu Gly Gly Val Gly Leu Ser Val
195 200 205
Val Met Gly Cys Lys Ala Ala Gly Ala Ala Arg Ile Ala Val Asp
210 215 220
Ile Asn Lys Asp Lys Phe Ala Lys Ala Lys Glu Leu Gly Ala Thr Glu
225 230 235 240
Cys Ile Asn Pro Gln Asp Tyr Lys Lys Pro Ile Gln Glu Val Leu Lys
245 250 255
Glu Met Thr Asp Gly Gly Val Asp Phe Ser Phe Glu Val Ile Gly Arg
260 265 270
Leu Asp Thr Met Met Ala Ser Leu Leu Cys Cys His Glu Ala Cys Gly
275 280 285
Thr Ser Val Ile Val Gly Val Pro Pro Asp Ser Gln Asn Leu Ser Ile
290 295 300
Asn Pro Met Leu Leu Leu Thr Gly Arg Thr Trp Lys Gly Ala Ile Phe
305 310 315 320
Gly Gly Phe Lys Ser Lys Glu Ser Val Pro Lys Leu Val Ala Asp Phe
325 330 335
Met Ala Lys Lys Phe Ser Leu Asp Ala Leu Ile Thr Asn Ile Leu Pro
340 345 350
Phe Glu Lys Ile Asn Glu Gly Phe Asp Leu Leu Arg Ser Gly Lys Ser
355 360 365
Ile Arg Thr Val Leu Thr Phe
370 375

```

<210> 162
 <211> 526
 <212> PRT
 <213> Homo sapiens

```

<400> 162
Met Gly His Leu Ser Ala Pro Leu His Arg Val Arg Val Pro Trp Gln
1 5 10 15
Gly Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr
20 25 30
Thr Ala Gln Leu Thr Thr Glu Ser Met Pro Phe Asn Val Ala Glu Gly
35 40 45
Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln Gln Leu Phe Gly
50 55 60
Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Val
65 70 75 80
Gly Tyr Ala Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Asn Ser
85 90 95
Gly Arg Glu Thr Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Val
100 105 110
Thr Gln Asn Asp Thr Gly Phe Tyr Thr Leu Gln Val Ile Lys Ser Asp
115 120 125
Leu Val Asn Glu Glu Ala Thr Gly Gln Phe His Val Tyr Pro Glu Leu

```

SEQUENCE LISTING 1657-2022.txt

130
 Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys
 145
 Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Thr Thr Tyr
 160
 Leu Trp Trp Ile Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln
 175
 Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Leu Ser Val Thr Arg Asn
 190
 Asp Thr Gly Pro Tyr Glu Cys Glu Ile Gln Asn Pro Val Ser Ala Asn
 205
 Arg Ser Asp Pro Val Thr Leu Asn Val Thr Tyr Gly Pro Asp Thr Pro
 220
 Thr Ile Ser Pro Ser Asp Thr Tyr Tyr Arg Pro Gly Ala Asn Leu Ser
 235
 Leu Ser Cys Tyr Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Leu
 250
 Ile Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn
 265
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys His Ala Asn Asn Ser
 280
 Val Thr Gly Cys Asn Arg Thr Thr Val Lys Thr Ile Ile Val Thr Glu
 295
 305
 Leu Ser Pro Val Val Ala Lys Pro Gln Ile Lys Ala Ser Lys Thr Thr
 315
 Val Thr Gly Asp Lys Asp Ser Val Asn Leu Thr Cys Ser Thr Asn Asp
 330
 Thr Gly Ile Ser Ile Arg Trp Phe Phe Lys Asn Gln Ser Leu Pro Ser
 345
 Ser Glu Arg Met Lys Leu Ser Gln Gly Asn Thr Thr Leu Ser Ile Asn
 360
 Pro Val Lys Arg Glu Asp Ala Gly Thr Tyr Trp Cys Glu Val Phe Asn
 375
 Pro Ile Ser Lys Asn Gln Ser Asp Pro Ile Met Leu Asn Val Asn Tyr
 390
 Asn Ala Leu Pro Gln Glu Asn Gly Leu Ser Pro Gly Ala Ile Ala Gly
 405
 Ile Val Ile Gly Val Val Ala Leu Val Ala Leu Ile Ala Val Ala Leu
 420
 Ala Cys Phe Leu His Phe Gly Lys Thr Gly Arg Ala Ser Asp Gln Arg
 435
 445
 Asp Leu Thr Glu His Lys Pro Ser Val Ser Asn His Thr Gln Asp His
 460
 Ser Asn Asp Pro Pro Asn Lys Met Asn Glu Val Thr Tyr Ser Thr Leu
 475
 Asn Phe Glu Ala Gln Gln Pro Thr Gln Pro Thr Ser Ala Ser Pro Ser
 490
 Leu Thr Ala Thr Glu Ile Ile Tyr Ser Glu Val Lys Lys Gln
 505
 515
 520
 525

<210> 163
 <211> 255
 <212> PRT
 <213> Homo sapiens

<400> 163
 Met His Gln Lys Ile Ala Arg Glu Met Asn Leu Ser Glu Thr Ala Phe
 1 5 10 15
 Ile Arg Lys Leu His Pro Thr Asp Asn Phe Ala Gln Ser Ser Cys Phe
 20 25 30
 Gly Leu Arg Trp Phe Thr Pro Ala Ser Glu Val Pro Leu Cys Gly His
 35 40 45
 Ala Thr Leu Ala Ser Ala Ala Val Leu Phe His Lys Ile Lys Asn Met
 50 55 60
 Asn Ser Thr Leu Thr Phe Val Thr Leu Ser Gly Glu Leu Arg Ala Arg
 65 70 75 80

SEQUENCE LISTING 1657-2022.txt

Arg Ala Glu Asp Gly Ile Val Leu Asp Leu Pro Leu Tyr Pro Ala His
 85 90 95
 Pro Gln Asp Phe His Glu Val Glu Asp Leu Ile Lys Thr Ala Ile Gly
 100 105 110
 Asn Thr Leu Val Gln Asp Ile Cys Tyr Ser Pro Asp Thr Gln Lys Leu
 115 120 125
 Leu Val Arg Leu Ser Asp Val Tyr Asn Arg Ser Phe Leu Glu Asn Leu
 130 135 140
 Lys Val Asn Thr Glu Asn Leu Leu Gln Val Glu Asn Thr Gly Lys Val
 145 150 155 160
 Lys Gly Leu Ile Leu Thr Leu Lys Gly Glu Pro Gly Gly Gln Thr Gln
 165 170 175
 Ala Phe Asp Phe Tyr Ser Arg Tyr Phe Ala Pro Trp Val Gly Val Ala
 180 185 190
 Glu Asp Pro Val Thr Gly Ser Ala His Ala Val Leu Ser Ser Tyr Trp
 195 200 205
 Ser Gln His Leu Gly Lys Lys Glu Met His Ala Phe Gln Cys Ser His
 210 215 220
 Arg Gly Gly Glu Leu Gly Ile Ser Leu Arg Pro Asp Gly Arg Val Asp
 225 230 235 240
 Ile Arg Gly Gly Ala Val Val Leu Glu Gly Thr Leu Thr Ala
 245 250 255

<210> 164
 <211> 622
 <212> PRT
 <213> Homo sapiens

<400> 164
 Met Pro Pro Gln Leu Gln Asn Gly Leu Asn Leu Ser Ala Lys Val Val
 1 5 10 15
 Gln Gly Ser Leu Asp Ser Leu Pro Gln Ala Val Arg Glu Phe Leu Glu
 20 25 30
 Asn Asn Ala Glu Leu Cys Gln Pro Asp His Ile His Ile Cys Asp Gly
 35 40 45
 Ser Glu Glu Glu Asn Gly Arg Leu Leu Gly Gln Met Glu Glu Glu Gly
 50 55 60
 Ile Leu Arg Arg Leu Lys Lys Tyr Asp Asn Cys Trp Leu Ala Leu Thr
 65 70 75 80
 Asp Pro Arg Asp Val Ala Arg Ile Glu Ser Lys Thr Val Ile Val Thr
 85 90 95
 Gln Glu Gln Arg Asp Thr Val Pro Ile Pro Lys Thr Gly Leu Ser Gln
 100 105 110
 Leu Gly Arg Trp Met Ser Glu Glu Asp Phe Glu Lys Ala Phe Asn Ala
 115 120 125
 Arg Phe Pro Gly Cys Met Lys Gly Arg Thr Met Tyr Val Ile Pro Phe
 130 135 140
 Ser Met Gly Pro Leu Gly Ser Pro Leu Ser Lys Ile Gly Ile Glu Leu
 145 150 155 160
 Thr Asp Ser Pro Tyr Val Val Ala Ser Met Arg Ile Met Thr Arg Met
 165 170 175
 Gly Thr Pro Val Leu Glu Ala Leu Gly Asp Gly Glu Phe Val Lys Cys
 180 185 190
 Leu His Ser Val Gly Cys Pro Leu Pro Leu Gln Lys Pro Leu Val Asn
 195 200 205
 Asn Trp Pro Cys Asn Pro Glu Leu Thr Leu Ile Ala His Leu Pro Asp
 210 215 220
 Arg Arg Glu Ile Ile Ser Phe Gly Ser Gly Tyr Gly Gly Asn Ser Leu
 225 230 235 240
 Leu Gly Lys Lys Cys Phe Ala Leu Arg Met Ala Ser Arg Leu Ala Glu
 245 250 255
 Glu Glu Gly Trp Leu Ala Glu His Met Leu Ile Leu Gly Ile Thr Asn
 260 265 270
 Pro Glu Gly Glu Lys Lys Tyr Leu Ala Ala Ala Phe Pro Ser Ala Cys
 275 280 285
 Gly Lys Thr Asn Leu Ala Met Met Asn Pro Ser Leu Pro Gly Trp Lys

SEQUENCE LISTING 1657-2022.txt

```

290          295          300
Val Glu Cys Val Gly Asp Asp Ile Ala Trp Met Lys Phe Asp Ala Gln
305          310          315          320
Gly His Leu Arg Ala Ile Asn Pro Glu Asn Gly Phe Phe Gly Val Ala
          325          330          335
Pro Gly Thr Ser Val Lys Thr Asn Pro Asn Ala Ile Lys Thr Ile Gln
          340          345          350
Lys Asn Thr Ile Phe Thr Asn Val Ala Glu Thr Ser Asp Gly Gly Val
          355          360          365
Tyr Trp Glu Gly Ile Asp Glu Pro Leu Ala Ser Gly Val Thr Ile Thr
          370          375          380
Ser Trp Lys Asn Lys Glu Trp Ser Ser Glu Asp Gly Glu Pro Cys Ala
          385          390          395          400
His Pro Asn Ser Arg Phe Cys Thr Pro Ala Ser Gln Cys Pro Ile Ile
          405          410          415
Asp Ala Ala Trp Glu Ser Pro Glu Gly Val Pro Ile Glu Gly Ile Ile
          420          425          430
Phe Gly Gly Arg Arg Pro Ala Gly Val Pro Leu Val Tyr Glu Ala Leu
          435          440          445
Ser Trp Gln His Gly Val Phe Val Gly Ala Ala Met Arg Ser Glu Ala
          450          455          460
Thr Ala Ala Ala Glu His Lys Gly Lys Ile Ile Met His Asp Pro Phe
          465          470          475          480
Ala Met Arg Pro Phe Gly Tyr Asn Phe Gly Lys Tyr Leu Ala His
          485          490          495
Trp Leu Ser Met Ala Gln His Pro Ala Ala Lys Leu Pro Lys Ile Phe
          500          505          510
His Val Asn Trp Phe Arg Lys Asp Lys Glu Gly Lys Phe Leu Trp Pro
          515          520          525
Gly Phe Gly Glu Asn Ser Arg Val Leu Glu Trp Met Phe Asn Arg Ile
          530          535          540
Asp Gly Lys Ala Ser Thr Asn Val Thr Pro Ile Gly Tyr Ile Pro Lys
          545          550          555          560
Glu Asp Ala Leu Asn Leu Lys Gly Leu Gly His Ile Asn Met Met Glu
          565          570          575
Leu Phe Ser Ile Ser Lys Glu Phe Trp Asp Lys Glu Val Glu Asp Ile
          580          585          590
Glu Lys Tyr Leu Val Asp Gln Val Asn Ala Asp Leu Pro Cys Glu Ile
          595          600          605
Glu Arg Glu Ile Leu Ala Leu Lys Gln Arg Ile Ser Gln Met
          610          615          620

```

<210> 165
 <211> 530
 <212> PRT
 <213> Homo sapiens

```

<400> 165
Met Ser Leu Lys Trp Met Ser Val Phe Leu Leu Met Gln Leu Ser Cys
1          5          10          15
Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
          20          25          30
Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu Leu Val Gln
          35          40          45
Arg Gly His Glu Val Ile Val Leu Thr Ser Ser Ala Ser Ile Leu Val
          50          55          60
Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr Pro Thr Ser
          65          70          75          80
Leu Thr Lys Asn Asp Leu Glu Asp Phe Phe Met Lys Met Phe Asp Arg
          85          90          95
Trp Thr Tyr Ser Ile Ser Lys Asn Thr Phe Trp Ser Tyr Phe Ser Gln
          100          105          110
Leu Gln Glu Leu Cys Trp Glu Tyr Ser Asp Tyr Asn Ile Lys Leu Cys
          115          120          125
Glu Asp Ala Val Leu Asn Lys Lys Leu Met Arg Lys Leu Gln Glu Ser
          130          135          140

```

SEQUENCE LISTING 1657-2022.txt

Lys Phe Asp Val Leu Leu Ala Asp Ala Val Asn Pro Cys Gly Glu Leu
 145 150 155 160
 Leu Ala Glu Leu Leu Asn Ile Pro Phe Leu Tyr Ser Leu Arg Phe Ser
 165 170 175
 Val Gly Tyr Thr Val Glu Lys Asn Gly Gly Gly Phe Leu Phe Pro Pro
 180 185 190
 Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Ile Phe
 195 200 205
 Met Glu Arg Ile Lys Asn Met Ile Tyr Met Leu Tyr Phe Asp Phe Trp
 210 215 220
 Phe Gln Ala Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val
 225 230 235 240
 Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Glu Met
 245 250 255
 Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg Pro Phe Leu
 260 265 270
 Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro
 275 280 285
 Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
 290 295 300
 Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met Ser Glu Glu
 305 310 315 320
 Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val
 325 330 335
 Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly Ser Asn Thr
 340 345 350
 Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro Lys
 355 360 365
 Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile Tyr Glu Ala
 370 375 380
 Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln
 385 390 395 400
 His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Leu Ser Val
 405 410 415
 Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala Leu Lys Ser
 420 425 430
 Val Ile Asn Asp Pro Ile Tyr Lys Glu Asn Ile Met Lys Leu Ser Arg
 435 440 445
 Ile His His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp
 450 455 460
 Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala
 465 470 475 480
 Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp Val Ile Ala
 485 490 495
 Phe Leu Leu Ala Cys Val Ala Thr Met Ile Phe Met Ile Thr Lys Cys
 500 505 510
 Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys Lys Lys Lys
 515 520 525
 Arg Asp
 530

<210> 166
 <211> 387
 <212> PRT
 <213> Homo sapiens

<400> 166
 Met Ser Thr Phe Phe Ser Asp Thr Ala Trp Ile Cys Leu Ala Val Pro
 1 5 10 15
 Thr Val Leu Cys Gly Thr Val Phe Cys Lys Tyr Lys Lys Ser Ser Gly
 20 25 30
 Gln Leu Trp Ser Trp Met Val Cys Leu Ala Gly Leu Cys Ala Val Cys
 35 40 45
 Leu Leu Ile Leu Ser Pro Phe Trp Gly Leu Ile Leu Phe Ser Val Ser
 50 55 60
 Cys Phe Leu Met Tyr Thr Tyr Leu Ser Gly Gln Glu Leu Leu Pro Val
 Page 153

SEQUENCE LISTING 1657-2022.txt

```

65      70      75      80
Asp Gln Lys Ala Val Leu Val Thr Gly Gly Asp Cys Gly Leu Gly His
      85      90      95
Ala Leu Cys Lys Tyr Leu Asp Glu Leu Gly Phe Thr Val Phe Ala Gly
      100      105      110
Val Leu Asn Glu Asn Gly Pro Gly Ala Glu Glu Leu Arg Arg Thr Cys
      115      120      125
Ser Pro Arg Leu Ser Val Leu Gln Met Asp Ile Thr Lys Pro Val Gln
      130      135      140
Ile Lys Asp Ala Tyr Ser Lys Val Ala Ala Met Leu Gln Asp Arg Gly
      145      150      155
Leu Trp Ala Val Ile Asn Asn Ala Gly Val Leu Gly Phe Pro Thr Asp
      160      165      170
Gly Glu Leu Leu Leu Met Thr Asp Tyr Lys Gln Cys Met Ala Val Asn
      175      180      185
Phe Phe Gly Thr Val Glu Val Thr Lys Thr Phe Leu Pro Leu Leu Arg
      190      195      200
Lys Ser Lys Gly Arg Leu Val Asn Val Ser Ser Met Gly Gly Ala
      205      210      215
Pro Met Glu Arg Leu Ala Ser Tyr Gly Ser Ser Lys Ala Ala Val Thr
      220      225      230
Met Phe Ser Ser Val Met Arg Leu Glu Leu Ser Lys Trp Gly Ile Lys
      235      240      245
Val Ala Ser Ile Gln Pro Gly Gly Phe Leu Thr Asn Ile Ala Gly Thr
      250      255      260
Ser Asp Lys Trp Glu Lys Leu Glu Lys Asp Ile Leu Asp His Leu Pro
      265      270      275
Ala Glu Val Gln Glu Asp Tyr Gly Gln Asp Tyr Ile Leu Ala Gln Arg
      280      285      290
Asn Phe Leu Leu Leu Ile Asn Ser Leu Ala Ser Lys Asp Phe Ser Pro
      295      300      305
Val Leu Arg Asp Ile Gln His Ala Ile Leu Ala Lys Ser Pro Phe Ala
      310      315      320
Tyr Tyr Thr Pro Gly Lys Gly Ala Tyr Leu Trp Ile Cys Leu Ala His
      325      330      335
Tyr Leu Pro Ile Gly Ile Tyr Asp Tyr Phe Ala Lys Arg His Phe Gly
      340      345      350
Gln Asp Lys Pro Met Pro Arg Ala Leu Arg Met Pro Asn Tyr Lys Lys
      355      360      365
Lys Ala Thr
      370      375      380
385

```

<210> 167

<211> 196

<212> PRT

<213> Homo sapiens

<400> 167

```

Met Gly Ser Arg Ser Ser His Ala Ala Val Ile Pro Asp Gly Asp Ser
1      5      10      15
Ile Arg Arg Glu Thr Gly Phe Ser Gln Ala Ser Leu Leu Arg Leu His
      20      25      30
His Arg Phe Arg Ala Leu Asp Arg Asn Lys Lys Gly Tyr Leu Ser Arg
      35      40      45
Met Asp Leu Gln Gln Ile Gly Ala Leu Ala Val Asn Pro Leu Gly Asp
      50      55      60
Arg Ile Ile Glu Ser Phe Pro Asp Gly Ser Gln Arg Val Asp Phe
      65      70      75
Pro Gly Phe Val Arg Val Leu Ala His Phe Arg Pro Val Glu Asp Glu
      80      85      90
Asp Thr Glu Thr Gln Asp Pro Lys Lys Pro Glu Pro Leu Asn Ser Arg
      95      100      105
Arg Asn Lys Leu His Tyr Ala Phe Gln Leu Tyr Asp Leu Asp Arg Asp
      110      115      120
Gly Lys Ile Ser Arg His Glu Met Leu Gln Val Leu Arg Leu Met Val
      125      130      135
130

```

SEQUENCE LISTING 1657-2022.txt

Gly Val Gln Val Thr Glu Glu Gln Leu Glu Asn Ile Ala Asp Arg Thr
 145 150 155 160
 Val Gln Glu Ala Asp Glu Asp Gly Asp Gly Ala Val Ser Phe Val Glu
 165 170 175
 Phe Thr Lys Ser Leu Glu Lys Met Asp Val Glu Gln Lys Met Ser Ile
 180 185 190
 Arg Ile Leu Lys
 195

<210> 168
 <211> 319
 <212> PRT
 <213> Homo sapiens

<400> 168
 Met Leu Phe Trp Val Leu Gly Leu Leu Ile Leu Cys Gly Phe Leu Trp
 1 5 10 15
 Thr Arg Lys Gly Lys Leu Lys Ile Glu Asp Ile Thr Asp Lys Tyr Ile
 20 25 30
 Phe Ile Thr Gly Cys Asp Ser Gly Phe Gly Asn Leu Ala Ala Arg Thr
 35 40 45
 Phe Asp Lys Lys Gly Phe His Val Ile Ala Ala Cys Leu Thr Glu Ser
 50 55 60
 Gly Ser Thr Ala Leu Lys Ala Glu Thr Ser Glu Arg Leu Arg Thr Val
 65 70 75 80
 Leu Leu Asp Val Thr Asp Pro Glu Asn Val Lys Arg Thr Ala Gln Trp
 85 90 95
 Val Lys Asn Gln Val Gly Glu Lys Gly Leu Trp Gly Leu Ile Asn Asn
 100 105 110
 Ala Gly Val Pro Gly Val Leu Ala Pro Thr Asp Trp Leu Thr Leu Glu
 115 120 125
 Asp Tyr Arg Glu Pro Ile Glu Val Asn Leu Phe Gly Leu Ile Ser Val
 130 135 140
 Thr Leu Asn Met Leu Pro Leu Val Lys Lys Ala Gln Gly Arg Val Ile
 145 150 155 160
 Asn Val Ser Ser Val Gly Gly Arg Leu Ala Ile Val Gly Gly Gly Tyr
 165 170 175
 Thr Pro Ser Lys Tyr Ala Val Glu Gly Phe Asn Asp Ser Leu Arg Arg
 180 185 190
 Asp Met Lys Ala Phe Gly Val His Val Ser Cys Ile Glu Pro Gly Leu
 195 200 205
 Phe Lys Thr Asn Leu Ala Asp Pro Val Lys Val Ile Glu Lys Lys Leu
 210 215 220
 Ala Ile Trp Glu Gln Leu Ser Pro Asp Ile Lys Gln Gln Tyr Gly Glu
 225 230 235 240
 Gly Tyr Ile Glu Lys Ser Leu Asp Lys Leu Lys Gly Asn Lys Ser Tyr
 245 250 255
 Val Asn Met Asp Leu Ser Pro Val Val Glu Cys Met Asp His Ala Leu
 260 265 270
 Thr Ser Leu Phe Pro Lys Thr His Tyr Ala Ala Gly Lys Asp Ala Lys
 275 280 285
 Ile Phe Trp Ile Pro Leu Ser His Met Pro Ala Ala Leu Gln Asp Phe
 290 295 300
 Leu Leu Leu Lys Gln Lys Ala Glu Leu Ala Asn Pro Lys Ala Val
 305 310 315

<210> 169
 <211> 200
 <212> PRT
 <213> Homo sapiens

<400> 169
 Met Gly Gln Glu Phe Ser Trp Glu Glu Ala Glu Ala Ala Gly Glu Ile
 1 5 10 15
 Asp Val Ala Glu Leu Gln Glu Trp Tyr Lys Lys Phe Val Met Glu Cys
 Page 155

SEQUENCE LISTING 1657-2022.txt

```

      20      25      30
Pro Ser Gly Thr Leu Phe Met His Glu Phe Lys Arg Phe Phe Lys Val
      35      40      45
Thr Asp Asp Glu Glu Ala Ser Gln Tyr Val Glu Gly Met Phe Arg Ala
      50      55      60
Phe Asp Lys Asn Gly Asp Asn Thr Ile Asp Phe Leu Glu Tyr Val Ala
      65      70      75      80
Ala Leu Asn Leu Val Leu Arg Gly Thr Leu Glu His Lys Leu Lys Trp
      85      90      95
Thr Phe Lys Ile Tyr Asp Lys Asp Gly Asn Gly Cys Ile Asp Arg Leu
      100      105      110
Glu Leu Leu Asn Ile Val Glu Gly Ile Tyr Gln Leu Lys Lys Ala Cys
      115      120      125
Arg Arg Glu Leu Gln Thr Glu Gln Asp Gln Leu Leu Thr Pro Glu Glu
      130      135      140
Val Val Asp Arg Ile Phe Leu Leu Val Asp Glu Asn Gly Asp Gly Gln
      145      150      155      160
Leu Ser Leu Asn Glu Phe Val Glu Gly Ala Arg Arg Asp Lys Trp Val
      165      170      175
Met Lys Met Leu Gln Met Asp Met Asn Pro Ser Ser Trp Leu Ala Gln
      180      185      190
Gln Arg Arg Lys Ser Ala Met Phe
      195      200

```

<210> 170
 <211> 280
 <212> PRT
 <213> Homo sapiens

```

<400> 170
Met Ala Glu Lys Phe Asp Cys His Tyr Cys Arg Asp Pro Leu Gln Gly
  1      5      10      15
Lys Lys Tyr Val Gln Lys Asp Gly His His Cys Cys Leu Lys Cys Phe
      20      25      30
Asp Lys Phe Cys Ala Asn Thr Cys Val Glu Cys Arg Lys Pro Ile Gly
      35      40      45
Ala Asp Ser Lys Glu Val His Tyr Lys Asn Arg Phe Trp His Asp Thr
      50      55      60
Cys Phe Arg Cys Ala Lys Cys Leu His Pro Leu Ala Asn Glu Thr Phe
      65      70      75      80
Val Ala Lys Asp Asn Lys Ile Leu Cys Asn Lys Cys Thr Thr Arg Glu
      85      90      95
Asp Ser Pro Lys Cys Lys Gly Cys Phe Lys Ala Ile Val Ala Gly Asp
      100      105      110
Gln Asn Val Glu Tyr Lys Gly Thr Val Trp His Lys Asp Cys Phe Thr
      115      120      125
Cys Ser Asn Cys Lys Gln Val Ile Gly Thr Gly Ser Phe Phe Pro Lys
      130      135      140
Gly Glu Asp Phe Tyr Cys Val Thr Cys His Glu Thr Lys Phe Ala Lys
      145      150      155      160
His Cys Val Lys Cys Asn Lys Ala Ile Thr Ser Gly Gly Ile Thr Tyr
      165      170      175
Gln Asp Gln Pro Trp His Ala Asp Cys Phe Val Cys Val Thr Cys Ser
      180      185      190
Lys Lys Leu Ala Gly Gln Arg Phe Thr Ala Val Glu Asp Gln Tyr Tyr
      195      200      205
Cys Val Asp Cys Tyr Lys Asn Phe Val Ala Lys Lys Cys Ala Gly Cys
      210      215      220
Lys Asn Pro Ile Thr Gly Phe Gly Lys Gly Ser Ser Val Val Ala Tyr
      225      230      235      240
Glu Gly Gln Ser Trp His Asp Tyr Cys Phe His Cys Lys Lys Cys Ser
      245      250      255
Val Asn Leu Ala Asn Lys Arg Phe Val Phe His Gln Glu Gln Val Tyr
      260      265      270
Cys Pro Asp Cys Ala Lys Lys Leu
      275      280

```

SEQUENCE LISTING 1657-2022.txt

<210> 171
 <211> 470
 <212> PRT
 <213> Homo sapiens

<400> 171
 Met Leu Arg Gly Ile Ser Gln Leu Pro Ala Val Ala Thr Met Ser Trp
 1 5 10 15
 Val Leu Leu Pro Val Leu Trp Leu Ile Val Gln Thr Gln Ala Ile Ala
 20 25 30
 Ile Lys Gln Thr Pro Glu Leu Thr Leu His Glu Ile Val Cys Pro Lys
 35 40 45
 Lys Leu His Ile Leu His Lys Arg Glu Ile Lys Asn Asn Gln Thr Glu
 50 55 60
 Lys His Gly Lys Glu Glu Arg Tyr Glu Pro Glu Val Gln Tyr Gln Met
 65 70 75 80
 Ile Leu Asn Gly Glu Glu Ile Ile Leu Ser Leu Gln Lys Thr Lys His
 85 90 95
 Leu Leu Gly Pro Asp Tyr Thr Glu Thr Leu Tyr Ser Pro Arg Gly Glu
 100 105 110
 Glu Ile Thr Thr Lys Pro Glu Asn Met Glu His Cys Tyr Tyr Lys Gly
 115 120 125
 Asn Ile Leu Asn Glu Lys Asn Ser Val Ala Ser Ile Ser Thr Cys Asp
 130 135 140
 Gly Leu Arg Gly Tyr Phe Thr His His His Gln Arg Tyr Gln Ile Lys
 145 150 155 160
 Pro Leu Lys Ser Thr Asp Glu Lys Glu His Ala Val Phe Thr Ser Asn
 165 170 175
 Gln Glu Glu Gln Asp Pro Ala Asn His Thr Cys Gly Val Lys Ser Thr
 180 185 190
 Asp Gly Lys Gln Gly Pro Ile Arg Ile Ser Arg Ser Leu Lys Ser Pro
 195 200 205
 Glu Lys Glu Asp Phe Leu Arg Ala Gln Lys Tyr Ile Asp Leu Tyr Leu
 210 215 220
 Val Leu Asp Asn Ala Phe Tyr Lys Asn Tyr Asn Glu Asn Leu Thr Leu
 225 230 235 240
 Ile Arg Ser Phe Val Phe Asp Val Met Asn Leu Leu Asn Val Ile Tyr
 245 250 255
 Asn Thr Ile Asp Val Gln Val Ala Leu Val Gly Met Glu Ile Trp Ser
 260 265 270
 Asp Gly Asp Lys Ile Lys Val Val Pro Ser Ala Ser Thr Thr Phe Asp
 275 280 285
 Asn Phe Leu Arg Trp His Ser Ser Asn Leu Gly Lys Lys Ile His Asp
 290 295 300
 His Ala Gln Leu Leu Ser Gly Ile Ser Phe Asn Asn Arg Arg Val Gly
 305 310 315 320
 Leu Ala Ala Ser Asn Ser Leu Cys Ser Pro Ser Ser Val Ala Val Ile
 325 330 335
 Glu Ala Lys Lys Lys Asn Asn Val Ala Leu Val Gly Val Met Ser His
 340 345 350
 Glu Leu Gly His Val Leu Gly Met Pro Asp Val Pro Phe Asn Thr Lys
 355 360 365
 Cys Pro Ser Gly Ser Cys Val Met Asn Gln Tyr Leu Ser Ser Lys Phe
 370 375 380
 Pro Lys Asp Phe Ser Thr Ser Cys Arg Ala His Phe Glu Arg Tyr Leu
 385 390 395 400
 Leu Ser Gln Lys Pro Lys Cys Leu Leu Gln Ala Pro Ile Pro Thr Asn
 405 410 415
 Ile Met Thr Thr Pro Val Cys Gly Asn His Leu Leu Glu Val Gly Glu
 420 425 430
 Asp Cys Asp Cys Gly Ser Pro Lys Glu Cys Thr Asn Leu Cys Cys Glu
 435 440 445
 Ala Leu Thr Cys Lys Leu Lys Pro Gly Thr Asp Cys Gly Gly Asp Ala
 450 455 460
 Pro Asn His Thr Thr Glu

SEQUENCE LISTING 1657-2022.txt

465

470

<210> 172
 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 172
 Met Ala Val Arg Gln Trp Val Ile Ala Leu Ala Leu Ala Ala Leu Leu
 1 5 10 15
 Val Val Asp Arg Glu Val Pro Val Ala Ala Gly Lys Leu Pro Phe Ser
 20 25 30
 Arg Met Pro Ile Cys Glu His Met Val Glu Ser Pro Thr Cys Ser Gln
 35 40 45
 Met Ser Asn Leu Val Cys Gly Thr Asp Gly Leu Thr Tyr Thr Asn Glu
 50 55 60
 Cys Gln Leu Cys Leu Ala Arg Ile Lys Thr Lys Gln Asp Ile Gln Ile
 65 70 75 80
 Met Lys Asp Gly Lys Cys
 85

<210> 173
 <211> 261
 <212> PRT
 <213> Homo sapiens

<400> 173
 Met Ala Ser Pro Asp Trp Gly Tyr Asp Asp Lys Asn Gly Pro Glu Gln
 1 5 10 15
 Trp Ser Lys Leu Tyr Pro Ile Ala Asn Gly Asn Asn Gln Ser Pro Val
 20 25 30
 Asp Ile Lys Thr Ser Glu Thr Lys His Asp Thr Ser Leu Lys Pro Ile
 35 40 45
 Ser Val Ser Tyr Asn Pro Ala Thr Ala Lys Glu Ile Ile Asn Val Gly
 50 55 60
 His Ser Phe His Val Asn Phe Glu Asp Asn Asp Asn Arg Ser Val Leu
 65 70 75 80
 Lys Gly Gly Pro Phe Ser Asp Ser Tyr Arg Leu Phe Gln Phe His Phe
 85 90 95
 His Trp Gly Ser Thr Asn Glu His Gly Ser Glu His Thr Val Asp Gly
 100 105 110
 Val Lys Tyr Ser Ala Glu Leu His Val Ala His Trp Asn Ser Ala Lys
 115 120 125
 Tyr Ser Ser Leu Ala Glu Ala Ala Ser Lys Ala Asp Gly Leu Ala Val
 130 135 140
 Ile Gly Val Leu Met Lys Val Gly Glu Ala Asn Pro Lys Leu Gln Lys
 145 150 155 160
 Val Leu Asp Ala Leu Gln Ala Ile Lys Thr Lys Gly Lys Arg Ala Pro
 165 170 175
 Phe Thr Asn Phe Asp Pro Ser Thr Leu Leu Pro Ser Ser Leu Asp Phe
 180 185 190
 Trp Thr Tyr Pro Gly Ser Leu Thr His Pro Pro Leu Tyr Glu Ser Val
 195 200 205
 Thr Trp Ile Ile Cys Lys Glu Ser Ile Ser Val Ser Ser Glu Gln Leu
 210 215 220
 Ala Gln Phe Arg Ser Leu Leu Ser Asn Val Glu Gly Asp Asn Ala Val
 225 230 235 240
 Pro Met Gln His Asn Asn Arg Pro Thr Gln Pro Leu Lys Gly Arg Thr
 245 250 255
 Val Arg Ala Ser Phe
 260

<210> 174
 <211> 431

SEQUENCE LISTING 1657-2022.txt

<212> PRT

<213> Homo sapiens

<400> 174

```

Met Thr Val Lys Thr Glu Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg
1      5      10      15
Met Arg Gly Met Val Ala Ile Leu Ile Ala Phe Met Lys Gln Arg Arg
20     25     30
Met Gly Leu Asn Asp Phe Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala
35     40     45
Cys Lys His Pro Glu Val Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln
50     55     60
Glu Pro Glu Leu Met Asn Ala Asn Pro Ser Pro Pro Ser Pro Ser
65     70     75     80
Gln Gln Ile Asn Leu Gly Pro Ser Ser Asn Pro His Ala Lys Pro Ser
85     90     95
Asp Phe His Phe Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val
100    105    110
Leu Leu Ala Arg His Lys Ala Glu Glu Val Phe Tyr Ala Val Lys Val
115    120    125
Leu Gln Lys Lys Ala Ile Leu Lys Lys Lys Glu Glu Lys His Ile Met
130    135    140
Ser Glu Arg Asn Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val
145    150    155    160
Gly Leu His Phe Ser Phe Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu
165    170    175
Asp Tyr Ile Asn Gly Gly Glu Leu Phe Tyr His Leu Gln Arg Glu Arg
180    185    190
Cys Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser
195    200    205
Ala Leu Gly Tyr Leu His Ser Leu Asn Ile Val Tyr Arg Asp Leu Lys
210    215    220
Pro Glu Asn Ile Leu Leu Asp Ser Gln Gly His Ile Val Leu Thr Asp
225    230    235    240
Phe Gly Leu Cys Lys Glu Asn Ile Glu His Asn Ser Thr Thr Ser Thr
245    250    255
Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu His Lys Gln
260    265    270
Pro Tyr Asp Arg Thr Val Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr
275    280    285
Glu Met Leu Tyr Gly Leu Pro Phe Tyr Ser Arg Asn Thr Ala Glu
290    295    300
Met Tyr Asp Asn Ile Leu Asn Lys Pro Leu Gln Leu Lys Pro Asn Ile
305    310    315    320
Thr Asn Ser Ala Arg His Leu Leu Glu Gly Leu Leu Gln Lys Asp Arg
325    330    335
Thr Lys Arg Leu Gly Ala Lys Asp Asp Phe Met Glu Ile Lys Ser His
340    345    350
Val Phe Phe Ser Leu Ile Asn Trp Asp Asp Leu Ile Asn Lys Lys Ile
355    360    365
Thr Pro Pro Phe Asn Pro Asn Val Ser Gly Pro Asn Asp Leu Arg His
370    375    380
Phe Asp Pro Glu Phe Thr Glu Glu Pro Val Pro Asn Ser Ile Gly Lys
385    390    395    400
Ser Pro Asp Ser Val Leu Val Thr Ala Ser Val Lys Glu Ala Ala Glu
405    410    415
Ala Phe Leu Gly Phe Ser Tyr Ala Pro Thr Asp Ser Phe Leu
420    425    430

```

<210> 175

<211> 381

<212> PRT

<213> Homo sapiens

<400> 175

Met Pro Phe Ser Asn Ser His Asn Ala Leu Lys Leu Arg Phe Pro Ala

SEQUENCE LISTING 1657-2022.txt

```

1      5      10      15
Glu Asp Glu Phe Pro Asp Leu Ser Ala His Asn Asn His Met Ala Lys
20      25      30
Val Leu Thr Pro Glu Leu Tyr Ala Glu Leu Arg Ala Lys Ser Thr Pro
35      40      45
Ser Gly Phe Thr Leu Asp Asp Val Ile Gln Thr Gly Val Asp Asn Pro
50      55      60
Gly His Pro Tyr Ile Met Thr Val Gly Cys Val Ala Gly Asp Glu Glu
65      70      75      80
Ser Tyr Glu Val Phe Lys Asp Leu Phe Asp Pro Ile Ile Glu Asp Arg
85      90      95
His Gly Gly Tyr Lys Pro Ser Asp Glu His Lys Thr Asp Leu Asn Pro
100     105     110
Asp Asn Leu Gln Gly Gly Asp Asp Leu Asp Pro Asn Tyr Val Leu Ser
115     120     125
Ser Arg Val Arg Thr Gly Arg Ser Ile Arg Gly Phe Cys Leu Pro Pro
130     135     140
His Cys Ser Arg Gly Glu Arg Arg Ala Ile Glu Lys Leu Ala Val Glu
145     150     155     160
Ala Leu Ser Ser Leu Asp Gly Asp Leu Ala Gly Arg Tyr Tyr Ala Leu
165     170     175
Lys Ser Met Thr Glu Ala Glu Gln Gln Gln Leu Ile Asp Asp His Phe
180     185     190
Leu Phe Asp Lys Pro Val Ser Pro Leu Leu Leu Ala Ser Gly Met Ala
195     200     205
Arg Asp Trp Pro Asp Ala Arg Gly Ile Trp His Asn Asp Asn Lys Thr
210     215     220
Phe Leu Val Trp Val Asn Glu Glu Asp His Leu Arg Val Ile Ser Met
225     230     235     240
Gln Lys Gly Gly Asn Met Lys Glu Val Phe Thr Arg Phe Cys Thr Gly
245     250     255
Leu Thr Gln Ile Glu Thr Leu Phe Lys Ser Lys Asp Tyr Glu Phe Met
260     265     270
Trp Asn Pro His Leu Gly Tyr Ile Leu Thr Cys Pro Ser Asn Leu Gly
275     280     285
Thr Gly Leu Arg Ala Gly Val His Ile Lys Leu Pro Asn Leu Gly Lys
290     295     300
His Glu Lys Phe Ser Glu Val Leu Lys Arg Leu Arg Leu Gln Lys Arg
305     310     315     320
Gly Thr Gly Gly Val Asp Thr Ala Ala Val Gly Gly Val Phe Asp Val
325     330     335
Ser Asn Ala Asp Arg Leu Gly Phe Ser Glu Val Glu Leu Val Gln Met
340     345     350
Val Val Asp Gly Val Lys Leu Leu Ile Glu Met Glu Gln Arg Leu Glu
355     360     365
Gln Gly Gln Ala Ile Asp Asp Leu Met Pro Ala Gln Lys
370     375     380

```

<210> 176

<211> 739

<212> PRT

<213> Homo sapiens

<400> 176

```

Met Ser Ser Glu Ser Lys Glu Gln His Asn Val Ser Pro Arg Asp Ser
1      5      10      15
Ala Glu Gly Asn Asp Ser Tyr Pro Ser Gly Ile His Leu Glu Leu Gln
20      25      30
Arg Glu Ser Ser Thr Asp Phe Lys Gln Phe Glu Thr Asn Asp Gln Cys
35      40      45
Arg Pro Tyr His Arg Ile Leu Ile Glu Arg Gln Glu Lys Ser Asp Thr
50      55      60
Asn Phe Lys Glu Phe Val Ile Lys Lys Leu Gln Lys Asn Cys Gln Cys
65      70      75      80
Ser Pro Ala Lys Ala Lys Asn Met Ile Leu Gly Phe Leu Pro Val Leu
85      90      95

```

SEQUENCE LISTING 1657-2022.txt

Gln Trp Leu Pro Lys Tyr Asp Leu Lys Lys Asn Ile Leu Gly Asp Val
 100 105 110
 Met Ser Gly Leu Ile Val Gly Ile Leu Leu Val Pro Gln Ser Ile Ala
 115 120 125
 Tyr Ser Leu Leu Ala Gly Gln Glu Pro Val Tyr Gly Leu Tyr Thr Ser
 130 135 140
 Phe Phe Ala Ser Ile Ile Tyr Phe Leu Leu Gly Thr Ser Arg His Ile
 145 150 155 160
 Ser Val Gly Ile Phe Gly Val Leu Cys Leu Met Ile Gly Glu Thr Val
 165 170 175
 Asp Arg Glu Leu Gln Lys Ala Gly Tyr Asp Asn Ala His Ser Ala Pro
 180 185 190
 Ser Leu Gly Met Val Ser Asn Gly Ser Thr Leu Leu Asn His Thr Ser
 195 200 205
 Asp Arg Ile Cys Asp Lys Ser Cys Tyr Ala Ile Met Val Gly Ser Thr
 210 215 220
 Val Thr Phe Ile Ala Gly Val Tyr Gln Val Ala Met Gly Phe Phe Gln
 225 230 235 240
 Val Gly Phe Val Ser Val Tyr Leu Ser Asp Ala Leu Leu Ser Gly Phe
 245 250 255
 Val Thr Gly Ala Ser Phe Thr Ile Leu Thr Ser Gln Ala Lys Tyr Leu
 260 265 270
 Leu Gly Leu Asn Leu Pro Arg Thr Asn Gly Val Gly Ser Leu Ile Thr
 275 280 285
 Thr Trp Ile His Val Phe Arg Asn Ile His Lys Thr Asn Leu Cys Asp
 290 295 300
 Leu Ile Thr Ser Leu Leu Cys Leu Leu Val Leu Leu Pro Thr Lys Glu
 305 310 315 320
 Leu Asn Glu His Phe Lys Ser Lys Leu Lys Ala Pro Ile Pro Ile Glu
 325 330 335
 Leu Val Val Val Val Ala Ala Thr Leu Ala Ser His Phe Gly Lys Leu
 340 345 350
 His Glu Asn Tyr Asn Ser Ser Ile Ala Gly His Ile Pro Thr Gly Phe
 355 360 365
 Met Pro Pro Lys Val Pro Glu Trp Asn Leu Ile Pro Ser Val Ala Val
 370 375 380
 Asp Ala Ile Ala Ile Ser Ile Ile Gly Phe Ala Ile Thr Val Ser Leu
 385 390 395 400
 Ser Glu Met Phe Ala Lys Lys His Gly Tyr Thr Val Lys Ala Asn Gln
 405 410 415
 Glu Met Tyr Ala Ile Gly Phe Cys Asn Ile Ile Pro Ser Phe Phe His
 420 425 430
 Cys Phe Thr Thr Ser Ala Ala Leu Ala Lys Thr Leu Val Lys Glu Ser
 435 440 445
 Thr Gly Cys His Thr Gln Leu Ser Gly Val Val Thr Ala Leu Val Leu
 450 455 460
 Leu Leu Val Leu Leu Val Ile Ala Pro Leu Phe Tyr Ser Leu Gln Lys
 465 470 475 480
 Ser Val Leu Gly Val Ile Thr Ile Val Asn Leu Arg Gly Ala Leu Arg
 485 490 495
 Lys Phe Arg Asp Leu Pro Lys Met Trp Ser Ile Ser Arg Met Asp Thr
 500 505 510
 Val Ile Trp Phe Val Thr Met Leu Ser Ser Ala Leu Leu Ser Thr Glu
 515 520 525
 Ile Gly Leu Leu Val Gly Val Cys Phe Ser Ile Phe Cys Val Ile Leu
 530 535 540
 Arg Thr Gln Lys Pro Lys Ser Ser Leu Leu Gly Leu Val Glu Glu Ser
 545 550 555 560
 Glu Val Phe Glu Ser Val Ser Ala Tyr Lys Asn Leu Gln Thr Lys Pro
 565 570 575
 Gly Ile Lys Ile Phe Arg Phe Val Ala Pro Leu Tyr Tyr Ile Asn Lys
 580 585 590
 Glu Cys Phe Lys Ser Ala Leu Tyr Lys Gln Thr Val Asn Pro Ile Leu
 595 600 605
 Ile Lys Val Ala Trp Lys Lys Ala Ala Lys Arg Lys Ile Lys Glu Lys
 610 615 620
 Val Val Thr Leu Gly Gly Ile Gln Asp Glu Met Ser Val Gln Leu Ser

SEQUENCE LISTING 1657-2022.txt															
625					630					635					640
His	Asp	Pro	Leu	Glu	Leu	His	Thr	Ile	Val	Ile	Asp	Cys	Ser	Ala	Ile
Gln	Phe	Leu	Asp	Thr	Ala	Gly	Ile	His	Thr	Leu	Lys	Glu	Val	Arg	Arg
Asp	Tyr	Glu	Ala	Ile	Gly	Ile	Gln	Val	Leu	Leu	Ala	Gln	Cys	Asn	Pro
Thr	Val	Arg	Asp	Ser	Leu	Thr	Asn	Gly	Glu	Tyr	Cys	Lys	Lys	Glu	Glu
Glu	Asn	Leu	Leu	Phe	Tyr	Ser	Val	Tyr	Glu	Ala	Met	Ala	Phe	Ala	Glu
Val	Ser	Lys	Asn	Gln	Lys	Gly	Val	Cys	Val	Pro	Asn	Gly	Leu	Ser	Leu
Ser	Ser	Asp													

```
<210> 177
<211> 709
<212> PRT
<213> Homo sapiens
```

<400> 177

Met 1	Ala 17	Glu 18	Val 19	Glu 5	Asp 6	Gln 7	Ala 8	Ala 9	Arg 10	Asp 11	Met 12	Lys 13	Arg 14	Leu 15	Glu 16
Glu 20	Lys 21	Asp 22	Lys 23	Glu 24	Arg 25	Lys 26	Asn 27	Val 28	Lys 29	Gly 30	Ile 31	Arg 32	Asp 33	Asp 34	Ile 35
Glu 36	Glu 37	Glu 38	Asp 39	Asp 40	Gln 41	Glu 42	Ala 43	Tyr 44	Phe 45	Arg 46	Tyr 47	Met 48	Ala 49	Glu 50	Asn 51
Pro 52	Thr 53	Ala 54	Gly 55	Val 56	Val 57	Gln 58	Glu 59	Glu 60	Glu 61	Glu 62	Asp 63	Asn 64	Leu 65	Glu 66	Tyr 67
Asp 68	Ser 69	Asp 70	Gly 71	Asn 72	Pro 73	Ile 74	Ala 75	Pro 76	Thr 77	Lys 78	Lys 79	Ile 80	Ile 81	Asp 82	Pro 83
Leu 84	Pro 85	Pro 86	Ile 87	Asp 88	His 89	Ser 90	Glu 91	Ile 92	Asp 93	Tyr 94	Pro 95	Pro 96	Phe 97	Glu 98	Lys 99
Asn 100	Phe 101	Tyr 102	Asn 103	Glu 104	His 105	Glu 106	Glu 107	Ile 108	Thr 109	Asn 110	Leu 111	Thr 112	Pro 113	Gln 114	Gln 115
Leu 116	Ile 117	Asp 118	Leu 119	Arg 120	His 121	Lys 122	Leu 123	Asn 124	Leu 125	Arg 126	Val 127	Ser 128	Gly 129	Ala 130	Ala 131
Pro 132	Pro 133	Arg 134	Pro 135	Gly 136	Ser 137	Ser 138	Phe 139	Ala 140	His 141	Phe 142	Gly 143	Phe 144	Asp 145	Glu 146	Gln 147
Leu 148	Met 149	His 150	Gln 151	Ile 152	Arg 153	Lys 154	Ser 155	Glu 156	Tyr 157	Thr 158	Gln 159	Pro 160	Thr 161	Pro 162	Ile 163
Gln 164	Cys 165	Gln 166	Gly 167	Val 168	Pro 169	Val 170	Ala 171	Leu 172	Ser 173	Gly 174	Arg 175	Asp 176	Met 177	Ile 178	Gly 179
Ile 180	Ala 181	Lys 182	Thr 183	Gly 184	Ser 185	Gly 186	Lys 187	Thr 188	Ala 189	Ala 190	Phe 191	Ile 192	Trp 193	Pro 194	Met 195
Leu 196	Ile 197	His 198	Ile 199	Met 200	Asp 201	Gln 202	Lys 203	Glu 204	Leu 205	Glu 206	Pro 207	Gly 208	Asp 209	Gly 210	Pro 211
Ile 212	Ala 213	Val 214	Ile 215	Val 216	Cys 217	Pro 218	Thr 219	Arg 220	Glu 221	Leu 222	Cys 223	Gln 224	Gln 225	Ile 226	His 227
Ala 228	Glu 229	Cys 230	Lys 231	Arg 232	Phe 233	Gly 234	Lys 235	Ala 236	Tyr 237	Asn 238	Leu 239	Arg 240	Ser 241	Val 242	Ala 243
Val 244	Tyr 245	Gly 246	Gly 247	Gly 248	Ser 249	Met 250	Trp 251	Glu 252	Gln 253	Ala 254	Lys 255	Ala 256	Leu 257	Gln 258	Glu 259
Gly 260	Ala 261	Glu 262	Ile 263	Val 264	Val 265	Cys 266	Thr 267	Pro 268	Gly 269	Arg 270	Leu 271	Ile 272	Asp 273	His 274	Val 275
Lys 276	Lys 277	Lys 278	Ala 279	Thr 280	Asn 281	Leu 282	Gln 283	Arg 284	Val 285	Ser 286	Tyr 287	Leu 288	Val 289	Phe 290	Asp 291
Glu 292	Ala 293	Asp 294	Arg 295	Met 296	Phe 297	Asp 298	Met 299	Gly 300	Phe 301	Glu 302	Tyr 303	Gln 304	Val 305	Arg 306	Ser 307
Ile 308	Ala 309	Ser 310	His 311	Val 312	Arg 313	Ile 314	Glu 315	Lys 316	Leu 317	Ala 318	Arg 319	Thr 320	Leu 321	Phe 322	Ser 323
Thr 324	Phe 325	Arg 326	Lys 327	Lys 328	Ile 329	Glu 330	Lys 331	Leu 332	Ala 333	Arg 334	Asp 335	Ile 336	Leu 337	Ile 338	Asp 339
Pro 340	Ile 341	Arg 342	Val 343	Val 344	Gln 345	Gly 346	Asp 347	Ile 348	Gly 349	Glu 350	Ala 351	Asn 352	Glu 353	Asp 354	Val 355

SEQUENCE LISTING 1657-2022.txt

Thr Gln Ile Val Glu Ile Leu His Ser Gly Pro Ser Lys Trp Asn Trp
 355 360 365
 Leu Thr Arg Arg Leu Val Glu Phe Thr Ser Ser Gly Ser Val Leu Leu
 370 375 380
 Phe Val Thr Lys Lys Ala Asn Ala Glu Glu Leu Ala Asn Asn Leu Lys
 385 390 395 400
 Gln Glu Gly His Asn Leu Gly Leu Leu His Gly Asp Met Asp Gln Ser
 405 410 415
 Glu Arg Asn Lys Val Ile Ser Asp Phe Lys Lys Asp Ile Pro Val
 420 425 430
 Leu Val Ala Thr Asp Val Ala Ala Arg Gly Leu Asp Ile Pro Ser Ile
 435 440 445
 Lys Thr Val Ile Asn Tyr Asp Val Ala Arg Asp Ile Asp Thr His Thr
 450 455 460
 His Arg Ile Gly Arg Thr Gly Arg Ala Gly Glu Lys Gly Val Ala Tyr
 465 470 475 480
 Thr Leu Leu Thr Pro Lys Asp Ser Asn Phe Ala Gly Asp Leu Val Arg
 485 490 495
 Asn Leu Glu Gly Ala Asn Gln His Val Ser Lys Glu Leu Leu Asp Leu
 500 505 510
 Ala Met Gln Asn Ala Trp Phe Arg Lys Ser Arg Phe Lys Gly Gly Lys
 515 520 525
 Gly Lys Lys Leu Asn Ile Gly Gly Gly Leu Gly Tyr Arg Glu Arg
 530 535 540
 Pro Gly Leu Gly Ser Glu Asn Met Asp Arg Gly Asn Asn Asn Val Met
 545 550 555 560
 Ser Asn Tyr Glu Ala Tyr Lys Pro Ser Thr Gly Ala Met Gly Asp Arg
 565 570 575
 Leu Thr Ala Met Lys Ala Ala Phe Gln Ser Gln Tyr Lys Ser His Phe
 580 585 590
 Val Ala Ala Ser Leu Ser Asn Gln Lys Ala Gly Ser Ser Ala Ala Gly
 595 600 605
 Ala Ser Gly Trp Thr Ser Ala Gly Ser Leu Asn Ser Val Pro Thr Asn
 610 615 620
 Ser Ala Gln Gln Gly His Asn Ser Pro Asp Ser Pro Val Thr Ser Ala
 625 630 635 640
 Ala Lys Gly Ile Pro Gly Phe Gly Asn Thr Gly Asn Ile Ser Gly Ala
 645 650 655
 Pro Val Thr Tyr Pro Ser Ala Gly Ala Gln Gly Val Asn Asn Thr Ala
 660 665 670
 Ser Gly Asn Asn Ser Arg Glu Gly Thr Gly Gly Ser Asn Gly Lys Arg
 675 680 685
 Glu Arg Tyr Thr Glu Asn Arg Gly Ser Ser Pro Ser Gln Ser Arg Arg
 690 695 700
 Asp Trp Gln Ser Ala
 705

<210> 178
 <211> 5178
 <212> PRT
 <213> Homo sapiens

<400> 178

Met Gly Leu Pro Leu Ala Arg Leu Ala Ala Val Cys Leu Ala Leu Ser
 1 5 10 15
 Leu Ala Gly Gly Ser Glu Leu Gln Thr Glu Gly Arg Thr Arg Tyr His
 20 25 30
 Gly Arg Asn Val Cys Ser Thr Trp Gly Asn Phe His Tyr Lys Thr Phe
 35 40 45
 Asp Gly Asp Val Phe Arg Phe Pro Gly Leu Cys Asp Tyr Asn Phe Ala
 50 55 60
 Ser Asp Cys Arg Gly Ser Tyr Lys Glu Phe Ala Val His Leu Lys Arg
 65 70 75 80
 Gly Pro Gly Gln Ala Glu Ala Pro Ala Gly Val Glu Ser Ile Leu Leu
 85 90 95
 Thr Ile Lys Asp Asp Thr Ile Tyr Leu Thr Arg His Leu Ala Val Leu

SEQUENCE LISTING 1657-2022.txt

```

100      105      110
Asn Gly Ala Val Val Ser Thr Pro His Tyr Ser Pro Gly Leu Leu Ile
115      120      125
Glu Lys Ser Asp Ala Tyr Thr Lys Val Tyr Ser Arg Ala Gly Leu Thr
130      135      140
Leu Met Trp Asn Arg Glu Asp Ala Leu Met Leu Glu Leu Asp Thr Lys
145      150      155
Phe Arg Asn His Thr Cys Gly Leu Cys Gly Val Leu Phe Ser Pro Leu Glu
165      170      175
Ser Tyr Ser Glu Phe Leu Ser Asp Gly Val Leu Phe Ser Pro Leu Glu
180      185      190
Phe Gly Asn Met Gln Lys Ile Asn Gln Pro Asp Val Val Cys Glu Asp
195      200      205
Pro Glu Glu Glu Val Ala Pro Ala Ser Cys Ser Glu His Arg Ala Glu
210      215      220
Cys Glu Arg Leu Leu Thr Ala Glu Ala Phe Ala Asp Cys Gln Asp Leu
225      230      235
Val Pro Leu Glu Pro Tyr Leu Arg Ala Cys Gln Gln Asp Arg Cys Arg
245      250      255
Cys Pro Gly Gly Asp Thr Cys Val Cys Ser Thr Val Ala Glu Phe Ser
260      265      270
Arg Gln Cys Ser His Ala Gly Gly Arg Pro Gly Asn Trp Arg Thr Ala
275      280      285
Thr Leu Cys Pro Lys Thr Cys Pro Gly Asn Leu Val Tyr Leu Glu Ser
290      295      300
Gly Ser Pro Cys Met Asp Thr Cys Ser His Leu Glu Val Ser Ser Leu
305      310      315
Cys Glu Glu His Arg Met Asp Gly Cys Phe Cys Pro Glu Gly Thr Val
325      330      335
Tyr Asp Asp Ile Gly Asp Ser Gly Cys Val Pro Val Ser Gln Cys His
340      345      350
Cys Arg Leu His Gly His Leu Tyr Thr Pro Gly Gln Glu Ile Thr Asn
355      360      365
Asp Cys Glu Gln Cys Val Cys Asn Ala Gly Arg Trp Val Cys Lys Asp
370      375      380
Leu Pro Cys Pro Gly Thr Cys Ala Leu Glu Gly Ser His Ile Thr
385      390      395
Thr Phe Asp Gly Lys Thr Tyr Thr Phe His Gly Asp Cys Tyr Tyr Val
405      410      415
Leu Ala Lys Gly Asp His Asn Asp Ser Tyr Ala Leu Leu Gly Glu Leu
420      425      430
Ala Pro Cys Gly Ser Thr Asp Lys Gln Thr Cys Leu Lys Thr Val Val
435      440      445
Leu Leu Ala Asp Lys Lys Lys Asn Ala Val Val Phe Lys Ser Asp Gly
450      455      460
Ser Val Leu Leu Asn Gln Leu Gln Val Asn Leu Pro His Val Thr Ala
465      470      475
Ser Phe Ser Val Phe Arg Pro Ser Ser Tyr His Ile Met Val Ser Met
485      490      495
Ala Ile Gly Val Arg Leu Gln Val Gln Leu Ala Pro Val Met Gln Leu
500      505      510
Phe Val Thr Leu Asp Gln Ala Ser Gln Gly Gln Val Gln Gly Leu Cys
515      520      525
Gly Asn Phe Asn Gly Leu Glu Gly Asp Asp Phe Lys Thr Ala Ser Gly
530      535      540
Leu Val Glu Ala Thr Gly Ala Gly Phe Ala Asn Thr Trp Lys Ala Gln
545      550      555
Ser Thr Cys His Asp Lys Leu Asp Trp Leu Asp Asp Pro Cys Ser Leu
565      570      575
Asn Ile Glu Ser Ala Asn Tyr Ala Glu His Trp Cys Ser Leu Lys
580      585      590
Lys Thr Glu Thr Pro Phe Gly Arg Cys His Ser Ala Val Asp Pro Ala
595      600      605
Glu Tyr Tyr Lys Arg Cys Lys Tyr Asp Thr Cys Asn Cys Gln Asn Asn
610      615      620
Glu Asp Cys Leu Cys Ala Ala Leu Ser Ser Tyr Ala Arg Ala Cys Thr
625      630      635      640

```

SEQUENCE LISTING 1657-2022.txt

Ala Lys Gly Val Met Leu Trp Gly Trp Arg Glu His Val Cys Asn Lys
 645 650 655
 Asp Val Gly Ser Cys Pro Asn Ser Gln Val Phe Leu Tyr Asn Leu Thr
 660 665 670
 Thr Cys Gln Gln Thr Cys Arg Ser Leu Ser Glu Ala Asp Ser His Cys
 675 680 685
 Leu Glu Gly Phe Ala Pro Val Asp Gly Cys Gly Cys Pro Asp His Thr
 690 695 700
 Phe Leu Asp Glu Lys Gly Arg Cys Val Pro Leu Ala Lys Cys Ser Cys
 705 710 715 720
 Tyr His Arg Gly Leu Tyr Leu Glu Ala Gly Asp Val Val Val Arg Gln
 725 730 735
 Glu Glu Arg Cys Val Cys Arg Asp Gly Arg Leu His Cys Arg Gln Ile
 740 745 750
 Arg Leu Ile Gly Gln Ser Cys Thr Ala Pro Lys Ile His Met Asp Cys
 755 760 765
 Ser Asn Leu Thr Ala Leu Ala Tyr Ser Lys Pro Arg Ala Leu Ser Cys
 770 775 780
 Gln Thr Leu Ala Ala Gly Tyr Tyr His Thr Glu Cys Val Ser Gly Cys
 785 790 795 800
 Val Cys Pro Asp Gly Leu Met Asp Asp Gly Arg Gly Gly Cys Val Val
 805 810 815
 Glu Lys Glu Cys Pro Cys Val His Asn Asn Asp Leu Tyr Ser Ser Gly
 820 825 830
 Ala Lys Ile Lys Val Asp Cys Asn Thr Cys Thr Cys Lys Arg Gly Arg
 835 840 845
 Trp Val Cys Thr Gln Ala Val Cys His Gly Thr Cys Ser Ile Tyr Gly
 850 855 860
 Ser Gly His Tyr Ile Thr Phe Asp Gly Lys Tyr Tyr Asp Phe Asp Gly
 865 870 875 880
 His Cys Ser Tyr Val Ala Val Gln Asp Tyr Cys Gly Gln Asn Ser Ser
 885 890 895
 Leu Gly Ser Phe Ser Ile Ile Thr Glu Asn Val Pro Cys Gly Thr Thr
 900 905 910
 Gly Val Thr Cys Ser Lys Ala Ile Lys Ile Phe Met Gly Arg Thr Glu
 915 920 925
 Leu Lys Leu Glu Asp Lys His Arg Val Val Ile Gln Arg Asp Glu Gly
 930 935 940
 His His Val Ala Tyr Thr Thr Arg Glu Val Gly Gln Tyr Leu Val Val
 945 950 955 960
 Glu Ser Ser Thr Gly Ile Ile Val Ile Trp Asp Lys Arg Thr Thr Val
 965 970 975
 Phe Ile Lys Leu Ala Pro Ser Tyr Lys Gly Thr Val Cys Gly Leu Cys
 980 985 990
 Gly Asn Phe Asp His Arg Ser Asn Asn Asp Phe Thr Thr Arg Asp His
 995 1000 1005
 Met Val Val Ser Ser Glu Leu Asp Phe Gly Asn Ser Trp Lys Glu Ala
 1010 1015 1020
 Pro Thr Cys Pro Asp Val Ser Thr Asn Pro Glu Pro Cys Ser Leu Asn
 1025 1030 1035 1040
 Pro His Arg Arg Ser Trp Ala Glu Lys Gln Cys Ser Ile Leu Lys Ser
 1045 1050 1055
 Ser Val Phe Ser Ile Cys His Ser Lys Val Asp Pro Lys Pro Phe Tyr
 1060 1065 1070
 Glu Ala Cys Val His Asp Ser Cys Ser Cys Asp Thr Gly Gly Asp Cys
 1075 1080 1085
 Glu Cys Phe Cys Ser Ala Val Ala Ser Tyr Ala Gln Glu Cys Thr Lys
 1090 1095 1100
 Glu Gly Ala Cys Val Phe Trp Arg Thr Pro Asp Leu Cys Pro Ile Phe
 1105 1110 1115 1120
 Cys Asp Tyr Tyr Asn Pro Pro His Glu Cys Glu Trp His Tyr Glu Pro
 1125 1130 1135
 Cys Gly Asn Arg Ser Phe Glu Thr Cys Arg Thr Ile Asn Gly Ile His
 1140 1145 1150
 Ser Asn Ile Ser Val Ser Tyr Leu Glu Gly Cys Tyr Pro Arg Cys Pro
 1155 1160 1165
 Lys Asp Arg Pro Ile Tyr Glu Glu Asp Leu Lys Lys Cys Val Thr Ala

SEQUENCE LISTING 1657-2022.txt

1170
 Asp Lys Cys Gly Cys Tyr Val Glu Asp Thr His Tyr Pro Pro Gly Ala
 1185
 Ser Val Pro Thr Glu Thr Cys Lys Ser Cys Val Cys Thr Asn Ser
 1205
 Ser Gln Val Val Cys Arg Pro Glu Glu Gly Lys Ile Leu Asn Gln Thr
 1220
 Gln Asp Gly Ala Phe Cys Tyr Trp Glu Ile Cys Gly Pro Asn Gly Thr
 1235
 Val Glu Lys His Phe Asn Ile Cys Ser Ile Thr Thr Arg Pro Ser Thr
 1250
 Leu Thr Thr Phe Thr Thr Ile Thr Leu Pro Thr Thr Pro Thr Ser Phe
 1265
 Thr Thr Thr Thr Thr Thr Thr Thr Pro Thr Ser Ser Thr Val Leu Ser
 1285
 Thr Thr Pro Lys Leu Cys Cys Leu Trp Ser Asp Trp Ile Asn Glu Asp
 1300
 His Pro Ser Ser Gly Ser Asp Asp Gly Asp Arg Glu Pro Phe Asp Gly
 1315
 Val Cys Gly Ala Pro Glu Asp Ile Glu Cys Arg Ser Val Lys Asp Pro
 1330
 His Leu Ser Leu Glu Gln His Gly Gln Lys Val Gln Cys Asp Val Ser
 1345
 Val Gly Phe Ile Cys Lys Asn Glu Asp Gln Phe Gly Asn Gly Pro Phe
 1365
 Gly Leu Cys Tyr Asp Tyr Lys Ile Arg Val Asn Cys Cys Trp Pro Met
 1380
 Asp Lys Cys Ile Thr Thr Pro Ser Pro Pro Thr Thr Thr Pro Ser Pro
 1395
 Pro Pro Thr Thr Thr Thr Thr Thr Leu Pro Pro Thr Thr Thr Pro Ser Pro
 1410
 Pro Thr Thr Thr Thr Thr Thr Pro Pro Pro Thr Thr Thr Pro Ser Pro
 1425
 Pro Ile Thr Thr Thr Thr Thr Pro Leu Pro Thr Thr Thr Pro Ser Pro
 1445
 Pro Ile Ser Thr Thr Thr Thr Pro Pro Pro Thr Thr Thr Pro Ser Pro
 1460
 Pro Thr Thr Thr Pro Ser Pro Pro Thr Thr Thr Pro Ser Pro Pro Thr
 1475
 Thr Thr Thr Thr Thr Pro Pro Thr Thr Thr Thr Pro Ser Pro Pro Met
 1490
 Thr Thr Pro Ile Thr Pro Pro Ala Ser Thr Thr Thr Leu Pro Pro Thr
 1505
 Thr Thr Pro Ser Pro Pro Thr Thr Thr Thr Thr Thr Pro Pro Pro Thr
 1525
 Thr Thr Pro Ser Pro Pro Thr Thr Thr Thr Pro Ile Thr Pro Pro Thr Ser
 1540
 Thr Thr Thr Leu Pro Pro Thr Thr Thr Pro Ser Pro Pro Pro Thr Thr
 1555
 Thr Thr Thr Pro Pro Pro Thr Thr Thr Pro Ser Pro Pro Thr Thr Thr
 1570
 Thr Pro Ser Pro Pro Thr Ile Thr Thr Thr Thr Pro Pro Pro Thr Thr
 1585
 Thr Pro Ser Pro Pro Thr Thr Thr Thr Thr Thr Pro Pro Pro Thr Thr
 1605
 Thr Pro Ser Pro Pro Thr Thr Thr Thr Thr Thr Pro Pro Pro Thr Thr
 1620
 Thr Thr Leu Pro Pro Thr Thr Thr Pro Ser Pro Pro Pro Thr Thr Thr
 1635
 Thr Thr Pro Pro Pro Thr Thr Thr Pro Ser Pro Pro Thr Thr Thr Thr
 1650
 Pro Ser Pro Pro Ile Thr Thr Thr Thr Thr Pro Pro Pro Thr Thr Thr
 1665
 Pro Ser Ser Pro Ile Thr Thr Thr Pro Ser Pro Pro Thr Thr Thr Met
 1685
 Thr Thr Pro Ser Pro Thr Thr Thr Pro Ser Ser Pro Ile Thr Thr Thr
 1700
 1705
 1710

SEQUENCE LISTING 1657-2022.txt

Thr Thr Pro Ser Ser Thr Thr Thr Pro Ser Pro Pro Pro Thr Thr Met
1715 1720 1725
Thr Thr Pro Ser Pro Thr Thr Thr Pro Ser Pro Pro Thr Thr Thr Met
1730 1735 1740
Thr Thr Leu Pro Pro Thr Thr Thr Ser Ser Pro Leu Thr Thr Thr Pro
1745 1750 1755 1760
Leu Pro Pro Ser Ile Thr Pro Pro Thr Phe Ser Pro Phe Ser Thr Thr
1765 1770 1775
Thr Pro Thr Thr Pro Cys Val Pro Leu Cys Asn Trp Thr Gly Trp Leu
1780 1785 1790
Asp Ser Gly Lys Pro Asn Phe His Lys Pro Gly Gly Asp Thr Glu Leu
1795 1800 1805
Ile Gly Asp Val Cys Gly Pro Gly Trp Ala Ala Asn Ile Ser Cys Arg
1810 1815 1820
Ala Thr Met Tyr Pro Asp Val Pro Ile Gly Gln Leu Gly Gln Thr Val
1825 1830 1835 1840
Val Cys Asp Val Ser Val Gly Leu Ile Cys Lys Asn Glu Asp Gln Lys
1845 1850 1855
Pro Gly Gly Val Ile Pro Met Ala Phe Cys Leu Asn Tyr Glu Ile Asn
1860 1865 1870
Val Gln Cys Cys Glu Cys Val Thr Gln Pro Thr Thr Met Thr Thr Thr
1875 1880 1885
Thr Thr Glu Asn Pro Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
1890 1895 1900
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
1905 1910 1915 1920
Thr Thr Pro Ile Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
1925 1930 1935
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
1940 1945 1950
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
1955 1960 1965
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
1970 1975 1980
Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Val Thr
1985 1990 1995 2000
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
2005 2010 2015
Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
2020 2025 2030
Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr
2035 2040 2045
Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
2050 2055 2060
Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
2065 2070 2075 2080
Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
2085 2090 2095
Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
2100 2105 2110
Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
2115 2120 2125
Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
2130 2135 2140
Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
2145 2150 2155 2160
Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro
2165 2170 2175
Ile Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
2180 2185 2190
Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
2195 2200 2205
Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr
2210 2215 2220
Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr
2225 2230 2235 2240
Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro

SEQUENCE LISTING 1657-2022.txt

2245 2250 2255
Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Pro Ile Thr Thr Thr
2260 2265 2270
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
2275 2280 2285
Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
2290 2295 2300
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
2305 2310 2315 2320
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
2325 2330 2335
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
2340 2345 2350
Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr
2355 2360 2365
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
2370 2375 2380
Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
2385 2390 2395 2400
Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr
2405 2410 2415
Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
2420 2425 2430
Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
2435 2440 2445
Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
2450 2455 2460
Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
2465 2470 2475 2480
Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
2485 2490 2495
Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
2500 2505 2510
Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
2515 2520 2525
Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro
2530 2535 2540
Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
2545 2550 2555 2560
Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
2565 2570 2575
Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr
2580 2585 2590
Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr
2595 2600 2605
Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro
2610 2615 2620
Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
2625 2630 2635 2640
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
2645 2650 2655
Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
2660 2665 2670
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
2675 2680 2685
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
2690 2695 2700
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
2705 2710 2715 2720
Thr Gln Thr Pro Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr
2725 2730 2735
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
2740 2745 2750
Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
2755 2760 2765
Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr
2770 2775 2780

SEQUENCE LISTING 1657-2022.txt

Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
2785 2790 2795 2800
Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
2805 2810 2815
Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
2820 2825 2830
Pro Thr Gly Thr Gln Thr Pro Thr Thr Pro Ile Thr Thr Thr Thr
2835 2840 2845
Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
2850 2855 2860
Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
2865 2870 2875 2880
Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
2885 2890 2895
Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Pro
2900 2905 2910
Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
2915 2920 2925
Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
2930 2935 2940
Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr
2945 2950 2955 2960
Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr
2965 2970 2975
Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro
2980 2985 2990
Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
2995 3000 3005
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
3010 3015 3020
Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
3025 3030 3035 3040
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
3045 3050 3055
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
3060 3065 3070
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
3075 3080 3085
Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr
3090 3095 3100
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
3105 3110 3115 3120
Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
3125 3130 3135
Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr
3140 3145 3150
Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
3155 3160 3165
Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
3170 3175 3180
Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
3185 3190 3195 3200
Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
3205 3210 3215
Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
3220 3225 3230
Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
3235 3240 3245
Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
3250 3255 3260
Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro
3265 3270 3275 3280
Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
3285 3290 3295
Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
3300 3305 3310
Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr

SEQUENCE LISTING 1657-2022.txt

3315
Thr Thr Thr Val Thr Pro Thr Pro Thr Gly Thr Gln Thr
3330
Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Val Thr Pro Thr Pro
3345
Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
3365
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
3380
Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
3395
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
3410
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
3425
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
3445
Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr
3460
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
3475
Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
3490
Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr
3505
Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
3525
Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
3540
Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
3555
Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
3570
Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
3585
Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
3605
Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
3620
Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Pro
3635
Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
3650
Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
3665
Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr
3685
Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr
3700
Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro
3715
Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
3730
Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
3745
Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
3765
Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
3780
Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
3795
Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
3810
Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr
3825
Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile
3845
3850
3855

SEQUENCE LISTING 1657-2022.txt

Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln
 3860 3865 3870
 Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Val Thr Pro Thr
 3875 3880 3885
 Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr
 3890 3895 3900
 Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro
 3905 3910 3915 3920
 Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr
 3925 3930 3935
 Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr
 3940 3945 3950
 Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr
 3955 3960 3965
 Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr
 3970 3975 3980
 Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val
 3985 3990 3995 4000
 Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro
 4005 4010 4015
 Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr
 4020 4025 4030
 Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro
 4035 4040 4045
 Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr
 4050 4055 4060
 Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr
 4065 4070 4075 4080
 Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro
 4085 4090 4095
 Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr
 4100 4105 4110
 Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr
 4115 4120 4125
 Thr Thr Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro
 4130 4135 4140
 Thr Gly Thr Gln Thr Pro Thr Thr Thr Pro Ile Thr Thr Thr Thr Thr
 4145 4150 4155 4160
 Val Thr Pro Thr Pro Thr Pro Thr Gly Thr Gln Thr Pro Thr Thr Thr
 4165 4170 4175
 Pro Ile Thr Thr Thr Thr Thr Val Thr Pro Thr Pro Thr Pro Thr Gly
 4180 4185 4190
 Thr Gln Thr Gly Pro Pro Thr His Thr Ser Thr Ala Pro Ile Ala Glu
 4195 4200 4205
 Leu Thr Thr Ser Asn Pro Pro Pro Glu Ser Ser Thr Pro Gln Thr Ser
 4210 4215 4220
 Arg Ser Thr Ser Ser Pro Leu Thr Glu Ser Thr Thr Leu Leu Ser Thr
 4225 4230 4235 4240
 Leu Pro Pro Ala Ile Glu Met Thr Ser Thr Ala Pro Pro Ser Thr Pro
 4245 4250 4255
 Thr Ala Pro Thr Thr Ser Gly Gly His Thr Leu Ser Pro Pro Pro
 4260 4265 4270
 Ser Thr Thr Thr Ser Pro Pro Gly Thr Pro Thr Arg Gly Thr Thr Thr
 4275 4280 4285
 Gly Ser Ser Ser Ala Pro Thr Pro Ser Thr Val Gln Thr Thr Thr Thr
 4290 4295 4300
 Ser Ala Trp Thr Pro Thr Pro Thr Pro Leu Ser Thr Pro Ser Ile Ile
 4305 4310 4315 4320
 Arg Thr Thr Gly Leu Arg Pro Tyr Pro Ser Ser Val Leu Ile Cys Cys
 4325 4330 4335
 Val Leu Asn Asp Thr Tyr Tyr Ala Pro Gly Glu Glu Val Tyr Asn Gly
 4340 4345 4350
 Thr Tyr Gly Asp Thr Cys Tyr Phe Val Asn Cys Ser Leu Ser Cys Thr
 4355 4360 4365
 Leu Glu Phe Tyr Asn Trp Ser Cys Pro Ser Thr Pro Ser Pro Thr Pro
 4370 4375 4380
 Thr Pro Ser Lys Ser Thr Pro Thr Pro Ser Lys Pro Ser Ser Thr Pro

SEQUENCE LISTING 1657-2022.txt

4385 4390 4395 4400
 Ser Lys Pro Thr Pro Gly Thr Lys Pro Pro Glu Cys Pro Asp Phe Asp
 4405 4410 4415
 Pro Pro Arg Gln Glu Asn Glu Thr Trp Trp Leu Cys Asp Cys Phe Met
 4420 4425 4430
 Ala Thr Cys Lys Tyr Asn Asn Thr Val Glu Ile Val Lys Val Glu Cys
 4435 4440 4445
 Glu Pro Pro Pro Met Pro Thr Cys Ser Asn Gly Leu Gln Pro Val Arg
 4450 4455 4460
 Val Glu Asp Pro Asp Gly Cys Cys Trp His Trp Glu Cys Asp Cys Tyr
 4465 4470 4475 4480
 Cys Thr Gly Trp Gly Asp Pro His Tyr Val Thr Phe Asp Gly Leu Tyr
 4485 4490 4495
 Tyr Ser Tyr Gln Gly Asn Cys Thr Tyr Val Leu Val Glu Glu Ile Ser
 4500 4505 4510
 Pro Ser Val Asp Asn Phe Gly Val Tyr Ile Asp Asn Tyr His Cys Asp
 4515 4520 4525
 Pro Asn Asp Lys Val Ser Cys Pro Arg Thr Leu Ile Val Arg His Glu
 4530 4535 4540
 Thr Gln Glu Val Leu Ile Lys Thr Val His Met Met Pro Met Gln Val
 4545 4550 4555 4560
 Gln Val Gln Val Asn Arg Gln Ala Val Ala Leu Pro Tyr Lys Lys Tyr
 4565 4570 4575
 Gly Leu Glu Val Tyr Gln Ser Gly Ile Asn Tyr Val Val Asp Ile Pro
 4580 4585 4590
 Glu Leu Gly Val Leu Val Ser Tyr Asn Gly Leu Ser Phe Ser Val Arg
 4595 4600 4605
 Leu Pro Tyr His Arg Phe Gly Asn Asn Thr Lys Gly Gln Cys Gly Thr
 4610 4615 4620
 Cys Thr Asn Thr Thr Ser Asp Asp Cys Ile Leu Pro Ser Gly Glu Ile
 4625 4630 4635 4640
 Val Ser Asn Cys Glu Ala Ala Ala Asp Gln Trp Leu Val Asn Asp Pro
 4645 4650 4655
 Ser Lys Pro His Cys Pro His Ser Ser Ser Thr Thr Lys Arg Pro Ala
 4660 4665 4670
 Val Thr Val Pro Gly Gly Gly Lys Thr Thr Pro His Lys Asp Cys Thr
 4675 4680 4685
 Pro Ser Pro Leu Cys Gln Leu Ile Lys Asp Ser Leu Phe Ala Gln Cys
 4690 4695 4700
 His Ala Leu Val Pro Pro Gln His Tyr Tyr Asp Ala Cys Val Phe Asp
 4705 4710 4715 4720
 Ser Cys Phe Met Pro Gly Ser Ser Leu Glu Cys Ala Ser Leu Gln Ala
 4725 4730 4735
 Tyr Ala Ala Leu Cys Ala Gln Gln Asn Ile Cys Leu Asp Trp Arg Asn
 4740 4745 4750
 His Thr His Gly Ala Cys Leu Val Glu Cys Pro Ser His Arg Glu Tyr
 4755 4760 4765
 Gln Ala Cys Gly Pro Ala Glu Glu Pro Thr Cys Lys Ser Ser Ser Ser
 4770 4775 4780
 Gln Gln Asn Asn Thr Val Leu Val Glu Gly Cys Phe Cys Pro Glu Gly
 4785 4790 4795 4800
 Thr Met Asn Tyr Ala Pro Gly Phe Asp Val Cys Val Lys Thr Cys Gly
 4805 4810 4815
 Cys Val Gly Pro Asp Asn Val Pro Arg Glu Phe Gly Glu His Phe Glu
 4820 4825 4830
 Phe Asp Cys Lys Asn Cys Val Cys Leu Glu Gly Gly Ser Gly Ile Ile
 4835 4840 4845
 Cys Gln Pro Lys Arg Cys Ser Gln Lys Pro Val Thr His Cys Val Glu
 4850 4855 4860
 Asp Gly Thr Tyr Leu Ala Thr Glu Val Asn Pro Ala Asp Thr Cys Cys
 4865 4870 4875 4880
 Asn Ile Thr Val Cys Lys Cys Asn Thr Ser Leu Cys Lys Glu Lys Pro
 4885 4890 4895
 Ser Val Cys Pro Leu Gly Phe Glu Val Lys Ser Lys Met Val Pro Gly
 4900 4905 4910
 Arg Cys Cys Pro Phe Tyr Trp Cys Glu Ser Lys Gly Val Cys Val His
 4915 4920 4925

SEQUENCE LISTING 1657-2022.txt

Gly Asn Ala Glu Tyr Gln Pro Gly Ser Pro Val Tyr Ser Ser Lys Cys
 4930 4935 4940
 Gln Asp Cys Val Cys Thr Asp Lys Val Asp Asn Asn Thr Leu Leu Asn
 4945 4950 4955 4960
 Val Ile Ala Cys Thr His Val Pro Cys Asn Thr Ser Cys Ser Pro Gly
 4965 4970 4975
 Phe Glu Leu Met Glu Ala Pro Gly Glu Cys Cys Lys Lys Cys Glu Gln
 4980 4985 4990
 Thr His Cys Ile Ile Lys Arg Pro Asp Asn Gln His Val Ile Leu Lys
 4995 5000 5005
 Pro Gly Asp Phe Lys Ser Asp Pro Lys Asn Asn Cys Thr Phe Phe Ser
 5010 5015 5020
 Cys Val Lys Ile His Asn Gln Leu Ile Ser Ser Val Ser Asn Ile Thr
 5025 5030 5035 5040
 Cys Pro Asn Phe Asp Ala Ser Ile Cys Ile Pro Gly Ser Ile Thr Phe
 5045 5050 5055
 Met Pro Asn Gly Cys Cys Lys Thr Cys Thr Pro Arg Asn Glu Thr Arg
 5060 5065 5070
 Val Pro Cys Ser Thr Val Pro Val Thr Thr Glu Val Ser Tyr Ala Gly
 5075 5080 5085
 Cys Thr Lys Thr Val Leu Met Asn His Cys Ser Gly Ser Cys Gly Thr
 5090 5095 5100
 Phe Val Met Tyr Ser Ala Lys Ala Gln Ala Leu Asp His Ser Cys Ser
 5105 5110 5115 5120
 Cys Cys Lys Glu Glu Lys Thr Ser Gln Arg Glu Val Val Leu Ser Cys
 5125 5130 5135
 Pro Asn Gly Gly Ser Leu Thr His Thr Tyr Thr His Ile Glu Ser Cys
 5140 5145 5150
 Gln Cys Gln Asp Thr Val Cys Gly Leu Pro Thr Gly Thr Ser Arg Arg
 5155 5160 5165
 Ala Arg Arg Ser Pro Arg His Leu Gly Ser
 5170 5175

<210> 179
 <211> 508
 <212> PRT
 <213> Homo sapiens

<400> 179
 Met Gln Arg Leu Leu Thr Pro Val Lys Arg Ile Leu Gln Leu Thr Arg
 1 5 10 15
 Ala Val Gln Glu Thr Ser Leu Thr Pro Ala Arg Leu Leu Pro Val Ala
 20 25 30
 His Gln Arg Phe Ser Thr Ala Ser Ala Val Pro Leu Ala Lys Thr Asp
 35 40 45
 Thr Trp Pro Lys Asp Val Gly Ile Leu Ala Leu Glu Val Tyr Phe Pro
 50 55 60
 Ala Gln Tyr Val Asp Gln Thr Asp Leu Glu Lys Tyr Asn Asn Val Glu
 65 70 75 80
 Ala Gly Lys Tyr Thr Val Gly Leu Gly Gln Thr Arg Met Gly Phe Cys
 85 90 95
 Ser Val Gln Glu Asp Ile Asn Ser Leu Cys Leu Thr Val Val Gln Arg
 100 105 110
 Leu Met Glu Arg Ile Gln Leu Pro Trp Asp Ser Val Gly Arg Leu Glu
 115 120 125
 Val Gly Thr Glu Thr Ile Ile Asp Lys Ser Lys Ala Val Lys Thr Val
 130 135 140
 Leu Met Glu Leu Phe Gln Asp Ser Gly Asn Thr Asp Ile Glu Gly Ile
 145 150 155 160
 Asp Thr Thr Asn Ala Cys Tyr Gly Gly Thr Ala Ser Leu Phe Asn Ala
 165 170 175
 Ala Asn Trp Met Glu Ser Ser Ser Trp Asp Gly Arg Tyr Ala Met Val
 180 185 190
 Val Cys Gly Asp Ile Ala Val Tyr Pro Ser Gly Asn Ala Arg Pro Thr
 195 200 205
 Gly Gly Ala Gly Ala Val Ala Met Leu Ile Gly Pro Lys Ala Pro Leu
 Page 173

SEQUENCE LISTING 1657-2022.txt

```

210          215          220
Ala Leu Glu Arg Gly Leu Arg Gly Thr His Met Glu Asn Val Tyr Asp
225          230          235          240
Phe Tyr Lys Pro Asn Leu Ala Ser Glu Tyr Pro Ile Val Asp Gly Lys
245          250          255
Leu Ser Ile Gln Cys Tyr Leu Arg Ala Leu Asp Arg Cys Tyr Thr Ser
260          265          270
Tyr Arg Lys Lys Ile Gln Asn Gln Trp Lys Gln Ala Gly Ser Asp Arg
275          280          285
Pro Phe Thr Leu Asp Asp Leu Gln Tyr Met Ile Phe His Thr Pro Phe
290          295          300
Cys Lys Met Val Gln Lys Ser Leu Ala Arg Leu Met Phe Asn Asp Phe
305          310          315          320
Leu Ser Ala Ser Ser Asp Thr Gln Thr Ser Leu Tyr Lys Gly Leu Glu
325          330          335
Ala Phe Gly Gly Leu Lys Leu Glu Asp Thr Tyr Thr Asn Lys Asp Leu
340          345          350
Asp Lys Ala Leu Leu Lys Ala Ser Gln Asp Met Phe Asp Lys Lys Thr
355          360          365
Lys Ala Ser Leu Tyr Leu Ser Thr His Asn Gly Asn Met Tyr Thr Ser
370          375          380
Ser Leu Tyr Gly Cys Leu Ala Ser Leu Leu Ser His His Ser Ala Gln
385          390          395          400
Glu Leu Ala Gly Ser Arg Ile Gly Ala Phe Ser Tyr Gly Ser Gly Leu
405          410          415
Ala Ala Ser Phe Phe Ser Phe Arg Val Ser Gln Asp Ala Ala Pro Gly
420          425          430
Ser Pro Leu Asp Lys Leu Val Ser Thr Ser Asp Leu Pro Lys Arg
435          440          445
Leu Ala Ser Arg Lys Cys Val Ser Pro Glu Glu Phe Thr Glu Ile Met
450          455          460
Asn Gln Arg Glu Gln Phe Tyr His Lys Val Asn Phe Ser Pro Pro Gly
465          470          475          480
Asp Thr Asn Ser Leu Phe Pro Gly Thr Trp Tyr Leu Glu Arg Val Asp
485          490          495
Glu Gln His Arg Arg Lys Tyr Ala Arg Arg Pro Val
500          505

```

<210> 180
 <211> 914
 <212> PRT
 <213> Homo sapiens

```

<400> 180
Met Gly Pro Phe Lys Ser Ser Val Phe Ile Leu Ile Leu His Leu Leu
1      5      10      15
Glu Gly Ala Leu Ser Asn Ser Leu Ile Gln Leu Asn Asn Asn Gly Tyr
20      25      30
Glu Gly Ile Val Val Ala Ile Asp Pro Asn Val Pro Glu Asp Glu Thr
35      40      45
Leu Ile Gln Gln Ile Lys Asp Met Val Thr Gln Ala Ser Leu Tyr Leu
50      55      60
Phe Glu Ala Thr Gly Lys Arg Phe Tyr Phe Lys Asn Val Ala Ile Leu
65      70      75      80
Ile Pro Glu Thr Trp Lys Thr Lys Ala Asp Tyr Val Arg Pro Lys Leu
85      90      95
Glu Thr Tyr Lys Asn Ala Asp Val Leu Val Ala Glu Ser Thr Pro Pro
100      105      110
Gly Asn Asp Glu Pro Tyr Thr Glu Gln Met Gly Asn Cys Gly Glu Lys
115      120      125
Gly Glu Arg Ile His Leu Thr Pro Asp Phe Ile Ala Gly Lys Lys Leu
130      135      140
Ala Glu Tyr Gly Pro Gln Gly Lys Ala Phe Val His Glu Trp Ala His
145      150      155      160
Leu Arg Trp Gly Val Phe Asp Glu Tyr Asn Asn Asp Glu Lys Phe Tyr
165      170      175

```


SEQUENCE LISTING 1657-2022.txt

Leu Ser Asn Gly Arg Ile Gln Ala Val Arg Cys Ser Ala Gly Ile Thr
 Gly Thr Asn Val Val Lys Lys Cys Gln Gly Gly Ser Cys Tyr Thr Lys
 Arg Cys Thr Phe Asn Lys Val Thr Gly Leu Tyr Glu Lys Gly Cys Glu
 Phe Val Leu Gln Ser Arg Gln Thr Glu Lys Ala Ser Ile Met Phe Ala
 Gln His Val Asp Ser Ile Val Glu Phe Cys Thr Glu Gln Asn His Asn
 Lys Glu Ala Pro Asn Lys Gln Asn Gln Lys Cys Asn Leu Arg Ser Thr
 Trp Glu Val Ile Arg Asp Ser Glu Asp Phe Lys Lys Thr Thr Pro Met
 Thr Thr Gln Pro Pro Asn Pro Thr Phe Ser Leu Leu Gln Ile Gly Gln
 Arg Ile Val Cys Leu Val Leu Asp Lys Ser Gly Ser Met Ala Thr Gly
 Asn Arg Leu Asn Arg Leu Asn Gln Ala Gly Gln Leu Phe Leu Leu Gln
 Thr Val Glu Leu Gly Ser Trp Val Gly Met Val Thr Phe Asp Ser Ala
 Ala His Val Gln Ser Glu Leu Ile Gln Ile Asn Ser Gly Ser Asp Arg
 Asp Thr Leu Ala Lys Arg Leu Pro Ala Ala Ala Ser Gly Gly Thr Ser
 Ile Cys Ser Gly Leu Arg Ser Ala Phe Thr Val Ile Arg Lys Lys Tyr
 Pro Thr Asp Gly Ser Glu Ile Val Leu Leu Thr Asp Gly Glu Asp Asn
 Thr Ile Ser Gly Cys Phe Asn Glu Val Lys Gln Ser Gly Ala Ile Ile
 His Thr Val Ala Leu Gly Pro Ser Ala Ala Gln Glu Leu Glu Glu Leu
 Ser Lys Met Thr Gly Gly Leu Gln Thr Tyr Ala Ser Asp Gln Val Gln
 Asn Asn Gly Leu Ile Asp Ala Phe Gly Ala Leu Ser Ser Gly Asn Gly
 Ala Val Ser Gln Arg Ser Ile Gln Leu Glu Ser Lys Gly Leu Thr Leu
 Gln Asn Ser Gln Trp Met Asn Gly Thr Val Ile Val Asp Ser Thr Val
 Gly Lys Asp Thr Leu Phe Leu Ile Thr Trp Thr Thr Gln Pro Pro Gln
 Ile Leu Leu Trp Asp Pro Ser Gly Gln Lys Gln Gly Phe Val Val
 Asp Lys Asn Thr Lys Met Ala Tyr Leu Gln Ile Pro Gly Ile Ala Lys
 Val Gly Thr Trp Lys Tyr Ser Leu Gln Ala Ser Ser Gln Thr Leu Thr
 Leu Thr Val Thr Ser Arg Ala Ser Asn Ala Thr Leu Pro Pro Ile Thr
 Val Thr Ser Lys Thr Asn Lys Asp Thr Ser Lys Phe Pro Ser Pro Leu
 Val Val Tyr Ala Asn Ile Arg Gln Gly Ala Ser Pro Ile Leu Arg Ala
 Ser Val Thr Ala Leu Ile Glu Ser Val Asn Gly Lys Thr Val Thr Leu
 Glu Leu Leu Asp Asn Gly Ala Gly Ala Asp Ala Thr Lys Asp Asp Gly
 Val Tyr Ser Arg Tyr Phe Thr Thr Tyr Asp Thr Asn Gly Arg Tyr Ser
 Val Lys Val Arg Ala Leu Gly Gly Val Asn Ala Ala Arg Arg Arg Val
 Ile Pro Gln Gln Ser Gly Ala Leu Tyr Ile Pro Gly Trp Ile Glu Asn
 Asp Glu Ile Gln Trp Asn Pro Pro Arg Pro Glu Ile Asn Lys Asp Asp

SEQUENCE LISTING 1657-2022.txt

```

705          710          715          720
Val Gln His Lys Gln Val Cys Phe Ser Arg Thr Ser Ser Gly Gly Ser
725          730          735
Phe Val Ala Ser Asp Val Pro Asn Ala Pro Ile Pro Asp Leu Phe Pro
740          745          750
Pro Gly Gln Ile Thr Asp Leu Lys Ala Glu Ile His Gly Gly Ser Leu
755          760          765
Ile Asn Leu Thr Trp Thr Ala Pro Gly Asp Asp Tyr Asp His Gly Thr
770          775          780
Ala His Lys Tyr Ile Ile Arg Ile Ser Thr Ser Ile Leu Asp Leu Arg
785          790          795          800
Asp Lys Phe Asn Glu Ser Leu Gln Val Asn Thr Thr Ala Leu Ile Pro
805          810          815
Lys Glu Ala Asn Ser Glu Glu Val Phe Leu Phe Lys Pro Glu Asn Ile
820          825          830
Thr Phe Glu Asn Gly Thr Asp Leu Phe Ile Ala Ile Gln Ala Val Asp
835          840          845
Lys Val Asp Leu Lys Ser Glu Ile Ser Asn Ile Ala Arg Val Ser Leu
850          855          860
Phe Ile Pro Pro Gln Thr Pro Pro Glu Thr Pro Ser Pro Asp Glu Thr
865          870          875          880
Ser Ala Pro Cys Pro Asn Ile His Ile Asn Ser Thr Ile Pro Gly Ile
885          890          895
His Ile Leu Lys Ile Met Trp Lys Trp Ile Gly Glu Leu Gln Leu Ser
900          905          910
Ile Ala

```

```

<210> 181
<211> 61
<212> PRT
<213> Homo sapiens

```

```

<400> 181
Met Asp Pro Asn Cys Ser Cys Ala Ala Gly Val Ser Cys Thr Cys Ala
1      5      10      15
Gly Ser Cys Lys Cys Lys Glu Cys Lys Cys Thr Ser Cys Lys Lys Ser
20      25      30
Cys Cys Ser Cys Cys Pro Val Gly Cys Ser Lys Cys Ala Gln Gly Cys
35      40      45
Val Cys Lys Gly Ala Ser Glu Lys Cys Ser Cys Cys Asp
50      55      60

```

```

<210> 182
<211> 260
<212> PRT
<213> Homo sapiens

```

```

<400> 182
Met Ser His His Trp Gly Tyr Gly Lys His Asn Gly Pro Glu His Trp
1      5      10      15
His Lys Asp Phe Pro Ile Ala Lys Gly Glu Arg Gln Ser Pro Val Asp
20      25      30
Ile Asp Thr His Thr Ala Lys Tyr Asp Pro Ser Leu Lys Pro Leu Ser
35      40      45
Val Ser Tyr Asp Gln Ala Thr Ser Leu Arg Ile Leu Asn Asn Gly His
50      55      60
Ala Phe Asn Val Glu Phe Asp Asp Ser Gln Asp Lys Ala Val Leu Lys
65      70      75      80
Gly Gly Pro Leu Asp Gly Thr Tyr Arg Leu Ile Gln Phe His Phe His
85      90      95
Trp Gly Ser Leu Asp Gly Gln Gly Ser Glu His Thr Val Asp Lys Lys
100      105      110
Lys Tyr Ala Ala Glu Leu His Leu Val His Trp Asn Thr Lys Tyr Gly
115      120      125

```

SEQUENCE LISTING 1657-2022.txt

```

Asp Phe Gly Lys Ala Val Gln Gln Pro Asp Gly Leu Ala Val Leu Gly
130 135 140
Ile Phe Leu Lys Val Gly Ser Ala Lys Pro Gly Leu Gln Lys Val Val
145 150 155 160
Asp Val Leu Asp Ser Ile Lys Thr Lys Gly Lys Ser Ala Asp Phe Thr
165 170 175
Asn Phe Asp Pro Arg Gly Leu Leu Pro Glu Ser Leu Asp Tyr Trp Thr
180 185 190
Tyr Pro Gly Ser Leu Thr Thr Pro Pro Leu Leu Glu Cys Val Thr Trp
195 200 205
Ile Val Leu Lys Glu Pro Ile Ser Val Ser Ser Glu Gln Val Leu Lys
210 215 220
Phe Arg Lys Leu Asn Phe Asn Gly Glu Gly Glu Pro Glu Glu Leu Met
225 230 235 240
Val Asp Asn Trp Arg Pro Ala Gln Pro Leu Lys Asn Arg Gln Ile Lys
245 250 255
Ala Ser Phe Lys
260

```

```

<210> 183
<211> 61
<212> PRT
<213> Homo sapiens

```

```

<400> 183
Met Asp Pro Asn Cys Ser Cys Glu Ala Gly Gly Ser Cys Ala Cys Ala
1 5 10 15
Gly Ser Cys Lys Cys Lys Lys Cys Lys Cys Thr Ser Cys Lys Lys Ser
20 25 30
Cys Cys Ser Cys Cys Pro Leu Gly Cys Ala Lys Cys Ala Gln Gly Cys
35 40 45
Ile Cys Lys Gly Ala Ser Glu Lys Cys Ser Cys Cys Ala
50 55 60

```

```

<210> 184
<211> 61
<212> PRT
<213> Homo sapiens

```

```

<400> 184
Met Asp Pro Asn Cys Ser Cys Ala Ala Gly Val Ser Cys Thr Cys Ala
1 5 10 15
Ser Ser Cys Lys Cys Lys Glu Cys Lys Cys Thr Ser Cys Lys Lys Ser
20 25 30
Cys Cys Ser Cys Cys Pro Val Gly Cys Ala Lys Cys Ala Gln Gly Cys
35 40 45
Ile Cys Lys Gly Ala Ser Glu Lys Cys Ser Cys Cys Ala
50 55 60

```

```

<210> 185
<211> 167
<212> PRT
<213> Homo sapiens

```

```

<400> 185
Met Leu Thr Val Ala Leu Leu Ala Leu Leu Cys Ala Ser Ala Ser Gly
1 5 10 15
Asn Ala Ile Gln Ala Arg Ser Ser Tyr Ser Gly Glu Tyr Gly Ser
20 25 30
Gly Gly Gly Lys Arg Phe Ser His Ser Gly Asn Gln Leu Asp Gly Pro
35 40 45
Ile Thr Ala Leu Arg Val Arg Val Asn Thr Tyr Tyr Ile Val Gly Leu
50 55 60
Gln Val Arg Tyr Gly Lys Val Trp Ser Asp Tyr Val Gly Gly Arg Asn
Page 177

```

SEQUENCE LISTING 1657-2022.txt

```

65      70      75      80
Gly Asp Leu Glu Glu Ile Phe Leu His Pro Gly Glu Ser Val Ile Gln
85
Val Ser Gly Lys Tyr Lys Trp Tyr Leu Lys Lys Leu Val Phe Val Thr
100
Asp Lys Gly Arg Tyr Leu Ser Phe Gly Lys Asp Ser Gly Thr Ser Phe
115
Asn Ala Val Pro Leu His Pro Asn Thr Val Leu Arg Phe Ile Ser Gly
130
Arg Ser Gly Ser Leu Ile Asp Ala Ile Gly Leu His Trp Asp Val Tyr
145
Pro Thr Ser Cys Ser Arg Cys
165

```

<210> 186

<211> 61

<212> PRT

<213> Homo sapiens

<400> 186

```

Met Asp Pro Asn Cys Ser Cys Ser Pro Val Gly Ser Cys Ala Cys Ala
1      5      10
Gly Ser Cys Lys Cys Lys Glu Cys Lys Cys Thr Ser Cys Lys Lys Ser
20
Cys Cys Ser Cys Cys Pro Val Gly Cys Ala Lys Cys Ala Gln Gly Cys
35
Ile Cys Lys Gly Thr Ser Asp Lys Cys Ser Cys Cys Ala
50      55      60

```